Clustering O 0 0.0001435520825907588
of O 0 4.029702267871471e-06
missense O 0 0.0010611756006255746
mutations O 0 0.0004197482776362449
in O 0 5.2921409405826125e-06
the O 0 2.5071380150620826e-05
ataxia B-Disease 1 0.9999711513519287
- I-Disease 1 0.9946959614753723
telangiectasia I-Disease 1 0.9973998069763184
gene O 0 2.9288847144925967e-05
in O 0 1.3513252952179755e-06
a O 0 4.066051133122528e-06
sporadic B-Disease 0 0.0005344816599972546
T I-Disease 1 0.9873021841049194
- I-Disease 0 0.048487551510334015
cell I-Disease 0 0.01641424559056759
leukaemia I-Disease 1 0.9889532327651978
. O 0 1.824063656385988e-05

Ataxia B-Disease 1 0.9999068975448608
- I-Disease 1 0.997632622718811
telangiectasia I-Disease 1 0.9996240139007568
( O 0 0.0002307305549038574
A B-Disease 1 0.9995023012161255
- I-Disease 1 0.9948369264602661
T I-Disease 1 0.9995937943458557
) O 0 3.096701561844384e-07
is O 0 1.3858148406598048e-07
a O 0 1.164579998658155e-06
recessive B-Disease 0 0.001998747466132045
multi I-Disease 1 0.9361985921859741
- I-Disease 1 0.9985266923904419
system I-Disease 0 0.44645440578460693
disorder I-Disease 1 0.9996607303619385
caused O 0 9.469386714044958e-05
by O 0 2.986598701681942e-07
mutations O 0 5.387775672716089e-06
in O 0 5.532868740942831e-08
the O 0 7.416346647914906e-08
ATM O 0 1.5693185559939593e-05
gene O 0 8.001571586646605e-06
at O 0 4.461512071429752e-05
11q22 O 0 9.509400115348399e-05
- O 0 7.424908108077943e-05
q23 O 0 7.918514893390238e-05
( O 0 9.253302550860099e-07
ref O 0 0.00020553710055537522
. O 0 2.635714508869569e-07
3 O 0 9.24800929169578e-07
) O 0 2.996352463924268e-07
. O 0 1.024503148983058e-06

The O 0 1.820792749640532e-05
risk O 0 0.00020229701476637274
of O 0 5.927720394538483e-06
cancer B-Disease 1 0.9985766410827637
, O 0 2.3359787064691773e-06
especially O 0 4.236725544615183e-06
lymphoid B-Disease 0 0.0014820017386227846
neoplasias I-Disease 0 0.0022101986687630415
, O 0 9.830570206759148e-07
is O 0 1.819629318333682e-07
substantially O 0 3.591984068407328e-06
elevated O 0 0.00012069681542925537
in O 0 2.501289145584451e-06
A B-Disease 1 0.9970732927322388
- I-Disease 1 0.9973942041397095
T I-Disease 1 0.9998574256896973
patients O 0 2.7857393433805555e-05
and O 0 5.816817747472669e-07
has O 0 6.112931032475899e-07
long O 0 2.686356538106338e-06
been O 0 7.721986889919208e-07
associated O 0 2.134329406544566e-06
with O 0 1.3508894880942535e-05
chromosomal O 1 0.9999511241912842
instability O 1 0.9994171857833862
. O 0 4.6111515985103324e-05

By O 0 4.619258561433526e-06
analysing O 0 0.0003690458252094686
tumour B-Disease 1 0.9993799924850464
DNA O 0 1.372411225020187e-05
from O 0 7.328600872824609e-07
patients O 0 9.216982448378985e-07
with O 0 3.1676535172664444e-07
sporadic B-Disease 0 0.0004833822895307094
T I-Disease 1 0.7818167209625244
- I-Disease 0 0.0033274241723120213
cell I-Disease 0 0.0018845361191779375
prolymphocytic I-Disease 0 0.008726905100047588
leukaemia I-Disease 1 0.9881905317306519
( O 0 9.393444997840561e-06
T B-Disease 0 0.01719813421368599
- I-Disease 0 0.0002012108889175579
PLL I-Disease 0 0.000350294285453856
) O 0 3.523136626881751e-07
, O 0 1.5251802665261494e-07
a O 0 6.922953730281733e-07
rare O 0 4.328038630774245e-05
clonal B-Disease 0 0.0004388321249280125
malignancy I-Disease 0 0.094991534948349
with O 0 1.9200099643512658e-07
similarities O 0 7.040496825538867e-07
to O 0 5.398405278356222e-08
a O 0 1.6229079164986615e-06
mature B-Disease 0 2.159323776140809e-05
T I-Disease 0 0.021454602479934692
- I-Disease 0 0.0004779784649144858
cell I-Disease 0 0.0004113128816243261
leukaemia I-Disease 0 0.08211130648851395
seen O 0 1.6641688489471562e-05
in O 0 1.0274208079863456e-06
A B-Disease 1 0.7174263000488281
- I-Disease 0 0.2789306044578552
T I-Disease 1 0.9994279742240906
, O 0 3.354217028572748e-07
we O 0 2.9169965998221414e-08
demonstrate O 0 4.020854404984675e-08
a O 0 9.459272831691123e-08
high O 0 1.1825991350633558e-06
frequency O 0 6.216707788553322e-07
of O 0 5.12726678891795e-08
ATM O 0 5.394050822360441e-05
mutations O 0 6.957575533306226e-05
in O 0 8.485631042276509e-06
T B-Disease 0 0.44586026668548584
- I-Disease 0 0.0013544692192226648
PLL I-Disease 0 0.002694031922146678
. O 0 2.0864430553046986e-05

In O 0 2.7056887574872235e-06
marked O 0 7.576359621452866e-06
contrast O 0 8.766853056840773e-07
to O 0 2.9074147533947325e-08
the O 0 2.1290020413289312e-07
ATM O 0 5.8238925703335553e-05
mutation O 0 4.55107401649002e-05
pattern O 0 1.990833152376581e-05
in O 0 2.300710548297502e-06
A B-Disease 1 0.9730414748191833
- I-Disease 1 0.9556939005851746
T I-Disease 1 0.9997995495796204
, O 0 3.664229950572917e-07
the O 0 3.766315614939231e-08
most O 0 3.355195232757069e-08
frequent O 0 6.731904136358935e-07
nucleotide O 0 5.777828278041852e-07
changes O 0 3.8287367942757555e-07
in O 0 1.6492404597556742e-07
this O 0 2.4995341618705424e-07
leukaemia B-Disease 0 0.04159915819764137
were O 0 1.822524154704297e-06
missense O 0 0.0004645977169275284
mutations O 0 0.0004920018254779279
. O 0 9.130421858571935e-06

These O 0 3.2795176707622886e-07
clustered O 0 1.5282672393368557e-05
in O 0 3.547106643964071e-07
the O 0 8.814876650831138e-08
region O 0 2.2303835578441067e-07
corresponding O 0 8.716917676565572e-08
to O 0 1.1670194588475624e-08
the O 0 3.692813521638527e-08
kinase O 0 6.047380338713992e-07
domain O 0 2.3594058973230858e-07
, O 0 5.921675594322551e-08
which O 0 1.132625193633885e-08
is O 0 1.5160825483917506e-08
highly O 0 1.1007347211489105e-07
conserved O 0 2.4761237682469073e-07
in O 0 6.060970036969593e-08
ATM O 0 9.291289643442724e-06
- O 0 6.555861546075903e-06
related O 0 2.0660851873799402e-07
proteins O 0 8.91138682845849e-08
in O 0 1.0859454135925262e-07
mouse O 0 3.6026808629685547e-06
, O 0 1.0514849435594442e-07
yeast O 0 1.3966802043796633e-06
and O 0 4.099760531062202e-07
Drosophila O 0 3.33174534716818e-06
. O 0 3.639749593276065e-06

The O 0 1.9567119124985766e-06
resulting O 0 6.336055776046123e-06
amino O 0 4.585423539538169e-06
- O 0 2.8993246814934537e-05
acid O 0 5.615301688521868e-06
substitutions O 0 5.82457232667366e-07
are O 0 1.4211614995929267e-08
predicted O 0 2.677803365713771e-07
to O 0 6.819925957302075e-09
interfere O 0 3.4267299042767263e-07
with O 0 5.53410302472912e-07
ATP O 0 0.005352671258151531
binding O 0 7.469734100595815e-06
or O 0 1.1227739378227852e-06
substrate O 0 9.797692655411083e-06
recognition O 0 9.852318726188969e-06
. O 0 8.455200259049889e-06

Two O 0 7.279944043148134e-07
of O 0 2.5203468112522387e-07
seventeen O 0 5.475090347317746e-06
mutated O 0 0.00017149023187812418
T B-Disease 0 0.04275595769286156
- I-Disease 0 0.00011088511382695287
PLL I-Disease 0 0.0001714876270852983
samples O 0 6.676891644019634e-07
had O 0 5.03397870943445e-07
a O 0 4.671190652061341e-07
previously O 0 3.882966666424181e-06
reported O 0 2.649951056810096e-05
A B-Disease 1 0.8026288747787476
- I-Disease 1 0.8836705088615417
T I-Disease 1 0.9980005621910095
allele O 0 0.00021333112090360373
. O 0 9.924649020831566e-06

In O 0 2.1350581391743617e-06
contrast O 0 3.2113312045112252e-06
, O 0 3.0977267329035385e-07
no O 0 1.9001149098585302e-07
mutations O 0 1.4617637589253718e-06
were O 0 1.1643418673656925e-07
detected O 0 2.4310820663231425e-06
in O 0 2.01704803970415e-08
the O 0 1.956941098057996e-08
p53 O 0 6.239617391656793e-07
gene O 0 6.708486353090848e-07
, O 0 1.2253893544311723e-07
suggesting O 0 3.889853701366519e-07
that O 0 3.135909665274994e-08
this O 0 6.340827098938462e-07
tumour B-Disease 1 0.9998816251754761
suppressor O 0 0.00010497192124603316
is O 0 2.3295440598758432e-07
not O 0 1.626190382353343e-08
frequently O 0 3.571413742520235e-07
altered O 0 2.3781246909493348e-06
in O 0 5.287491831040825e-07
this O 0 7.766720386825909e-07
leukaemia B-Disease 1 0.9655647277832031
. O 0 1.2143775165895931e-05

Occasional O 0 0.0003619273193180561
missense O 0 0.0012537093134596944
mutations O 0 0.00012943282490596175
in O 0 5.38312463049806e-07
ATM O 0 1.372563110635383e-05
were O 0 4.1848250020848354e-07
also O 0 2.4503870577063935e-07
found O 0 6.63536468437087e-07
in O 0 1.9633419015008258e-06
tumour B-Disease 1 0.9995251893997192
DNA O 0 9.970639439416118e-06
from O 0 5.991146849737561e-07
patients O 0 8.358946388398181e-07
with O 0 3.3294600143563e-07
B B-Disease 0 9.147227683570236e-05
- I-Disease 0 0.0001491754810558632
cell I-Disease 0 0.00025405632914043963
non I-Disease 0 0.0005190987722016871
- I-Disease 1 0.7224962115287781
Hodgkins I-Disease 1 0.9993789196014404
lymphomas I-Disease 1 0.69410240650177
( O 0 1.8882516314988607e-06
B B-Disease 0 2.9984534194227308e-05
- I-Disease 0 1.851133129093796e-05
NHL I-Disease 0 1.4815363101661205e-05
) O 0 3.884248300778381e-08
and O 0 3.611944165982095e-08
a O 0 7.449492045452644e-07
B B-Disease 0 3.927769648726098e-05
- I-Disease 0 4.0644001273903996e-05
NHL I-Disease 0 0.00010852621198864654
cell O 0 7.742564048385248e-05
line O 0 0.00013699363626074046
. O 0 6.465071692218771e-06

The O 0 7.481929742425564e-07
evidence O 0 1.166594785217967e-07
of O 0 2.1664172678015348e-08
a O 0 4.5144611249270383e-07
significant O 0 5.194903565097775e-07
proportion O 0 6.488831445494725e-07
of O 0 3.7785119388900057e-07
loss O 0 0.00030278050689958036
- O 0 9.573480383551214e-06
of O 0 7.916614208625106e-08
- O 0 1.1085023288615048e-05
function O 0 1.4108411505731056e-06
mutations O 0 5.982907168800011e-06
and O 0 5.252511670050808e-08
a O 0 1.4033062711860111e-07
complete O 0 1.1291222108411603e-06
absence O 0 1.711776803858811e-06
of O 0 3.0394801342481514e-08
the O 0 6.880737402070736e-08
normal O 0 7.063025577735971e-07
copy O 0 1.2034570318064652e-06
of O 0 4.395498720555224e-08
ATM O 0 1.1717605957528576e-05
in O 0 1.455399711858263e-07
the O 0 2.0926692911871214e-07
majority O 0 4.1229722569369187e-07
of O 0 6.617341909986862e-07
mutated O 0 0.0034935190342366695
tumours B-Disease 1 0.9997183680534363
establishes O 0 0.000302089931210503
somatic O 0 7.059509516693652e-05
inactivation O 0 0.002282464411109686
of O 0 9.667408562563651e-08
this O 0 2.9249019206645244e-08
gene O 0 4.500850820932101e-07
in O 0 1.1112950915048714e-07
the O 0 1.6957530135641719e-07
pathogenesis O 0 9.049259824678302e-05
of O 0 5.351176355361531e-07
sporadic B-Disease 0 0.0008954680524766445
T I-Disease 1 0.9428997039794922
- I-Disease 0 0.0004712565569207072
PLL I-Disease 0 0.00035740190651267767
and O 0 5.378475975703623e-07
suggests O 0 4.77770697671076e-07
that O 0 1.4692918881564765e-08
ATM O 0 1.0020896297646686e-05
acts O 0 3.863239271595376e-06
as O 0 4.48604214398074e-06
a O 0 0.00018669103155843914
tumour B-Disease 1 0.9998934268951416
suppressor O 0 0.0033488282933831215
. O 0 2.168498576793354e-05

As O 0 1.3976394939163583e-06
constitutional O 0 3.3469038953626296e-06
DNA O 0 1.8983231484526186e-06
was O 0 2.278104147990234e-06
not O 0 1.3202639870257826e-08
available O 0 3.740307619182204e-08
, O 0 1.3836465484473592e-07
a O 0 1.972389100046712e-06
putative O 0 0.00024089861835818738
hereditary O 1 0.9858371019363403
predisposition O 0 0.009473007172346115
to O 0 7.45380839362042e-06
T B-Disease 1 0.8088982105255127
- I-Disease 0 0.00016406900249421597
PLL I-Disease 0 0.00015897388220764697
will O 0 1.6468672470182355e-07
require O 0 8.849141153177698e-08
further O 0 8.182306743265144e-08
investigation O 0 6.896444233461807e-07
. O 0 2.5024368710546696e-07
. O 0 1.576770387146098e-06

Myotonic B-Disease 1 0.9993364214897156
dystrophy I-Disease 1 0.9994056224822998
protein O 0 8.010090823518112e-05
kinase O 0 7.668081525480375e-05
is O 0 2.462780344103521e-07
involved O 0 6.281254627538146e-08
in O 0 1.1775844299677374e-08
the O 0 1.0672428274460799e-08
modulation O 0 3.3907141983036126e-07
of O 0 1.5584992851813695e-08
the O 0 1.1540101496620991e-07
Ca2 O 0 1.7641210433794186e-05
+ O 0 5.490335024660453e-05
homeostasis O 0 0.004176669288426638
in O 0 7.1395779741578735e-06
skeletal O 0 0.011602774262428284
muscle O 0 0.004602108616381884
cells O 0 7.632291089976206e-05
. O 0 5.548775334318634e-06

Myotonic B-Disease 1 0.9998774528503418
dystrophy I-Disease 1 0.9999721050262451
( O 0 0.0005931710475124419
DM B-Disease 1 0.9998152852058411
) O 0 1.5792263639013981e-06
, O 0 2.992015311065188e-07
the O 0 2.2048530468055105e-07
most O 0 1.6790617110018502e-06
prevalent O 0 0.0004542730748653412
muscular B-Disease 1 0.9985049962997437
disorder I-Disease 1 0.9989637136459351
in O 0 4.674872343457537e-06
adults O 0 6.399966423487058e-06
, O 0 7.415879395011871e-07
is O 0 8.08838990451477e-07
caused O 0 7.704671588726342e-06
by O 0 1.5188386726094905e-07
( O 0 3.469699834113271e-07
CTG O 0 3.255130286561325e-05
) O 0 1.743530759767964e-07
n O 0 1.044531018123962e-05
- O 0 1.0924559319391847e-05
repeat O 0 2.7003345621778863e-06
expansion O 0 5.125707502884325e-07
in O 0 3.108000257157073e-08
a O 0 2.2566739588114615e-08
gene O 0 1.5027215027885177e-08
encoding O 0 2.4615117055759583e-08
a O 0 2.8225173309692764e-07
protein O 0 7.544394975411706e-07
kinase O 0 1.2379082363622729e-05
( O 0 8.645376396998472e-07
DM B-Disease 1 0.7531337141990662
protein O 0 5.268663699098397e-06
kinase O 0 3.089843085035682e-05
; O 0 4.062746086219704e-07
DMPK O 0 8.047453593462706e-05
) O 0 1.0151725859941507e-07
and O 0 1.0979605491456823e-07
involves O 0 3.9774232618583483e-07
changes O 0 1.0461692454555305e-06
in O 0 6.851310558886325e-07
cytoarchitecture O 0 0.00010373029363108799
and O 0 2.9940183594590053e-06
ion O 0 0.0012400845298543572
homeostasis O 1 0.6353119611740112
. O 0 4.176053334958851e-05

To O 0 1.5083475091159926e-07
obtain O 0 2.5700461492306204e-07
clues O 0 1.1326735602779081e-06
to O 0 4.518475194004168e-08
the O 0 9.998265682042984e-08
normal O 0 1.129374254560389e-06
biological O 0 1.1778976158893784e-06
role O 0 3.826692704933521e-07
of O 0 5.700470850911188e-08
DMPK O 0 0.0001017745235003531
in O 0 6.631177029703395e-07
cellular O 0 6.34643729426898e-05
ion O 0 0.0001717399718472734
homeostasis O 0 0.00242282054387033
, O 0 4.42858805627111e-07
we O 0 5.059757413050647e-08
have O 0 3.290965366886667e-08
compared O 0 5.418830255621288e-07
the O 0 1.7501376703421556e-07
resting O 0 2.615153425722383e-05
[ O 0 1.9272247300250456e-06
Ca2 O 0 2.577886789367767e-06
+ O 0 7.831518814782612e-06
] O 0 9.376135494676419e-06
i O 0 3.981035661126953e-06
, O 0 3.905033096884836e-08
the O 0 1.3959296829568757e-08
amplitude O 0 3.025641888143582e-07
and O 0 8.332539636057845e-08
shape O 0 4.328398972575087e-06
of O 0 3.455045600730955e-07
depolarization O 0 5.007519939681515e-05
- O 0 9.485219197813421e-05
induced O 0 6.388875772245228e-05
Ca2 O 0 5.912381311645731e-06
+ O 0 6.422380920412252e-06
transients O 0 2.778745511022862e-05
, O 0 5.117486878702948e-08
and O 0 1.0041396159010674e-08
the O 0 8.827861996962838e-09
content O 0 3.028178596764519e-08
of O 0 5.8458361706925643e-08
ATP O 0 0.0011215893318876624
- O 0 1.803587110771332e-05
driven O 0 4.329171133576892e-06
ion O 0 3.749944517039694e-05
pumps O 0 1.7258873413084075e-05
in O 0 5.038099857301859e-07
cultured O 0 1.7686625142232515e-05
skeletal O 0 0.0007635789224877954
muscle O 0 0.0001930452126543969
cells O 0 3.349410690134391e-06
of O 0 8.112749583233381e-08
wild O 0 6.403641691576922e-06
- O 0 3.476492565823719e-05
type O 0 2.7466296160127968e-05
and O 0 2.4711184778425377e-06
DMPK O 0 0.0006303981645032763
[ O 0 4.239791087456979e-05
- O 0 0.00017025200941134244
/ O 0 0.00021756185742560774
- O 0 0.0005649632657878101
] O 0 7.371672109002247e-05
knockout O 0 0.004206414334475994
mice O 0 0.0003461407031863928
. O 0 5.197161499381764e-06

In O 0 3.886415470333304e-06
vitro O 0 3.534101415425539e-05
- O 0 6.450283399317414e-05
differentiated O 0 2.5551791623001918e-05
DMPK O 0 0.0005004784907214344
[ O 0 2.560103530413471e-05
- O 0 0.00010848461533896625
/ O 0 8.396928751608357e-05
- O 0 9.639997006161138e-05
] O 0 1.0889049917750526e-05
myotubes O 0 6.607375689782202e-05
exhibit O 0 1.7730925492287497e-06
a O 0 8.885891702448134e-07
higher O 0 1.925244305311935e-06
resting O 0 2.6583873477648012e-05
[ O 0 1.3123025155437062e-06
Ca2 O 0 2.561431529102265e-06
+ O 0 5.389852049120236e-06
] O 0 4.723081019619713e-06
i O 0 2.7670484996633604e-06
than O 0 7.021052539357697e-08
do O 0 1.1501273178282645e-07
wild O 0 2.1862961148144677e-06
- O 0 2.4518258214811794e-05
type O 0 1.4989596820669249e-05
myotubes O 0 8.393246389459819e-05
because O 0 2.043808819962578e-07
of O 0 4.821361532236779e-09
an O 0 3.412455029661032e-08
altered O 0 1.6104135056593805e-06
open O 0 2.2338840608426835e-06
probability O 0 2.299506896008552e-08
of O 0 2.738263482626735e-08
voltage O 0 1.0909358934441116e-05
- O 0 1.0458446922712028e-05
dependent O 0 2.522812110328232e-06
l O 0 6.269285950111225e-05
- O 0 1.1623757927736733e-05
type O 0 6.1384407672449015e-06
Ca2 O 0 3.943215233448427e-06
+ O 0 3.5139062219968764e-06
and O 0 4.7188669327624666e-07
Na O 0 3.095667852903716e-05
+ O 0 8.154967872542329e-06
channels O 0 1.3191889593144879e-05
. O 0 5.804255124530755e-06

The O 0 5.765142759628361e-06
mutant O 0 3.795912198256701e-05
myotubes O 0 9.789120667846873e-05
exhibit O 0 2.3512438929174095e-06
smaller O 0 6.21998765382159e-07
and O 0 1.7219726089479082e-07
slower O 0 1.946118800333352e-06
Ca2 O 0 1.0374101293564308e-05
+ O 0 3.4352315196883865e-06
responses O 0 2.9887925734328746e-07
upon O 0 2.6087442961397755e-07
triggering O 0 1.2589068319357466e-05
by O 0 7.555282621751758e-08
acetylcholine O 0 1.979108310479205e-05
or O 0 1.4746593706149724e-06
high O 0 1.2993216842005495e-05
external O 0 1.219086152559612e-05
K O 0 6.323854177026078e-05
+ O 0 6.988016684772447e-05
. O 0 8.511257874488365e-06

In O 0 1.1659769825200783e-06
addition O 0 3.6586916962733085e-07
, O 0 1.1194643434464524e-07
we O 0 4.0851865890090266e-08
observed O 0 2.32020980206471e-07
that O 0 4.1556313945534384e-09
these O 0 8.825118413824384e-09
Ca2 O 0 4.626537702279165e-06
+ O 0 2.6318006348446943e-05
transients O 0 0.00021741875389125198
partially O 0 6.0071932239225134e-05
result O 0 4.1308479126200837e-07
from O 0 4.971782985307982e-08
an O 0 1.1000668820315695e-08
influx O 0 4.335291947654696e-08
of O 0 5.197358987629741e-09
extracellular O 0 2.897672004564811e-07
Ca2 O 0 1.2708311487585888e-06
+ O 0 5.862562488800904e-07
through O 0 5.097963295952468e-08
the O 0 1.7129120521985897e-07
l O 0 1.9367913409951143e-05
- O 0 6.7286764533491805e-06
type O 0 5.344675628293771e-06
Ca2 O 0 5.598201823886484e-06
+ O 0 1.2137360499764327e-05
channel O 0 2.6161213099840097e-05
. O 0 5.015787337470101e-06

Neither O 0 4.918023023492424e-06
the O 0 2.2167823487961869e-07
content O 0 5.637250524159754e-07
nor O 0 1.5961420558596728e-06
the O 0 2.0187613358757517e-07
activity O 0 2.699371748349222e-07
of O 0 5.365597033346603e-08
Na O 0 3.574449510779232e-05
+ O 0 2.2763648303225636e-05
/ O 0 2.246127769467421e-05
K O 0 1.1720399925252423e-05
+ O 0 1.6417394363088533e-05
ATPase O 0 6.643281085416675e-05
and O 0 2.6917728064290714e-06
sarcoplasmic O 0 0.0004678954719565809
reticulum O 0 0.00017077586380764842
Ca2 O 0 2.4448496333207004e-05
+ O 0 3.011653279827442e-05
- O 0 2.5169623768306337e-05
ATPase O 0 3.974904757342301e-05
are O 0 2.204966591534685e-07
affected O 0 1.1704343023666297e-06
by O 0 6.11177085829695e-07
DMPK O 0 0.0025648418813943863
absence O 0 8.954286749940366e-05
. O 0 8.273694220406469e-06

In O 0 1.3170417787478073e-06
conclusion O 0 6.659848281742597e-07
, O 0 6.871032098842988e-08
our O 0 3.240648283053815e-08
data O 0 1.6924555268360564e-07
suggest O 0 4.18403487856267e-07
that O 0 6.656242135250068e-08
DMPK O 0 6.36880868114531e-05
is O 0 2.4096036099763296e-07
involved O 0 2.1957229989766347e-07
in O 0 1.2031696883241239e-07
modulating O 0 9.171972124022432e-06
the O 0 9.715580517877243e-08
initial O 0 4.183144994840404e-07
events O 0 1.5877857606483303e-07
of O 0 8.292695952150098e-08
excitation O 0 7.869832188589498e-05
- O 0 0.00041373909334652126
contraction O 0 4.8577541747363284e-05
coupling O 0 1.7962007405003533e-05
in O 0 1.9397743926674593e-06
skeletal O 0 0.0039025559090077877
muscle O 0 0.0010939013445749879
. O 0 1.153940047515789e-06
. O 0 2.1401547201094218e-06

Constitutional O 0 0.0007724977913312614
RB1 O 0 0.01659373752772808
- O 0 0.00028104468947276473
gene O 0 2.9170911147957668e-05
mutations O 0 6.524034688482061e-05
in O 0 9.050060043591657e-07
patients O 0 3.4829615742637543e-06
with O 0 9.122832693719829e-07
isolated O 0 0.0003201892541255802
unilateral B-Disease 0 0.0007188732270151377
retinoblastoma I-Disease 1 0.5612954497337341
. O 0 2.5717854441609234e-05

In O 0 2.021024101850344e-06
most O 0 7.365090368693927e-07
patients O 0 3.3037438242899952e-06
with O 0 3.4324961006859667e-07
isolated O 0 0.00019588730356190354
unilateral B-Disease 0 0.0003529098175931722
retinoblastoma I-Disease 0 0.2406274825334549
, O 0 1.9356613847776316e-05
tumor B-Disease 0 0.0015362004050984979
development O 0 2.783731360977981e-07
is O 0 1.9334751755195612e-07
initiated O 0 6.994694103923393e-07
by O 0 3.1348154294619235e-08
somatic O 0 3.380502903382876e-06
inactivation O 0 0.00012124636850785464
of O 0 2.3661247183781597e-08
both O 0 7.429031256833696e-08
alleles O 0 1.2117340020267875e-06
of O 0 1.742875639365593e-07
the O 0 3.524780368024949e-06
RB1 O 0 0.005129758268594742
gene O 0 0.00014866882702335715
. O 0 1.7122212739195675e-05

However O 0 7.730924949100881e-07
, O 0 6.409553066077933e-08
some O 0 2.322895875650488e-09
of O 0 1.2717892516889151e-08
these O 0 6.898648763353776e-08
patients O 0 1.5788708651598427e-06
can O 0 2.785287449569296e-07
transmit O 0 8.597121632192284e-05
retinoblastoma B-Disease 0 0.021298052743077278
predisposition O 0 0.00021093232498969883
to O 0 9.921271981738755e-08
their O 0 2.4498729089827975e-07
offspring O 0 2.381849662924651e-05
. O 0 6.004765509715071e-06

To O 0 1.846747892386702e-07
determine O 0 3.013066987023194e-07
the O 0 1.6785689638254553e-07
frequency O 0 5.347102614905452e-06
and O 0 5.220919092607801e-07
nature O 0 3.2095460937853204e-06
of O 0 3.188624475569668e-07
constitutional O 0 6.023898095008917e-05
RB1 O 0 0.004561271984130144
- O 0 0.00010395050776423886
gene O 0 1.4006676792632788e-05
mutations O 0 3.630293576861732e-05
in O 0 8.610628583483049e-07
patients O 0 2.8379797640809556e-06
with O 0 3.7584507595056493e-07
isolated O 0 7.342808385146782e-05
unilateral B-Disease 0 3.2624237064737827e-05
retinoblastoma I-Disease 0 0.0008524479926563799
, O 0 3.587488492939883e-07
we O 0 9.263318645480467e-08
analyzed O 0 4.097977921446727e-07
DNA O 0 6.337598961181357e-07
from O 0 2.48323260620964e-07
peripheral O 0 5.378257264965214e-05
blood O 0 0.00011636610724963248
and O 0 2.3182155928225257e-06
from O 0 1.2127606169087812e-05
tumor B-Disease 1 0.8432037830352783
tissue O 0 0.0022524890955537558
. O 0 9.543917258270085e-06

The O 0 2.181874378948123e-06
analysis O 0 1.9400131350266747e-06
of O 0 1.9178046386514325e-06
tumors B-Disease 1 0.9998592138290405
from O 0 2.2449128209700575e-06
54 O 0 4.6117934289213736e-06
( O 0 2.0521447652299685e-07
71 O 0 1.2385982017804054e-06
% O 0 1.4873715592500503e-08
) O 0 1.3394855891135649e-08
of O 0 1.9802731898721504e-08
76 O 0 6.0450488490459975e-06
informative O 0 1.0314801329514012e-05
patients O 0 5.050932668382302e-05
showed O 0 3.17696321872063e-05
loss O 0 8.833568426780403e-05
of O 0 5.5597166692678e-07
constitutional O 0 0.00029276622808538377
heterozygosity O 0 0.010399054735898972
( O 0 3.501553874230012e-05
LOH O 1 0.9906918406486511
) O 0 2.33564674090303e-06
at O 0 3.197247860953212e-05
intragenic O 0 0.0003095338761340827
loci O 0 0.0001114621409215033
. O 0 8.034971870074514e-06

Three O 0 2.0981899524485925e-06
of O 0 7.675020583519654e-07
13 O 0 3.737848237506114e-05
uninformative O 0 0.042370717972517014
patients O 0 0.00020121701527386904
had O 0 1.6555657566641457e-05
constitutional O 0 4.331387754064053e-05
deletions O 0 0.00037994739250279963
. O 0 1.983232687052805e-05

For O 0 6.163849093354656e-07
39 O 0 5.778584181825863e-06
randomly O 0 2.7333851448929636e-06
selected O 0 6.113838935561944e-06
tumors B-Disease 1 0.9998668432235718
, O 0 2.42464534494502e-06
SSCP O 0 0.0005679105524905026
, O 0 1.9000220845555305e-06
hetero O 0 0.00018705043476074934
- O 0 4.35714318882674e-05
duplex O 0 6.030403892509639e-05
analysis O 0 2.9637135412485804e-07
, O 0 3.8295102200436304e-08
sequencing O 0 1.679167809243154e-07
, O 0 1.1807763655724557e-07
and O 0 7.939796375922015e-08
Southern O 0 9.051907454704633e-07
blot O 0 3.263410326326266e-05
analysis O 0 7.052957329278797e-08
were O 0 3.0306804177371305e-08
used O 0 3.4241388391365035e-08
to O 0 6.609168679005961e-08
identify O 0 3.3073627037083497e-06
mutations O 0 0.0001380452886223793
. O 0 8.73679164214991e-06

Mutations O 0 0.00013410519750323147
were O 0 8.053083888626134e-07
detected O 0 1.7029813534463756e-05
in O 0 1.522629844430412e-07
21 O 0 8.507935262969113e-07
( O 0 5.7441397416369e-08
91 O 0 6.724313266204263e-07
% O 0 1.1463522575638763e-08
) O 0 3.417770244595886e-08
of O 0 2.463559951593197e-07
23 O 0 0.0021062372252345085
tumors B-Disease 1 0.9999746084213257
with O 0 0.00024230444978456944
LOH O 1 0.9992244243621826
. O 0 7.801463652867824e-05

In O 0 3.293906047474593e-06
6 O 0 3.396693500690162e-06
( O 0 1.0605386790984994e-07
38 O 0 5.070955353403406e-07
% O 0 1.3573342450001746e-08
) O 0 3.973941886670218e-08
of O 0 2.7113432565784024e-07
16 O 0 0.0004721338045783341
tumors B-Disease 1 0.9999704360961914
without O 0 3.346546509419568e-05
LOH O 1 0.9928056597709656
, O 0 5.04479260143853e-07
one O 0 1.2464337828532734e-07
mutation O 0 2.3856753159634536e-06
was O 0 2.3744444206386106e-06
detected O 0 4.241949227434816e-06
, O 0 2.8237899130090227e-08
and O 0 3.465466136276518e-08
in O 0 9.401426837030158e-08
9 O 0 1.6377999827454914e-06
( O 0 7.320707595681597e-08
56 O 0 4.959154011885403e-07
% O 0 2.0877312323364094e-08
) O 0 3.7159029631084195e-08
of O 0 8.241135418529666e-08
the O 0 2.9167322281864472e-05
tumors B-Disease 1 0.999980092048645
without O 0 5.22116242791526e-05
LOH O 1 0.9948627352714539
, O 0 6.374927465913061e-07
both O 0 1.730731469251623e-07
mutations O 0 7.103108146111481e-06
were O 0 3.766912186620175e-07
found O 0 2.3185252757684793e-06
. O 0 2.15179352380801e-06

Thus O 0 4.612448719854001e-06
, O 0 2.562794350069453e-07
a O 0 1.5126288133160415e-07
total O 0 2.414491007129982e-08
of O 0 2.5081176246999348e-08
45 O 0 3.047677239464974e-07
mutations O 0 2.674072447916842e-06
were O 0 2.5498368927401316e-07
identified O 0 2.084613470287877e-06
in O 0 4.456705028133001e-06
tumors B-Disease 1 0.9999089241027832
of O 0 1.861425289462204e-06
36 O 0 3.896030466421507e-05
patients O 0 4.813999839825556e-05
. O 0 3.7518582303164294e-06

Thirty O 0 2.6185394744970836e-05
- O 0 2.3619828425580636e-05
nine O 0 4.6870678716004477e-07
of O 0 2.4577115453894294e-08
the O 0 1.9742850554393954e-07
mutations O 0 8.741275451029651e-06
- O 0 6.055457561160438e-06
including O 0 2.1915788295245875e-07
34 O 0 9.751836387295043e-07
small O 0 2.988906828704785e-07
mutations O 0 1.1927023479074705e-05
, O 0 1.967343905562302e-07
2 O 0 4.5266051529324614e-07
large O 0 4.880328106082743e-07
structural O 0 0.00022300136333797127
alterations O 0 0.00018164172070100904
, O 0 1.0924225080088945e-06
and O 0 6.675306281067606e-07
hypermethylation O 0 0.0007321156444959342
in O 0 6.162929821584839e-06
3 O 0 0.00022915116278454661
tumors O 1 0.9998739957809448
- O 0 3.560113691492006e-05
were O 0 1.6602966468326485e-07
not O 0 2.514248542695441e-08
detected O 0 2.9140408059902256e-06
in O 0 1.2291693884947108e-08
the O 0 3.965900674529621e-08
corresponding O 0 4.1006211404237547e-07
peripheral O 0 9.446063631912693e-05
blood O 0 0.0003074372070841491
DNA O 0 5.063293065177277e-05
. O 0 5.7701918194652535e-06

In O 0 1.986753886740189e-06
6 O 0 4.539459041552618e-06
( O 0 1.0415863727075703e-07
17 O 0 4.5650631363969296e-07
% O 0 1.24818075875055e-08
) O 0 6.94282720203887e-09
of O 0 8.431706000067152e-09
the O 0 1.7888339698401978e-07
36 O 0 2.884167543015792e-06
patients O 0 1.0385209634478088e-06
, O 0 4.2834933822177845e-08
a O 0 4.654133363146684e-07
mutation O 0 8.39890526549425e-06
was O 0 5.596044957201229e-06
detected O 0 9.316045179730281e-06
in O 0 8.050199795661683e-08
constitutional O 0 4.3179622366551484e-07
DNA O 0 4.6244238660619885e-07
, O 0 6.778016370390105e-08
and O 0 3.037266083083523e-08
1 O 0 1.4981232254740462e-07
of O 0 1.0045802412150806e-08
these O 0 2.971693646713902e-08
mutations O 0 4.529495527094696e-06
is O 0 7.804693780144589e-08
known O 0 2.8968707965759677e-07
to O 0 3.419595984155421e-08
be O 0 9.399509082186341e-08
associated O 0 4.1875958345372055e-07
with O 0 3.891582878168265e-07
reduced O 0 2.7170037355972454e-05
expressivity O 0 0.009334801696240902
. O 0 2.0434774341993034e-05

The O 0 1.460233875150152e-06
presence O 0 1.6522487840120448e-06
of O 0 1.261697661902872e-07
a O 0 2.308622924829251e-06
constitutional O 0 9.537247933621984e-06
mutation O 0 1.788937152014114e-05
was O 0 3.0013798095751554e-06
not O 0 3.048304719754924e-08
associated O 0 6.215659453800981e-08
with O 0 2.680572208646481e-08
an O 0 1.0821657525639239e-07
early O 0 3.3702183372952277e-06
age O 0 1.0212517736363225e-05
at O 0 7.10127642378211e-05
treatment O 0 8.848692959873006e-05
. O 0 3.7426023027364863e-06

In O 0 6.18838475929806e-06
1 O 0 1.367705044685863e-05
patient O 0 3.428407944738865e-05
, O 0 5.639078608510317e-07
somatic O 0 1.882908691186458e-05
mosaicism O 0 0.0010709126945585012
was O 0 8.872073522070423e-06
demonstrated O 0 5.22884192832862e-07
by O 0 1.6278599801466953e-08
molecular O 0 1.0624899005051702e-06
analysis O 0 5.6906827694547246e-08
of O 0 1.3493605344194748e-08
DNA O 0 8.836345273266488e-07
and O 0 1.6232998234499973e-07
RNA O 0 3.9600081436219625e-06
from O 0 4.99756765748316e-07
peripheral O 0 0.00023165062884800136
blood O 0 0.0013370112283155322
. O 0 1.1309842193441e-05

In O 0 5.007222171116155e-06
2 O 0 7.376207122433698e-06
patients O 0 2.0064442196598975e-06
without O 0 3.2578216746514954e-07
a O 0 1.7972263322008075e-06
detectable O 0 0.00012781511759385467
mutation O 0 1.3128359569236636e-05
in O 0 4.37156160160157e-07
peripheral O 0 0.00013594554911833256
blood O 0 0.0007952856249175966
, O 0 4.3615814320219215e-06
mosaicism O 0 0.0006731712492182851
was O 0 3.1030489481054246e-05
suggested O 0 1.6311441868310794e-06
because O 0 4.6959715405137104e-07
1 O 0 6.999618449299305e-07
of O 0 8.459771549951256e-08
the O 0 2.2474532670457847e-06
patients O 0 0.00013463861250784248
showed O 0 0.0007285223109647632
multifocal O 1 0.9998447895050049
tumors B-Disease 1 0.9999969005584717
and O 0 8.382735927625617e-07
the O 0 6.511917405305212e-08
other O 0 2.8245494831935503e-08
later O 0 6.028308803252003e-07
developed O 0 2.482082209098735e-06
bilateral B-Disease 0 0.00019243618589825928
retinoblastoma I-Disease 0 0.28938940167427063
. O 0 7.03975820215419e-05

In O 0 1.452276137570152e-06
conclusion O 0 1.5672565041313646e-06
, O 0 1.9836554088215053e-07
our O 0 6.379233497000314e-08
results O 0 1.848739117349396e-07
emphasize O 0 3.0875983725309197e-07
that O 0 1.1654223364132577e-08
the O 0 6.247214656696087e-08
manifestation O 0 7.065733825584175e-06
and O 0 5.847196575814451e-07
transmissibility O 0 6.412852235371247e-05
of O 0 1.4193064146184042e-07
retinoblastoma B-Disease 0 0.00012763314589392394
depend O 0 5.790703880848014e-07
on O 0 7.676857762817235e-07
the O 0 7.250587685803112e-08
nature O 0 3.414457694361772e-07
of O 0 1.2295914508797523e-08
the O 0 7.924092670918981e-08
first O 0 3.6623990240514104e-07
mutation O 0 1.0362672355768154e-06
, O 0 2.324634351680288e-08
its O 0 7.861343576109903e-09
time O 0 4.172168743821203e-08
in O 0 1.5250327223270688e-08
development O 0 2.009184463247493e-08
, O 0 2.7685443271252552e-08
and O 0 1.0327688926281553e-08
the O 0 1.2353248202146005e-08
number O 0 8.204525947519414e-09
and O 0 2.454226333270526e-08
types O 0 1.1239936981155552e-07
of O 0 2.553306188701754e-08
cells O 0 4.5656119596060307e-07
that O 0 2.2981039293767935e-08
are O 0 1.9400610895559112e-08
affected O 0 6.494663580269844e-07
. O 0 4.0280860957864206e-07
. O 0 1.0298850838807994e-06

Hereditary B-Disease 1 0.9998465776443481
deficiency I-Disease 1 0.9999264478683472
of I-Disease 0 6.506014642582159e-07
the I-Disease 0 6.929440701242129e-07
fifth I-Disease 0 1.30462622109917e-05
component I-Disease 0 1.762785700520908e-06
of I-Disease 0 2.8846349309219477e-08
complement I-Disease 0 1.0587060614852817e-06
in O 0 1.2655580121645471e-06
man O 0 0.0001355838612653315
. O 0 4.774277840624563e-06

I O 0 0.01909649185836315
. O 0 2.991872861457523e-05

Clinical O 0 0.00036870664916932583
, O 0 3.725878741533961e-06
immunochemical O 0 0.00015528337098658085
, O 0 8.182086048691417e-07
and O 0 6.22802474481432e-07
family O 0 6.223872333066538e-06
studies O 0 2.2748499759472907e-06
. O 0 3.97299072574242e-06

The O 0 4.1204333456335007e-07
first O 0 6.994093268986035e-07
recognized O 0 1.9022993456019321e-06
human O 0 6.4783598645590246e-06
kindred O 0 0.0027638119645416737
with O 0 0.0003719324595294893
hereditary B-Disease 1 0.9999855756759644
deficiency I-Disease 1 0.9999678134918213
of I-Disease 0 4.0674680690244713e-07
the I-Disease 0 7.788942752995354e-07
fifth I-Disease 0 1.8928396457340568e-05
component I-Disease 0 1.992218130908441e-06
of I-Disease 0 4.830403455002852e-08
complement I-Disease 0 1.8784251096803928e-06
( O 0 2.157405106117949e-06
C5 O 0 0.0006428983760997653
) O 0 5.802489795314614e-07
is O 0 8.077867619249446e-07
described O 0 1.2347155461611692e-05
. O 0 3.3030853501259116e-06

The O 0 3.488606353130308e-06
proband O 0 0.00012282124953344464
, O 0 5.47080787782761e-07
a O 0 8.427696798207762e-07
20 O 0 1.8087879425365827e-06
- O 0 1.4881022252666298e-05
year O 0 1.3385071042648633e-06
- O 0 3.5907327401218936e-05
old O 0 4.293090387363918e-05
black O 0 2.0049934391863644e-05
female O 0 1.3895529264118522e-05
with O 0 0.0002647500659804791
systemic B-Disease 1 0.9999953508377075
lupus I-Disease 1 0.9999754428863525
erythematosus I-Disease 1 0.9999758005142212
since O 0 0.0015994665445759892
age O 0 6.736908107995987e-05
11 O 0 4.803704086953076e-06
, O 0 6.058180019863357e-07
lacked O 0 2.708983447519131e-05
serum O 0 0.0003195933240931481
hemolytic O 1 0.9055713415145874
complement O 0 5.586985025729518e-06
activity O 0 2.365480668231612e-06
, O 0 2.3436942342414113e-07
even O 0 6.49042192435445e-07
during O 0 1.7354632291244343e-05
remission O 0 0.0005526253371499479
. O 0 5.592769412032794e-06

C5 O 0 0.04167456924915314
was O 0 0.00019170694577042013
undetectable O 0 0.00037158411578275263
in O 0 5.973153065497172e-07
her O 0 1.2226454373376328e-06
serum O 0 4.5342026169237215e-06
by O 0 2.5085338251074063e-08
both O 0 1.4249498292429053e-07
immunodiffusion O 0 0.0005559256533160806
and O 0 1.201858412969159e-05
hemolytic O 1 0.9978445768356323
assays O 0 0.0003261365054640919
. O 0 1.5873478332650848e-05

Other O 0 5.618583998057147e-08
complement O 0 2.7347985565029376e-07
components O 0 1.1205596592844813e-06
were O 0 4.2169955349891097e-07
normal O 0 3.44876866620325e-06
during O 0 9.841350220085587e-06
remission O 0 0.00021837362146470696
of O 0 6.392607474481338e-07
lupus O 1 0.9978267550468445
, O 0 1.9012148868569057e-06
but O 0 6.969284527258424e-07
C1 O 0 0.00047854261356405914
, O 0 1.3990544402986416e-06
C4 O 0 0.0006904528709128499
, O 0 2.2324954898067517e-06
C2 O 0 0.00023388081172015518
, O 0 3.849363849894871e-07
and O 0 7.474227459169924e-07
C3 O 0 0.008502797223627567
levels O 0 9.784137364476919e-05
fell O 0 0.01950429193675518
during O 0 3.398639091756195e-05
exacerbations O 0 0.02327711135149002
. O 0 1.5100103155418765e-05

A O 0 1.4465644198935479e-05
younger O 0 5.998263532092096e-06
half O 0 1.822420017560944e-06
- O 0 3.7450845411513e-05
sister O 0 4.783686017617583e-05
, O 0 1.1112289257653174e-06
who O 0 1.7973959529626882e-06
had O 0 2.5479755549895344e-06
no O 0 4.544795956462622e-06
underlying O 0 0.0007620821124874055
disease O 1 0.9908964037895203
, O 0 1.0410407185190707e-06
was O 0 8.975421224022284e-06
also O 0 1.2126641024678975e-07
found O 0 1.1714210046420703e-07
to O 0 5.2535735761694013e-08
lack O 0 8.681443432578817e-06
immunochemically O 0 0.008995484560728073
detectable O 0 0.04451076686382294
C5 O 0 0.14524108171463013
. O 0 3.461381493252702e-05

By O 0 3.7322635762393475e-05
hemolytic O 1 0.9920143485069275
assay O 0 0.0001803755876608193
, O 0 1.2297693956497824e-06
she O 0 1.0481085155333858e-06
exhibited O 0 2.137486717401771e-06
1 O 0 9.260515412279346e-07
- O 0 2.3512750431109453e-06
2 O 0 2.6719004608821706e-07
% O 0 5.346409537310137e-09
of O 0 5.4684896610979195e-09
the O 0 6.160939136634624e-08
normal O 0 8.06232765171444e-06
serum O 0 3.252076930948533e-05
C5 O 0 0.0001506797270849347
level O 0 3.4674344533414114e-06
and O 0 1.764439474527535e-07
normal O 0 1.1625913884927286e-06
concentrations O 0 1.5131148529690108e-06
of O 0 7.2347536850259075e-09
other O 0 8.089553027446073e-09
complement O 0 6.449962484111893e-07
components O 0 1.7894319171318784e-05
. O 0 7.892754183558282e-06

C5 O 0 0.01498777512460947
levels O 0 3.9245831430889666e-05
of O 0 1.0871142563928515e-07
other O 0 6.545015196479653e-08
family O 0 6.246220323191665e-07
members O 0 2.810383925577753e-08
were O 0 3.845092777510217e-08
either O 0 6.910909888802053e-08
normal O 0 6.736013915542571e-07
or O 0 1.808819263260375e-07
approximately O 0 9.016878266265849e-08
half O 0 4.923269898426952e-07
- O 0 1.204100226459559e-05
normal O 0 4.012338649772573e-06
, O 0 3.264240717726352e-07
consistent O 0 1.6481538978041499e-06
with O 0 1.695869173090614e-06
autosomal O 1 0.8907918334007263
codominant O 0 0.0043404982425272465
inheritance O 0 5.57742896489799e-05
of O 0 3.2482972756042727e-07
the O 0 2.342711468372727e-06
gene O 0 0.00020267309446353465
determining O 0 0.002425933023914695
C5 B-Disease 1 0.9999680519104004
deficiency I-Disease 1 0.9999946355819702
. O 0 0.00012995510769542307

Normal O 0 0.0024502314627170563
hemolytic O 1 0.9948123693466187
titers O 0 0.004232182167470455
were O 0 1.5076758472787333e-06
restored O 0 9.851934009930119e-06
to O 0 1.8304726268070226e-07
both O 0 2.4308133106387686e-06
homozygous O 0 0.000765086617320776
C5 B-Disease 1 0.9996160268783569
- I-Disease 1 0.9984616041183472
deficient I-Disease 1 0.9994584918022156
( O 0 7.030835695331916e-05
C5D B-Disease 1 0.9987503290176392
) O 0 2.4373871383431833e-06
sera O 0 8.76147169037722e-05
by O 0 2.776603835741298e-08
addition O 0 1.1608924666006715e-07
of O 0 6.150161624418615e-08
highly O 0 7.366709724010434e-06
purified O 0 5.6788430811138824e-05
human O 0 4.246022581355646e-05
C5 O 0 0.013317037373781204
. O 0 1.3495310668076854e-05

In O 0 1.973860435100505e-06
specific O 0 1.0873978908421122e-06
C5 O 0 0.0031292112544178963
titrations O 0 0.001203772029839456
, O 0 1.4447281273533008e-06
however O 0 2.5005951442835794e-07
, O 0 8.901177750431088e-08
it O 0 4.8115616380073334e-08
was O 0 1.7325608041574014e-06
noted O 0 1.4010997517743817e-07
that O 0 4.143735576889185e-09
when O 0 3.297374107091855e-08
limited O 0 2.3224938416888108e-08
amounts O 0 2.198570570044467e-07
of O 0 8.269304174746139e-08
C5 O 0 0.00012033723032800481
were O 0 1.6137606451138709e-07
assayed O 0 1.7720731193549e-06
in O 0 3.900998279959822e-08
the O 0 2.263701048832445e-08
presence O 0 1.7945923502793448e-07
of O 0 7.801835977261362e-08
low O 0 3.05334287986625e-05
dilutions O 0 0.00024100496375467628
of O 0 6.737247417731851e-07
either O 0 3.984973591286689e-05
C5D B-Disease 1 0.9997581839561462
serum O 0 0.00043867924250662327
, O 0 3.7502658756238816e-07
curving O 0 5.214398697717115e-06
rather O 0 1.2154579565049062e-07
than O 0 7.80439535219557e-08
linear O 0 3.267481361035607e-06
dose O 0 4.7514426114503294e-05
- O 0 1.334224725724198e-05
response O 0 7.743764172118972e-07
plots O 0 1.0423370895296102e-06
were O 0 1.9073844725880917e-07
consistently O 0 1.915201892188634e-06
obtained O 0 3.1570229452881904e-07
, O 0 9.329242800504289e-08
suggesting O 0 5.317894533618528e-07
some O 0 3.928700564870269e-08
inhibitory O 0 8.120789971144404e-06
effect O 0 1.010478717944352e-05
. O 0 2.3429661268892232e-06

Further O 0 2.153183231712319e-06
studies O 0 9.234702815774654e-07
suggested O 0 1.333128466285416e-06
that O 0 7.249979461221301e-08
low O 0 2.3064680135576054e-05
dilutions O 0 0.0006063943728804588
of O 0 5.787617737951223e-06
C5D B-Disease 1 0.9993352293968201
serum O 0 9.540972678223625e-05
contain O 0 8.441476211373811e-07
a O 0 1.1456176025603781e-06
factor O 0 1.2600975196619402e-06
( O 0 1.53635838273658e-07
or O 0 2.9336467832763446e-07
factors O 0 2.0228894470619707e-07
) O 0 5.967675065221556e-08
interfering O 0 3.3897974844876444e-06
at O 0 4.6635623220936395e-06
some O 0 1.8601916451643774e-08
step O 0 2.0474387838476105e-06
in O 0 2.0354370633413055e-07
the O 0 7.761670985928504e-07
hemolytic O 1 0.9860904216766357
assay O 0 4.940144208376296e-05
of O 0 3.3187259873557196e-07
C5 O 0 0.0010162759572267532
, O 0 1.1489905205053219e-07
rather O 0 3.0241498194527594e-08
than O 0 4.160312272460942e-08
a O 0 6.229248583622393e-07
true O 0 4.7725388867547736e-06
C5 O 0 0.0021325862035155296
inhibitor O 0 9.325062274001539e-05
or O 0 7.3822166086756624e-06
inactivator O 0 0.0010602191323414445
. O 0 1.3323149687494151e-05

Of O 0 3.100731873928453e-06
clinical O 0 3.423546877456829e-05
interest O 0 5.617940246338549e-07
are O 0 3.695843275863808e-08
( O 0 7.675811986018743e-08
a O 0 2.746170082446042e-07
) O 0 4.805783504480132e-08
the O 0 6.512526340429758e-08
documentation O 0 2.4964540443761507e-06
of O 0 6.03394391873735e-06
membranous O 1 0.9993322491645813
glomerulonephritis B-Disease 1 0.9999886751174927
, O 0 0.28298014402389526
vasculitis B-Disease 1 0.9999889135360718
, O 0 0.0004907544935122132
and O 0 0.024142727255821228
arthritis B-Disease 1 0.9999988079071045
in O 0 6.145530164758384e-07
an O 0 8.802041406852368e-08
individual O 0 9.035281323122035e-08
lacking O 0 2.2940388589631766e-05
C5 O 0 0.003234797390177846
( O 0 2.5105640588662936e-07
and O 0 6.304276212176774e-08
its O 0 4.006057352512471e-08
biologic O 0 5.511647032108158e-06
functions O 0 3.424616181746387e-07
) O 0 9.241894360911829e-08
, O 0 9.017377067266352e-08
and O 0 8.58793143265757e-08
( O 0 1.9068642131969682e-07
b O 0 2.2112997157819336e-06
) O 0 5.4387736980743284e-08
a O 0 3.001864286034106e-07
remarkable O 0 6.126434072939446e-06
propensity O 0 0.00015296964556910098
to O 0 1.6507479813299142e-05
bacterial B-Disease 1 0.999922513961792
infections I-Disease 1 0.9999765157699585
in O 0 9.217280876328005e-07
the O 0 3.351531177031575e-07
proband O 0 8.312019781442359e-05
, O 0 4.6693645572304376e-07
even O 0 1.795418995698128e-07
during O 0 1.1282007790214266e-06
periods O 0 1.3490358696799376e-06
of O 0 8.226153624946164e-08
low O 0 4.906906542601064e-05
- O 0 4.615934085450135e-05
dose O 0 8.66710706759477e-06
or O 0 2.391148257174791e-07
alternate O 0 1.0357238124925061e-06
- O 0 0.00012753388728015125
day O 0 1.552043431729544e-05
corticosteroid O 0 0.0027356119826436043
therapy O 0 0.00028132909210398793
. O 0 3.5085620311292587e-06

Other O 0 2.7746537512030045e-07
observations O 0 4.438665200723335e-06
indicate O 0 1.8705453612710699e-06
that O 0 9.42291578098775e-08
the O 0 8.755506542001967e-07
C5D B-Disease 1 0.9983017444610596
state O 0 6.573977771040518e-07
is O 0 3.755190292054067e-08
compatible O 0 1.744054429764219e-07
with O 0 1.8883763175381318e-07
normal O 0 5.251036782283336e-06
coagulation O 0 2.2637525034951977e-05
function O 0 5.571457108999311e-07
and O 0 6.895741222479046e-08
the O 0 3.736492715233908e-08
capacity O 0 4.083099724994099e-07
to O 0 1.0999791300037032e-07
mount O 0 4.951109804096632e-05
a O 0 4.329310468165204e-05
neutrophilic O 1 0.8703319430351257
leukocytosis O 1 0.9620139002799988
during O 0 0.002059169812127948
pyogenic B-Disease 1 0.9571613669395447
infection I-Disease 1 0.9777424931526184
. O 0 2.1261787424009526e-06
. O 0 3.10294149130641e-06

Susceptibility O 0 0.034045808017253876
to O 0 0.0006210585706867278
ankylosing B-Disease 1 0.9999973773956299
spondylitis I-Disease 1 0.9999998807907104
in O 0 0.0004962899256497622
twins O 0 0.004622354172170162
: O 0 1.5822806176402082e-07
the O 0 1.3894695172211868e-08
role O 0 8.155647890362161e-08
of O 0 2.0597870076244362e-08
genes O 0 6.320559577943641e-07
, O 0 8.116446110761899e-07
HLA O 0 3.599396222853102e-05
, O 0 3.920332574125496e-07
and O 0 2.8249544925529335e-07
the O 0 9.123207291850122e-07
environment O 0 2.4873925212887116e-05
. O 0 6.378457328537479e-06

OBJECTIVE O 0 5.627717655443121e-06
To O 0 7.145097669081224e-08
determine O 0 9.83620012107167e-08
the O 0 1.0063180155839291e-07
relative O 0 1.4853666243652697e-06
effects O 0 6.491668955277419e-06
of O 0 1.0563314845057903e-07
genetic O 0 1.3420063623925671e-05
and O 0 6.96559027346666e-07
environmental O 0 4.292590347176883e-06
factors O 0 6.381977755154367e-07
in O 0 1.3292856237967499e-06
susceptibility O 0 0.000550749886315316
to O 0 0.0002670407120604068
ankylosing B-Disease 1 0.9999991655349731
spondylitis I-Disease 1 1.0
( O 0 0.00039189119706861675
AS B-Disease 1 0.9976288676261902
) O 0 2.682222202565754e-06
. O 0 3.1071404009708203e-06

METHODS O 0 5.420866364147514e-05
Twins O 0 0.0002481456031091511
with O 0 1.153150265054137e-06
AS B-Disease 0 0.09368199110031128
were O 0 3.884700845446787e-07
identified O 0 6.832440249127103e-07
from O 0 9.333478345752155e-08
the O 0 2.6718086587607104e-07
Royal O 0 0.0003954174171667546
National O 0 0.00028991143335588276
Hospital O 0 0.4450518786907196
for O 0 0.00014511580229736865
Rheumatic B-Disease 1 0.9999738931655884
Diseases I-Disease 1 0.9997001886367798
database O 0 0.0002921422419603914
. O 0 3.6655303119914606e-05

Clinical O 0 0.00024676212342455983
and O 0 1.2902629578093183e-06
radiographic O 0 0.00022914832516107708
examinations O 0 1.6273361325147562e-05
were O 0 3.710747762397659e-07
performed O 0 1.951099420693936e-06
to O 0 8.337706702832293e-08
establish O 0 2.6448649350641062e-06
diagnoses O 0 0.0009103284101001918
, O 0 5.818209956487408e-06
and O 0 4.4381220504874364e-05
disease O 1 0.9988622665405273
severity O 0 0.00409941328689456
was O 0 2.1439916963572614e-05
assessed O 0 1.2641104376598378e-06
using O 0 1.20510591727907e-07
a O 0 5.43964461030555e-07
combination O 0 2.808854333125055e-06
of O 0 1.2767138457547844e-07
validated O 0 6.564107025042176e-06
scoring O 0 5.183203484193655e-06
systems O 0 0.0002403406542725861
. O 0 1.5403358702315018e-05

HLA O 0 0.0020413908641785383
typing O 0 0.00016063248040154576
for O 0 3.1007703000796027e-06
HLA O 0 0.00046802169526927173
- O 0 0.00011320349585730582
B27 O 0 8.53526871651411e-05
, O 0 1.8755703194983653e-06
HLA O 0 5.288511238177307e-05
- O 0 1.7757474779500626e-05
B60 O 0 1.8100588931702077e-05
, O 0 4.752091911086609e-07
and O 0 1.1697335366989137e-06
HLA O 0 0.000541212793905288
- O 0 0.00043433954124338925
DR1 O 0 0.007644173223525286
was O 0 1.970315679500345e-05
performed O 0 1.0164799277845304e-06
by O 0 3.404627335612531e-08
polymerase O 0 2.722038061619969e-06
chain O 0 3.880712029058486e-06
reaction O 0 4.943340172758326e-07
with O 0 6.647677963655951e-08
sequence O 0 5.118541253068543e-07
- O 0 1.8144011164622498e-06
specific O 0 3.631160794270727e-08
primers O 0 2.887508571802755e-06
, O 0 2.438009687466547e-07
and O 0 2.457658183629974e-07
zygosity O 0 0.00018881671712733805
was O 0 1.3250051779323258e-05
assessed O 0 5.191538548388053e-06
using O 0 2.0181410036457237e-06
microsatellite O 0 0.0006561329355463386
markers O 0 0.00031060786568559706
. O 0 1.8669417841010727e-05

Genetic O 0 0.00023567270545754582
and O 0 1.953106220753398e-06
environmental O 0 2.401925030426355e-06
variance O 0 2.652632531408017e-07
components O 0 1.3476136473400402e-06
were O 0 3.1321050641963666e-07
assessed O 0 1.9373599116079276e-06
with O 0 7.062514839617506e-08
the O 0 1.9594666866851185e-07
program O 0 1.1906564623131999e-06
Mx O 0 4.2945473978761584e-05
, O 0 3.248073809913876e-08
using O 0 1.0271563155583863e-08
data O 0 4.087524629881045e-08
from O 0 1.652921177708322e-08
this O 0 4.885857496361723e-09
and O 0 2.7702929727979608e-08
previous O 0 2.1804899574817682e-07
studies O 0 8.189894629140326e-08
of O 0 8.929371375643314e-08
twins O 0 0.0001379271416226402
with O 0 1.44959722092608e-06
AS B-Disease 1 0.9960201382637024
. O 0 1.3846703950548545e-05

RESULTS O 0 1.9000848624273203e-05
Six O 0 8.790194101493398e-07
of O 0 1.9539841389359935e-07
8 O 0 1.3893197319703177e-05
monozygotic O 0 0.00035012871376238763
( O 0 3.898695467796642e-06
MZ O 0 0.006763168144971132
) O 0 1.217472345160786e-06
twin O 0 9.341046097688377e-05
pairs O 0 1.0507363185752183e-05
were O 0 4.621201696863864e-06
disease O 0 0.011114363558590412
concordant O 0 3.874935646308586e-05
, O 0 2.1706263453324937e-07
compared O 0 2.2843951796858164e-07
with O 0 6.088442461305021e-08
4 O 0 8.371167723453254e-07
of O 0 7.149432690312096e-08
15 O 0 1.5652669844712364e-06
B27 O 0 4.38189490523655e-05
- O 0 5.4680400353390723e-05
positive O 0 1.7928422266777488e-06
dizygotic O 0 0.0002279278851347044
( O 0 2.0033273813169217e-06
DZ O 0 0.0012201453791931272
) O 0 4.353771316800703e-07
twin O 0 2.9710487069678493e-05
pairs O 0 2.404652605036972e-06
( O 0 1.836270513422278e-07
27 O 0 8.517554874742927e-07
% O 0 1.0145702056263417e-08
) O 0 9.398644529312605e-09
and O 0 1.99606731143831e-08
4 O 0 3.9935386553224816e-07
of O 0 8.882607005489263e-08
32 O 0 6.488864983111853e-06
DZ O 0 0.004287772811949253
twin O 0 0.00017771241255104542
pairs O 0 3.360535401952802e-06
overall O 0 1.4529147165376344e-06
( O 0 9.113409760175273e-08
12 O 0 2.480269358784426e-07
. O 0 3.849260465926818e-08
5 O 0 3.8964330428825633e-07
% O 0 5.033786720787248e-08
) O 0 1.8624182018811553e-07
. O 0 1.0077410479425453e-06

Nonsignificant O 0 0.002391122281551361
increases O 0 1.4376085346157197e-05
in O 0 2.3547191574380122e-07
similarity O 0 3.4905491475001327e-07
with O 0 1.4258239389164373e-07
regard O 0 6.179623142088531e-07
to O 0 2.4752031890784565e-07
age O 0 2.1858271793462336e-05
at O 0 0.0012066552881151438
disease O 1 0.9491036534309387
onset O 0 0.0005060632829554379
and O 0 1.4636898981734703e-07
all O 0 2.244363273007366e-08
of O 0 8.483427649252917e-08
the O 0 7.258720870595425e-06
disease O 1 0.9946966171264648
severity O 0 0.0003869159845635295
scores O 0 3.9292435758397914e-06
assessed O 0 2.4926430342020467e-06
were O 0 2.617928203108022e-07
noted O 0 2.351876219108817e-06
in O 0 4.974177045369288e-06
disease O 1 0.993777871131897
- O 0 0.011014469899237156
concordant O 0 0.004995856434106827
MZ O 1 0.7551897168159485
twins O 0 0.002527238568291068
compared O 0 1.4298657333711162e-05
with O 0 3.3643577808106784e-06
concordant O 0 0.01437582727521658
DZ O 1 0.9915724992752075
twins O 0 0.2173248678445816
. O 0 1.8266766346641816e-05

HLA O 0 0.007076713256537914
- O 0 0.00040272067417390645
B27 O 0 8.758564217714593e-05
and O 0 7.842571676519583e-07
B60 O 0 1.4871559869789053e-05
were O 0 2.868603701244865e-07
associated O 0 7.036301781226939e-07
with O 0 2.718483926855697e-07
the O 0 5.6111689445970114e-06
disease O 1 0.7267348170280457
in O 0 6.859377776891051e-07
probands O 0 8.93494943738915e-05
, O 0 4.000503111001308e-07
and O 0 1.1196629401410974e-07
the O 0 5.531987312679121e-07
rate O 0 6.772072083549574e-06
of O 0 6.693742307106731e-07
disease O 0 0.06933965533971786
concordance O 0 1.5192345927061979e-05
was O 0 2.8689314603980165e-06
significantly O 0 6.692995953017089e-07
increased O 0 1.4808445314429264e-07
among O 0 3.6617916521208826e-07
DZ O 0 0.0034349337220191956
twin O 0 0.00012166560918558389
pairs O 0 1.1689151051541558e-06
in O 0 9.836725212153397e-08
which O 0 3.928161262933827e-08
the O 0 1.7273477226353862e-07
co O 0 2.888079507101793e-05
- O 0 5.697334199794568e-05
twin O 0 0.0001723222667351365
was O 0 4.0466475184075534e-06
positive O 0 3.3974465907249396e-08
for O 0 8.154803943227762e-09
both O 0 1.325495162518564e-07
B27 O 0 3.8119022065075114e-05
and O 0 3.4447059533704305e-06
DR1 O 0 0.06419260799884796
. O 0 2.7247177058598027e-05

Additive O 0 6.768009188817814e-05
genetic O 0 4.872006320510991e-05
effects O 0 4.9449240577814635e-06
were O 0 1.4884960819472326e-07
estimated O 0 4.886615201371569e-08
to O 0 3.5052978297756e-09
contribute O 0 4.958704380442214e-08
97 O 0 8.38073788145266e-07
% O 0 1.9983072974127936e-08
of O 0 8.854877719954857e-09
the O 0 8.625803360473583e-08
population O 0 2.3889754174888367e-08
variance O 0 8.499038699483208e-07
. O 0 2.837243755493546e-06

CONCLUSION O 0 5.305008016875945e-05
Susceptibility O 0 5.435738421510905e-05
to O 0 5.250238359622017e-07
AS B-Disease 0 0.10667609423398972
is O 0 4.211280497656844e-07
largely O 0 5.004692980037362e-07
genetically O 0 7.08543780092441e-07
determined O 0 1.9476451598166022e-06
, O 0 2.113397101766168e-07
and O 0 1.3926405983966106e-07
the O 0 4.640872077743552e-07
environmental O 0 1.7184278476634063e-05
trigger O 0 2.9506509235943668e-05
for O 0 3.879451071497897e-07
the O 0 1.5005100976850372e-05
disease O 1 0.9809814691543579
is O 0 1.111652977670019e-06
probably O 0 3.4846129892684985e-06
ubiquitous O 0 7.46043078834191e-05
. O 0 1.1383142918930389e-05

HLA O 0 0.005653741769492626
- O 0 0.00019405712373554707
B27 O 0 3.2992080377880484e-05
accounts O 0 1.9834492093195877e-07
for O 0 3.781020296855786e-08
a O 0 4.027525335459359e-07
minority O 0 2.0169485992482805e-07
of O 0 1.782882641521155e-08
the O 0 2.3047591923841537e-07
overall O 0 3.6436322261579335e-06
genetic O 0 4.622096093953587e-05
susceptibility O 0 6.737454532412812e-05
to O 0 1.1829827144538285e-06
AS B-Disease 1 0.954640805721283
. O 0 1.3465266420098487e-05

Cell O 0 0.0009970151586458087
cycle O 0 0.00014713699056301266
- O 0 5.252569098956883e-05
dependent O 0 4.0719728531257715e-06
colocalization O 0 0.00016562937526032329
of O 0 3.4504159884818364e-07
BARD1 O 0 0.00037392089143395424
and O 0 1.0252693982693017e-06
BRCA1 O 0 1.2087379218428396e-05
proteins O 0 2.363008917427578e-07
in O 0 1.1992760562407057e-07
discrete O 0 1.745811346154369e-06
nuclear O 0 0.0003308537998236716
domains O 0 7.188213203335181e-05
. O 0 8.67884409672115e-06

Germ O 0 0.007773828227072954
- O 0 0.0006208348786458373
line O 0 9.96823946479708e-05
mutations O 0 3.225520777050406e-05
of O 0 9.638796427680063e-08
the O 0 2.7630801469058497e-07
BRCA1 O 0 4.9777769163483754e-05
gene O 0 6.216398105607368e-06
predispose O 0 7.4619019869714975e-06
women O 0 2.5823652549661347e-07
to O 0 1.3421559685866669e-07
early O 0 4.3199404899496585e-05
- O 1 0.5178723931312561
onset O 1 0.9829572439193726
breast B-Disease 1 0.998672366142273
and I-Disease 1 0.887126624584198
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999896287918091
by O 0 7.50382469050237e-07
compromising O 0 2.9468099455698393e-05
the O 0 2.921348709605809e-07
genes O 0 3.3074190923798596e-06
presumptive O 0 0.00040591516881249845
function O 0 2.2519202502735425e-06
as O 0 1.1875084737766883e-06
a O 0 2.1261088477331214e-05
tumor B-Disease 0 0.043037835508584976
suppressor O 0 0.00041384005453437567
. O 0 4.174054083705414e-06

Although O 0 1.9740750758501235e-06
the O 0 3.768683711768972e-07
biochemical O 0 1.7007969290716574e-05
properties O 0 2.876630105674849e-06
of O 0 3.557303784873511e-07
BRCA1 O 0 5.018022420699708e-05
polypeptides O 0 3.435899770920514e-06
are O 0 5.165164651543819e-08
not O 0 4.8316930900682564e-08
understood O 0 6.934438374628371e-07
, O 0 5.482162634962151e-08
their O 0 2.2818644751509964e-08
expression O 0 1.1191178828084958e-06
pattern O 0 8.74863144417759e-06
and O 0 2.8546745056701184e-07
subcellular O 0 1.6773537936387584e-05
localization O 0 1.3909344488638453e-05
suggest O 0 2.8063968215974455e-07
a O 0 1.979888821779241e-07
role O 0 5.040223527430499e-07
in O 0 6.251088393582904e-07
cell O 0 0.00013061787467449903
- O 0 0.0003678971843328327
cycle O 0 5.6208809837698936e-05
regulation O 0 2.992780355270952e-05
. O 0 4.689411071012728e-06

When O 0 5.322379001881927e-05
resting O 0 0.00041794180287979543
cells O 0 6.121423666627379e-06
are O 0 1.321393199305021e-07
induced O 0 1.64435914484784e-05
to O 0 4.437507783450201e-08
proliferate O 0 3.7960687677696114e-06
, O 0 1.1281453993206014e-07
the O 0 4.6938758657688595e-08
steady O 0 5.122104539623251e-06
- O 0 1.042785333993379e-05
state O 0 2.202137920903624e-07
levels O 0 5.479679430209217e-07
of O 0 2.6075174019979386e-08
BRCA1 O 0 7.106556495273253e-06
increase O 0 1.1772592500847168e-07
in O 0 2.0479531315231725e-07
late O 0 8.882078873284627e-06
G1 O 0 5.366893674363382e-05
and O 0 6.368534855027974e-08
reach O 0 1.0629890567770417e-07
a O 0 2.444304527671193e-07
maximum O 0 4.311567920467496e-07
during O 0 5.878445335838478e-06
S O 0 0.00038587689050473273
phase O 0 5.369089558371343e-05
. O 0 6.434679562516976e-06

Moreover O 0 1.576550494064577e-05
, O 0 8.634969503873435e-07
in O 0 4.6446976398328843e-07
S O 0 0.00010603217378957197
phase O 0 8.84320070326794e-06
cells O 0 3.00041256195982e-06
, O 0 4.546936054339312e-07
BRCA1 O 0 8.071358934103046e-06
polypeptides O 0 1.4804734291828936e-06
are O 0 7.437638060991958e-08
hyperphosphorylated O 0 1.2643307854887098e-05
and O 0 1.4317470231617335e-07
accumulate O 0 2.7791581942437915e-06
into O 0 1.673955409842165e-07
discrete O 0 7.639422619831748e-06
subnuclear O 0 0.0017706949729472399
foci O 0 0.0005475834477692842
termed O 0 0.0002652725379448384
" O 0 2.06726308533689e-05
BRCA1 O 0 0.0003744422283489257
nuclear O 0 0.001353573054075241
dots O 0 0.0008721277699805796
. O 0 2.1630088667734526e-05

" O 0 3.534485585987568e-05
BRCA1 O 0 0.00029282039031386375
associates O 0 6.991435657255352e-05
in O 0 3.426621901780891e-07
vivo O 0 4.749314939545002e-06
with O 0 1.0119460824853377e-07
a O 0 1.0623582511470886e-06
structurally O 0 7.086070399964228e-05
related O 0 3.994158305431483e-06
protein O 0 1.1525935406098142e-05
termed O 0 0.0003573514404706657
BARD1 O 0 0.005951142404228449
. O 0 8.545318451069761e-06

Here O 0 2.1126968476892216e-06
we O 0 1.7798052454054414e-07
show O 0 8.865561795801113e-08
that O 0 4.76588191133942e-09
the O 0 3.9648718086482404e-08
steady O 0 3.84503027817118e-06
- O 0 9.178560503642075e-06
state O 0 2.3135987703426508e-07
levels O 0 1.3889840602132608e-06
of O 0 6.041821620783594e-08
BARD1 O 0 7.376748544629663e-05
, O 0 9.646336707191949e-08
unlike O 0 1.9950898888509982e-07
those O 0 2.7766301258225212e-08
of O 0 1.6413230241596466e-07
BRCA1 O 0 6.499432493001223e-05
, O 0 4.822421715289238e-07
remain O 0 2.7276666969555663e-07
relatively O 0 1.7682145880826283e-07
constant O 0 1.5608516150678042e-06
during O 0 5.593974947259994e-06
cell O 0 0.00018046850163955241
cycle O 0 9.91949054878205e-05
progression O 0 0.00042912011849693954
. O 0 1.4384300811798312e-05

However O 0 8.890460776456166e-06
, O 0 2.7195676466362784e-06
immunostaining O 0 0.0004005707742180675
revealed O 0 2.52355239354074e-05
that O 0 3.312313765491126e-07
BARD1 O 0 0.000637632911093533
resides O 0 2.7186470106244087e-05
within O 0 1.7863123957795324e-06
BRCA1 O 0 0.0001562529942020774
nuclear O 0 0.00018659864144865423
dots O 0 7.297671254491434e-05
during O 0 1.1279102182015777e-05
S O 0 6.186343671288341e-05
phase O 0 1.6455499007861363e-06
of O 0 2.4666297449016383e-08
the O 0 1.341670952115237e-07
cell O 0 1.2692816198978107e-05
cycle O 0 3.459206936895498e-06
, O 0 3.648830215752241e-08
but O 0 1.2529751458600913e-08
not O 0 1.1076294548217902e-08
during O 0 2.925416424659488e-07
the O 0 3.225478906188073e-07
G1 O 0 0.0003306088037788868
phase O 0 5.356677866075188e-05
. O 0 4.821088168682763e-06

Nevertheless O 0 0.00010760126315290108
, O 0 2.4125129129970446e-06
BARD1 O 0 8.875092316884547e-05
polypeptides O 0 1.7258410025533522e-06
are O 0 1.1451022352559903e-08
found O 0 2.993510506144048e-08
exclusively O 0 3.995701902681503e-08
in O 0 2.643164798143971e-08
the O 0 2.5258179547904547e-08
nuclear O 0 1.955383595486637e-06
fractions O 0 8.791621297632446e-08
of O 0 1.4160717931588351e-08
both O 0 1.7517641026643105e-07
G1 O 0 0.0001929966383613646
- O 0 2.337878686375916e-05
and O 0 2.2059180082578678e-06
S O 0 0.00032666054903529584
- O 0 6.188709812704474e-05
phase O 0 2.9026308766333386e-05
cells O 0 2.1835290681337938e-05
. O 0 2.7212022359890398e-06

Therefore O 0 5.059293016529409e-06
, O 0 1.4046092928765574e-06
progression O 0 2.3837106709834188e-05
to O 0 3.381672115665424e-07
S O 0 0.00014863084652461112
phase O 0 6.115839369158493e-06
is O 0 1.7698965848467196e-07
accompanied O 0 3.050352290756564e-07
by O 0 2.6256735452534485e-08
the O 0 1.045044868419609e-07
aggregation O 0 6.265458068810403e-06
of O 0 5.575890327236266e-07
nuclear O 0 0.00025741354329511523
BARD1 O 0 0.0003407270705793053
polypeptides O 0 9.26828033698257e-06
into O 0 2.3752688775857678e-06
BRCA1 O 0 0.0005956193781457841
nuclear O 0 0.0014118648832663894
dots O 0 0.0014251589309424162
. O 0 2.5708217435749248e-05

This O 0 1.4132907608654932e-06
cell O 0 5.241726103122346e-05
cycle O 0 4.1824416257441044e-05
- O 0 3.0202645575627685e-05
dependent O 0 1.96996415979811e-06
colocalization O 0 7.100673974491656e-05
of O 0 3.732148172730376e-07
BARD1 O 0 0.000540445907972753
and O 0 1.7972297428059392e-06
BRCA1 O 0 4.7919918870320544e-05
indicates O 0 5.076282718619041e-07
a O 0 1.9839997378312546e-07
role O 0 5.905866942157445e-07
for O 0 1.575087082983373e-07
BARD1 O 0 0.00017292980919592083
in O 0 2.5182328045048052e-06
BRCA1 O 0 0.000870192889124155
- O 0 0.004275586921721697
mediated O 0 0.02766556851565838
tumor B-Disease 1 0.7253363728523254
suppression O 0 0.0003539016761351377
. O 0 1.1763701877498534e-05

Ethnic O 0 5.585099188465392e-06
differences O 0 1.6960220818873495e-05
in O 0 1.6660241044519353e-06
the O 0 1.995327011172776e-06
HFE O 0 0.002802696079015732
codon O 0 0.00015636686293873936
282 O 0 5.927899474045262e-05
( O 0 6.18885133008007e-06
Cys O 0 0.009103394113481045
/ O 0 0.0005403470131568611
Tyr O 0 0.0009149021352641284
) O 0 1.3191497600928415e-06
polymorphism O 0 2.0540943296509795e-05
. O 0 3.832356924249325e-06

Recent O 0 1.3611405847768765e-05
studies O 0 1.084332666323462e-06
have O 0 2.1930465265995736e-07
shown O 0 1.887927624011354e-06
that O 0 1.0044173905043863e-05
hereditary B-Disease 1 0.9999967813491821
hemochromatosis I-Disease 1 0.9999998807907104
( O 0 0.0003922089235857129
HH B-Disease 1 0.9951367974281311
) O 0 1.022823880703072e-06
is O 0 2.480737748555839e-07
likely O 0 1.6274726988285693e-07
to O 0 2.607711380164801e-08
be O 0 2.3310865060466313e-07
caused O 0 1.2333058521107887e-06
by O 0 4.087774385652665e-08
homozygosity O 0 1.0295207175659016e-05
for O 0 3.883611299215772e-08
a O 0 1.0278009767716867e-06
Cys282Tyr O 0 0.00010802277392940596
mutation O 0 9.775741091289092e-06
in O 0 1.440777595007603e-07
the O 0 3.7755296489194734e-07
HFE O 0 0.00019205674470867962
gene O 0 6.352185209834715e-06
located O 0 1.2236007023602724e-05
4 O 0 1.3051687346887775e-05
. O 0 2.772973857645411e-06

5 O 0 2.6247877030982636e-05
Mb O 0 0.0002150174550479278
telomeric O 0 0.0006717474898323417
to O 0 1.6306651104969205e-06
HLA O 0 0.0008853112813085318
- O 0 0.0002829638251569122
A O 0 3.270426168455742e-05
. O 0 6.339149877021555e-06

Population O 0 1.5943560072173568e-07
studies O 0 1.249851067086638e-07
of O 0 6.2381038112846454e-09
this O 0 6.859650181212373e-09
polymorphism O 0 2.6437882638674637e-07
are O 0 3.7420324616732614e-09
facilitated O 0 1.57592552341157e-07
by O 0 4.199769776391804e-08
the O 0 6.321156575950226e-08
fact O 0 1.2685109140875284e-07
that O 0 1.957859474543966e-08
the O 0 2.0999844707603188e-07
Cys282Tyr O 0 0.00026764938957057893
mutation O 0 5.5870106734801084e-05
creates O 0 6.702163318550447e-06
a O 0 2.2868155156174907e-06
Rsal O 0 0.00015792009071446955
restriction O 0 3.824047325906577e-06
site O 0 3.495755299809389e-05
. O 0 5.01199065183755e-06

We O 0 4.183646524325013e-06
have O 0 2.0743516415677732e-07
studied O 0 1.5898918945822516e-06
the O 0 3.7682775655412115e-07
codon O 0 2.315121855644975e-05
282 O 0 1.799961319193244e-05
( O 0 5.1855276979040354e-06
Cys O 0 0.006830531172454357
/ O 0 0.00024969014339149
Tyr O 0 0.0003716994251590222
) O 0 1.5421655064074002e-07
polymorphism O 0 5.495206210071046e-07
in O 0 2.165648993468494e-08
different O 0 8.559375430650107e-09
ethnic O 0 2.834553640695958e-07
groups O 0 4.994689675186237e-07
. O 0 3.7097356653248426e-06

In O 0 1.4088645912124775e-06
agreement O 0 1.645295583330153e-06
with O 0 1.2676510152687115e-07
previous O 0 1.218517809320474e-06
observations O 0 1.3041307056482765e-06
the O 0 2.9654833610948117e-07
Tyr O 0 6.987150118220598e-05
allele O 0 3.877988547174027e-06
appeared O 0 2.6579325549391797e-06
to O 0 2.323446501861781e-08
be O 0 6.676496866475645e-08
rare O 0 2.710406988626346e-06
or O 0 2.077563976854435e-06
absent O 0 2.475914516253397e-05
in O 0 1.1566295370357693e-06
Asiatic O 0 2.5382802050444297e-05
( O 0 1.9671281847877253e-07
Indian O 0 2.480662146808754e-07
, O 0 9.677739853941603e-08
Chinese O 0 6.899319515696334e-08
) O 0 1.8555572012246557e-07
populations O 0 8.731742013878829e-07
. O 0 2.509341129552922e-06

The O 0 2.062088469756418e-06
highest O 0 7.930130777822342e-06
allele O 0 3.994771304860478e-06
frequency O 0 5.8113782870350406e-06
( O 0 2.1592769883227447e-07
7 O 0 6.673836310255865e-07
. O 0 1.8952677649508587e-08
5 O 0 1.036384418284797e-07
% O 0 5.408234304837833e-09
) O 0 1.9745856505437587e-08
was O 0 1.6182066246983595e-06
found O 0 2.5448665041949425e-07
in O 0 2.527124252083013e-07
Swedes O 0 4.9766098527470604e-05
. O 0 4.31379066867521e-06

Saamis O 0 0.0004665273299906403
( O 0 7.057020070533326e-07
2 O 0 9.450830020796275e-07
% O 0 4.122790997485026e-08
) O 0 4.126724562070194e-08
and O 0 1.2574430741096876e-07
Mordvinians O 0 1.7471040337113664e-05
( O 0 1.1247421838334049e-07
1 O 0 2.888305346004927e-07
. O 0 2.6463629509976272e-08
8 O 0 1.9042401788738061e-07
% O 0 1.0331412170216936e-08
) O 0 1.525719284245497e-08
had O 0 1.1855786397063639e-07
significantly O 0 2.1633582036884036e-07
lower O 0 4.300012506064377e-07
frequencies O 0 5.717048452424933e-07
of O 0 4.110416540470396e-08
the O 0 1.0357910014135996e-06
Tyr O 0 0.0005633083055727184
allele O 0 7.299864228116348e-05
. O 0 9.675848559709266e-06

Comparisons O 0 1.8590515082905767e-06
with O 0 3.0281213980742905e-07
allele O 0 4.912238637189148e-06
frequencies O 0 4.836062998947455e-06
based O 0 5.691703108823276e-07
on O 0 3.6208330129738897e-06
prevalence O 0 7.337319402722642e-05
estimates O 0 6.658304982920527e-07
of O 0 2.1318423648608587e-07
HH B-Disease 1 0.9092671871185303
showed O 0 1.0947796909022145e-05
some O 0 2.6048878609685744e-08
disagreements O 0 5.545215117308544e-06
with O 0 1.8251805045110814e-07
the O 0 2.4021306899157935e-07
RFLP O 0 2.0574174413923174e-05
data O 0 2.730758978941594e-07
, O 0 1.2858649256486387e-07
particularly O 0 3.9171484900180076e-07
in O 0 7.651707392142271e-07
Finns O 0 5.8434416132513434e-05
. O 0 8.455014722130727e-06

The O 0 1.972449126697029e-06
newly O 0 3.0111019441392273e-05
described O 0 2.873995981644839e-05
HFE O 0 0.0013221859699115157
marker O 0 1.1331479072396178e-05
provides O 0 6.281302944444178e-08
a O 0 1.0186036547565891e-07
new O 0 5.565902938542422e-08
approach O 0 9.250959465134656e-08
to O 0 6.347032233122718e-09
the O 0 3.010022453509009e-08
screening O 0 1.358291683573043e-07
of O 0 1.1488151585581363e-07
HH B-Disease 0 0.0042122406885027885
as O 0 2.8228052428858064e-07
well O 0 9.9840114842209e-08
as O 0 7.489340703159542e-08
studies O 0 2.7101325628109407e-08
of O 0 5.2730766419983865e-09
the O 0 3.2236826541520713e-08
relationship O 0 8.502005925947742e-07
between O 0 6.536020578096213e-07
the O 0 2.2883666588313645e-06
HFE O 0 0.003808439476415515
Tyr O 0 0.0008718951721675694
allele O 0 2.125561331922654e-05
and O 0 1.482366542404634e-06
different O 0 3.5470427519612713e-06
disorders O 1 0.999477207660675
including O 0 0.001251943176612258
cancer B-Disease 1 0.9995627999305725

Autosomal B-Disease 1 0.9966824650764465
dominant I-Disease 1 0.997798502445221
neurohypophyseal I-Disease 1 0.999202311038971
diabetes I-Disease 1 0.9999284744262695
insipidus I-Disease 1 0.9925113916397095
associated O 0 1.9786155462497845e-05
with O 0 3.233899690258113e-07
a O 0 3.320522637295653e-06
missense O 0 6.251799641177058e-05
mutation O 0 7.833049494365696e-06
encoding O 0 2.6969294140144484e-06
Gly23 O 0 0.0012140612816438079
- O 0 0.0008813394233584404
- O 0 0.00035953830229118466
> O 0 0.00011255391291342676
Val O 0 0.0007020268822088838
in O 0 2.9149555302865338e-06
neurophysin O 0 0.0005933534121140838
II O 0 0.13272954523563385
. O 0 1.7941274563781917e-05

Autosomal B-Disease 1 0.9967650175094604
dominant I-Disease 1 0.9978772401809692
neurohypophyseal I-Disease 1 0.9995101690292358
diabetes I-Disease 1 0.999925971031189
insipidus I-Disease 1 0.9912273287773132
( O 0 1.1795684258686379e-05
ADNDI B-Disease 0 0.002602818887680769
) O 0 8.10077210644522e-07
is O 0 2.4797730020509334e-06
an O 0 0.0001516830234322697
inherited B-Disease 1 0.9999985694885254
disease I-Disease 1 0.9999992847442627
caused O 0 0.23294275999069214
by O 0 8.52368521009339e-06
progressive O 1 0.7654030919075012
degeneration O 1 0.9982081651687622
of O 0 3.5051834856858477e-07
the O 0 1.873012365649629e-06
magnocellular O 0 0.0007276418618857861
neurons O 0 2.5171686502289958e-05
of O 0 1.4817712212789047e-07
the O 0 7.151886620704317e-07
hypothalamus O 0 8.490199252264574e-05
leading O 0 5.789616352558369e-06
to O 0 3.771886980530326e-08
decreased O 0 1.3968027587907272e-06
ability O 0 9.755373042708015e-08
to O 0 1.990042264310432e-08
produce O 0 2.0089071028905892e-07
the O 0 5.840051926497836e-07
hormone O 0 1.6110056094476022e-05
arginine O 0 1.6602236428298056e-05
vasopressin O 0 3.0312467060866766e-05
( O 0 1.0738339142335462e-06
AVP O 0 0.00019461504416540265
) O 0 1.0255099596179207e-06
. O 0 2.091142278004554e-06

Affected O 0 8.779488780419342e-06
individuals O 0 6.76886884320993e-08
are O 0 4.852889290418716e-08
not O 0 2.3697158724189649e-07
symptomatic O 0 0.00016833111294545233
at O 0 0.00010606119758449495
birth O 0 1.7447131540393457e-05
, O 0 3.349518067352619e-07
but O 0 2.734485633482109e-07
usually O 0 2.5703111532493494e-06
develop O 0 6.738231604686007e-05
diabetes B-Disease 1 0.9945098161697388
insipidus I-Disease 0 0.026055457070469856
at O 0 0.00023281222092919052
1 O 0 2.431765096844174e-05
- O 0 0.0002499626425560564
6 O 0 4.0096794691635296e-05
yr O 0 0.002087838016450405
of O 0 5.050000595474557e-07
age O 0 1.5426525351358578e-05
. O 0 4.110192094231024e-06

The O 0 2.086267841150402e-06
genetic O 0 3.7361201975727454e-05
locus O 0 2.23128135985462e-05
of O 0 5.818470754093141e-07
the O 0 1.824091305024922e-05
disease O 1 0.9983457326889038
is O 0 5.127619147060614e-07
the O 0 7.362604037552956e-07
AVP O 0 0.001144750276580453
- O 0 0.0005312556750141084
neurophysin O 0 0.0010931737488135695
II O 0 0.009565410204231739
( O 0 9.016617354973278e-07
NPII O 0 5.4341991926776245e-05
) O 0 5.381401280146747e-08
gene O 0 2.3756466305258073e-07
, O 0 1.0988279086632247e-07
and O 0 2.4524069885956123e-07
mutations O 0 1.6384610717068426e-05
that O 0 2.0315410154125857e-07
cause O 0 1.3091552318655886e-05
ADNDI B-Disease 0 0.00027882997528649867
have O 0 1.0713343812085441e-07
been O 0 1.1337928640386963e-07
found O 0 2.4813049392946596e-08
in O 0 7.160989135002183e-09
both O 0 7.482455544050026e-09
the O 0 3.3728785098219305e-08
signal O 0 1.1445878271842957e-06
peptide O 0 1.348490513919387e-06
of O 0 2.0030277880778158e-08
the O 0 5.302823069541773e-07
prepro O 0 0.0009099138551391661
- O 0 0.0008405921398662031
AVP O 0 0.0013688552426174283
- O 0 0.0002913811767939478
NPII O 0 0.0004026875249110162
precursor O 0 9.451927326153964e-06
and O 0 5.661160003000987e-07
within O 0 1.1484344213386066e-06
NPII O 0 0.001599139184691012
itself O 0 3.6371064197737724e-05
. O 0 6.712941740261158e-06

An O 0 3.0869614420225844e-06
affected O 0 1.4390145224751905e-05
girl O 0 9.586919622961432e-05
who O 0 8.747377933104872e-07
presented O 0 6.564255272678565e-07
at O 0 1.1029263077944051e-05
9 O 0 2.7365149435354397e-06
months O 0 8.012772809706803e-07
of O 0 2.0132352673840614e-08
age O 0 1.490004478910123e-06
and O 0 2.1854445719782234e-07
her O 0 1.166062475022045e-06
similarly O 0 2.681933437997941e-06
affected O 0 8.705318350621383e-07
younger O 0 1.5729721098978189e-06
brother O 0 1.4046564501768444e-05
and O 0 3.231224070532335e-07
father O 0 1.7343263607472181e-06
were O 0 7.63347216548027e-08
all O 0 7.388810896458153e-09
found O 0 7.828636938711497e-08
to O 0 8.072860602226228e-09
have O 0 3.002041282229584e-08
a O 0 4.109915323624591e-07
novel O 0 3.2236077913694317e-06
missense O 0 0.00014969373296480626
mutation O 0 3.260376979596913e-05
( O 0 6.066071023269615e-07
G1758 O 0 5.3732641390524805e-05
- O 0 5.595083348453045e-05
- O 0 6.330950418487191e-05
> O 0 2.2199261366040446e-05
T O 0 5.822770981467329e-05
) O 0 8.316769495309018e-09
encoding O 0 4.097969608096719e-08
the O 0 7.721097006196942e-08
amino O 0 3.706065285769e-07
acid O 0 1.6016161907828064e-06
substitution O 0 7.178714440669864e-07
Gly23 O 0 0.00023484232951886952
- O 0 0.0003979861212428659
- O 0 0.0005421165260486305
> O 0 0.00024243522784672678
Val O 0 0.0017219891306012869
within O 0 1.6021911505958997e-05
NPII O 0 0.0033796271309256554
. O 0 1.9204131604055874e-05

The O 0 5.8804184845939744e-06
mutation O 0 9.101842442760244e-05
was O 0 1.6031999621191062e-05
confirmed O 0 1.7353372641082387e-06
by O 0 8.511401716759792e-08
restriction O 0 1.507444380877132e-06
endonuclease O 0 5.438175503513776e-05
analysis O 0 2.843861921064672e-06
. O 0 4.068107045895886e-06

A O 0 4.656658347812481e-05
T1 O 0 0.0031837618444114923
- O 0 3.37016572302673e-05
weighted O 0 3.6389374145073816e-06
magnetic O 0 2.696381898203981e-06
resonance O 0 1.525212519482011e-05
imaging O 0 4.793687185156159e-05
of O 0 3.722479391399247e-07
the O 0 4.317165348766139e-06
fathers O 0 0.00022900832118466496
pituitary O 1 0.6883063912391663
gland O 0 0.0198367852717638
demonstrates O 0 2.0226465494488366e-05
an O 0 2.7649036837829044e-06
attenuated O 0 0.0020578757394105196
posterior O 0 0.010397416539490223
pituitary O 1 0.6642571091651917
bright O 0 0.0011947659077122808
spot O 0 0.0006745680584572256
. O 0 1.1968954822805244e-05

This O 0 1.464920501348388e-06
mutation O 0 1.7338141333311796e-05
may O 0 6.289886869126349e-07
be O 0 1.572599472865477e-08
valuable O 0 7.505557420017794e-08
for O 0 2.755306027779625e-08
developing O 0 1.008737172014662e-06
models O 0 4.5307742766453885e-06
of O 0 3.0791757126280572e-06
dominantly B-Disease 1 0.7786878347396851
inherited I-Disease 1 0.9994561076164246
neurodegeneration I-Disease 1 0.999968409538269
, O 0 5.175439127924619e-06
as O 0 2.5686816229608667e-07
the O 0 9.270671341710113e-08
early O 0 1.4399880683413357e-06
age O 0 1.1931958852073876e-06
of O 0 2.964476664146787e-07
onset O 0 0.008345923386514187
of O 0 3.2732702948123915e-06
symptoms O 0 0.3236526846885681
suggests O 0 8.471088790429349e-07
that O 0 1.687687145590644e-08
this O 0 3.777978108132629e-08
mutation O 0 2.2933149921300355e-06
may O 0 5.338250161912583e-07
be O 0 7.907213017688264e-08
particularly O 0 3.396947931832983e-07
deleterious O 0 7.4694921750051435e-06
to O 0 1.0675444883645469e-07
the O 0 1.0978679938489222e-06
magnocellular O 0 0.0014791552675887942
neuron O 0 0.0006407293258234859
. O 0 1.1905360679520527e-06
. O 0 3.0242536013247445e-06

Frequent O 0 0.0005692638223990798
inactivation O 0 0.010111150331795216
of O 0 6.866302555863513e-06
PTEN O 0 0.02230546623468399
/ O 0 0.0036160354502499104
MMAC1 O 0 0.02194303460419178
in O 0 0.00012316137144807726
primary O 1 0.9671335816383362
prostate B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999960660934448
. O 0 3.834587550954893e-05

Sporadic B-Disease 1 0.9930439591407776
prostate I-Disease 1 0.9999932050704956
carcinoma I-Disease 1 0.9999998807907104
is O 0 1.390385386912385e-05
the O 0 2.407127794867847e-07
most O 0 1.9429981534813123e-07
common O 0 4.337436621426605e-06
male B-Disease 0 5.873318514204584e-05
cancer I-Disease 1 0.5316184163093567
in O 0 8.948056517965597e-08
the O 0 3.4669934478870346e-08
Western O 0 2.823957743203209e-07
world O 0 8.658207093503734e-07
, O 0 7.419926362217666e-08
yet O 0 3.7188740975580004e-08
many O 0 3.398280767896722e-09
of O 0 5.193434571282296e-09
the O 0 6.666355290008141e-08
major O 0 1.659702888900938e-06
genetic O 0 1.5573456266793073e-06
events O 0 1.9355672975507332e-07
involved O 0 2.7315923034620937e-07
in O 0 8.121140382399972e-08
the O 0 1.0036651332256952e-07
progression O 0 9.974900422093924e-06
of O 0 8.412080632069774e-08
this O 0 3.3073044392040174e-07
often O 0 3.5120949178235605e-05
fatal O 1 0.9996888637542725
cancer B-Disease 1 0.9988561868667603
remain O 0 2.9376856218732428e-06
to O 0 8.525342565235405e-08
be O 0 4.985267310075869e-07
elucidated O 0 8.888906450010836e-05
. O 0 5.772084932686994e-06

Numerous O 0 1.9131435692543164e-05
cytogenetic O 0 0.006632775533944368
and O 0 5.115221028972883e-06
allelotype O 0 0.00019365693151485175
studies O 0 1.0988337635353673e-06
have O 0 4.113381635306723e-07
reported O 0 7.416936114168493e-06
frequent O 0 3.2880448998184875e-05
loss O 0 0.00031605310505256057
of O 0 4.74342556344709e-07
heterozygosity O 0 0.0013165771961212158
on O 0 4.84219599456992e-05
chromosomal O 1 0.5278989672660828
arm O 0 0.03258185461163521
10q O 0 0.0006437886622734368
in O 0 8.276601874968037e-05
sporadic B-Disease 1 0.9905202388763428
prostate I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999923706054688
. O 0 3.044532786589116e-05

Deletion O 0 0.00017827723058871925
mapping O 0 1.9102868463960476e-05
studies O 0 1.79596179350483e-06
have O 0 1.5733562008790614e-07
unambiguously O 0 9.393193977302872e-06
identified O 0 7.239324872898578e-07
a O 0 5.075773970020236e-07
region O 0 1.8616985926200869e-06
of O 0 1.1880212014148128e-07
chromosome O 0 2.8053931600879878e-05
10q23 O 0 1.4485326573776547e-05
to O 0 2.5361435618265205e-08
be O 0 4.31885958107614e-08
the O 0 6.877509406422178e-08
minimal O 0 3.908188318746397e-06
area O 0 3.566152599887573e-06
of O 0 1.651193429097475e-06
loss O 0 0.0035711403470486403
. O 0 1.0992363968398422e-05

A O 0 4.1209135815734044e-05
new O 0 2.059297912637703e-05
tumor B-Disease 0 0.0037945564836263657
suppressor O 0 0.00011949665349675342
gene O 0 1.3543593922804575e-05
, O 0 2.2983463168202434e-06
PTEN O 0 0.0006895799306221306
/ O 0 0.00018659741908777505
MMAC1 O 0 0.0008751682471483946
, O 0 1.2267262263776502e-06
was O 0 8.39963377075037e-06
isolated O 0 1.3525371286959853e-05
recently O 0 2.113706068485044e-05
at O 0 5.2429159040912054e-06
this O 0 3.013589733313893e-08
region O 0 8.66589004999696e-07
of O 0 9.807967416008978e-08
chromosome O 0 3.0133884138194844e-05
10q23 O 0 2.3362472347798757e-05
and O 0 1.884954201614164e-07
found O 0 1.2957214323705557e-07
to O 0 1.535546267916743e-08
be O 0 5.102535283185716e-08
inactivated O 0 3.630715355029679e-06
by O 0 6.276129482785109e-08
mutation O 0 2.512834953449783e-06
in O 0 1.5776728332639323e-06
three O 0 0.0002788161509670317
prostate B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999927282333374
cell O 0 0.0063125877641141415
lines O 0 0.00048602555762045085
. O 0 1.2809162399207707e-05

We O 0 2.1615036530420184e-05
screened O 0 0.0003358658868819475
80 O 0 0.0008510314510203898
prostate B-Disease 1 0.999889612197876
tumors I-Disease 1 0.9999165534973145
by O 0 3.111784963039099e-07
microsatellite O 0 2.24136674660258e-05
analysis O 0 3.384350293345051e-07
and O 0 1.872266182090243e-07
found O 0 6.401489827112528e-07
chromosome O 0 8.852904102241155e-06
10q23 O 0 6.712103186146123e-06
to O 0 2.782966213032978e-08
be O 0 5.2417728824138976e-08
deleted O 0 1.1928522098969552e-06
in O 0 3.370892045495566e-07
23 O 0 3.1548429433314595e-06
cases O 0 9.81916741693567e-07
. O 0 2.2486110538011417e-06

We O 0 1.6143715129146585e-06
then O 0 3.69026508906245e-07
proceeded O 0 2.0940389333645726e-07
with O 0 1.4847440610310514e-08
sequence O 0 1.2635666735150153e-07
analysis O 0 4.388696339674425e-08
of O 0 2.216735239812806e-08
the O 0 2.930168534476252e-07
entire O 0 2.4689967176527716e-05
PTEN O 0 0.0028290434274822474
/ O 0 0.0004036102327518165
MMAC1 O 0 0.001006994629278779
coding O 0 0.00016825535567477345
region O 0 1.3087133083899971e-05
and O 0 4.933835953124799e-07
tested O 0 2.1817868400830775e-06
for O 0 3.747362598005566e-08
homozygous O 0 1.998726474994328e-06
deletion O 0 1.6531503206351772e-06
with O 0 1.4063635944694397e-07
new O 0 9.867615062830737e-07
intragenic O 0 7.630864274688065e-05
markers O 0 4.343869022704894e-06
in O 0 5.678236192352415e-08
these O 0 8.894062375475187e-09
23 O 0 6.000456096444395e-07
cases O 0 9.648140064655308e-08
with O 0 4.1005273487826344e-07
10q23 O 0 0.0006915820413269103
loss O 0 0.0009057731367647648
of O 0 3.183791704941541e-06
heterozygosity O 0 0.005378964822739363
. O 0 2.75347974820761e-05

The O 0 2.3092650280887028e-07
identification O 0 2.4468536707900057e-07
of O 0 3.364820955198411e-08
the O 0 3.1250368692781194e-07
second O 0 3.104229108430445e-06
mutational O 0 6.972580740693957e-05
event O 0 5.583836809819331e-06
in O 0 1.4125656377927953e-07
10 O 0 2.853661840163113e-07
( O 0 1.0740924238916705e-07
43 O 0 1.8169881741414429e-06
% O 0 2.8829580855926906e-07
) O 0 6.635505997110158e-06
tumors B-Disease 1 0.9996618032455444
establishes O 0 0.00041294118273071945
PTEN O 0 0.004683720413595438
/ O 0 0.00019976720795966685
MMAC1 O 0 0.00024073511303868145
as O 0 2.937762246801867e-07
a O 0 6.146139526208572e-07
main O 0 6.156691142678028e-06
inactivation O 0 0.0003205967659596354
target O 0 2.3970646907400806e-06
of O 0 4.193958318410296e-07
10q O 0 0.00032767298398539424
loss O 0 0.0007281193975359201
in O 0 5.0291699153603986e-05
sporadic B-Disease 1 0.9950917959213257
prostate I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999945163726807
. O 0 3.2465306958329165e-06
. O 0 3.6939236451871693e-06

Risk O 0 0.0006661837105639279
reversals O 0 0.00015626238018739969
in O 0 9.685288659966318e-07
predictive O 0 3.574674701667391e-05
testing O 0 0.00011828397691715509
for O 0 8.417211938649416e-05
Huntington B-Disease 1 0.9999822378158569
disease I-Disease 1 0.9999949932098389
. O 0 4.520441871136427e-05

The O 0 9.408042842551367e-07
first O 0 1.3278943242767127e-06
predictive O 0 1.6334810425178148e-05
testing O 0 3.9172617107396945e-05
for O 0 1.370624522678554e-05
Huntington B-Disease 1 0.9998157620429993
disease I-Disease 1 0.9999485015869141
( O 0 8.738906558392046e-07
HD B-Disease 0 4.475860623642802e-05
) O 0 1.3729051318023267e-07
was O 0 7.065943350426096e-07
based O 0 2.4698639577991344e-08
on O 0 9.238915765763522e-08
analysis O 0 9.911984477639635e-08
of O 0 7.672343826925498e-08
linked O 0 2.6513389457250014e-05
polymorphic O 0 4.215030639898032e-05
DNA O 0 6.738314368703868e-06
markers O 0 3.7776724184368504e-06
to O 0 4.976821088575889e-08
estimate O 0 2.8884593916700396e-07
the O 0 4.3416221728875826e-08
likelihood O 0 6.224355502126855e-07
of O 0 3.8369385890746344e-08
inheriting O 0 2.113331174768973e-05
the O 0 9.177214224109775e-07
mutation O 0 9.445762771065347e-06
for O 0 6.400952656804293e-07
HD B-Disease 0 0.0008048279560171068
. O 0 1.5295505363610573e-05

Limits O 0 3.2885984637687216e-06
to O 0 3.412337790109632e-08
accuracy O 0 1.930626609691899e-07
included O 0 7.997887507826817e-08
recombination O 0 7.869415412642411e-07
between O 0 8.976877552413498e-08
the O 0 9.698953817860456e-08
DNA O 0 1.944285941135604e-06
markers O 0 6.095360731706023e-06
and O 0 2.7103607180833933e-07
the O 0 3.2512539860363177e-07
mutation O 0 1.2827425052819308e-05
, O 0 5.389633770391811e-07
pedigree O 0 2.7876871172338724e-05
structure O 0 7.686530807404779e-06
, O 0 2.8046281386195915e-07
and O 0 4.0581607407830234e-08
whether O 0 1.037176922125127e-08
DNA O 0 7.369405352619651e-08
samples O 0 2.5759151256465884e-08
were O 0 1.290413464971607e-08
available O 0 1.0706374453661738e-08
from O 0 6.296993149135233e-08
family O 0 4.7368121158797294e-07
members O 0 1.357007306523883e-07
. O 0 2.1778389509563567e-06

With O 0 1.8211639485343767e-07
direct O 0 2.0789701693502138e-07
tests O 0 6.195277819642797e-07
for O 0 1.3012289912239794e-08
the O 0 1.0053146581867622e-07
HD B-Disease 0 8.17305626696907e-05
mutation O 0 9.938685252564028e-06
, O 0 1.0948258477583295e-07
we O 0 6.445203126759225e-08
have O 0 3.4607236187866874e-08
assessed O 0 6.171648578856548e-07
the O 0 3.929914882405683e-08
accuracy O 0 8.629569379081659e-07
of O 0 8.517670835317404e-08
results O 0 7.270015771609906e-07
obtained O 0 2.417864948256465e-07
by O 0 4.918285867461236e-08
linkage O 0 3.9084079617168754e-06
approaches O 0 8.847307526593795e-07
when O 0 3.4617011124282726e-07
requested O 0 8.971263554258257e-08
to O 0 1.0635525349300678e-08
do O 0 2.487612071888634e-08
so O 0 1.4129287073672003e-08
by O 0 1.3690867106674887e-08
the O 0 7.923064515580336e-08
test O 0 5.443858412945701e-07
individuals O 0 5.445053830044344e-08
. O 0 1.5506514046137454e-06

For O 0 2.87696536815929e-07
six O 0 2.396232332557702e-07
such O 0 2.9405308410446196e-08
individuals O 0 3.2649936088091636e-08
, O 0 1.3800607234770723e-07
there O 0 8.895203507108818e-08
was O 0 2.5916936010617064e-06
significant O 0 3.2820395290400484e-07
disparity O 0 3.5725995530810906e-06
between O 0 2.437781745356915e-07
the O 0 1.090026785277587e-06
tests O 0 8.882062502379995e-06
. O 0 1.8842833924281877e-06

Three O 0 8.225680971918337e-07
went O 0 3.1288172976928763e-06
from O 0 9.890550956015431e-08
a O 0 6.970999493205454e-07
decreased O 0 1.4991856005508453e-05
risk O 0 2.852970055755577e-06
to O 0 1.037701302664118e-08
an O 0 5.183897400229398e-08
increased O 0 3.201672313934978e-07
risk O 0 2.3302559384319466e-06
, O 0 4.0910659748760736e-08
while O 0 2.3115118708005866e-08
in O 0 1.0880203404894928e-08
another O 0 3.939791426432748e-08
three O 0 9.666910472105883e-08
the O 0 2.9925831768196076e-07
risk O 0 2.563154703238979e-05
was O 0 4.600294050760567e-05
decreased O 0 4.495816756389104e-05
. O 0 4.301515218685381e-06

Knowledge O 0 4.4447356231103186e-06
of O 0 3.3252331377298106e-07
the O 0 4.600998977366544e-07
potential O 0 1.3392425444180844e-06
reasons O 0 1.8577138405362348e-07
for O 0 8.10096434378238e-09
these O 0 2.046397273858247e-09
changes O 0 1.958708111260421e-07
in O 0 1.5014916243671905e-07
results O 0 3.16395528443536e-07
and O 0 9.772469411473139e-08
impact O 0 3.618543473749014e-07
of O 0 4.442640033630596e-08
these O 0 8.434268039536619e-08
risk O 0 7.903940058895387e-06
reversals O 0 1.3499854503606912e-05
on O 0 8.671279942973342e-07
both O 0 3.69053253734819e-07
patients O 0 4.001524303021142e-06
and O 0 1.4549486593296024e-07
the O 0 1.6628779064831178e-07
counseling O 0 9.576834827385028e-07
team O 0 9.925283706024857e-08
can O 0 1.1928364962443538e-08
assist O 0 6.61146302149973e-08
in O 0 3.163490092106258e-08
the O 0 1.392475379446978e-08
development O 0 3.0351408497608645e-08
of O 0 1.4800731307218484e-08
strategies O 0 5.273421948004398e-07
for O 0 4.486750881937951e-08
the O 0 2.432602741464507e-07
prevention O 0 1.648507713980507e-05
and O 0 1.3324671499503893e-07
, O 0 7.576336713555065e-08
where O 0 6.683683295705123e-08
necessary O 0 1.624718493076216e-07
, O 0 3.7706070088461274e-07
management O 0 2.478453779986012e-06
of O 0 6.31084446922614e-08
a O 0 5.405790034274105e-06
risk O 0 3.1275078072212636e-05
reversal O 0 5.247702574706636e-06
in O 0 6.618427761395651e-08
any O 0 2.9280165847467288e-08
predictive O 0 1.7935125242729555e-06
testing O 0 1.9230644738854608e-06
program O 0 7.37279947315983e-07
. O 0 2.0561959956921783e-07
. O 0 1.0612343430693727e-06

A O 0 2.5362767701153643e-05
novel O 0 1.3318931451067328e-05
common O 0 1.8162767446483485e-05
missense O 0 0.0005473167984746397
mutation O 0 7.590149471070617e-05
G301C O 0 1.9382658138056286e-05
in O 0 2.373099050601013e-07
the O 0 2.725160186400899e-07
N O 0 7.684829324716702e-05
- O 0 7.03113037161529e-05
acetylgalactosamine O 0 0.00034647996653802693
- O 0 0.00028575293254107237
6 O 0 5.296940071275458e-05
- O 0 0.00020270592358428985
sulfate O 0 0.0009742619004100561
sulfatase O 0 0.001821632031351328
gene O 0 2.983314152515959e-05
in O 0 1.0504799320187885e-05
mucopolysaccharidosis B-Disease 0 0.006458515767008066
IVA I-Disease 0 0.419084757566452
. O 0 2.6452953534317203e-05

Mucopolysaccharidosis B-Disease 1 0.8423137068748474
IVA I-Disease 1 0.9860129952430725
( O 0 0.0003344994911458343
MPS B-Disease 1 0.998503565788269
IVA I-Disease 1 0.9997027516365051
) O 0 3.0081914701440837e-06
is O 0 1.6303572465403704e-06
an O 0 5.412051905295812e-06
autosomal B-Disease 1 0.9992892742156982
recessive I-Disease 1 0.9997422099113464
lysosomal I-Disease 1 0.999823272228241
storage I-Disease 1 0.9998443126678467
disorder I-Disease 1 0.9999605417251587
caused O 0 0.0020249467343091965
by O 0 9.301344903178688e-07
a O 0 1.9801957023446448e-05
genetic B-Disease 1 0.9833516478538513
defect I-Disease 1 0.9978652596473694
in O 0 2.6403088213555748e-06
N O 0 0.00019619126396719366
- O 0 0.00014499644748866558
acetylgalactosamine O 0 0.0005330913700163364
- O 0 0.000571803015191108
6 O 0 0.00010849992395378649
- O 0 0.0009373257635161281
sulfate O 0 0.005904610734432936
sulfatase O 0 0.00565301813185215
( O 0 3.2352863854612224e-06
GALNS O 0 0.00047776728752069175
) O 0 8.611860380369762e-07
. O 0 2.562924464655225e-06

In O 0 2.3451348170056008e-06
previous O 0 2.140105607395526e-06
studies O 0 2.4291531985909387e-07
, O 0 4.670860676014854e-08
we O 0 2.2013059819414593e-08
have O 0 9.425249025696303e-09
found O 0 5.2500276126465906e-08
two O 0 2.6073930570191806e-08
common O 0 1.1032997235815856e-06
mutations O 0 6.514987489936175e-06
in O 0 1.8112082500465476e-07
Caucasians O 0 1.6086362393252784e-06
and O 0 2.4986687208183866e-07
Japanese O 0 3.2857519727258477e-06
, O 0 7.33755200599262e-07
respectively O 0 9.779378160601482e-06
. O 0 4.017959781776881e-06

To O 0 7.405059818665904e-07
characterize O 0 1.5302595784305595e-05
the O 0 6.389370810211403e-07
mutational O 0 9.093843982554972e-05
spectrum O 0 1.2711723684333265e-05
in O 0 8.355345926247537e-08
various O 0 1.803933180610784e-08
ethnic O 0 6.028400179047821e-08
groups O 0 9.082971530460782e-08
, O 0 2.0201248673856753e-07
mutations O 0 2.019598468905315e-06
in O 0 7.942492885604224e-08
the O 0 1.7403576180186064e-07
GALNS O 0 0.00012582764611579478
gene O 0 7.5848615779250395e-06
in O 0 5.267177130008349e-06
Colombian O 0 0.0005759581108577549
MPS B-Disease 1 0.993660032749176
IVA I-Disease 1 0.9996942281723022
patients O 0 0.0001537791104055941
were O 0 1.9455660549283493e-06
investigated O 0 7.274985546246171e-05
, O 0 3.6277555182095966e-07
and O 0 1.524661144003403e-07
genetic O 0 1.5059544011819526e-06
backgrounds O 0 5.190338470129063e-07
were O 0 1.0543588047084995e-07
extensively O 0 1.4143437283564708e-06
analyzed O 0 1.1914038395843818e-06
to O 0 2.042759916776049e-08
identify O 0 1.3253497854748275e-07
racial O 0 1.8440587723489443e-07
origin O 0 4.29241637789346e-08
, O 0 4.251018026479869e-08
based O 0 2.688231859337975e-08
on O 0 1.522028725275959e-07
mitochondrial O 0 1.190439547826827e-06
DNA O 0 2.153756213374436e-06
( O 0 1.3448236302338046e-07
mtDNA O 0 4.590655464653537e-07
) O 0 2.3435175933173014e-07
lineages O 0 6.637043952650856e-06
. O 0 4.154352154728258e-06

Three O 0 2.7589351248025196e-06
novel O 0 1.0987710993504152e-05
missense O 0 0.0003776712401304394
mutations O 0 0.0001341716997558251
never O 0 7.0932246671873145e-06
identified O 0 7.220460247481242e-07
previously O 0 2.9672881396436424e-07
in O 0 3.286060135110347e-08
other O 0 6.105394856348312e-09
populations O 0 4.282733456761889e-08
and O 0 3.3983084790634166e-08
found O 0 1.201719044274796e-07
in O 0 3.759834044103627e-08
16 O 0 1.5305730016734742e-07
out O 0 2.354729744524775e-08
of O 0 7.138504543036106e-08
19 O 0 1.5414187146234326e-05
Colombian O 0 0.00014618101704400033
MPS B-Disease 1 0.9844586849212646
IVA I-Disease 1 0.9981537461280823
unrelated O 0 5.0981485401280224e-05
alleles O 0 3.716655555763282e-06
account O 0 5.355761345526844e-07
for O 0 5.457706606648571e-07
84 O 0 5.1312672439962626e-05
. O 0 5.619673174805939e-06

2 O 0 3.0996407076600008e-06
% O 0 1.9663549011283976e-08
of O 0 2.620683892118336e-09
the O 0 3.645365964644043e-08
alleles O 0 4.86288740830787e-07
in O 0 1.8485593500372488e-07
this O 0 6.943134422954245e-08
study O 0 7.328475248868926e-07
. O 0 1.8289770196133759e-06

The O 0 4.40352278019418e-06
G301C O 0 0.00012072605022694916
and O 0 1.026243694468576e-06
S162F O 0 5.772113217972219e-05
mutations O 0 1.603497912583407e-05
account O 0 4.293677591249434e-07
for O 0 2.3049746289416362e-07
68 O 0 5.0881335482699797e-05
. O 0 4.676513526646886e-06

4 O 0 1.2306481039559003e-05
% O 0 2.047611360467272e-07
and O 0 7.883146508902428e-07
10 O 0 4.070912837050855e-06
. O 0 3.939723683288321e-06

5 O 0 6.7561131800175644e-06
% O 0 9.290532432260079e-08
of O 0 6.363447369039932e-08
mutations O 0 7.423772331094369e-06
, O 0 1.738668942152799e-07
respectively O 0 7.714147614024114e-07
, O 0 1.1387081144675903e-07
whereas O 0 1.6599926766502904e-07
the O 0 7.799634005323242e-08
remaining O 0 5.105446234665578e-07
F69V O 0 0.0001882577926153317
is O 0 1.1635082586280987e-07
limited O 0 3.358441702516757e-08
to O 0 7.70955566053999e-09
a O 0 2.953516116122046e-07
single O 0 7.330292532969906e-07
allele O 0 1.0492292858543806e-05
. O 0 5.880956905457424e-06

The O 0 5.8336727306596e-06
skewed O 0 8.357728802366182e-05
prevalence O 0 0.00010081219807034358
of O 0 1.6870924923750863e-07
G301C O 0 1.9714490917976946e-05
in O 0 1.5117794305297139e-07
only O 0 5.7713638312861804e-08
Colombian O 0 6.534713520522928e-06
patients O 0 1.9241945210524136e-06
and O 0 1.0991758614409264e-07
haplotype O 0 1.491769671702059e-05
analysis O 0 1.8428492865041335e-07
by O 0 3.724041519603816e-08
restriction O 0 3.186028720847389e-07
fragment O 0 1.6676677887517144e-06
length O 0 1.0169879942623083e-06
polymorphisms O 0 9.235634934157133e-06
in O 0 1.824745368139702e-07
the O 0 2.1072206379812997e-07
GALNS O 0 0.00011057700612582266
gene O 0 3.5104965263599297e-06
suggest O 0 6.632315034948988e-07
that O 0 3.106601553781729e-08
G301C O 0 4.197737780486932e-06
originated O 0 5.127697590978642e-07
from O 0 1.0871536915146862e-07
a O 0 6.0564065051949e-07
common O 0 3.0774963306612335e-06
ancestor O 0 4.6369699703063816e-05
. O 0 1.813952076190617e-05

Investigation O 0 1.7380041754222475e-05
of O 0 1.0966294894387829e-07
the O 0 2.906195959440083e-07
genetic O 0 1.0332159035897348e-05
background O 0 2.8591475711436942e-06
by O 0 7.616979758040543e-08
means O 0 2.317476486268788e-07
of O 0 2.399323228985395e-08
mtDNA O 0 5.410309995568241e-07
lineages O 0 1.8816831470758189e-06
indicate O 0 4.0111157773026207e-07
that O 0 9.158695135624839e-09
all O 0 1.2100089819000459e-08
our O 0 4.056149123243813e-07
patients O 0 1.9626811535999877e-06
are O 0 3.50173117169561e-08
probably O 0 1.1230052905375487e-06
of O 0 7.882186281449322e-08
native O 0 1.6417376400568173e-06
American O 0 1.2624464034161065e-05
descent O 0 0.0007555654156021774

Low O 0 6.525179196614772e-05
frequency O 0 1.798192533897236e-05
of O 0 1.036571688928234e-06
BRCA1 O 0 0.00044006056850776076
germline O 0 0.00045894901268184185
mutations O 0 8.20396380731836e-05
in O 0 3.6349699712445727e-06
45 O 0 1.8309230654267594e-05
German O 1 0.9932010769844055
breast B-Disease 1 0.9999613761901855
/ I-Disease 1 0.999936580657959
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999955892562866
families O 0 1.4282519259722903e-05
. O 0 9.480308108322788e-06

In O 0 8.080841666924243e-07
this O 0 5.487529008973979e-08
study O 0 9.293101754792588e-08
we O 0 1.7327313628356933e-07
investigated O 0 2.5708561224746518e-05
45 O 0 8.408617759414483e-06
German O 1 0.9799277782440186
breast B-Disease 1 0.9999508857727051
/ I-Disease 1 0.9998793601989746
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999816417694092
families O 0 1.084777409232629e-06
for O 0 3.4882660315815883e-07
germline O 0 0.0001539098157081753
mutations O 0 2.7562173272599466e-05
in O 0 2.3890808620308235e-07
the O 0 4.216971376536094e-07
BRCA1 O 0 0.0001436901220586151
gene O 0 5.070730185252614e-05
. O 0 8.02579779701773e-06

We O 0 6.313111498457147e-06
identified O 0 4.345626166468719e-06
four O 0 9.636863751438796e-07
germline O 0 0.00011382155207684264
mutations O 0 6.384313746821135e-05
in O 0 1.616365011614107e-06
three O 0 1.1692657608364243e-05
breast B-Disease 1 0.9946503043174744
cancer I-Disease 1 0.6857194304466248
families O 0 8.675666407498284e-08
and O 0 1.9186794020242814e-07
in O 0 8.77540173860325e-07
one O 0 0.00015484572213608772
breast B-Disease 1 0.9999229907989502
- I-Disease 1 0.9999816417694092
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999914169311523
family O 0 8.029548553167842e-06
. O 0 4.475375092738432e-08
among O 0 1.3333019133199286e-08
these O 0 4.913726314725864e-09
were O 0 5.0133394324802794e-08
one O 0 4.754516851335211e-07
frameshift O 0 0.00024164161004591733
mutation O 0 2.4627741368021816e-05
, O 0 3.206433234481665e-07
one O 0 3.6385728208188084e-07
nonsense O 0 2.6900101147475652e-05
mutation O 0 1.218381839862559e-05
, O 0 1.2681613270615344e-07
one O 0 3.9996670864184125e-08
novel O 0 4.974619400854863e-07
splice O 0 4.380733662401326e-05
site O 0 1.0279411981173325e-05
mutation O 0 1.599270945007447e-05
, O 0 2.2813777889041376e-07
and O 0 1.3019507605349645e-07
one O 0 1.151266815213603e-06
missense O 0 0.0005132657242938876
mutation O 0 0.0003457416605670005
. O 0 9.734611012390815e-06

The O 0 8.83561369846575e-06
missense O 0 0.0007766037015244365
mutation O 0 9.68894237303175e-05
was O 0 1.4273559827415738e-05
also O 0 2.3773124269155232e-07
found O 0 2.44324183995559e-07
in O 0 2.079380578834389e-07
2 O 0 5.3873955039307475e-06
. O 0 1.6222209069383098e-06

8 O 0 8.590405741415452e-06
% O 0 3.4433938367328665e-08
of O 0 2.4232569728610542e-08
the O 0 1.4210874610398605e-07
general O 0 2.9593556405416166e-07
population O 0 1.549813966050806e-08
, O 0 5.705496519681219e-08
suggesting O 0 2.484239303157665e-07
that O 0 1.5732144476032772e-08
it O 0 6.772588534431634e-08
is O 0 4.173020613507106e-07
not O 0 1.9425883692747448e-06
disease O 0 0.2995428144931793
associated O 0 2.1308951545506716e-05
. O 0 4.796754637936829e-06

The O 0 1.8610595589052537e-06
average O 0 1.2407129361236002e-05
age O 0 9.88478677754756e-06
of O 0 3.635864231910091e-06
disease O 1 0.9958956241607666
onset O 0 0.008108425885438919
in O 0 4.077690505255305e-07
those O 0 8.594781064630297e-08
families O 0 2.773648191123357e-07
harbouring O 0 0.00043792594806291163
causative O 0 0.00023947762383613735
mutations O 0 6.209559796843678e-05
was O 0 7.728028322162572e-06
between O 0 7.788326001900714e-07
32 O 0 1.0474137525307015e-05
. O 0 3.660807351479889e-06

3 O 0 2.1528057914110832e-05
and O 0 1.7684906197246164e-06
37 O 0 1.5799139873706736e-05
. O 0 4.242693194100866e-06

4 O 0 1.8577169612399302e-05
years O 0 2.0463846794882556e-06
, O 0 1.1532498689348358e-07
whereas O 0 1.6356460719180177e-07
the O 0 1.8308043081560754e-07
family O 0 2.304294184796163e-06
harbouring O 0 0.0003119837201666087
the O 0 1.6552405668335268e-06
missense O 0 0.00018800364341586828
mutation O 0 1.2814880392397754e-05
had O 0 5.136095637681137e-07
an O 0 6.380340522582628e-08
average O 0 2.3465709091397002e-06
age O 0 1.8128254168914282e-06
of O 0 1.1098186547542355e-07
onset O 0 0.0006581461639143527
of O 0 8.338698762599961e-07
51 O 0 5.2855823014397174e-05
. O 0 6.3046577452041674e-06

2 O 0 5.8030473155668005e-05
years O 0 1.2550279279821552e-05
. O 0 3.962460141337942e-06

These O 0 1.6504645827808417e-07
findings O 0 9.58348664426012e-07
show O 0 5.17913406383741e-07
that O 0 1.0751850254564488e-07
BRCA1 O 0 2.6116340450244024e-05
is O 0 4.458327111933613e-07
implicated O 0 8.38843516248744e-06
in O 0 1.2202349353174213e-07
a O 0 2.880693443785276e-07
small O 0 5.414428869698895e-07
fraction O 0 1.3439505892165471e-05
of O 0 6.0399579524528235e-05
breast B-Disease 1 0.9998857975006104
/ I-Disease 1 0.9998964071273804
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999936819076538
families O 0 8.316501975969004e-07
suggesting O 0 1.6043280766098178e-06
the O 0 1.334001780151084e-07
involvement O 0 1.8947511080114054e-06
of O 0 1.0248182036320941e-07
another O 0 2.338865215278929e-06
susceptibility O 0 4.4256503315409645e-05
gene O 0 1.0523539458517917e-05
( O 0 5.440160748548806e-06
s O 0 0.0007624250138178468
) O 0 1.486897781433072e-05

Paternal O 0 0.02067040652036667
transmission O 1 0.985186755657196
of O 0 0.03799134120345116
congenital B-Disease 1 0.9999996423721313
myotonic I-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999977350234985
. O 0 0.001681518042460084

We O 0 8.232389518525451e-06
report O 0 9.650622132539866e-07
a O 0 1.0465244031365728e-06
rare O 0 1.7543736248626374e-05
case O 0 1.0906240277108736e-05
of O 0 6.97787663739291e-06
paternally O 1 0.9928615689277649
transmitted O 1 0.9997105002403259
congenital B-Disease 1 0.9999992847442627
myotonic I-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999986886978149
( O 0 0.004423400852829218
DM B-Disease 1 0.9999277591705322
) O 0 1.4444634871324524e-05
. O 0 5.704968771169661e-06

The O 0 3.114064156761742e-06
proband O 0 0.00014706347428727895
is O 0 4.59695542076588e-07
a O 0 8.081118494374095e-07
23 O 0 3.3276996873610187e-06
year O 0 7.27018971247162e-07
old O 0 0.0001688345510046929
, O 0 4.589063973980956e-05
mentally B-Disease 1 0.9998194575309753
retarded I-Disease 1 0.9963395595550537
male O 0 0.000243149625021033
who O 0 0.003725141752511263
suffers O 1 0.9992712140083313
severe O 1 0.9995989203453064
muscular B-Disease 1 0.9997962117195129
weakness I-Disease 1 0.9964312314987183
. O 0 9.837932157097384e-05

He O 0 5.274052091408521e-05
presented O 0 9.2527006927412e-06
with O 0 2.771060826489702e-05
respiratory O 1 0.99982750415802
and O 0 1.3847325135429855e-05
feeding O 0 8.844998228596523e-05
difficulties O 0 0.00016063752991613
at O 0 0.0003464024921413511
birth O 0 0.00013102554657962173
. O 0 8.990241440187674e-06

His O 0 4.278841879568063e-05
two O 0 1.9809209334198385e-05
sibs O 1 0.5647252202033997
suffer O 0 0.024980172514915466
from O 0 2.1961552192806266e-05
childhood O 0 0.09176711738109589
onset O 1 0.9981561303138733
DM B-Disease 1 0.9999628067016602
. O 0 0.0001044961391016841

Their O 0 1.0682110769266728e-06
late O 0 3.4464115742594004e-05
father O 0 1.1303027349640615e-05
had O 0 4.895132406090852e-07
the O 0 3.555586403081179e-08
adult O 0 6.546106874338875e-07
type O 0 1.5971796528901905e-05
of O 0 2.7410753773438046e-06
DM B-Disease 1 0.9999054670333862
, O 0 1.6951253201114014e-06
with O 0 4.7135236513895507e-07
onset O 0 0.0005197330028750002
around O 0 1.2460349125831272e-06
30 O 0 1.820814645725477e-06
years O 0 1.002784642878396e-06
. O 0 9.086044769901491e-07

Only O 0 3.0583510124415625e-07
six O 0 1.535890987724997e-07
other O 0 3.710421481173398e-08
cases O 0 4.000587239261222e-07
of O 0 1.0071110523313109e-07
paternal O 0 0.00026471319142729044
transmission O 1 0.9016700387001038
of O 0 0.0004967168206349015
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 0.9999960660934448
have O 0 4.6023214963497594e-05
been O 0 1.1734133295249194e-05
reported O 0 3.4275613870704547e-05
recently O 0 5.7492987252771854e-05
. O 0 4.856148734688759e-06

We O 0 2.826864374583238e-06
review O 0 5.222393042458862e-07
the O 0 7.417166614231974e-08
sex O 0 8.737055736673938e-07
related O 0 2.038534603343578e-06
effects O 0 1.5049168723635375e-05
on O 0 1.592185435583815e-05
transmission O 0 0.00946012046188116
of O 0 0.0004030799900647253
congenital B-Disease 1 0.9999990463256836
DM I-Disease 1 0.9999902248382568
. O 0 0.0002755361783783883

Decreased O 0 0.0005226388457231224
fertility O 0 0.00019679490651469678
of O 0 9.726185368208462e-08
males O 0 5.549266006710241e-07
with O 0 4.918417175758805e-07
adult O 0 3.465199188212864e-05
onset O 1 0.9429882168769836
DM B-Disease 1 0.999962568283081
and O 0 1.9359307771082968e-05
contraction O 0 2.3138041797210462e-05
of O 0 6.233194227434069e-08
the O 0 1.8576039906292863e-07
repeat O 0 6.941041647223756e-06
upon O 0 3.3931146958821046e-07
male O 0 1.8156924852519296e-06
transmission O 0 1.7110593034885824e-05
contribute O 0 1.2162162477125094e-07
to O 0 1.2875173815984908e-08
the O 0 1.12691523668218e-07
almost O 0 6.530326004394738e-07
absent O 0 1.8575274225440808e-05
occurrence O 0 2.619181395857595e-05
of O 0 2.2878923289226805e-07
paternal O 0 0.00015484514005947858
transmission O 1 0.7198271751403809
of O 0 0.002626130124554038
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 0.9999954700469971
. O 0 0.0005045989528298378

Also O 0 2.355481001359294e-06
the O 0 2.787535606785241e-07
fathers O 0 1.795519892766606e-06
of O 0 7.374115540415005e-08
the O 0 1.5337393506342778e-06
reported O 0 7.658675167476758e-05
congenitally O 0 0.0022421276662498713
affected O 0 3.9355518310912885e-06
children O 0 4.250929066529352e-07
showed O 0 1.2358501635389985e-06
, O 0 5.4302020657814865e-08
on O 0 3.3395187415408145e-07
average O 0 2.3079116999724647e-06
, O 0 5.648088290399755e-07
shorter O 0 1.6532872905372642e-05
CTG O 0 0.000578025879804045
repeat O 0 6.853407103335485e-05
lengths O 0 0.00013957990449853241
and O 0 1.045181988956756e-06
hence O 0 6.917331575095886e-06
less O 0 1.1988465303147677e-05
severe O 1 0.6790993213653564
clinical O 0 0.0007728345808573067
symptoms O 0 0.004706221166998148
than O 0 4.4984307834283754e-08
the O 0 1.5195168145965e-07
mothers O 0 1.4077512560106697e-06
of O 0 8.021200414987106e-08
children O 0 2.3646641693630954e-06
with O 0 0.0019133613677695394
congenital B-Disease 1 0.9999985694885254
DM I-Disease 1 0.999992847442627
. O 0 0.00020090816542506218

We O 0 2.8682363790721865e-06
conclude O 0 3.2372834084526403e-06
that O 0 6.010386499610831e-08
paternal O 0 6.689318252028897e-05
transmission O 0 0.03848685324192047
of O 0 0.00032076670322567225
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 0.9999977350234985
is O 0 2.9983162676217034e-05
rare O 0 2.0333027350716293e-05
and O 0 5.431019189927611e-07
preferentially O 0 4.563219135889085e-06
occurs O 0 7.416642802127171e-07
with O 0 3.7650448803105974e-07
onset O 0 0.0005519785918295383
of O 0 3.6010662824992323e-06
DM B-Disease 1 0.9996986389160156
past O 0 1.2655949831241742e-05
30 O 0 1.11036456473812e-06
years O 0 3.0054505373300344e-07
in O 0 6.24251015324262e-08
the O 0 8.867777268051213e-08
father O 0 1.0936411854345351e-05
. O 0 5.167431140762346e-07
. O 0 2.068836920443573e-06

The O 0 1.21751536426018e-05
RB1 O 0 0.002570767654106021
gene O 0 2.5220560928573832e-05
mutation O 0 1.6731089999666438e-05
in O 0 4.301218439195509e-07
a O 0 2.291513510499499e-06
child O 0 3.575158916646615e-05
with O 0 2.73747955361614e-05
ectopic B-Disease 1 0.9980249404907227
intracranial I-Disease 1 0.9997079968452454
retinoblastoma I-Disease 1 0.99054354429245
. O 0 5.884687925572507e-05

The O 0 2.2902135242475197e-05
RB1 O 0 0.0042844549752771854
gene O 0 4.6936984290368855e-05
mutation O 0 6.170665437821299e-05
was O 0 1.920598151627928e-05
investigated O 0 1.4489789464278147e-05
in O 0 3.696182204748766e-07
a O 0 5.172493274585577e-06
child O 0 5.5104777857195586e-05
with O 0 1.174741282738978e-05
ectopic B-Disease 1 0.9860326647758484
intracranial I-Disease 1 0.996266782283783
retinoblastoma I-Disease 0 0.0008176779956556857
using O 0 5.586818474512256e-07
DNA O 0 1.045179942593677e-06
obtained O 0 1.9049885224831087e-07
from O 0 3.741313392424672e-08
both O 0 4.688963528565182e-08
the O 0 4.96639984248759e-07
pineal B-Disease 0 0.0021030104253441095
and I-Disease 0 7.787445065332577e-05
retinal I-Disease 1 0.9114128947257996
tumours I-Disease 1 0.9999576807022095
of O 0 2.0038089587615104e-06
the O 0 3.233938696212135e-05
patient O 0 0.0009963405318558216
. O 0 7.892227586125955e-06

A O 0 9.515569399809465e-05
nonsense O 0 0.00034452261752448976
mutation O 0 4.5874145143898204e-05
in O 0 8.80585901086306e-07
exon O 0 3.2805844966787845e-05
17 O 0 5.090538707008818e-06
( O 0 1.7272225250053452e-07
codon O 0 2.687525011424441e-06
556 O 0 2.9157561129977694e-06
) O 0 2.3193287290723674e-08
of O 0 1.1405074218373557e-08
the O 0 2.700545849165792e-07
RB1 O 0 0.00018613628344610333
gene O 0 2.1988946627971018e-06
was O 0 3.990526238339953e-06
found O 0 6.112575334782377e-08
to O 0 4.222015181909455e-09
be O 0 1.8763303799573805e-08
present O 0 6.533589669288631e-08
homozygously O 0 1.741843698255252e-05
in O 0 6.757117887445929e-08
both O 0 6.223880433253726e-08
the O 0 3.876012044656818e-07
retinal B-Disease 0 0.0003490125818643719
and I-Disease 0 6.224465778359445e-06
the I-Disease 0 3.459483923506923e-05
pineal I-Disease 1 0.9782817959785461
tumours I-Disease 1 0.9999030828475952
. O 0 8.366636029677466e-05

The O 0 7.882853196861106e-07
same O 0 7.538288855357678e-07
mutation O 0 1.2704779692285229e-05
was O 0 2.987361540363054e-06
present O 0 1.5603946224018728e-07
heterozygously O 0 2.7409307222114876e-05
in O 0 7.673953916764731e-08
the O 0 6.042328948296927e-08
DNA O 0 6.116482609286322e-07
from O 0 6.791863427224598e-08
the O 0 5.952465897962611e-08
constitutional O 0 2.012538288909127e-06
cells O 0 4.4849460323348467e-07
of O 0 3.123546932215504e-08
the O 0 5.802755254080694e-07
patient O 0 2.9760818506474607e-05
, O 0 4.065125835950312e-07
proving O 0 2.7492435492604272e-06
it O 0 2.230276585635238e-08
to O 0 6.86137724414948e-09
be O 0 7.105278143626492e-08
of O 0 1.1782813658101077e-07
germline O 0 8.90413430170156e-05
origin O 0 3.8498114918184e-06
. O 0 8.60262935020728e-06

The O 0 1.3669337022292893e-06
initial O 0 2.2406006792152766e-06
mutation O 0 9.660008799983189e-06
was O 0 1.94840322365053e-06
shown O 0 7.556492676030757e-08
to O 0 1.4331576814186064e-08
have O 0 7.340324259530462e-08
occurred O 0 3.3368519325449597e-06
in O 0 1.3825689393343055e-07
the O 0 3.586496291063668e-07
paternally O 0 0.00025291633210144937
derived O 0 2.3456748749595135e-05
RB1 O 0 0.0061097401194274426
allele O 0 0.00025266854208894074
. O 0 1.6175406926777214e-05

The O 0 4.002871264674468e-06
mutation O 0 3.7093945138622075e-05
is O 0 4.9354076736563e-07
in O 0 5.151420268134643e-08
an O 0 3.133416370815212e-08
area O 0 2.405977852504293e-07
of O 0 7.457663819820937e-09
the O 0 1.8890494501988542e-08
gene O 0 7.866717055549088e-08
that O 0 1.9845527443607125e-09
encodes O 0 6.593314338942946e-09
the O 0 2.8588312162014518e-08
protein O 0 2.886028198645363e-07
- O 0 4.44061697635334e-06
binding O 0 1.944215682669892e-06
region O 0 1.973947064470849e-06
known O 0 5.829356837239175e-07
as O 0 2.447460474286345e-07
the O 0 3.3751186379049614e-07
pocket O 0 9.58474338403903e-05
region O 0 1.9973679172835546e-06
and O 0 3.546558957623347e-07
has O 0 4.1149431240228296e-07
been O 0 1.7604929780645762e-07
detected O 0 2.13253088077181e-06
in O 0 3.4706125973116286e-08
other O 0 9.515166432549904e-09
cases O 0 1.3836886125773162e-07
of O 0 8.430986753182879e-08
retinoblastoma B-Disease 0 0.005980800837278366
. O 0 2.507812268959242e-06
. O 0 3.891652795573464e-06

Low O 0 0.0002222344628535211
levels O 0 1.5208666809485294e-05
of O 0 1.41328243330463e-07
beta O 0 5.142220288689714e-06
hexosaminidase O 0 2.0000168660772033e-05
A O 0 1.791929435057682e-06
in O 0 1.6322475460128771e-07
healthy O 0 1.8871733118430711e-06
individuals O 0 9.090978636550062e-08
with O 0 5.920054263697239e-06
apparent O 0 0.46591243147850037
deficiency O 1 0.999221682548523
of O 0 5.257844577499782e-07
this O 0 4.526195311882475e-07
enzyme O 0 3.4898526791948825e-05
. O 0 4.944726242683828e-06

Appreciable O 0 0.00035986167495138943
beta O 0 6.0293226852081716e-05
hexosaminidase O 0 0.00016019868780858815
A O 0 7.874176844779868e-06
( O 0 3.2792641491141694e-07
hex O 0 1.0334079888707493e-05
A O 0 1.1886596666954574e-06
) O 0 5.9184802836398376e-08
activity O 0 1.2780856195604429e-07
has O 0 1.3971369128285005e-07
been O 0 1.4342560916702496e-07
detected O 0 4.020520009362372e-06
in O 0 2.010843047628441e-07
cultured O 0 2.5865308998618275e-05
skin O 0 0.00809020921587944
fibroblasts O 0 0.00010688174370443448
and O 0 8.10864003142342e-05
melanoma B-Disease 1 0.9993742108345032
tissue O 0 0.00032268435461446643
from O 0 7.226997809084423e-07
healthy O 0 1.5245201439029188e-06
individuals O 0 3.91088441631382e-08
previously O 0 3.4196791602880694e-06
reported O 0 2.0217170458636247e-05
as O 0 2.9364339297899278e-06
having O 0 0.0004488700069487095
deficiency B-Disease 1 0.9964045286178589
of I-Disease 0 1.5485852600249927e-07
hex I-Disease 0 4.937233461532742e-05
A I-Disease 0 2.0777856661879923e-06
activity O 0 4.876648063145694e-07
indistinguishable O 0 1.0327333939130767e-06
from O 0 8.375545945682461e-08
that O 0 1.1464702964758544e-08
of O 0 5.4434025287264376e-08
patients O 0 9.624935955798719e-06
with O 0 0.0003372606879565865
Tay B-Disease 1 0.9999922513961792
- I-Disease 1 0.9998935461044312
Sachs I-Disease 1 0.9999208450317383
disease I-Disease 1 0.9990893602371216
( O 0 1.1977782378380653e-05
TSD B-Disease 0 0.004810330457985401
) O 0 2.9212001209089067e-06
. O 0 4.102774710190715e-06

Identification O 0 3.3703920507832663e-06
and O 0 1.4183068515194464e-06
quantitation O 0 0.00037632149178534746
of O 0 1.1915697086806176e-06
hex O 0 9.024338214658201e-05
A O 0 4.186663772998145e-06
, O 0 1.3740681481522188e-07
amounting O 0 5.299486360854644e-07
to O 0 6.414983744207348e-08
3 O 0 4.922461812384427e-06
. O 0 2.526469188524061e-06

5 O 0 1.4386990187631454e-05
% O 0 6.505623559860396e-07
- O 0 0.0001230507914442569
6 O 0 2.771092658804264e-05
. O 0 3.6306114452600013e-06

9 O 0 1.4047636796021834e-05
% O 0 3.35830705466833e-08
of O 0 2.2318468850812678e-08
total O 0 1.2356480283415294e-07
beta O 0 4.519480626186123e-06
hexosaminidase O 0 3.90132081520278e-05
activity O 0 5.636455284729891e-07
, O 0 9.918376520090533e-08
has O 0 9.431024494688245e-08
been O 0 5.24995726891575e-08
obtained O 0 1.3877300375497725e-07
by O 0 2.81029912230224e-07
cellulose O 0 0.000772314437199384
acetate O 0 0.00026554736541584134
gel O 0 0.00047900836216285825
electrophoresis O 0 7.681892020627856e-05
, O 0 1.1256579455221072e-06
DEAE O 0 0.00017724672215990722
- O 0 6.522540934383869e-05
cellulose O 0 0.000128570303786546
ion O 0 9.675657202024013e-05
- O 0 5.346114267013036e-05
exchange O 0 1.2893212442577351e-05
chromatography O 0 0.00028496343293227255
, O 0 1.09386428448488e-06
radial O 0 7.547724089818075e-05
immunodiffusion O 0 0.0002550742938183248
, O 0 1.8074791796607315e-06
and O 0 1.580838670633966e-06
radioimmunoassay O 0 0.0010360447922721505
. O 0 1.338139372819569e-05

Previous O 0 2.502143252058886e-05
family O 0 5.054238954471657e-06
studies O 0 4.3005087491110316e-07
suggested O 0 4.5310625296224316e-07
that O 0 9.082656404757472e-09
these O 0 5.549956494377284e-09
individuals O 0 7.710879046385344e-09
may O 0 3.018716085989581e-07
be O 0 3.753306998532935e-08
compound O 0 8.086068419288495e-07
heterozygotes O 0 2.515966798455338e-06
for O 0 1.5550222443039274e-08
the O 0 6.981419176099735e-08
common O 0 2.004573616432026e-06
mutant O 0 2.97023852908751e-05
TSD B-Disease 0 0.0004903432563878596
gene O 0 4.718075615528505e-06
and O 0 7.284145908670325e-07
a O 0 1.8158690409109113e-06
rare O 0 2.5414048650418408e-05
( O 0 1.0641591643434367e-06
allelic O 0 6.683285755570978e-05
) O 0 9.376352636536467e-07
mutant O 0 1.9474391592666507e-05
gene O 0 3.830479909083806e-05
. O 0 7.202632332337089e-06

Thus O 0 1.1271897164988331e-05
, O 0 6.741141760358005e-07
the O 0 1.990895128756165e-07
postulated O 0 8.176990377251059e-06
rate O 0 9.076552487385925e-07
mutant O 0 9.624574204281089e-07
gene O 0 4.1955584606512275e-07
appears O 0 5.501210011971125e-07
to O 0 4.75391592758001e-09
code O 0 3.502539414057537e-08
for O 0 5.644801071014172e-09
the O 0 2.9725949701742138e-08
expression O 0 1.6765451960054634e-07
of O 0 1.1523999887685932e-07
low O 0 8.492786946590059e-06
amounts O 0 1.6385608887503622e-06
of O 0 3.788535991589015e-07
hex O 0 0.00011157560220453888
A O 0 3.1163523090071976e-05
. O 0 4.572196303342935e-06

Heterozygotes O 0 0.00014617152919527143
for O 0 2.9350655950111104e-07
the O 0 5.046591695645475e-07
rare O 0 1.645388147153426e-05
mutant O 0 1.7155556633952074e-05
may O 0 1.5431571682711365e-06
be O 0 4.625548299941329e-08
indistinguishable O 0 1.047042587742908e-06
from O 0 2.0145975554441975e-07
heterozygotes O 0 2.3101513306755805e-06
for O 0 3.9700783105445225e-08
the O 0 3.1114288390199363e-07
common O 0 2.3996810341486707e-05
TSD B-Disease 0 0.00807126984000206
mutant O 0 0.0002117476105922833
. O 0 9.392280844622292e-06

However O 0 2.1926125555182807e-06
, O 0 9.03903938365147e-08
direct O 0 6.990959633412785e-08
visualization O 0 7.922103577584494e-06
and O 0 1.0146939075639239e-06
quantitation O 0 0.000222242102609016
of O 0 6.465605224548199e-07
hex O 0 6.450326327467337e-05
A O 0 8.432190838902898e-07
by O 0 2.8929550310863306e-08
the O 0 5.875940800592616e-08
methods O 0 9.180777169603971e-07
described O 0 5.373536623665132e-06
may O 0 1.2522126553449198e-06
prevent O 0 2.1010232558182906e-06
false O 0 5.164059984963387e-06
- O 0 0.00010002908675232902
positive O 0 2.3260063244379126e-06
prenatal O 0 0.0005832890165038407
diagnosis O 0 0.0021469746716320515
of O 0 7.893694373706239e-07
TSD B-Disease 0 0.004322121851146221
in O 0 2.3851341666158987e-06
fetuses O 0 3.3295320463366807e-05
having O 0 1.4013739928486757e-06
the O 0 3.7578311662400665e-07
incomplete O 0 7.201152766356245e-05
hex B-Disease 0 0.0032918869983404875
A I-Disease 0 0.0007690228521823883
deficiency I-Disease 1 0.9966996312141418
of O 0 5.6290211603027274e-08
the O 0 1.4517841862016212e-07
type O 0 9.396562745678239e-06
described O 0 2.7434027742856415e-06
in O 0 1.0943853823164318e-07
the O 0 1.4810056825353968e-07
four O 0 1.28416434108658e-06
healthy O 0 1.8500795704312623e-05
individuals O 0 5.4260467550193425e-06

The O 0 3.826194006251171e-05
tumor B-Disease 0 0.008431359194219112
suppressor O 0 0.00028907295200042427
gene O 0 4.816235741600394e-05
Smad4 O 0 0.000697652401868254
/ O 0 0.00014475634088739753
Dpc4 O 0 0.00017526530427858233
is O 0 2.3193558718048735e-07
required O 0 9.724479355099902e-08
for O 0 3.567256712244671e-08
gastrulation O 0 2.338407102797646e-05
and O 0 1.8117057720701268e-07
later O 0 6.883105925226118e-07
for O 0 6.151733344950117e-08
anterior O 0 0.00017521182599011809
development O 0 2.748032841282111e-07
of O 0 7.193723661202966e-08
the O 0 3.7750615433651546e-07
mouse O 0 5.082949428469874e-05
embryo O 0 6.088963709771633e-05
. O 0 6.3500897340418305e-06

Mutations O 0 0.0004997686482965946
in O 0 3.395650537640904e-06
the O 0 3.2569316772423917e-06
SMAD4 O 0 0.014925784431397915
/ O 0 0.003946889191865921
DPC4 O 0 0.032815929502248764
tumor B-Disease 0 0.005382098723202944
suppressor O 0 4.314538455219008e-05
gene O 0 1.9716367205546703e-06
, O 0 8.74280985385667e-08
a O 0 2.831840788530826e-07
key O 0 2.317048711120151e-06
signal O 0 4.387969966046512e-06
transducer O 0 1.2465396139305085e-05
in O 0 3.5324288205629273e-07
most O 0 3.729124102846981e-07
TGFbeta O 0 0.00011000195081578568
- O 0 4.60335286334157e-05
related O 0 1.926660615936271e-06
pathways O 0 3.5984228361485293e-06
, O 0 5.627153143450414e-08
are O 0 2.309593849503244e-09
involved O 0 1.711046770935809e-08
in O 0 6.314312628319385e-08
50 O 0 4.526739303400973e-07
% O 0 1.5563908561944118e-07
of O 0 7.936440852063242e-06
pancreatic B-Disease 1 0.999968409538269
cancers I-Disease 1 0.9998410940170288
. O 0 2.2959122361498885e-05

Homozygous O 0 0.0012374605285003781
Smad4 O 0 0.0017651619855314493
mutant O 0 0.0005464442074298859
mice O 0 0.0003393250808585435
die O 0 0.0005170767544768751
before O 0 1.865035869741405e-06
day O 0 3.154126943627489e-06
7 O 0 8.811128282104619e-06
. O 0 1.5067329286466702e-06

5 O 0 1.8963610273203813e-05
of O 0 6.155736400614842e-07
embryogenesis O 0 0.00033694025478325784
. O 0 2.1809255486004986e-05

Mutant O 0 6.669953290838748e-05
embryos O 0 3.851717337965965e-06
have O 0 4.457545230707183e-07
reduced O 0 1.0382575510448078e-06
size O 0 3.92666242987616e-06
, O 0 1.4033265642865445e-06
fail O 0 1.6475536540383473e-05
to O 0 1.808608800502043e-07
gastrulate O 0 7.607904262840748e-05
or O 0 6.987306164774054e-07
express O 0 9.024402629620454e-07
a O 0 1.243180349774775e-06
mesodermal O 0 5.9062429500045255e-05
marker O 0 2.6745934519567527e-05
, O 0 2.7293580728837696e-07
and O 0 1.3785860630832758e-07
show O 0 3.7133711430215044e-06
abnormal O 0 0.0001609714818187058
visceral O 0 0.00010908565309364349
endoderm O 0 0.0022818585857748985
development O 0 6.702668542857282e-06
. O 0 1.1882802937179804e-05

Growth B-Disease 1 0.9955036044120789
retardation I-Disease 1 0.9999011754989624
of O 0 1.8613791326060891e-06
the O 0 9.624845006328542e-06
Smad4 O 0 0.03977194428443909
- O 0 0.00553958909586072
deficient O 0 0.00045638985466212034
embryos O 0 1.8158586954086786e-06
results O 0 6.475318059528945e-07
from O 0 7.114662992080412e-08
reduced O 0 4.0159346781365457e-07
cell O 0 2.7987657631456386e-06
proliferation O 0 1.0381712854723446e-05
rather O 0 8.012974461735212e-08
than O 0 4.671074549378318e-08
increased O 0 6.729194979016029e-07
apoptosis O 0 6.456782284658402e-05
. O 0 3.6779226775252027e-06

Aggregation O 0 7.671694038435817e-05
of O 0 1.0790324722620426e-06
mutant O 0 7.416147855110466e-05
Smad4 O 0 0.0007441100897267461
ES O 0 0.00017996055248659104
cells O 0 2.2917058686289238e-06
with O 0 3.6036627193425375e-07
wild O 0 1.3260506420920137e-05
- O 0 0.0001827986998250708
type O 0 9.609884000383317e-05
tetraploid O 0 0.0012301226379349828
morulae O 0 0.009696592576801777
rescues O 0 0.0006613513105548918
the O 0 1.4295246728579514e-05
gastrulation B-Disease 0 0.030399829149246216
defect I-Disease 0 0.10331428796052933
. O 0 2.8980750357732177e-05

These O 0 2.900685842632811e-07
results O 0 2.4642231437610462e-06
indicate O 0 7.973408742145693e-07
that O 0 6.190930434968323e-08
Smad4 O 0 3.218082565581426e-05
is O 0 1.729592895571841e-07
initially O 0 9.810961643097471e-08
required O 0 1.085129230915527e-08
for O 0 1.7393836371226712e-09
the O 0 8.67819416328075e-09
differentiation O 0 1.3375611729316006e-07
of O 0 3.5566856126934e-08
the O 0 1.9975401244209934e-07
visceral O 0 3.96585492126178e-05
endoderm O 0 0.0005960310227237642
and O 0 1.0343972007831326e-06
that O 0 5.2955659413100875e-08
the O 0 8.580396979596117e-07
gastrulation B-Disease 0 0.001389060984365642
defect I-Disease 0 0.0013687986647710204
in O 0 8.169813554559369e-07
the O 0 1.1047790167140192e-06
epiblast O 0 0.0005596861010417342
is O 0 5.800973781333596e-07
secondary O 0 4.383774466987234e-06
and O 0 8.459866762677848e-07
non O 0 1.4586955330742057e-05
- O 0 0.0004928672569803894
cell O 0 0.00022204025299288332
autonomous O 0 2.2050237021176144e-05
. O 0 6.522746389237e-06

Rescued O 0 0.0006275181076489389
embryos O 0 4.6894841943867505e-05
show O 0 0.0001857304887380451
severe O 1 0.7047215104103088
anterior O 0 0.12575750052928925
truncations O 0 0.0021130433306097984
, O 0 2.5253082185372477e-06
indicating O 0 1.0918454336206196e-06
a O 0 3.6693108995677903e-07
second O 0 2.0478475448726385e-07
important O 0 6.386257922486038e-08
role O 0 3.864739426262531e-07
for O 0 2.7065121344094223e-07
Smad4 O 0 0.0002423143741907552
in O 0 3.510831220410182e-06
anterior O 0 0.0057467385195195675
patterning O 0 0.0012512053363025188
during O 0 3.7659854569938034e-05
embryogenesis O 0 0.0004680056299548596
. O 0 1.7672513422439806e-05

Prevalence O 0 0.0008804253884591162
of O 0 1.2457735465432052e-06
p16 O 0 0.00012540255556814373
and O 0 6.334031240839977e-06
CDK4 O 0 0.002377839758992195
germline O 0 0.0007488031988032162
mutations O 0 0.00022341760632116348
in O 0 9.182447683997452e-06
48 O 0 0.0005515287048183382
melanoma B-Disease 1 0.9995957016944885
- O 0 0.42115318775177
prone O 0 0.006686950568109751
families O 0 2.6250685891682224e-07
in O 0 1.1066138085880084e-06
France O 0 0.00025766718317754567
. O 0 9.076094102056231e-06

The O 0 2.8838301659561694e-05
French O 0 0.008268262259662151
Familial B-Disease 1 0.9968668818473816
Melanoma I-Disease 1 0.9994353652000427
Study O 0 1.918998168548569e-05
Group O 0 1.1131529390695505e-05
. O 0 3.852918780467007e-06

Germline O 0 0.005093720275908709
mutations O 0 0.00039288547122851014
in O 0 1.226493509420834e-06
the O 0 3.4819711913769424e-07
p16 O 0 2.035118632193189e-05
and O 0 5.164051799511071e-07
CDK4 O 0 5.383203460951336e-05
genes O 0 7.222140538942767e-07
have O 0 4.4334299786896736e-08
been O 0 2.771784295418911e-07
reported O 0 4.5778108415106544e-07
in O 0 3.427549444268152e-08
a O 0 2.051862963980966e-07
subset O 0 4.883801238975138e-07
of O 0 1.3268044085634756e-06
melanoma B-Disease 1 0.9983172416687012
pedigrees O 0 9.077105642063543e-05
, O 0 8.574033358854649e-07
but O 0 8.232416348619154e-08
their O 0 4.5002757076417765e-08
prevalence O 0 2.1175876099732704e-05
is O 0 8.633177372985301e-08
not O 0 1.7887618497525182e-08
well O 0 1.360125878591134e-07
known O 0 3.5491846119839465e-06
. O 0 2.986797426274279e-06

We O 0 5.742879238823662e-07
searched O 0 2.9866237127862405e-06
for O 0 3.118296376669605e-08
such O 0 1.751219542711624e-07
germline O 0 0.00026605979655869305
mutations O 0 9.180591587210074e-05
in O 0 2.555214678068296e-06
48 O 0 4.224205986247398e-05
French O 0 0.381273478269577
melanoma B-Disease 1 0.9999696016311646
- O 1 0.8901057839393616
prone O 0 0.004258523695170879
families O 0 5.126983282366382e-08
selected O 0 4.9893003506440436e-08
according O 0 1.4237932610683401e-08
to O 0 5.124340507478564e-09
two O 0 4.162265199170179e-08
major O 0 1.2902136177217471e-06
criteria O 0 2.9104896270837344e-07
families O 0 6.135466357193309e-09
with O 0 7.633122578454277e-08
at O 0 6.5239287323493045e-06
least O 0 5.0498847770086286e-08
three O 0 3.420914040930256e-08
affected O 0 7.972498394792638e-08
members O 0 1.3901268580696069e-08
( O 0 6.57367777989748e-08
n O 0 4.724558948510094e-06
= O 0 4.249674930179026e-06
20 O 0 2.1844549280558567e-07
) O 0 1.0441717712694754e-08
or O 0 2.5791305091615868e-08
families O 0 4.031688316530335e-09
with O 0 1.1858767301475837e-08
two O 0 5.08528010811915e-08
affected O 0 1.3191268521950406e-07
members O 0 1.2380374059262067e-08
, O 0 3.0975254361464977e-08
one O 0 1.7915104066901222e-08
of O 0 2.8550317665576586e-09
them O 0 5.6884883470331715e-09
affected O 0 1.301979324352942e-07
before O 0 7.573909499569709e-08
the O 0 2.3832363638121024e-08
age O 0 2.147706226196533e-07
of O 0 1.3140085464158346e-08
50 O 0 1.5791269447618106e-07
( O 0 9.926609578769785e-08
n O 0 5.58946885576006e-06
= O 0 9.319457603851333e-06
28 O 0 1.212502752423461e-06
) O 0 2.1630688351592653e-08
, O 0 1.853685382968706e-08
and O 0 2.2546519318211722e-08
one O 0 6.020403020556842e-08
additional O 0 9.130947375979304e-08
minor O 0 0.0005405484116636217
criterion O 0 0.00011655267007881775
. O 0 8.431768947048113e-06

Sixteen O 0 5.924567176407436e-06
different O 0 2.894570343414671e-07
p16 O 0 9.870519716059789e-05
germline O 0 0.000125744758406654
mutations O 0 1.1707441444741562e-05
were O 0 1.0737217337464244e-07
found O 0 1.3779119001355866e-07
in O 0 5.978704109566024e-08
21 O 0 3.173319953475584e-07
families O 0 1.1487620632522066e-08
, O 0 6.106910888092898e-08
while O 0 2.160869314593583e-07
one O 0 4.5931517433928093e-07
germline O 0 8.336087194038555e-05
mutation O 0 5.148540003574453e-05
, O 0 9.660105888542603e-07
Arg24His O 0 5.4587821068707854e-05
, O 0 4.997863243261236e-07
was O 0 6.286939878918929e-06
detected O 0 1.2938638064952102e-05
in O 0 1.1435857771857627e-07
the O 0 4.470478245366394e-07
CDK4 O 0 0.00037362228613346815
gene O 0 3.122909038211219e-05
. O 0 8.995060852612369e-06

The O 0 5.697405072169204e-07
frequency O 0 5.156668521522079e-06
of O 0 1.2454262332539656e-07
p16 O 0 1.6316966139129363e-05
gene O 0 4.727479790744837e-06
mutation O 0 7.514647677453468e-06
in O 0 1.1742115901824945e-07
our O 0 6.8661066165987e-08
sample O 0 8.806340190403716e-08
( O 0 4.5646626034567817e-08
44 O 0 1.2345927302703785e-07
% O 0 7.718722550009716e-09
) O 0 1.3217707817148039e-08
is O 0 2.790971720401103e-08
among O 0 2.4243943741453222e-08
the O 0 1.0480830781034456e-07
highest O 0 2.5452125555602834e-05
rates O 0 2.4921889689721866e-06
yet O 0 9.503177693659381e-07
reported O 0 2.2614322006120346e-06
and O 0 7.765892462430202e-08
the O 0 3.1454408144782064e-07
CDK4 O 0 0.00039125888724811375
mutation O 0 1.0087399459735025e-05
is O 0 9.908034570571544e-08
the O 0 6.248203732184265e-08
second O 0 1.4550377045452478e-06
mutation O 0 9.608391337678768e-06
detected O 0 1.3144307558832224e-05
in O 0 4.162003008900683e-08
this O 0 8.93901219711779e-09
gene O 0 6.025262564435252e-07
worldwide O 0 1.5839262914596475e-06
. O 0 2.970582727357396e-06

In O 0 3.089270649070386e-06
summary O 0 3.969385488744592e-06
, O 0 2.6594031510285276e-07
our O 0 1.1082427420205931e-07
results O 0 3.2213290523941396e-07
show O 0 4.6994389890642196e-07
frequent O 0 2.4919775114540244e-06
involvement O 0 7.968467343744123e-07
of O 0 4.940757492022385e-08
the O 0 3.3591018677725515e-07
p16 O 0 2.192081228713505e-05
gene O 0 6.741348443028983e-06
in O 0 4.9792697609518655e-06
familial B-Disease 1 0.9742899537086487
melanoma I-Disease 1 0.9996823072433472
and O 0 1.1018013310604147e-06
confirm O 0 6.870180300211359e-07
the O 0 1.0072954381712407e-07
role O 0 5.592815455202071e-07
of O 0 3.948156290789484e-08
the O 0 3.019893881628377e-07
CDK4 O 0 0.00012106994836358353
gene O 0 2.555826540628914e-06
as O 0 1.4549973457178567e-06
a O 0 2.6188015908701345e-05
melanoma B-Disease 1 0.9945205450057983
- O 0 0.00010369686788180843
predisposing O 0 4.3580115743679926e-05
gene O 0 7.4133017733402085e-06
. O 0 6.111282004894747e-07
. O 0 1.8318293086849735e-06

Progression O 0 0.0011257859878242016
of O 0 2.8045742510585114e-06
somatic O 0 0.00027552148094400764
CTG O 0 0.0031728772446513176
repeat O 0 6.112322444096208e-05
length O 0 3.3663477552181575e-06
heterogeneity O 0 6.225493052625097e-06
in O 0 2.0443273740511358e-07
the O 0 3.9160912024271965e-07
blood O 0 0.00018425568123348057
cells O 0 6.350008334266022e-05
of O 0 8.237924339482561e-05
myotonic B-Disease 1 0.9999842643737793
dystrophy I-Disease 1 0.9999953508377075
patients O 0 0.0950133353471756
. O 0 2.787642188195605e-05

The O 0 3.2744721920607844e-06
genetic O 0 3.678609573398717e-05
basis O 0 7.98542532720603e-06
of O 0 8.731819252716377e-05
myotonic B-Disease 1 0.9999872446060181
dystrophy I-Disease 1 0.9999934434890747
( O 0 0.000465399120002985
DM B-Disease 1 0.9998984336853027
) O 0 6.730126074216969e-07
is O 0 1.3053185909939202e-07
the O 0 2.928765141518852e-08
expansion O 0 4.966125288774492e-07
of O 0 8.31731199468777e-08
an O 0 1.8844162923414842e-06
unstable O 0 0.012568722479045391
CTG O 0 0.0007445467635989189
repeat O 0 1.3556787962443195e-05
in O 0 1.6787707579624112e-07
the O 0 1.8165776793921395e-07
34 O 0 6.07497554483416e-07
UTR O 0 1.2630208402697463e-05
of O 0 1.3016986599723168e-07
the O 0 1.7304851098742802e-06
DM B-Disease 1 0.9818065166473389
protein O 0 3.552662519723526e-06
kinase O 0 8.313937541970517e-06
gene O 0 1.8109576558344997e-06
on O 0 1.8119733340427047e-06
chromosome O 0 7.19124436727725e-05
19 O 0 1.1564846317924093e-05
. O 0 1.680388209024386e-06

One O 0 2.00443969333719e-06
of O 0 1.0179549292388401e-07
the O 0 1.6458670870633796e-07
principal O 0 2.0932072857249295e-06
features O 0 6.033548629602592e-07
of O 0 6.203932798598544e-07
the O 0 1.603693817742169e-05
DM B-Disease 1 0.9998282194137573
mutation O 0 0.00013579166261479259
is O 0 6.525606863760913e-07
an O 0 1.3743800764132175e-07
extraordinarily O 0 5.6938522902783006e-05
high O 0 2.7318339562043548e-05
level O 0 2.618362714201794e-06
of O 0 1.812113481491906e-07
somatic O 0 4.376591095933691e-05
mosaicism O 0 0.0023557126987725496
, O 0 1.0175186844207929e-06
due O 0 1.4377458228409523e-06
to O 0 2.5460652253173066e-08
an O 0 1.2811352689823252e-07
extremely O 0 6.730236236762721e-06
high O 0 1.3172090802981984e-05
degree O 0 1.8576231468614424e-06
of O 0 1.577704438204819e-07
somatic O 0 2.3884278562036343e-05
instability O 0 3.8535697967745364e-05
both O 0 1.2956350303738873e-07
within O 0 1.7284288844621187e-07
and O 0 6.699816168520556e-08
between O 0 1.159418800966705e-07
different O 0 6.878925660203095e-07
tissues O 0 0.00041921684169210494
. O 0 1.1709765203704592e-05

This O 0 5.031645287090214e-06
instability O 0 0.00011021676618838683
appears O 0 2.869051741072326e-06
to O 0 2.230570217420791e-08
be O 0 3.126974235101443e-08
biased O 0 3.016114362708322e-07
towards O 0 5.1582432547547796e-08
further O 0 2.782859986893982e-08
expansion O 0 1.9442586562945507e-07
and O 0 5.4120757653208784e-08
continuous O 0 3.14900034936727e-07
throughout O 0 2.4132185671987827e-07
the O 0 8.381586980021893e-08
life O 0 2.379449171030501e-07
of O 0 7.122141099102919e-09
an O 0 2.7579719841241968e-08
individual O 0 1.771601532141176e-08
, O 0 4.265735853437036e-08
features O 0 2.5802012260101037e-07
that O 0 2.2322556247900138e-08
could O 0 7.59971072739063e-08
be O 0 3.6818416759842876e-08
associated O 0 1.6524678869700438e-07
with O 0 1.1911205177739248e-07
the O 0 1.0845869837794453e-06
progressive O 0 0.00020937978115398437
nature O 0 1.0204971658822615e-05
of O 0 9.193946084451454e-07
the O 0 5.49226206203457e-05
disease O 1 0.9959650039672852
. O 0 8.717698619875591e-06

Although O 0 1.8185517092206283e-06
increasing O 0 9.362306627735961e-07
measured O 0 6.619805390073452e-06
allele O 0 7.481054581148783e-06
size O 0 9.896794836095069e-06
between O 0 3.907607151631964e-06
patients O 0 1.472027270210674e-05
clearly O 0 5.35397418843786e-07
correlates O 0 1.2382072327454807e-06
with O 0 7.469127183412638e-08
an O 0 1.8219388664419967e-07
increased O 0 1.6076116935437312e-06
severity O 0 0.00011514070502016693
of O 0 5.382519248087192e-07
symptoms O 0 0.009358988143503666
and O 0 2.0010693901895138e-07
an O 0 1.0135299532976205e-07
earlier O 0 2.632225687193568e-06
age O 0 1.8534858554630773e-06
of O 0 1.4041845020074106e-07
onset O 0 0.000576994672883302
, O 0 1.2849001507220237e-07
this O 0 5.39959676970625e-09
correlation O 0 4.674158304851517e-08
is O 0 2.0406414336093803e-08
not O 0 6.400217689161991e-09
precise O 0 1.8581675931272912e-07
and O 0 1.55206578256184e-07
measured O 0 2.0502211555140093e-06
allele O 0 2.101554400724126e-06
length O 0 1.0446038913869415e-06
cannot O 0 3.009184581515001e-07
be O 0 9.702539216505102e-09
used O 0 1.4235733480916224e-08
as O 0 3.239097168261651e-08
an O 0 1.3656076269796813e-08
accurate O 0 5.497118991115713e-07
predictor O 0 1.8996464859810658e-05
of O 0 1.9607603007898433e-07
age O 0 6.596626917598769e-06
of O 0 1.233743546436017e-06
onset O 0 0.09920911490917206
. O 0 2.332404619664885e-05

In O 0 5.797301128040999e-07
order O 0 1.0785102233512589e-07
to O 0 8.863157319183301e-09
further O 0 1.877182320697557e-08
characterize O 0 2.291876398885506e-06
the O 0 1.0785436188598396e-06
dynamics O 0 0.00021332583855837584
of O 0 1.9043694919673726e-05
DM B-Disease 1 0.9996857643127441
CTG O 0 0.02034488320350647
repeat O 0 0.0005250530666671693
somatic O 0 0.0001716754777589813
instability O 0 0.0001996624778257683
, O 0 6.03866624260263e-07
we O 0 1.1811142286433096e-07
have O 0 4.2194493232727837e-08
studied O 0 1.1714549827956944e-06
repeat O 0 1.8073861838274752e-06
length O 0 3.158028505367838e-07
changes O 0 7.936374402106594e-08
over O 0 1.1134846999993897e-07
time O 0 5.901728741264378e-07
in O 0 3.283246087448788e-06
111 O 0 0.0014334399020299315
myotonic B-Disease 1 0.9998977184295654
dystrophy I-Disease 1 0.9999747276306152
patients O 0 0.00015449179045390338
with O 0 5.030571514907933e-07
varying O 0 9.533701813779771e-06
clinical O 0 0.0005569150089286268
severity O 0 0.000871131953317672
and O 0 4.414029717736412e-06
CTG O 0 0.0006616295431740582
repeat O 0 1.5834952137083746e-05
size O 0 1.7633170728004188e-06
over O 0 1.626698349355138e-07
time O 0 1.1819852119288043e-07
intervals O 0 1.416762870576349e-06
of O 0 3.103516021951691e-08
1 O 0 1.9668746062961873e-06
- O 0 3.5235345421824604e-05
7 O 0 1.1251385330979247e-05
years O 0 3.6363078379508806e-06
. O 0 1.7052041130227735e-06

We O 0 1.0186361123487586e-06
have O 0 3.043459528839776e-08
found O 0 3.7828524312999434e-08
a O 0 2.5844093087812325e-08
direct O 0 6.697669618915825e-08
progression O 0 1.993299156310968e-05
of O 0 3.170956830444993e-08
the O 0 7.683136260538959e-08
size O 0 1.0262936029903358e-06
heterogeneity O 0 2.604292376418016e-06
over O 0 2.6473330194676237e-07
time O 0 1.594074774402543e-07
related O 0 5.440101062959002e-07
to O 0 7.059551876409387e-08
initial O 0 1.7290449250140227e-06
CTG O 0 0.00013839060557074845
repeat O 0 7.705788448220119e-06
size O 0 1.3151842495062738e-06
and O 0 9.121322364080697e-08
the O 0 4.45730634623942e-08
time O 0 2.1419911888642673e-07
interval O 0 9.42454846608598e-07
and O 0 1.1171969305223683e-07
always O 0 4.1026393660104077e-07
biased O 0 5.913605605201155e-07
towards O 0 9.953664914519322e-08
further O 0 1.9652381411106035e-07
expansion O 0 9.986646546167322e-06
. O 0 4.474027718970319e-06

Attempts O 0 3.353537067596335e-06
to O 0 5.540926295566351e-08
mathematically O 0 1.0247688351228135e-06
model O 0 4.6969253730821947e-07
the O 0 9.924829669216706e-08
dynamics O 0 2.731208769546356e-05
have O 0 1.5263080399563478e-07
proved O 0 2.3391573904518737e-06
only O 0 9.081897900387048e-08
partially O 0 7.69199959904654e-06
successful O 0 1.1626401601461112e-06
suggesting O 0 9.97616552922409e-07
that O 0 5.799953406437908e-09
individual O 0 9.247127508160702e-09
specific O 0 1.070456079332871e-07
genetic O 0 6.015277904225513e-06
and O 0 2.6686204819270642e-06
/ O 0 0.00016829163359943777
or O 0 4.590778644342208e-06
environmental O 0 6.342046162899351e-06
factors O 0 1.2159043194515107e-07
also O 0 7.010895330950007e-08
play O 0 6.324231804910596e-08
a O 0 1.5089547389379732e-07
role O 0 7.507961754527059e-07
in O 0 3.3480617389614054e-07
somatic O 0 1.9899145627277903e-05
mosaicism O 0 0.001036702306009829
. O 0 1.434702312508307e-06
. O 0 5.158930889592739e-06

Aspartylglucosaminuria B-Disease 1 0.9913870692253113
among O 0 6.282079084485304e-06
Palestinian O 0 5.041428448748775e-05
Arabs O 0 6.289081647992134e-05
. O 0 3.9451842894777656e-05

Aspartylglucosaminuria B-Disease 1 0.9991903901100159
( O 0 0.0002185777557315305
AGU B-Disease 1 0.9978557229042053
) O 0 1.1611089121288387e-06
is O 0 4.244245417339698e-07
a O 0 4.818546585738659e-06
rare O 0 0.0024204060900956392
disorder B-Disease 1 0.9984402060508728
of I-Disease 0 1.8160975514547317e-06
glycoprotein I-Disease 0 0.04575086385011673
metabolism I-Disease 1 0.9008327126502991
caused O 0 0.00024307728745043278
by O 0 7.632029905835225e-07
the O 0 1.5276684280252084e-05
deficiency B-Disease 1 0.9985804557800293
of I-Disease 0 3.3459070891694864e-07
the I-Disease 0 3.3397491279174574e-06
lysosomal I-Disease 0 0.022057335823774338
enzyme I-Disease 0 0.0002949807676486671
aspartylglucosaminidase I-Disease 0 0.002328954404219985
( O 0 3.697744205055642e-06
AGA O 0 0.00021057462436147034
) O 0 2.273273139508092e-06
. O 0 2.8607514650502708e-06

AGU B-Disease 1 0.999170184135437
is O 0 9.133813728112727e-05
inherited O 0 0.019677288830280304
as O 0 4.754762358061271e-06
an O 0 3.2041696158557897e-06
autosomal O 1 0.9952715039253235
recessive O 1 0.9950336217880249
trait O 0 0.004636609926819801
and O 0 2.77321692010446e-06
occurs O 0 1.1827243042716873e-06
with O 0 4.911779782901249e-08
a O 0 4.706817549049447e-07
high O 0 5.108542154630413e-06
frequency O 0 1.9467538550088648e-06
in O 0 2.0474257667046913e-07
Finland O 0 4.713928774435772e-06
because O 0 7.177688843285068e-08
of O 0 3.0053183053269095e-08
a O 0 1.5654102298867656e-06
founder O 0 5.161493754712865e-05
effect O 0 1.9515608073561452e-05
. O 0 4.911634732707171e-06

While O 0 4.785678811458638e-06
very O 0 2.957619017252e-06
few O 0 2.954704086732818e-06
patients O 0 7.780192390782759e-06
with O 0 5.118666194903199e-06
AGU B-Disease 1 0.9990172386169434
have O 0 1.1003868394254823e-06
been O 0 9.948319075192558e-07
reported O 0 1.4964853107812814e-06
from O 0 1.638984485907713e-07
non O 0 3.2304581054631853e-06
- O 0 3.906398706021719e-05
Finnish O 0 6.738552474416792e-05
origin O 0 4.281349390566902e-07
, O 0 1.7812990336096846e-06
we O 0 1.0561472663539462e-05
diagnosed O 1 0.9981093406677246
the O 0 3.364229314684053e-06
disorder O 1 0.9924334287643433
in O 0 7.739290026620438e-07
8 O 0 4.95511039844132e-06
patients O 0 5.879179525436484e-07
originating O 0 3.007016005085461e-07
from O 0 1.886367613224138e-07
3 O 0 5.645471219395404e-07
unrelated O 0 1.0297416110915947e-06
families O 0 2.0037003167772127e-08
, O 0 1.6017606796481232e-08
all O 0 4.188775992730598e-09
Palestinian O 0 3.4662005532482e-07
Arabs O 0 5.303516559251875e-07
from O 0 3.7596663560179877e-07
the O 0 1.725398419694102e-07
region O 0 1.705714794297819e-06
of O 0 2.6628953264662414e-07
Jerusalem O 0 0.00037408186472021043
. O 0 1.7562970242579468e-05

The O 0 3.0206909286789596e-05
clinical O 0 0.0010040441993623972
diagnosis O 1 0.7638766765594482
of O 0 1.5136782167246565e-05
AGU B-Disease 1 0.9997933506965637
is O 0 4.3455638660816476e-06
often O 0 1.1955171430599876e-06
difficult O 0 1.568078801028605e-06
, O 0 7.811201641061416e-08
in O 0 2.8612040736675226e-08
particular O 0 3.137351356485851e-08
early O 0 3.1432335845238413e-07
in O 0 3.845063289986683e-08
the O 0 5.521240709072117e-08
course O 0 2.3016848444967763e-06
of O 0 6.923615103460179e-08
the O 0 1.8434027424518717e-06
disease O 0 0.3672734200954437
, O 0 1.1229844432136815e-07
and O 0 2.8958698550241024e-08
most O 0 1.9271785944852127e-08
of O 0 1.519591386056618e-08
the O 0 5.753666982855066e-07
patients O 0 7.382337116723647e-06
are O 0 2.85500675545336e-07
diagnosed O 1 0.5591765642166138
after O 0 6.548455075972015e-07
the O 0 3.733151743290364e-08
age O 0 4.642563169454661e-07
of O 0 5.5744873606045076e-08
5 O 0 2.325261220903485e-06
years O 0 3.0539258659700863e-06
. O 0 1.8341403347221785e-06

However O 0 2.895809302572161e-06
, O 0 7.660074174964393e-07
since O 0 1.3166550161258783e-06
these O 0 5.6762001321430944e-08
patients O 0 3.088065795964212e-06
excrete O 0 1.5085349332366604e-05
early O 0 7.503209076276107e-07
large O 0 2.853460614460346e-07
amounts O 0 1.3083487147014239e-06
of O 0 2.616166341340431e-07
aspartylglucosamine O 0 0.00011735797306755558
in O 0 5.566332106354821e-07
urine O 0 6.685852440568851e-06
, O 0 1.1492556950543076e-07
biochemical O 0 3.6191343042446533e-06
screening O 0 9.198024599754717e-07
is O 0 1.1514135422885374e-07
easy O 0 4.707737559783709e-07
by O 0 3.4596155273902696e-07
urine O 0 2.7328449505148456e-05
chromatography O 0 0.0005340200150385499
. O 0 1.1727337323463871e-06
. O 0 2.800154106807895e-06

Detection O 0 5.0863724027294666e-05
of O 0 2.960278493446822e-07
heterozygous O 0 3.3020680803019786e-06
carriers O 0 5.024443453294225e-06
of O 0 4.7653665546931734e-07
the O 0 5.351183790480718e-05
ataxia B-Disease 1 0.9999934434890747
- I-Disease 1 0.9993664622306824
telangiectasia I-Disease 1 0.9997439980506897
( O 0 4.354582415544428e-06
ATM O 0 3.842707519652322e-05
) O 0 3.1348335483016854e-07
gene O 0 1.2979033954252372e-06
by O 0 8.567673717152502e-07
G2 O 0 0.00048611636157147586
phase O 0 7.948934944579378e-05
chromosomal O 0 0.002268667798489332
radiosensitivity O 0 0.00043760481639765203
of O 0 1.694385105110996e-06
peripheral O 0 0.005501739215105772
blood O 0 0.01850585639476776
lymphocytes O 0 0.010928093455731869
. O 0 3.146159360767342e-05

In O 0 0.0002608185459394008
ataxia B-Disease 1 0.999940037727356
- I-Disease 1 0.9982503056526184
telangiectasia I-Disease 1 0.9997521042823792
( O 0 0.00012638754560612142
A B-Disease 1 0.999466598033905
- I-Disease 1 0.9966782331466675
T I-Disease 1 0.9997232556343079
) O 0 1.2788918866135646e-06
patients O 0 1.9634881027741358e-06
, O 0 9.539191836438476e-08
mutations O 0 2.5217701704605133e-07
in O 0 1.4883138277355101e-08
a O 0 4.033898193256391e-08
single O 0 1.1709976632801045e-07
gene O 0 5.1726976835198e-07
, O 0 1.44458596196273e-07
ATM O 0 1.058005182130728e-05
, O 0 3.938890529298078e-07
result O 0 1.401112058374565e-06
in O 0 1.2467480701161548e-06
an O 0 0.00010491728608030826
autosomal B-Disease 1 0.999996542930603
recessive I-Disease 1 0.9999948740005493
syndrome I-Disease 1 0.9999998807907104
that O 0 2.340607807127526e-06
embraces O 0 7.682830073463265e-06
a O 0 8.642697366667562e-07
variety O 0 1.0369711844759877e-06
of O 0 1.435322047882437e-07
clinical O 0 5.517405497812433e-06
features O 0 2.391641601207084e-06
and O 0 2.3710592813586118e-06
manifests O 0 4.472148430068046e-05
extreme O 0 5.4432908655144274e-05
radiosensitivity O 0 0.0002526321623008698
and O 0 7.0781032945888e-07
a O 0 1.2499446029323735e-06
strong O 0 2.897110334743047e-06
pre O 0 0.00046848724014125764
- O 0 0.0006134198047220707
disposition O 0 0.00022370794613379985
to O 0 7.352356988121755e-06
malignancy B-Disease 1 0.96479731798172
. O 0 1.4493301023321692e-05

Heterozygotes O 0 0.00010142970859305933
for O 0 8.706116716439283e-08
the O 0 7.481231278916312e-08
ATM O 0 1.978051477635745e-05
gene O 0 3.7251254525472177e-06
have O 0 2.0954654189608846e-07
no O 0 3.2272387784360035e-07
clinical O 0 1.0959348628603038e-06
expression O 0 2.071034685968698e-07
of O 0 5.3680633982367e-07
A B-Disease 1 0.9993515610694885
- I-Disease 1 0.9972905516624451
T I-Disease 1 0.9998797178268433
but O 0 4.484322289499687e-06
may O 0 5.72672433918342e-06
be O 0 6.363414286170155e-06
cancer B-Disease 1 0.5141697525978088
prone O 0 6.447392661357298e-05
with O 0 6.804206975630223e-08
a O 0 4.955707026965683e-07
moderate O 0 2.6979405447491445e-06
increase O 0 1.4019097704931482e-07
in O 0 1.3164624590444873e-07
in O 0 2.754689489847806e-07
vitro O 0 1.6084712115116417e-05
radiosensitivity O 0 0.00047844479558989406
. O 0 4.860633453063201e-06

We O 0 3.3749429348972626e-06
performed O 0 9.309845154348295e-06
a O 0 2.654127911227988e-06
blind O 0 2.0386034520925023e-05
chromosomal O 0 0.00023651233641430736
analysis O 0 1.8952950995299034e-06
on O 0 6.097680397942895e-06
G2 O 0 0.0005494445795193315
- O 0 7.380253373412415e-05
phase O 0 2.1743135221186094e-05
lymphocytes O 0 4.181799522484653e-05
from O 0 4.0126039380083967e-07
7 O 0 4.122439349885099e-06
unrelated O 0 5.169409269001335e-05
A B-Disease 1 0.998618483543396
- I-Disease 1 0.9975444674491882
T I-Disease 1 0.9998113512992859
patients O 0 4.120209996472113e-05
, O 0 5.647059424518375e-07
13 O 0 1.1395667343094829e-06
obligate O 0 1.1750235898944084e-05
A B-Disease 1 0.9963811039924622
- I-Disease 1 0.9809881448745728
T I-Disease 1 0.9989633560180664
heterozygotes O 0 9.774476347956806e-05
( O 0 3.609331145071337e-07
parents O 0 1.4609538823151524e-07
of O 0 1.906841795573655e-08
the O 0 2.489468613475765e-07
patients O 0 1.2005316420982126e-06
) O 0 3.383723168326469e-08
, O 0 3.383264868261904e-08
and O 0 2.6233758276816843e-08
14 O 0 2.2500000795844244e-07
normal O 0 2.6272047648490116e-07
controls O 0 1.1461553413028014e-06
following O 0 7.786343871885038e-07
X O 0 3.203333471901715e-05
- O 0 7.357448794209631e-06
irradiation O 0 1.6596189880146994e-06
with O 0 1.4528480107856012e-07
1 O 0 1.1147782288389863e-06
Gy O 0 1.8311868188902736e-05
in O 0 1.3238403084869788e-07
order O 0 3.0438542353294906e-08
to O 0 1.1197414551133988e-08
evaluate O 0 5.134127150085988e-07
this O 0 2.1880781631011814e-08
cytogenetic O 0 2.941133061540313e-05
method O 0 1.0063276079108618e-07
as O 0 5.0695721398597016e-08
a O 0 1.3161775314074475e-07
tool O 0 1.0721475973696215e-06
for O 0 2.8424166131912898e-08
detection O 0 1.7455716943004518e-06
of O 0 1.276503240887905e-07
ATM O 0 0.00020180977298878133
carriers O 0 6.31900766165927e-05
. O 0 1.1402285963413306e-05

Both O 0 1.6475300071761012e-05
A B-Disease 1 0.9982962012290955
- I-Disease 1 0.9964877367019653
T I-Disease 1 0.9993072748184204
homozygotes O 0 0.0010997358476743102
and O 0 2.2104543404566357e-06
heterozygotes O 0 4.600987085723318e-05
showed O 0 3.2959455893433187e-06
significantly O 0 1.0091432613990037e-06
increased O 0 6.021006129230955e-07
levels O 0 6.2361827986023854e-06
of O 0 3.070577804464847e-06
radiation O 1 0.9957922697067261
- O 0 0.3169442117214203
induced O 0 0.014683427289128304
chromatid O 0 0.08008366823196411
damage O 0 0.0002869807358365506
relative O 0 1.4813518873779685e-06
to O 0 3.211261656588249e-08
that O 0 2.5124123226305528e-08
of O 0 5.668335134600966e-08
normal O 0 9.575754120305646e-06
controls O 0 5.445824353955686e-05
. O 0 9.320621757069603e-06

These O 0 1.6183766149424628e-07
results O 0 6.571050903403375e-07
show O 0 4.312332464451174e-07
that O 0 2.0007252743425852e-08
the O 0 3.737804377124121e-07
G2 O 0 0.0006150297704152763
- O 0 0.0001143511472037062
phase O 0 3.4634285839274526e-05
chromosomal O 0 0.001004943740554154
radiosensitivity O 0 0.00012194588634883985
assay O 0 3.5521070458344184e-06
can O 0 5.5683450739252294e-08
be O 0 4.3469978727728176e-09
used O 0 1.4504551337779503e-08
for O 0 4.7930202029533575e-09
the O 0 2.3679531224729544e-08
detection O 0 1.90848481906869e-06
of O 0 6.906072940182639e-07
A B-Disease 1 0.9993880987167358
- I-Disease 1 0.9990352392196655
T I-Disease 1 0.9997161030769348
heterozygotes O 0 0.0008088636095635593
. O 0 2.0005243641207926e-05

In O 0 1.2964213738086983e-06
combination O 0 3.563962991393055e-06
with O 0 2.327567614202053e-07
molecular O 0 2.5502249627606943e-05
genetic O 0 1.4099417057877872e-05
analyses O 0 1.5200718053165474e-06
, O 0 9.938695910705064e-08
this O 0 9.821293112111107e-09
test O 0 1.3604476123418863e-07
may O 0 7.884892738729832e-08
be O 0 4.170273015802195e-09
of O 0 1.5683599974281037e-09
value O 0 1.8759331865680906e-08
in O 0 5.464373842301029e-08
studies O 0 9.804190170825677e-08
of O 0 4.010828291711732e-08
familial B-Disease 0 0.0007597182993777096
and I-Disease 0 1.0561321687418967e-05
sporadic I-Disease 0 0.0018067832570523024
cancers I-Disease 1 0.9948694705963135
aimed O 0 1.3419218703347724e-05
at O 0 2.4670571292517707e-05
determination O 0 7.387312166429183e-07
of O 0 3.22380522277399e-08
the O 0 7.587514971874043e-08
potential O 0 2.687143592083885e-07
involvement O 0 1.6068792092482909e-06
of O 0 2.0751707552335574e-07
ATM O 0 0.0007872115820646286
mutations O 0 0.0006819602567702532
in O 0 2.9055661798338406e-05
tumor B-Disease 0 0.3975464701652527
risk O 0 3.616806861828081e-05
or O 0 8.674191462887393e-07
development O 0 3.2522990522920736e-07
. O 0 3.854937062897079e-07
. O 0 1.8859660713133053e-06

Ataxia B-Disease 1 0.999942421913147
- I-Disease 1 0.9982119798660278
telangiectasia I-Disease 1 0.999427318572998
: O 0 2.1296243630786194e-06
identification O 0 3.970018269683351e-07
and O 0 2.4783778940218326e-07
detection O 0 6.8281551648397e-06
of O 0 2.664297369392443e-07
founder O 0 6.82471800246276e-05
- O 0 7.178883242886513e-05
effect O 0 2.0502093320828862e-06
mutations O 0 2.4346177269762848e-06
in O 0 2.1994342347397833e-08
the O 0 1.4691293515056714e-08
ATM O 0 5.852139111084398e-06
gene O 0 2.0171037249383517e-06
in O 0 2.5881737997224263e-07
ethnic O 0 7.168097226895043e-07
populations O 0 4.759171588375466e-06
. O 0 4.224444637657143e-06

To O 0 4.0966643410911274e-08
facilitate O 0 1.3992290348596725e-07
the O 0 2.0646335485707823e-07
evaluation O 0 4.6778822593296354e-07
of O 0 9.392734057200869e-08
ATM O 0 8.868645818438381e-05
heterozygotes O 0 5.7048968301387504e-05
for O 0 2.871806259463483e-07
susceptibility O 0 2.842839057848323e-05
to O 0 2.495092417120759e-07
other O 0 1.2978043741895817e-06
diseases O 1 0.9983084201812744
, O 0 4.6475599901896203e-07
such O 0 3.302687048289954e-07
as O 0 0.00010864984506042674
breast B-Disease 1 0.9985333681106567
cancer I-Disease 1 0.9770286679267883
, O 0 1.264157134528432e-07
we O 0 3.533775938535655e-08
have O 0 1.2905241320027017e-08
attempted O 0 2.047156328899291e-07
to O 0 8.411675800346075e-09
define O 0 1.4673769044293294e-07
the O 0 4.124725805354501e-08
most O 0 4.851260726468354e-08
common O 0 2.668808747330331e-07
mutations O 0 1.2232368362674606e-06
and O 0 3.945642390590365e-08
their O 0 6.261995366685369e-08
frequencies O 0 1.4920642570359632e-05
in O 0 2.8749062039423734e-05
ataxia B-Disease 1 0.9999477863311768
- I-Disease 1 0.9985047578811646
telangiectasia I-Disease 1 0.9996941089630127
( O 0 0.00011571358481887728
A B-Disease 1 0.999460756778717
- I-Disease 1 0.9889293313026428
T I-Disease 1 0.9993817806243896
) O 0 8.500417152390582e-07
homozygotes O 0 3.182403452228755e-05
from O 0 3.1974187209016236e-07
10 O 0 2.97292473305788e-07
ethnic O 0 2.8187540124235966e-07
populations O 0 2.198177526224754e-06
. O 0 2.876459802791942e-06

Both O 0 2.8110757739341352e-06
genomic O 0 4.988555156160146e-05
mutations O 0 4.227275712764822e-05
and O 0 2.3644945201795053e-07
their O 0 4.624428129318403e-08
effects O 0 2.7384155600884696e-06
on O 0 3.936081611755071e-07
cDNA O 0 5.789555643787025e-07
were O 0 6.914442565175705e-07
characterized O 0 3.2912823371589184e-05
. O 0 4.056314537592698e-06

Protein O 0 3.6043114960193634e-05
- O 0 6.0738799220416695e-05
truncation O 0 4.362560866866261e-05
testing O 0 2.2234164589463035e-06
of O 0 1.9128195916096047e-08
the O 0 5.720981377521639e-08
entire O 0 1.1780470003941446e-06
ATM O 0 1.562103716423735e-05
cDNA O 0 4.605982667271746e-06
detected O 0 5.506978413905017e-05
92 O 0 5.4448319133371115e-06
( O 0 1.1885968831393257e-07
66 O 0 2.103713995893486e-06
% O 0 2.893247419422096e-08
) O 0 5.698785798813333e-08
truncating O 0 1.577467810420785e-05
mutations O 0 7.901430763013195e-06
in O 0 3.4456019193385146e-07
140 O 0 7.190794804046163e-07
mutant O 0 5.646921181323705e-06
alleles O 0 1.4057259249966592e-05
screened O 0 6.408676563296467e-05
. O 0 8.905844879336655e-06

The O 0 5.9986073210893665e-06
haplotyping O 0 0.0008518171380273998
of O 0 9.599054919817718e-07
patients O 0 6.868136551929638e-06
with O 0 1.8287069281086588e-07
identical O 0 3.2849737181095406e-05
mutations O 0 6.421021680580452e-05
indicates O 0 6.542243795593095e-07
that O 0 5.5396980336297474e-09
almost O 0 5.339716224739277e-08
all O 0 3.320167696330145e-09
of O 0 5.026147498199407e-09
these O 0 6.542042019219707e-09
represent O 0 3.746647792013391e-08
common O 0 7.308611316148017e-07
ancestry O 0 9.236966320713691e-07
and O 0 3.1556621138406626e-07
that O 0 2.843446900158142e-08
very O 0 3.412716012007877e-07
few O 0 1.0370364407208399e-06
spontaneously O 0 2.359681820962578e-05
recurring O 0 0.00016993314784485847
ATM O 0 0.0006962383049540222
mutations O 0 0.0003268705040682107
exist O 0 1.47397968248697e-05
. O 0 8.356240869034082e-06

Assays O 0 0.00018405253649689257
requiring O 0 1.4726420886290725e-05
minimal O 0 1.8439073755871505e-05
amounts O 0 2.0395070805534488e-06
of O 0 7.137347068919553e-08
genomic O 0 1.9744027213164372e-06
DNA O 0 9.075989737539203e-07
were O 0 5.1138961509877845e-08
designed O 0 1.8213376051789965e-07
to O 0 1.046708231200455e-08
allow O 0 1.987637254785568e-08
rapid O 0 1.8649612911758595e-06
screening O 0 6.873352162983792e-07
for O 0 2.2625181728130883e-08
common O 0 1.3050712368567474e-06
ethnic O 0 2.5924919100361876e-06
mutations O 0 0.0002544361923355609
. O 0 1.226776385010453e-05

These O 0 3.031166500022664e-07
rapid O 0 2.623056025186088e-05
assays O 0 3.840882709482685e-05
detected O 0 8.127016917569563e-05
mutations O 0 8.970047019829508e-06
in O 0 2.253990345479906e-07
76 O 0 3.6192518564348575e-06
% O 0 4.034297873545256e-08
of O 0 7.699905069102897e-08
Costa O 0 9.326111467089504e-05
Rican O 0 3.6944438761565834e-05
patients O 0 3.1624756502424134e-06
( O 0 4.608772030678665e-08
3 O 0 1.2915921843159595e-07
) O 0 1.353781708957058e-08
, O 0 1.6233578037372354e-08
50 O 0 4.348824589328615e-08
% O 0 6.9762777776816165e-09
of O 0 2.8803027518620183e-08
Norwegian O 0 0.00012315232015680522
patients O 0 3.883392309944611e-06
( O 0 6.944843278233748e-08
1 O 0 4.775639013132604e-07
) O 0 2.7181929596054033e-08
, O 0 2.335122140095791e-08
25 O 0 8.045072519280438e-08
% O 0 1.0870640387850017e-08
of O 0 3.725142860844244e-08
Polish O 0 0.0029567303135991096
patients O 0 1.6693173165549524e-05
( O 0 1.6143518166700233e-07
4 O 0 4.057310150074045e-07
) O 0 3.055027519849318e-08
, O 0 3.206762499985416e-08
and O 0 6.000249896942478e-08
14 O 0 3.0116595439722005e-07
% O 0 1.4083332722236719e-08
of O 0 5.692256976885801e-08
Italian O 0 0.0001093511309591122
patients O 0 6.624365141760791e-06
( O 0 1.0555621088315092e-07
1 O 0 3.293465056231071e-07
) O 0 2.0934214362000603e-08
, O 0 1.2570972707237615e-08
as O 0 1.8101543375337315e-08
well O 0 3.9445886557132326e-08
as O 0 1.6627606669317174e-07
in O 0 2.002130656819645e-07
patients O 0 5.182325821806444e-07
of O 0 5.067290587135176e-08
Amish O 0 1.4126172573014628e-05
/ O 0 0.00012217878247611225
Mennonite O 0 4.882685243501328e-05
and O 0 3.0861608593113488e-06
Irish O 0 2.6279636585968547e-05
English O 0 4.384004569146782e-06
backgrounds O 0 1.737752063490916e-05
. O 0 1.2750540008710232e-05

Additional O 0 1.1102332564405515e-06
mutations O 0 2.1765332348877564e-05
were O 0 1.8478577601399593e-07
observed O 0 9.708926427265396e-07
in O 0 1.273814547175789e-07
Japanese O 0 1.1939948763028951e-06
, O 0 2.5247467760891595e-07
Utah O 0 2.6235268251184607e-06
Mormon O 0 1.1515750486523757e-07
, O 0 3.024328520950803e-08
and O 0 6.448670575309734e-08
African O 0 2.0790949406546133e-07
American O 0 3.0870205591781996e-06
patients O 0 2.6034627808257937e-05
. O 0 2.6788302420754917e-06

These O 0 8.104738213887686e-08
assays O 0 1.9243082078901352e-06
should O 0 1.8192402251315798e-08
facilitate O 0 4.6569478939773035e-08
screening O 0 5.381174901231134e-07
for O 0 2.862853420992906e-07
A B-Disease 1 0.9816660284996033
- I-Disease 1 0.9420352578163147
T I-Disease 1 0.9986435770988464
heterozygotes O 0 2.13369530683849e-05
in O 0 2.1778609493594558e-07
the O 0 7.01518985124494e-08
populations O 0 1.0574401443363968e-07
studied O 0 1.9834485556202708e-06
. O 0 2.7782229494732746e-07
. O 0 1.4390709566214355e-06

The O 0 0.00011040579556720331
von B-Disease 1 0.9875857830047607
Hippel I-Disease 1 0.9911524653434753
- I-Disease 1 0.9861272573471069
Lindau I-Disease 1 0.9597411751747131
tumor I-Disease 0 0.03805851563811302
suppressor O 0 4.771721796714701e-05
gene O 0 1.5187849840003764e-06
is O 0 9.187708371882763e-08
required O 0 3.887464927743167e-08
for O 0 3.5283004962138875e-08
cell O 0 2.0310471882112324e-05
cycle O 0 1.7507565644336864e-05
exit O 0 1.3339907127374317e-05
upon O 0 4.099285888514714e-06
serum O 0 0.00027623240021057427
withdrawal O 0 0.0001484595995862037
. O 0 8.201154741982464e-06

The O 0 7.911111424618866e-06
inactivation O 0 0.001710873213596642
of O 0 1.3892489505451522e-06
the O 0 1.844741200329736e-05
von B-Disease 1 0.9940185546875
Hippel I-Disease 1 0.9916996955871582
- I-Disease 1 0.9820677638053894
Lindau I-Disease 1 0.9500959515571594
( I-Disease 0 3.577177267288789e-05
VHL I-Disease 0 0.06108484044671059
) I-Disease 0 1.4654970073024742e-05
tumor I-Disease 0 0.003769777249544859
suppressor O 0 0.00010356720304116607
gene O 0 1.0749039574875496e-05
predisposes O 0 3.459850267972797e-05
affected O 0 5.27567522112804e-07
individuals O 0 1.2361049961384651e-08
to O 0 6.063155666424791e-08
the O 0 2.630160452099517e-06
human O 0 0.001253618043847382
VHL B-Disease 1 0.9996011853218079
cancer I-Disease 1 0.9999816417694092
syndrome I-Disease 1 0.9999761581420898
and O 0 1.917830104503082e-06
is O 0 7.362674523392343e-07
associated O 0 1.8986580698765465e-06
with O 0 3.5060866139247082e-06
sporadic B-Disease 0 0.18528740108013153
renal I-Disease 1 0.9999513626098633
cell I-Disease 1 0.9993667006492615
carcinomas I-Disease 1 0.9999897480010986
( O 0 0.0001441689528292045
RCC B-Disease 1 0.9934366345405579
) O 0 1.88007936685608e-06
and O 0 4.830536454392131e-06
brain B-Disease 1 0.9135237336158752
hemangioblastomas I-Disease 0 0.01316217239946127
. O 0 1.5273915778379887e-05

VHL O 0 0.147344172000885
- O 0 0.0011230732779949903
negative O 0 3.672321327030659e-05
786 O 0 0.00038447623956017196
- O 0 0.00033424608409404755
0 O 0 2.6596961106406525e-05
RCC B-Disease 0 0.014604371041059494
cells O 0 5.540331130760023e-06
are O 0 1.5760203098125203e-07
tumorigenic O 0 3.574203947209753e-05
in O 0 7.877855523474864e-07
nude O 0 0.0002025673893513158
mice O 0 1.108969809138216e-05
which O 0 9.4202562195278e-08
is O 0 8.38699207861282e-08
suppressed O 0 9.038416237672209e-07
by O 0 3.2895531631993435e-08
the O 0 1.2650519920498482e-07
reintroduction O 0 9.772385965334252e-06
of O 0 1.1283793810434872e-06
VHL B-Disease 0 0.03366412967443466
. O 0 1.7788524928619154e-05

Remarkably O 0 0.00042761326767504215
, O 0 9.874619308902766e-07
this O 0 5.5872295234848934e-08
occurs O 0 3.503168102270138e-07
without O 0 6.333635838018381e-08
affecting O 0 4.718583284102351e-07
the O 0 1.3428820011540665e-07
growth O 0 4.7653892920607177e-07
rate O 0 5.445873512144317e-07
and O 0 5.56657191452814e-08
cell O 0 3.2637162803439423e-06
cycle O 0 2.0672946448030416e-06
profile O 0 6.15657029356953e-07
of O 0 1.8265033929765195e-08
these O 0 1.9233668879792276e-08
cells O 0 6.023010996614175e-07
in O 0 3.2085986845231673e-07
culture O 0 4.628921033145161e-06
. O 0 4.270459612598643e-06

The O 0 4.595610334945377e-06
786 O 0 9.471715020481497e-05
- O 0 3.3072348742280155e-05
0 O 0 2.890737960115075e-06
cell O 0 1.051623621606268e-05
line O 0 8.767783583607525e-06
, O 0 3.4828613593163027e-07
like O 0 8.484032605338143e-07
many O 0 6.370661367327557e-07
cancer B-Disease 0 0.07216853648424149
cells O 0 1.893965190902236e-06
, O 0 2.1425101692784665e-07
fails O 0 1.1710484386640019e-06
to O 0 1.0082062296135064e-08
exit O 0 1.2863436040788656e-06
the O 0 1.4582367668936058e-07
cell O 0 2.0718140149256214e-05
cycle O 0 8.313366379297804e-06
upon O 0 1.5051531363496906e-06
serum O 0 8.397921192226931e-05
withdrawal O 0 4.514319516601972e-05
. O 0 3.34934338752646e-06

Here O 0 7.613298748765374e-06
, O 0 3.762933999951201e-07
it O 0 3.3348747763284337e-08
is O 0 3.9226655701440905e-08
shown O 0 2.783550101526089e-08
that O 0 5.1648960663897014e-09
reintroduction O 0 3.754496162855503e-07
of O 0 1.5517750640015038e-08
the O 0 1.6859071649832913e-07
wild O 0 8.933056051319e-06
- O 0 0.00011557728430489078
type O 0 7.000329060247168e-05
VHL B-Disease 0 0.002492520259693265
gene O 0 6.870920969959116e-06
restores O 0 2.273878089908976e-05
the O 0 1.472513275757592e-07
ability O 0 1.1244756024098024e-06
of O 0 1.5382275933006895e-06
VHL O 1 0.6806268692016602
- O 0 0.04985462874174118
negative O 0 0.0003300233802292496
RCC B-Disease 1 0.9970801472663879
cancer I-Disease 1 0.6704290509223938
cells O 0 5.081925564809353e-07
to O 0 1.6654340129207412e-08
exit O 0 9.916274166243966e-07
the O 0 2.2704426783093368e-07
cell O 0 1.683518712525256e-05
cycle O 0 6.104761723690899e-06
and O 0 2.322297376622373e-07
enter O 0 3.5345422020327533e-06
G0 O 0 0.0009396439418196678
/ O 0 0.0001422475470462814
quiescence O 0 0.00018984409689437598
in O 0 4.2717101678135805e-06
low O 0 0.00015369013999588788
serum O 0 0.0002862120745703578
. O 0 6.041389042366063e-06

Both O 0 1.5886153050814755e-05
VHL O 0 0.021765805780887604
- O 0 0.0004003302601631731
positive O 0 2.968524086099933e-06
and O 0 2.910188868554542e-06
VHL O 0 0.012858371250331402
- O 0 0.0005896220100112259
negative O 0 2.1471121726790443e-05
RCC B-Disease 0 0.01365362387150526
cells O 0 2.4005191789910896e-06
exit O 0 3.716885885296506e-06
the O 0 3.0103817039162095e-07
cell O 0 3.883332828991115e-05
cycle O 0 7.77170862420462e-06
by O 0 2.3552829020445643e-07
contact O 0 1.315959707426373e-05
inhibition O 0 4.397416705614887e-05
. O 0 6.170504548208555e-06

The O 0 8.714258001418784e-06
cyclin O 0 0.000691025925334543
- O 0 8.013797196326777e-05
dependent O 0 9.534637683827896e-06
kinase O 0 6.959672464290634e-05
inhibitor O 0 3.208442285540514e-05
, O 0 4.0627230646350654e-07
p27 O 0 3.974836363340728e-05
, O 0 3.038477416339447e-07
accumulates O 0 5.379202775657177e-06
upon O 0 3.7560968735306233e-07
serum O 0 1.083983534044819e-05
withdrawal O 0 1.682370111666387e-06
, O 0 3.353583011289629e-08
only O 0 1.1416108058881491e-08
in O 0 1.7754713255158094e-08
the O 0 5.903260458239856e-08
presence O 0 5.244033332019171e-07
of O 0 1.0449532794609695e-07
VHL B-Disease 0 0.0007299142889678478
, O 0 2.820587781116046e-07
as O 0 6.516775385989604e-08
a O 0 1.8019252934209362e-07
result O 0 1.1565673219138262e-07
of O 0 9.729484773401964e-09
the O 0 7.37097920477936e-08
stabilization O 0 3.70209841094038e-06
of O 0 3.7485921922097987e-08
the O 0 2.649381372066273e-07
protein O 0 4.286160219635349e-06
. O 0 3.1756981115904637e-06

We O 0 2.6528070975473383e-06
propose O 0 3.740864713108749e-06
that O 0 5.0554742614394854e-08
the O 0 3.509334192131064e-07
loss O 0 4.3349202314857394e-05
of O 0 2.512652770292334e-07
wild O 0 2.0838360796915367e-05
- O 0 0.00024784388369880617
type O 0 0.00011535279918462038
VHL B-Disease 0 0.0035748258233070374
gene O 0 7.527042271249229e-06
results O 0 1.189771069221024e-06
in O 0 3.9368167392694886e-08
a O 0 1.1906423225127583e-07
specific O 0 7.429839143924255e-08
cellular O 0 0.0022979904897511005
defect O 0 0.004638212267309427
in O 0 1.705357021819509e-06
serum O 0 5.8182195061817765e-05
- O 0 1.2643728950934019e-05
dependent O 0 1.3380910104388022e-06
growth O 0 4.3319693077137345e-07
control O 0 1.5933132999634836e-06
, O 0 2.070404718779173e-07
which O 0 1.4923594449101074e-07
may O 0 2.0988461528759217e-06
initiate O 0 2.4933919121394865e-05
tumor B-Disease 0 0.11359909921884537
formation O 0 0.00021145145001355559
. O 0 1.0476675015524961e-05

This O 0 1.3718845366383903e-06
is O 0 8.946125262809801e-07
corrected O 0 1.6241425328189507e-05
by O 0 3.226518074939122e-08
the O 0 6.551572084845247e-08
reintroduction O 0 1.948905037352233e-06
of O 0 2.0707345527171128e-07
wild O 0 4.6281700633699074e-05
- O 0 0.0047883023507893085
type O 0 0.00289910938590765
VHL B-Disease 1 0.9256266355514526
, O 0 1.3186656360630877e-05
implicating O 0 0.0034327181056141853
VHL B-Disease 0 0.005782787222415209
as O 0 6.582736205018591e-07
the O 0 1.2091130940916628e-07
first O 0 9.24562868931389e-07
tumor B-Disease 0 0.00020238265278749168
suppressor O 0 7.990254744072445e-06
involved O 0 1.461631171650879e-07
in O 0 2.6681668430228456e-08
the O 0 3.218699617946186e-08
regulation O 0 5.849237822985742e-07
of O 0 4.5437108298074236e-08
cell O 0 1.5835767044336535e-05
cycle O 0 4.010379598184954e-06
exit O 0 4.751425876747817e-06
, O 0 1.1549988698789093e-07
which O 0 1.367972046750765e-08
is O 0 1.8302241500123273e-08
consistent O 0 8.327089773274565e-08
with O 0 3.279723514992838e-08
its O 0 1.595452658875729e-07
gatekeeper O 0 2.1303687390172854e-05
function O 0 8.115331411318039e-07
in O 0 2.504766882793774e-07
the O 0 1.3284111446409952e-06
kidney O 1 0.962028443813324
. O 0 1.1914709148186375e-06
. O 0 2.0372713152028155e-06

Piebaldism B-Disease 1 0.9991886019706726
with O 0 0.014077478088438511
deafness B-Disease 1 0.9999970197677612
: O 0 4.494023869483499e-06
molecular O 0 1.0260978342557792e-05
evidence O 0 3.4873679055635876e-07
for O 0 7.037328941805754e-08
an O 0 1.6551853150303941e-06
expanded O 0 0.0004337629652582109
syndrome O 1 0.9999343156814575
. O 0 9.39231631491566e-06

In O 0 1.7610332179174293e-06
a O 0 1.4990379213486449e-06
South O 0 1.916007477120729e-06
African O 0 2.1135274437256157e-06
girl O 0 4.806357537745498e-05
of O 0 4.59522397022738e-07
Xhosa O 0 0.0005210704985074699
stock O 0 0.0001955957995960489
with O 0 1.9208784578950144e-05
severe O 1 0.9750775694847107
piebaldism B-Disease 0 0.25962838530540466
and O 0 0.00037631107261404395
profound O 1 0.9942083358764648
congenital O 1 0.9999997615814209
sensorineural B-Disease 1 0.9999963045120239
deafness I-Disease 1 0.9999998807907104
we O 0 0.0005183771136216819
identified O 0 9.915122063830495e-06
a O 0 9.303367392021755e-07
novel O 0 1.6860740288393572e-06
missense O 0 1.7240841771126725e-05
substitution O 0 4.3086123469038284e-07
at O 0 3.8000459881004645e-06
a O 0 4.2815085521397123e-07
highly O 0 1.850229182309704e-06
conserved O 0 1.7536406176077435e-06
residue O 0 4.848651769862045e-06
in O 0 6.028837162830314e-08
the O 0 3.607613052736269e-08
intracellular O 0 5.174594662094023e-06
kinase O 0 3.4820716336980695e-06
domain O 0 7.505034318455728e-07
of O 0 6.476084024598094e-08
the O 0 1.048029616868007e-06
KIT O 0 0.00026831115246750414
proto O 0 0.020181268453598022
- O 0 0.003739434527233243
oncogene O 0 0.0034248388838022947
, O 0 7.128223387553589e-06
R796G O 0 0.0001610874169273302
. O 0 6.996968295425177e-06

Though O 0 5.3872092394158244e-05
auditory B-Disease 0 0.0012317525688558817
anomalies I-Disease 0 0.01235476229339838
have O 0 5.612274662780692e-07
been O 0 5.598728307631973e-07
observed O 0 1.2329401215538383e-06
in O 0 2.280916504560082e-07
mice O 0 3.8256375773926266e-06
with O 0 4.277557934528886e-07
dominant O 0 0.00032798241591081023
white O 0 0.0002130749635398388
spotting O 0 0.001757684862241149
( O 0 4.377729965199251e-06
W O 0 0.004258825443685055
) O 0 3.3985813274739485e-07
due O 0 2.334272949156002e-06
to O 0 4.154742612172413e-07
KIT O 0 0.000783969764597714
mutations O 0 0.0014037243090569973
, O 0 0.00013513778685592115
deafness B-Disease 1 0.9999967813491821
is O 0 5.212429641687777e-06
not O 0 2.930062237282982e-07
typical O 0 3.7910183436906664e-06
in O 0 1.3426019904727582e-06
human O 0 1.0153755283681676e-05
piebaldism B-Disease 0 0.001954885432496667
. O 0 1.3500214663508814e-05

Thus O 0 1.0293792911397759e-05
, O 0 8.15020257505239e-07
the O 0 9.395848223903158e-07
occurrence O 0 0.0005718244938179851
of O 0 5.1133007218595594e-05
sensorineural B-Disease 1 0.9999784231185913
deafness I-Disease 1 0.9999997615814209
in O 0 5.7480814575683326e-05
this O 0 9.101507316700008e-07
patient O 0 1.4896485481585842e-05
extends O 0 1.151301944446459e-06
considerably O 0 1.631579721106391e-06
the O 0 6.151581288804664e-08
phenotypic O 0 3.3325713957310654e-06
range O 0 3.066211775148986e-06
of O 0 1.8403096646579797e-07
piebaldism B-Disease 0 0.00021915703837294132
due O 0 3.616312142185052e-06
to O 0 1.1070892469433602e-07
KIT O 0 2.2011137843946926e-05
gene O 0 4.600205556926085e-06
mutation O 0 9.755996870808303e-06
in O 0 1.457235754287467e-07
humans O 0 6.313721883088874e-07
and O 0 4.1001752038027917e-07
tightens O 0 8.769211854087189e-05
the O 0 2.2899224916272942e-07
clinical O 0 3.020238636963768e-06
similarity O 0 8.404765594605124e-07
between O 0 1.0481784329385846e-06
piebaldism B-Disease 0 0.00018772759358398616
and O 0 1.5759179916585708e-07
the O 0 4.4328555048878115e-08
various O 0 1.2079927103059163e-07
forms O 0 1.581724609422963e-05
of O 0 0.00024813757045194507
Waardenburg B-Disease 1 0.9999397993087769
syndrome I-Disease 1 0.9999868869781494
. O 0 1.2328847333265003e-05
. O 0 7.104273208824452e-06

Cycloheximide O 0 0.0006777617381885648
facilitates O 0 7.809457201801706e-06
the O 0 2.0944803225120268e-07
identification O 0 3.3953224942706584e-07
of O 0 1.1544273803565375e-07
aberrant O 0 5.4394567996496335e-05
transcripts O 0 1.22916544569307e-05
resulting O 0 1.9099632027064217e-06
from O 0 1.1946880817959027e-07
a O 0 2.5130793801508844e-07
novel O 0 5.28606051375391e-07
splice O 0 4.8013411287683994e-05
- O 0 4.75012966489885e-05
site O 0 7.042322522465838e-06
mutation O 0 3.4672427773330128e-06
in O 0 2.1196788679844758e-07
COL17A1 O 0 3.2604111765976995e-05
in O 0 2.3443425334335188e-07
a O 0 2.9124294087523594e-06
patient O 0 4.065640678163618e-05
with O 0 8.25577080831863e-06
generalized O 0 0.11851995438337326
atrophic B-Disease 1 0.9998916387557983
benign I-Disease 1 0.9994804263114929
epidermolysis I-Disease 1 0.9972148537635803
bullosa I-Disease 1 0.9910457730293274
. O 0 0.0002059042890323326

Patients O 0 0.0008708838140591979
with O 0 7.528085552621633e-05
generalized O 1 0.5611227750778198
atrophic B-Disease 1 0.9998279809951782
benign I-Disease 1 0.9991336464881897
epidermolysis I-Disease 1 0.9934892654418945
bullosa I-Disease 1 0.9631783366203308
often O 0 2.799550748022739e-05
show O 0 6.689194378850516e-06
decreased O 0 1.3792049685434904e-05
expression O 0 1.5100933978828834e-06
of O 0 4.767457539855968e-07
type O 0 0.0004574063641484827
XVII O 0 0.14895814657211304
collagen O 0 0.0012794426875188947
, O 0 1.029062332236208e-06
a O 0 9.326589065494773e-07
transmembrane O 0 1.898903792607598e-05
hemidesmosomal O 0 2.5264613213948905e-05
protein O 0 2.4574708845648274e-07
encoded O 0 1.6434971428225253e-07
by O 0 9.943927352651372e-07
COL17A1 O 0 0.00132651231251657
. O 0 8.413414434471633e-06

This O 0 1.1669669675029581e-06
report O 0 5.929123290115967e-07
documents O 0 4.2106219666493416e-07
a O 0 5.147840056451969e-07
novel O 0 1.5496831338168704e-06
splice O 0 7.2997878305614e-05
- O 0 8.87510905158706e-05
site O 0 1.0257964277116116e-05
mutation O 0 8.04730188974645e-06
in O 0 3.705874576098722e-07
COL17A1 O 0 8.880561654223129e-05
in O 0 3.9183439071166504e-07
a O 0 3.127767058686004e-06
patient O 0 5.999682252877392e-05
with O 0 8.5754509200342e-06
generalized O 0 0.041759975254535675
atrophic B-Disease 1 0.9999035596847534
benign I-Disease 1 0.9992064833641052
epidermolysis I-Disease 1 0.9964522123336792
bullosa I-Disease 1 0.9837889671325684
, O 0 8.652992619317956e-06
and O 0 3.502653953546542e-07
applies O 0 2.106607723817433e-07
a O 0 1.5192341606962145e-07
new O 0 1.376623259830012e-07
methodology O 0 2.5860791197374056e-07
to O 0 1.0627778657124054e-08
define O 0 4.6472720782730903e-07
and O 0 2.0189153815408645e-07
characterize O 0 2.3842153495934326e-06
the O 0 1.1889686390986753e-07
resulting O 0 5.832871465827338e-07
mRNA O 0 8.951348036134732e-07
splice O 0 6.742756522726268e-05
variants O 0 2.0526160369627178e-05
. O 0 8.81746473169187e-06

Mutational O 0 0.003832554677501321
analysis O 0 6.14833561485284e-06
of O 0 9.535914955449698e-07
COL17A1 O 0 0.001534107024781406
identified O 0 1.2957184480910655e-05
a O 0 7.159508186305175e-06
maternally O 0 0.0005051245098002255
inherited O 0 0.04171530529856682
G O 0 0.0030837375670671463
- O 0 7.063455268507823e-05
to O 0 1.138876882578188e-06
- O 0 0.0001778892328729853
T O 0 0.0005725138471461833
transversion O 0 3.5620836570160463e-05
at O 0 4.627146608982002e-06
the O 0 1.4763435274289805e-07
- O 0 3.009362217198941e-06
1 O 0 4.02743694394303e-07
position O 0 9.119858077610843e-07
of O 0 1.2543480920612637e-07
exon O 0 3.692562677315436e-05
32 O 0 1.720559703244362e-05
. O 0 4.533813353191363e-06

This O 0 4.364646599697153e-07
acceptor O 0 8.99754923011642e-06
splice O 0 0.00023697754659224302
- O 0 0.0003661180380731821
site O 0 2.5066430680453777e-05
mutation O 0 1.1505388101795688e-05
led O 0 7.990910262378748e-07
to O 0 2.2665135546162674e-08
the O 0 9.611112261609378e-08
formation O 0 5.312416760716587e-06
of O 0 9.131662181971478e-08
aberrant O 0 1.4081921108299866e-05
transcripts O 0 6.399197445716709e-06
present O 0 1.0483074674993986e-06
at O 0 2.7131585738970898e-05
extremely O 0 2.561571091064252e-05
low O 0 0.00015995721332728863
levels O 0 4.95841886731796e-05
. O 0 5.85701354793855e-06

Based O 0 7.431369226651441e-07
on O 0 5.664843456543167e-07
our O 0 1.1138818933886796e-07
recent O 0 1.0008805020333966e-06
finding O 0 8.282498811240657e-07
that O 0 2.0670172773407103e-07
cycloheximide O 0 0.00022065328084863722
stabilized O 0 0.00024951164959929883
mutant O 0 3.390041820239276e-05
COL17A1 O 0 0.00018132230616174638
transcripts O 0 5.605681053566514e-06
in O 0 1.8654684197372262e-07
keratinocytes O 0 8.001639798749238e-06
homozygous O 0 2.5805777568166377e-06
for O 0 9.545689749757003e-08
a O 0 2.479475142536103e-06
frameshift O 0 0.00164140691049397
mutation O 0 4.833402999793179e-05
, O 0 3.0755904845136683e-07
the O 0 1.082830536347501e-07
effects O 0 1.9809265268122545e-06
of O 0 3.60575604929636e-08
the O 0 1.7168501642572664e-07
splice O 0 6.609480624319986e-05
- O 0 5.6774730182951316e-05
site O 0 5.6031262829492334e-06
mutation O 0 1.6544025811526808e-06
on O 0 1.0282426643470899e-07
splicing O 0 1.3175670119380811e-06
of O 0 1.6846003347836813e-07
COL17A1 O 0 8.36047183838673e-05
transcripts O 0 6.295555522228824e-06
were O 0 9.510741705298642e-08
determined O 0 1.7342308922252414e-07
using O 0 1.377022442738962e-07
reverse O 0 7.498647846659878e-06
transcriptase O 0 3.262747122789733e-05
polymerase O 0 5.931424766458804e-06
chain O 0 5.996799245622242e-06
reaction O 0 3.657090701381094e-07
of O 0 1.2131841309326319e-08
total O 0 2.6674644715285467e-08
RNA O 0 2.0424695321707986e-06
from O 0 2.0544865719784866e-07
keratinocytes O 0 4.333446213422576e-06
incubated O 0 7.349247539423232e-07
for O 0 4.393838892724489e-08
2 O 0 3.4605830023792805e-06
. O 0 2.247761813123361e-06

5 O 0 1.0264208867738489e-05
h O 0 1.8750710296444595e-05
in O 0 1.8917073418833752e-07
the O 0 9.250305765817757e-08
presence O 0 5.094595394439239e-07
or O 0 7.04320314071083e-07
absence O 0 1.8560682519819238e-06
of O 0 1.0871288225189346e-07
10 O 0 2.0941856746503618e-06
microg O 0 0.00017523956194054335
cycloheximide O 0 0.0001904870441649109
per O 0 3.2788464068289613e-06
ml O 0 0.000523219583556056
. O 0 6.630445568589494e-06

Using O 0 6.741707920809858e-07
this O 0 6.343041292211637e-08
approach O 0 8.828874342725612e-07
, O 0 1.9215231361613405e-07
an O 0 1.6392877455473354e-07
abnormally O 0 0.00010358163854107261
spliced O 0 5.712376514566131e-05
transcript O 0 6.277648935792968e-05
was O 0 8.190368134819437e-06
identified O 0 4.486443003770546e-07
that O 0 4.817059640060961e-09
contains O 0 1.0860402355206134e-08
an O 0 9.180626925342494e-09
extra O 0 7.596261042408514e-08
264 O 0 3.269381068093935e-07
bases O 0 4.818357979274879e-07
upstream O 0 1.5085446420926019e-06
from O 0 3.928348917270341e-07
exon O 0 1.1910166904272046e-05
32 O 0 2.883023626054637e-06
, O 0 1.8747121544038237e-07
resulting O 0 7.933050483188708e-07
in O 0 2.945881760751945e-07
a O 0 3.326214709886699e-06
premature O 0 0.00019768273341469467
termination O 0 6.27672707196325e-05
codon O 0 3.0216589948395267e-05
27 O 0 1.0670751180441584e-05
bp O 0 4.828519013244659e-05
downstream O 0 2.685337221919326e-06
from O 0 1.2122929149427364e-07
the O 0 1.76699899157029e-07
cryptic O 0 3.1463692721445113e-05
splice O 0 0.00015599082689732313
site O 0 8.089284528978169e-05
. O 0 8.931668162404094e-06

Three O 0 3.93125702657926e-07
other O 0 3.1538629485794445e-08
splice O 0 1.6346186384907924e-05
variants O 0 3.360426489962265e-06
, O 0 2.418107101220812e-07
including O 0 6.311470457376345e-08
one O 0 4.8443165923117704e-08
derived O 0 5.5024855782903614e-08
from O 0 5.335135355721832e-08
the O 0 4.8851894973722665e-08
skipping O 0 3.7366107790148817e-06
of O 0 6.391253748461168e-08
exon O 0 1.075570526154479e-05
32 O 0 2.0334009604994208e-06
, O 0 1.2716492392428336e-07
were O 0 1.6117934364956454e-07
also O 0 2.4222063643719594e-07
identified O 0 2.221845988970017e-06
. O 0 1.4421676723941346e-06

These O 0 2.6793668439495377e-07
results O 0 2.447631459290278e-06
indicate O 0 6.798148319830943e-07
the O 0 1.5358163807377423e-07
usefulness O 0 4.370471287984401e-06
of O 0 4.860420972363499e-07
cycloheximide O 0 0.0005235762801021338
treatment O 0 1.410629010933917e-05
in O 0 1.6017062876017008e-07
evaluating O 0 5.833093723595084e-07
the O 0 2.752428542862617e-07
abnormal O 0 1.0679842489480507e-05
processing O 0 3.8040167282815673e-07
of O 0 1.928270521034392e-08
mRNA O 0 2.2907218522050243e-07
due O 0 7.005849056440638e-07
to O 0 5.2862006327814015e-08
splice O 0 6.784758443245664e-05
- O 0 0.00020235986448824406
site O 0 2.2667380108032376e-05
mutations O 0 2.9733024348388426e-05
, O 0 5.465863637255097e-07
because O 0 3.625113151883852e-07
( O 0 1.664743933815771e-07
i O 0 3.0119176699372474e-06
) O 0 3.499767942116705e-08
aberrant O 0 1.460871771996608e-06
splicing O 0 2.821023144861101e-06
often O 0 1.0011734730142052e-06
generates O 0 1.0741320011220523e-06
a O 0 2.588198412922793e-06
premature O 0 0.00011783995432779193
termination O 0 2.6410580176161602e-05
codon O 0 1.2949500160175376e-05
, O 0 2.6743478542812227e-07
( O 0 9.671761347362917e-08
ii O 0 7.554896728834137e-05
) O 0 1.8230059595225612e-07
transcripts O 0 2.8532258511404507e-06
with O 0 9.9823523669329e-07
premature O 0 0.00022402341710403562
termination O 0 4.018368781544268e-05
codons O 0 1.108225387724815e-05
can O 0 5.199850647841231e-07
occur O 0 1.5438298532899353e-06
at O 0 1.0458506949362345e-05
low O 0 2.4477143597323447e-05
or O 0 3.4691213386395248e-06
undetectable O 0 0.0002864673442672938
levels O 0 6.56266729492927e-06
due O 0 1.5007958609203342e-06
to O 0 1.4779382695451204e-07
nonsense O 0 1.1312334208923858e-05
- O 0 5.95867277297657e-06
mediated O 0 9.248527931049466e-06
mRNA O 0 1.3307392237038584e-06
decay O 0 1.2364323083602358e-05
, O 0 2.9695300440835126e-07
and O 0 8.36756228750346e-08
( O 0 1.206111761575812e-07
iii O 0 7.108594581950456e-05
) O 0 5.57404113976645e-08
the O 0 5.192783802954182e-08
levels O 0 4.4863489279123314e-07
of O 0 8.012481345076594e-09
these O 0 6.862071355584476e-09
transcripts O 0 5.483207701217907e-07
can O 0 3.645643786853725e-08
be O 0 4.2117545007158697e-08
increased O 0 1.947203571717182e-07
by O 0 4.7018329496495426e-07
cycloheximide O 0 0.0004232932406011969
. O 0 8.698366400494706e-06

A O 0 3.3575586712686345e-05
deletion O 0 7.518185884691775e-05
mutation O 0 4.250896745361388e-05
in O 0 4.78607091736194e-07
COL17A1 O 0 0.00012686339323408902
in O 0 4.0984821225720225e-07
five O 0 7.511113722102891e-07
Austrian O 0 0.00030370274907909334
families O 0 1.0384753750258824e-06
with O 0 1.8170807379647158e-05
generalized O 1 0.6015282273292542
atrophic B-Disease 1 0.9999324083328247
benign I-Disease 1 0.9995477795600891
epidermolysis I-Disease 1 0.9942800998687744
bullosa I-Disease 1 0.9754158854484558
represents O 0 3.202025982318446e-05
propagation O 0 9.294178198615555e-06
of O 0 2.3548987826416123e-07
an O 0 5.761859824815474e-07
ancestral O 0 4.5595192204928026e-05
allele O 0 0.00018202801584266126
. O 0 1.4386221664608456e-05

Patients O 0 0.001069550635293126
with O 0 7.410393300233409e-05
generalized O 0 0.43413984775543213
atrophic B-Disease 1 0.9998955726623535
benign I-Disease 1 0.9995094537734985
epidermolysis I-Disease 1 0.9959294199943542
bullosa I-Disease 1 0.987327516078949
, O 0 1.4066726180317346e-05
a O 0 1.789401949281455e-06
usually O 0 1.1958569530179375e-06
nonlethal O 0 3.0625698855146766e-05
form O 0 5.821551440021722e-06
of O 0 1.1398632523196284e-05
junctional B-Disease 1 0.9787632822990417
epidermolysis I-Disease 1 0.9879135489463806
bullosa I-Disease 1 0.9633271098136902
, O 0 9.910329026752152e-06
have O 0 3.821003531356837e-07
generalized O 0 3.615099922171794e-05
blistering B-Disease 0 0.3787439465522766
, O 0 0.00010433543502585962
nail B-Disease 1 0.9996566772460938
dystrophy I-Disease 1 0.9995101690292358
, O 0 0.00015295681077986956
patchy B-Disease 1 0.9794883728027344
alopecia I-Disease 1 0.9998138546943665
, O 0 7.404346979456022e-05
and O 0 7.990957237780094e-05
dental B-Disease 1 0.9980337023735046
abnormalities I-Disease 1 0.9996511936187744
. O 0 6.533373380079865e-05

Skin B-Disease 1 0.9811711311340332
fragility I-Disease 0 0.005358556751161814
in O 0 1.0465784043844906e-06
most O 0 5.691854880751634e-07
cases O 0 6.767551781194925e-07
is O 0 3.218832489437773e-07
due O 0 5.770922939518641e-07
to O 0 3.901682532614359e-08
mutations O 0 1.7813891872719978e-06
in O 0 2.339544380447478e-08
the O 0 9.451965432560883e-09
gene O 0 1.8555608960468817e-07
encoding O 0 1.4560038152922061e-06
type O 0 0.0003235262120142579
XVII O 1 0.5237818360328674
collagen O 0 0.004252793733030558
( O 0 8.49912339617731e-06
COL17A1 O 0 0.0011404368560761213
) O 0 2.488733116479125e-06
. O 0 3.3606252145546023e-06

Recently O 0 0.00017455116903875023
, O 0 9.760153716342757e-07
we O 0 4.588974604757823e-07
reported O 0 2.747099642874673e-06
five O 0 3.16512938525193e-07
Austrian O 0 9.735221101436764e-05
families O 0 3.9387890637954115e-07
with O 0 1.6767618944868445e-05
generalized O 0 0.4218374490737915
atrophic B-Disease 1 0.9999333620071411
benign I-Disease 1 0.9992191791534424
epidermolysis I-Disease 1 0.9907705783843994
bullosa I-Disease 1 0.9743236303329468
who O 0 3.114305582130328e-05
share O 0 1.1376480415492551e-06
the O 0 6.613505547647947e-07
same O 0 3.83055885322392e-06
COL17A1 O 0 0.005686311516910791
mutation O 0 0.00035896257031708956
. O 0 8.992248694994487e-06

Affected O 0 9.486530871072318e-06
individuals O 0 9.640451281711648e-08
in O 0 5.8101647937292e-08
three O 0 3.0498284786517615e-08
families O 0 2.115481834152888e-08
are O 0 1.4119211577678925e-08
homozygous O 0 7.305308145078016e-07
for O 0 6.259082141468753e-08
4003delTC O 0 1.797703589545563e-05
, O 0 1.3490033268226398e-07
whereas O 0 1.0096363922684759e-07
those O 0 9.346587503955561e-09
in O 0 1.5376036444081365e-08
two O 0 2.5442107087769728e-08
others O 0 7.933847001595495e-08
are O 0 3.88677570128948e-08
compound O 0 8.822158633847721e-06
heterozygotes O 0 0.00017284690693486482
. O 0 6.677804321952863e-06

To O 0 5.947869112787885e-07
determine O 0 1.1770139280997682e-06
if O 0 3.493299800538807e-07
the O 0 1.5803291830707167e-07
occurrence O 0 2.6470392185728997e-05
of O 0 1.436673784382947e-07
4003delTC O 0 4.326544876676053e-05
in O 0 1.5999934532828775e-07
these O 0 1.481572908801354e-08
unrelated O 0 3.2702653243177338e-06
families O 0 7.220378250849535e-08
signifies O 0 9.96478433989978e-07
propagation O 0 1.7151119209302124e-06
of O 0 3.150988803213295e-08
an O 0 1.3439441204354807e-07
ancestral O 0 1.0154917617910542e-05
allele O 0 2.228744051535614e-05
or O 0 3.6911135339323664e-06
a O 0 6.2937428992881905e-06
mutational O 0 0.0005030075553804636
hot O 0 0.0005002791294828057
spot O 0 6.075206692912616e-05
, O 0 2.53153388030114e-07
haplotypes O 0 4.9589589252718724e-06
were O 0 2.2556332623935305e-07
determined O 0 3.674374227102817e-07
for O 0 4.166061629007345e-08
polymorphisms O 0 6.74172133585671e-06
both O 0 1.358453545208249e-07
within O 0 5.262976401354535e-07
and O 0 1.0934835472653504e-06
flanking O 0 0.0020030206069350243
COL17A1 O 0 0.225355327129364
. O 0 3.682171882246621e-05

Five O 0 7.733940947218798e-06
intragenic O 0 0.00036554899998009205
polymorphisms O 0 4.0259514207718894e-05
were O 0 2.3303418572595547e-07
chosen O 0 1.6640439071125002e-07
based O 0 8.92249261141842e-08
on O 0 7.121817020561139e-07
their O 0 2.459311190250446e-07
informativeness O 0 0.0011331954738125205
. O 0 1.2150285328971222e-05

One O 0 6.111573043199314e-07
of O 0 1.7053579881576297e-08
these O 0 1.4815474180807087e-08
, O 0 5.8889778387083425e-08
not O 0 4.3042053476938236e-08
previously O 0 1.141841380558617e-06
reported O 0 4.7611597437935416e-06
, O 0 1.6437446959116642e-07
was O 0 2.667541593837086e-06
2988 O 0 1.2600358786585275e-05
A O 0 1.8566065591585357e-06
or O 0 7.401197308354313e-07
C O 0 5.300869361235527e-06
that O 0 1.1829535573326666e-08
introduces O 0 5.7464188074618505e-08
a O 0 9.231199982195903e-08
new O 0 1.4762323985451076e-07
restriction O 0 1.0793560534239077e-07
site O 0 7.558149377473455e-07
for O 0 8.148806074359527e-08
Eco0109 O 0 3.564523649401963e-05
I O 0 0.00018298285431228578
. O 0 5.287741714710137e-06

All O 0 3.070333036703232e-07
the O 0 3.458658852650842e-07
4003delTC O 0 2.365576074225828e-05
alleles O 0 1.5301263829314848e-06
showed O 0 1.4250858839659486e-06
the O 0 4.042516721369793e-08
same O 0 5.526192481397629e-08
haplotype O 0 2.325159130123211e-06
for O 0 9.307520087986632e-09
these O 0 1.1021166201885535e-08
five O 0 4.767389327753335e-07
polymorphic O 0 9.928746294463053e-05
markers O 0 0.000265613169176504
. O 0 1.0564705917204265e-05

Fourteen O 0 2.516899985494092e-05
microsatellite O 0 0.00016519517521373928
polymorphisms O 0 2.6683184842113405e-05
were O 0 1.9896063463420433e-07
selected O 0 4.2527052102059315e-08
based O 0 3.1633998531788166e-08
on O 0 1.6273531855404144e-07
their O 0 1.0804455996549223e-07
high O 0 3.489699520287104e-05
heterozygosity O 0 7.181499677244574e-05
and O 0 1.8519861555432726e-07
their O 0 3.417535765493085e-08
location O 0 1.675875182627351e-06
within O 0 1.968074911928852e-06
10q23 O 0 0.00017523120914120227
- O 0 0.0001998662919504568
q25 O 0 0.00022532713774126023
near O 0 0.00024120220041368157
COL17A1 O 0 0.003930914681404829
. O 0 1.370740938000381e-05

Three O 0 1.5588924497933476e-06
families O 0 3.2908593539104913e-07
shared O 0 4.157955572736682e-06
microsatellite O 0 0.0007233828073367476
polymorphisms O 0 0.00025178526993840933
covering O 0 3.570814078557305e-05
at O 0 1.7536058294354007e-05
most O 0 4.1317778709526465e-07
19 O 0 2.327834863535827e-06
cM O 0 3.842735623038607e-06
, O 0 7.585692429756818e-08
whereas O 0 1.395714690488603e-07
the O 0 6.229426929849069e-08
others O 0 7.970886883867934e-08
shared O 0 1.5056184565764852e-07
smaller O 0 9.288385172112612e-07
regions O 0 9.774014415597776e-07
consistent O 0 1.7326318584309774e-06
with O 0 3.2424787832496804e-07
cross O 0 1.0671229574654717e-05
- O 0 2.140787910320796e-05
over O 0 3.281895430973236e-07
events O 0 2.0619455654014018e-07
during O 0 6.602389817089716e-07
passage O 0 1.7236287419564178e-07
of O 0 1.454513842702454e-08
this O 0 3.5395231634538504e-08
mutation O 0 1.0057794952444965e-06
through O 0 6.040600908363558e-08
several O 0 1.0089318180916962e-07
generations O 0 3.5120101529173553e-06
. O 0 5.070557108410867e-06

These O 0 4.2956924062309554e-07
results O 0 1.9063420495513128e-06
indicate O 0 7.261589871632168e-07
that O 0 5.874270669892212e-08
4003delTC O 0 2.8883907361887395e-05
occurs O 0 6.929268465682981e-07
on O 0 1.0844488684824682e-07
a O 0 1.0989536747274542e-07
single O 0 2.0025508717935736e-07
ancestral O 0 5.270423116598977e-06
allele O 0 1.6110976503114216e-05
. O 0 8.252490601989848e-07
. O 0 2.400665607638075e-06

The O 0 1.0276980901835486e-05
haptoglobin O 0 0.0014728563837707043
- O 0 0.00011509842443047091
gene O 0 1.0772766472655348e-05
deletion O 0 2.5888310119626112e-05
responsible O 0 4.565230028674705e-06
for O 0 4.4898675355398154e-07
anhaptoglobinemia B-Disease 0 0.0015011493815109134
. O 0 5.712765414500609e-06

We O 0 3.2501427540410077e-06
have O 0 1.7001752894429956e-07
found O 0 3.5217695426581486e-07
an O 0 1.363039672241939e-07
allelic O 0 6.129161920398474e-05
deletion O 0 2.2736006940249354e-05
of O 0 2.555852915975265e-07
the O 0 1.1939129080928979e-06
haptoglobin O 0 0.00013894701260142028
( O 0 3.6837283801105514e-07
Hp O 0 2.384533672739053e-06
) O 0 4.803767694738781e-08
gene O 0 1.8974058946241712e-07
from O 0 4.2852583703734126e-08
an O 0 2.0286073265651794e-08
individual O 0 3.8104865041077574e-08
with O 0 1.4144178521746653e-06
anhaptoglobinemia B-Disease 0 0.008268957957625389
. O 0 2.1119771190569736e-05

The O 0 3.6450921925279545e-06
Hp O 0 1.943477946042549e-05
gene O 0 5.826660981256282e-06
cluster O 0 1.0583321454760153e-05
consists O 0 4.0276557911056443e-07
of O 0 3.424340988544827e-08
coding O 0 1.7749989638105035e-05
regions O 0 1.2312410717640887e-06
of O 0 5.008675074691382e-08
the O 0 1.2731283050015918e-07
alpha O 0 2.2116182663012296e-06
chain O 0 7.539038961112965e-06
and O 0 2.0831417657518614e-07
beta O 0 2.2138337953947484e-06
chain O 0 4.2158558244409505e-06
of O 0 3.644545643055608e-08
the O 0 1.9360305714144488e-07
haptoglobin O 0 3.727880903170444e-05
gene O 0 1.2792480674761464e-06
( O 0 1.1788905140974748e-07
Hp O 0 9.823372693062993e-07
) O 0 1.8852627903243047e-08
and O 0 1.984038888735995e-08
of O 0 1.0067131128721485e-08
the O 0 9.944650258830734e-08
alpha O 0 1.1467062677184003e-06
chain O 0 7.724859642621595e-06
and O 0 2.500575817521167e-07
beta O 0 1.6794845123513369e-06
chain O 0 5.767682978330413e-06
of O 0 5.3039357794659736e-08
the O 0 2.946036090634152e-07
haptoglobin O 0 0.000318567588692531
- O 0 4.7151963372016326e-05
related O 0 2.4074061002465896e-06
gene O 0 3.348746304254746e-06
( O 0 3.0542500439878495e-07
Hpr O 0 6.651051808148623e-05
) O 0 2.686428501874616e-07
, O 0 1.5892918270310474e-07
in O 0 6.813648667503003e-08
tandem O 0 6.0669899539789185e-06
from O 0 1.9249051774750114e-07
the O 0 3.0141995921439957e-07
5 O 0 4.101867034478346e-06
side O 0 1.0060759450425394e-05
. O 0 4.094590167369461e-06

Southern O 0 0.000171992665855214
blot O 0 0.0016527873231098056
and O 0 2.2268945940595586e-06
PCR O 0 1.8416616512695327e-05
analyses O 0 1.7315020386377e-06
have O 0 9.011152712901094e-08
indicated O 0 2.6532043762017565e-07
that O 0 3.015330429789742e-09
the O 0 8.485431024496393e-09
individual O 0 1.1180683046063677e-08
with O 0 1.9597300138229912e-07
anhaptoglobinemia B-Disease 0 0.0002965389285236597
was O 0 1.3528789168049116e-05
homozygous O 0 8.684653494128725e-07
for O 0 8.120609962247727e-09
the O 0 4.64252778442642e-08
gene O 0 5.68388088595384e-07
deletion O 0 1.5197761058516335e-06
and O 0 6.006799679880714e-08
that O 0 3.4735776477390345e-09
the O 0 1.4586560403984095e-08
gene O 0 3.641492014594405e-07
deletion O 0 1.925205879160785e-06
was O 0 8.555385306863172e-07
included O 0 5.7221381410954564e-08
at O 0 2.1334908524295315e-06
least O 0 4.1306776665805955e-08
from O 0 2.4967960143840173e-08
the O 0 7.952451142045902e-08
promoter O 0 6.102310726419091e-05
region O 0 9.67611185842543e-07
of O 0 7.037342442117733e-08
Hp O 0 3.7512068047362845e-06
to O 0 1.0221106094832066e-07
Hpr O 0 4.0899762097978964e-05
alpha O 0 1.805170768420794e-06
but O 0 1.0436724551254883e-07
not O 0 1.5204784986622144e-08
to O 0 5.426919358342275e-08
Hpr O 0 9.931161184795201e-05
beta O 0 1.2228821105964016e-05
( O 0 6.223405648597691e-07
Hpdel O 0 8.590138895669952e-05
) O 0 1.0014742883868166e-06
. O 0 2.8307897537160898e-06

In O 0 9.004604635265423e-07
addition O 0 4.972134206582268e-07
, O 0 1.8719376271292276e-07
we O 0 8.071446444546382e-08
found O 0 8.632930104113257e-08
seven O 0 4.0740360418567434e-08
individuals O 0 2.3355972711414097e-09
with O 0 5.2076021717084586e-08
hypohaptoglobinemia B-Disease 0 3.0218661777325906e-05
in O 0 6.118920481412715e-08
three O 0 3.8819671033252234e-08
families O 0 1.1258062926344792e-08
, O 0 4.663338870614098e-08
and O 0 2.9822835756476707e-08
the O 0 6.475318059528945e-08
genotypes O 0 2.307579507032642e-06
of O 0 2.107748819923927e-08
six O 0 9.655983035372628e-08
of O 0 1.3608077331639379e-08
the O 0 3.955512895004176e-08
seven O 0 5.969087624180247e-08
individuals O 0 3.145654625669181e-09
were O 0 3.453529728858484e-08
found O 0 5.956054849320935e-08
to O 0 2.4909260432082192e-08
be O 0 3.5225181704845454e-07
Hp2 O 0 0.0004225384909659624
/ O 0 0.000500053633004427
Hpdel O 0 0.0023948366288095713
. O 0 2.0310277250246145e-05

The O 0 5.0638982429518364e-06
phenotypes O 0 0.000238821841776371
and O 0 1.4574485476259724e-06
genotypes O 0 1.3683365068573039e-05
in O 0 2.2894703022302565e-07
one O 0 3.4952851279967945e-08
of O 0 4.016000865192382e-09
these O 0 1.282582706707558e-09
three O 0 2.4898715977883512e-08
families O 0 2.4458662650772567e-08
showed O 0 3.3625570949880057e-07
the O 0 7.716209182717648e-08
father O 0 2.2889232695888495e-06
to O 0 4.239965178953753e-08
be O 0 4.3976794472655456e-07
hypohaptoglobinemic B-Disease 0 4.2032537749037147e-05
( O 0 5.94896960137703e-07
Hp2 O 0 5.1208349759690464e-05
) O 0 2.4238491391770367e-07
and O 0 4.950870220454817e-07
Hp2 O 0 0.0002004418638534844
/ O 0 9.306726133218035e-05
Hpdel O 0 0.000247718213358894
, O 0 4.623952065685444e-07
the O 0 1.5883387050052988e-07
mother O 0 2.9737800559814787e-06
to O 0 2.472664029085081e-08
be O 0 2.7258852242084686e-07
Hp2 O 0 2.256073639728129e-05
- O 0 1.693442573014181e-05
1 O 0 1.3432050991468714e-06
and O 0 5.953021968707617e-07
Hp1 O 0 8.635772246634588e-05
/ O 0 2.866343129426241e-05
Hp2 O 0 6.47457709419541e-05
, O 0 1.6836993665947375e-07
one O 0 2.0695571478768215e-08
of O 0 4.355072746875521e-09
the O 0 2.5747558751731958e-08
two O 0 4.697556832411465e-08
children O 0 3.213234123222719e-08
to O 0 1.553442352530965e-08
be O 0 1.7194963675137842e-07
hypohaptoglobinemic B-Disease 0 3.408454358577728e-05
( O 0 3.272768935858039e-07
Hp2 O 0 2.6947216611006297e-05
) O 0 1.4626489530655817e-07
and O 0 3.5782696272690373e-07
Hp2 O 0 0.00010909760749200359
/ O 0 5.694612627848983e-05
Hpdel O 0 9.28358276723884e-05
, O 0 3.4487186439946527e-07
and O 0 5.878261077896241e-08
the O 0 3.3705120472404815e-08
other O 0 3.582256979939302e-08
child O 0 1.8254273754791939e-06
to O 0 5.532034919042417e-08
be O 0 4.337455266067991e-07
Hp1 O 0 7.774089317535982e-05
and O 0 2.55493455370015e-06
Hp1 O 0 0.0004957067430950701
/ O 0 0.00016421002510469407
Hpdel O 0 0.0002437403454678133
, O 0 4.080413589235832e-07
showing O 0 1.6038875401136465e-06
an O 0 2.621505927891121e-07
anomalous O 0 7.651142368558794e-05
inheritance O 0 4.620386243914254e-05
of O 0 6.959189136068744e-07
Hp O 0 4.3607513362076133e-05
phenotypes O 0 4.943093881593086e-05
in O 0 3.732432958258869e-07
the O 0 4.40989225580779e-07
child O 0 1.1866325621667784e-05
with O 0 3.3785272535169497e-06
Hp1 O 0 0.006076254416257143
. O 0 1.9994751710328273e-05

The O 0 2.2536694814334624e-05
Hp2 O 0 0.0012402345892041922
/ O 0 0.0002419480006210506
Hpdel O 0 0.00012108413648093119
individuals O 0 1.3220726202689548e-07
had O 0 7.913562853900658e-07
an O 0 1.0103838832264955e-07
extremely O 0 5.786414476460777e-06
low O 0 1.785342647053767e-05
level O 0 2.1213218133198097e-06
of O 0 7.895035736282807e-08
Hp O 0 3.5260379718238255e-06
( O 0 1.764557282513124e-07
mean O 0 1.4041485201232717e-06
+ O 0 4.025112502858974e-06
/ O 0 1.1644305232039187e-05
- O 0 1.3316213880898431e-05
SD O 0 8.034617349039763e-05
= O 0 9.880734978651162e-06
0 O 0 7.129427785912412e-07
. O 0 9.244114806961079e-08
049 O 0 2.103169754263945e-05
+ O 0 3.6906981222273316e-06
/ O 0 8.59960255183978e-06
- O 0 1.0308922355761752e-05
0 O 0 1.3631349702336593e-06
. O 0 1.1396663524010364e-07
043 O 0 4.2073643271578476e-05
mg O 0 4.819668174604885e-05
/ O 0 1.0853551430045627e-05
ml O 0 1.6320405848091468e-05
; O 0 2.2734936067081435e-07
n O 0 5.131555099069374e-06
= O 0 4.078556685271906e-06
6 O 0 5.57221710550948e-07
) O 0 1.4458672481509893e-08
, O 0 1.235353064288347e-08
compared O 0 5.120748269860087e-08
with O 0 9.460044303466475e-09
the O 0 7.066597618177184e-08
level O 0 3.975140145939804e-07
( O 0 2.4603052040106377e-08
1 O 0 9.822064583886458e-08
. O 0 1.1086989992747931e-08
64 O 0 1.388892343356929e-07
+ O 0 9.83386144071119e-07
/ O 0 4.345137313066516e-06
- O 0 4.025381258543348e-06
1 O 0 5.022853315495013e-07
. O 0 6.958394038747429e-08
07 O 0 5.910661457164679e-06
mg O 0 2.2575737602892332e-05
/ O 0 7.170598109951243e-06
ml O 0 1.1528485629241914e-05
) O 0 2.0007597356652695e-08
obtained O 0 6.96402295830012e-08
from O 0 8.819905161772112e-08
52 O 0 2.033684268099023e-06
healthy O 0 2.020970214289264e-06
volunteers O 0 1.4904477438903996e-06
having O 0 2.29468446377723e-06
phenotype O 0 3.111624755547382e-05
Hp2 O 0 0.00010934101010207087
, O 0 2.9874931328777166e-07
whereas O 0 2.1745113087945356e-07
the O 0 1.3382334884681768e-07
serum O 0 4.744330453831935e-06
Hp O 0 1.5230435792545904e-06
level O 0 6.646067163273983e-07
of O 0 1.0659468863138954e-08
an O 0 3.01689659920612e-08
individual O 0 3.172983653598749e-08
with O 0 1.3617149079436786e-06
Hp1 O 0 0.0013641825644299388
/ O 0 0.0002822952810674906
Hpdel O 0 0.0006166602834127843
was O 0 0.00013102580851409584
0 O 0 1.7715490685077384e-05
. O 0 2.9651935165020404e-06

50 O 0 2.9782000638078898e-05
mg O 0 0.00017196492990478873
/ O 0 3.9436719816876575e-05
ml O 0 7.334606198128313e-05
, O 0 2.3795897163836344e-07
which O 0 2.8049376155081518e-08
was O 0 2.229379845175572e-07
approximately O 0 9.479443896509565e-09
half O 0 2.6867402524999306e-08
the O 0 2.737563775667695e-08
level O 0 4.658831755932624e-07
of O 0 4.5878540078092556e-08
Hp O 0 6.663255135208601e-06
in O 0 9.974719432648271e-07
control O 0 2.084831976389978e-05
sera O 0 0.0006421084399335086
from O 0 2.0666783484557527e-07
the O 0 2.3823008632462006e-07
Hp1 O 0 5.945086377323605e-05
phenotype O 0 5.8142941270489246e-06
( O 0 1.0653069892896383e-07
1 O 0 2.322058065828969e-07
. O 0 5.293829019592522e-08
26 O 0 7.129115147108678e-07
+ O 0 9.659166835263022e-07
/ O 0 3.973566890635993e-06
- O 0 4.970596819475759e-06
0 O 0 4.7396360969287343e-07
. O 0 4.7658570423436686e-08
33 O 0 1.330117470388359e-06
mg O 0 1.568784318806138e-05
/ O 0 8.743977559788618e-06
ml O 0 2.642171602929011e-05
; O 0 4.810218001694011e-07
n O 0 8.65598030941328e-06
= O 0 8.022323527256958e-06
9 O 0 1.5059629276947817e-06
) O 0 2.358280681846736e-08
, O 0 2.2530871390813445e-08
showing O 0 2.3078867172898754e-07
a O 0 8.669609883327212e-07
gene O 0 1.3824182133248542e-05
- O 0 0.0002459836541675031
dosage O 0 0.0002706873638089746
effect O 0 1.6889751350390725e-05
. O 0 5.529573627427453e-06

The O 0 8.461649940727511e-07
other O 0 2.425578884412971e-07
allele O 0 7.449204076692695e-06
( O 0 6.837557293692953e-07
Hp2 O 0 3.97407820855733e-05
) O 0 7.183591321791027e-08
of O 0 2.0766272257333185e-08
individuals O 0 2.8152339126563675e-08
with O 0 1.201737859446439e-06
Hp2 O 0 0.0015296537894755602
/ O 0 0.00019729748601093888
Hpdel O 0 0.00024024647427722812
was O 0 1.0516196198295802e-05
found O 0 5.229120958460953e-08
to O 0 2.5816047077853455e-09
have O 0 7.814134228567582e-09
, O 0 8.326355604992841e-09
in O 0 5.89007598250646e-09
all O 0 7.360552167767764e-09
exons O 0 2.07909010896401e-06
, O 0 2.3119622483136482e-07
no O 0 2.689961320356815e-07
mutation O 0 9.508689799986314e-07
, O 0 5.090695154308378e-08
by O 0 2.702075363458789e-08
DNA O 0 1.5995783542166464e-06
sequencing O 0 5.27968950336799e-06
. O 0 4.440541033545742e-06

On O 0 2.1045889297965914e-06
the O 0 4.6362981009906434e-08
basis O 0 4.2933088195695746e-08
of O 0 1.9180767196758097e-08
the O 0 1.0080008649993033e-07
present O 0 1.692889810556153e-07
study O 0 1.2990324194106506e-07
, O 0 2.506654261935637e-08
the O 0 2.9947440083333277e-08
mechanism O 0 1.1236159025429515e-06
of O 0 1.026741429654976e-07
anhaptoglobinemia B-Disease 0 0.00010708047921070829
and O 0 2.1845464459602226e-07
the O 0 1.8494516496048163e-07
mechanism O 0 4.346339210314909e-06
of O 0 2.7234818844590336e-07
anomalous O 0 0.00016821030294522643
inheritance O 0 0.00010267064499203116
of O 0 1.5840500964259263e-06
Hp O 0 7.653850479982793e-05
phenotypes O 0 0.00011201961024198681
were O 0 9.881138112177723e-07
well O 0 1.0867271384995547e-06
explained O 0 1.8099794033332728e-05
. O 0 3.398993612790946e-06

However O 0 2.7115911507280543e-06
, O 0 2.1608363454106438e-07
the O 0 7.61705223339959e-08
mechanism O 0 2.7500459509610664e-06
of O 0 8.011855925360578e-07
hypohaptoglobinemia B-Disease 0 0.005860563367605209
remains O 0 0.0002298969920957461
unknown O 0 0.0003714406630024314

ATM O 0 0.0027871972415596247
mutations O 0 0.0011311129201203585
and O 0 1.3099745046929456e-05
phenotypes O 0 0.0010938977357000113
in O 0 0.00013309673522599041
ataxia B-Disease 1 0.999984622001648
- I-Disease 1 0.9993415474891663
telangiectasia I-Disease 1 0.9997521042823792
families O 0 1.6213593880820554e-06
in O 0 5.609213644675037e-07
the O 0 2.3620152944658912e-07
British O 0 2.7271723865851527e-06
Isles O 0 8.121022801788058e-06
: O 0 1.042504607084993e-07
expression O 0 1.4737818787580181e-07
of O 0 4.372595441282101e-08
mutant O 0 3.919512892025523e-06
ATM O 0 2.952598879346624e-05
and O 0 8.240253350777493e-07
the O 0 1.4412656810236513e-06
risk O 0 4.789939703186974e-05
of O 0 8.884147064236458e-06
leukemia B-Disease 1 0.9999771118164062
, O 0 0.19973509013652802
lymphoma B-Disease 1 0.9999998807907104
, O 0 7.034451118670404e-05
and O 0 0.0011411975137889385
breast B-Disease 1 0.9997336268424988
cancer I-Disease 1 0.9993367791175842
. O 0 1.2068016985722352e-05

We O 0 2.7781034077634104e-06
report O 0 1.543679672977305e-07
the O 0 2.2699788715385694e-08
spectrum O 0 2.16331795854785e-06
of O 0 1.1028172508531497e-07
59 O 0 1.4098489373282064e-05
ATM O 0 0.00019437505397945642
mutations O 0 0.0002795553591568023
observed O 0 9.341313125332817e-05
in O 0 2.4731913072173484e-05
ataxia B-Disease 1 0.9999433755874634
- I-Disease 1 0.9988743662834167
telangiectasia I-Disease 1 0.9997840523719788
( O 0 0.000129957334138453
A B-Disease 1 0.9995697140693665
- I-Disease 1 0.9974794983863831
T I-Disease 1 0.9996746778488159
) O 0 1.7778454548533773e-06
patients O 0 3.269071157774306e-06
in O 0 1.0186929699784741e-07
the O 0 1.8355001429881668e-07
British O 0 1.8006274331128225e-05
Isles O 0 6.938513251952827e-05
. O 0 7.978938810992986e-06

Of O 0 1.8778824824039475e-06
51 O 0 2.5404839107068256e-05
ATM O 0 0.00024377125373575836
mutations O 0 0.00011462624388514087
identified O 0 4.20148671764764e-06
in O 0 1.246173439994891e-07
families O 0 2.1098241376193982e-08
native O 0 9.674048584429329e-08
to O 0 2.057211290207306e-08
the O 0 7.938145785146844e-08
British O 0 2.37217659559974e-06
Isles O 0 7.365494639088865e-06
, O 0 2.038117514757687e-07
11 O 0 2.6276683229298214e-07
were O 0 2.0322637794834009e-07
founder O 0 5.30721126779099e-06
mutations O 0 2.770298578980146e-06
, O 0 8.372575166504248e-08
and O 0 3.312705132429983e-08
2 O 0 1.5996317870303756e-07
of O 0 1.2431176088512075e-08
these O 0 2.658773645691781e-08
11 O 0 6.592323416043655e-07
conferred O 0 8.658754268253688e-06
a O 0 2.5948863822122803e-06
milder O 0 9.368146857013926e-05
clinical O 0 1.3792234312859364e-05
phenotype O 0 5.2156915444356855e-06
with O 0 8.11959210977875e-08
respect O 0 2.447257543281012e-07
to O 0 3.0475231937998615e-07
both O 0 4.305636139179114e-06
cerebellar B-Disease 1 0.9973888993263245
degeneration I-Disease 1 0.9982732534408569
and O 0 2.7716675958799897e-06
cellular O 0 0.0006721154786646366
features O 0 6.292273610597476e-05
. O 0 1.8006652680924162e-05

We O 0 6.036931154085323e-06
report O 0 7.592783504151157e-07
, O 0 4.037215362018287e-08
in O 0 3.220019806349228e-08
two O 0 2.4172240387088095e-07
A B-Disease 1 0.9495885372161865
- I-Disease 1 0.8622287511825562
T I-Disease 1 0.9992133378982544
families O 0 2.820466988850967e-07
, O 0 1.6437290639714774e-07
an O 0 7.470251972563346e-08
ATM O 0 4.429140972206369e-05
mutation O 0 2.1372794435592368e-05
( O 0 3.1712022519059246e-07
7271T O 0 7.867339263611939e-06
- O 0 1.4570493476639967e-05
- O 0 2.204542215622496e-05
> O 0 1.3253779798105825e-05
G O 0 1.2234607311256696e-05
) O 0 3.138075399533591e-08
that O 0 3.5090574890261905e-09
may O 0 6.420626874614754e-08
be O 0 1.3288664391097882e-08
associated O 0 4.922180707467305e-08
with O 0 1.5560905453071427e-08
an O 0 7.597391515901109e-08
increased O 0 1.3056489933660487e-06
risk O 0 3.806682434515096e-05
of O 0 3.4491633869038196e-06
breast B-Disease 1 0.9991331696510315
cancer I-Disease 1 0.9900768399238586
in O 0 4.651808183098183e-07
both O 0 5.727258667320712e-07
homozygotes O 0 0.0001352226099697873
and O 0 9.716948170535034e-07
heterozygotes O 0 1.9384782717679627e-05
( O 0 2.5298638206550095e-07
relative O 0 2.4561195459682494e-06
risk O 0 5.904019417357631e-06
12 O 0 4.811268468074559e-07
. O 0 4.233330841429961e-08
7 O 0 9.78268644757918e-07
; O 0 5.386124257711344e-07
P O 0 0.00014109119365457445
= O 0 2.2651842300547287e-05
. O 0 3.5569507872423856e-07
0025 O 0 0.00013813206169288605
) O 0 5.130543812015276e-08
, O 0 3.22033955058032e-08
although O 0 2.377248264906484e-08
there O 0 1.4205490117547015e-08
is O 0 4.424923361057154e-08
a O 0 4.061204492700199e-07
less O 0 2.8016763735649874e-06
severe O 0 0.41096964478492737
A B-Disease 1 0.999548614025116
- I-Disease 1 0.9960829019546509
T I-Disease 1 0.9990554451942444
phenotype O 0 2.3346436137217097e-05
in O 0 1.215934446463507e-07
terms O 0 1.1752389639241301e-07
of O 0 7.077763708451812e-09
the O 0 1.6337644126451778e-07
degree O 0 9.292086360801477e-06
of O 0 1.1957945389440283e-05
cerebellar B-Disease 1 0.9996174573898315
degeneration I-Disease 1 0.9998433589935303
. O 0 0.00010236630623694509

This O 0 1.8723353605309967e-06
mutation O 0 2.5576362531865016e-05
( O 0 5.426825850918249e-07
7271T O 0 3.393482984392904e-05
- O 0 3.2446860132040456e-05
- O 0 2.6069832529174164e-05
> O 0 1.544302358524874e-05
G O 0 1.6300418792525306e-05
) O 0 2.205542060096377e-08
also O 0 1.8834764858866038e-08
allows O 0 5.238142364305531e-09
expression O 0 4.421919541641728e-08
of O 0 8.396608741634282e-09
full O 0 1.6686604453752807e-07
- O 0 2.402926384093007e-06
length O 0 2.171353088442629e-07
ATM O 0 2.4402456801908556e-06
protein O 0 3.2996709364851995e-07
at O 0 1.3397343536780681e-06
a O 0 7.85744944664657e-08
level O 0 2.8666673301813717e-07
comparable O 0 1.0561919907559059e-06
with O 0 9.680638868303504e-08
that O 0 3.104196721892549e-08
in O 0 1.8458744932559057e-07
unaffected O 0 1.1704985809046775e-05
individuals O 0 2.1809640315950674e-07
. O 0 2.2248482309805695e-06

In O 0 1.052579023053113e-06
addition O 0 3.6149288007436553e-07
, O 0 1.3897296469167486e-07
we O 0 5.279450121520313e-08
have O 0 2.978361202110591e-08
studied O 0 2.742926881182939e-06
18 O 0 3.8184166442079e-06
A B-Disease 1 0.9437833428382874
- I-Disease 1 0.9812927842140198
T I-Disease 1 0.9995579123497009
patients O 0 1.5393929061247036e-05
, O 0 1.0926062543603621e-07
in O 0 4.283771204427467e-08
15 O 0 2.3585735675624164e-07
families O 0 2.56922234598278e-08
, O 0 1.371243314451931e-07
who O 0 2.327168886040454e-06
developed O 0 0.000387427193345502
leukemia B-Disease 1 0.9999576807022095
, O 0 0.005849794484674931
lymphoma B-Disease 1 0.9999996423721313
, O 0 3.103347626165487e-05
preleukemic O 0 0.004236010368913412
T O 0 0.27673137187957764
- O 0 0.0007051481516100466
cell O 0 0.0006413409137167037
proliferation O 0 0.00468151131644845
, O 0 1.4321666640171316e-05
or O 0 0.049122270196676254
Hodgkin B-Disease 1 0.9999961853027344
lymphoma I-Disease 1 0.9999998807907104
, O 0 1.090410842152778e-05
mostly O 0 1.2915309071104275e-06
in O 0 3.302338654975756e-06
childhood O 0 0.0006591197452507913
. O 0 7.198038929345785e-06

A O 0 1.0144714906346053e-05
wide O 0 4.048511527798837e-06
variety O 0 1.336717332378612e-06
of O 0 1.9122528271964256e-07
ATM O 0 0.0001619109680177644
mutation O 0 5.260033140075393e-05
types O 0 4.288793206796981e-06
, O 0 4.848929506806599e-07
including O 0 5.701394911739044e-07
missense O 0 0.00014598376583307981
mutations O 0 3.870880391332321e-05
and O 0 4.397964232794038e-07
in O 0 4.616312025973457e-07
- O 0 2.8113867301726714e-05
frame O 0 1.527553285995964e-05
deletions O 0 1.2076882740075234e-05
, O 0 2.1219439361175318e-07
were O 0 7.724160155930804e-08
seen O 0 6.311807965175831e-07
in O 0 5.5133170917542884e-08
these O 0 8.193457290417427e-08
patients O 0 6.765113539586309e-06
. O 0 3.714051217684755e-06

We O 0 1.1101230938947992e-06
also O 0 1.305984795862969e-07
show O 0 7.127864876110834e-08
that O 0 5.913332046247888e-09
25 O 0 3.881322996335257e-08
% O 0 2.8567965770776027e-09
of O 0 4.55621407269291e-09
all O 0 1.0548838247359527e-07
A B-Disease 1 0.999247670173645
- I-Disease 1 0.9986668825149536
T I-Disease 1 0.9997783303260803
patients O 0 1.43261731864186e-05
carried O 0 1.2166111673650448e-06
in O 0 2.555160847350635e-07
- O 0 1.8791128240991384e-05
frame O 0 2.7204676371184178e-05
deletions O 0 2.76070768450154e-05
or O 0 9.109305210586172e-06
missense O 0 0.00023172906367108226
mutations O 0 5.7479388487990946e-05
, O 0 1.4890298416503356e-07
many O 0 1.1301435343114008e-08
of O 0 8.427284647893885e-09
which O 0 2.9373243393138182e-08
were O 0 5.6886538146727617e-08
also O 0 6.572636834789591e-08
associated O 0 6.961552401207882e-08
with O 0 1.9041559440324818e-08
expression O 0 1.2643090485653374e-07
of O 0 3.783588553574191e-08
mutant O 0 3.0181165584508562e-06
ATM O 0 3.571709748939611e-05
protein O 0 1.0640134860295802e-05
. O 0 4.015761078335345e-06

The O 0 8.117553079500794e-06
DMPK O 0 0.0006554388673976064
gene O 0 5.292052810546011e-05
of O 0 8.405570952163544e-06
severely O 1 0.9898597598075867
affected O 0 0.031929902732372284
myotonic B-Disease 1 0.9999774694442749
dystrophy I-Disease 1 0.9999953508377075
patients O 0 0.010785833932459354
is O 0 3.531583615767886e-06
hypermethylated O 0 0.00020286717335693538
proximal O 0 0.00013772920647170395
to O 0 1.4001594195178768e-07
the O 0 2.1185307730320346e-07
largely O 0 1.9618689748313045e-06
expanded O 0 1.105426053982228e-05
CTG O 0 0.0019966938998550177
repeat O 0 0.0003371976490598172
. O 0 1.262150180991739e-05

Using O 0 2.2623555651080096e-06
methylation O 0 4.5365279220277444e-05
- O 0 4.0773433283902705e-05
sensitive O 0 3.326256410218775e-05
restriction O 0 1.3128508271620376e-06
enzymes O 0 2.5547055884089787e-06
, O 0 3.9767860471329186e-07
we O 0 1.6603600272446783e-07
characterized O 0 2.1327402919268934e-06
the O 0 6.584406264664722e-08
methylation O 0 2.139844582416117e-06
pattern O 0 5.881596734980121e-06
on O 0 1.0969638424285222e-06
the O 0 1.956658053359206e-07
5 O 0 1.1077203225795529e-06
side O 0 8.940190241446544e-07
of O 0 3.457820341168372e-08
the O 0 6.556521725542552e-07
CTG O 0 0.0002498249232303351
repeat O 0 1.2656552826229017e-05
in O 0 1.2996420650779328e-07
the O 0 6.469442581646945e-08
DMPK O 0 3.1421321182278916e-05
gene O 0 6.224711341928924e-07
of O 0 5.596732677304317e-08
normal O 0 2.6662623895390425e-06
individuals O 0 4.14815772842303e-08
and O 0 9.022107860801043e-08
of O 0 3.6262093772165827e-07
patients O 0 3.2398253097198904e-05
affected O 0 1.4725507753610145e-05
with O 0 0.0015278048813343048
myotonic B-Disease 1 0.9999964237213135
dystrophy I-Disease 1 0.9999947547912598
, O 0 2.960870233437163e-06
showing O 0 2.534109171392629e-06
expansions O 0 6.525590379169444e-06
of O 0 1.854683375768218e-07
the O 0 1.4572414102076436e-06
repetitive O 0 0.002911574672907591
sequence O 0 2.843500260496512e-05
. O 0 7.065935733407969e-06

The O 0 8.333364576174063e-07
gene O 0 2.5649828785390127e-06
segment O 0 4.141923000133829e-06
analyzed O 0 1.7673777392701595e-06
corresponds O 0 3.501000662708975e-07
to O 0 1.9923133365296053e-08
the O 0 1.4212744758879126e-07
genomic O 0 9.916890121530741e-06
SacI O 0 0.000423432415118441
- O 0 4.323039320297539e-05
HindIII O 0 5.710317782359198e-05
fragment O 0 3.813329612967209e-06
carrying O 0 7.682783120799286e-07
exons O 0 1.3103093806421384e-05
11 O 0 8.600242836109828e-06
- O 0 6.180399941513315e-05
15 O 0 5.373429303290322e-06
. O 0 2.3344086912402418e-06

There O 0 1.6814591390357236e-06
is O 0 3.660848904019076e-07
constitutive O 0 1.1091686246800236e-05
methylation O 0 6.366473826346919e-06
in O 0 4.4440642454901536e-07
intron O 0 8.467568113701418e-05
12 O 0 2.4703692815819522e-06
at O 0 1.8703045725487755e-06
restriction O 0 6.334843760669173e-08
sites O 0 1.5241828066336893e-07
of O 0 4.838388534267324e-08
SacII O 0 4.439984695636667e-05
and O 0 4.812470706383465e-07
HhaI O 0 8.023821283131838e-05
, O 0 2.7183543238606944e-07
localized O 0 1.3787314856017474e-05
1 O 0 1.4656862958872807e-06
, O 0 1.0024388075180468e-07
159 O 0 1.0197344408879871e-06
- O 0 5.952487754257163e-06
1 O 0 1.1624429134826642e-06
, O 0 1.8823996583705593e-07
232 O 0 9.982466053770622e-07
bp O 0 1.3250873053038958e-05
upstream O 0 3.4993081499123946e-07
of O 0 3.1765864605404204e-08
the O 0 3.168813975662488e-07
CTG O 0 0.00019127747509628534
repeat O 0 1.302957480220357e-05
, O 0 2.1999632338065567e-07
whereas O 0 1.4986261476224172e-07
most O 0 6.8461773139461e-08
, O 0 4.0501188180996905e-08
if O 0 2.565872492255039e-08
not O 0 5.117366974616289e-09
all O 0 3.486155364385013e-09
, O 0 3.323755137785156e-08
of O 0 3.2723923570898705e-09
the O 0 1.2199621757247314e-08
other O 0 9.108331866514163e-09
sites O 0 2.2359294860052614e-07
of O 0 1.0361946323200755e-07
SacII O 0 0.0001428622199455276
, O 0 9.358298029837897e-07
HhaI O 0 3.844752427539788e-05
, O 0 3.4910351587313926e-07
and O 0 1.6385672552132746e-07
HpaII O 0 3.9613874832866713e-05
in O 0 2.257126681115551e-07
this O 0 1.7841990995748347e-08
region O 0 4.790646812580235e-07
are O 0 4.378888718292728e-08
unmethylated O 0 1.882912329165265e-05
, O 0 9.90814754686653e-08
in O 0 3.239875567828676e-08
normal O 0 2.2657879128473724e-07
individuals O 0 6.649019557158908e-09
and O 0 3.458691111291046e-08
most O 0 3.6314169449269684e-08
of O 0 4.6034656975280086e-08
the O 0 1.8626274140842725e-06
patients O 0 3.160259439027868e-05
. O 0 4.081731731275795e-06

In O 0 9.846728517004522e-07
a O 0 4.319630306781619e-07
number O 0 1.0887328016906395e-07
of O 0 8.76752537237735e-08
young O 0 4.769485713040922e-06
and O 0 6.478458544734167e-06
severely O 0 0.2944459617137909
affected O 0 1.564116246299818e-05
patients O 0 9.620164746593218e-06
, O 0 1.5720017643161555e-07
however O 0 4.7059685925887607e-08
, O 0 2.6127697339006772e-08
complete O 0 9.757792440723279e-08
methylation O 0 5.031483283346461e-07
of O 0 1.109794922626861e-08
these O 0 5.950510306718115e-09
restriction O 0 7.939372181908766e-08
sites O 0 3.467827411895996e-07
was O 0 3.9764781831763685e-06
found O 0 1.6424284865479422e-07
in O 0 2.797938059018179e-08
the O 0 9.551390434126006e-08
mutated O 0 1.6163192412932403e-05
allele O 0 3.904663026332855e-05
. O 0 4.437839834281476e-06

In O 0 6.807892987126252e-07
most O 0 6.521102591250383e-08
of O 0 2.945594168579646e-08
these O 0 7.997461182185361e-08
patients O 0 2.6850552785617765e-06
, O 0 2.0832231939493795e-07
the O 0 2.3954825678629277e-07
onset O 0 0.0004259123816154897
of O 0 1.1788629308284726e-06
the O 0 8.638259168947116e-05
disease O 1 0.9997802376747131
was O 1 0.9877497553825378
congenital O 1 0.9999912977218628
. O 0 9.597438474884257e-05

Preliminary O 0 2.8679776733042672e-05
in O 0 4.657703811972169e-06
vivo O 0 0.00016116823826450855
footprinting O 0 0.0005215986748225987
data O 0 4.5114137492419104e-07
gave O 0 2.1624093449190696e-07
evidence O 0 4.30288373820531e-08
for O 0 1.0628346203134242e-08
protein O 0 3.5646729656946263e-07
- O 0 3.143934009131044e-06
DNA O 0 5.126973405822355e-07
contact O 0 1.0040286042567459e-06
in O 0 1.0890318691281209e-07
normal O 0 1.0616472536639776e-06
genes O 0 6.550872626576165e-07
at O 0 4.243429884809302e-06
an O 0 2.369169038729524e-07
Sp1 O 0 2.623190994199831e-05
consensus O 0 2.833794212619978e-07
binding O 0 1.3513820249499986e-06
site O 0 1.3085009413771331e-06
upstream O 0 5.265441700430529e-07
of O 0 2.7105151900741475e-08
the O 0 3.624373619004473e-07
CTG O 0 0.00012798182433471084
repeat O 0 6.8584490691137034e-06
and O 0 1.9992057787021622e-07
for O 0 1.939036309295261e-08
a O 0 1.6373067524000362e-07
significant O 0 1.765799737540874e-07
reduction O 0 8.029004447962507e-07
of O 0 5.443025585805117e-09
this O 0 4.175988443932965e-09
interaction O 0 1.755850931317582e-08
in O 0 6.120998108372078e-08
cells O 0 1.8581781091597804e-07
with O 0 1.278029628792865e-07
a O 0 2.3722241166979074e-06
hypermethylated O 0 0.00024232108262367547
DMPK O 0 0.0004077421617694199
gene O 0 1.1700666618708055e-05
. O 0 9.82350456979475e-07
. O 0 2.3153324946179055e-06

The O 0 7.697870023548603e-05
hemochromatosis B-Disease 1 0.9982017278671265
gene O 0 1.3041808415437117e-05
product O 0 8.594663540861802e-07
complexes O 0 1.9282983885204885e-06
with O 0 1.0156838925468037e-07
the O 0 1.3418591038316663e-07
transferrin O 0 1.7500820831628516e-05
receptor O 0 1.4567898460882134e-06
and O 0 2.047129044058238e-07
lowers O 0 5.084114945930196e-06
its O 0 1.047720932234597e-08
affinity O 0 1.9094976266842423e-07
for O 0 4.8125716745062164e-08
ligand O 0 5.300818429532228e-06
binding O 0 2.902005144278519e-05
. O 0 7.853081115172245e-06

We O 0 1.2865723874710966e-05
recently O 0 3.773290154640563e-05
reported O 0 2.855294496839633e-06
the O 0 3.214533705886424e-08
positional O 0 6.741830475220922e-06
cloning O 0 1.6982484112304519e-06
of O 0 8.140261797962012e-08
a O 0 1.0081101891046274e-06
candidate O 0 4.361494120530551e-06
gene O 0 1.6708814655430615e-05
for O 0 5.368142228689976e-05
hereditary B-Disease 1 0.9999983310699463
hemochromatosis I-Disease 1 0.9999998807907104
called O 1 0.8461580872535706
HFE O 1 0.951732337474823
. O 0 0.00011170760990353301

The O 0 7.748816415187321e-07
gene O 0 1.5043208350107307e-06
product O 0 8.167733085429063e-07
, O 0 1.9199696055238746e-07
a O 0 2.2543216005033173e-07
member O 0 1.6766267663115286e-07
of O 0 1.6532901270238654e-08
the O 0 1.7997649592871312e-07
major O 0 1.1651414752122946e-05
histocompatibility O 0 0.018579794093966484
complex O 0 0.00014702422777190804
class O 0 2.2620302843279205e-05
I O 0 0.0003476714773569256
- O 0 1.4756617019884288e-05
like O 0 8.610037411926896e-07
family O 0 9.977563877328066e-07
, O 0 1.7853471945272759e-07
was O 0 8.987719866127009e-07
found O 0 5.1364775544016084e-08
to O 0 5.773210798309947e-09
have O 0 1.8978722593487873e-08
a O 0 4.270347631063487e-07
mutation O 0 5.058714123151731e-06
, O 0 7.583043384329358e-07
Cys O 0 0.00046910170931369066
- O 0 5.248278466751799e-05
282 O 0 2.415269955235999e-05
- O 0 0.00013873862917535007
- O 0 0.0001321340532740578
> O 0 3.136300801998004e-05
Tyr O 0 7.447003008564934e-05
( O 0 2.1811906947277748e-07
C282Y O 0 2.6760267246572766e-06
) O 0 1.9027256215053967e-08
, O 0 2.5970246397832852e-08
in O 0 2.326124537432861e-08
85 O 0 2.2421602352551417e-07
% O 0 2.265273124635314e-08
of O 0 7.170928739697047e-08
patient O 0 2.388732900726609e-05
chromosomes O 0 3.27948946505785e-05
. O 0 5.0345879571978e-06

This O 0 4.127277861698531e-06
mutation O 0 6.37883713352494e-05
eliminates O 0 2.0854702597716823e-05
the O 0 2.7857126383423747e-07
ability O 0 1.0110602488566656e-06
of O 0 2.340578362236556e-07
HFE O 0 0.00045875218347646296
to O 0 2.143021049505478e-07
associate O 0 3.8870234675414395e-06
with O 0 1.6159704046003753e-06
beta2 O 0 0.0036835207138210535
- O 0 0.0007594686467200518
microglobulin O 0 0.0003874159010592848
( O 0 4.254912084888929e-07
beta2m O 0 1.9696299204952084e-05
) O 0 7.136707580457369e-08
and O 0 1.3535124310237734e-07
prevents O 0 3.2552238735661376e-06
cell O 0 0.00010563567047938704
- O 0 8.106482709990814e-05
surface O 0 5.387322380556725e-05
expression O 0 3.067404395551421e-05
. O 0 8.344804882653989e-06

A O 0 2.1408452084870078e-05
second O 0 1.0955316611216404e-05
mutation O 0 2.045797555183526e-05
that O 0 9.197368200375422e-08
has O 0 2.1134736982730828e-07
no O 0 2.1959806417726213e-07
effect O 0 6.023986998116015e-07
on O 0 3.2873881536943372e-06
beta2m O 0 0.00032925690175034106
association O 0 4.177992650511442e-06
, O 0 4.2587689108586346e-07
H63D O 0 6.925695925019681e-05
, O 0 2.560891232405993e-07
was O 0 1.5996225783965201e-06
found O 0 7.008956970366853e-08
in O 0 1.344369149336444e-08
eight O 0 7.385939682080789e-08
out O 0 4.8282569053981206e-08
of O 0 2.311987934433546e-08
nine O 0 7.065046929710661e-07
patients O 0 1.5667186517021037e-06
heterozygous O 0 1.908738340716809e-07
for O 0 2.3762600775967258e-08
the O 0 2.3261918613570742e-07
C282Y O 0 8.321155473822728e-05
mutant O 0 5.8761423133546486e-05
. O 0 6.797365131205879e-06

In O 0 1.3820299500366673e-06
this O 0 1.099423272421518e-07
report O 0 1.710037764723893e-07
, O 0 4.3963037654748405e-08
we O 0 1.8649947364224317e-08
demonstrate O 0 9.412353563220677e-08
in O 0 6.389863926870021e-08
cultured O 0 6.427932476071874e-06
293 O 0 1.4866680430714041e-05
cells O 0 6.244991254789056e-06
overexpressing O 0 0.0001336086861556396
wild O 0 2.511356615286786e-05
- O 0 5.864755075890571e-05
type O 0 1.4603518138756044e-05
or O 0 2.0237803255440667e-06
mutant O 0 1.2178009455965366e-05
HFE O 0 0.00013198258238844573
proteins O 0 1.747255993223007e-07
that O 0 1.2408079896886193e-08
both O 0 2.1485826451339562e-08
the O 0 8.934379280844951e-08
wild O 0 2.5814933906076476e-06
- O 0 4.768828512169421e-05
type O 0 1.4374330930877477e-05
and O 0 1.5715760355305974e-06
H63D O 0 0.0006601894274353981
HFE O 0 0.00042894299258477986
proteins O 0 6.327573487396876e-07
form O 0 6.238885816856055e-07
stable O 0 3.58364900421293e-06
complexes O 0 8.616198101663031e-07
with O 0 7.429456871932416e-08
the O 0 2.1595282362341095e-07
transferrin O 0 4.635771983885206e-05
receptor O 0 9.876986041490454e-06
( O 0 7.757940920782858e-07
TfR O 0 0.00022388040088117123
) O 0 9.890094361253432e-07
. O 0 2.4439320895908168e-06

The O 0 1.0328483767807484e-05
C282Y O 0 0.0002605530899018049
mutation O 0 5.7117664255201817e-05
nearly O 0 1.8189507500210311e-06
completely O 0 4.100732894585235e-06
prevents O 0 1.5135710782487877e-06
the O 0 1.408790524237702e-07
association O 0 2.2916614739187935e-07
of O 0 1.2635107182745742e-08
the O 0 1.5606075010055065e-07
mutant O 0 5.850509751326172e-06
HFE O 0 0.00015021506987977773
protein O 0 1.3348765151022235e-06
with O 0 3.123898864032526e-07
the O 0 2.1224893771432107e-06
TfR O 0 0.0022277082316577435
. O 0 1.0470781489857472e-05

Studies O 0 3.523785608194885e-06
on O 0 4.201182491669897e-06
cell O 0 6.737993680872023e-05
- O 0 3.345145523780957e-05
associated O 0 1.9418955616856692e-06
transferrin O 0 2.1597892555291764e-05
at O 0 6.837897217337741e-06
37 O 0 1.249955403181957e-06
degrees O 0 2.312141532456735e-06
C O 0 6.53033384878654e-06
suggest O 0 1.9745769463952456e-07
that O 0 1.2625999801230137e-08
the O 0 1.3051281655407365e-07
overexpressed O 0 4.3311109038768336e-05
wild O 0 8.397919373237528e-06
- O 0 2.7422274797572754e-05
type O 0 1.4981966160121374e-05
HFE O 0 0.00033086957409977913
protein O 0 2.6686000182962744e-06
decreases O 0 2.5004521830851445e-06
the O 0 3.0192566669029475e-08
affinity O 0 3.813897251347953e-07
of O 0 6.295287846569408e-08
the O 0 4.4604962567973416e-07
TfR O 0 0.00012616872845683247
for O 0 5.288580950946198e-07
transferrin O 0 0.0003161033964715898
. O 0 6.597936135221971e-06

The O 0 7.907356120995246e-06
overexpressed O 0 0.00040048814844340086
H63D O 0 0.00024692495935596526
protein O 0 1.2171682328698807e-06
does O 0 1.4880873777656234e-07
not O 0 1.0466083999460807e-08
have O 0 9.459665939459683e-09
this O 0 5.7906683892383626e-09
effect O 0 6.90874841779987e-08
, O 0 1.309200392540788e-08
providing O 0 8.820759234140496e-09
the O 0 9.778003295934923e-09
first O 0 2.125143261366702e-08
direct O 0 1.2363100765355739e-08
evidence O 0 2.3548375693849266e-08
for O 0 1.2460874110331588e-08
a O 0 2.216976895397238e-07
functional O 0 1.277541173294594e-06
consequence O 0 7.53198264646926e-06
of O 0 1.0553124951684367e-07
the O 0 1.8283037661603885e-06
H63D O 0 0.007633336819708347
mutation O 0 0.00027280094218440354
. O 0 8.006655662029516e-06

Addition O 0 2.1385674244811526e-06
of O 0 8.241833029387635e-07
soluble O 0 0.0005152455996721983
wild O 0 0.00011294181604171172
- O 0 0.0011866501299664378
type O 0 0.00034832870005629957
HFE O 0 0.032272279262542725
/ O 0 0.0011288810055702925
beta2m O 0 0.0008530110935680568
heterodimers O 0 0.00018228752014692873
to O 0 1.4687068983221252e-07
cultured O 0 7.925277714093681e-06
cells O 0 3.3137653190351557e-06
also O 0 3.3705001101225207e-07
decreased O 0 1.9760227587539703e-06
the O 0 8.707213794423296e-08
apparent O 0 2.887222308345372e-06
affinity O 0 1.3790912589684012e-06
of O 0 1.0122703741899386e-07
the O 0 1.9886084601239418e-07
TfR O 0 3.500138336676173e-05
for O 0 1.2589064901646907e-08
its O 0 1.377358138654472e-08
ligand O 0 1.3872207773601986e-06
under O 0 6.432345571738551e-07
steady O 0 1.3830221178068314e-05
- O 0 3.828208355116658e-05
state O 0 6.190541057549126e-07
conditions O 0 3.1120393941819202e-06
, O 0 6.649783301782008e-08
both O 0 3.681602933625072e-08
in O 0 9.683390089776367e-08
293 O 0 1.7612650253795437e-06
cells O 0 6.258861162677931e-07
and O 0 1.4859571706438146e-07
in O 0 5.823767423862591e-07
HeLa O 0 0.00020211844821460545
cells O 0 1.3378687981457915e-05
. O 0 3.1300946830015164e-06

Furthermore O 0 1.3380831660469994e-05
, O 0 6.082082677494327e-07
at O 0 3.6025160170538584e-06
4 O 0 7.294962642845348e-07
degrees O 0 2.0234733710822184e-06
C O 0 1.0668382856238168e-05
, O 0 1.0506409608979084e-07
the O 0 1.0619839230230355e-07
added O 0 1.3140571581971017e-06
soluble O 0 1.8991826436831616e-05
complex O 0 1.0670191841199994e-05
of O 0 9.148849358098232e-07
HFE O 0 0.004548848140984774
/ O 0 0.00022828434885013849
beta2m O 0 0.0002649702364578843
inhibited O 0 7.984236617630813e-06
binding O 0 2.6394777705718298e-06
of O 0 8.98626524303836e-08
transferrin O 0 4.103736864635721e-05
to O 0 4.3821094664053817e-07
HeLa O 0 0.00013688944454770535
cell O 0 3.572547939256765e-05
TfR O 0 7.438912143697962e-05
in O 0 2.0446978510335612e-07
a O 0 8.924839676183183e-07
concentration O 0 0.00012162061466369778
- O 0 5.1553397497627884e-05
dependent O 0 2.7670880626828875e-06
manner O 0 4.3184907553950325e-05
. O 0 7.729524440946989e-06

Scatchard O 0 0.00047156523214653134
plots O 0 5.783931555924937e-06
of O 0 1.0710729014817844e-07
these O 0 2.2540714184060562e-08
data O 0 2.5479093324065616e-07
indicate O 0 2.9369556386882323e-07
that O 0 1.8942017732115346e-08
the O 0 9.860638527925403e-08
added O 0 1.0655523965397151e-06
heterodimer O 0 3.1509785912930965e-05
substantially O 0 3.9779042708687484e-06
reduced O 0 3.63064543762448e-07
the O 0 3.6808025072332384e-08
affinity O 0 6.505964620373561e-07
of O 0 1.7680542896414408e-07
TfR O 0 0.00020273454720154405
for O 0 5.868413381904247e-07
transferrin O 0 0.000526698655448854
. O 0 1.2873529158241581e-05

These O 0 3.6075965681447997e-07
results O 0 7.154902164074883e-07
establish O 0 1.565859690799698e-07
a O 0 3.0061758593546983e-07
molecular O 0 6.802455573051702e-06
link O 0 1.0533018212299794e-05
between O 0 1.1095949048467446e-06
HFE O 0 0.00033901043934747577
and O 0 3.6164459515930503e-07
a O 0 3.7102805094946234e-07
key O 0 1.3562003005063161e-06
protein O 0 2.763786426385195e-07
involved O 0 4.532972752713249e-07
in O 0 2.480278737948538e-07
iron O 0 0.0006058173021301627
transport O 0 7.156108495109947e-06
, O 0 3.313836600682407e-07
the O 0 2.523651687624806e-07
TfR O 0 9.030896762851626e-05
, O 0 3.21541762104971e-07
and O 0 9.50718757053437e-08
raise O 0 3.8732332541258074e-07
the O 0 1.766436241723568e-07
possibility O 0 7.735865779068263e-07
that O 0 3.3203086502453516e-08
alterations O 0 5.905297712160973e-06
in O 0 1.2686548700457934e-07
this O 0 1.9510004278799897e-08
regulatory O 0 2.573058054622379e-06
mechanism O 0 4.096566044609062e-06
may O 0 3.0067806733313773e-07
play O 0 6.105723571181443e-08
a O 0 1.2349012479262456e-07
role O 0 4.758844909247273e-07
in O 0 2.2703908086896263e-07
the O 0 1.126583811128512e-06
pathogenesis O 0 0.013490418903529644
of O 0 0.00018937962886411697
hereditary B-Disease 1 0.9999990463256836
hemochromatosis I-Disease 1 0.9999998807907104
. O 0 0.0003614577290136367
. O 0 1.855650589277502e-05

Genomic O 0 0.00016072041762527078
organization O 0 4.3303521124471445e-06
of O 0 8.937004736253584e-08
the O 0 9.050664289134147e-07
UBE3A O 0 0.002201829571276903
/ O 0 0.00043508774251677096
E6 O 0 0.002182768424972892
- O 0 0.00031754752853885293
AP O 0 5.226961729931645e-05
gene O 0 2.198005859099794e-06
and O 0 5.133015861247259e-07
related O 0 4.640483439288801e-06
pseudogenes O 0 0.00017132518405560404
. O 0 1.3281287465360947e-05

The O 0 6.070682047720766e-06
UBE3A O 0 0.0005052150227129459
gene O 0 2.2677299966744613e-06
encodes O 0 4.4132875132163463e-07
the O 0 7.216591484393575e-07
E6 O 0 0.00037425197660923004
- O 0 7.869081309763715e-05
AP O 0 3.908478174707852e-05
ubiquitin O 0 3.5288430808577687e-06
- O 0 3.5595198824012186e-06
protein O 0 2.2696850976444694e-07
ligase O 0 1.6281974239973351e-06
and O 0 8.981879062730513e-08
has O 0 1.3667859377619607e-07
recently O 0 1.595953335709055e-06
been O 0 7.09181975366846e-08
shown O 0 5.687644843987982e-08
to O 0 2.7991124085247066e-08
be O 0 8.834719551487069e-07
mutated O 0 0.0001800463505787775
in O 0 0.0004260512359905988
Angelman B-Disease 1 0.9999649524688721
syndrome I-Disease 1 0.9999991655349731
patients O 0 0.006936601363122463
who O 0 1.404854810971301e-05
lack O 0 8.254306521848775e-06
15q11 O 0 0.0005432694451883435
- O 0 0.0007544666877947748
q13 O 0 0.00021939411817584187
deletions O 0 9.213743032887578e-05
or O 0 1.6597012290731072e-05
chromosome O 0 0.00036491360515356064
15 O 0 1.435735794075299e-05
paternal O 0 0.0004718091804534197
uniparental B-Disease 1 0.9127930998802185
disomy I-Disease 1 0.5444857478141785
. O 0 5.890274769626558e-05

Previous O 0 1.6968278941931203e-05
UBE3A O 0 0.0005080770934000611
cDNA O 0 2.0089446479687467e-06
analysis O 0 4.7013440962473396e-07
has O 0 1.97054546902109e-07
shown O 0 1.0501380387495374e-07
a O 0 2.9280511171236867e-07
coding O 0 2.0954978026566096e-05
region O 0 2.5135134364973055e-06
of O 0 4.5294768824533094e-08
approximately O 0 3.015435936504218e-07
2 O 0 8.080655788944568e-06
. O 0 3.1379731808556244e-06

6 O 0 3.9595142879989e-05
kb O 0 2.337794103368651e-05
and O 0 6.616306791329407e-07
a O 0 3.0152166345942533e-06
3 O 0 1.6976533515844494e-05
- O 0 0.00016932918515522033
untranslated O 0 0.0006257222848944366
region O 0 1.0722502338467166e-05
( O 0 2.961317306926503e-07
UTR O 0 2.1064035536255687e-05
) O 0 7.12166823291227e-08
of O 0 4.8005251329641396e-08
< O 0 1.3575638149632141e-05
50 O 0 1.3438316273095552e-06
bp O 0 2.4491177100571804e-05
, O 0 1.0634474278958805e-07
whereas O 0 7.438303839535365e-08
Northern O 0 2.6152056875616836e-07
analysis O 0 9.168083892063805e-08
has O 0 9.776627507562807e-08
indicated O 0 6.439759658860567e-08
mRNA O 0 2.010138722141619e-08
sizes O 0 3.52715744611487e-07
of O 0 9.587036231550883e-08
5 O 0 3.213270247215405e-06
- O 0 3.269590524723753e-05
8 O 0 6.6371389948471915e-06
kb O 0 5.8482462918618694e-05
. O 0 4.676915068557719e-06

We O 0 2.626706418595859e-06
have O 0 9.277535184537555e-08
analyzed O 0 2.0393501642956835e-07
additional O 0 1.5399603370269688e-08
cDNA O 0 2.0630865549264854e-07
clones O 0 1.0152098184335046e-06
and O 0 2.478178551257315e-08
provide O 0 8.767454318103773e-09
evidence O 0 3.149462557416882e-08
for O 0 9.607755480089963e-09
an O 0 1.933747384441631e-08
additional O 0 8.146366070604927e-08
0 O 0 5.323107416188577e-06
. O 0 3.3558756058482686e-06

5 O 0 8.547616744181141e-06
kb O 0 1.4823813216935378e-05
of O 0 2.279015944850471e-07
5 O 0 5.041020358476089e-06
- O 0 2.1538653527386487e-05
UTR O 0 4.725920007331297e-05
and O 0 5.94332163927902e-07
> O 0 3.485198021735414e-06
2 O 0 4.816125169782026e-07
kb O 0 4.004822585557122e-06
of O 0 3.449267751420848e-07
3 O 0 2.6773210265673697e-05
- O 0 0.0005244390922598541
UTR O 0 0.0017320893239229918
. O 0 2.1553734768531285e-05

We O 0 2.2056656234781258e-06
have O 0 1.495351256153299e-07
established O 0 2.191459600453527e-07
the O 0 1.232368305181808e-07
genomic O 0 3.968492364947451e-06
organization O 0 4.904347292722377e-07
of O 0 8.409145380028349e-08
UBE3A O 0 0.00022204575361683965
and O 0 3.3408659305678157e-07
the O 0 8.875714030409654e-08
sequence O 0 7.822217753528093e-07
of O 0 6.050887577657704e-07
intron O 0 0.001696905354037881
- O 0 0.0013919139746576548
exon O 0 0.0005252133123576641
borders O 0 5.962676368653774e-05
. O 0 9.49311834119726e-06

We O 0 2.4002902136999182e-06
have O 0 1.1397445831562436e-07
also O 0 7.355502873451769e-08
mapped O 0 9.458656222705031e-07
two O 0 4.4211013516815e-08
highly O 0 1.4437791833188385e-06
homologous O 0 9.07090179680381e-06
processed O 0 1.0663529792509507e-05
pseudogenes O 0 8.797235932433978e-05
, O 0 1.8493489051252254e-06
UBE3AP1 O 0 0.00016695416707079858
and O 0 1.0268663572787773e-06
UBE3AP2 O 0 0.0001189788818010129
, O 0 6.979927036354638e-08
to O 0 6.2485590035521454e-09
chromosomes O 0 2.408103512152593e-07
2 O 0 3.704284381456091e-07
and O 0 8.602390977330288e-08
21 O 0 4.207928441246622e-07
, O 0 5.156876170531177e-08
respectively O 0 4.132979540827364e-07
, O 0 4.5905764523013204e-08
and O 0 3.121867209188167e-08
determined O 0 2.6396386942906247e-07
their O 0 1.542985046398826e-07
genomic O 0 1.4358015505422372e-05
organization O 0 7.107011242624139e-06
. O 0 4.4439470912038814e-06

These O 0 1.654031933639999e-07
results O 0 2.444155825287453e-06
will O 0 6.389048223809368e-08
form O 0 5.465061292397877e-08
the O 0 2.505688456722055e-08
basis O 0 3.119462377298987e-08
for O 0 1.1866414517669455e-08
studies O 0 5.6380898172392335e-08
of O 0 5.129076185994563e-08
mutation O 0 4.407404503581347e-06
and O 0 2.8425745313143125e-07
imprinting O 0 9.917201532516629e-05
of O 0 1.9645688098535175e-06
UBE3A O 0 0.030660932883620262
. O 0 5.175466867513023e-05

Mutation O 0 0.0005525386659428477
spectrum O 0 0.0001454735320294276
and O 0 4.75386423204327e-06
genotype O 0 0.00040346768219023943
- O 0 0.001275805407203734
phenotype O 0 0.00031206250423565507
analyses O 0 5.444588896352798e-05
in O 0 1.6381423847633414e-05
Cowden B-Disease 1 0.9525511264801025
disease I-Disease 1 0.9981914162635803
and O 0 0.00011026680294889957
Bannayan B-Disease 1 0.9957759976387024
- I-Disease 1 0.9996980428695679
Zonana I-Disease 1 0.9991911053657532
syndrome I-Disease 1 0.9999707937240601
, O 0 9.15467808226822e-06
two O 0 1.4188764907885343e-05
hamartoma B-Disease 1 0.9791872501373291
syndromes I-Disease 1 0.976547122001648
with O 0 3.244865365559235e-05
germline O 0 0.0368812270462513
PTEN O 0 0.15243370831012726
mutation O 0 0.002197159919887781
. O 0 1.7279146049986593e-05

The O 0 0.00014980981359258294
tumour B-Disease 1 0.9991835951805115
suppressor O 0 0.0009310396853834391
gene O 0 5.190789670450613e-05
PTEN O 0 0.0009984804783016443
, O 0 6.544315738210571e-07
which O 0 3.24887921010486e-08
maps O 0 6.151757361294585e-07
to O 0 2.4098355311252817e-07
10q23 O 0 0.0001568560692248866
. O 0 5.145016530150315e-06

3 O 0 4.166084636381129e-06
and O 0 1.8773100407543097e-07
encodes O 0 2.789178950024507e-07
a O 0 5.916538725614373e-07
403 O 0 9.527261681796517e-07
amino O 0 5.235198727859824e-07
acid O 0 2.884585683204932e-06
dual O 0 2.1777643723908113e-06
specificity O 0 3.406265705052647e-06
phosphatase O 0 0.0006767193553969264
( O 0 5.468820063470048e-07
protein O 0 3.3499920846224995e-06
tyrosine O 0 3.851783912978135e-05
phosphatase O 0 0.0005572004010900855
; O 0 5.317651243785804e-07
PTPase O 0 2.9750946850981563e-05
) O 0 1.0195132915669092e-07
, O 0 8.811783658302375e-08
was O 0 6.913980996614555e-07
shown O 0 1.3741154702984204e-07
recently O 0 6.975042765589023e-07
to O 0 5.122777313459892e-09
play O 0 1.1413152378736413e-07
a O 0 2.7590144213718304e-07
broad O 0 9.126871418629889e-07
role O 0 3.384076990187168e-06
in O 0 2.496354227332631e-06
human O 0 4.2758638301165774e-05
malignancy B-Disease 1 0.967158854007721
. O 0 1.1338981494191103e-05

Somatic O 0 0.0036218781024217606
PTEN O 0 0.012188194319605827
deletions O 0 0.00025425240164622664
and O 0 3.1033675895741908e-06
mutations O 0 2.689127722987905e-05
were O 0 4.2971919356205035e-07
observed O 0 3.352852672833251e-06
in O 0 7.3262111754957e-07
sporadic B-Disease 0 0.0004999408847652376
breast I-Disease 1 0.9901665449142456
, I-Disease 0 3.05736975860782e-05
brain I-Disease 1 0.9792201519012451
, I-Disease 0 5.5157554015750065e-05
prostate I-Disease 1 0.9995191097259521
and I-Disease 0 0.0003905167686752975
kidney I-Disease 1 0.9997937083244324
cancer I-Disease 1 0.996887743473053
cell O 0 4.575477942125872e-05
lines O 0 7.995766281965189e-06
and O 0 1.5189863233899814e-07
in O 0 8.529831774239938e-08
several O 0 1.5262672548033152e-07
primary O 0 4.4202552089700475e-05
tumours B-Disease 1 0.9998735189437866
such O 0 7.769870535412338e-06
as O 0 0.005281769670546055
endometrial B-Disease 1 0.9998834133148193
carcinomas I-Disease 1 0.9999982118606567
, O 1 0.9994651675224304
malignant B-Disease 1 0.9999998807907104
melanoma I-Disease 1 0.9999998807907104
and O 1 0.9990823268890381
thyroid B-Disease 1 0.9999977350234985
tumours I-Disease 1 0.9999920129776001
. O 0 0.00013107553240843117

In O 0 1.5805915154487593e-06
addition O 0 5.785460075458104e-07
, O 0 8.412688430325943e-07
PTEN O 0 0.0002554559032432735
was O 0 5.906249498366378e-06
identified O 0 4.912511144539167e-07
as O 0 6.352557591071673e-08
the O 0 6.956761211540652e-08
susceptibility O 0 5.918902843404794e-06
gene O 0 1.3579345932157594e-06
for O 0 4.4893022277392447e-07
two O 0 2.3138196411309764e-05
hamartoma B-Disease 1 0.9933631420135498
syndromes I-Disease 1 0.9989784955978394
Cowden B-Disease 1 0.9978571534156799
disease I-Disease 1 0.9996023774147034
( O 0 1.6481286593261757e-06
CD B-Disease 0 6.63355749566108e-05
; O 0 3.744369450942031e-06
MIM O 0 0.00040249116136692464
158350 O 0 0.00010415630094939843
) O 0 4.662494177409826e-07
and O 0 1.175541001430247e-06
Bannayan B-Disease 0 0.0038179524708539248
- I-Disease 0 0.019217129796743393
Zonana I-Disease 0 0.05733385309576988
( I-Disease 0 3.6439519135456067e-06
BZS I-Disease 0 0.0005360374343581498
) I-Disease 0 4.842238467972493e-07
or I-Disease 0 2.598055971247959e-06
Ruvalcaba I-Disease 0 0.0013240189291536808
- I-Disease 0 0.0024052304215729237
Riley I-Disease 0 0.001492527313530445
- I-Disease 0 0.4138670861721039
Smith I-Disease 0 0.013717861846089363
syndrome I-Disease 1 0.999679446220398
( O 0 8.555755812267307e-06
MIM O 0 0.0014735982986167073
153480 O 0 0.0004231951024848968
) O 0 2.4043179109867197e-06
. O 0 3.2961718261503847e-06

Constitutive O 0 4.648432513931766e-05
DNA O 0 5.23893231729744e-06
from O 0 3.372184664840461e-07
37 O 0 8.199349394999444e-07
CD B-Disease 0 2.33387436310295e-06
families O 0 1.3389330888458062e-07
and O 0 4.060859453147714e-07
seven O 0 1.4828359553575865e-06
BZS B-Disease 0 0.00022377022833097726
families O 0 2.7162397486790724e-07
was O 0 6.063403816369828e-06
screened O 0 8.828933459881227e-06
for O 0 1.2364997701297398e-06
germline O 0 0.0015109933447092772
PTEN O 0 0.011835199780762196
mutations O 0 0.0018252059817314148
. O 0 1.8360675312578678e-05

PTEN O 0 0.0070218355394899845
mutations O 0 0.0001612171035958454
were O 0 4.881799213762861e-07
identified O 0 8.167679084181145e-07
in O 0 1.0733224087289273e-07
30 O 0 3.648253255050804e-07
of O 0 3.086473299163117e-08
37 O 0 2.007404873438645e-06
( O 0 1.3758240413608291e-07
81 O 0 2.1146604467503494e-06
% O 0 2.9618361097050183e-08
) O 0 2.5212210985614547e-08
CD B-Disease 0 1.7078193650377216e-06
families O 0 6.991599832417705e-08
, O 0 1.0807383432620554e-07
including O 0 1.4948321336305526e-07
missense O 0 6.586457311641425e-05
and O 0 3.7068957681185566e-06
nonsense O 0 0.00016355996194761246
point O 0 3.641410148702562e-05
mutations O 0 6.057643622625619e-05
, O 0 6.151299771772756e-07
deletions O 0 5.767770744569134e-06
, O 0 5.225940640229965e-07
insertions O 0 1.4669652955490164e-05
, O 0 4.1833646946543013e-07
a O 0 1.3741065458816593e-06
deletion O 0 5.538810364669189e-05
/ O 0 3.300403477624059e-05
insertion O 0 1.1090511179645546e-05
and O 0 8.144670573528856e-07
splice O 0 0.00028229557210579515
site O 0 0.0001684755989117548
mutations O 0 0.0001707045448711142
. O 0 7.331561391765717e-06

These O 0 5.39406073585269e-07
mutations O 0 2.118884731316939e-05
were O 0 3.72254362446256e-07
scattered O 0 1.1801733990068897e-06
over O 0 4.4353927819429373e-07
the O 0 1.8941010182516038e-07
entire O 0 1.4600389022234594e-06
length O 0 2.3121372123569017e-06
of O 0 2.494997204394167e-07
PTEN O 0 0.00016770086949691176
, O 0 1.866433052555294e-07
with O 0 3.1554151291857124e-08
the O 0 6.210871106304694e-08
exception O 0 2.5219770805051667e-07
of O 0 1.256763937362848e-08
the O 0 7.336684859637899e-08
first O 0 6.906843168508203e-07
, O 0 3.406011614970339e-07
fourth O 0 3.3374124086549273e-06
and O 0 3.684722571506427e-07
last O 0 6.040305834176252e-06
exons O 0 3.276510688010603e-05
. O 0 5.57452540306258e-06

A O 0 6.601996574318036e-05
hot O 0 0.0002465556317474693
spot O 0 3.3522159355925396e-05
for O 0 5.698089466932288e-07
PTEN O 0 0.00036191559047438204
mutation O 0 1.716933911666274e-05
in O 0 2.9546234259214543e-07
CD B-Disease 0 9.037700692715589e-06
was O 0 8.835959306452423e-06
identified O 0 5.243762757345394e-07
in O 0 1.0297617336618714e-07
exon O 0 5.935283752478426e-06
5 O 0 5.609299478237517e-07
that O 0 8.02315547332455e-09
contains O 0 5.943786973716669e-08
the O 0 1.997679106580108e-07
PTPase O 0 7.33750857762061e-05
core O 0 7.803093467373401e-06
motif O 0 1.6476116798003204e-05
, O 0 1.5028238919967407e-07
with O 0 6.275099906360992e-08
13 O 0 4.2603531369422853e-07
of O 0 2.889612993328683e-08
30 O 0 2.6302006972400704e-07
( O 0 4.570979328377689e-08
43 O 0 1.849829089906052e-07
% O 0 7.2845183218817056e-09
) O 0 1.694315265865498e-08
CD B-Disease 0 2.4836688226059778e-06
mutations O 0 3.422569761823979e-06
identified O 0 8.069343380157079e-07
in O 0 1.5855327717417822e-07
this O 0 1.567969576399264e-07
exon O 0 8.054477802943438e-05
. O 0 7.588942025904544e-06

Seven O 0 1.7429351828468498e-06
of O 0 1.7145627850823075e-07
30 O 0 1.4162010302243289e-06
( O 0 1.221471279677644e-07
23 O 0 7.381347586488118e-07
% O 0 7.798544920945005e-09
) O 0 8.304437137951481e-09
were O 0 8.376692228750926e-09
within O 0 2.0806592004873892e-08
the O 0 2.864360304499769e-08
core O 0 3.1815275178814773e-06
motif O 0 6.465521437348798e-06
, O 0 1.0361907243350288e-07
the O 0 3.63489576216125e-08
majority O 0 3.907499035449291e-08
( O 0 4.0480333751702346e-08
five O 0 3.0037366371971075e-08
of O 0 7.807638091605895e-09
seven O 0 6.201153013307703e-08
) O 0 9.262873135185146e-09
of O 0 2.9047249050506707e-09
which O 0 2.9461109107842276e-08
were O 0 2.130163778701899e-07
missense O 0 8.327537216246128e-05
mutations O 0 0.00011054390779463574
, O 0 8.114519687296706e-07
possibly O 0 2.1090695554448757e-06
pointing O 0 1.8905760725829168e-06
to O 0 1.2011881267426361e-08
the O 0 4.944943299278748e-08
functional O 0 4.784045017913741e-07
significance O 0 6.070272320357617e-07
of O 0 7.354689302019324e-08
this O 0 1.4245911472698936e-07
region O 0 7.952965461299755e-06
. O 0 4.384497970022494e-06

Germline O 0 0.01039522048085928
PTEN O 0 0.00469356682151556
mutations O 0 7.766093767713755e-05
were O 0 4.7544446601932577e-07
identified O 0 5.575730597229267e-07
in O 0 4.794010166619955e-08
four O 0 2.729315617955308e-08
of O 0 1.674764327219691e-08
seven O 0 4.133302979880682e-07
( O 0 2.2341431815675605e-07
57 O 0 2.3656700705032563e-06
% O 0 9.363863284761464e-08
) O 0 1.4825275229668478e-07
BZS B-Disease 0 0.00012628188414964825
families O 0 4.291057393857045e-07
studied O 0 2.5117877157754265e-05
. O 0 8.449686902167741e-06

Interestingly O 0 0.0001103181202779524
, O 0 1.705065869828104e-06
none O 0 4.1173811382577696e-07
of O 0 1.5836311817452042e-08
these O 0 4.4089333073316084e-08
mutations O 0 1.7448062862968072e-05
was O 0 1.3400140232988633e-05
observed O 0 2.9543714390456444e-06
in O 0 1.5414069309827028e-07
the O 0 4.632346701782808e-07
PTPase O 0 0.0003078915469814092
core O 0 9.505547495791689e-05
motif O 0 0.0004911030409857631
. O 0 1.3763446986558847e-05

It O 0 1.2125685771025019e-06
is O 0 3.348981465478573e-07
also O 0 9.276420342985148e-08
worthy O 0 5.307082915351202e-07
of O 0 6.096844629155385e-08
note O 0 1.4446729892370058e-06
that O 0 1.2041449615196598e-08
a O 0 1.381776684183933e-07
single O 0 7.600796720907965e-07
nonsense O 0 3.614610250224359e-05
point O 0 3.865483449772e-06
mutation O 0 9.760379725776147e-06
, O 0 1.5386575569209526e-07
R233X O 0 4.7820794861763716e-06
, O 0 2.0018767088458844e-07
was O 0 1.0887873713727458e-06
observed O 0 3.847425773528812e-07
in O 0 1.2909648461345569e-08
the O 0 2.585829328438649e-08
germline O 0 7.756632840028033e-06
DNA O 0 8.365022949874401e-07
from O 0 8.358247072237646e-08
two O 0 3.1095300556671646e-08
unrelated O 0 1.2636379551622667e-06
CD B-Disease 0 9.290226444136351e-06
families O 0 1.7784562089673273e-07
and O 0 5.545054477806843e-07
one O 0 1.8956582152895862e-06
BZS B-Disease 0 0.0016470880946144462
family O 0 4.951945447828621e-05
. O 0 7.746993105683941e-06

Genotype O 0 0.001239124801941216
- O 0 0.000627098313998431
phenotype O 0 4.255085877957754e-05
studies O 0 4.147960908085224e-07
were O 0 5.31321049379585e-08
not O 0 2.277846355980273e-08
performed O 0 5.852830895491934e-07
on O 0 1.7111422323523584e-07
this O 0 7.689994419024515e-09
small O 0 1.4937177184037864e-07
group O 0 3.2547535511184833e-07
of O 0 1.898546173606519e-07
BZS B-Disease 0 0.001390959951095283
families O 0 3.1251670407073107e-06
. O 0 9.570221664034761e-06

However O 0 7.170420758484397e-06
, O 0 1.7247994037461467e-06
genotype O 0 3.5382461646804586e-05
- O 0 0.0001146746872109361
phenotype O 0 3.5978791856905445e-05
analysis O 0 7.066246325848624e-07
inthe O 0 5.0433714932296425e-05
group O 0 6.699228833895177e-07
of O 0 2.286151179475837e-08
CD B-Disease 0 1.4654719052487053e-05
families O 0 1.796830417788442e-07
revealed O 0 1.9813744529528776e-06
two O 0 4.59521025675258e-08
possible O 0 2.1954780038413446e-07
associations O 0 1.4145282989375119e-07
worthy O 0 1.0703862471928005e-06
of O 0 4.628363825531778e-08
follow O 0 4.791487526745186e-07
- O 0 1.3631306501338258e-05
up O 0 1.0455747769810841e-06
in O 0 1.540290099910635e-07
independent O 0 2.522650390801573e-07
analyses O 0 2.5930335141310934e-06
. O 0 2.382083494012477e-06

The O 0 7.201370522125217e-07
first O 0 8.722528264115681e-07
was O 0 3.668226327135926e-06
an O 0 1.2742883370719937e-07
association O 0 6.930874860699987e-07
noted O 0 2.653227113569301e-07
in O 0 2.7781188904896226e-08
the O 0 4.709740153430175e-08
group O 0 1.488403853500131e-07
of O 0 1.656765569180152e-08
CD B-Disease 0 1.5471385268028826e-05
families O 0 7.411410365421034e-07
with O 0 0.0001608642196515575
breast B-Disease 1 0.9998334646224976
disease I-Disease 1 0.9992710947990417
. O 0 1.5710751540609635e-05

A O 0 6.3637121456849854e-06
correlation O 0 1.9926189906982472e-06
was O 0 4.112199349037837e-06
observed O 0 7.935645953693893e-07
between O 0 1.1446288539218585e-07
the O 0 2.562794350069453e-07
presence O 0 1.7066943200916285e-06
/ O 0 6.0944836150156334e-05
absence O 0 5.1404945224931e-06
of O 0 1.594962810713696e-07
a O 0 1.0363164619775489e-05
PTEN O 0 0.0013896689051762223
mutation O 0 3.4549375413917005e-05
and O 0 3.775799655159062e-07
the O 0 2.0913188336635358e-07
type O 0 3.6824774724664167e-05
of O 0 3.4837059956771554e-06
breast O 1 0.8660482168197632
involvement O 0 0.00010844240750884637
( O 0 7.541369086538907e-06
unaffected O 0 0.0010065429378300905
versus O 0 0.0058962260372936726
benign O 1 0.9851235747337341
versus O 0 0.4580267667770386
malignant O 1 0.9991457462310791
) O 0 5.801952738693217e-06
. O 0 5.1999868446728215e-06

Specifically O 0 1.530346821709827e-06
and O 0 1.7035870314430213e-07
more O 0 1.8614553454199267e-08
directly O 0 1.0327476474003561e-07
, O 0 1.1430297064407569e-07
an O 0 8.561289632780245e-08
association O 0 8.078714586190472e-07
was O 0 2.501010158084682e-06
also O 0 8.326708922368198e-08
observed O 0 1.4534978731717274e-07
between O 0 2.9771456411253894e-08
the O 0 5.009056991411853e-08
presence O 0 2.079414258560064e-07
of O 0 6.4215576855986e-08
a O 0 1.524278923170641e-05
PTEN O 0 0.012128325179219246
mutation O 0 0.0035644660238176584
and O 0 0.0024165292270481586
malignant B-Disease 1 0.999972939491272
breast I-Disease 1 0.9998878240585327
disease I-Disease 1 0.9996633529663086
. O 0 1.594729292264674e-05

Secondly O 0 0.0001008625840768218
, O 0 5.113394081490696e-07
there O 0 3.426981010079544e-08
appeared O 0 7.184488595157745e-07
to O 0 5.576100914339577e-09
be O 0 2.550619271346477e-08
an O 0 5.064227792672682e-08
interdependent O 0 6.417703116312623e-05
association O 0 1.8159868204747909e-06
between O 0 2.6139315423279186e-07
mutations O 0 8.077712664089631e-06
upstream O 0 1.113019038712082e-06
and O 0 5.4484196709836397e-08
within O 0 6.483387693378972e-08
the O 0 1.6450871953566093e-07
PTPase O 0 4.2401268729008734e-05
core O 0 7.126374384824885e-06
motif O 0 3.2823496439959854e-05
, O 0 1.5298360267479438e-07
the O 0 3.7489211734964556e-08
core O 0 1.9469321159704123e-06
motif O 0 7.920622920210008e-06
containing O 0 3.700386344007711e-07
the O 0 1.1961816426264704e-07
majority O 0 1.5875511394369823e-07
of O 0 1.591466656236662e-07
missense O 0 0.0001580962270963937
mutations O 0 7.254887168528512e-05
, O 0 3.5815332921629306e-07
and O 0 7.833372706045338e-08
the O 0 1.4123151004241663e-07
involvement O 0 1.4811456594543415e-06
of O 0 3.698128026030645e-08
all O 0 1.6797892499198497e-07
major O 0 2.851913814083673e-05
organ O 0 0.3766328692436218
systems O 0 0.008838687092065811
( O 0 4.088167770532891e-06
central O 0 1.375288593408186e-05
nervous O 0 0.00204721768386662
system O 0 0.0004743410099763423
, O 0 0.0002087837056024
thyroid O 1 0.9999281167984009
, O 0 0.0001430411939509213
breast O 1 0.9917961359024048
, O 0 5.531030546990223e-05
skin O 1 0.9986973404884338
and O 0 0.0429932065308094
gastrointestinal O 1 0.9999285936355591
tract O 1 0.9968010187149048
) O 0 1.0627661140460987e-05
. O 0 8.145003448589705e-06

However O 0 2.0590857729985146e-06
, O 0 1.0923812254759468e-07
these O 0 2.950878652541178e-09
observations O 0 2.298271084555381e-07
would O 0 2.334142301663178e-08
need O 0 1.2164605323050637e-08
to O 0 5.674000380651023e-09
be O 0 3.3890970030370227e-08
confirmed O 0 9.626890573599667e-08
by O 0 3.859558450614031e-09
studying O 0 5.556939797202176e-08
a O 0 3.8649449862759866e-08
larger O 0 5.047188622597787e-08
number O 0 3.336586118507512e-08
of O 0 5.15160678560278e-08
CD B-Disease 0 1.8648224795470014e-05
families O 0 6.168406798678916e-07
. O 0 4.680600341089303e-06

Molecular O 0 0.1044507622718811
defects O 1 0.9969275593757629
leading O 0 4.441364944796078e-05
to O 0 1.0140887951592958e-07
human O 0 1.8360022977503831e-06
complement B-Disease 0 2.5204402845702134e-05
component I-Disease 0 0.2048434466123581
C6 I-Disease 1 0.9999898672103882
deficiency I-Disease 1 0.999993085861206
in O 0 4.601745047239092e-07
an O 0 8.836087062036313e-08
African O 0 5.860393343937176e-07
- O 0 2.349263559153769e-05
American O 0 2.0168979517620755e-06
family O 0 9.304785635322332e-06
. O 0 4.958632416673936e-06

Complement B-Disease 0 0.0016598443035036325
component I-Disease 1 0.9688628315925598
C6 I-Disease 1 0.999984622001648
deficiency I-Disease 1 0.9999922513961792
( O 0 1.7250464225071482e-05
C6D B-Disease 0 0.0020810964051634073
) O 0 1.94255517271813e-06
was O 0 0.00014784721133764833
diagnosed O 0 0.10390222072601318
in O 0 1.557352931058631e-07
a O 0 4.6952192178650876e-07
16 O 0 2.2228100533538964e-06
- O 0 9.997919732995797e-06
year O 0 1.3829937870468711e-06
- O 0 8.84253404365154e-06
old O 0 1.0996033779520076e-05
African O 0 5.481754214997636e-07
- O 0 8.87669375515543e-06
American O 0 4.157925559411524e-07
male O 0 5.397794211603468e-06
with O 0 0.00013086797844152898
meningococcal B-Disease 1 0.9999159574508667
meningitis I-Disease 1 0.999950647354126
. O 0 3.4195396438008174e-05

The O 0 1.0115066288562957e-05
patients O 0 2.637599754962139e-05
father O 0 8.916213118936867e-06
and O 0 2.3777977276040474e-07
two O 0 1.882679754316996e-07
brothers O 0 2.3272681573871523e-05
also O 0 1.0711745517255622e-06
had O 0 1.948488488778821e-06
C6D B-Disease 0 0.00012266442354302853
, O 0 2.2341451710872207e-07
but O 0 6.730491719508791e-08
gave O 0 3.543820241702633e-07
no O 0 4.349816151716368e-07
history O 0 1.940596121130511e-06
of O 0 2.2952119707042584e-06
meningitis B-Disease 1 0.9998511075973511
or O 0 9.69668872130569e-06
other O 0 3.6042442843609024e-06
neisserial B-Disease 1 0.932135283946991
infection I-Disease 1 0.9924673438072205
. O 0 1.3377285540627781e-05

By O 0 2.5046213636414905e-07
using O 0 6.032529995536606e-07
exon O 0 3.092688348260708e-05
- O 0 7.427978744090069e-06
specific O 0 8.896407877045931e-08
polymerase O 0 1.0514911991776899e-05
chain O 0 2.2481184714706615e-05
reaction O 0 2.8615315841307165e-06
( O 0 8.212764868176237e-08
PCR O 0 1.6364433577109594e-06
) O 0 4.258630426079435e-08
/ O 0 1.4332882756207255e-06
single O 0 1.0315050076314947e-06
- O 0 8.602047273598146e-06
strand O 0 2.8124004529672675e-06
conformation O 0 2.1336190911824815e-06
polymorphism O 0 9.726109055918641e-07
as O 0 5.138211989219599e-08
a O 0 8.805903206621224e-08
screening O 0 2.1881035650039848e-07
step O 0 2.7361809884496324e-07
and O 0 1.869332599824247e-08
nucleotide O 0 9.14183928557577e-08
sequencing O 0 7.899313914094819e-08
of O 0 2.3802336102107802e-08
target O 0 2.6730575086730823e-07
exons O 0 4.065616849402431e-06
, O 0 2.2565197355106648e-07
we O 0 6.799484708608361e-08
determined O 0 1.7486929948518082e-07
that O 0 8.688711972126839e-09
the O 0 1.7911385441493621e-07
proband O 0 7.477731560356915e-05
was O 0 3.429087655604235e-06
a O 0 3.4154282957388205e-07
compound O 0 2.8317915621300926e-06
heterozygote O 0 4.810039172298275e-06
for O 0 7.152787873110356e-08
two O 0 7.798107048984093e-07
C6 O 0 0.005411401856690645
gene O 0 6.693299656035379e-05
mutations O 0 0.00047464537783525884
. O 0 8.910177712095901e-06

The O 0 9.096145276998868e-07
first O 0 1.3703768217965262e-06
, O 0 2.6467222369319643e-07
1195delC O 0 1.2720734957838431e-05
located O 0 6.69646283313341e-07
in O 0 2.0210093509831495e-07
exon O 0 8.100942068267614e-06
7 O 0 3.377228949830169e-06
, O 0 1.476656308341262e-07
is O 0 5.278382531059833e-08
a O 0 2.3779041669058643e-07
novel O 0 7.170490334829083e-07
mutation O 0 2.356146296733641e-06
, O 0 7.96728443219763e-08
while O 0 5.8361322885502886e-08
the O 0 4.7919627377268625e-08
second O 0 9.62319745667628e-07
, O 0 1.923547330306974e-07
1936delG O 0 1.0378901606600266e-05
in O 0 1.7583887768068962e-07
exon O 0 7.19731815479463e-06
12 O 0 1.993485739149037e-06
, O 0 1.2922008352234116e-07
has O 0 1.6735435792725184e-07
been O 0 1.0493952373735738e-07
described O 0 7.376393682534399e-07
before O 0 2.830013272614451e-07
to O 0 9.476319462464744e-08
cause O 0 9.849706657405477e-06
C6D B-Disease 0 0.0002504301955923438
in O 0 2.4867350134627486e-07
an O 0 1.4551123683759215e-07
unrelated O 0 5.329472514858935e-06
African O 0 6.490935788860952e-07
- O 0 1.2964378584001679e-05
American O 0 6.98883923178073e-07
individual O 0 3.2391005788667826e-07
. O 0 5.509287348104408e-06

Both O 0 9.857450095296372e-06
mutations O 0 0.0003934911801479757
result O 0 2.4632157874293625e-05
in O 0 5.598094958259026e-06
premature O 0 0.0005495802615769207
termination O 0 0.00013960147043690085
codons O 0 5.478253660839982e-05
and O 0 6.384896551026031e-06
C6 O 0 0.022821094840765
null O 0 0.0003273535694461316
alleles O 0 7.16845752322115e-05
. O 0 1.3032582501182333e-05

Allele O 0 0.00016340984439011663
- O 0 4.279168206267059e-05
specific O 0 6.741591960235382e-07
PCR O 0 1.840969707700424e-05
indicated O 0 1.8685253735384322e-06
that O 0 1.5226493843556455e-08
the O 0 4.6689905275343335e-08
probands O 0 2.365558066230733e-05
two O 0 3.63708778650107e-07
brothers O 0 3.25076216540765e-05
also O 0 2.4839625893946504e-06
inherited O 0 0.0015285398112609982
the O 0 1.3237787470643525e-06
1195delC O 0 0.00014233913680072874
mutation O 0 8.966009772848338e-06
from O 0 4.981788492841588e-08
their O 0 2.6813340880949e-08
heterozygous O 0 1.8473360796633642e-06
mother O 0 1.3037455573794432e-05
and O 0 2.0227641073233826e-07
the O 0 3.0926730687497184e-07
1936delG O 0 7.028368418104947e-05
mutation O 0 7.40978839530726e-06
from O 0 8.262193773589388e-08
their O 0 4.265068653808157e-08
homozygous O 0 6.920736268511973e-06
father O 0 1.5581355910398997e-05
. O 0 6.754173114131845e-07
. O 0 2.366645048823557e-06

PAX6 O 0 0.07512906938791275
mutations O 0 0.0055343639105558395
reviewed O 0 0.00036943162558600307
. O 0 3.070471211685799e-05

Mutations O 0 0.001037513604387641
in O 0 4.4363164306560066e-06
PAX6 O 0 0.0006202118238434196
are O 0 3.7731899737991625e-07
responsible O 0 2.15116779145319e-06
for O 0 1.8257063061355439e-07
human O 0 4.251960945111932e-06
aniridia B-Disease 1 0.9994981288909912
and O 0 7.617820756422589e-07
have O 0 6.689141685001232e-08
also O 0 5.631254751392589e-08
been O 0 1.1219866991041272e-07
found O 0 1.5261070984706748e-07
in O 0 3.263587018409453e-07
patients O 0 2.385570951446425e-06
with O 0 5.0852786444011144e-06
Peters B-Disease 1 0.9989185333251953
anomaly I-Disease 1 0.9997507929801941
, O 0 7.707963231950998e-05
with O 0 0.022805269807577133
congenital B-Disease 1 0.9999996423721313
cataracts I-Disease 1 0.9999879598617554
, O 0 1.1123358490294777e-05
with O 0 7.964532414916903e-06
autosomal B-Disease 1 0.9971707463264465
dominant I-Disease 1 0.9778177738189697
keratitis I-Disease 1 0.995585560798645
, O 0 9.46688396652462e-06
and O 0 2.00248518922308e-06
with O 0 1.7432428649044596e-05
isolated B-Disease 1 0.9783671498298645
foveal I-Disease 1 0.9999161958694458
hypoplasia I-Disease 1 0.9999465942382812
. O 0 0.00019618602527771145

No O 0 2.8010622372676153e-06
locus O 0 7.970726073835976e-06
other O 0 4.310136603180581e-08
than O 0 9.945731704874561e-08
chromosome O 0 3.0311137379612774e-05
11p13 O 0 2.5519255359540693e-05
has O 0 8.07022900062293e-07
been O 0 8.090681262729049e-07
implicated O 0 3.0056511604925618e-05
in O 0 2.856329501810251e-06
aniridia B-Disease 1 0.9989942908287048
, O 0 2.1757402919320157e-06
and O 0 1.3434255379252136e-06
PAX6 O 0 0.0008593901293352246
is O 0 1.009347329272714e-06
clearly O 0 4.4747392280442e-07
the O 0 9.357042785040903e-08
major O 0 2.6343025183450663e-06
, O 0 9.479429508019166e-08
if O 0 1.9866176259597523e-08
not O 0 1.025279239286192e-08
only O 0 1.6929195822967813e-08
, O 0 6.180594880333956e-08
gene O 0 7.673366440030804e-07
responsible O 0 1.4123937944532372e-05
. O 0 6.431562724174e-06

Twenty O 0 1.796929063857533e-05
- O 0 2.6069485102198087e-05
eight O 0 1.0259257123834686e-06
percent O 0 7.808786222085473e-07
of O 0 4.283975485463998e-08
identified O 0 3.859862317767693e-06
PAX6 O 0 0.0004179511743132025
mutations O 0 1.794103445718065e-05
are O 0 3.0436922315857373e-07
C O 0 0.0003379235276952386
- O 0 0.0008608857751823962
T O 0 0.0012453662930056453
changes O 0 5.569063432631083e-06
at O 0 1.3901097190682776e-05
CpG O 0 5.3305309847928584e-05
dinucleotides O 0 4.4645847083302215e-05
, O 0 1.9432724229773157e-07
20 O 0 1.0540411210513412e-07
% O 0 3.1620528417874993e-09
are O 0 4.733891945107871e-09
splicing O 0 1.7036272765835747e-06
errors O 0 3.7316654925234616e-05
, O 0 3.598281139716164e-08
and O 0 8.915411520149519e-09
more O 0 1.048454101315599e-09
than O 0 1.301224017424829e-08
30 O 0 1.1089405660413831e-07
% O 0 7.727841477844777e-09
are O 0 1.1013769452006272e-08
deletion O 0 3.3561957479832927e-06
or O 0 8.945426088757813e-07
insertion O 0 1.3946894796390552e-05
events O 0 8.022538168006577e-06
. O 0 6.812284937041113e-06

There O 0 1.963905788215925e-06
is O 0 6.17464536389889e-07
a O 0 1.066621962309e-06
noticeably O 0 3.1713268981548026e-05
elevated O 0 0.00022381504822988063
level O 0 2.8391168598318473e-06
of O 0 8.744994062226397e-08
mutation O 0 3.0502642403007485e-06
in O 0 5.0453213162882093e-08
the O 0 1.5544232567776817e-08
paired O 0 5.63501430406177e-07
domain O 0 3.515913533647108e-07
compared O 0 6.67863673697866e-07
with O 0 5.387337154161287e-08
the O 0 9.759039443224538e-08
rest O 0 1.7669890439719893e-07
of O 0 7.1497847642376655e-09
the O 0 9.961071611996886e-08
gene O 0 4.280188022676157e-06
. O 0 3.0247613267420093e-06

Increased O 0 9.651887012296356e-06
mutation O 0 2.2734382582711987e-05
in O 0 2.6191418101007e-07
the O 0 2.0486680796238943e-07
homeodomain O 0 3.185700552421622e-05
is O 0 2.985562161939015e-07
accounted O 0 3.6742235920428357e-07
for O 0 1.7133883645215064e-08
by O 0 7.545143887455197e-08
the O 0 7.554286298727675e-07
hypermutable O 0 0.0005761472857557237
CpG O 0 0.00014962325803935528
dinucleotide O 0 7.423144415952265e-05
in O 0 1.1027358368664864e-06
codon O 0 2.6997118766303174e-05
240 O 0 4.894529865850927e-06
. O 0 2.8392955755407456e-06

Very O 0 2.433067493257113e-06
nearly O 0 9.664298659117776e-07
all O 0 1.0193382848910915e-07
mutations O 0 1.0695937817217782e-05
appear O 0 2.0741947537317174e-06
to O 0 4.4000370280627976e-07
cause O 0 0.00019616151985246688
loss O 0 5.627403152175248e-05
of O 0 4.106381013002647e-08
function O 0 4.849299557463382e-07
of O 0 3.16604378269858e-08
the O 0 9.714023718743192e-08
mutant O 0 1.8949878040075419e-06
allele O 0 1.4563619288310292e-06
, O 0 3.860693809087934e-08
and O 0 6.977502131633173e-09
more O 0 1.64528957125043e-09
than O 0 1.5451945500899456e-08
80 O 0 1.5990475787930336e-07
% O 0 2.0356422325562562e-08
of O 0 4.3942328886714677e-08
exonic O 0 0.00014269762323237956
substitutions O 0 1.3477316315402277e-05
result O 0 3.0884339139447547e-06
in O 0 1.0733588169387076e-06
nonsense O 0 8.04248993517831e-05
codons O 0 0.00010253678919980302
. O 0 8.42116878629895e-06

In O 0 9.672661462900578e-07
a O 0 3.955332488203567e-07
gene O 0 3.448613199452666e-07
with O 0 9.89153150499078e-08
such O 0 1.503142073033814e-07
extraordinarily O 0 0.0002205375931225717
high O 0 1.353071002085926e-05
sequence O 0 8.212582542910241e-07
conservation O 0 3.12541857283577e-07
throughout O 0 4.8026222998487356e-08
evolution O 0 9.688415048003662e-08
, O 0 6.129714336111647e-08
there O 0 2.2779072850198645e-08
are O 0 4.491288763119883e-08
presumed O 0 2.133760426659137e-05
undiscovered O 0 0.0006299344822764397
missense O 0 0.0004125563718844205
mutations O 0 0.0001083173556253314
, O 0 2.3741472432448063e-07
these O 0 9.9272874365397e-09
are O 0 2.2102419450220623e-08
hypothesized O 0 5.86207022479357e-07
to O 0 1.333540833314828e-08
exist O 0 7.57711688947893e-08
in O 0 6.490935788860952e-08
as O 0 6.07829576892982e-07
- O 0 7.77873137849383e-05
yet O 0 4.75605475003249e-06
unidentified O 0 8.626437920611352e-05
phenotypes O 0 3.899788134731352e-05
. O 0 6.397999072760285e-07
. O 0 1.411740186085808e-06

Genetic O 0 0.0006854070234112442
heterogeneity O 0 0.00026054264162667096
and O 0 2.6423842882650206e-06
penetrance O 0 0.0004953042953275144
analysis O 0 3.6711273310174874e-07
of O 0 7.280604563675297e-08
the O 0 5.698883569493773e-07
BRCA1 O 0 0.00011633415124379098
and O 0 2.939950036306982e-06
BRCA2 O 0 0.00036459314287640154
genes O 0 4.24567042500712e-05
in O 0 7.408895180560648e-05
breast B-Disease 1 0.9979179501533508
cancer I-Disease 1 0.995133101940155
families O 0 2.4933231088652974e-06
. O 0 7.954307875479572e-06

The O 0 0.0037824015598744154
Breast B-Disease 1 0.999954104423523
Cancer I-Disease 1 0.9999394416809082
Linkage O 0 0.0023264840710908175
Consortium O 0 0.0005451612523756921
. O 0 2.2864598577143624e-05

The O 0 2.40962503994524e-06
contribution O 0 4.370246188045712e-06
of O 0 6.237261800379201e-07
BRCA1 O 0 0.00023307872470468283
and O 0 9.63192360359244e-06
BRCA2 O 0 0.0026615061797201633
to O 0 0.00020356610184535384
inherited B-Disease 1 0.9999983310699463
breast I-Disease 1 0.9999946355819702
cancer I-Disease 1 0.9999990463256836
was O 0 0.0004029937263112515
assessed O 0 2.9866948807466542e-06
by O 0 4.196366631958881e-08
linkage O 0 3.4341865102760494e-06
and O 0 3.261713743540895e-07
mutation O 0 1.4398796110981493e-06
analysis O 0 4.733921699084931e-08
in O 0 2.6153124110805948e-08
237 O 0 1.8835292792118707e-07
families O 0 7.700326598580887e-09
, O 0 1.436926666542604e-08
each O 0 3.361394051992761e-09
with O 0 7.242847743782477e-08
at O 0 5.7988777371065225e-06
least O 0 9.823207136605561e-08
four O 0 1.8939782364668645e-07
cases O 0 9.070149076251255e-07
of O 0 3.5977298011857783e-06
breast B-Disease 1 0.99953293800354
cancer I-Disease 1 0.997672975063324
, O 0 1.7845130173554935e-07
collected O 0 1.363338810733694e-07
by O 0 3.008366888934688e-07
the O 0 7.87161843618378e-05
Breast B-Disease 1 0.9999827146530151
Cancer I-Disease 1 0.9999508857727051
Linkage O 0 0.00048163297469727695
Consortium O 0 0.00031586873228661716
. O 0 1.4896542779752053e-05

Families O 0 8.55438997859892e-07
were O 0 1.856916753695259e-07
included O 0 1.1949092026952712e-07
without O 0 1.494917682975938e-07
regard O 0 1.7957941622626095e-07
to O 0 4.047493007419689e-08
the O 0 5.70205827443715e-07
occurrence O 0 0.0002848254516720772
of O 0 8.070866897469386e-06
ovarian B-Disease 1 0.9994934797286987
or I-Disease 0 2.810204568959307e-05
other I-Disease 0 8.205261110560969e-06
cancers I-Disease 1 0.9988512992858887
. O 0 2.1208375983405858e-05

Overall O 0 0.00033635456929914653
, O 0 0.00012182652426417917
disease O 1 0.9967922568321228
was O 0 2.7687492547556758e-05
linked O 0 8.40307075122837e-06
to O 0 8.08688795927992e-08
BRCA1 O 0 1.0853230378415901e-05
in O 0 9.557987823427538e-08
an O 0 3.2593810317393945e-08
estimated O 0 1.7506117444554548e-07
52 O 0 3.3140452160296263e-07
% O 0 7.465434492814893e-09
of O 0 6.675756392127141e-09
families O 0 1.710211527949923e-08
, O 0 4.7835246874683435e-08
to O 0 2.3114148817171554e-08
BRCA2 O 0 8.215150955948047e-06
in O 0 1.275764560659809e-07
32 O 0 1.9192411571111734e-07
% O 0 9.248379839732479e-09
of O 0 4.404039355421219e-09
families O 0 1.480592626279531e-08
, O 0 4.48675940845078e-08
and O 0 1.7484719450067132e-08
to O 0 8.274333218594165e-09
neither O 0 1.0190855448399816e-07
gene O 0 1.1766721996764318e-07
in O 0 9.249935573052426e-08
16 O 0 2.0287143343011849e-07
% O 0 8.504404291898027e-09
( O 0 2.9088846886793363e-08
95 O 0 2.408103512152593e-07
% O 0 6.182174416835551e-08
confidence O 0 3.275062454122235e-06
interval O 0 7.816155630280264e-06
[ O 0 1.0185761311731767e-05
CI O 0 0.0008114475640468299
] O 0 9.713997314975131e-06
6 O 0 2.431972461636178e-06
% O 0 7.113101929689947e-08
- O 0 6.2411450016952585e-06
28 O 0 1.63942672770645e-06
% O 0 2.224711082021713e-08
) O 0 4.171579703893258e-08
, O 0 7.852595729218592e-08
suggesting O 0 8.927776207201532e-07
other O 0 2.1836738994807092e-07
predisposition O 0 0.00018299385556019843
genes O 0 3.0352501198649406e-05
. O 0 9.931939530360978e-06

The O 0 2.867388730010134e-06
majority O 0 1.9121284822176676e-06
( O 0 3.2898049084906233e-07
81 O 0 2.4795745048322715e-06
% O 0 2.5722329155541956e-08
) O 0 2.7837145921694173e-08
of O 0 1.4999501729562326e-07
the O 0 0.0001457884645787999
breast B-Disease 1 0.9999547004699707
- I-Disease 1 0.999984860420227
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999728202819824
families O 0 1.6204414521325816e-07
were O 0 8.630279779708872e-08
due O 0 4.0642572685101186e-07
to O 0 4.5130832404538523e-08
BRCA1 O 0 6.7503169702831656e-06
, O 0 8.57426485367796e-08
with O 0 3.188186070701704e-08
most O 0 7.44222106163761e-08
others O 0 2.1632261848480994e-07
( O 0 6.184203726888882e-08
14 O 0 3.7558390886260895e-07
% O 0 1.9794990535615398e-08
) O 0 3.952797911210837e-08
due O 0 8.633060133433901e-07
to O 0 5.933631541665818e-07
BRCA2 O 0 0.00041207365575246513
. O 0 1.5040862308524083e-05

Conversely O 0 0.00011633104440988973
, O 0 1.0110333050761255e-06
the O 0 1.7932731566361326e-07
majority O 0 6.433743493516886e-08
of O 0 1.7712094901867204e-08
families O 0 1.6210034203822943e-08
with O 0 9.193948358188209e-08
male B-Disease 0 1.8127753946828307e-06
and I-Disease 0 3.311497039248934e-06
female I-Disease 0 0.00019771329243667424
breast I-Disease 1 0.9989084005355835
cancer I-Disease 1 0.9803469181060791
were O 0 2.6453491841493815e-07
due O 0 1.4771605947316857e-06
to O 0 2.201461910544822e-07
BRCA2 O 0 5.348612103261985e-05
( O 0 5.987222948533599e-07
76 O 0 9.179190783470403e-06
% O 0 1.1435595581588132e-07
) O 0 3.960628305321734e-07
. O 0 1.827317305469478e-06

The O 0 3.797321824094979e-06
largest O 0 1.5165767763392068e-05
proportion O 0 1.8128686178897624e-06
( O 0 3.0136592954477237e-07
67 O 0 2.1020573512942065e-06
% O 0 2.890527994736658e-08
) O 0 2.142656896353401e-08
of O 0 6.346475345253566e-09
families O 0 1.1432865321125973e-08
due O 0 2.91600457558161e-07
to O 0 6.132424790195046e-09
other O 0 8.543080909362288e-09
genes O 0 1.9275982765520894e-07
was O 0 9.664906883699587e-07
found O 0 5.6941573234325915e-08
in O 0 1.0712012610269994e-08
families O 0 2.958825184862235e-09
with O 0 3.249691005180466e-08
four O 0 6.806777719248203e-08
or O 0 2.2719893877365394e-07
five O 0 2.8930827511430834e-07
cases O 0 5.304623869051284e-07
of O 0 5.183670168662502e-07
female O 0 0.000668573600705713
breast B-Disease 1 0.999634861946106
cancer I-Disease 1 0.9984486103057861
only O 0 1.2595088492162176e-06
. O 0 3.346897528899717e-06

These O 0 3.508377233174542e-07
estimates O 0 1.1881236332556e-06
were O 0 5.189100704683369e-08
not O 0 3.6436279771123736e-08
substantially O 0 6.480074716819217e-07
affected O 0 1.9500375003644876e-07
either O 0 3.6703916350688814e-08
by O 0 2.9587814864839856e-08
changing O 0 1.785746917448705e-06
the O 0 4.2276502654203796e-07
assumed O 0 1.1592806004045997e-05
penetrance O 0 5.452793266158551e-05
model O 0 1.1547085705387872e-06
for O 0 8.481988089670267e-08
BRCA1 O 0 1.1597938282648101e-05
or O 0 2.0225076013957732e-07
by O 0 1.4782195023599343e-08
including O 0 5.396366731247326e-08
or O 0 9.455689564674685e-07
excluding O 0 7.060923962853849e-06
BRCA1 O 0 0.00026935484493151307
mutation O 0 4.1324277844978496e-05
data O 0 5.0458497753425036e-06
. O 0 6.03879698246601e-06

Among O 0 1.3285543900565244e-06
those O 0 2.439763306938403e-07
families O 0 3.0739249723410467e-07
with O 0 2.369310095673427e-05
disease O 1 0.998193085193634
due O 0 7.033831934677437e-06
to O 0 8.132704465424467e-08
BRCA1 O 0 8.353723387699574e-06
that O 0 2.0255450650097373e-08
were O 0 6.400293273145508e-08
tested O 0 5.477114086716028e-07
by O 0 5.675093284196464e-09
one O 0 1.0982911469170631e-08
of O 0 3.1241886855326584e-09
the O 0 4.095641159551633e-08
standard O 0 9.139692451753945e-07
screening O 0 5.247815693110169e-07
methods O 0 3.5322065627951815e-07
, O 0 2.2739229166290897e-07
mutations O 0 1.687716576270759e-06
were O 0 1.4992265562341345e-07
detected O 0 7.978132998687215e-06
in O 0 4.51434054582478e-08
the O 0 2.1096550284482873e-08
coding O 0 2.0491499981289962e-06
sequence O 0 3.0020760277693626e-07
or O 0 1.3172675039641035e-07
splice O 0 4.135024028073531e-06
sites O 0 4.598034024638764e-07
in O 0 2.4910258744625935e-08
an O 0 2.5215868504346872e-08
estimated O 0 1.1416026524102563e-07
63 O 0 4.3341100308680325e-07
% O 0 1.2608144750458905e-08
( O 0 2.1049043397169953e-08
95 O 0 2.3896643597254297e-07
% O 0 7.201960983138633e-08
CI O 0 0.00019886829250026494
51 O 0 4.230233571433928e-06
% O 0 1.927561470438377e-07
- O 0 1.117273041018052e-05
77 O 0 3.7061538478155853e-06
% O 0 1.2178702490928117e-07
) O 0 2.3106528601601894e-07
. O 0 1.2423115549609065e-06

The O 0 1.0729934274422703e-06
estimated O 0 5.363796731217008e-07
sensitivity O 0 1.173243845187244e-06
was O 0 1.0410258255433291e-06
identical O 0 1.7647997196945653e-07
for O 0 2.6076500958538418e-09
direct O 0 5.356616483709331e-09
sequencing O 0 1.10972337097337e-07
and O 0 6.817158748617658e-08
other O 0 2.3483966771209452e-08
techniques O 0 6.575535280717304e-06
. O 0 5.9668332141882274e-06

The O 0 8.43131056171842e-06
penetrance O 0 0.0023234609980136156
of O 0 1.491290845478943e-06
BRCA2 O 0 0.0004327003553044051
was O 0 1.56105979840504e-05
estimated O 0 1.3496133988155634e-07
by O 0 2.8421887066087947e-08
maximizing O 0 9.335897743767418e-07
the O 0 3.2269556982100767e-07
LOD O 0 0.00021443971490953118
score O 0 1.7846742821348016e-06
in O 0 1.0524676099521457e-06
BRCA2 O 0 8.941078704083338e-05
- O 0 6.275117630138993e-05
mutation O 0 8.77007460076129e-06
families O 0 4.960927668662407e-08
, O 0 7.697011739082882e-08
over O 0 1.251812307145883e-07
all O 0 6.69200090896993e-08
possible O 0 2.468118054821389e-06
penetrance O 0 0.0006721437093801796
functions O 0 1.0643728273862507e-05
. O 0 1.730720032355748e-05

The O 0 5.29189856024459e-06
estimated O 0 4.647374225896783e-06
cumulative O 0 1.6919608242460527e-05
risk O 0 7.675294182263315e-05
of O 0 5.262090780888684e-06
breast B-Disease 1 0.9985257983207703
cancer I-Disease 1 0.9916765689849854
reached O 0 1.0746784937509801e-05
28 O 0 2.3714301278232597e-06
% O 0 2.1677690753563184e-08
( O 0 2.7216014331088445e-08
95 O 0 3.763630047615152e-07
% O 0 8.817298180474609e-08
CI O 0 0.000216918284422718
9 O 0 2.1077803467051126e-06
% O 0 3.282677241145393e-08
- O 0 1.9642764073068975e-06
44 O 0 2.669083585260523e-07
% O 0 9.297016489995258e-09
) O 0 3.097263778784054e-09
by O 0 7.1724990391430765e-09
age O 0 2.43781443032276e-07
50 O 0 1.50912754293131e-07
years O 0 8.067953416457385e-08
and O 0 8.636899195835213e-08
84 O 0 1.3473799072016845e-06
% O 0 2.0718163185051708e-08
( O 0 4.290820143637575e-08
95 O 0 3.7623095749950153e-07
% O 0 1.1961816426264704e-07
CI O 0 0.00014218935393728316
43 O 0 1.2954265002917964e-06
% O 0 4.147366894358129e-08
- O 0 1.4893807929183822e-06
95 O 0 3.121010365703114e-07
% O 0 9.893716068631875e-09
) O 0 6.621216019908616e-09
by O 0 1.8528512057969238e-08
age O 0 7.954224656714359e-07
70 O 0 5.848980890732491e-07
years O 0 1.5112473192857578e-06
. O 0 1.376370278194372e-06

The O 0 8.964035077951849e-05
corresponding O 1 0.8918030261993408
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999966621398926
risks O 0 0.002419542521238327
were O 0 2.9470859317370923e-06
0 O 0 1.311458254349418e-05
. O 0 3.5926143482356565e-06

4 O 0 9.193540790874977e-06
% O 0 1.0116758630829281e-07
( O 0 8.988939725895762e-08
95 O 0 4.509168718414003e-07
% O 0 1.3374692287015932e-07
CI O 0 0.00016514651360921562
0 O 0 1.1531941481734975e-06
% O 0 5.968608718376345e-08
- O 0 1.603589225851465e-06
1 O 0 2.101723453051818e-07
% O 0 4.244712581424892e-09
) O 0 2.2373354280347257e-09
by O 0 3.7151928200529483e-09
age O 0 1.2434892937562836e-07
50 O 0 5.418458925987579e-08
years O 0 6.358278881180013e-08
and O 0 3.633523348867129e-08
27 O 0 6.599041171284625e-07
% O 0 7.81298581387091e-09
( O 0 1.9164751563494065e-08
95 O 0 2.1111631554049382e-07
% O 0 5.460227470166501e-08
CI O 0 8.516642265021801e-05
0 O 0 7.619884172527236e-07
% O 0 3.3424459644493254e-08
- O 0 1.4205268143996364e-06
47 O 0 4.006402036793588e-07
% O 0 7.587425798760705e-09
) O 0 5.527465152255218e-09
by O 0 1.3587277969406841e-08
age O 0 6.303374107119453e-07
70 O 0 9.110921155297547e-07
years O 0 3.0342896479851333e-06
. O 0 2.463565351717989e-06

The O 0 8.183965292118955e-06
lifetime O 0 0.0005120684509165585
risk O 0 0.00042746312101371586
of O 0 1.2965466339665e-05
breast B-Disease 1 0.9997660517692566
cancer I-Disease 1 0.9993001222610474
appears O 0 2.0230527297826484e-06
similar O 0 1.1615269812637052e-07
to O 0 2.6677495768012705e-08
the O 0 3.0212302704057947e-07
risk O 0 3.098399474765756e-06
in O 0 1.081460041518767e-07
BRCA1 O 0 1.1959063158428762e-05
carriers O 0 2.0236411728546955e-06
, O 0 1.0413162243594343e-07
but O 0 5.150496562578155e-08
there O 0 2.4492601724546148e-08
was O 0 9.93160711004748e-07
some O 0 9.162835823417481e-09
suggestion O 0 1.1184222330484772e-06
of O 0 4.6591246416483045e-08
a O 0 3.0057340154598933e-06
lower O 0 8.194487600121647e-05
risk O 0 1.706678631308023e-05
in O 0 4.6115243890199054e-07
BRCA2 O 0 4.837990854866803e-05
carriers O 0 5.6208737078122795e-06
< O 0 1.4255603673518635e-05
50 O 0 7.324164243982523e-07
years O 0 4.233415609178337e-07
of O 0 1.5579665557652334e-07
age O 0 1.0495115930098109e-05
. O 0 3.864735390379792e-06

Eye B-Disease 1 0.9292310476303101
movement I-Disease 0 0.0009393037762492895
abnormalities I-Disease 0 0.14039656519889832
correlate O 0 2.3535016225650907e-05
with O 0 2.568963282101322e-06
genotype O 0 0.00024677245528437197
in O 0 1.3706428944715299e-05
autosomal O 1 0.9970890879631042
dominant O 1 0.9956306219100952
cerebellar B-Disease 1 0.9992154836654663
ataxia I-Disease 1 0.9992789626121521
type I-Disease 1 0.9977403879165649
I I-Disease 1 0.9973813891410828
. O 0 2.760957613645587e-05

We O 0 7.649206963833421e-06
compared O 0 1.861459168139845e-05
horizontal O 0 0.00012939829321112484
eye O 0 0.0174590814858675
movements O 0 3.4092470741597936e-05
( O 0 7.769831427140161e-07
visually O 0 1.6333407984348014e-05
guided O 0 3.855900285998359e-05
saccades O 0 0.002726085251197219
, O 0 2.184162212870433e-06
antisaccades O 0 6.930829840712249e-05
, O 0 2.505483678305609e-07
and O 0 1.0032746189381214e-07
smooth O 0 4.1327334656671155e-06
pursuit O 0 1.0074729289044626e-05
) O 0 1.4032140427389095e-07
in O 0 8.441880083864817e-08
control O 0 1.6803304561108234e-06
subjects O 0 3.829901288554538e-06
( O 0 3.809458632986207e-07
n O 0 1.4487675798591226e-05
= O 0 1.1722288945748005e-05
14 O 0 6.844289828222827e-07
) O 0 3.420789695951498e-08
and O 0 1.3418411981547251e-07
patients O 0 2.5307735995738767e-07
with O 0 1.2497529233712612e-08
three O 0 6.233396732113761e-08
forms O 0 1.053846631293709e-06
of O 0 1.59913906827569e-06
autosomal O 1 0.9971952438354492
dominant O 1 0.9842055439949036
cerebellar B-Disease 1 0.997740626335144
ataxias I-Disease 1 0.7769954800605774
type I-Disease 0 0.2953532934188843
I I-Disease 0 0.11057425290346146
spinocerebellar B-Disease 1 0.7966704964637756
ataxias I-Disease 0 0.001688281074166298
1 I-Disease 0 6.487608970928704e-06
and I-Disease 0 6.20274988705205e-07
2 I-Disease 0 1.950809064510395e-06
( O 0 2.603085533792182e-07
SCA1 B-Disease 0 5.262682680040598e-05
, O 0 5.916234044889279e-07
n O 0 9.729905286803842e-06
= O 0 1.3983867575007025e-05
11 O 0 1.1971806088695303e-06
; O 0 1.266616607153992e-07
SCA2 B-Disease 0 3.119372922810726e-05
, O 0 2.556464835379302e-07
n O 0 6.763520104868803e-06
= O 0 5.933087777520996e-06
10 O 0 3.4239369028910005e-07
) O 0 7.404798907373333e-08
and O 0 7.264665669026726e-07
SCA3 B-Disease 1 0.9989655017852783
/ O 0 0.003346171462908387
Machado B-Disease 0 0.007505926303565502
- I-Disease 0 0.04376773163676262
Joseph I-Disease 0 0.003214214462786913
disease I-Disease 1 0.9841374158859253
( O 0 2.8113438474974828e-06
MJD B-Disease 1 0.9892809987068176
) O 0 3.538099804245576e-07
( O 0 3.3665614296296553e-07
n O 0 1.9075541786151007e-05
= O 0 3.5295648558530957e-05
16 O 0 4.931600869895192e-06
) O 0 5.268615836939716e-07
. O 0 1.3561045761889545e-06

In O 0 1.3800812666886486e-05
SCA1 B-Disease 0 0.0008142953156493604
, O 0 9.148971003014594e-07
saccade O 0 2.640451020852197e-05
amplitude O 0 6.3430325099034235e-06
was O 0 5.167976723896572e-06
significantly O 0 1.2353975762380287e-06
increased O 0 2.421848250833136e-07
, O 0 1.3269939813653764e-07
resulting O 0 1.6038951571317739e-06
in O 0 2.0871354990958935e-06
hypermetria B-Disease 0 0.0009679317008703947
. O 0 7.272621132869972e-06

The O 0 6.961512326597585e-07
smooth O 0 2.1526724594878033e-05
pursuit O 0 2.7860316549777053e-05
gain O 0 1.37646029543248e-05
was O 0 5.659332236973569e-05
decreased O 0 0.00011208245268790051
. O 0 5.061223419033922e-06

In O 0 1.7974945876630954e-05
SCA2 B-Disease 0 0.0009056186536327004
, O 0 1.0784151527332142e-06
saccade O 0 4.0589849959360436e-05
velocity O 0 1.0993664545821957e-05
was O 0 8.975319360615686e-06
markedly O 0 4.843775604967959e-05
decreased O 0 7.302572339540347e-05
. O 0 3.7719485135312425e-06

The O 0 4.992183676222339e-06
percentage O 0 1.4548110812029336e-05
of O 0 3.8692536463713623e-07
errors O 0 0.0007761857123114169
in O 0 1.833926944527775e-06
antisaccades O 0 0.00024537439458072186
was O 0 7.397341050818795e-06
greatly O 0 8.786472562860581e-07
increased O 0 2.3369094037661853e-07
and O 0 9.733571459946688e-08
was O 0 1.0091230251418892e-06
significantly O 0 3.975269464717712e-07
correlated O 0 5.227370820648503e-07
with O 0 3.351051702793484e-07
age O 0 3.380420821486041e-05
at O 0 0.00482805585488677
disease O 1 0.9958621263504028
onset O 0 0.312216579914093
. O 0 1.5020220416772645e-05

In O 0 5.82423353989725e-07
addition O 0 2.34294333267826e-07
, O 0 6.259034535105457e-08
a O 0 5.902381872147089e-08
correlation O 0 9.85069448233844e-08
between O 0 6.848998168607068e-08
smooth O 0 3.45862304129696e-06
pursuit O 0 3.6632550290960353e-06
gain O 0 1.1264569366176147e-06
and O 0 2.2705337698880612e-07
the O 0 1.26127062571868e-07
number O 0 5.828957228004583e-08
of O 0 1.788850880757309e-07
trinucleotide O 0 0.002047051442787051
repeats O 0 0.00022916056332178414
was O 0 7.449390250258148e-05
found O 0 5.276035153656267e-06
. O 0 3.025312253157608e-06

In O 0 0.0001074736937880516
SCA3 B-Disease 1 0.9974488615989685
, O 0 3.312404442112893e-05
gaze B-Disease 0 0.0041403332725167274
- I-Disease 0 0.004716137424111366
evoked I-Disease 0 0.0004954154719598591
nystagmus I-Disease 0 0.0038739938754588366
was O 0 1.745442204992287e-05
often O 0 2.2172896763095196e-07
present O 0 9.887645546768908e-08
as O 0 4.877517767454265e-07
was O 0 3.875955371768214e-06
saccade O 0 3.8724017940694466e-05
hypometria O 0 4.0961043850984424e-05
and O 0 2.1197433852648828e-07
smooth O 0 8.008006261661649e-06
pursuit O 0 1.1393525710445829e-05
gain O 0 7.523597105318913e-06
was O 0 3.4890472306869924e-05
markedly O 0 5.7210556406062096e-05
decreased O 0 4.965535117662512e-05
. O 0 3.326576461404329e-06

Three O 0 3.4668062198761618e-06
major O 0 8.871320460457355e-06
criteria O 0 4.593984613165958e-06
, O 0 3.515712307944341e-07
saccade O 0 1.4919062778062653e-05
amplitude O 0 2.6569009605736937e-06
, O 0 2.441872197778139e-07
saccade O 0 7.709249985055067e-06
velocity O 0 1.7765115671863896e-06
, O 0 1.4737932474417903e-07
and O 0 6.392936313659447e-08
presence O 0 4.1972475628426764e-07
of O 0 4.076570689903747e-07
gaze B-Disease 0 0.003778846003115177
- I-Disease 0 0.001861634198576212
evoked I-Disease 0 0.00033480324782431126
nystagmus I-Disease 0 0.0008563142037019134
, O 0 4.1378146420356643e-07
permitted O 0 1.0279681106339922e-07
the O 0 8.826586395116465e-08
correct O 0 2.482555828464683e-06
assignment O 0 1.0906715033343062e-06
of O 0 1.4489923927385462e-08
90 O 0 1.880913913510085e-07
% O 0 1.549932093780626e-08
of O 0 1.3074286542291702e-08
the O 0 1.7928782369835972e-07
SCA1 B-Disease 0 8.611381781520322e-05
, O 0 1.2788049730261264e-07
90 O 0 8.891081648698673e-08
% O 0 1.0044115761331796e-08
of O 0 8.063549827852512e-09
the O 0 2.5609423914829677e-07
SCA2 B-Disease 0 9.975113061955199e-05
, O 0 2.3020791672934138e-07
and O 0 6.785052164559602e-08
93 O 0 8.026539717320702e-07
% O 0 1.8652333011459632e-08
of O 0 1.85793300744308e-08
the O 0 4.301940350615041e-07
patients O 0 4.548507604340557e-06
with O 0 9.243865406460827e-07
SCA3 B-Disease 1 0.9991268515586853
to O 0 4.70060435020514e-08
their O 0 5.976332317914057e-08
genetically O 0 3.896197995345574e-06
confirmed O 0 6.989645498833852e-06
patient O 0 5.968112873233622e-06
group O 0 2.4076993554444925e-07
and O 0 7.103665922159053e-08
, O 0 8.532533257721298e-08
therefore O 0 1.4839717721315537e-07
, O 0 1.9052737343372428e-07
may O 0 8.204448818105448e-07
help O 0 3.552868861333991e-07
orient O 0 0.00044245144817978144
diagnoses O 0 0.00040604377863928676
of O 0 8.078298492364411e-07
SCA1 B-Disease 0 0.0037215743213891983
, O 0 3.082369403273333e-06
SCA2 B-Disease 0 0.0004748338833451271
, O 0 1.0446537999087013e-06
and O 0 2.840850129359751e-06
SCA3 B-Disease 1 0.998264729976654
at O 0 4.834905485040508e-05
early O 0 3.816279786406085e-06
clinical O 0 1.1161419934069272e-05
stages O 0 1.3405188838078175e-05
of O 0 6.893281465636392e-07
the O 0 2.1567222574958578e-05
diseases O 1 0.9991869330406189
. O 0 1.6871226762305014e-06
. O 0 3.883421868522419e-06

Genetic O 0 3.192291114828549e-05
basis O 0 1.0027770258602686e-06
and O 0 7.580556484754197e-07
molecular O 0 8.959667320596054e-05
mechanism O 0 0.0002670203393790871
for O 0 0.0003210316936019808
idiopathic B-Disease 1 0.9999967813491821
ventricular I-Disease 1 0.9999696016311646
fibrillation I-Disease 1 0.999995231628418
. O 0 0.0002589875948615372

Ventricular B-Disease 1 0.9950597286224365
fibrillation I-Disease 1 0.9937602877616882
causes O 0 0.00014999393897596747
more O 0 2.568707735406406e-08
than O 0 7.128409151846427e-08
300 O 0 3.7986222878316767e-07
, O 0 1.5591109558954486e-07
000 O 0 1.1096054777226527e-06
sudden O 0 1.9064556909142993e-05
deaths O 0 1.9177953163307393e-06
each O 0 2.3695706730109123e-08
year O 0 4.722324433714675e-07
in O 0 6.46738200771324e-08
the O 0 4.7544446601932577e-07
USA O 0 6.0122481954749674e-05
alone O 0 9.273478099203203e-06
. O 0 3.0274336495494936e-06

In O 0 7.739592433608777e-07
approximately O 0 2.4591423652964295e-07
5 O 0 8.716516504136962e-07
- O 0 4.158593583269976e-06
12 O 0 2.674493089216412e-07
% O 0 5.877910158602617e-09
of O 0 2.5046742457845994e-09
these O 0 8.16565215444598e-09
cases O 0 1.4899106304255838e-07
, O 0 6.690417819754657e-08
there O 0 1.7364344628845174e-08
are O 0 1.118573855762861e-08
no O 0 4.3538295813050354e-07
demonstrable O 0 0.0016330898506566882
cardiac O 1 0.9797794222831726
or O 0 2.7177291485713795e-05
non O 0 0.0035533311311155558
- O 1 0.9976304769515991
cardiac O 1 0.9970467686653137
causes O 0 4.0881321183405817e-05
to O 0 2.2826609935577835e-08
account O 0 3.19437063467376e-08
for O 0 9.80564429653441e-09
the O 0 3.842247764396234e-08
episode O 0 1.1010890830220887e-06
, O 0 1.4830692407485913e-07
which O 0 2.259210596378125e-08
is O 0 8.22242043341248e-08
therefore O 0 2.745685492300254e-07
classified O 0 4.8998506827047095e-05
as O 0 0.0009017233387567103
idiopathic B-Disease 1 0.9999967813491821
ventricular I-Disease 1 0.9999651908874512
fibrillation I-Disease 1 0.9999918937683105
( O 0 0.00048667803639546037
IVF B-Disease 1 0.9979107975959778
) O 0 6.462156761699589e-06
. O 0 5.931871783104725e-06

A O 0 9.126033546635881e-06
distinct O 0 3.1969630072126165e-06
group O 0 4.833121693081921e-06
of O 0 1.240803157998016e-06
IVF B-Disease 1 0.9991387128829956
patients O 0 3.486533023533411e-05
has O 0 2.6133733399547054e-07
been O 0 8.406146179140705e-08
found O 0 4.512790852118087e-08
to O 0 4.044257817525931e-09
present O 0 3.05572100955942e-08
with O 0 8.55126884857782e-08
a O 0 2.022412218138925e-06
characteristic O 0 9.573198622092605e-05
electrocardiographic O 0 0.006217284128069878
pattern O 0 0.0004937941557727754
. O 0 1.4176402146404143e-05

Because O 0 3.103320068476023e-06
of O 0 5.7078587190062535e-08
the O 0 9.134222977991158e-08
small O 0 1.0452423282458767e-07
size O 0 1.2634186532523017e-06
of O 0 6.034393607023958e-08
most O 0 7.631114584683019e-08
pedigrees O 0 4.27707072958583e-06
and O 0 2.8684561925729213e-07
the O 0 9.825827191889402e-07
high O 0 0.0003612289438024163
incidence O 0 0.003150474512949586
of O 0 5.297889629218844e-07
sudden B-Disease 0 0.0024180926848202944
death I-Disease 0 5.020625758334063e-05
, O 0 1.2797859483271168e-07
however O 0 5.300264760421669e-08
, O 0 5.355444088195327e-08
molecular O 0 2.9630114113388117e-06
genetic O 0 3.2239856864180183e-06
studies O 0 2.92889723141343e-07
of O 0 1.6692700910425629e-07
IVF B-Disease 1 0.9578401446342468
have O 0 1.4086749899888673e-07
not O 0 5.3518910192451585e-08
yet O 0 3.3059706083804485e-07
been O 0 6.350159083012841e-07
done O 0 2.0759318886121036e-06
. O 0 2.4807097815937595e-06

Because O 0 0.001204786472953856
IVF B-Disease 1 0.9956606030464172
causes O 0 0.2445780634880066
cardiac O 1 0.997277557849884
rhythm O 1 0.8271485567092896
disturbance O 0 0.015924783423542976
, O 0 9.904251783154905e-07
we O 0 4.6143571807988337e-07
investigated O 0 1.1578575140447356e-05
whether O 0 4.4081050987188064e-07
malfunction O 0 0.002551460638642311
of O 0 8.284933272761918e-08
ion O 0 2.5793802706175484e-05
channels O 0 9.456163752474822e-06
could O 0 1.244810027856147e-05
cause O 0 4.38977476733271e-05
the O 0 2.7665391826303676e-06
disorder O 0 0.1303877830505371
by O 0 1.050378415357045e-07
studying O 0 9.371954092785018e-07
mutations O 0 4.00790986532229e-06
in O 0 1.3073841387267748e-07
the O 0 3.9361378867397434e-07
cardiac O 0 0.0023964024148881435
sodium O 0 2.0372081053210422e-05
channel O 0 3.311198088340461e-05
gene O 0 4.215899025439285e-05
SCN5A O 0 0.0022653392516076565
. O 0 1.4100062799116131e-05

We O 0 3.94228300137911e-06
have O 0 3.1565772928843217e-07
now O 0 7.182152330642566e-07
identified O 0 6.045834197720978e-07
a O 0 8.810041549622838e-07
missense O 0 0.00010229165491182357
mutation O 0 2.1789132006233558e-05
, O 0 1.1226288876287072e-07
a O 0 3.3185045822392567e-07
splice O 0 6.391088390955701e-05
- O 0 9.559477621223778e-05
donor O 0 7.3222968239861075e-06
mutation O 0 1.1221423847018741e-05
, O 0 1.3411208499292115e-07
and O 0 6.815364628209863e-08
a O 0 1.2858555464845267e-06
frameshift O 0 0.0003021594020538032
mutation O 0 1.2085800335626118e-05
in O 0 9.221415808724487e-08
the O 0 7.766040965861976e-08
coding O 0 1.7824830138124526e-05
region O 0 3.704570644913474e-06
of O 0 3.148979601519386e-07
SCN5A O 0 0.0007128568831831217
in O 0 1.1302685152259073e-06
three O 0 2.83263148048718e-06
IVF B-Disease 1 0.8550531268119812
families O 0 2.001398797801812e-06
. O 0 4.641099167201901e-06

We O 0 6.951057685000706e-07
show O 0 3.0377097459677316e-07
that O 0 5.8473608177678216e-09
sodium O 0 2.7939975666413375e-07
channels O 0 2.1381583792390302e-07
with O 0 9.072341100591075e-08
the O 0 9.399460623171763e-07
missense O 0 0.00024512349045835435
mutation O 0 8.300296758534387e-05
recover O 0 2.2167443603393622e-05
from O 0 2.5743537435118924e-07
inactivation O 0 2.696405499591492e-05
more O 0 7.526570477978112e-09
rapidly O 0 4.122382790683332e-07
than O 0 4.708392964403174e-08
normal O 0 6.049577905287151e-07
and O 0 1.2989332276447385e-07
that O 0 2.3544826532884144e-08
the O 0 8.608543566879234e-07
frameshift O 0 0.0012799977557733655
mutation O 0 7.407426164718345e-05
causes O 0 7.486179129045922e-06
the O 0 7.302035243128557e-08
sodium O 0 1.330116219833144e-06
channel O 0 1.2216327149872086e-06
to O 0 4.889645310868218e-08
be O 0 1.1056521742602854e-07
non O 0 2.5937060854630545e-06
- O 0 4.899187115370296e-05
functional O 0 2.526220487197861e-05
. O 0 1.1163464478158858e-05

Our O 0 5.1026454457314685e-06
results O 0 3.44827867593267e-06
indicate O 0 8.432777462985541e-07
that O 0 6.730761015205644e-08
mutations O 0 8.13928090792615e-06
in O 0 1.3653154837811599e-06
cardiac O 0 0.001687310403212905
ion O 0 6.394513911800459e-05
- O 0 8.495639121974818e-06
channel O 0 2.034793851635186e-06
genes O 0 2.3047218178362527e-07
contribute O 0 6.942154584521631e-08
to O 0 2.060824400018646e-08
the O 0 2.1272161632168718e-07
risk O 0 3.5923676477978006e-06
of O 0 8.960472541730269e-08
developing O 0 3.370008198544383e-05
IVF B-Disease 1 0.9949644804000854
. O 0 2.6992170205630828e-06
. O 0 3.482719193925732e-06

Molecular O 0 0.0006657340563833714
heterogeneity O 0 0.00043821154395118356
in O 0 1.2176663403806742e-05
mucopolysaccharidosis B-Disease 0 0.002444016980007291
IVA I-Disease 0 0.0027922685258090496
in O 0 6.801494691899279e-07
Australia O 0 9.460048033815838e-08
and O 0 1.2843281638197368e-07
Northern O 0 4.907814172838698e-07
Ireland O 0 4.163832272752188e-06
: O 0 4.2298842117816093e-07
nine O 0 2.7563660864871053e-07
novel O 0 7.495327736251056e-07
mutations O 0 3.1995557492336957e-06
including O 0 1.886511569182403e-07
T312S O 0 2.6211679141852073e-05
, O 0 2.2723403958480048e-07
a O 0 3.5056348224316025e-07
common O 0 1.5177483874140307e-06
allele O 0 8.077057827904355e-06
that O 0 2.0664417377247446e-07
confers O 0 2.8303089493419975e-05
a O 0 2.5388393623870797e-05
mild O 0 0.018878553062677383
phenotype O 0 0.0008545674500055611
. O 0 1.4606624063162599e-05

Mucopolysaccharidosis B-Disease 1 0.8568620085716248
IVA I-Disease 1 0.9835862517356873
( O 0 0.0002185069170081988
MPS B-Disease 1 0.9983898401260376
IVA I-Disease 1 0.9996944665908813
) O 0 2.5420433757972205e-06
is O 0 1.5823892454136512e-06
an O 0 7.470190212188754e-06
autosomal B-Disease 1 0.9990485310554504
recessive I-Disease 1 0.9997147917747498
lysosomal I-Disease 1 0.9998879432678223
storage I-Disease 1 0.9998457431793213
disorder I-Disease 1 0.9999825954437256
caused O 0 0.0017712910193949938
by O 0 5.818010322400369e-07
a O 0 1.8897229892900214e-05
genetic B-Disease 1 0.986807644367218
defect I-Disease 1 0.9983086585998535
in O 0 5.626279744319618e-06
N O 0 0.00033375760540366173
- O 0 0.0001973654143512249
acetylgalactosamine O 0 0.0011566630564630032
- O 0 0.000498734530992806
6 O 0 0.0001224141160491854
- O 0 0.0012743081897497177
sulfate O 0 0.006922609638422728
sulfatase O 0 0.0078546442091465
( O 0 3.3859912491607247e-06
GALNS O 0 0.0006712224567309022
) O 0 1.6160813629539916e-06
. O 0 2.854739250324201e-06

Previous O 0 1.0269162885379046e-05
studies O 0 1.2374777043078211e-06
of O 0 1.1122896381721148e-07
patients O 0 1.242548592017556e-06
from O 0 9.329065164820349e-08
a O 0 6.112773576205655e-07
British O 0 1.075332511391025e-05
- O 0 8.551016071578488e-05
Irish O 0 1.434114165022038e-05
population O 0 9.80989440790836e-08
showed O 0 5.035765298089245e-07
that O 0 6.4920477882424166e-09
the O 0 1.0431649855036085e-07
I113F O 0 1.926945878949482e-05
mutation O 0 4.3300879042362794e-06
is O 0 7.38077119422087e-08
the O 0 3.0375847615005114e-08
most O 0 4.151228694126985e-08
common O 0 1.0358621693740133e-06
single O 0 1.1120663657493424e-05
mutation O 0 0.00015171253471635282
among O 0 1.831550252973102e-05
MPS B-Disease 1 0.9982176423072815
IVA I-Disease 1 0.9998359680175781
patients O 0 0.00041042029624804854
and O 0 2.2472581804322544e-06
produces O 0 2.2263795472099446e-05
a O 0 8.572857041144744e-05
severe O 1 0.8527210354804993
clinical O 0 0.0010124085238203406
phenotype O 0 0.0014228519285097718
. O 0 1.4939877473807428e-05

We O 0 6.1412565628415905e-06
studied O 0 1.6693651559762657e-05
mutations O 0 2.057297751889564e-05
in O 0 2.3106838398234686e-07
the O 0 2.3458051146008074e-07
GALNS O 0 5.670065729646012e-05
gene O 0 2.22390212911705e-06
from O 0 4.291810569156951e-07
23 O 0 3.7676054489566013e-06
additional O 0 1.319769012297911e-06
MPS B-Disease 1 0.993135929107666
IVA I-Disease 1 0.9996414184570312
patients O 0 6.523051706608385e-05
( O 0 2.254865449913268e-07
15 O 0 3.773506591642217e-07
from O 0 5.6380251578502794e-08
Australia O 0 3.5712801604859123e-08
, O 0 3.427131289868157e-08
8 O 0 2.2632525542576332e-07
from O 0 3.554149330398104e-08
Northern O 0 2.7414571945882926e-07
Ireland O 0 6.949420026103326e-07
) O 0 3.74236286404539e-08
, O 0 3.012721805362162e-08
with O 0 3.412695903648455e-08
various O 0 1.0017676004281384e-06
clinical O 0 0.00031403652974404395
phenotypes O 0 0.0009795448277145624
( O 0 9.382549251313321e-06
severe O 0 0.06633593887090683
, O 0 6.013499955770385e-07
16 O 0 8.320341748913052e-07
cases O 0 1.2734913923395652e-07
; O 0 6.159083199008819e-08
intermediate O 0 1.874311351457436e-06
, O 0 2.812261357121315e-07
4 O 0 1.5854798220971134e-06
cases O 0 9.293613061345241e-07
; O 0 9.998967698265915e-07
mild O 0 0.00042960551218129694
, O 0 6.647912300650205e-07
3 O 0 3.072376330237603e-06
cases O 0 9.00371958323376e-07
) O 0 6.214829113559972e-07
. O 0 1.5573366454191273e-06

We O 0 1.5554693391095498e-06
found O 0 1.6536377245301992e-07
two O 0 3.912085233537255e-08
common O 0 4.153288841735048e-07
mutations O 0 2.4763369310676353e-06
that O 0 3.454957653303836e-09
together O 0 1.7885094294456394e-08
accounted O 0 1.2351414113709325e-07
for O 0 8.601681145137263e-09
32 O 0 1.790192385442424e-07
% O 0 5.260429425391067e-09
of O 0 5.630177657423019e-09
the O 0 8.553178076908807e-08
44 O 0 8.925222800826305e-07
unrelated O 0 1.6453567468488473e-06
alleles O 0 7.957714842632413e-07
in O 0 1.3578771529410005e-07
these O 0 1.2326232479153987e-07
patients O 0 1.2363060704956297e-05
. O 0 2.7408243568061152e-06

One O 0 2.9440661819535308e-06
is O 0 4.844058025810227e-07
the O 0 3.6918277146469336e-07
T312S O 0 5.184417386772111e-05
mutation O 0 1.5447471014340408e-05
, O 0 1.785813736887576e-07
a O 0 2.935630902811681e-07
novel O 0 9.243653948942665e-07
mutation O 0 5.6171652431658e-06
found O 0 2.0052722504715348e-07
exclusively O 0 3.454531736224453e-07
in O 0 1.092457864615426e-06
milder O 0 0.00027443215367384255
patients O 0 5.120649439049885e-05
. O 0 6.231165116332704e-06

The O 0 6.415198186005e-07
other O 0 7.296814885648928e-08
is O 0 1.40260127068359e-07
the O 0 7.549707703446984e-08
previously O 0 1.1423206842664513e-06
described O 0 1.863384341049823e-06
I113F O 0 1.2785219041688833e-05
that O 0 1.1553999001989723e-07
produces O 0 5.595863967755577e-06
a O 0 2.148965904780198e-05
severe O 0 0.42221513390541077
phenotype O 0 0.0014009730657562613
. O 0 1.4946760529710446e-05

The O 0 4.7308799366874155e-06
I113F O 0 9.523683547740802e-05
and O 0 1.3017921673963428e-06
T312S O 0 4.6691980969626456e-05
mutations O 0 9.864776075119153e-06
accounted O 0 1.5523841057074605e-06
for O 0 3.8515519662496445e-08
8 O 0 1.0992592933689593e-06
( O 0 7.103164278987606e-08
18 O 0 1.9400025053073477e-07
% O 0 6.689113707381011e-09
) O 0 1.081977440975379e-08
and O 0 7.586646688650944e-08
6 O 0 9.205386959365569e-07
( O 0 6.551071862759272e-08
14 O 0 2.504633300759451e-07
% O 0 6.838474675419093e-09
) O 0 1.312295427879917e-08
of O 0 1.8544067614811865e-08
44 O 0 6.71755174153077e-07
unrelated O 0 3.1014858450362226e-06
alleles O 0 2.1833770915691275e-06
, O 0 8.728744660402299e-07
respectively O 0 9.561399565427564e-06
. O 0 3.450821623118827e-06

The O 0 1.834231170505518e-06
relatively O 0 5.29094450030243e-06
high O 0 6.0236914578126743e-05
residual O 0 4.1706167394295335e-05
GALNS O 0 0.0002745716483332217
activity O 0 9.746192972670542e-07
seen O 0 2.9005964279349428e-06
when O 0 3.2063505273072224e-07
the O 0 7.281729352826005e-08
T312S O 0 5.016561772208661e-06
mutant O 0 1.2099926607334055e-06
cDNA O 0 5.314437316883414e-07
is O 0 2.81208997421345e-07
overexpressed O 0 2.3522719857282937e-05
in O 0 1.3989421177029726e-07
mutant O 0 1.6486662843817612e-06
cells O 0 3.224316174055275e-07
provides O 0 5.3159880053499364e-08
an O 0 1.925539905300866e-08
explanation O 0 2.782927026601101e-07
for O 0 6.615827885525505e-08
the O 0 4.86728140458581e-07
mild O 0 0.0004124360275454819
phenotype O 0 2.549947748775594e-05
in O 0 3.500630327835097e-07
patients O 0 6.418154043785762e-07
with O 0 7.049339245668307e-08
this O 0 3.327619140236493e-07
mutation O 0 4.9041424063034356e-05
. O 0 2.9494140107999556e-06

The O 0 3.532543360051932e-07
distribution O 0 2.4444770474474353e-07
and O 0 8.5757697831923e-08
relative O 0 2.611539571262256e-07
frequencies O 0 1.1457258324298891e-06
of O 0 4.5472827281400896e-08
the O 0 1.8104829280218837e-07
I113F O 0 1.782518666004762e-05
and O 0 5.315390012583521e-07
T312S O 0 2.34834060393041e-05
mutations O 0 8.219727533287369e-06
in O 0 1.5191805857739382e-07
Australia O 0 3.942144388702218e-08
corresponded O 0 7.822547587466033e-08
to O 0 5.557784898968521e-09
those O 0 1.408451488771334e-08
observed O 0 5.852596700606227e-07
in O 0 4.2454516346879245e-08
Northern O 0 3.070069283239718e-07
Ireland O 0 6.963198870835186e-07
and O 0 7.798756485044578e-08
are O 0 4.615640314398206e-09
unique O 0 3.256944935969841e-08
to O 0 6.769576454956905e-09
these O 0 6.935388707773882e-09
two O 0 5.5476206739513145e-08
populations O 0 1.2170748675544019e-07
, O 0 6.13789197245751e-08
suggesting O 0 1.2287689798995416e-07
that O 0 2.6724948920531233e-09
both O 0 2.6770161198896858e-08
mutations O 0 1.1738370631064754e-06
were O 0 6.050147760561231e-08
probably O 0 1.4222167976640776e-07
introduced O 0 5.2125013638715245e-08
to O 0 7.024211434725203e-09
Australia O 0 3.950137283936783e-08
by O 0 4.985856705275182e-08
Irish O 0 2.503709310985869e-06
migrants O 0 2.0720008819807845e-07
during O 0 4.82532016121695e-07
the O 0 1.0104301395585935e-07
19th O 0 6.546165423060302e-06
century O 0 9.578092431183904e-06
. O 0 6.373751148203155e-06

Haplotype O 0 0.0003501477185636759
analysis O 0 1.311661890213145e-06
using O 0 9.654727364249993e-07
6 O 0 6.9663078647863586e-06
RFLPs O 0 3.4342425351496786e-05
provides O 0 5.646527156955017e-08
additional O 0 1.2668310844787811e-08
data O 0 1.475314803656147e-07
that O 0 1.62359334865414e-08
the O 0 1.450841722316909e-07
I113F O 0 2.6696470740716904e-05
mutation O 0 5.001247245672857e-06
originated O 0 5.401911380431557e-07
from O 0 7.850408678677923e-08
a O 0 5.261812248136266e-07
common O 0 1.9842298115690937e-06
ancestor O 0 4.802417606697418e-05
. O 0 2.4125010895659216e-05

The O 0 8.914886961974844e-07
other O 0 2.1193169175148796e-07
9 O 0 2.9834666293027112e-06
novel O 0 6.739843456671224e-07
mutations O 0 4.583272129821125e-06
identified O 0 2.9235562237772683e-07
in O 0 2.3393392112325273e-08
these O 0 1.0621820756284706e-08
23 O 0 1.5717349697297323e-06
patients O 0 2.7958847681475163e-07
were O 0 1.5695997390707817e-08
each O 0 2.1470001332346556e-09
limited O 0 1.3986748648164848e-08
to O 0 7.964819914718646e-09
a O 0 3.0602708989135863e-07
single O 0 1.7796637621358968e-06
family O 0 1.5121373508009128e-05
. O 0 5.9221092669758946e-06

These O 0 8.838918574838317e-08
data O 0 1.0490550295116918e-07
provide O 0 2.67122199915093e-08
further O 0 3.488584709998577e-08
evidence O 0 5.19848200042361e-08
for O 0 4.048651192078978e-08
extensive O 0 6.298017069639172e-06
allelic O 0 0.00034880571183748543
heterogeneity O 0 0.0004165724676568061
in O 0 4.4104694097768515e-05
MPS B-Disease 1 0.9940955638885498
IVA I-Disease 1 0.9986311793327332
in O 0 6.208980266819708e-06
British O 0 0.00011172636732226238
- O 0 0.0028999391943216324
Irish O 0 0.00025050132535398006
patients O 0 9.996670996770263e-06
and O 0 4.32247766468663e-08
provide O 0 1.7480152436633034e-08
evidence O 0 3.1093165375750687e-08
for O 0 9.37508204401638e-09
their O 0 2.3112033176175828e-08
transmission O 0 7.147657925088424e-06
to O 0 4.155633348545962e-08
Australia O 0 5.2038885201000085e-08
by O 0 3.4860171638229076e-08
British O 0 3.6663448099716334e-06
- O 0 6.34360549156554e-05
Irish O 0 2.0337312889751047e-05
migrants O 0 1.1073940413552918e-06
. O 0 5.733849661737622e-07
. O 0 1.4003907153892214e-06

Identification O 0 8.994597919809166e-06
of O 0 1.4259042018238688e-06
constitutional O 0 0.00015116699796635658
WT1 O 0 0.010177196934819221
mutations O 0 0.0004135212511755526
, O 0 1.409642777616682e-06
in O 0 7.976914844221028e-07
patients O 0 4.036794962303247e-06
with O 0 4.209372036712011e-06
isolated O 0 0.06093950569629669
diffuse B-Disease 1 0.9973875880241394
mesangial I-Disease 1 0.9999315738677979
sclerosis I-Disease 1 0.9999927282333374
, O 0 4.098691988474457e-06
and O 0 2.245395762656699e-07
analysis O 0 1.801799953682348e-07
of O 0 1.574034484974618e-07
genotype O 0 4.282336158212274e-05
/ O 0 7.760860171401873e-05
phenotype O 0 1.2765688552462962e-05
correlations O 0 1.1417848782002693e-06
by O 0 1.4672251857916763e-08
use O 0 3.2735922417259644e-08
of O 0 2.439301916012937e-08
a O 0 9.66854827311181e-07
computerized O 0 0.0003120845649391413
mutation O 0 9.986534132622182e-05
database O 0 1.7380472854711115e-05
. O 0 5.587033228948712e-06

Constitutional O 0 0.00018525293853599578
mutations O 0 5.618812792818062e-05
of O 0 1.1896491969309864e-07
the O 0 4.353140354851348e-07
WT1 O 0 0.0002319704508408904
gene O 0 2.42254213844717e-06
, O 0 9.610892703904028e-08
encoding O 0 2.861355028471735e-07
a O 0 1.1079274372605141e-05
zinc O 0 0.0025636295322328806
- O 0 0.00011772942525567487
finger O 0 0.00010566880519036204
transcription O 0 7.576041298307246e-06
factor O 0 9.617583600629587e-07
involved O 0 1.1153822470078012e-06
in O 0 2.462912334522116e-06
renal O 1 0.9984637498855591
and O 0 2.8803551685996354e-06
gonadal O 0 0.0006731064640916884
development O 0 7.94230800238438e-07
, O 0 2.55029902973547e-07
are O 0 8.349942071106398e-09
found O 0 6.441234035037269e-08
in O 0 4.136022724310351e-08
most O 0 1.2412617422796757e-07
patients O 0 2.6835577955353074e-06
with O 0 3.3446640372858383e-06
Denys B-Disease 1 0.9978135824203491
- I-Disease 1 0.9995971322059631
Drash I-Disease 1 0.9980880618095398
syndrome I-Disease 1 0.9999792575836182
( O 0 2.5201183234457858e-05
DDS B-Disease 1 0.9995980858802795
) O 0 2.1879191081097815e-06
, O 0 2.1346224912122125e-06
or O 0 9.011042857309803e-05
diffuse B-Disease 1 0.9957155585289001
mesangial I-Disease 1 0.9999388456344604
sclerosis I-Disease 1 0.9999961853027344
( O 0 8.080195402726531e-05
DMS B-Disease 0 0.12257109582424164
) O 0 9.788192301130039e-07
associated O 0 2.276340865137172e-06
with O 0 2.580981572464225e-06
pseudohermaphroditism B-Disease 1 0.9996470212936401
and O 0 7.618081872351468e-05
/ O 0 0.007243701256811619
or O 0 0.0009612230351194739
Wilms B-Disease 1 0.998557984828949
tumor I-Disease 1 0.99517822265625
( O 0 2.319035047548823e-05
WT B-Disease 1 0.9908232688903809
) O 0 4.2218830458296e-06
. O 0 4.262273250787985e-06

Most O 0 1.4788457519898657e-05
mutations O 0 0.0009175980230793357
in O 0 5.584789323620498e-05
DDS B-Disease 1 0.9996947050094604
patients O 0 0.0003947261138819158
lie O 0 4.7206314775394276e-05
in O 0 6.496013611467788e-07
exon O 0 2.7208749088458717e-05
8 O 0 3.4357819913566345e-06
or O 0 8.605653647464351e-07
exon O 0 1.692044679657556e-05
9 O 0 2.707244902921957e-06
, O 0 7.58786242727183e-08
encoding O 0 1.544595647828828e-06
zinc O 0 0.003608686849474907
finger O 0 0.001379838096909225
2 O 0 8.637212886242196e-06
or O 0 4.408977019920712e-06
zinc O 0 0.0013968278653919697
finger O 0 0.0006843652809038758
3 O 0 1.551229843244073e-06
, O 0 8.111450000569675e-08
respectively O 0 1.8981950233865064e-07
, O 0 3.055214037317455e-08
with O 0 4.918060625414e-08
a O 0 2.494612090231385e-06
hot O 0 0.00022335715766530484
spot O 0 3.124562499579042e-05
( O 0 5.169245582692383e-07
R394W O 0 8.369129318452906e-06
) O 0 1.1368590691063218e-07
in O 0 2.0397625632995187e-07
exon O 0 3.997690510004759e-05
9 O 0 2.5932686185115017e-05
. O 0 2.798095920297783e-06

We O 0 1.9527244603523286e-06
analyzed O 0 1.4162482102619833e-06
a O 0 2.1768661895293917e-07
series O 0 2.628214588185074e-07
of O 0 8.006954743677852e-08
24 O 0 6.874525297462242e-06
patients O 0 1.95370239453041e-06
, O 0 1.152548492200367e-07
10 O 0 3.4920606140076416e-07
with O 0 5.767544735135743e-07
isolated B-Disease 0 0.0008633214747533202
DMS I-Disease 0 0.19146481156349182
( O 0 2.082328592223348e-06
IDMS B-Disease 0 0.0017340289195999503
) O 0 3.3918851727321453e-07
, O 0 1.3876783100386092e-07
10 O 0 2.63129948052665e-07
with O 0 7.315800871765532e-07
DDS B-Disease 1 0.9998121857643127
, O 0 1.3426199529931182e-06
and O 0 9.841638757279725e-07
4 O 0 6.964594376768218e-06
with O 0 1.100656754715601e-05
urogenital B-Disease 1 0.9984910488128662
abnormalities I-Disease 1 0.9996904134750366
and O 0 6.092245894251391e-05
/ O 0 0.005881347693502903
or O 0 0.0005622580065391958
WT B-Disease 1 0.9985654950141907
. O 0 3.910394661943428e-05

We O 0 1.6417081496911123e-05
report O 0 4.823773906537099e-06
WT1 O 0 0.0005112735088914633
heterozygous O 0 5.088024863653118e-06
mutations O 0 1.555542075948324e-05
in O 0 5.971160135231912e-07
16 O 0 2.5552319584676297e-06
patients O 0 1.0888029464695137e-06
, O 0 8.932829587138258e-08
4 O 0 4.1212229007214773e-07
of O 0 9.048733318195445e-08
whom O 0 2.469158516760217e-06
presented O 0 4.3994596126140095e-06
with O 0 1.3070544810034335e-05
IDMS B-Disease 1 0.9637672305107117
. O 0 5.528636393137276e-05

One O 0 1.8040194618151872e-06
male O 0 2.202890982516692e-06
and O 0 2.6134182462556055e-07
two O 0 6.506554086627148e-07
female O 0 2.0776986275450327e-05
IDMS B-Disease 1 0.9105287194252014
patients O 0 6.729754386469722e-05
with O 0 3.5201512673666002e-06
WT1 O 0 0.17123575508594513
mutations O 0 0.0034862642642110586
underwent O 0 0.17508137226104736
normal O 0 0.00014165697211865336
puberty O 0 0.0019436549628153443
. O 0 6.941729679965647e-06

Two O 0 5.0488338274590205e-06
mutations O 0 0.00012045237235724926
associated O 0 5.701988357031951e-06
with O 0 1.4661756040368346e-06
IDMS B-Disease 0 0.016231078654527664
are O 0 5.3512067665906216e-08
different O 0 1.7707501243080515e-08
from O 0 1.0021557983463936e-07
those O 0 6.726449441885052e-08
described O 0 9.241078259947244e-06
in O 0 1.1139345588162541e-05
DDS B-Disease 1 0.9997773766517639
patients O 0 0.0012495487462729216
. O 0 1.1632586392806843e-05

No O 0 3.3907850593095645e-05
WT1 O 0 0.0025266993325203657
mutations O 0 9.074821718968451e-05
were O 0 7.459565267708967e-07
detected O 0 1.4432750504056457e-05
in O 0 7.575137317417102e-08
the O 0 8.028532505477415e-08
six O 0 3.4753227851069823e-07
other O 0 2.3877095145508065e-07
IDMS B-Disease 1 0.7695491909980774
patients O 0 6.335021316772327e-05
, O 0 6.639871799052344e-07
suggesting O 0 2.4281625883304514e-06
genetic O 0 4.336923666414805e-06
heterogeneity O 0 2.539912202337291e-05
of O 0 7.736381917311519e-07
this O 0 8.441269528702833e-06
disease O 1 0.9959656000137329
. O 0 1.170724044641247e-05

We O 0 1.1230416930629872e-05
analyzed O 0 2.3248167053679936e-05
genotype O 0 9.327675797976553e-05
/ O 0 6.719699740642682e-05
phenotype O 0 3.8391943235183135e-05
correlations O 0 6.614984613406705e-06
, O 0 1.7359350579226884e-07
on O 0 1.0623202939541443e-07
the O 0 1.0017063623024569e-08
basis O 0 2.064239090771025e-08
of O 0 9.79459713335018e-09
the O 0 9.046801352496914e-08
constitution O 0 2.748294889443059e-07
of O 0 3.6731933050759835e-08
a O 0 1.7125050817412557e-06
WT1 O 0 0.0008004500414244831
mutation O 0 2.2051646737963893e-05
database O 0 2.50960670200584e-06
of O 0 5.30206477833417e-07
84 O 0 2.4856046366039664e-05
germ O 0 0.001104665920138359
- O 0 0.00020173646043986082
line O 0 3.852599547826685e-05
mutations O 0 1.675860221439507e-05
, O 0 5.266686642357854e-08
to O 0 5.32463095836988e-09
compare O 0 8.867269940537881e-08
the O 0 1.1690066692437995e-08
distribution O 0 6.455488232859352e-08
and O 0 9.55755012910231e-08
type O 0 3.836474206764251e-06
of O 0 1.013499044688615e-07
mutations O 0 1.0008967365138233e-05
, O 0 1.0814724760166428e-07
according O 0 1.3718914892990597e-08
to O 0 9.917787480162588e-09
the O 0 1.7918458183885377e-07
different O 0 1.2285291859370773e-06
symptoms O 0 0.013997596688568592
. O 0 5.732904355681967e-06

This O 0 8.01335374944756e-07
demonstrated O 0 4.090094080311246e-06
( O 0 1.352133267573663e-07
1 O 0 6.066383662073349e-07
) O 0 2.609950655596549e-08
the O 0 2.536811471998135e-08
association O 0 1.8546195690305467e-07
between O 0 1.6228850086008606e-07
mutations O 0 2.8303172712185187e-06
in O 0 1.1153083789849916e-07
exons O 0 2.264540171381668e-06
8 O 0 1.5548197325188085e-06
and O 0 3.021374368472607e-07
9 O 0 4.138101303396979e-06
and O 0 6.0190029671503e-07
DMS B-Disease 0 0.0013270392082631588
; O 0 4.3839611407747725e-07
( O 0 1.353653118485454e-07
2 O 0 5.475213242789323e-07
) O 0 7.42802512831986e-08
among O 0 2.386539392773557e-07
patients O 0 1.3041928923485102e-06
with O 0 3.4873679055635876e-07
DMS B-Disease 0 0.0026146152522414923
, O 0 1.1303283287134036e-07
a O 0 1.2814919614356768e-07
higher O 0 4.838393010686559e-07
frequency O 0 1.2908709550174535e-06
of O 0 8.453658750795512e-08
exon O 0 2.3445765691576526e-05
8 O 0 3.722618203028105e-06
mutations O 0 8.182389137800783e-06
among O 0 3.8252255762927234e-07
46 O 0 4.217351488478016e-06
, O 0 9.669286100688623e-07
XY O 0 0.0005920152179896832
patients O 0 4.7657299546699505e-06
with O 0 1.0014755957854504e-07
female O 0 1.7802885849960148e-06
phenotype O 0 2.9895045372541063e-06
than O 0 9.137568213191116e-08
among O 0 1.7991848721976567e-07
46 O 0 4.039197847305331e-06
, O 0 2.3554068775410997e-06
XY O 0 0.0010766084305942059
patients O 0 8.956661076808814e-06
with O 0 2.566960120020667e-07
sexual O 0 1.4009116284796619e-06
ambiguity O 0 3.30924285663059e-06
or O 0 1.607139665793511e-06
male O 0 3.831165486190002e-06
phenotype O 0 6.824001957284054e-06
; O 0 1.2503863899837597e-07
and O 0 1.1052178194859152e-07
( O 0 1.1690751477999584e-07
3 O 0 2.944381662928208e-07
) O 0 1.913334024550295e-08
statistically O 0 1.0524179572257708e-07
significant O 0 2.563612611083954e-08
evidence O 0 2.5068453979315564e-08
that O 0 8.95559981728411e-09
mutations O 0 9.326890904048923e-07
in O 0 9.502546305384385e-08
exons O 0 2.4845453481248114e-06
8 O 0 1.155801442109805e-06
and O 0 6.82059209111685e-08
9 O 0 6.335085345199332e-07
preferentially O 0 2.8692605269498017e-07
affect O 0 8.725884015348129e-08
amino O 0 6.445326050652511e-08
acids O 0 2.5450114904401744e-08
with O 0 5.385505819077707e-09
different O 0 3.484606159176451e-09
functions O 0 3.188022503763932e-07
. O 0 6.275459440985287e-07
. O 0 1.5793589227541815e-06

The O 0 2.1880376152694225e-05
185delAG O 0 0.0014242416946217418
BRCA1 O 0 0.0008551201899535954
mutation O 0 2.860035419871565e-05
originated O 0 8.045300319281523e-07
before O 0 2.433489214581641e-07
the O 0 2.5483727128516875e-08
dispersion O 0 1.1352776709827594e-06
of O 0 2.1770835800793975e-08
Jews O 0 1.9362539660505718e-07
in O 0 1.0816828677207013e-07
the O 0 4.1792251437300365e-08
diaspora O 0 1.9853493427035573e-07
and O 0 1.2883702993349289e-07
is O 0 6.479988456931096e-08
not O 0 7.498027976282629e-09
limited O 0 5.842179717774343e-08
to O 0 2.80726681012311e-07
Ashkenazim O 0 0.0006664164247922599
. O 0 1.3643649253936019e-05

The O 0 4.414863269630587e-06
185delAG O 0 0.00027760505327023566
mutation O 0 3.7092282582307234e-05
in O 0 1.7314540627921815e-06
BRCA1 O 0 0.00014282966731116176
is O 0 1.6725859950383892e-06
detected O 0 2.3996055460884236e-05
in O 0 3.3048863201656786e-07
Ashkenazi O 0 1.706737202766817e-05
Jews O 0 6.680815545223595e-07
both O 0 5.654415531353152e-07
in O 0 1.2645670722122304e-05
familial B-Disease 1 0.9935996532440186
breast I-Disease 1 0.9998577833175659
and I-Disease 1 0.9988768696784973
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999978542327881
and O 0 1.6614195601505344e-06
in O 0 1.713941486514159e-07
the O 0 1.571486194507088e-07
general O 0 3.971832143179199e-07
population O 0 9.548676871418138e-08
. O 0 2.0245388441253453e-06

All O 0 4.487231308303308e-06
tested O 0 5.9147088904865086e-05
Ashkenazi O 0 0.0001667982287472114
mutation O 0 1.3874502656108234e-05
carriers O 0 8.915295097722264e-07
share O 0 6.449544542874719e-08
the O 0 3.1937187117137e-08
same O 0 4.456677800135367e-07
allelic O 0 5.785565372207202e-05
pattern O 0 7.089983409969136e-05
at O 0 5.051722837379202e-05
the O 0 4.028864623251138e-06
BRCA1 O 0 0.0005158347776159644
locus O 0 0.00041493368917144835
. O 0 2.056887751678005e-05

Our O 0 4.67109339297167e-06
previous O 0 5.878837782802293e-06
study O 0 1.007496962301957e-06
showed O 0 1.484332869949867e-06
that O 0 2.8768656790134628e-08
this O 0 9.302306125391624e-08
Ashkenazi O 0 8.548684127163142e-05
mutation O 0 3.0318857170641422e-05
also O 0 5.524590278582764e-07
occurs O 0 4.066777705702407e-07
in O 0 2.691700373702588e-08
Iraqi O 0 1.9403871931444883e-07
Jews O 0 1.1013122502845363e-07
with O 0 7.403372137559927e-08
a O 0 8.477537676299107e-07
similar O 0 2.5084486878768075e-06
allelic O 0 0.0005388747085817158
pattern O 0 0.0004888440016657114
. O 0 2.169950857933145e-05

We O 0 6.354902666316775e-07
extended O 0 1.3465933079714887e-07
our O 0 4.3983501285538296e-08
analysis O 0 2.184925129711246e-08
to O 0 1.2951576700004352e-08
other O 0 2.309475810591266e-08
non O 0 2.379758143433719e-06
- O 0 2.5802242817007937e-05
Ashkenazi O 0 3.0325480111059733e-05
subsets O 0 3.97949042962864e-06
354 O 0 5.945503744442249e-06
of O 0 6.568124888417515e-08
Moroccan O 0 5.740591404901352e-06
origin O 0 1.3383382224674278e-07
, O 0 1.207226887345314e-07
200 O 0 1.7189242385029502e-07
Yemenites O 0 2.4321059754583985e-05
and O 0 2.4986235303003923e-07
150 O 0 5.217743819230236e-07
Iranian O 0 3.6540229757520137e-06
Jews O 0 5.263004368316615e-06
. O 0 6.278689397731796e-06

Heteroduplex O 0 0.0005987623590044677
analysis O 0 8.288172352877154e-07
complemented O 0 1.3443456055028946e-06
by O 0 1.6446879413933857e-08
direct O 0 2.7228578503013523e-08
DNA O 0 5.949003707428346e-07
sequencing O 0 5.080117944089579e-07
of O 0 1.6711784667222673e-07
abnormally O 0 0.00011821642692666501
migrating O 0 1.410432219017821e-06
bands O 0 5.9530266298679635e-06
were O 0 4.69980221851074e-07
employed O 0 5.00306987305521e-06
. O 0 3.501949777273694e-06

Four O 0 1.7831243894761428e-06
of O 0 1.8035277093986224e-07
Moroccan O 0 7.396833098027855e-06
origin O 0 2.061202479808344e-07
( O 0 1.0340130529584712e-07
1 O 0 2.578777014150546e-07
. O 0 2.2825783929647514e-08
1 O 0 2.149603801626654e-07
% O 0 8.095696557575138e-09
) O 0 1.2233175361586746e-08
and O 0 5.2376055492686646e-08
none O 0 1.1749700234986449e-07
of O 0 1.3442563506771421e-08
the O 0 1.3839736823229032e-07
Yemenites O 0 1.976637213374488e-05
or O 0 3.4974868867720943e-07
Iranians O 0 3.959499110806064e-07
was O 0 4.316399554227246e-06
a O 0 7.315124435081088e-07
carrier O 0 4.2382935134810396e-06
of O 0 3.9966167264537944e-08
the O 0 6.926744617885561e-07
185delAG O 0 0.0005098909023217857
mutation O 0 0.00012672047887463123
. O 0 5.422849881142611e-06

BRCA1 O 0 0.004972497466951609
allelic O 0 0.000706265855114907
patterns O 0 4.531594822765328e-05
were O 0 2.2893065931839374e-07
determined O 0 2.130785503595689e-07
for O 0 7.370892340929913e-09
four O 0 1.895278600727579e-08
of O 0 1.3540806254042081e-09
these O 0 1.4192158559467316e-09
individuals O 0 2.9379951804742177e-09
and O 0 3.189165553862949e-08
for O 0 2.5847345597185267e-08
12 O 0 4.546792808923783e-07
additional O 0 8.956491370781805e-08
non O 0 1.701539986243006e-05
- O 0 0.0002674846036825329
Ashkenazi O 0 0.00027507293270900846
185delAG O 0 0.0002780373324640095
mutation O 0 4.683441511588171e-05
carriers O 0 3.062926043639891e-05
who O 0 3.635518078226596e-05
had O 0 0.0027900137938559055
breast B-Disease 1 0.9998096823692322
/ I-Disease 1 0.999911904335022
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999922513961792
. O 0 8.411786984652281e-05

Six O 0 2.813344690366648e-05
non O 0 6.587739335373044e-05
- O 0 0.0002980553254019469
Ashkenazi O 0 0.00010816151188919321
individuals O 0 8.289723041343677e-08
shared O 0 2.3559074691092974e-07
the O 0 3.4944659432767367e-07
common O 0 6.451497029047459e-06
Ashkenazi O 0 9.20541788218543e-05
haplotype O 0 7.565112173324451e-05
, O 0 3.940603789942543e-07
four O 0 9.195088779279104e-08
had O 0 2.946362087641319e-07
a O 0 1.2763766221723927e-07
closely O 0 3.866294946419657e-07
related O 0 9.059991157300828e-07
pattern O 0 9.422891707799863e-06
, O 0 4.156759985107783e-07
and O 0 6.768185301098129e-08
the O 0 6.029917898331405e-08
rest O 0 4.94965206598863e-07
( O 0 1.0870831346210252e-07
n O 0 7.588703283545328e-06
= O 0 1.2166772648924962e-05
6 O 0 1.6582379203100572e-06
) O 0 1.944729177694171e-08
displayed O 0 4.87138152038824e-07
a O 0 8.607426593698619e-07
distinct O 0 4.789464128407417e-06
BRCA1 O 0 0.0009897979907691479
allelic O 0 0.0014582769945263863
pattern O 0 0.0010668040486052632
. O 0 4.600943429977633e-05

We O 0 3.4146180496463785e-06
conclude O 0 5.210128620092291e-06
that O 0 4.8447510891946877e-08
the O 0 5.733898547077843e-07
185delAG O 0 0.00025595223996788263
BRCA1 O 0 0.00042506796307861805
mutation O 0 4.846242518397048e-05
occurs O 0 2.2459214505943237e-06
in O 0 6.689486298228076e-08
some O 0 2.2340103100759734e-08
non O 0 8.695836186234374e-06
- O 0 0.00016540953947696835
Ashkenazi O 0 0.0001103507456718944
populations O 0 1.1667455055430764e-06
at O 0 6.2402882576861884e-06
rates O 0 7.356400146818487e-07
comparable O 0 6.270822723308811e-07
with O 0 4.3316468634202465e-08
that O 0 2.969534840246979e-08
of O 0 2.095531357326763e-07
Ashkenazim O 0 0.0015411657514050603
. O 0 2.4334562112926506e-05

The O 0 1.8152179563912796e-06
majority O 0 7.037166938062001e-07
of O 0 2.8460735279622895e-07
Jewish O 0 1.296054688282311e-05
185delAG O 0 0.0004692300281021744
mutation O 0 4.076581171830185e-05
carriers O 0 2.8977983674849384e-06
have O 0 6.296704668784514e-08
a O 0 3.1662673904975236e-07
common O 0 2.185687435485306e-06
allelic O 0 0.00011236152204219252
pattern O 0 8.358740888070315e-05
, O 0 6.232290843399824e-07
supporting O 0 6.438236823669286e-07
the O 0 2.5853370289041777e-07
founder O 0 1.5250684555212501e-05
effect O 0 6.778525971640192e-07
notion O 0 7.141173341551621e-07
, O 0 3.4765028544825327e-07
but O 0 1.0958454055298716e-07
dating O 0 1.6020163684515865e-06
the O 0 6.314120071237994e-08
mutations O 0 8.697103339727619e-07
origin O 0 1.178521369382679e-08
to O 0 8.621094949035069e-09
an O 0 6.579083589031143e-08
earlier O 0 5.629943302665197e-07
date O 0 4.145675234212831e-07
than O 0 8.262178141649201e-08
currently O 0 3.7393164120658184e-07
estimated O 0 7.464240638910269e-07
. O 0 1.3444866908685071e-06

However O 0 2.24567065743031e-06
, O 0 1.1083548656642961e-07
the O 0 3.195717113158025e-08
different O 0 2.5038350059958248e-08
allelic O 0 6.179339834488928e-05
pattern O 0 4.7019868361530825e-05
at O 0 2.265778493892867e-05
the O 0 8.454285875814094e-07
BRCA1 O 0 3.782805652008392e-05
locus O 0 8.066604095802177e-06
even O 0 3.7732328905804025e-07
in O 0 4.1417699492285465e-08
some O 0 7.277171754083156e-09
Jewish O 0 1.0694556067392114e-06
mutation O 0 1.1703948075592052e-05
carriers O 0 5.550156402023276e-06
, O 0 3.1974980174709344e-07
might O 0 3.5975267564936075e-07
suggest O 0 1.0193829780291708e-07
that O 0 9.93122739600949e-09
the O 0 1.1370586605607969e-07
mutation O 0 3.847047992167063e-06
arose O 0 1.0067976745631313e-06
independently O 0 4.5601461806654697e-07
. O 0 3.7193640878285805e-07
. O 0 1.2676911183007178e-06

Crystal O 0 0.0023129114415496588
structure O 0 5.304249134496786e-05
of O 0 8.374705657843151e-07
the O 0 9.209898962581065e-06
hemochromatosis B-Disease 1 0.9998805522918701
protein O 0 8.214955596486107e-05
HFE O 0 0.003655495122075081
and O 0 4.7058657060006226e-07
characterization O 0 1.1887004802701995e-06
of O 0 1.6720704820727406e-08
its O 0 2.69976254685389e-08
interaction O 0 1.281086383642105e-07
with O 0 3.944404909361765e-07
transferrin O 0 0.00015316596545744687
receptor O 0 2.5220029783667997e-05
. O 0 2.661826329131145e-06

HFE O 0 0.01773032918572426
is O 0 6.309812761173816e-06
an O 0 1.0522609272811678e-06
MHC O 0 0.00016985522233881056
- O 0 1.9470919141895138e-05
related O 0 6.976532631597365e-07
protein O 0 1.521953123528874e-07
that O 0 1.1346966921621515e-08
is O 0 3.3893815754026946e-08
mutated O 0 9.757073939908878e-07
in O 0 1.8133167145606421e-07
the O 0 3.2787465897854418e-06
iron B-Disease 1 0.9994885921478271
- I-Disease 1 0.9996585845947266
overload I-Disease 1 0.9992281198501587
disease I-Disease 1 0.9999445676803589
hereditary B-Disease 1 0.9999988079071045
hemochromatosis I-Disease 1 0.9999997615814209
. O 0 0.002102234400808811

HFE O 0 0.0030618589371442795
binds O 0 1.1326465028105304e-05
to O 0 2.372981384723971e-07
transferrin O 0 8.447026630165055e-05
receptor O 0 9.397978828928899e-06
( O 0 6.135726948741649e-07
TfR O 0 6.466561171691865e-05
) O 0 7.567714277456616e-08
and O 0 4.433007205761896e-08
reduces O 0 2.481506840013026e-07
its O 0 7.389783451827725e-09
affinity O 0 1.9581290189307765e-07
for O 0 1.4283688187788357e-07
iron O 0 0.006910333875566721
- O 0 6.857715925434604e-05
loaded O 0 1.2476182746468112e-05
transferrin O 0 0.00013106403639540076
, O 0 2.4830910660966765e-06
implicating O 0 0.0004394519201014191
HFE O 0 0.0034867958165705204
in O 0 1.0565310731180944e-05
iron O 0 0.1659649908542633
metabolism O 0 0.01108483411371708
. O 0 1.3629760360345244e-05

The O 0 7.961988558236044e-06
2 O 0 3.218742131139152e-05
. O 0 7.717584594502114e-06

6 O 0 5.548035915126093e-05
A O 0 1.2662880180869251e-05
crystal O 0 0.0009642820223234594
structure O 0 7.009279943304136e-05
of O 0 1.8405025912215933e-06
HFE O 0 0.005475969985127449
reveals O 0 2.3828082703403197e-05
the O 0 3.310501028863655e-07
locations O 0 1.760222289703961e-06
of O 0 5.042568773205858e-06
hemochromatosis B-Disease 1 0.9999436140060425
mutations O 0 0.0030065691098570824
and O 0 7.99206827650778e-06
a O 0 1.6809888620628044e-05
patch O 0 0.09093013405799866
of O 0 7.636529062438058e-07
histidines O 0 0.0001272388471988961
that O 0 5.496171340269029e-08
could O 0 9.402538836411622e-08
be O 0 4.2491862473070796e-08
involved O 0 1.5546315523806697e-07
in O 0 3.152858880639542e-07
pH O 0 0.00014232759713195264
- O 0 1.7625974578550085e-05
dependent O 0 1.870151209004689e-06
interactions O 0 5.261865226202644e-06
. O 0 4.249751782481326e-06

We O 0 2.730841970333131e-06
also O 0 2.3340582799846743e-07
demonstrate O 0 3.0714866738890123e-07
that O 0 1.216210421262076e-07
soluble O 0 0.00023548964236397296
TfR O 0 0.0004498877970036119
and O 0 8.153747899086738e-07
HFE O 0 0.0004710353969130665
bind O 0 7.356662990787299e-06
tightly O 0 1.8244707462145016e-05
at O 0 9.930566193361301e-06
the O 0 9.680213963747519e-08
basic O 0 1.1905337942152983e-06
pH O 0 2.2446844013757072e-05
of O 0 2.0099394149042382e-08
the O 0 9.326947747467784e-08
cell O 0 8.650236850371584e-06
surface O 0 1.0316690350009594e-05
, O 0 1.3146133426289452e-07
but O 0 3.4782399183086454e-08
not O 0 1.9048171040481066e-08
at O 0 1.9142594283039216e-06
the O 0 3.1173453862720635e-07
acidic O 0 0.00012389411858748645
pH O 0 0.00012624119699466974
of O 0 3.131161463443277e-07
intracellular O 0 8.033905032789335e-05
vesicles O 0 0.0011428706347942352
. O 0 1.5696237824158743e-05

TfR O 0 0.03271625190973282
HFE O 0 0.008565159514546394
stoichiometry O 0 0.0002322942455066368
( O 0 1.1151174703627476e-06
2 O 0 1.841074890762684e-06
1 O 0 9.592768037691712e-07
) O 0 5.623462584480876e-08
differs O 0 7.523515250795754e-07
from O 0 3.410874569453881e-07
TfR O 0 0.00014857244968879968
transferrin O 0 5.509636685019359e-05
stoichiometry O 0 1.497999437560793e-05
( O 0 3.8003037161615794e-07
2 O 0 6.909775152053044e-07
2 O 0 6.213631991158763e-07
) O 0 3.535184944780667e-08
, O 0 4.001727305080749e-08
implying O 0 1.2038330510222295e-07
a O 0 3.762703926213362e-08
different O 0 9.437679082680006e-09
mode O 0 7.784249760334205e-07
of O 0 2.426767586882761e-08
binding O 0 1.0407339914308977e-06
for O 0 1.6746035669257253e-07
HFE O 0 0.0004911541473120451
and O 0 5.730596512876218e-07
transferrin O 0 4.9371814384358004e-05
to O 0 2.7243288514000596e-07
TfR O 0 0.00015020462160464376
, O 0 1.646618983386361e-07
consistent O 0 3.995191946160048e-07
with O 0 6.155677567676321e-08
our O 0 2.8312979338807054e-07
demonstration O 0 2.386963615208515e-06
that O 0 7.593393291926986e-08
HFE O 0 0.00019435725698713213
, O 0 4.999321845389204e-07
transferrin O 0 1.713155688776169e-05
, O 0 2.0881580553577805e-07
and O 0 2.219959895910506e-07
TfR O 0 4.837792585021816e-05
form O 0 5.244333465270756e-07
a O 0 2.1942903458693763e-06
ternary O 0 0.0001430983393220231
complex O 0 0.0005455537466332316
. O 0 2.0336690795375034e-05

Identification O 0 2.9429938877001405e-06
of O 0 2.0871306105618714e-07
three O 0 1.9832826581023255e-07
novel O 0 1.2323969258432044e-06
mutations O 0 6.535318334499607e-06
and O 0 1.4106392143276025e-07
a O 0 3.3003414046106627e-07
high O 0 2.380457317485707e-06
frequency O 0 1.5136575939322938e-06
of O 0 6.503179150740834e-08
the O 0 5.592794423137093e-07
Arg778Leu O 0 0.0001526540145277977
mutation O 0 1.9825536583084613e-05
in O 0 8.603864785072801e-07
Korean O 0 5.682054688804783e-05
patients O 0 2.5216519134119153e-05
with O 0 1.465266541345045e-05
Wilson B-Disease 0 0.11292750388383865
disease I-Disease 1 0.9954469799995422
. O 0 1.6727404727134854e-05

Four O 0 6.298317657638108e-06
mutations O 0 0.00015719774819444865
- O 0 0.00025915037258528173
- O 0 0.00013271112402435392
R778L O 0 4.93598599859979e-05
, O 0 5.289963382892893e-07
A874V O 0 9.720057278173044e-06
, O 0 1.4896264133312798e-07
L1083F O 0 3.0035132567718392e-06
, O 0 1.8346828767334955e-07
and O 0 2.0121417776408634e-07
2304delC O 0 2.7670572308124974e-05
- O 0 2.3864355171099305e-05
- O 0 1.1718679161276668e-05
in O 0 7.613421360019856e-08
the O 0 1.6364106159016956e-07
copper O 0 6.38615238131024e-05
- O 0 3.6547687614074675e-06
transporting O 0 1.4008742255100515e-06
enzyme O 0 3.012543857039418e-06
, O 0 5.915534870837291e-07
P O 0 4.6013956307433546e-05
- O 0 1.3780703739030287e-05
type O 0 1.3621377547679003e-05
ATPase O 0 5.1754079322563484e-05
( O 0 5.644093334922218e-07
ATP7B O 0 6.67188796796836e-05
) O 0 6.656622986156435e-08
, O 0 3.454570318695005e-08
were O 0 2.3873266030705054e-08
identified O 0 2.5794756197683455e-07
in O 0 1.5172722100942337e-07
Korean O 0 1.4684993402624968e-05
Patients O 0 8.8854512796388e-06
with O 0 6.655379820585949e-06
Wilson B-Disease 0 0.14864350855350494
disease I-Disease 1 0.9967058300971985
. O 0 1.2064484508300666e-05

Arg778Leu O 0 0.002143797930330038
, O 0 1.2234385167175788e-06
the O 0 1.1703378532956776e-07
most O 0 1.8056685746614676e-07
frequently O 0 3.082795728914789e-06
reported O 0 3.4542588309705025e-06
mutation O 0 7.699433126617805e-07
of O 0 5.883046938492953e-09
this O 0 1.1019884560425908e-08
enzyme O 0 3.447133565259719e-07
, O 0 1.1976882774433761e-07
was O 0 8.947951641857799e-07
found O 0 2.9676607837814117e-08
in O 0 1.0627251967321172e-08
six O 0 5.605706832056967e-08
of O 0 1.4124680092209019e-08
eight O 0 6.471268534369301e-07
unrelated O 0 1.0146359272766858e-05
patients O 0 3.314264631626429e-06
studied O 0 9.196454584525782e-07
, O 0 2.0853315518820636e-08
an O 0 1.189657883315931e-08
allele O 0 5.724298830500629e-07
frequency O 0 2.1799899059260497e-06
of O 0 3.2405094430032477e-07
37 O 0 1.754045661073178e-05
. O 0 4.891146545560332e-06

5 O 0 6.8828894654870965e-06
% O 0 9.858776195414976e-08
, O 0 4.784966378679201e-08
which O 0 2.758445383221897e-08
is O 0 2.8761743209315682e-08
considerably O 0 3.685467788727692e-07
higher O 0 2.066631026309551e-07
than O 0 8.268496998198316e-09
those O 0 1.3679590793458374e-08
in O 0 2.990554293091918e-08
other O 0 1.981414321505781e-08
Asian O 0 7.809725275365054e-07
populations O 0 1.7521394966024673e-06
. O 0 3.407659505683114e-06

The O 0 7.024186743365135e-07
novel O 0 1.0661419764801394e-06
single O 0 8.132314519571082e-07
nucleotide O 0 6.6676475398708135e-06
deletion O 0 1.5840070773265325e-05
, O 0 5.603909585261135e-07
2304delC O 0 1.9575516489567235e-05
, O 0 2.400248320100218e-07
was O 0 2.119732243954786e-06
found O 0 1.600323003003723e-07
in O 0 1.0208287193336218e-07
one O 0 1.5290921737687313e-06
patient O 0 6.829138874309137e-05
. O 0 4.35805122833699e-06

Since O 0 1.0923768059001304e-05
a O 0 1.996396576942061e-06
mutation O 0 1.1459779670985881e-05
at O 0 2.76114110420167e-06
cDNA O 0 2.0497323021118063e-06
nucleotide O 0 3.018652023456525e-05
2302 O 0 0.0013149994192644954
( O 0 5.97396251578175e-07
2302insC O 0 2.8053047572029755e-05
) O 0 1.6029808591611072e-07
had O 0 6.842495281489391e-07
been O 0 3.3196502613463963e-07
previously O 0 6.749021963514679e-07
described O 0 8.995935445454961e-07
, O 0 8.923650796077709e-08
this O 0 1.7810846131283142e-08
region O 0 3.5592785252447356e-07
of O 0 2.094763473792227e-08
the O 0 3.0464511269201466e-07
ATP7B O 0 0.00029436772456392646
gene O 0 6.776116606488358e-06
may O 0 2.048893975370447e-06
be O 0 1.2257727632913884e-07
susceptible O 0 7.2179382186732255e-06
to O 0 1.8043671445866494e-07
gene O 0 3.959076275350526e-05
rearrangements O 0 0.019557982683181763
causing O 1 0.8517948985099792
Wilson B-Disease 1 0.7438349723815918
disease I-Disease 1 0.9977030158042908
. O 0 1.5763369447086006e-05

Disruption O 0 0.00021011974604334682
of O 0 1.4827523386884423e-07
splicing O 0 6.291312274697702e-06
regulated O 0 6.804895747336559e-06
by O 0 1.6768858301929868e-07
a O 0 1.1186388064743369e-06
CUG O 0 0.00020482596301008016
- O 0 1.873008477559779e-05
binding O 0 7.828777597751468e-06
protein O 0 1.5500938388868235e-05
in O 0 4.419188917381689e-05
myotonic B-Disease 1 0.9999010562896729
dystrophy I-Disease 1 0.9999887943267822
. O 0 8.730796253075823e-05

Myotonic B-Disease 1 0.9999657869338989
dystrophy I-Disease 1 0.999988317489624
( O 0 0.001104673370718956
DM B-Disease 1 0.9999393224716187
) O 0 6.7036526161246e-06
is O 0 1.7019596043610363e-06
caused O 0 3.824878604063997e-06
by O 0 6.821359477271471e-08
a O 0 9.428603107153322e-07
CTG O 0 5.027141742175445e-05
expansion O 0 1.1950544376304606e-06
in O 0 1.1127140453481843e-07
the O 0 9.865905781225592e-08
3 O 0 1.843757900132914e-06
untranslated O 0 9.950374806066975e-05
region O 0 4.635122877516551e-06
of O 0 3.297833757187618e-07
the O 0 1.8528304281062447e-05
DM B-Disease 1 0.9995754361152649
gene O 0 0.00016349367797374725
. O 0 1.2462448466976639e-05

One O 0 1.677538080002705e-06
model O 0 7.552863735327264e-06
of O 0 7.041510343697155e-06
DM B-Disease 1 0.999864935874939
pathogenesis O 0 0.04486195743083954
suggests O 0 4.516908575169509e-06
that O 0 7.45271862001573e-08
RNAs O 0 1.0015679436037317e-05
from O 0 3.328576880790024e-08
the O 0 7.054770545522615e-09
expanded O 0 7.976772309348235e-08
allele O 0 1.3675943932867085e-07
create O 0 1.7419409914509743e-08
a O 0 1.1664378973819112e-07
gain O 0 3.434178950101341e-07
- O 0 5.5233122111530975e-06
of O 0 8.157172715073102e-08
- O 0 1.1151546459586825e-05
function O 0 1.0117180408997228e-06
mutation O 0 1.5294903050744324e-06
by O 0 1.2895818635172418e-08
the O 0 3.007950510891533e-08
inappropriate O 0 1.5243761026795255e-06
binding O 0 5.389412081058254e-07
of O 0 1.726744258689905e-08
proteins O 0 5.868984587209525e-08
to O 0 2.7434127858327884e-08
the O 0 4.585881470120512e-07
CUG O 0 0.0017028999282047153
repeats O 0 0.00020421756198629737
. O 0 5.664795480697649e-06

Data O 0 4.94412734042271e-06
presented O 0 3.588457275327528e-06
here O 0 6.196069648467528e-07
indicate O 0 1.5662405417060654e-07
that O 0 3.788114266711773e-09
the O 0 3.8895045406661666e-08
conserved O 0 2.34302865464997e-06
heterogeneous O 0 7.99822955741547e-05
nuclear O 0 0.002064309548586607
ribonucleoprotein O 0 0.001597684109583497
, O 0 2.0776076326001203e-06
CUG O 0 0.0001439309271518141
- O 0 7.001934591244208e-06
binding O 0 1.848585384323087e-06
protein O 0 2.0318716451583896e-06
( O 0 5.543811880670546e-07
CUG O 0 0.00016418859013356268
- O 0 6.681705417577177e-05
BP O 0 0.0001321752497460693
) O 0 1.267607530053283e-07
, O 0 8.282390240310633e-08
may O 0 1.8275387958510692e-07
mediate O 0 4.648163212550571e-06
the O 0 4.855004931414442e-07
trans O 0 3.3090676879510283e-05
- O 0 3.888187347911298e-05
dominant O 0 2.4381250113947317e-05
effect O 0 1.0874601912291837e-06
of O 0 2.6033479372244983e-08
the O 0 3.4343102583989094e-07
RNA O 0 2.3844926545280032e-05
. O 0 2.1801561160827987e-06

CUG O 0 0.03460764139890671
- O 0 0.002766295801848173
BP O 0 0.0015537848230451345
was O 0 6.0440916058723815e-06
found O 0 1.1752310768997631e-07
to O 0 5.023070848153566e-09
bind O 0 2.5744324716470146e-07
to O 0 5.374713296646405e-08
the O 0 4.909513222628448e-07
human O 0 2.6521634936216287e-05
cardiac O 1 0.9418869614601135
troponin O 1 0.94682377576828
T O 0 0.14411379396915436
( O 0 8.646828177916177e-07
cTNT O 0 8.992959919851273e-06
) O 0 8.74481074220057e-08
pre O 0 7.157712843763875e-06
- O 0 5.832109309267253e-06
messenger O 0 3.435906364757102e-06
RNA O 0 9.708472816782887e-07
and O 0 3.4180700936303765e-08
regulate O 0 1.830849782891164e-07
its O 0 3.706799489577861e-08
alternative O 0 6.00885073254176e-07
splicing O 0 2.5341319997096434e-05
. O 0 4.718417585536372e-06

Splicing O 0 0.0001290783693548292
of O 0 3.768662054426386e-06
cTNT O 0 0.000732593412976712
was O 0 0.00018405744049232453
disrupted O 0 0.0035413186997175217
in O 0 4.510305370786227e-05
DM B-Disease 1 0.9997599720954895
striated O 1 0.9773573279380798
muscle O 0 0.0015975238056853414
and O 0 7.24761434867105e-07
in O 0 2.6316683943150565e-07
normal O 0 2.144436848539044e-06
cells O 0 1.1265944976912579e-06
expressing O 0 6.354799211294448e-07
transcripts O 0 3.1782219593878835e-06
that O 0 7.18756609785487e-08
contain O 0 3.906258370989235e-06
CUG O 0 0.0026041301898658276
repeats O 0 0.00046517912414856255
. O 0 1.0656403901521116e-05

Altered O 0 5.123545997776091e-05
expression O 0 2.489901362423552e-06
of O 0 1.144742398651033e-07
genes O 0 2.514863354008412e-06
regulated O 0 3.494761767797172e-05
posttranscriptionally O 0 0.0002550436183810234
by O 0 1.3707847301702714e-06
CUG O 0 0.0017845389666035771
- O 0 0.00041425233939662576
BP O 0 0.0003327019221615046
therefore O 0 4.0606505535834003e-07
may O 0 3.9898995396470127e-07
contribute O 0 2.8398460472089937e-07
to O 0 1.6463849306092015e-06
DM B-Disease 1 0.999863862991333
pathogenesis O 0 0.024121996015310287
. O 0 2.789992777252337e-06
. O 0 3.6638070923800115e-06

Identification O 0 1.2231377013449674e-06
of O 0 2.2633301455243782e-07
a O 0 2.0382080947456416e-06
novel O 0 6.056919119146187e-06
nonsense O 0 0.00011700454342644662
mutation O 0 2.7328604119247757e-05
and O 0 2.3966023832144856e-07
a O 0 6.298698735918151e-07
missense O 0 1.8646678654477e-05
substitution O 0 4.310202825763554e-07
in O 0 1.579179667032804e-07
the O 0 2.6419809273647843e-07
vasopressin O 0 4.3075251596746966e-05
- O 0 7.238647958729416e-05
neurophysin O 0 0.00012562084884848446
II O 0 0.00029992443160153925
gene O 0 1.2254097327968339e-06
in O 0 1.7663553819602384e-07
two O 0 1.9918427085485746e-07
Spanish O 0 1.561702993058134e-05
kindreds O 0 0.0003319428360555321
with O 0 4.025410089525394e-05
familial B-Disease 1 0.998069703578949
neurohypophyseal I-Disease 1 0.9988184571266174
diabetes I-Disease 1 0.9998824596405029
insipidus I-Disease 1 0.9934037327766418
. O 0 7.28390587028116e-05

Familial B-Disease 1 0.9955001473426819
neurohypophyseal I-Disease 1 0.9985688924789429
diabetes I-Disease 1 0.9999309778213501
insipidus I-Disease 1 0.9944721460342407
( O 0 8.11382124084048e-05
FNDI B-Disease 1 0.9994004964828491
) O 0 1.2771416777468403e-06
is O 0 9.411453447683016e-07
an O 0 2.7216278795094695e-06
autosomal B-Disease 1 0.9990222454071045
dominant I-Disease 1 0.9997525811195374
disease I-Disease 1 0.9999622106552124
caused O 1 0.5621852278709412
by O 0 6.159289478091523e-05
deficiency O 1 0.9993547797203064
in O 0 1.3655161410497385e-06
the O 0 1.8340808765060501e-06
antidiuretic O 0 0.0025693036150187254
hormone O 0 0.00014659753651358187
arginine O 0 5.087706813355908e-05
vasopressin O 0 2.6978559617418796e-05
( O 0 1.1083061934868965e-07
AVP O 0 4.968625489709666e-06
) O 0 5.242950074091368e-09
encoded O 0 4.029382161263584e-09
by O 0 3.073930443520112e-08
the O 0 3.570426372334623e-07
AVP O 0 0.0005488746101036668
- O 0 0.00026000666548497975
neurophysin O 0 0.0010257951216772199
II O 0 0.01944108121097088
( O 0 3.873960395139875e-06
AVP O 0 0.00044675273238681257
- O 0 9.65230428846553e-05
NPII O 0 0.000199623653315939
) O 0 1.1850666226109752e-07
gene O 0 5.492649393090687e-07
on O 0 2.0941856746503618e-06
chromosome O 0 9.37536678975448e-05
20p13 O 0 0.0002931634080596268
. O 0 6.979274076002184e-06

In O 0 1.0135469210581505e-06
this O 0 6.168041011278547e-08
study O 0 1.2858832576512214e-07
, O 0 4.9574936156204785e-08
we O 0 2.5715216622756998e-08
analyzed O 0 2.1848340736596583e-07
two O 0 3.0509685444712886e-08
families O 0 1.8199688867071018e-08
with O 0 2.1444030551265314e-07
FNDI B-Disease 0 0.3512744903564453
using O 0 6.306957800461532e-08
direct O 0 7.641236265953921e-08
automated O 0 1.0521211152081378e-05
fluorescent O 0 3.544598803273402e-05
, O 0 2.626465800403821e-07
solid O 0 2.629734126458061e-06
phase O 0 3.334367647767067e-06
, O 0 9.587493821072712e-08
single O 0 5.683327799488325e-07
- O 0 4.467432518140413e-06
stranded O 0 1.2541261185106123e-06
DNA O 0 1.2197823195947421e-07
sequencing O 0 6.669650076673861e-08
of O 0 7.556290881893801e-08
PCR O 0 2.2236592485569417e-05
- O 0 6.290317105595022e-05
amplified O 0 0.0001005010271910578
AVP O 0 0.0012148767709732056
- O 0 0.00029754030401818454
NPII O 0 0.0008001377573236823
DNA O 0 2.85791938949842e-05
. O 0 4.2846072574320715e-06

In O 0 1.1319966688461136e-06
one O 0 1.562522555786927e-07
of O 0 2.3350951394718322e-08
the O 0 1.426011522198678e-07
families O 0 6.124594875700495e-08
, O 0 2.0296198499636375e-07
affected O 0 1.931282014311364e-07
individuals O 0 1.2194386833641602e-08
presented O 0 7.151546128625341e-07
a O 0 1.2730595244647702e-06
novel O 0 1.7168481463158969e-06
nonsense O 0 4.802050898433663e-05
mutation O 0 6.333204055408714e-06
in O 0 1.2458087894628989e-07
exon O 0 5.880833668925334e-06
3 O 0 4.353181566330022e-07
of O 0 7.579195049345344e-09
the O 0 1.8927424960679673e-08
gene O 0 1.0964684804548597e-07
, O 0 1.3728834957760228e-08
consisting O 0 1.642261793222133e-08
in O 0 3.1544644230052654e-08
a O 0 5.220999241828395e-07
G O 0 1.7251137251150794e-05
to O 0 1.7511862893115904e-07
T O 0 0.0003200482460670173
transition O 0 3.2072207432065625e-06
at O 0 6.113325980550144e-06
nucleotide O 0 1.0487191502761561e-05
2101 O 0 0.00026283456827513874
, O 0 1.6659494406212616e-07
which O 0 1.3255198716422001e-08
produces O 0 1.373419706851564e-07
a O 0 2.2415402156639175e-07
stop O 0 1.0129151633009315e-06
signal O 0 1.1413972060836386e-06
in O 0 2.934279166311171e-07
codon O 0 5.679617515852442e-06
82 O 0 1.1747009011742193e-05
( O 0 6.014021778355527e-07
Glu O 0 0.0008948356262408197
) O 0 5.889236263101338e-07
of O 0 8.829615580907557e-07
NPII O 0 0.005156745668500662
. O 0 2.6325536964577623e-05

The O 0 3.238478166167624e-05
premature O 0 0.0019085382809862494
termination O 0 9.446567128179595e-05
eliminates O 0 1.8241054931422696e-05
part O 0 7.758310971439641e-07
of O 0 6.005722497093302e-08
the O 0 3.903499816715339e-07
C O 0 3.1782055884832516e-05
- O 0 8.328364856424741e-06
terminal O 0 7.841391379770357e-06
domain O 0 4.7108451894928294e-07
of O 0 1.326423415548561e-07
NPII O 0 0.0002203891781391576
, O 0 1.6609902786512976e-07
including O 0 3.2185340614887537e-08
a O 0 2.8096826554246945e-07
cysteine O 0 2.2754941255698213e-06
residue O 0 2.849799329851521e-06
in O 0 1.2015931361020193e-07
position O 0 8.515833087585634e-07
85 O 0 5.158775024938222e-07
, O 0 3.481704524688212e-08
which O 0 1.0370523106928431e-08
could O 0 2.0764488795066427e-08
be O 0 7.601345330954246e-09
involved O 0 2.3983531605153985e-08
in O 0 2.968113577139775e-08
the O 0 1.4862349928534968e-07
correct O 0 1.3458257853926625e-05
folding O 0 9.718220098875463e-05
of O 0 2.9131388146197423e-07
the O 0 2.4895023216231493e-06
prohormone O 0 0.01457369327545166
. O 0 1.986971437872853e-05

In O 0 1.073403950613283e-06
the O 0 2.256386295584889e-07
second O 0 1.1940039712499129e-06
family O 0 1.0751680292742094e-06
, O 0 1.447887854055807e-07
a O 0 3.7122660501154314e-07
G279A O 0 5.2240147851989605e-06
substitution O 0 4.715313366432383e-07
at O 0 5.333636636351002e-06
position O 0 1.6145378367582452e-06
- O 0 3.5279683743283385e-06
1 O 0 1.958726727480098e-07
of O 0 7.21131909742212e-09
the O 0 3.1542775502657605e-08
signal O 0 1.4066495168663096e-06
peptide O 0 1.559151201036002e-06
was O 0 9.024772680277238e-07
observed O 0 4.061800780164049e-07
in O 0 2.4797293107781115e-08
all O 0 1.8676113100468683e-08
affected O 0 5.190031515667215e-07
individuals O 0 1.1383812648091407e-07
. O 0 3.7024831271992298e-06

This O 0 2.6452785277797375e-06
missense O 0 0.000500079826451838
mutation O 0 9.961292380467057e-05
, O 0 7.516867412959982e-07
which O 0 6.028412258274329e-07
replaces O 0 0.0002471991756465286
Ala O 0 0.00018062653543893248
with O 0 9.227395025845908e-07
Thr O 0 0.0013534319587051868
, O 0 9.210242524204659e-07
is O 0 2.439479374061193e-07
frequent O 0 5.510485607373994e-06
among O 0 8.652926226204727e-06
FNDI B-Disease 1 0.9998030066490173
patients O 0 4.98597692057956e-05
and O 0 2.1146935580418358e-07
is O 0 9.726890937145072e-08
thought O 0 7.208833352478905e-08
to O 0 1.106943070539046e-08
reduce O 0 2.7935209345741896e-07
the O 0 8.075620172576237e-08
efficiency O 0 1.2179125405964442e-06
of O 0 6.402368768476663e-08
cleavage O 0 1.9092121874564327e-05
by O 0 3.881457075749495e-07
signal O 0 1.4972767530707642e-05
peptidases O 0 0.0002263689530082047
. O 0 1.599189317857963e-06
. O 0 3.0491182769765146e-06

Genetic O 0 0.0007531593437306583
heterogeneity O 0 0.0008517408859916031
of O 0 2.70893160632113e-05
Saethre B-Disease 1 0.9851009249687195
- I-Disease 1 0.9991592168807983
Chotzen I-Disease 1 0.9979650974273682
syndrome I-Disease 1 0.9999734163284302
, O 0 2.2963174615142634e-06
due O 0 1.4978189710745937e-06
to O 0 9.698435832206087e-08
TWIST O 0 5.372925807023421e-05
and O 0 5.132886599312769e-06
FGFR O 0 0.005749687552452087
mutations O 0 0.0004939756472595036
. O 0 1.0772345376608428e-05

Thirty O 0 4.7142795665422454e-05
- O 0 7.162040856201202e-05
two O 0 6.910342449373275e-07
unrelated O 0 3.3326319680782035e-05
patients O 0 2.8293916329857893e-06
with O 0 3.7628328897199026e-08
features O 0 2.326707317479304e-06
of O 0 3.2695479603717104e-06
Saethre B-Disease 1 0.9262308478355408
- I-Disease 1 0.9973950386047363
Chotzen I-Disease 1 0.9930369257926941
syndrome I-Disease 1 0.9999310970306396
, O 0 6.140796813269844e-07
a O 0 1.2887514913018094e-06
common O 0 2.4163966372725554e-05
autosomal B-Disease 1 0.9981233477592468
dominant I-Disease 1 0.9952085614204407
condition I-Disease 1 0.9970211386680603
of O 0 2.9913077014498413e-05
craniosynostosis B-Disease 1 0.9990335702896118
and O 0 0.0008858014480210841
limb B-Disease 1 0.998729407787323
anomalies I-Disease 1 0.6693519353866577
, O 0 4.584132682339259e-07
were O 0 5.1816630985968004e-08
screened O 0 4.7384295953634137e-07
for O 0 4.310424372988564e-08
mutations O 0 2.11193946597632e-06
in O 0 2.006810291277361e-07
TWIST O 0 2.8307895263424143e-05
, O 0 1.2941385421072482e-06
FGFR2 O 0 0.00037965105730108917
, O 0 9.637129778639064e-07
and O 0 1.9441026779531967e-06
FGFR3 O 0 0.004121746402233839
. O 0 8.312922545883339e-06

Nine O 0 4.8608562792651355e-06
novel O 0 1.8139322719434858e-06
and O 0 6.089894668548368e-07
three O 0 9.298968279836117e-07
recurrent O 0 0.0011842161184176803
TWIST O 0 7.280738645931706e-05
mutations O 0 2.0880814190604724e-05
were O 0 1.779448695060637e-07
found O 0 1.1126503096647866e-07
in O 0 6.994587664621577e-08
12 O 0 4.897883059129526e-07
families O 0 1.4707561035720573e-07
. O 0 1.8172653426518082e-06

Seven O 0 1.5882521893217927e-06
families O 0 7.305364846388329e-08
were O 0 4.518578577972221e-08
found O 0 5.3164139757200246e-08
to O 0 8.2600157824686e-09
have O 0 3.644183976803106e-08
the O 0 3.114813580396003e-07
FGFR3 O 0 0.0007040697382763028
P250R O 0 0.0001106158088077791
mutation O 0 2.0813036826439202e-05
, O 0 1.8512268695758394e-07
and O 0 5.369446398617583e-08
one O 0 3.905539358584065e-08
individual O 0 2.23036593638426e-08
was O 0 6.442471203627065e-06
found O 0 1.305587602473679e-07
to O 0 1.4960608751835025e-08
have O 0 3.305623152982662e-08
an O 0 2.0471212280881446e-07
FGFR2 O 0 0.00041081052040681243
VV269 O 0 0.00015967224317137152
- O 0 0.00011773694859584793
270 O 0 1.41161544888746e-05
deletion O 0 0.00011732855637092143
. O 0 7.018734777375357e-06

To O 0 4.027994009447866e-07
date O 0 2.487852952981484e-06
, O 0 1.1762940488324602e-07
our O 0 7.855965833414302e-08
detection O 0 6.305770511971787e-06
rate O 0 1.4622894468629966e-06
for O 0 4.767839456576439e-08
TWIST O 0 2.8535108867799863e-05
or O 0 4.420428922458086e-06
FGFR O 0 0.0004885016242042184
mutations O 0 1.629280268389266e-05
is O 0 5.135302671988029e-07
68 O 0 1.494377443123085e-06
% O 0 2.5254758284631862e-08
in O 0 1.0541376127548574e-07
our O 0 2.6447387426742353e-06
Saethre B-Disease 0 0.06883745640516281
- I-Disease 1 0.9943453669548035
Chotzen I-Disease 1 0.9872065782546997
syndrome I-Disease 1 0.9998735189437866
patients O 0 5.3953473980072886e-05
, O 0 1.174397539216443e-07
including O 0 4.7790106094680596e-08
our O 0 1.9765835190810321e-07
five O 0 9.839593531069113e-07
patients O 0 4.959256784786703e-06
elsewhere O 0 3.6169019494991517e-06
reported O 0 4.134140908718109e-06
with O 0 3.221753104298841e-07
TWIST O 0 0.00030231435084715486
mutations O 0 0.00043713764171116054
. O 0 9.95211667031981e-06

More O 0 3.068359433200385e-08
than O 0 4.304722267534089e-08
35 O 0 1.6553353532344772e-07
different O 0 2.2748158912122562e-08
TWIST O 0 1.0966606168949511e-05
mutations O 0 3.390275878700777e-06
are O 0 2.0748494478084467e-08
now O 0 1.9328666667206562e-07
known O 0 4.119372363220464e-07
in O 0 8.816962093760594e-08
the O 0 1.563630291911977e-07
literature O 0 1.5891400835243985e-06
. O 0 4.147464551351732e-06

The O 0 1.3234100606496213e-06
most O 0 2.023923713068143e-07
common O 0 3.4371018386991636e-07
phenotypic O 0 4.046670255775098e-06
features O 0 2.5437507247261237e-06
, O 0 1.2883272404451418e-07
present O 0 2.6472060099536066e-08
in O 0 1.3054849645754985e-08
more O 0 1.3545197186104474e-09
than O 0 8.30426305498122e-09
a O 0 9.212133278424517e-08
third O 0 3.546274740529043e-07
of O 0 2.359711359645189e-08
our O 0 4.348858055891469e-07
patients O 0 1.5325433651014464e-06
with O 0 2.2985955183685292e-07
TWIST O 0 0.00013321940787136555
mutations O 0 5.978492845315486e-05
, O 0 6.430125267797848e-07
are O 0 8.926799921482598e-08
coronal B-Disease 0 0.0006902664317749441
synostosis I-Disease 0 0.000978952506557107
, O 0 3.1652698453399353e-06
brachycephaly B-Disease 0 0.00033006080775521696
, O 0 4.384155090519926e-06
low B-Disease 0 0.0031111184507608414
frontal I-Disease 1 0.998066246509552
hairline I-Disease 1 0.9999023675918579
, O 0 6.469453364843503e-05
facial B-Disease 1 0.9942500591278076
asymmetry I-Disease 0 0.12747587263584137
, O 0 7.987688150024042e-05
ptosis B-Disease 1 0.9943325519561768
, O 0 1.662029535509646e-05
hypertelorism B-Disease 0 0.01488175056874752
, O 0 1.608393858987256e-06
broad B-Disease 0 1.367553704767488e-05
great I-Disease 0 0.00012459157733246684
toes I-Disease 0 0.10657275468111038
, O 0 2.747225380517193e-06
and O 0 2.0414081518538296e-06
clinodactyly B-Disease 0 0.0016385153867304325
. O 0 8.827721103443764e-06

Significant O 0 1.1913848538824823e-05
intra O 0 0.0007774670957587659
- O 0 0.0006783207063563168
and O 0 2.2867368443257874e-06
interfamilial O 0 0.0002389781002420932
phenotypic O 0 6.597748870262876e-05
variability O 0 9.615319140721112e-05
is O 0 1.5540726394647209e-07
present O 0 4.9233353394129153e-08
for O 0 2.4320499392160855e-08
either O 0 1.2529413879747153e-06
TWIST O 0 0.00025525622186250985
mutations O 0 0.00021153473062440753
or O 0 3.0799736123299226e-05
FGFR O 0 0.01921331137418747
mutations O 0 0.0014491119654849172
. O 0 1.9169274310115725e-05

The O 0 5.472227257996565e-07
overlap O 0 2.6637867449608166e-06
in O 0 5.799601581202296e-07
clinical O 0 1.909671937028179e-06
features O 0 6.405691692634718e-07
and O 0 2.4008161858546373e-07
the O 0 8.014487207219645e-08
presence O 0 2.748247709405405e-07
, O 0 9.545744461547656e-08
in O 0 1.4433543249481318e-08
the O 0 1.130311755304092e-08
same O 0 2.2478889860622076e-08
genes O 0 9.975121884053806e-08
, O 0 4.95634040476034e-08
of O 0 1.2335306998068063e-08
mutations O 0 9.508816560810374e-07
for O 0 1.2363407186910536e-08
more O 0 5.634711364166378e-09
than O 0 4.823433741307781e-08
one O 0 3.456337651641661e-07
craniosynostotic B-Disease 0 0.0003523386549204588
condition I-Disease 0 0.0005010727909393609
- O 0 1.0914021004282404e-05
such O 0 1.1866736571164438e-07
as O 0 2.995597697008634e-06
Saethre B-Disease 0 0.00034956104354932904
- I-Disease 0 0.0002354483149247244
Chotzen I-Disease 0 0.0002549517375882715
, I-Disease 0 2.233080977021018e-06
Crouzon I-Disease 0 0.00013016308366786689
, I-Disease 0 1.460654516449722e-06
and I-Disease 0 3.4829051855922444e-06
Pfeiffer I-Disease 1 0.7002077698707581
syndromes I-Disease 1 0.9353998899459839
- O 0 6.898262654431164e-05
support O 0 1.6610488273727242e-07
the O 0 2.1881996303818596e-07
hypothesis O 0 8.611154385107511e-07
that O 0 2.3406691695981863e-08
TWIST O 0 7.703804840275552e-06
and O 0 2.597325021724828e-07
FGFRs O 0 2.763101838354487e-05
are O 0 2.4351738403538548e-08
components O 0 4.063250003127905e-07
of O 0 1.2645812397238387e-08
the O 0 2.0763460284456414e-08
same O 0 2.2456861259456673e-08
molecular O 0 9.548637081024935e-07
pathway O 0 6.313691756076878e-07
involved O 0 3.1588479032507166e-07
in O 0 5.176220341240878e-08
the O 0 8.91946427827861e-08
modulation O 0 8.10369965620339e-06
of O 0 2.764455530268606e-06
craniofacial O 1 0.9980489015579224
and O 0 4.9893536925083026e-05
limb O 0 0.11694544553756714
development O 0 3.8660334666928975e-07
in O 0 3.105885184595536e-07
humans O 0 1.1535792054928606e-06
. O 0 5.001763270229276e-07
. O 0 1.1243555491091684e-06

Mutation O 0 0.0003376496606506407
analysis O 0 6.253865649341606e-06
of O 0 8.338600309798494e-06
UBE3A O 1 0.7991423606872559
in O 0 0.041565146297216415
Angelman B-Disease 1 0.9999852180480957
syndrome I-Disease 1 0.9999997615814209
patients O 0 0.19330523908138275
. O 0 3.068826481467113e-05

Angelman B-Disease 1 0.9999901056289673
syndrome I-Disease 1 0.9999997615814209
( O 0 0.00011854140757350251
AS B-Disease 1 0.9916399717330933
) O 0 1.0811573929458973e-06
is O 0 7.657269520677801e-07
caused O 0 5.834546300320653e-06
by O 0 3.3855511105684855e-07
chromosome O 0 0.00014996176469139755
15q11 O 0 0.0002758305927272886
- O 0 0.0001667359028942883
q13 O 0 9.732242324389517e-05
deletions O 0 1.4706058209412731e-05
of O 0 2.4138239496096503e-07
maternal O 0 3.56361924787052e-05
origin O 0 8.02488671070023e-07
, O 0 5.170921895114589e-07
by O 0 6.68224288347119e-07
paternal O 0 0.0006475842674262822
uniparental B-Disease 1 0.9639382362365723
disomy I-Disease 0 0.38619115948677063
( O 0 2.9084994821459986e-05
UPD B-Disease 1 0.9897835850715637
) O 0 9.610715778762824e-07
15 O 0 1.7216884771187324e-06
, O 0 2.1826224383403314e-07
by O 0 6.435228669943172e-07
imprinting O 0 0.004203231539577246
defects O 1 0.996684730052948
, O 0 5.008207040191337e-07
and O 0 1.7444055799842317e-07
by O 0 1.1808315747430242e-07
mutations O 0 6.697390290355543e-06
in O 0 2.825951526119752e-07
the O 0 1.0041243285741075e-06
UBE3A O 0 0.0010931434808298945
gene O 0 5.294809307088144e-05
. O 0 8.896966392057948e-06

UBE3A O 0 0.002400937955826521
encodes O 0 2.4777330054348568e-06
a O 0 1.8925422864413122e-06
ubiquitin O 0 8.281256668851711e-06
- O 0 8.28775046102237e-06
protein O 0 8.922286838242144e-07
ligase O 0 3.673393621284049e-06
and O 0 1.8772026066926628e-07
shows O 0 2.8687945814453997e-06
brain O 0 0.005074420012533665
- O 0 2.9433218514895998e-05
specific O 0 6.151464049253264e-07
imprinting O 0 0.0003770693438127637
. O 0 1.065455398929771e-05

Here O 0 9.261581908504013e-06
we O 0 1.809231321203697e-06
describe O 0 1.2866851648141164e-05
UBE3A O 0 0.002098121214658022
coding O 0 0.0006990149850025773
- O 0 0.0004994645714759827
region O 0 1.9478831745800562e-05
mutations O 0 6.863348244223744e-05
detected O 0 5.7083467254415154e-05
by O 0 7.798369949796324e-08
SSCP O 0 2.7290632715448737e-05
analysis O 0 1.3370943463542062e-07
in O 0 2.347658352164217e-07
13 O 0 1.7022241536324145e-06
AS B-Disease 0 0.0011548002948984504
individuals O 0 2.922125119653174e-08
or O 0 8.443697652182891e-07
families O 0 5.269560574561183e-07
. O 0 4.974552211933769e-06

Two O 0 1.5906866792647634e-06
identical O 0 2.573451456555631e-05
de O 0 0.0002775870671030134
novo O 0 8.451731991954148e-05
5 O 0 8.701253136678133e-06
- O 0 4.1279698052676395e-05
bp O 0 5.421884634415619e-05
duplications O 0 1.868566141638439e-05
in O 0 4.376671824957157e-07
exon O 0 9.53410108195385e-06
16 O 0 1.5487094060517848e-06
were O 0 2.692327427666896e-07
found O 0 2.1932901290711015e-06
. O 0 1.858462951531692e-06

Among O 0 7.38407891276438e-07
the O 0 1.4188314878538222e-07
other O 0 6.388511764043869e-08
11 O 0 3.654416502740787e-07
unique O 0 2.8337240109976847e-07
mutations O 0 8.459466698695906e-06
, O 0 2.588855068097473e-07
8 O 0 3.8708327565473155e-07
were O 0 3.8353654474576615e-08
small O 0 2.3596579978857335e-07
deletions O 0 9.498932740825694e-06
or O 0 2.972748006868642e-06
insertions O 0 7.643339631613344e-05
predicted O 0 1.1769996490329504e-05
to O 0 5.043806368121295e-07
cause O 0 1.7783944713301025e-05
frameshifts O 0 0.0001392433186993003
, O 0 4.156839281677094e-07
1 O 0 5.248756451692316e-07
was O 0 1.8037562767858617e-06
a O 0 2.2197141902324802e-07
mutation O 0 7.137741704354994e-07
to O 0 7.590262640633227e-09
a O 0 2.37799270053074e-07
stop O 0 6.77119260217296e-07
codon O 0 2.1082933017169125e-06
, O 0 1.20860576657833e-07
1 O 0 2.2977209823693556e-07
was O 0 6.607743330278026e-07
a O 0 5.366327968658879e-07
missense O 0 2.721780583669897e-05
mutation O 0 6.207748356246157e-06
, O 0 1.444271902073524e-07
and O 0 1.3780288554698927e-07
1 O 0 2.492314933988382e-06
was O 0 4.2622665205271915e-05
predicted O 0 2.9794232432323042e-06
to O 0 4.700128997114916e-08
cause O 0 2.2038786937628174e-06
insertion O 0 2.466085106789251e-06
of O 0 9.881989626592258e-08
an O 0 7.836194413357589e-07
isoleucine O 0 0.0006561576155945659
in O 0 3.4656918046493956e-07
the O 0 1.9617141333583277e-07
hect O 0 1.2471614354581106e-05
domain O 0 3.5583690305429627e-07
of O 0 2.5816110138521253e-08
the O 0 1.408919558798516e-07
UBE3A O 0 9.359485557070002e-05
protein O 0 8.599025136390992e-07
, O 0 4.754852511723584e-08
which O 0 4.768382577680086e-09
functions O 0 1.9366337866699723e-08
in O 0 4.870173597737448e-08
E2 O 0 6.4733694671303965e-06
binding O 0 1.1781571629398968e-06
and O 0 2.2177633240971772e-07
ubiquitin O 0 4.794838332600193e-06
transfer O 0 4.271616035111947e-06
. O 0 6.116340955486521e-06

Eight O 0 4.120914582017576e-06
of O 0 7.570110938104335e-08
the O 0 1.8799310907979816e-07
cases O 0 4.200755370220577e-07
were O 0 2.1738767941315018e-07
familial O 0 0.00017067395674530417
, O 0 1.0567864592303522e-06
and O 0 2.7655158874040353e-07
five O 0 2.0304118208969157e-07
were O 0 3.400176353807183e-07
sporadic O 0 3.144260699627921e-05
. O 0 4.498912403505528e-06

In O 0 1.6836188478919212e-06
two O 0 3.3876955285450094e-07
familial O 0 0.0010829097591340542
cases O 0 5.306745606503682e-06
and O 0 2.2336148219892493e-07
one O 0 4.793187713403313e-07
sporadic O 0 6.228454731171951e-05
case O 0 7.558837296528509e-06
, O 0 1.075211116585706e-06
mosaicism O 0 0.0002713144349399954
for O 0 1.4268374570747255e-06
UBE3A O 0 0.0016334294341504574
mutations O 0 0.00013026513624936342
was O 0 2.1218003894318826e-05
detected O 0 1.9100298231933266e-05
in O 0 8.954749119993721e-08
the O 0 1.348945488643949e-07
mother O 0 3.6216617900208803e-06
of O 0 2.794029008157395e-08
three O 0 4.6427402367044124e-07
AS B-Disease 1 0.7131139039993286
sons O 0 0.0001115587874664925
, O 0 2.7348585263098357e-07
in O 0 6.578230227205495e-08
the O 0 9.099861131289799e-08
maternal O 0 9.41522102948511e-06
grandfather O 0 1.3254538316687103e-05
of O 0 2.7665596036285933e-08
two O 0 1.4015634519637388e-07
AS B-Disease 0 0.005834666546434164
first O 0 4.3080535760964267e-07
cousins O 0 6.787797701690579e-06
, O 0 1.8885079100527946e-07
and O 0 6.26710985329737e-08
in O 0 5.560639948498647e-08
the O 0 1.263407511942205e-07
mother O 0 3.218321126041701e-06
of O 0 4.10638882897274e-08
an O 0 1.232472186529776e-06
AS B-Disease 1 0.9994818568229675
daughter O 0 0.007127121556550264
. O 0 1.3292411495058332e-05

The O 0 1.849753203941873e-07
frequencies O 0 1.377147441417037e-06
with O 0 1.3549343691465765e-07
which O 0 8.968834208644694e-08
we O 0 2.6167873556914856e-07
detected O 0 6.168657364469254e-06
mutations O 0 1.4957405483073671e-06
were O 0 1.5056542679303675e-07
5 O 0 2.2233837171370396e-07
( O 0 2.193543835460332e-08
14 O 0 1.2030459117795544e-07
% O 0 4.016728727407326e-09
) O 0 5.81774672880897e-09
of O 0 5.718360451822946e-09
35 O 0 2.1719827714150597e-07
in O 0 4.6103547646225707e-08
sporadic O 0 5.6369026424363256e-06
cases O 0 5.197808263801562e-07
and O 0 1.6867690533217683e-07
8 O 0 7.052108799143753e-07
( O 0 4.545444554082678e-08
80 O 0 1.4821826255229098e-07
% O 0 7.163325044245994e-09
) O 0 7.468282881006871e-09
of O 0 1.3441845858608303e-08
10 O 0 3.0300105891001294e-07
in O 0 4.0463396544510033e-07
familial O 0 0.0013238302199169993
cases O 0 9.443925591767766e-06
. O 0 1.8039627320831642e-06
. O 0 4.386304681247566e-06

The O 0 0.0001429791300324723
hemochromatosis B-Disease 1 0.9989461302757263
845 O 0 0.0018074765102937818
G O 0 0.0007900063646957278
- O 0 4.174842615611851e-05
- O 0 9.409261110704392e-06
> O 0 1.9613132735685213e-06
A O 0 4.556516444154113e-07
and O 0 2.776072278720676e-07
187 O 0 1.194908463730826e-06
C O 0 1.6881440387805924e-05
- O 0 2.0141484128544107e-05
- O 0 5.110122583573684e-05
> O 0 2.6858575438382104e-05
G O 0 0.00011486346193123609
mutations O 0 2.8515463782241568e-05
: O 0 1.0923974969045958e-06
prevalence O 0 1.9913914002245292e-05
in O 0 5.024616598348075e-07
non O 0 2.759578637778759e-05
- O 0 0.0007688975892961025
Caucasian O 0 0.00018492044182494283
populations O 0 6.910527190484572e-06
. O 0 4.351365532784257e-06

Hemochromatosis B-Disease 1 0.9916425943374634
, O 0 0.0001250820205314085
the O 0 0.00036579949664883316
inherited B-Disease 1 0.9999963045120239
disorder I-Disease 1 0.999998927116394
of I-Disease 0 1.8890888895839453e-05
iron I-Disease 1 0.9984593391418457
metabolism I-Disease 1 0.824816882610321
, O 0 4.031397565995576e-06
leads O 0 8.161768164427485e-06
, O 0 7.562893529211578e-07
if O 0 1.7157907450382481e-06
untreated O 0 0.002413638634607196
, O 0 4.152187784711714e-07
to O 0 2.086923700517218e-07
progressive O 0 0.004932229407131672
iron B-Disease 1 0.9979159235954285
overload I-Disease 1 0.6287375688552856
and O 0 1.4854847904643975e-05
premature B-Disease 0 0.0051161847077310085
death I-Disease 0 0.00033577188150957227
. O 0 7.2108728090825025e-06

The O 0 0.0001031918145599775
hemochromatosis B-Disease 1 0.9993067979812622
gene O 0 0.0001722046872600913
, O 0 6.413371011149138e-06
HFE O 0 0.0010664936853572726
, O 0 1.7175228776977747e-06
recently O 0 1.0363610272179358e-05
has O 0 2.639661431658169e-07
been O 0 1.813123020610874e-07
identified O 0 1.820563255705565e-07
, O 0 4.051942070759651e-08
and O 0 5.246594270147398e-08
characterization O 0 9.742558404468582e-07
of O 0 2.8134303775573244e-08
this O 0 1.4098007206087004e-08
gene O 0 2.5907024792104494e-07
has O 0 1.099886830502328e-07
shown O 0 4.2931286969860594e-08
that O 0 2.386296493739337e-09
it O 0 5.2109374593101165e-09
contains O 0 2.046589564486112e-08
two O 0 4.814839371647395e-08
mutations O 0 1.7481138456787448e-06
that O 0 1.8154757697175228e-08
result O 0 1.6503183530858223e-07
in O 0 4.374914652771622e-08
amino O 0 1.5763149008307664e-07
acid O 0 7.686659841965593e-07
substitutions O 0 5.643872214022849e-07
- O 0 9.254961810256646e-07
cDNA O 0 5.207721756050887e-07
nucleotides O 0 1.998751258724951e-06
845 O 0 2.686861807887908e-05
G O 0 6.005022078170441e-05
- O 0 2.111892717948649e-05
- O 0 1.835808507166803e-05
> O 0 4.3596146497293375e-06
A O 0 1.388055693496426e-06
( O 0 8.454190947304596e-08
C282Y O 0 1.636650949876639e-06
) O 0 2.138060040124401e-08
and O 0 5.8017040061031366e-08
187 O 0 1.728855295368703e-06
C O 0 2.0864092221017927e-05
- O 0 2.633952499309089e-05
- O 0 5.1668077503563836e-05
> O 0 4.013145007775165e-05
G O 0 0.00010621685942169279
( O 0 8.735006531424006e-07
H63D O 0 0.00021050557552371174
) O 0 1.068150936589518e-06
. O 0 2.8820916213589953e-06

Although O 0 0.00047162690316326916
hemochromatosis B-Disease 1 0.9997908473014832
is O 0 6.57693362882128e-06
common O 0 2.201740244345274e-06
in O 0 4.694682047556853e-07
Caucasians O 0 7.020917564659612e-06
, O 0 5.385984991335135e-07
affecting O 0 5.41942790732719e-06
> O 0 1.9485818484099582e-05
= O 0 1.3160451089788694e-05
1 O 0 1.4776635453017661e-06
/ O 0 3.9732335608277936e-06
300 O 0 1.8272635315952357e-07
individuals O 0 8.481158886297635e-09
of O 0 1.755255141233647e-08
northern O 0 4.1207397316611605e-07
European O 0 4.337244092766923e-07
origin O 0 1.241631224502271e-07
, O 0 1.5159098154526873e-07
it O 0 1.4036564799368989e-08
has O 0 5.676785264085993e-08
not O 0 7.213782016179948e-09
been O 0 7.383573574770708e-08
recognized O 0 1.557153979092618e-07
in O 0 7.605800789178829e-08
other O 0 6.677388597609024e-08
populations O 0 1.7491911421529949e-06
. O 0 4.4657158468908165e-06

The O 0 7.080601562847733e-07
present O 0 1.9415051610849332e-07
study O 0 6.981658629001686e-08
used O 0 5.413768633388827e-08
PCR O 0 1.6716611526135239e-06
and O 0 1.0185414822672101e-07
restriction O 0 4.6746131943109503e-07
- O 0 4.7122071009653155e-06
enzyme O 0 1.0947441069220076e-06
digestion O 0 3.8658631638099905e-06
to O 0 1.6186769258297318e-08
analyze O 0 1.8920863453786296e-07
the O 0 3.545279980698979e-08
frequency O 0 8.564144877709623e-07
of O 0 3.6672638259460655e-08
the O 0 3.1256686838787573e-07
845 O 0 2.7225620215176605e-05
G O 0 4.209700273349881e-05
- O 0 8.541415809304453e-06
- O 0 6.3002639762999024e-06
> O 0 1.5744113852633745e-06
A O 0 3.46874685419607e-07
and O 0 1.0914190795574541e-07
187 O 0 9.081513780984096e-07
C O 0 1.1382318007235881e-05
- O 0 1.2190454981464427e-05
- O 0 1.6727883121347986e-05
> O 0 1.3904570550948847e-05
G O 0 3.418085543671623e-05
mutations O 0 1.0020781701314263e-05
in O 0 6.592624686163617e-07
HLA O 0 2.8960390409338288e-05
- O 0 4.053831617056858e-06
typed O 0 2.251902969874209e-06
samples O 0 4.791090191247349e-07
from O 0 3.120114513421868e-07
non O 0 5.524286734726047e-06
- O 0 8.194683323381469e-05
Caucasian O 0 2.833968392224051e-05
populations O 0 7.695806516494486e-07
, O 0 1.257517396879848e-07
comprising O 0 2.184521576964471e-07
Australian O 0 1.1928840422115172e-06
Aboriginal O 0 3.172058029576874e-07
, O 0 8.893473335547242e-08
Chinese O 0 9.483461838044605e-08
, O 0 4.272787634818087e-07
and O 0 2.6381742372905137e-06
Pacific O 0 6.92704415996559e-05
Islanders O 0 0.00016187144501600415
. O 0 4.644538876164006e-06

Results O 0 1.6268088074866682e-05
showed O 0 4.203073785902234e-06
that O 0 4.10852720733601e-08
the O 0 1.9422867580942693e-07
845 O 0 3.199382990715094e-05
G O 0 6.611213757423684e-05
- O 0 3.8804675568826497e-05
- O 0 2.5561199436197057e-05
> O 0 3.699239641719032e-06
A O 0 1.474546820645628e-06
mutation O 0 1.3277993957672152e-06
was O 0 5.550265882448002e-07
present O 0 2.36813821885562e-08
in O 0 1.4659718772236374e-08
these O 0 2.064935111789623e-09
populations O 0 1.1793353849043342e-08
( O 0 5.4324265086336254e-09
allele O 0 7.263432877380183e-08
frequency O 0 6.486567372121499e-07
0 O 0 2.4727117420297873e-07
. O 0 1.717927133881858e-08
32 O 0 1.2421936901318986e-07
% O 0 4.822309218610599e-09
) O 0 1.198519683498489e-08
, O 0 3.405718729254659e-08
and O 0 6.174750666332329e-08
, O 0 1.1129070998094903e-07
furthermore O 0 3.0023107910892577e-07
, O 0 1.1043496783713636e-07
it O 0 5.532119473627972e-08
was O 0 4.0381119106314145e-06
always O 0 4.5841761675546877e-07
seen O 0 8.11535528555396e-07
in O 0 4.8509832595300395e-08
conjunction O 0 5.991404350425e-07
with O 0 1.2260057928870083e-06
HLA O 0 0.0001661737187532708
haplotypes O 0 3.75024501408916e-05
common O 0 3.3554565561644267e-06
in O 0 6.775093766009377e-07
Caucasians O 0 5.680094545823522e-06
, O 0 1.965393749969735e-07
suggesting O 0 4.352019686848507e-07
that O 0 8.048173327779296e-08
845 O 0 1.5377378076664172e-05
G O 0 6.670456059509888e-05
- O 0 3.98526644858066e-05
- O 0 3.0023218641872518e-05
> O 0 6.716898951708572e-06
A O 0 3.171028538417886e-06
may O 0 3.823124927748722e-07
have O 0 9.939792100510658e-09
been O 0 1.294367368842586e-08
introduced O 0 2.985709812719506e-08
into O 0 1.1513987985267704e-08
these O 0 8.084755975801272e-09
populations O 0 7.468941731758605e-08
by O 0 8.819854713237874e-08
Caucasian O 0 4.1490049625281245e-05
admixture O 0 0.00016895405133254826
. O 0 1.827608866733499e-05

187 O 0 7.098622154444456e-05
C O 0 8.837882342049852e-05
- O 0 3.111841215286404e-05
- O 0 3.094989006058313e-05
> O 0 1.3966461665404495e-05
G O 0 3.1081101042218506e-05
was O 0 1.1876308008140768e-06
present O 0 3.483491539668648e-08
at O 0 5.802290843348601e-07
an O 0 1.4776838419550131e-08
allele O 0 1.9400876283270918e-07
frequency O 0 1.5358557448053034e-06
of O 0 3.090367499680724e-07
2 O 0 1.3943889825895894e-05
. O 0 3.0472576781903626e-06

68 O 0 3.140274930046871e-05
% O 0 8.101862647436064e-08
in O 0 4.66109781882551e-08
the O 0 3.0930149108598926e-08
two O 0 6.701937849129536e-08
populations O 0 2.9930740197414707e-07
analyzed O 0 1.95910934053245e-06
( O 0 9.428956815327183e-08
Australian O 0 3.436482245433581e-07
Aboriginal O 0 1.212789015880844e-07
and O 0 1.544762113780962e-07
Chinese O 0 3.0163906217239855e-07
) O 0 8.026830755625269e-07
. O 0 2.3037184746499406e-06

In O 0 1.7570774843989057e-06
the O 0 2.862564087990904e-07
Australian O 0 7.084012167979381e-07
Aboriginal O 0 2.0052951299476263e-07
samples O 0 1.4804096792886412e-07
, O 0 1.1516870301875315e-07
187 O 0 4.828606847695482e-07
C O 0 1.0333823411201593e-05
- O 0 1.4358151929627638e-05
- O 0 1.7642101738601923e-05
> O 0 1.1405895747884642e-05
G O 0 2.6782761779031716e-05
was O 0 2.055193363048602e-06
found O 0 5.45531406714872e-08
to O 0 6.9993624229880425e-09
be O 0 3.301414253087387e-08
associated O 0 1.9598085998495662e-07
with O 0 4.413780061440775e-07
HLA O 0 0.00019355244876351207
haplotypes O 0 4.360601815278642e-05
common O 0 6.627499715250451e-06
in O 0 7.633019549757591e-07
Caucasians O 0 5.0432226998964325e-06
, O 0 3.028982007435843e-07
suggesting O 0 3.9171931121018133e-07
that O 0 7.559314951777196e-09
it O 0 2.95272677419689e-08
was O 0 9.755760856933193e-07
introduced O 0 1.9883923130237235e-07
by O 0 6.40580140043312e-08
recent O 0 2.4050011688814266e-06
admixture O 0 0.000106349732959643
. O 0 1.0399250641057733e-05

In O 0 6.368510412357864e-07
the O 0 2.768565643407328e-08
Chinese O 0 4.959139587867867e-08
samples O 0 4.081347526607715e-07
analyzed O 0 1.7195815189552377e-06
, O 0 2.4106768137244217e-07
187 O 0 8.122300414470374e-07
C O 0 1.6755677279434167e-05
- O 0 1.5488672943320125e-05
- O 0 2.183751894335728e-05
> O 0 9.863750165095553e-06
G O 0 2.82720666291425e-05
was O 0 3.2807045045046834e-06
present O 0 1.1069118954765145e-07
in O 0 9.972573167260634e-08
association O 0 1.5959152221967088e-07
with O 0 2.533310805574729e-08
a O 0 3.022181260803336e-07
wide O 0 1.066308755071077e-06
variety O 0 1.2197059504615027e-06
of O 0 3.0787745686211565e-07
HLA O 0 0.00011088490282418206
haplotypes O 0 1.1971078492933884e-05
, O 0 1.986709037282708e-07
showing O 0 3.854322869756288e-07
this O 0 2.6838566924425322e-08
mutation O 0 5.949542583039147e-07
to O 0 1.1142490485838152e-08
be O 0 5.788418633301262e-08
widespread O 0 2.9480062835318677e-07
and O 0 1.8906612808677892e-07
likely O 0 2.2321241033296246e-07
to O 0 2.2309956548838272e-08
predate O 0 2.104203531416715e-06
the O 0 3.720938579476751e-08
more O 0 1.263727611444665e-08
genetically O 0 1.1786111144829192e-06
restricted O 0 1.2803392337445985e-06
845 O 0 5.368931306293234e-05
G O 0 0.00026042890385724604
- O 0 0.00010155261406907812
- O 0 7.043559162411839e-05
> O 0 2.06264103326248e-05
A O 0 9.653369488660246e-06
mutation O 0 5.894247806281783e-05
. O 0 3.157690343869035e-06

Genotype O 0 0.0018357029184699059
- O 0 0.001459263265132904
phenotype O 0 0.00035452673910185695
correlations O 0 0.00034805102040991187
in O 0 0.0001255116512766108
attenuated B-Disease 1 0.9861117601394653
adenomatous I-Disease 1 0.9998606443405151
polyposis I-Disease 1 0.9993171691894531
coli I-Disease 1 0.9989380240440369
. O 0 0.00015914755931589752

Germ O 0 0.008812016807496548
- O 0 0.0004999892553314567
line O 0 7.186417496996e-05
mutations O 0 3.8865859096404165e-05
of O 0 2.3221002720674733e-07
the O 0 2.2523474854097003e-06
tumor B-Disease 0 0.005978685338050127
suppressor O 0 0.00012545660138130188
APC O 0 0.00011359483323758468
are O 0 5.530567932510166e-07
implicated O 0 0.0010736181866377592
in O 0 6.776514783268794e-05
attenuated B-Disease 1 0.9877142906188965
adenomatous I-Disease 1 0.9999709129333496
polyposis I-Disease 1 0.9997556805610657
coli I-Disease 1 0.9997655749320984
( O 0 0.00023442911333404481
AAPC B-Disease 1 0.997244119644165
) O 0 8.889774107956327e-07
, O 0 2.282781395024358e-07
a O 0 9.218652508025116e-07
variant O 0 0.0007810266106389463
of O 0 0.00010591141472104937
familial B-Disease 1 0.9999920129776001
adenomatous I-Disease 1 0.999982476234436
polyposis I-Disease 1 0.9999855756759644
( O 0 0.0006693271570838988
FAP B-Disease 0 0.004491654224693775
) O 0 5.499004146258812e-06
. O 0 7.342154731304618e-06

AAPC B-Disease 1 0.9967994689941406
is O 0 4.035086021758616e-06
recognized O 0 2.4133137230819557e-06
by O 0 1.5232035366352648e-07
the O 0 2.923115403064003e-07
occurrence O 0 2.6016658011940308e-05
of O 0 5.001429599360563e-07
< O 0 0.00019943494407925755
100 O 0 1.283321307710139e-05
colonic B-Disease 0 0.03479717671871185
adenomas I-Disease 0 0.009571474976837635
and O 0 1.414605435456906e-06
a O 0 3.757787681024638e-06
later O 0 3.5644112358568236e-05
onset O 0 0.4566008746623993
of O 0 0.014255428686738014
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
( O 0 3.385219315532595e-06
age O 0 7.989828191057313e-06
> O 0 9.44833936955547e-06
40 O 0 1.412526785316004e-06
years O 0 1.186179702017398e-06
) O 0 2.7362125365471e-07
. O 0 1.5229071550493245e-06

The O 0 9.806225307329441e-07
aim O 0 3.2363543596147792e-06
of O 0 5.2155545660070857e-08
this O 0 5.5246960783961185e-08
study O 0 1.3378800645114097e-07
was O 0 5.833005047861661e-07
to O 0 4.37997442759297e-08
assess O 0 7.1889758146426175e-06
genotype O 0 5.5033877288224176e-05
- O 0 0.00024388749443460256
phenotype O 0 0.0001307093189097941
correlations O 0 7.604088023072109e-05
in O 0 2.2957412511459552e-05
AAPC B-Disease 1 0.9925301671028137
families O 0 7.054247362248134e-06
. O 0 9.906020750349853e-06

By O 0 6.530674454552354e-07
protein O 0 6.322305580397369e-06
- O 0 2.871168908313848e-05
truncation O 0 3.324594581499696e-05
test O 0 2.9081024877086747e-06
( O 0 2.481939702647651e-07
PTT O 0 3.4597247577039525e-05
) O 0 1.0512442827348423e-07
assay O 0 1.530294184703962e-06
, O 0 4.024752442433055e-08
the O 0 2.3446013130978827e-08
entire O 0 7.497172305193089e-07
coding O 0 1.5095351045602001e-05
region O 0 1.7191747474498698e-06
of O 0 2.8809234109417048e-08
the O 0 2.2843734370781021e-07
APC B-Disease 0 1.2816615708288737e-05
gene O 0 8.152138661898789e-07
was O 0 2.119101736752782e-06
screened O 0 8.026187288123765e-07
in O 0 7.661653711465988e-08
affected O 0 1.9087637781467492e-07
individuals O 0 5.195855123929505e-08
from O 0 1.6298099581035785e-06
11 O 0 7.898054172983393e-05
AAPC B-Disease 1 0.997601330280304
kindreds O 0 0.0008707908564247191
, O 0 6.442708126996877e-07
and O 0 5.53573968886667e-08
their O 0 1.545474681563519e-08
phenotypic O 0 7.683701369387563e-06
differences O 0 8.571028047299478e-06
were O 0 4.317494585848181e-06
examined O 0 0.00013468059478327632
. O 0 4.348196398495929e-06

Five O 0 4.777447884407593e-06
novel O 0 8.407014320255257e-06
germ O 0 0.0007883706712163985
- O 0 0.00018903757154475898
line O 0 6.0882903198944405e-05
APC B-Disease 0 5.788202543044463e-05
mutations O 0 7.648280188732315e-06
were O 0 2.1171010189391382e-07
identified O 0 2.988803942116647e-07
in O 0 1.0709748465842495e-07
seven O 0 1.636544766370207e-06
kindreds O 0 0.00041654607048258185
. O 0 1.0849805221369024e-05

Mutations O 0 8.363716187886894e-05
were O 0 5.340338020687341e-07
located O 0 8.240347710852802e-07
in O 0 2.1688524753926686e-08
three O 0 1.1675849620473855e-08
different O 0 3.5040546020326246e-09
regions O 0 1.2760686729507142e-07
of O 0 1.6791590340403673e-08
the O 0 1.6413605408160947e-07
APC B-Disease 0 6.81729534335318e-06
gene O 0 5.830012810292828e-07
( O 0 1.0877240441686808e-07
1 O 0 2.620581085466256e-07
) O 0 3.256510083815556e-08
at O 0 9.151126505457796e-07
the O 0 8.834283704572954e-08
5 O 0 2.868012813905807e-07
end O 0 4.093685390671453e-07
spanning O 0 3.2986370115395403e-06
exons O 0 7.25283916835906e-06
4 O 0 1.7889394712256035e-06
and O 0 1.497121928650813e-07
5 O 0 5.910549703003198e-07
, O 0 1.0338197853343445e-07
( O 0 4.7138922099065894e-08
2 O 0 2.2533821208980953e-07
) O 0 1.815413241956776e-08
within O 0 4.467247904926808e-08
exon O 0 3.6528313103190158e-06
9 O 0 2.6596212592266966e-06
, O 0 6.583024969586404e-08
and O 0 8.056850475668398e-08
( O 0 5.7338283454555494e-08
3 O 0 3.037104363556864e-07
) O 0 3.4688984129616074e-08
at O 0 1.5530563359789085e-06
the O 0 1.0145550533025016e-07
3 O 0 5.642941118821909e-07
distal O 0 2.2667683879262768e-05
end O 0 2.109419483531383e-06
of O 0 3.5869540226940444e-08
the O 0 1.6469205377234175e-07
gene O 0 1.074316787708085e-05
. O 0 4.76489367429167e-06

Variability O 0 0.0005885187420062721
in O 0 1.9886799691448687e-06
the O 0 5.46177886917576e-07
number O 0 2.5274237032135716e-06
of O 0 0.0003331494808662683
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999752044677734
was O 0 0.00221802806481719
most O 0 6.58870305869641e-07
apparent O 0 1.1133610314573161e-05
in O 0 2.1099212688113766e-07
individuals O 0 1.6766724897365748e-08
with O 0 1.9366528647424275e-07
mutations O 0 1.3570796909334604e-05
in O 0 2.723830050399556e-07
region O 0 2.868887577278656e-06
1 O 0 3.520601012496627e-06
, O 0 5.987491817904811e-07
and O 0 2.8429424219211796e-06
upper O 1 0.9106440544128418
- O 1 0.9980611205101013
gastrointestinal O 1 0.9983863830566406
manifestations O 0 0.00024478157865814865
were O 0 1.5164664546318818e-06
more O 0 1.7592358858564694e-07
severe O 0 0.002611452480778098
in O 0 2.1541268324654084e-07
them O 0 1.1430842050685897e-07
. O 0 1.9189076283510076e-06

In O 0 6.664677130174823e-07
individuals O 0 4.315944579502684e-08
with O 0 2.0750658791257592e-07
mutations O 0 1.0681248568289448e-05
in O 0 1.756441321276725e-07
either O 0 3.4194141562693403e-07
region O 0 2.118206566592562e-06
2 O 0 2.005068608923466e-06
or O 0 7.051826287352014e-07
region O 0 1.1473035783637897e-06
3 O 0 5.705234684683091e-07
, O 0 2.852045000167891e-08
the O 0 2.674275734193543e-08
average O 0 5.76213494696276e-07
number O 0 3.910018975261664e-08
of O 0 9.043557014365433e-08
adenomas B-Disease 0 0.0008050097967498004
tended O 0 2.036711975961225e-06
to O 0 2.8676673480276804e-08
be O 0 6.485243631004778e-08
lower O 0 8.932503305913997e-07
than O 0 1.9306774845517793e-08
those O 0 1.1828993784490649e-08
in O 0 1.9710524767901916e-08
individuals O 0 2.3905331048013068e-09
with O 0 1.0005152262237971e-07
mutations O 0 6.956853667361429e-06
in O 0 2.3250186131917872e-07
region O 0 1.0300481108060922e-06
1 O 0 1.0519960369492765e-06
, O 0 1.4068974962810898e-07
although O 0 1.685276913576672e-07
age O 0 3.1110719191929093e-06
at O 0 4.585223359754309e-05
diagnosis O 0 0.003125190269201994
was O 0 1.6881200281204656e-05
similar O 0 1.285096686842735e-06
. O 0 2.603731218187022e-06

In O 0 1.7934880816028453e-05
all O 0 8.765032362134662e-06
AAPC B-Disease 1 0.9949404001235962
kindreds O 0 0.002637675730511546
, O 0 1.7845551383288694e-06
a O 0 1.3718453146793763e-06
predominance O 0 3.635802568169311e-05
of O 0 7.216878202598309e-06
right O 1 0.9960663914680481
- O 1 0.9997406601905823
sided O 1 0.9997970461845398
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999784231185913
and O 0 0.1881309598684311
rectal B-Disease 1 0.9997766613960266
polyp I-Disease 1 0.996920108795166
sparing O 0 0.00010560201917542145
was O 0 8.913641067920253e-05
observed O 0 2.3682550818193704e-05
. O 0 2.3605275600857567e-06

No O 0 0.00024513379321433604
desmoid B-Disease 1 0.944000780582428
tumors I-Disease 1 0.9999547004699707
were O 0 1.1569252365006832e-06
found O 0 3.626828402047977e-07
in O 0 1.5583781021177856e-07
these O 0 1.1454545045808118e-07
kindreds O 0 0.0003967060474678874
. O 0 8.64415051182732e-06

Our O 0 2.952205477413372e-06
data O 0 1.1064893215007032e-06
suggest O 0 4.1025688801710203e-07
that O 0 3.28128173521236e-08
, O 0 2.703210384424892e-07
in O 0 1.53793416757253e-06
AAPC B-Disease 1 0.9947329759597778
families O 0 1.472322423978767e-07
, O 0 6.962694953926984e-08
the O 0 3.090773859071305e-08
location O 0 4.3415482764430635e-07
of O 0 1.222520182864173e-07
the O 0 2.3098364181350917e-06
APC B-Disease 0 0.0007038674084469676
mutation O 0 0.00019702734425663948
may O 0 5.9394287745817564e-06
partially O 0 2.489058351784479e-05
predict O 0 2.8472402391344076e-06
specific O 0 2.1780645909075247e-07
phenotypic O 0 2.3040145606501028e-05
expression O 0 2.0734962163260207e-05
. O 0 1.1047472980862949e-05

This O 0 3.280725024978892e-07
should O 0 1.4271965653733787e-07
help O 0 4.60539766322654e-08
in O 0 3.32644418676864e-08
the O 0 2.489833583751988e-08
design O 0 7.087593871801801e-07
of O 0 6.833483467971746e-08
tailored O 0 8.913661986298393e-06
clinical O 0 4.556355270324275e-05
- O 0 0.00010229380859527737
management O 0 3.939554517273791e-06
protocols O 0 6.137885065982118e-06
in O 0 1.4417726390547614e-07
this O 0 2.3031192952771562e-08
subset O 0 8.460963840661861e-07
of O 0 1.194000674331619e-06
FAP B-Disease 0 0.0030244411900639534
patients O 0 4.334990808274597e-05
. O 0 1.1247233260291978e-06
. O 0 2.127799461959512e-06

Wilms B-Disease 1 0.9186640381813049
' I-Disease 0 0.002643160754814744
tumor I-Disease 0 0.004139511846005917
1 O 0 3.8108971693873173e-06
and O 0 1.1840820661745965e-06
Dax O 1 0.7846558094024658
- O 0 8.540755516150966e-05
1 O 0 1.7457614376326092e-06
modulate O 0 7.495887984987348e-06
the O 0 1.1322600812491146e-06
orphan O 0 2.457228401908651e-05
nuclear O 0 3.2252071832772344e-05
receptor O 0 6.909710009495029e-06
SF O 0 0.0018414739752188325
- O 0 9.31316662899917e-06
1 O 0 4.216854563310335e-07
in O 0 5.969656768911591e-08
sex O 0 2.5650561497059243e-07
- O 0 1.7246004517801339e-06
specific O 0 8.35018383327224e-08
gene O 0 2.458008111716481e-06
expression O 0 8.66587561176857e-06
. O 0 4.4426251406548545e-06

Products O 0 7.0135829446371645e-06
of O 0 1.6497422166139586e-06
steroidogenic O 0 0.0005357095506042242
factor O 0 5.055877863924252e-06
1 O 0 8.328634976351168e-06
( O 0 1.052477728080703e-06
SF O 0 0.003802824765443802
- O 0 3.310067404527217e-05
1 O 0 1.3323151506483555e-06
) O 0 1.6855790363479173e-07
and O 0 1.7691502307570772e-06
Wilms B-Disease 1 0.9763086438179016
tumor I-Disease 0 0.13933205604553223
1 O 0 5.629585757560562e-06
( O 0 2.774899883206672e-07
WT1 O 0 7.314210961339995e-05
) O 0 5.7930460428679e-08
genes O 0 9.184010707485868e-08
are O 0 3.06542147221478e-09
essential O 0 2.7029981808368575e-08
for O 0 2.1564488861258724e-08
mammalian O 0 2.661209691723343e-06
gonadogenesis O 0 5.9869711549254134e-05
prior O 0 5.28831890278525e-07
to O 0 6.194568413775414e-08
sexual O 0 1.2778311884176219e-06
differentiation O 0 1.3414715795079246e-05
. O 0 6.797630703658797e-06

In O 0 3.260965968365781e-06
males O 0 2.1680023110093316e-06
, O 0 1.4285966472016298e-06
SF O 0 0.0036511612124741077
- O 0 3.877094422932714e-05
1 O 0 1.4392919638339663e-06
participates O 0 1.7288882645516424e-06
in O 0 1.0722870769086512e-07
sexual O 0 9.303547443550997e-08
development O 0 1.994876086541808e-08
by O 0 3.4219318933992326e-08
regulating O 0 3.795120619543013e-06
expression O 0 1.7315315972155076e-06
of O 0 1.556487490006475e-07
the O 0 1.887761868601956e-06
polypeptide O 0 0.0004311333177611232
hormone O 0 0.0006813618820160627
Mullerian O 0 0.006865704897791147
inhibiting O 0 0.00045982745359651744
substance O 0 0.0006548420060425997
( O 0 4.252735834597843e-06
MIS O 0 0.006006710231304169
) O 0 2.6778186565934448e-06
. O 0 2.9805032681906596e-06

Here O 0 8.566190444980748e-06
, O 0 3.776681865019782e-07
we O 0 1.1616820927429217e-07
show O 0 4.770486157212872e-07
that O 0 1.454121871802272e-07
WT1 O 0 0.0005018095253035426
- O 0 0.00010991303133778274
KTS O 0 0.000993429566733539
isoforms O 0 1.3225622979007312e-06
associate O 0 3.906850452040089e-06
and O 0 3.749625818727509e-07
synergize O 0 7.916242611827329e-05
with O 0 4.852852271142183e-06
SF O 0 0.27384063601493835
- O 0 4.59506809420418e-05
1 O 0 7.023342618595052e-07
to O 0 4.443673873311127e-08
promote O 0 9.242710916623764e-07
MIS O 0 0.004970672074705362
expression O 0 4.786159115610644e-05
. O 0 1.4862768694001716e-05

In O 0 4.910730240226258e-06
contrast O 0 1.4609075151383877e-05
, O 0 5.711055109713925e-06
WT1 O 0 0.0038884379900991917
missense O 0 0.001584347104653716
mutations O 0 0.00027841213159263134
, O 0 1.529060000393656e-06
associated O 0 1.2134269127273e-06
with O 0 6.596612251996703e-07
male B-Disease 0 6.692215538350865e-05
pseudohermaphroditism I-Disease 1 0.9993682503700256
in O 0 5.808667265227996e-05
Denys B-Disease 1 0.9928885102272034
- I-Disease 1 0.9992521405220032
Drash I-Disease 1 0.9973462820053101
syndrome I-Disease 1 0.9999444484710693
, O 0 4.4178200369060505e-06
fail O 0 1.6126348782563582e-05
to O 0 1.9292755837341247e-07
synergize O 0 0.0001157748483819887
with O 0 8.397319106734358e-06
SF O 1 0.965732216835022
- O 0 0.0009877538541331887
1 O 0 2.1947753339190967e-05
. O 0 4.324953806644771e-06

Additionally O 0 9.77529361989582e-06
, O 0 6.809438559685077e-07
the O 0 4.7683485604466114e-07
X O 0 0.0019019824685528874
- O 0 0.0006935846176929772
linked O 0 0.0002784219686873257
, O 0 1.0038237405751715e-06
candidate O 0 2.44244097302726e-06
dosage O 0 3.162336361128837e-05
- O 0 2.0103161659790203e-05
sensitive O 0 3.1256979127647355e-05
sex O 0 5.540537131309975e-06
- O 0 2.095130184898153e-05
reversal O 0 3.6436183563637314e-06
gene O 0 1.244723648596846e-06
, O 0 6.924591957613302e-07
Dax O 0 0.0198130514472723
- O 0 6.733761256327853e-05
1 O 0 3.570433364075143e-06
, O 0 2.375533370013727e-07
antagonizes O 0 1.1473931408545468e-05
synergy O 0 5.0837561502703466e-06
between O 0 3.758898856176529e-06
SF O 0 0.01648963801562786
- O 0 5.1592051022453234e-05
1 O 0 2.082126002278528e-06
and O 0 3.730269213519932e-07
WT1 O 0 0.0001832795242080465
, O 0 2.735664565989282e-07
most O 0 5.243852996272835e-08
likely O 0 2.9713762117467013e-08
through O 0 8.509498883313427e-09
a O 0 2.6011740317244403e-08
direct O 0 1.482186196000157e-08
interaction O 0 1.5248559748215484e-07
with O 0 2.7262490220891777e-06
SF O 1 0.8589176535606384
- O 0 0.0005013971822336316
1 O 0 1.7333892174065113e-05
. O 0 2.8484328140621074e-06

We O 0 3.2056243526312755e-06
propose O 0 8.74259330885252e-06
that O 0 1.9617290547557786e-07
WT1 O 0 0.00015898009587544948
and O 0 2.1913144792051753e-06
Dax O 1 0.8600974678993225
- O 0 0.00014024149277247488
1 O 0 2.4819071313686436e-06
functionally O 0 6.621358352276729e-06
oppose O 0 3.5510566931407084e-07
each O 0 1.8627446252139634e-08
other O 0 1.3934982945329466e-08
in O 0 1.9305748821807356e-07
testis O 0 2.1915588149568066e-05
development O 0 2.1513181991394958e-07
by O 0 4.476186461488396e-07
modulating O 0 0.0003211170551367104
SF O 1 0.7064722180366516
- O 0 0.00026784700457938015
1 O 0 1.6704670997569337e-05
- O 0 5.514556323760189e-05
mediated O 0 0.00011249864473938942
transactivation O 0 0.0004218486719764769
. O 0 1.8046373497782042e-06
. O 0 3.840845238300972e-06

A O 0 1.7431231754017062e-05
mouse O 0 3.1610310543328524e-05
model O 0 9.013229828269687e-06
for O 0 2.053538446489256e-05
Prader B-Disease 1 0.9999803304672241
- I-Disease 1 0.9999521970748901
Willi I-Disease 1 0.9999845027923584
syndrome I-Disease 1 0.9999783039093018
imprinting O 1 0.7103238105773926
- O 0 0.06356851756572723
centre O 0 0.0005037211813032627
mutations O 0 0.0005552457296289504
. O 0 8.232389518525451e-06

Imprinting O 0 0.0003952009428758174
in O 0 2.601060486995266e-06
the O 0 1.0847204521269305e-06
15q11 O 0 0.00018387554155196995
- O 0 0.0002629683876875788
q13 O 0 0.00010521063086343929
region O 0 2.7622998004517285e-06
involves O 0 1.3747120419793646e-06
an O 0 4.471578449738445e-07
imprinting O 0 9.710660378914326e-05
centre O 0 2.807839155138936e-05
( O 0 2.9917640631538234e-07
IC O 0 1.7197657143697143e-05
) O 0 1.3153268696441955e-07
, O 0 7.007513147527789e-08
mapping O 0 4.929005967824196e-07
in O 0 6.255287132717058e-08
part O 0 6.289634768563701e-08
to O 0 2.65066688598381e-08
the O 0 2.255086855029731e-07
promoter O 0 0.00011990735220024362
and O 0 5.991946636640932e-07
first O 0 1.6285297306239954e-06
exon O 0 6.848540215287358e-05
of O 0 1.1229645906496444e-06
SNRPN O 0 0.010733998380601406
. O 0 2.133046291419305e-05

Deletion O 0 0.00014685468340758234
of O 0 8.132569746521767e-07
this O 0 8.239923090513912e-07
IC O 0 0.00042891025077551603
abolishes O 0 0.0006738982046954334
local O 0 1.7262656228922424e-06
paternally O 0 0.00011618626012932509
derived O 0 6.760262749594403e-07
gene O 0 2.302027269251994e-06
expression O 0 1.885602728179947e-06
and O 0 7.900329137555673e-07
results O 0 1.2400445484672673e-05
in O 0 0.00010992435272783041
Prader B-Disease 1 0.9999916553497314
- I-Disease 1 0.9999924898147583
Willi I-Disease 1 0.9999957084655762
syndrome I-Disease 1 0.9999974966049194
( O 0 0.0003982255875598639
PWS B-Disease 1 0.9991451501846313
) O 0 1.652855280553922e-05
. O 0 9.394340850121807e-06

We O 0 2.002284645641339e-06
have O 0 7.886517749966515e-08
created O 0 2.4040375024014793e-07
two O 0 1.7269161389776855e-07
deletion O 0 1.424543825123692e-05
mutations O 0 1.732425698719453e-05
in O 0 3.605460960898199e-07
mice O 0 6.525048775074538e-06
to O 0 1.0276348660909207e-07
understand O 0 5.5111158872023225e-06
PWS B-Disease 1 0.9991679191589355
and O 0 7.376435746664356e-07
the O 0 1.0585076637426027e-07
mechanism O 0 1.5003150792836095e-06
of O 0 9.336612549759593e-08
this O 0 1.5277890952347661e-07
IC O 0 0.00030615724972449243
. O 0 1.2496057024691254e-05

Mice O 0 0.0036010046023875475
harbouring O 0 0.003811081638559699
an O 0 3.4875251913035754e-06
intragenic O 0 0.0007417090237140656
deletion O 0 9.728010627441108e-05
in O 0 2.579460669949185e-06
Snrpn O 0 0.0002342168882023543
are O 0 3.428635579894035e-07
phenotypically O 0 0.00017776056483853608
normal O 0 2.0342820789664984e-05
, O 0 6.232379519133247e-07
suggesting O 0 1.2848711321566952e-06
that O 0 9.351047935979295e-08
mutations O 0 5.000436431146227e-06
of O 0 1.1762379870106088e-07
SNRPN O 0 0.00013980154471937567
are O 0 3.7534000796313194e-08
not O 0 2.0605767758752336e-08
sufficient O 0 1.3933845366409514e-07
to O 0 4.24868375148435e-07
induce O 0 0.00011128296318929642
PWS B-Disease 1 0.9989140033721924
. O 0 4.79305672342889e-05

Mice O 0 8.400276419706643e-05
with O 0 5.108154823574296e-07
a O 0 8.169720331352437e-07
larger O 0 6.010020001667726e-07
deletion O 0 1.112853624363197e-05
involving O 0 1.9030431985811447e-06
both O 0 5.362261958907766e-07
Snrpn O 0 0.00019671198970172554
and O 0 1.2908118378618383e-06
the O 0 3.3117876228061505e-06
putative O 0 0.002100147772580385
PWS O 1 0.9988675117492676
- O 0 0.005159622523933649
IC O 0 0.00030166946817189455
lack O 0 3.450545136729488e-06
expression O 0 1.3576030823969631e-06
of O 0 9.898212027792397e-08
the O 0 5.613425742012623e-07
imprinted O 0 0.0001559356605866924
genes O 0 1.6807100109872408e-05
Zfp127 O 0 0.000325133471051231
( O 0 8.791266736807302e-07
mouse O 0 2.2740518033970147e-05
homologue O 0 5.98897022427991e-05
of O 0 5.38072299605119e-07
ZNF127 O 0 0.000695522059686482
) O 0 1.0331048088119132e-06
, O 0 7.996558792910946e-07
Ndn O 0 0.00032819699845276773
and O 0 5.312344342200959e-07
Ipw O 0 0.00018685217946767807
, O 0 5.566910772358824e-07
and O 0 1.2197368448596535e-07
manifest O 0 2.4923008368205046e-06
several O 0 3.694638337492506e-07
phenotypes O 0 4.5294127630768344e-05
common O 0 2.292092722200323e-05
to O 0 1.76657904376043e-05
PWS B-Disease 1 0.999610960483551
infants O 0 0.042651232331991196
. O 0 3.038911017938517e-05

These O 0 5.6264234160607884e-08
data O 0 2.800207710151881e-07
demonstrate O 0 2.0314305970714486e-07
that O 0 7.26859905597621e-09
both O 0 1.6403021163569065e-08
the O 0 3.8630439291864604e-08
position O 0 5.948992338744574e-07
of O 0 1.7496729398658317e-08
the O 0 1.0169613062771532e-07
IC O 0 1.4316245142254047e-05
and O 0 1.7341051261610119e-07
its O 0 4.41144010210337e-08
role O 0 4.89829403704789e-07
in O 0 6.622165216185749e-08
the O 0 1.6617596187984418e-08
coordinate O 0 3.0828232411295176e-07
expression O 0 3.475273047115479e-07
of O 0 8.154139408134142e-08
genes O 0 9.678853984951274e-07
is O 0 1.7131210938714503e-07
conserved O 0 9.097169026972551e-07
between O 0 2.844055018158542e-07
mouse O 0 8.061267180892173e-06
and O 0 3.6827515259574284e-07
human O 0 6.942682944099943e-07
, O 0 1.1113904463400104e-07
and O 0 7.071289331861408e-08
indicate O 0 1.38239357738712e-07
that O 0 6.356773329940779e-09
the O 0 2.69768278826632e-08
mouse O 0 2.2364781671058154e-06
is O 0 1.8037885851640567e-08
a O 0 1.8959800840434582e-08
suitable O 0 6.923627893229423e-08
model O 0 2.2370683439021377e-07
system O 0 7.869160754125915e-07
in O 0 7.075796304434334e-08
which O 0 1.4544943027772206e-08
to O 0 1.0327688926281553e-08
investigate O 0 2.617179291064531e-07
the O 0 7.765907383827653e-08
molecular O 0 3.0590035748900846e-06
mechanisms O 0 3.687454181999783e-06
of O 0 1.8106555899066734e-07
imprinting O 0 2.846430470526684e-05
in O 0 4.676708726947254e-07
this O 0 4.0854747140883774e-08
region O 0 4.7391026214427256e-07
of O 0 4.975331080459e-08
the O 0 3.8852641637276975e-07
genome O 0 5.5531954785692506e-06
. O 0 9.893075230138493e-07
. O 0 3.1654751637688605e-06

Mutations O 0 0.00015680880460422486
of O 0 1.8701781812069385e-07
the O 0 4.527257146946795e-07
ATM O 0 6.180634954944253e-05
gene O 0 2.8896112780785188e-05
detected O 0 0.0001974039914784953
in O 0 2.380552814429393e-06
Japanese O 0 0.000381116580683738
ataxia B-Disease 1 0.9999923706054688
- I-Disease 1 0.9998914003372192
telangiectasia I-Disease 1 0.999962568283081
patients O 0 0.006105838343501091
: O 0 1.3009779422645806e-06
possible O 0 8.899528438632842e-07
preponderance O 0 1.0243809811072424e-05
of O 0 6.620927450740055e-08
the O 0 2.0188076632621232e-07
two O 0 4.366245320852613e-07
founder O 0 5.0405156798660755e-05
mutations O 0 5.279577453620732e-05
4612del165 O 0 7.213854405563325e-05
and O 0 2.5713115974212997e-06
7883del5 O 0 0.00014815384929534048
. O 0 7.221525265777018e-06

The O 0 1.4360301747728954e-06
ATM O 0 0.00018786279542837292
( O 0 6.478081559180282e-06
A O 1 0.9858330488204956
- O 1 0.9798934459686279
T O 1 0.9996054768562317
, O 0 7.102215136001178e-07
mutated O 0 1.7491310018158401e-06
) O 0 5.99812111090614e-08
gene O 0 4.045263324314874e-07
on O 0 8.887739681995299e-07
human O 0 4.819318746740464e-06
chromosome O 0 0.00014588050544261932
11q22 O 0 0.00027870561461895704
. O 0 1.1993234693363775e-05

3 O 0 2.331933137611486e-05
has O 0 1.8499239331504214e-06
recently O 0 5.751567641709698e-06
been O 0 3.181659451456653e-07
identified O 0 1.7381549355377501e-07
as O 0 1.508105107461688e-08
the O 0 2.4002661191957486e-08
gene O 0 1.963136355698225e-07
responsible O 0 4.797184374183416e-07
for O 0 2.166611601239765e-08
the O 0 9.582828397469711e-07
human O 0 0.000346508517395705
recessive B-Disease 1 0.999363362789154
disease I-Disease 1 0.999958872795105
ataxia B-Disease 1 0.9999942779541016
- I-Disease 1 0.9994714856147766
telangiectasia I-Disease 1 0.9997590184211731
( O 0 0.00018460402498021722
A B-Disease 1 0.9996676445007324
- I-Disease 1 0.9985607266426086
T I-Disease 1 0.9998090863227844
) O 0 5.602912551694317e-06
. O 0 4.407640062709106e-06

In O 0 9.205527362610155e-07
order O 0 1.9927661298879684e-07
to O 0 3.0185429267248765e-08
define O 0 7.90342596701521e-07
the O 0 1.1305159119956443e-07
types O 0 3.223718294975697e-06
of O 0 6.9473467192437965e-06
disease O 1 0.9993265867233276
- O 0 0.003135307924821973
causing O 0 0.000126926795928739
ATM O 0 9.531605610391125e-05
mutations O 0 2.638465230120346e-05
in O 0 4.652571305996389e-07
Japanese O 0 7.320006716327043e-06
A B-Disease 1 0.9975482821464539
- I-Disease 1 0.9986414313316345
T I-Disease 1 0.9998620748519897
patients O 0 7.792801625328138e-06
as O 0 4.942105391592122e-08
well O 0 3.0400073569580854e-08
as O 0 2.4210025983961714e-08
to O 0 8.226589187643185e-09
look O 0 3.0006907536517247e-07
for O 0 3.485033417405248e-08
possible O 0 1.186592612612003e-06
mutational O 0 9.745605348143727e-05
hotspots O 0 4.050088318763301e-05
, O 0 8.301018397105508e-07
reverse O 0 9.730712918099016e-06
- O 0 1.546753446746152e-05
transcribed O 0 6.634360488533275e-06
RNA O 0 1.7105301139963558e-06
derived O 0 8.666950179758715e-08
from O 0 8.203497259273718e-08
ten O 0 3.2059563181974227e-07
patients O 0 6.671405117231188e-07
belonging O 0 5.344352302927291e-07
to O 0 3.683906868445774e-08
eight O 0 2.2374096886323969e-07
unrelated O 0 4.4451762732933275e-06
Japanese O 0 1.7259695596294478e-05
A B-Disease 1 0.9994723200798035
- I-Disease 1 0.9946059584617615
T I-Disease 1 0.999703586101532
families O 0 1.300892051858682e-07
was O 0 9.872942428046372e-07
analyzed O 0 3.4276516203135543e-07
for O 0 2.8531712104040707e-08
mutations O 0 1.2042962680425262e-06
by O 0 2.2716854175541812e-08
the O 0 6.03884942051991e-08
restriction O 0 5.654361530105234e-07
endonuclease O 0 2.8361666409182362e-05
fingerprinting O 0 1.1810532669187523e-05
method O 0 3.273188895036583e-06
. O 0 3.9830065361456946e-06

As O 0 4.172947683400707e-06
has O 0 1.6701919776096474e-06
been O 0 3.868703686293884e-07
reported O 0 5.364522053241672e-07
by O 0 1.7950778641306897e-08
others O 0 1.1366184793359935e-07
, O 0 9.753902929787728e-08
mutations O 0 1.0827764072018908e-06
that O 0 1.821517692235375e-08
lead O 0 6.756575885447091e-07
to O 0 9.972135472935406e-08
exon O 0 4.2971492803189903e-05
skipping O 0 5.852162939845584e-05
or O 0 1.9017951444766368e-06
premature O 0 1.6166615750989877e-05
protein O 0 2.695770149330201e-07
truncation O 0 4.039837676828029e-06
were O 0 9.672295675500209e-08
also O 0 8.67662564019156e-08
predominant O 0 9.612613212084398e-07
in O 0 1.6934210123054072e-07
our O 0 9.335033723800734e-07
mutants O 0 6.709300942020491e-05
. O 0 6.526405741169583e-06

Six O 0 6.590939847228583e-07
different O 0 2.397255549624333e-08
mutations O 0 2.9456275569827994e-06
were O 0 9.269752609952775e-08
identified O 0 4.3319610654179996e-07
on O 0 3.643823163201887e-07
12 O 0 3.955151441914495e-07
of O 0 1.6928421331385834e-08
the O 0 2.828278127253725e-07
16 O 0 4.0093777897709515e-06
alleles O 0 1.1244991583225783e-05
examined O 0 0.00020924967247992754
. O 0 7.919157724245451e-06

Four O 0 1.574891825839586e-06
were O 0 2.7395284973863454e-07
deletions O 0 8.68233746587066e-06
involving O 0 1.106368927139556e-05
a O 0 1.2863368283433374e-05
loss O 0 8.885135321179405e-05
of O 0 5.121607671298989e-08
a O 0 7.102296990524337e-07
single O 0 2.6205211725027766e-06
exon O 0 5.851219975738786e-05
exon O 0 8.049164898693562e-05
7 O 0 7.664234544790816e-06
, O 0 4.301423359720502e-07
exon O 0 1.2106217582186218e-05
16 O 0 1.836282535805367e-06
, O 0 2.323172338947188e-07
exon O 0 1.0630388715071604e-05
33 O 0 3.7289998999767704e-06
or O 0 1.9212864117434947e-06
exon O 0 6.238596688490361e-05
35 O 0 1.458795668440871e-05
. O 0 8.248734957305714e-06

The O 0 1.0739382787505747e-06
others O 0 8.178247981049935e-07
were O 0 1.9683329810504802e-07
minute O 0 1.6716292066121241e-06
deletions O 0 8.93366177479038e-06
, O 0 5.066962671662623e-07
4649delA O 0 2.6917292416328564e-05
in O 0 3.843391880309355e-07
exon O 0 1.6165737179107964e-05
33 O 0 3.728736601260607e-06
and O 0 2.0798147204459383e-07
7883del5 O 0 6.689162546535954e-06
in O 0 4.6466468006656214e-07
exon O 0 6.012970698066056e-05
55 O 0 2.8012438633595593e-05
. O 0 3.712836360136862e-06

The O 0 1.5045983673189767e-05
mutations O 0 0.00021222380746621639
4612del165 O 0 7.14143825462088e-05
and O 0 4.790134653376299e-07
7883del5 O 0 8.005082236195449e-06
were O 0 2.249939967668979e-07
found O 0 4.9989210992862354e-08
in O 0 7.670599266873523e-09
more O 0 1.0432894548273453e-09
than O 0 8.394766659591824e-09
two O 0 2.1209116241038828e-08
unrelated O 0 8.147110293066362e-07
families O 0 1.4976368589714184e-08
; O 0 5.950990455971805e-08
44 O 0 1.466186461129837e-07
% O 0 1.0509351611176498e-08
( O 0 3.1300352532070974e-08
7 O 0 2.892619477279368e-07
of O 0 1.5675533759917926e-08
16 O 0 2.2728951876160863e-07
) O 0 7.2417671859170696e-09
of O 0 2.4426622946549514e-09
the O 0 4.024038702254984e-08
mutant O 0 9.89448153632111e-07
alleles O 0 4.023409871933836e-07
had O 0 3.0400428840948734e-07
one O 0 2.4272999610275292e-08
of O 0 1.3763339801187158e-08
the O 0 1.0722032328658315e-07
two O 0 8.855419650899421e-07
mutations O 0 7.662905409233645e-05
. O 0 5.159373813512502e-06

The O 0 6.72721398586873e-06
4612del165 O 0 0.00011986949539277703
mutations O 0 8.145283572957851e-06
in O 0 6.275171671177304e-08
three O 0 1.1302341285102102e-08
different O 0 2.9412920987681446e-09
families O 0 9.058711114562357e-09
were O 0 3.454221442211747e-08
all O 0 5.816836790017987e-09
ascribed O 0 2.979057853735867e-07
to O 0 1.4017569327506862e-08
the O 0 4.811653653291614e-08
same O 0 4.3471413846418727e-07
T O 0 0.00048425394925288856
- O 0 1.521673402749002e-05
- O 0 5.5362852435791865e-06
> O 0 7.601912557220203e-07
A O 0 1.1855289017148607e-07
substitution O 0 5.8624845422627914e-08
at O 0 6.263429099817586e-07
the O 0 3.0249168503360124e-08
splice O 0 1.8483546227798797e-05
donor O 0 3.2020313938119216e-06
site O 0 5.705795956600923e-06
in O 0 7.07973697444686e-07
intron O 0 0.0002002076944336295
33 O 0 2.4651970306877047e-05
. O 0 3.513571073199273e-06

Microsatellite O 0 0.0036530853249132633
genotyping O 0 0.00033376491046510637
around O 0 1.7322651046924875e-06
the O 0 2.4740279513935093e-07
ATM O 0 4.912726581096649e-05
locus O 0 4.1776467696763575e-05
also O 0 1.2791651897714473e-06
indicated O 0 8.736772656448011e-07
that O 0 7.177247685064003e-09
a O 0 9.948008283799936e-08
common O 0 6.471694291576569e-07
haplotype O 0 3.509979433147237e-05
was O 0 2.5040985747182276e-06
shared O 0 8.073633495087051e-08
by O 0 1.7380049399662312e-08
the O 0 4.834910427575778e-08
mutant O 0 8.682567340656533e-07
alleles O 0 2.875511597721925e-07
in O 0 1.3987326497044705e-07
both O 0 4.931488319925847e-07
mutations O 0 0.00010706434841267765
. O 0 5.129397777636768e-06

This O 0 4.6575701162510086e-07
suggests O 0 4.153526447225886e-07
that O 0 5.304863659461034e-09
these O 0 5.913399991896995e-09
two O 0 8.758499348004989e-08
founder O 0 1.8985198039445095e-05
mutations O 0 9.9401077022776e-06
may O 0 5.877834041712049e-07
be O 0 3.130955050778539e-08
predominant O 0 6.503266263280238e-07
among O 0 8.860963163215274e-08
Japanese O 0 2.6205036647297675e-06
ATM O 0 8.818585774861276e-05
mutant O 0 6.381441926350817e-05
alleles O 0 3.908560029231012e-05
. O 0 8.783608791418374e-06

W474C O 0 0.0005412180908024311
amino O 0 7.321556495298864e-06
acid O 0 8.164383871189784e-06
substitution O 0 1.995443881241954e-07
affects O 0 6.394345177795913e-07
early O 0 9.072236650808918e-08
processing O 0 9.346055662717845e-08
of O 0 1.0728594901365796e-08
the O 0 6.314071043789227e-08
alpha O 0 4.727190798803349e-07
- O 0 4.778536890626128e-07
subunit O 0 1.923492192190679e-07
of O 0 6.321639034467808e-08
beta O 0 4.913775683235144e-06
- O 0 8.852769497025292e-06
hexosaminidase O 0 1.736774720484391e-05
A O 0 1.4781991239942727e-06
and O 0 2.6259098717673623e-07
is O 0 2.8805948204535525e-07
associated O 0 2.1442488105094526e-06
with O 0 4.571742920234101e-06
subacute O 1 0.9899256229400635
G B-Disease 0 0.06973687559366226
( I-Disease 0 3.18540446642146e-06
M2 I-Disease 0 0.0003328726452309638
) I-Disease 0 2.3649483864573995e-06
gangliosidosis I-Disease 0 0.0003807203902397305
. O 0 8.230269486375619e-06

Mutations O 0 0.0002119154523825273
in O 0 9.65299705057987e-07
the O 0 4.857445787820325e-07
HEXA O 0 0.0002563647576607764
gene O 0 6.502571636701759e-07
, O 0 1.6533972413412812e-08
encoding O 0 1.7255919360081862e-08
the O 0 4.525219665652003e-08
alpha O 0 2.8985979838580533e-07
- O 0 3.486416915166046e-07
subunit O 0 8.113678262589019e-08
of O 0 4.2089677521062185e-08
beta O 0 4.0103032006300054e-06
- O 0 1.5760484529891983e-05
hexosaminidase O 0 2.8754653612850234e-05
A O 0 3.339781187605695e-06
( O 0 2.3041856422878482e-07
Hex O 0 6.960145583434496e-06
A O 0 6.798472895752639e-07
) O 0 4.0348215435415113e-08
, O 0 3.134026016482494e-08
that O 0 9.530241484867474e-09
abolish O 0 2.4479229523421964e-06
Hex O 0 8.779170457273722e-06
A O 0 2.372357357671717e-06
enzyme O 0 1.5944435290293768e-05
activity O 0 3.7880901800235733e-05
cause O 0 0.010952021926641464
Tay B-Disease 1 0.9999854564666748
- I-Disease 1 0.9998650550842285
Sachs I-Disease 1 0.9999256134033203
disease I-Disease 1 0.9990516304969788
( O 0 3.162789425914525e-06
TSD B-Disease 0 0.0011538923718035221
) O 0 8.218748916988261e-07
, O 0 5.752718266194279e-07
the O 0 1.6267197224806296e-06
fatal O 1 0.9661055207252502
infantile B-Disease 0 0.020427562296390533
form I-Disease 0 4.790847924596164e-06
of I-Disease 0 9.81868993221724e-07
G I-Disease 0 0.00043723377166315913
( I-Disease 0 9.780075060916715e-07
M2 I-Disease 0 9.701470116851851e-05
) I-Disease 0 6.358376367643359e-07
gangliosidosis I-Disease 0 3.892041786457412e-05
, I-Disease 0 5.112715939503687e-07
Type I-Disease 0 1.0205955732089933e-05
1 I-Disease 0 2.554094862716738e-05
. O 0 4.740956228488358e-06

Less O 0 0.00022261682897806168
severe O 1 0.9904428124427795
, O 0 5.387383862398565e-05
subacute O 1 0.9936922788619995
( O 0 7.073013694025576e-05
juvenile O 1 0.7981100082397461
- O 0 0.011507101356983185
onset O 0 0.025799253955483437
) O 0 4.3415666368673556e-06
and O 0 2.214876440120861e-05
chronic O 1 0.999460756778717
( O 0 1.5696379023211193e-06
adult O 0 1.3307022527442314e-05
- O 0 0.0013181775575503707
onset O 0 0.0008143305312842131
) O 0 7.635044596554508e-08
variants O 0 3.8620018472101947e-07
are O 0 2.521682773704015e-08
characterized O 0 1.3745927844865946e-06
by O 0 4.181043067319479e-08
a O 0 5.705354624296888e-07
broad O 0 6.064878107281402e-06
spectrum O 0 3.598658076953143e-05
of O 0 9.16371106995939e-07
clinical O 0 2.849738666554913e-05
manifestations O 0 5.54798825760372e-05
and O 0 4.5658555336558493e-07
are O 0 3.710768226028449e-08
associated O 0 4.353065321538452e-07
with O 0 3.0005074336258986e-07
residual O 0 7.743812602711841e-05
levels O 0 1.1384455319785047e-05
of O 0 1.9136521700602316e-07
Hex O 0 5.078544927528128e-05
A O 0 7.3784235610219184e-06
enzyme O 0 1.2086238712072372e-05
activity O 0 9.322266123490408e-06
. O 0 3.017241851921426e-06

We O 0 3.13903274218319e-06
identified O 0 3.0168789635354187e-06
a O 0 3.1631514048058307e-06
1422 O 0 0.0008338164770975709
G O 0 0.0004658633843064308
- O 0 6.491168460343033e-05
- O 0 4.296932092984207e-05
> O 0 1.4726898371009156e-05
C O 0 1.1069261745433323e-05
( O 0 6.32978327530509e-08
amino O 0 2.3102539614683337e-07
acid O 0 1.6004221379262162e-06
W474C O 0 1.4822026059846394e-06
) O 0 4.934331609973697e-09
substitution O 0 1.3070422077987587e-08
in O 0 1.3259624509487367e-08
the O 0 1.0864712685076938e-08
first O 0 1.62690781735364e-07
position O 0 9.967321830117726e-07
of O 0 1.0711382003592007e-07
exon O 0 2.5166596969938837e-05
13 O 0 2.3872639758337755e-06
of O 0 2.056231238611872e-07
HEXA O 0 0.0009616634924896061
of O 0 2.4547281896047934e-07
a O 0 4.5669021346839145e-06
non O 0 3.7104240618646145e-05
- O 0 0.00021654156444128603
Jewish O 0 2.22933722398011e-05
proband O 0 0.0026735360734164715
who O 0 1.2721535313175991e-05
manifested O 0 3.4658605727599934e-05
a O 0 9.534046512271743e-06
subacute O 0 0.06589240580797195
variant O 0 0.0004629518371075392
of O 0 3.844565071631223e-06
G B-Disease 0 0.002441585762426257
( I-Disease 0 1.8837910147340153e-06
M2 I-Disease 0 0.000300590560073033
) I-Disease 0 3.8950056477915496e-06
gangliosidosis I-Disease 0 0.0004420749319251627
. O 0 1.1184883987880312e-05

On O 0 1.4630644727731124e-05
the O 0 2.3925338155095233e-06
second O 0 2.2099289708421566e-05
maternally O 0 0.0005303884390741587
inherited O 0 0.005294444039463997
allele O 0 5.0565620767883956e-05
, O 0 9.40465213261632e-07
we O 0 3.3885808647937665e-07
identified O 0 1.3697915619559353e-06
the O 0 9.190106879941595e-07
common O 0 0.00040677253855392337
infantile O 1 0.9992890357971191
disease O 1 0.9994927644729614
- O 0 0.006419487297534943
causing O 0 0.0002929209149442613
4 O 0 1.314672681473894e-05
- O 0 5.179633808438666e-05
bp O 0 5.3639410907635465e-05
insertion O 0 4.3893342080991715e-06
, O 0 6.050910315025249e-07
+ O 0 1.3323149687494151e-05
TATC O 0 0.00034330456401221454
1278 O 0 0.0004815363499801606
, O 0 1.1147187706228578e-06
in O 0 5.370413873606594e-07
exon O 0 6.001513611408882e-05
11 O 0 1.4108375580690335e-05
. O 0 3.5420130188867915e-06

Pulse O 0 0.0010580235393717885
- O 0 0.00010342391033191234
chase O 0 1.0830121937033255e-05
analysis O 0 2.295775942684486e-07
using O 0 6.114534585321962e-07
proband O 0 5.818341378471814e-05
fibroblasts O 0 3.281198814875097e-06
revealed O 0 3.7454803987202467e-06
that O 0 1.2388759351722456e-08
the O 0 4.0538594703320996e-08
W474C O 0 4.723162419395521e-06
- O 0 2.706499117266503e-06
containing O 0 4.1412491214032343e-07
alpha O 0 8.913867191040481e-07
- O 0 1.1209925787625252e-06
subunit O 0 3.9035106169649225e-07
precursor O 0 3.760655772566679e-06
was O 0 9.508490279586113e-07
normally O 0 1.708999235461306e-07
synthesized O 0 1.1127028756163782e-06
, O 0 1.0176307085885128e-07
but O 0 2.9151664193705074e-08
not O 0 6.019711396021421e-09
phosphorylated O 0 3.474683296644798e-07
or O 0 1.4363983780185663e-07
secreted O 0 5.741181325902289e-07
, O 0 5.9272238672747335e-08
and O 0 3.318586294653869e-08
the O 0 1.3430511103251774e-07
mature O 0 2.943369736385648e-06
lysosomal O 0 0.00010839859169209376
alpha O 0 3.4926977150462335e-06
- O 0 4.499298484006431e-06
subunit O 0 1.7472037825427833e-06
was O 0 5.6774247241264675e-06
not O 0 3.0816153184787254e-07
detected O 0 2.8316908355918713e-05
. O 0 1.4145838349577389e-06

When O 0 6.204440069268458e-06
the O 0 4.206127073302923e-07
W474C O 0 1.1967026694037486e-05
- O 0 3.008128487635986e-06
containing O 0 3.707249334183871e-07
alpha O 0 8.724001077098364e-07
- O 0 1.5646833162463736e-06
subunit O 0 7.803292874086765e-07
was O 0 5.136828804097604e-06
transiently O 0 2.4940814910223708e-05
co O 0 1.1902400729013607e-05
- O 0 2.822524493240053e-06
expressed O 0 4.4529134157755834e-08
with O 0 2.8089532477793e-08
the O 0 6.134626318043956e-08
beta O 0 3.9091622738851584e-07
- O 0 2.759461779078265e-07
subunit O 0 4.55239401730978e-08
to O 0 6.007919939321482e-09
produce O 0 8.380276028674416e-08
Hex O 0 1.0265960554534104e-05
A O 0 2.0798931927856756e-06
( O 0 1.7733533752561925e-07
alphabeta O 0 2.243892777187284e-05
) O 0 9.609352957795636e-08
in O 0 2.952389763777319e-07
COS O 0 0.0002420718956273049
- O 0 1.5856454410823062e-05
7 O 0 1.5240243556036148e-06
cells O 0 2.222578245891782e-07
, O 0 1.847522490550091e-08
the O 0 1.5615075454888938e-08
mature O 0 2.8852247169197653e-07
alpha O 0 3.43148798265247e-07
- O 0 5.884991196580813e-07
subunit O 0 2.387518520663434e-07
was O 0 7.771862442496058e-07
present O 0 2.6804240604860752e-08
, O 0 2.8906384841320687e-08
but O 0 7.346637964644742e-09
its O 0 6.8133210184839754e-09
level O 0 3.3288694112343364e-07
was O 0 7.383318916254211e-07
much O 0 4.059770830622256e-08
lower O 0 5.402400802267948e-07
than O 0 8.061626921573861e-09
that O 0 2.5012321103190516e-09
from O 0 1.9156892960836558e-08
normal O 0 2.466326805006247e-07
alpha O 0 5.571744168264559e-07
- O 0 1.4011079656484071e-06
subunit O 0 4.452293751455727e-07
transfections O 0 1.1181118679814972e-05
, O 0 4.7875406750108596e-08
although O 0 1.471375643546935e-08
higher O 0 9.929335931246897e-08
than O 0 8.486336966484487e-09
in O 0 9.67893587500157e-09
those O 0 9.648173815435257e-09
cells O 0 9.30184427261338e-08
transfected O 0 2.1337207272154046e-06
with O 0 2.377683649967821e-08
an O 0 5.905512523440848e-08
alpha O 0 9.285993769481138e-07
- O 0 4.132382400712231e-06
subunit O 0 1.507911633780168e-06
associated O 0 4.109180736122653e-06
with O 0 4.888759121968178e-06
infantile O 1 0.9851005673408508
TSD B-Disease 1 0.55338454246521
. O 0 6.262116221478209e-05

Furthermore O 0 1.7359086996293627e-05
, O 0 2.996264072407939e-07
the O 0 1.232719739618915e-07
precursor O 0 4.912669737677788e-06
level O 0 2.1912894681008765e-06
of O 0 2.5654028235067017e-08
the O 0 1.3347845140287973e-07
W474C O 0 7.099708000168903e-06
alpha O 0 1.0205011449215817e-06
- O 0 1.2366518831186113e-06
subunit O 0 3.694081840421859e-07
was O 0 1.1068502772104694e-06
found O 0 6.529814555733537e-08
to O 0 1.194719612129802e-08
accumulate O 0 8.745642503527051e-07
in O 0 2.2844860225745833e-08
comparison O 0 4.662814134803739e-08
to O 0 8.720339117473941e-09
the O 0 2.824420164415642e-08
normal O 0 5.766961521658232e-07
alpha O 0 1.0081514574267203e-06
- O 0 2.105307430610992e-06
subunit O 0 1.1208428531972459e-06
precursor O 0 1.1921076293219812e-05
levels O 0 2.1404248400358483e-05
. O 0 2.2881963559484575e-06

We O 0 2.5519927930872655e-06
conclude O 0 1.6803336393422796e-06
that O 0 3.5595359548779015e-08
the O 0 3.9019886344249244e-07
1422 O 0 0.0005854120827279985
G O 0 0.00032212401856668293
- O 0 8.031851757550612e-05
- O 0 5.1336257456569e-05
> O 0 2.587507879070472e-05
C O 0 2.3615437385160476e-05
mutation O 0 2.5422568796784617e-06
is O 0 9.624081798165207e-08
the O 0 8.842864218649993e-08
cause O 0 2.6499749310460174e-06
of O 0 1.3616275396088895e-07
Hex B-Disease 0 0.00036273212754167616
A I-Disease 0 0.0016118560452014208
enzyme I-Disease 1 0.9996798038482666
deficiency I-Disease 1 0.999994158744812
in O 0 3.0403780328924768e-06
the O 0 2.5447020561841782e-06
proband O 0 0.0015991636319085956
. O 0 1.0510962056287099e-05

The O 0 3.041422132810112e-06
resulting O 0 9.508983566774987e-06
W474C O 0 2.7272291845292784e-05
substitution O 0 4.508575273121096e-07
clearly O 0 8.765198344917735e-07
interferes O 0 3.830018158623716e-06
with O 0 1.1976827352100372e-07
alpha O 0 9.432461069991405e-07
- O 0 9.515439387541846e-07
subunit O 0 2.2135036203962954e-07
processing O 0 6.544078701153921e-07
, O 0 1.6050489648478106e-07
but O 0 2.8693854403627483e-08
because O 0 3.269517634407748e-08
the O 0 2.1247865689133505e-08
base O 0 5.660631359205581e-07
substitution O 0 3.9061288248376513e-07
falls O 0 9.113115083891898e-05
at O 0 2.8092588308936683e-06
the O 0 6.167452681893337e-08
first O 0 1.219018344045253e-07
position O 0 5.54039218059188e-07
of O 0 5.3444747294406625e-08
exon O 0 2.307246541022323e-05
13 O 0 1.924679054354783e-06
, O 0 1.0644093606515526e-07
aberrant O 0 3.707383939399733e-06
splicing O 0 3.2623811421217397e-06
may O 0 7.256397793753422e-07
also O 0 4.203424097681818e-08
contribute O 0 8.822647856732146e-08
to O 0 1.1888995032904859e-07
Hex B-Disease 0 0.0004198883834760636
A I-Disease 0 0.0008654893026687205
deficiency I-Disease 1 0.9968644976615906
in O 0 3.44921176065327e-07
this O 0 7.271694357768865e-08
proband O 0 0.00010760044096969068
. O 0 1.0879944056796376e-06
. O 0 2.185691528211464e-06

Two O 0 6.983668754401151e-06
frequent O 0 0.00033755466574802995
missense O 0 0.0029713883996009827
mutations O 0 0.00683681620284915
in O 0 0.0009736489737406373
Pendred B-Disease 1 0.9999394416809082
syndrome I-Disease 1 0.9999994039535522
. O 0 0.00015102192992344499

Pendred B-Disease 1 0.9999160766601562
syndrome I-Disease 1 0.9999994039535522
is O 0 0.000974484661128372
an O 0 0.006273995153605938
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
characterized O 1 0.9422838091850281
by O 0 1.793303272279445e-05
early O 0 0.0033817703370004892
childhood O 1 0.9978631138801575
deafness B-Disease 1 0.9999995231628418
and O 1 0.9979397654533386
goiter B-Disease 1 0.9999990463256836
. O 0 0.00030919528217054904

A O 0 7.4644858614192344e-06
century O 0 1.7199521380462102e-06
after O 0 6.959056690902798e-07
its O 0 2.924745778898341e-08
recognition O 0 3.3955845424316067e-07
as O 0 3.135307906632079e-06
a O 0 0.00021173548884689808
syndrome O 1 0.9994474053382874
by O 0 8.741815236135153e-07
Vaughan O 0 6.244965334190056e-05
Pendred O 0 0.0003635779139585793
, O 0 1.145700593951915e-06
the O 0 3.204658696631668e-06
disease O 0 0.06920337677001953
gene O 0 1.405362672812771e-05
( O 0 2.0868728825007565e-06
PDS O 0 0.0004732169327326119
) O 0 2.2822001710665063e-07
was O 0 2.0309651063143974e-06
mapped O 0 1.8891811350840726e-06
to O 0 1.403541745048642e-07
chromosome O 0 7.209686009446159e-05
7q22 O 0 0.00038068098365329206
- O 0 0.0006280586821958423
q31 O 0 0.00043073194683529437
. O 0 1.0900520464929286e-05

1 O 0 1.4167482731863856e-05
and O 0 1.0488885209269938e-06
, O 0 5.998373353577335e-07
recently O 0 1.0821263458637986e-05
, O 0 6.743778868667505e-08
found O 0 2.923602338000819e-08
to O 0 3.3399334409267567e-09
encode O 0 2.965223018236429e-07
a O 0 6.42647364657023e-06
putative O 0 0.0003078827285207808
sulfate O 0 0.008276629261672497
transporter O 0 0.007732408586889505
. O 0 2.2740561689715832e-05

We O 0 4.786756107932888e-06
performed O 0 8.836271263135131e-06
mutation O 0 4.363166681287112e-06
analysis O 0 1.2002759319784673e-07
of O 0 1.6010549330758295e-08
the O 0 3.1402916533807e-07
PDS B-Disease 0 0.00013528477575164288
gene O 0 3.4767458600981627e-06
in O 0 8.985808790384908e-07
patients O 0 2.62103844761441e-06
from O 0 1.4918428803412098e-07
14 O 0 8.005150675671757e-07
Pendred B-Disease 0 6.633936664002249e-06
families O 0 1.388521031486789e-08
originating O 0 3.6482600762610673e-07
from O 0 2.9579917182331883e-08
seven O 0 4.0292380987239085e-08
countries O 0 5.972455863201276e-09
and O 0 6.179934786132435e-08
identified O 0 1.369457208966196e-06
all O 0 1.6907938515942078e-07
mutations O 0 5.464766582008451e-05
. O 0 6.120256330177654e-06

The O 0 1.1678341707010986e-06
mutations O 0 6.9395323407661635e-06
include O 0 1.1360722851350147e-07
three O 0 7.325205331198958e-08
single O 0 4.0322524341718236e-07
base O 0 1.0228591236227658e-06
deletions O 0 3.186610683769686e-06
, O 0 7.762397302712998e-08
one O 0 5.81655150710958e-08
splice O 0 1.6242029232671484e-05
site O 0 9.782045708561782e-06
mutation O 0 9.243643035006244e-06
and O 0 5.125301640873658e-07
10 O 0 2.872136974474415e-06
missense O 0 0.00026460314984433353
mutations O 0 0.0004498616617638618
. O 0 1.2173760296718683e-05

One O 0 2.029871757258661e-05
missense O 0 0.0009388930629938841
mutation O 0 0.0001456659083487466
( O 0 7.494813303310366e-07
L236P O 0 9.653838787926361e-06
) O 0 1.2445165964436455e-07
was O 0 1.1768757985919365e-06
found O 0 6.452152945257694e-08
in O 0 1.7127577578435194e-08
a O 0 1.5508967976529675e-07
homozygous O 0 1.0008279787143692e-06
state O 0 5.4809287775015036e-08
in O 0 3.5708442425175235e-08
two O 0 5.048844542443476e-08
consanguineous O 0 4.5531145588029176e-05
families O 0 1.5837375144656107e-07
and O 0 1.872869859198545e-07
in O 0 9.788494281792737e-08
a O 0 2.2600904969749536e-07
heterozygous O 0 2.752229022462416e-07
state O 0 5.716203688166388e-08
in O 0 1.9611036350397626e-08
five O 0 3.201867215807397e-08
additional O 0 4.279875298607294e-08
non O 0 1.1344194717821665e-05
- O 0 0.0006844562594778836
consanguineous O 0 0.001488925889134407
families O 0 4.725401595351286e-06
. O 0 9.758677151694428e-06

Another O 0 5.7523859140928835e-05
missense O 0 0.001345088821835816
mutation O 0 0.0002250038378406316
( O 0 1.0856571179829189e-06
T416P O 0 2.6107178200618364e-05
) O 0 2.166331256603371e-07
was O 0 1.4392632010640227e-06
found O 0 5.701634364640995e-08
in O 0 1.6305479633160758e-08
a O 0 1.2515472747054446e-07
homozygous O 0 7.984907028912858e-07
state O 0 9.162665293160899e-08
in O 0 2.0663584621161135e-08
one O 0 5.170901573592346e-08
family O 0 4.580422512390214e-07
and O 0 9.538574374801101e-08
in O 0 5.5232003859373435e-08
a O 0 2.2340151417665766e-07
heterozygous O 0 2.205900386798021e-07
state O 0 5.604808706038966e-08
in O 0 2.8507995963877875e-08
four O 0 7.441695970555884e-08
families O 0 9.520815069663513e-08
. O 0 2.025183903242578e-06

Pendred B-Disease 0 0.007687225006520748
patients O 0 2.897243575716857e-05
in O 0 3.682288252093713e-07
three O 0 3.05966096902921e-07
non O 0 1.0146755812456831e-05
- O 0 9.038126154337078e-05
consanguineous O 0 0.00024244218366220593
families O 0 2.0336364059403422e-07
were O 0 8.715870336573062e-08
shown O 0 7.639167876050124e-08
to O 0 1.1139409394900213e-08
be O 0 4.298765787780212e-08
compound O 0 1.6317540030286182e-06
heterozygotes O 0 4.438762516656425e-06
for O 0 9.262205225013531e-08
L236P O 0 2.066476554318797e-05
and O 0 1.4390901696970104e-06
T416P O 0 0.00013028028479311615
. O 0 7.550242571596755e-06

In O 0 6.179257638905256e-07
total O 0 9.591553862264846e-08
, O 0 8.891267810895442e-08
one O 0 3.3542608690595443e-08
or O 0 7.707412663648938e-08
both O 0 1.8071187213308804e-08
of O 0 1.5225332106183487e-08
these O 0 1.3122553710331886e-08
mutations O 0 1.8330980537939467e-06
were O 0 7.113739997066659e-08
found O 0 1.383174179636626e-07
in O 0 3.1140945822016874e-08
nine O 0 1.5796224772657297e-07
of O 0 1.0812740036669766e-08
the O 0 1.9602255463269103e-07
14 O 0 1.1046462304875604e-06
families O 0 8.466583523158988e-08
analyzed O 0 1.106993749999674e-05
. O 0 2.4510743514838396e-06

The O 0 3.7888142401243385e-07
identification O 0 5.172086048332858e-07
of O 0 1.010728851724707e-07
two O 0 3.6938317293788714e-07
frequent O 0 4.3461706809466705e-05
PDS B-Disease 0 0.005766117945313454
mutations O 0 1.9448909370112233e-05
will O 0 3.8776011734853455e-08
facilitate O 0 5.270977965210477e-08
the O 0 5.918638521507091e-07
molecular O 0 0.0004423552891239524
diagnosis O 1 0.7234262228012085
of O 0 0.0005756370956078172
Pendred B-Disease 1 0.9999911785125732
syndrome I-Disease 1 0.9999996423721313
. O 0 0.000148035105667077

Insertional O 0 0.002509455196559429
mutation O 0 0.00011039010860258713
by O 0 3.7809994068993547e-07
transposable O 0 0.00013263065193314105
element O 0 1.7790458514355123e-05
, O 0 1.7064679695977247e-06
L1 O 0 6.80123848724179e-05
, O 0 3.1448800541511446e-07
in O 0 1.2396955639815133e-07
the O 0 6.910671572768479e-07
DMD B-Disease 1 0.7219442129135132
gene O 0 3.698883574543288e-06
results O 0 1.7923617861015373e-06
in O 0 1.8874055740525364e-06
X B-Disease 1 0.9681416153907776
- I-Disease 1 0.9976479411125183
linked I-Disease 1 0.9930419921875
dilated I-Disease 1 0.9964615702629089
cardiomyopathy I-Disease 1 0.9999887943267822
. O 0 7.855616422602907e-05

X B-Disease 1 0.9947073459625244
- I-Disease 1 0.996483564376831
linked I-Disease 1 0.9929420948028564
dilated I-Disease 1 0.9967336654663086
cardiomyopathy I-Disease 1 0.9999786615371704
( O 0 1.5940207958919927e-05
XLDCM B-Disease 0 0.0013463750947266817
) O 0 2.056333272548727e-07
is O 0 1.6012694459277554e-07
a O 0 6.714579399158538e-07
clinical O 0 2.4684881282155402e-05
phenotype O 0 2.4402675990131684e-05
of O 0 2.0850538362537918e-07
dystrophinopathy B-Disease 0 0.0009288520086556673
which O 0 5.018998763262061e-07
is O 0 5.068431505605986e-07
characterized O 0 1.0821717296494171e-05
by O 0 5.491444881045027e-07
preferential O 0 5.3822379413759336e-05
myocardial B-Disease 1 0.9964841604232788
involvement I-Disease 0 2.7957938073086552e-05
without O 0 6.93113918259769e-07
any O 0 3.599318176839006e-07
overt O 0 2.965814564959146e-05
clinical O 0 0.0003108836244791746
signs O 0 0.0014756520977243781
of O 0 7.64546130085364e-05
skeletal B-Disease 1 0.9999958276748657
myopathy I-Disease 1 1.0
. O 0 0.002086898311972618

To O 0 3.3582819014554843e-07
date O 0 1.912524112412939e-06
, O 0 1.1864484150692078e-07
several O 0 1.2608990118678776e-07
mutations O 0 1.047747446136782e-05
in O 0 1.0234210776616237e-06
the O 0 2.9827566322637722e-05
Duchenne B-Disease 1 0.9996852874755859
muscular I-Disease 1 0.9994310736656189
dystrophy I-Disease 1 0.997736930847168
gene O 0 0.00022487601381726563
, O 0 1.7650669178692624e-05
DMD O 1 0.9985912442207336
, O 0 9.857053555606399e-07
have O 0 8.609892176991707e-08
been O 0 3.3449211400693457e-07
identified O 0 4.5211564270175586e-07
in O 0 2.6823400389730523e-07
patients O 0 1.2584870319187758e-06
with O 0 3.5287888522361754e-07
XLDCM B-Disease 0 0.0031594368629157543
, O 0 6.913677452757838e-07
but O 0 5.934520785899622e-08
a O 0 1.390517212485065e-07
pathogenic O 0 2.765921863101539e-06
correlation O 0 1.1724011272917778e-07
of O 0 2.2959131484867612e-08
these O 0 1.048843003559341e-07
cardiospecific O 0 0.0002907517773564905
mutations O 0 9.3413756985683e-05
in O 0 4.5961446630826686e-06
DMD O 1 0.9983952641487122
with O 0 1.7812599253375083e-06
the O 0 3.508675490593305e-06
XLDCM B-Disease 0 0.00653839111328125
phenotype O 0 8.682939369464293e-05
has O 0 1.278150534744782e-06
remained O 0 2.103441147482954e-06
to O 0 2.6226205207535713e-08
be O 0 4.218910305553436e-07
elucidated O 0 0.00011533298675203696
. O 0 5.91357593293651e-06

We O 0 1.5754005289636552e-05
report O 0 7.724262331976206e-07
here O 0 5.3780560449467885e-08
the O 0 6.7886487542523355e-09
identification O 0 3.814580296079839e-08
of O 0 2.8124324202849493e-08
a O 0 1.2242252296346123e-06
unique O 0 2.6243076263199328e-06
de O 0 0.0002797998604364693
novo O 0 7.644010474905372e-05
L1 O 0 6.289957673288882e-05
insertion O 0 4.4907246774528176e-06
in O 0 3.325369846152171e-07
the O 0 2.609042724088795e-07
muscle O 0 3.112630656687543e-05
exon O 0 2.1648413166985847e-05
1 O 0 3.5983578072773525e-06
in O 0 2.04645880330645e-06
DMD O 1 0.997531533241272
in O 0 1.5729315236967523e-06
three O 0 1.7827146621129941e-06
XLDCM B-Disease 0 0.0023807045072317123
patients O 0 9.890803084999789e-06
from O 0 2.4290699229823076e-07
two O 0 1.2540418481421511e-07
unrelated O 0 6.853716058685677e-06
Japanese O 0 5.8954342421202455e-06
families O 0 9.983199333873927e-07
. O 0 6.535112788697006e-06

The O 0 1.0051149956780137e-06
insertion O 0 5.583081019722158e-06
was O 0 7.276047654158901e-06
a O 0 6.890822987770662e-07
5 O 0 1.0379259265391738e-06
- O 0 3.4816334846254904e-06
truncated O 0 2.8788338113372447e-06
form O 0 3.0539703743670543e-07
of O 0 4.3355566248237665e-08
human O 0 7.880380508140661e-07
L1 O 0 3.4741002309601754e-05
inversely O 0 1.1018413715646602e-05
integrated O 0 6.820059297751868e-06
in O 0 3.6807119840887026e-07
the O 0 2.1289818619152356e-07
5 O 0 4.745520527649205e-06
- O 0 4.428474130691029e-05
untranslated O 0 0.0001669791672611609
region O 0 6.000392204441596e-06
in O 0 2.549297164478048e-07
the O 0 4.214261650758999e-07
muscle O 0 3.1784846214577556e-05
exon O 0 1.6595397028140724e-05
1 O 0 2.156092932636966e-06
, O 0 6.510849459573365e-08
which O 0 2.7083498110869186e-08
affected O 0 8.505397630642619e-08
the O 0 2.5817785243020808e-08
transcription O 0 1.1566648936423007e-06
or O 0 4.575872765144595e-07
the O 0 1.8506337085000268e-07
stability O 0 3.0091614462435246e-06
of O 0 1.1942756827920675e-07
the O 0 7.461465543201484e-07
muscle O 0 4.005100709036924e-05
form O 0 7.026706043689046e-07
of O 0 9.47052001265547e-08
dystrophin O 0 5.77811042603571e-05
transcripts O 0 1.2325226634857245e-05
but O 0 1.0679028861204642e-07
not O 0 2.068136595312353e-08
that O 0 3.713605867261549e-09
of O 0 7.784100475305422e-09
the O 0 9.519504828858771e-07
brain O 0 0.023553671315312386
or O 0 1.22862165881088e-05
Purkinje O 0 0.0016979866195470095
cell O 0 0.00012207176769152284
form O 0 6.3821325966273434e-06
, O 0 1.0305109299224569e-06
probably O 0 9.726034022605745e-07
due O 0 3.2940997130026517e-07
to O 0 5.504361855201978e-09
its O 0 1.663316595568176e-08
unique O 0 1.6174460881757113e-07
site O 0 3.579946223908337e-06
of O 0 1.1113671405382775e-07
integration O 0 6.4278528952854685e-06
. O 0 5.319600859365892e-06

We O 0 3.6435210404306417e-06
speculate O 0 6.903570692884387e-07
that O 0 9.192682171033084e-09
this O 0 9.714650417436133e-09
insertion O 0 4.4825256395597535e-07
of O 0 2.0640579023734063e-08
an O 0 1.5351734816704266e-07
L1 O 0 5.288491229293868e-05
sequence O 0 4.7066519073268864e-06
in O 0 4.17878163716523e-06
DMD O 1 0.997870922088623
is O 0 4.4665236487162474e-07
responsible O 0 6.338590310406289e-07
for O 0 1.1735125760026222e-08
some O 0 3.9658458739211255e-09
of O 0 8.685497654425944e-09
the O 0 4.033813283399468e-08
population O 0 8.739604595575656e-09
of O 0 2.8738492474644772e-08
Japanese O 0 2.6840211830858607e-06
patients O 0 2.6430018351675244e-06
with O 0 5.10822246724274e-07
XLDCM B-Disease 0 0.0039498088881373405
. O 0 1.5863508906477364e-06
. O 0 2.1900839328736765e-06

Severe O 1 0.9656087160110474
early O 0 0.00902160070836544
- O 1 0.9972611665725708
onset O 1 0.9984669089317322
obesity B-Disease 1 0.999984860420227
, O 0 0.004416658543050289
adrenal B-Disease 1 0.9999758005142212
insufficiency I-Disease 1 0.9999836683273315
and O 0 0.0007524362299591303
red O 1 0.9537829756736755
hair O 1 0.9976778626441956
pigmentation O 1 0.9883168339729309
caused O 0 0.0017235366394743323
by O 0 2.6106881705345586e-06
POMC O 0 0.0055037797428667545
mutations O 0 0.0001029036138788797
in O 0 1.0393096090410836e-06
humans O 0 9.542188308842015e-06
. O 0 4.058976628584787e-06

Sequential O 0 2.241775109723676e-05
cleavage O 0 8.768818224780262e-05
of O 0 1.1637767727279424e-07
the O 0 8.840689247335831e-08
precursor O 0 3.779538928938564e-06
protein O 0 2.4268615561595652e-06
pre O 0 0.00015714470646344125
- O 0 0.000293757941108197
pro O 0 0.0008134061354212463
- O 0 0.0005655063432641327
opiomelanocortin O 0 0.0006285923300310969
( O 0 1.8347876675761654e-06
POMC O 0 0.0003603223303798586
) O 0 2.2921904019312933e-07
generates O 0 9.438084589419304e-07
the O 0 8.872630701262096e-07
melanocortin O 0 0.0023447091225534678
peptides O 0 9.25518324947916e-05
adrenocorticotrophin O 0 0.00042817823123186827
( O 0 1.8838881032934296e-06
ACTH O 0 0.0001847125095082447
) O 0 5.340541520126862e-07
, O 0 9.830552016865113e-07
melanocyte O 0 0.000690029002726078
- O 0 0.000544646056368947
stimulating O 0 9.977587615139782e-05
hormones O 0 9.917713032336906e-05
( O 0 8.512333238286374e-07
MSH O 0 0.00023279002925846726
) O 0 3.2673856509291e-08
alpha O 0 1.4680641413633566e-07
, O 0 2.2646553077265708e-08
beta O 0 1.666788449483647e-07
and O 0 2.5045466145456885e-08
gamma O 0 2.8040130928275175e-07
as O 0 1.743170763290891e-08
well O 0 1.247718905972306e-08
as O 0 4.328376235207543e-08
the O 0 4.856130075836518e-08
opioid O 0 7.485421974706696e-06
- O 0 3.5838816074829083e-06
receptor O 0 1.1412948879296891e-06
ligand O 0 5.466085440275492e-06
beta O 0 5.1870287279598415e-05
- O 0 0.00019983160018455237
endorphin O 0 0.0019314922392368317
. O 0 7.681738679821137e-06

While O 0 2.8163674414827256e-06
a O 0 1.0564015155978268e-06
few O 0 9.573858505973476e-07
cases O 0 2.6349910058343085e-06
of O 0 2.557557536420063e-06
isolated O 0 0.33629757165908813
ACTH B-Disease 1 0.9873853921890259
deficiency I-Disease 1 0.9981610178947449
have O 0 1.5406000102302642e-06
been O 0 3.793535370277823e-06
reported O 0 1.9666378648253158e-05
( O 0 1.266465915250592e-06
OMIM O 0 0.002916885307058692
201400 O 0 0.0003375325177330524
) O 0 8.723584983272303e-07
, O 0 6.753909360668331e-07
an O 0 2.998321633640444e-06
inherited O 1 0.9965811371803284
POMC O 1 0.9800177812576294
defect O 0 0.24779345095157623
has O 0 1.2299290119699435e-06
not O 0 5.5229367745823765e-08
been O 0 2.684010951270466e-07
described O 0 1.1335522458466585e-06
so O 0 2.3423848460879526e-07
far O 0 2.3695401978329755e-06
. O 0 2.556392018959741e-06

Recent O 0 1.5019905731605832e-05
studies O 0 9.190877676701348e-07
in O 0 9.622025487487917e-08
animal O 0 3.8306137639665394e-07
models O 0 4.888489115728589e-07
elucidated O 0 8.042009540076833e-06
a O 0 3.004877271450823e-07
central O 0 2.187006344911424e-07
role O 0 2.962947576179431e-07
of O 0 1.230903592386312e-07
alpha O 0 1.3023909559706226e-05
- O 0 0.00012261902156751603
MSH O 0 0.0012711199233308434
in O 0 2.439402635445731e-07
the O 0 1.0215123324996966e-07
regulation O 0 1.8978236084876698e-06
of O 0 3.1635867259183215e-08
food O 0 4.250961751495197e-07
intake O 0 1.0703188308980316e-06
by O 0 1.527087611918887e-08
activation O 0 6.32608930573042e-07
of O 0 4.9622713049757294e-08
the O 0 8.455656370642828e-07
brain O 0 0.0026912738103419542
melanocortin O 0 0.0014869942096993327
- O 0 5.9416408475954086e-05
4 O 0 6.505935289169429e-06
- O 0 1.3047070751781575e-05
receptor O 0 4.665710548579227e-06
( O 0 7.351953286161006e-07
MC4 O 0 0.00047382223419845104
- O 0 4.645959415938705e-05
R O 0 6.668834976153448e-05
; O 0 2.000149663672346e-07
refs O 0 1.9470437109703198e-05
3 O 0 1.0468208984093508e-06
- O 0 2.463337523295195e-06
5 O 0 1.5072014036832115e-07
) O 0 6.126204876721886e-09
and O 0 8.075216939573693e-09
the O 0 2.5384327528854556e-08
linkage O 0 5.235655862634303e-06
of O 0 5.437601089397504e-07
human O 0 6.892923556733876e-05
obesity B-Disease 1 0.999290943145752
to O 0 2.3561432271890226e-07
chromosome O 0 1.3476545973389875e-05
2 O 0 6.077154353079095e-07
in O 0 4.050304269753724e-08
close O 0 4.86031865420955e-07
proximity O 0 4.002185960416682e-07
to O 0 6.588287959630179e-08
the O 0 5.941122935837484e-07
POMC O 0 0.00032666989136487246
locus O 0 3.043673677893821e-05
, O 0 6.338547677842143e-07
led O 0 2.6520228857407346e-07
to O 0 7.815594393889569e-09
the O 0 5.949945958150238e-08
proposal O 0 7.378461646112555e-07
of O 0 3.086343980385209e-08
an O 0 1.9116967564514198e-07
association O 0 1.2316332913542283e-06
of O 0 1.9204642853765108e-07
POMC O 0 0.0036378875374794006
with O 0 2.605797453725245e-05
human O 0 0.004300074186176062
obesity B-Disease 1 0.9999337196350098
. O 0 2.2400610760087147e-05

The O 0 4.809525080418098e-07
dual O 0 4.462693141249474e-06
role O 0 6.238145942916162e-06
of O 0 1.7532527181174373e-06
alpha O 0 6.995751027716324e-05
- O 0 0.0004523971292655915
MSH O 0 0.002618007129058242
in O 0 8.108725069178035e-07
regulating O 0 9.219214007316623e-06
food O 0 1.3858640386388288e-06
intake O 0 1.1919666576432064e-05
and O 0 5.790488444290531e-07
influencing O 0 4.9384434532839805e-05
hair O 1 0.8505202531814575
pigmentation O 0 0.1107189878821373
predicts O 0 3.547462620190345e-05
that O 0 5.559982696468069e-08
the O 0 2.7873016961166286e-07
phenotype O 0 1.604519820830319e-05
associated O 0 1.0519679563003592e-06
with O 0 2.578363762495428e-07
a O 0 1.7480973838246427e-05
defect O 0 0.0021267596166580915
in O 0 1.6981172166197211e-06
POMC O 0 0.0006337777012959123
function O 0 3.654692136478843e-06
would O 0 2.094034016408841e-06
include O 0 2.2754618839826435e-05
obesity B-Disease 1 0.9999262094497681
, O 0 3.97742269342416e-06
alteration O 0 0.00018859756528399885
in O 0 7.851066584407818e-06
pigmentation O 1 0.7409734725952148
and O 0 0.0010113308671861887
ACTH B-Disease 1 0.9862761497497559
deficiency I-Disease 1 0.999329686164856
. O 0 2.5903151254169643e-05

The O 0 2.668635715963319e-06
observation O 0 2.6413856176077388e-05
of O 0 1.637450424141207e-07
these O 0 2.921462964877719e-07
symptoms O 0 0.000892633746843785
in O 0 1.8727948258856486e-07
two O 0 2.1578998143922945e-07
probands O 0 8.5036015661899e-05
prompted O 0 1.0624980859574862e-06
us O 0 1.2743527122438536e-07
to O 0 4.147538756882341e-09
search O 0 8.87618725187167e-08
for O 0 4.209674031585564e-08
mutations O 0 2.5022698082466377e-06
within O 0 1.323895730820368e-07
their O 0 3.049273402666586e-07
POMC O 0 0.002065166598185897
genes O 0 5.873934424016625e-05
. O 0 1.3783661415800452e-05

Patient O 0 0.00022480569896288216
1 O 0 8.336104656336829e-06
was O 0 9.052780114870984e-06
found O 0 1.2916919445160602e-07
to O 0 5.5500199991342924e-09
be O 0 1.0268938588353649e-08
a O 0 5.3209788575259154e-08
compound O 0 6.127539791123127e-07
heterozygote O 0 8.33974070246768e-07
for O 0 1.4633068978753272e-08
two O 0 5.28195762683481e-08
mutations O 0 3.6163257846055785e-06
in O 0 2.3711672270110284e-07
exon O 0 1.617721136426553e-05
3 O 0 2.8487072540883673e-06
( O 0 2.8506727289823175e-07
G7013T O 0 1.3296722499944735e-05
, O 0 6.161480428090726e-07
C7133delta O 0 1.958007487701252e-05
) O 0 6.978197575335798e-08
which O 0 1.3715591329344079e-08
interfere O 0 1.6808613167995645e-07
with O 0 2.9724589012403158e-08
appropriate O 0 7.733402895837571e-08
synthesis O 0 1.5001805877545848e-06
of O 0 4.04374361551163e-07
ACTH O 0 0.00012804004654753953
and O 0 1.964894863704103e-06
alpha O 0 3.1018269510241225e-05
- O 0 0.00126088026445359
MSH O 0 0.024629738181829453
. O 0 1.1743358300009277e-05

Patient O 0 0.0003815897216554731
2 O 0 5.228450390859507e-06
was O 0 2.560386064942577e-06
homozygous O 0 5.539134804166679e-07
for O 0 1.3409604981973189e-08
a O 0 2.1812033423884714e-07
mutation O 0 3.056624109376571e-06
in O 0 1.7234842175639642e-07
exon O 0 1.1939531759708188e-05
2 O 0 2.936528971986263e-06
( O 0 4.101102035747317e-07
C3804A O 0 1.935056207003072e-05
) O 0 1.656791539517144e-07
which O 0 2.321010867945006e-07
abolishes O 0 0.0003684852854348719
POMC O 0 0.0024701945949345827
translation O 0 3.162357461405918e-05
. O 0 1.7466809367761016e-05

These O 0 2.896351531944674e-07
findings O 0 9.134917036135448e-07
represent O 0 2.986062597187811e-08
the O 0 3.4411876015383314e-08
first O 0 1.2540036209429672e-07
examples O 0 4.49228735988072e-07
of O 0 3.43289912052569e-07
a O 0 0.00020595673413481563
genetic B-Disease 1 0.9990082383155823
defect I-Disease 1 0.9997376799583435
within O 0 3.091168309765635e-06
the O 0 1.0260479257340194e-06
POMC O 0 0.0003987156378570944
gene O 0 3.658475861811894e-06
and O 0 3.611200725117669e-07
define O 0 2.5396154796908377e-06
a O 0 1.115679151553195e-05
new O 0 0.00011206459748791531
monogenic B-Disease 1 0.9937366247177124
endocrine I-Disease 1 0.9998207688331604
disorder I-Disease 1 0.999372661113739
resulting O 0 5.9577538195298985e-05
in O 0 4.5297028918867e-06
early O 0 0.000499510089866817
- O 1 0.9944429993629456
onset O 1 0.9983479976654053
obesity B-Disease 1 0.9999841451644897
, O 0 0.007945406250655651
adrenal B-Disease 1 0.9999760389328003
insufficiency I-Disease 1 0.9999850988388062
and O 0 0.0004442640929482877
red O 0 0.438841849565506
hair O 1 0.9744396805763245
pigmentation O 0 0.0501021146774292
. O 0 5.102436261950061e-06
. O 0 6.175261205498828e-06

A O 0 4.722149242297746e-05
European O 0 6.432033842429519e-05
multicenter O 0 0.005948384292423725
study O 0 1.942740345839411e-05
of O 0 4.119593359064311e-05
phenylalanine B-Disease 1 0.9998093247413635
hydroxylase I-Disease 1 0.9997619986534119
deficiency I-Disease 1 0.9999979734420776
: O 0 7.155405455705477e-06
classification O 0 1.3062768630334176e-05
of O 0 9.849003390627331e-08
105 O 0 2.60725960288255e-06
mutations O 0 3.951146936742589e-06
and O 0 6.680650699308899e-08
a O 0 1.432894549679986e-07
general O 0 1.5287641019767761e-07
system O 0 6.944881647541479e-07
for O 0 8.391440786681414e-08
genotype O 0 1.54212011693744e-05
- O 0 2.9486345738405362e-05
based O 0 1.3961048352939542e-06
prediction O 0 1.644214898988139e-05
of O 0 7.741386411908024e-07
metabolic O 0 0.3219532370567322
phenotype O 0 0.0013662700075656176
. O 0 1.2636653082154226e-05

Phenylketonuria B-Disease 1 0.9630987048149109
( O 0 6.961890176171437e-05
PKU B-Disease 0 0.01493977103382349
) O 0 4.619025276042521e-06
and O 0 1.250722834811313e-05
mild B-Disease 1 0.9953243136405945
hyperphenylalaninemia I-Disease 1 0.9999802112579346
( O 0 0.0016047980170696974
MHP B-Disease 1 0.9999574422836304
) O 0 2.836935436789645e-06
are O 0 2.5074057248275494e-06
allelic B-Disease 0 0.058241866528987885
disorders I-Disease 1 0.999804675579071
caused O 0 0.00027811367181129754
by O 0 2.6235542804897705e-07
mutations O 0 6.964833119127434e-06
in O 0 5.1116920474214567e-08
the O 0 5.221307475267167e-08
gene O 0 1.2579795338751865e-06
encoding O 0 1.6000365576473996e-05
phenylalanine O 0 0.012419438920915127
hydroxylase O 0 0.06268815696239471
( O 0 3.757408194360323e-05
PAH O 1 0.9946435689926147
) O 0 6.767152626707684e-06
. O 0 7.984648618730716e-06

Previous O 0 1.717421764624305e-05
studies O 0 5.554257995754597e-07
have O 0 3.8725158191255105e-08
suggested O 0 1.7759867887434666e-07
that O 0 4.892208416151789e-09
the O 0 6.479432101968996e-08
highly O 0 6.800613391533261e-06
variable O 0 0.00018401288252789527
metabolic O 1 0.9888530969619751
phenotypes O 0 0.030075719580054283
of O 0 0.0007401640759781003
PAH B-Disease 1 0.9999716281890869
deficiency I-Disease 1 0.9996862411499023
correlate O 0 0.0003176740719936788
with O 0 0.00013400395982898772
PAH O 1 0.998771607875824
genotypes O 0 0.006061401683837175
. O 0 2.5090586859732866e-05

We O 0 2.48110245593125e-06
identified O 0 1.3717419733438874e-06
both O 0 2.3330346721195383e-07
causative O 0 0.00012423496809788048
mutations O 0 7.194576755864546e-05
in O 0 2.004997895710403e-06
686 O 0 0.00012178864562883973
patients O 0 1.0235909940092824e-05
from O 0 2.0121916577409138e-07
seven O 0 2.686003313101537e-07
European O 0 1.343300027656369e-06
centers O 0 5.2408609008125495e-06
. O 0 5.357270310923923e-06

On O 0 2.69711745204404e-06
the O 0 7.972604976203002e-08
basis O 0 1.1763714979906581e-07
of O 0 1.4644879087200025e-08
the O 0 9.99130662648895e-08
phenotypic O 0 8.143270861182828e-06
characteristics O 0 2.248533746751491e-06
of O 0 5.130612521497824e-07
297 O 0 4.672931390814483e-05
functionally O 0 0.0006125306827016175
hemizygous O 0 0.0024358576629310846
patients O 0 2.273878089908976e-05
, O 0 1.8014992519965745e-07
105 O 0 2.6263455765729304e-07
of O 0 1.2133091864541257e-08
the O 0 4.8169429334166125e-08
mutations O 0 1.211264930134348e-06
were O 0 4.1001587902655956e-08
assigned O 0 9.319425942067028e-08
to O 0 3.6371339273699732e-09
one O 0 1.4829694805484905e-08
of O 0 1.0719186427365912e-08
four O 0 1.7070965441234875e-07
arbitrary O 0 1.9338931451784447e-06
phenotype O 0 4.239039117237553e-05
categories O 0 2.312445212737657e-05
. O 0 6.7276309891894925e-06

We O 0 3.590662117858301e-06
proposed O 0 1.8833707144949585e-06
and O 0 4.2268882793905505e-07
tested O 0 2.939809974122909e-06
a O 0 8.070369972301705e-08
simple O 0 8.976346776989885e-08
model O 0 9.951462232038466e-08
for O 0 5.776360723075413e-09
correlation O 0 7.144634395217508e-08
between O 0 1.3788122998903418e-07
genotype O 0 4.789651029568631e-06
and O 0 1.8977932825237076e-07
phenotypic O 0 1.9362965758773498e-05
outcome O 0 2.5325643946416676e-05
. O 0 1.2790133041562513e-05

The O 0 3.86569354304811e-06
observed O 0 1.303683347941842e-05
phenotype O 0 2.3228642021422274e-05
matched O 0 4.437162260728655e-06
the O 0 4.3417054484962136e-07
predicted O 0 8.003402399481274e-06
phenotype O 0 6.469296749855857e-06
in O 0 2.405477914635412e-07
79 O 0 2.1315711364877643e-06
% O 0 1.7163351628823875e-08
of O 0 7.4385426707124225e-09
the O 0 7.402934443234699e-08
cases O 0 2.6120775942217733e-07
, O 0 8.276152385633395e-08
and O 0 3.9842714016913305e-08
in O 0 3.5023457911620426e-08
only O 0 1.6806426472726343e-08
5 O 0 1.5980414502791973e-07
of O 0 2.5948114767970765e-08
184 O 0 2.793427256619907e-06
patients O 0 2.2919200546311913e-06
was O 0 1.302810574088653e-06
the O 0 6.622455828164675e-08
observed O 0 2.63703725522646e-07
phenotype O 0 2.590830945337075e-07
more O 0 1.730178555980899e-09
than O 0 5.633066901822303e-09
one O 0 2.283963240756748e-08
category O 0 4.77794003472809e-07
away O 0 3.3901389429047413e-07
from O 0 8.686378549782603e-08
that O 0 1.726658638290246e-08
expected O 0 1.148496721725678e-06
. O 0 1.97797976397851e-06

Among O 0 1.1318281849526102e-06
the O 0 2.512911692065245e-07
seven O 0 4.5687480110245815e-07
contributing O 0 1.0107016805704916e-06
centers O 0 7.205024985523778e-07
, O 0 8.91218618903622e-08
the O 0 1.0281210904850013e-07
proportion O 0 5.749542424382525e-07
of O 0 2.415497988295101e-07
patients O 0 2.635001010276028e-06
for O 0 4.135596753940263e-08
whom O 0 8.3322998989388e-07
the O 0 2.744177720614971e-07
observed O 0 4.581987468554871e-06
phenotype O 0 5.800348390039289e-06
did O 0 3.053542627640127e-07
not O 0 3.30687193184076e-08
match O 0 7.197147624538047e-07
the O 0 1.2464776943943434e-07
predicted O 0 2.21526579480269e-06
phenotype O 0 2.831742904163548e-06
was O 0 2.2039166651666164e-06
4 O 0 3.624895441589615e-07
% O 0 5.414956660843018e-08
- O 0 4.257901764503913e-06
23 O 0 1.295552465307992e-06
% O 0 3.422277927711548e-08
( O 0 1.5575579936921713e-07
P O 0 6.365650915540755e-05
< O 0 1.4775699128222186e-05
. O 0 2.6547812126409553e-07
0001 O 0 0.0002310171548742801
) O 0 1.500201989301786e-07
, O 0 1.0080373158416478e-07
suggesting O 0 2.4433560952275e-07
that O 0 5.590254037457498e-09
differences O 0 1.5787414042733872e-07
in O 0 2.6530999619467366e-08
methods O 0 5.310880268893925e-08
used O 0 1.4073403065140155e-07
for O 0 1.0387849869175625e-07
mutation O 0 1.5003698536020238e-05
detection O 0 2.6792775315698236e-05
or O 0 9.616733223083429e-06
phenotype O 0 0.0001203220963361673
classification O 0 9.965815843315795e-05
may O 0 6.771270477656799e-07
account O 0 3.309641982696121e-08
for O 0 1.3854284830472352e-08
a O 0 2.3556602002372529e-07
considerable O 0 3.211546868442383e-07
proportion O 0 8.457454896415584e-07
of O 0 5.633074806610239e-07
genotype O 0 0.00047241291031241417
- O 0 0.021811215206980705
phenotype O 0 0.0008706813678145409
inconsistencies O 0 0.0006033619283698499
. O 0 2.279914951941464e-05

Our O 0 2.5632318738644244e-06
data O 0 7.061032079036522e-07
indicate O 0 1.6606464896540274e-06
that O 0 9.797833655511567e-08
the O 0 4.897718554275343e-06
PAH O 1 0.9960750937461853
- O 0 0.00021052744705229998
mutation O 0 2.0412684534676373e-05
genotype O 0 7.723857379460242e-06
is O 0 1.1780431208308073e-07
the O 0 3.848908036729881e-08
main O 0 1.3763938113697805e-06
determinant O 0 8.298854481836315e-06
of O 0 6.298158155004785e-07
metabolic O 0 0.05207660049200058
phenotype O 0 9.955622954294086e-05
in O 0 1.5649386568838963e-06
most O 0 2.606841917440761e-06
patients O 0 0.0001479320926591754
with O 0 0.004802265204489231
PAH B-Disease 1 0.9999892711639404
deficiency I-Disease 1 0.9997593760490417
. O 0 5.9153633628739044e-05

In O 0 1.4890044894855237e-06
the O 0 2.5404438019904774e-07
present O 0 3.917574247225275e-07
study O 0 2.712600064569415e-07
, O 0 1.522873702697325e-07
the O 0 1.3922714003911096e-07
classification O 0 3.0276643883553334e-05
of O 0 8.548478263037396e-07
105 O 0 0.00010604754788801074
PAH O 1 0.9978477954864502
mutations O 0 0.00025078191538341343
may O 0 1.545189434182248e-06
allow O 0 2.5336490239169507e-08
the O 0 1.249269558911692e-07
prediction O 0 2.9671455195057206e-06
of O 0 1.4344731624760243e-08
the O 0 2.4140979348885594e-07
biochemical O 0 2.492564635758754e-05
phenotype O 0 1.0665391528164037e-05
in O 0 5.578624495683471e-07
> O 0 6.816898803663207e-06
10 O 0 4.766593519889284e-07
, O 0 6.986014255971895e-08
000 O 0 3.5112256568936573e-07
genotypes O 0 3.7204570162430173e-06
, O 0 2.2347781225562358e-07
which O 0 6.798421026132928e-08
may O 0 9.605247441868414e-08
be O 0 5.8290541282701724e-09
useful O 0 2.8904786120165227e-08
for O 0 1.3295103684640708e-08
the O 0 2.3318692399243446e-07
management O 0 8.531377716280986e-06
of O 0 1.4764999605176854e-06
hyperphenylalaninemia B-Disease 1 0.999309778213501
in O 0 2.4037670300458558e-05
newborns O 0 0.0006922697648406029
. O 0 8.057792001636699e-06

Somatic O 0 0.0010156526695936918
instability O 0 0.0005551234935410321
of O 0 4.7602972585991665e-07
the O 0 1.4347269825520925e-06
CTG O 0 0.0010496355826035142
repeat O 0 3.440904038143344e-05
in O 0 6.675962254121259e-07
mice O 0 8.349087693204638e-06
transgenic O 0 3.610460908021196e-06
for O 0 4.1683435370032385e-07
the O 0 7.108065619831905e-05
myotonic B-Disease 1 0.9999798536300659
dystrophy I-Disease 1 0.9999905824661255
region O 0 0.00017261944594793022
is O 0 9.646757916925708e-07
age O 0 9.277655408368446e-07
dependent O 0 2.783224601898837e-07
but O 0 6.683632136628148e-08
not O 0 1.6956827053604684e-08
correlated O 0 2.3750871491756698e-07
to O 0 1.0031346420191767e-08
the O 0 4.866208769271907e-08
relative O 0 2.03316449187696e-06
intertissue O 0 8.478435483993962e-05
transcription O 0 4.0263315895572305e-05
levels O 0 3.0530343792634085e-05
and O 0 2.4037217372097075e-06
proliferative O 0 0.11287728697061539
capacities O 0 0.0006152351852506399
. O 0 2.893907731049694e-05

A O 0 8.700078615220264e-05
( O 0 2.841289187927032e-06
CTG O 0 0.00016738935664761811
) O 0 2.454016510000656e-07
nexpansion O 0 1.9351484297658317e-05
in O 0 1.2282089301152155e-07
the O 0 1.70549370182016e-07
3 O 0 6.634626515733544e-06
- O 0 0.00010547240526648238
untranslated O 0 0.0004923496744595468
region O 0 1.7897393263410777e-05
( O 0 3.166194915138476e-07
UTR O 0 2.0459028746699914e-05
) O 0 7.638453780600685e-08
of O 0 3.660345626599337e-08
the O 0 1.0897056199610233e-06
DM O 1 0.991063117980957
protein O 0 4.598929081112146e-06
kinase O 0 1.5397423339891247e-05
gene O 0 2.9751813599432353e-06
( O 0 4.02672640120727e-07
DMPK O 0 6.088453665142879e-05
) O 0 1.1831998136813127e-07
is O 0 1.3652265806740616e-07
responsible O 0 2.480714556440944e-06
for O 0 5.8390992307977285e-06
causing O 1 0.9846790432929993
myotonic B-Disease 1 0.9999935626983643
dystrophy I-Disease 1 0.9999977350234985
( O 0 0.0008599470602348447
DM B-Disease 1 0.9998759031295776
) O 0 9.145202056970447e-06
. O 0 5.3970120461599436e-06

Major O 0 0.0005901505355723202
instability O 0 0.0003779314283747226
, O 0 4.744217392271821e-07
with O 0 6.451217871017434e-08
very O 0 1.0201279820876152e-07
large O 0 6.421949194646004e-08
expansions O 0 8.49250795909029e-07
between O 0 6.612648917325714e-08
generations O 0 2.0193294858472655e-07
and O 0 1.8785279110034026e-07
high O 0 6.618871339014731e-06
levels O 0 1.2505371387305786e-06
of O 0 7.397598977831876e-08
somatic O 0 1.4212924725143239e-05
mosaicism O 0 0.0013143810210749507
, O 0 9.063897437044943e-07
is O 0 4.2241117625962943e-07
observed O 0 3.3282644835708197e-06
in O 0 9.618316880732891e-07
patients O 0 9.9432363640517e-06
. O 0 1.983904212465859e-06

There O 0 7.458739901267109e-07
is O 0 1.1447041714518491e-07
a O 0 8.99533674214581e-08
good O 0 1.7955612463538273e-07
correlation O 0 8.536699880323795e-08
between O 0 1.320284610528688e-07
repeat O 0 5.721003162761917e-06
size O 0 1.803491500140808e-06
( O 0 1.8606357343742275e-07
at O 0 2.4461310204060283e-06
least O 0 9.231376196794372e-08
in O 0 2.1554666318479576e-07
leucocytes O 0 3.8237132685026154e-05
) O 0 1.4095162725880073e-07
, O 0 1.6009946079975634e-07
clinical O 0 5.426672942121513e-06
severity O 0 3.640375507529825e-05
and O 0 7.205148335742706e-07
age O 0 5.912257165618939e-06
of O 0 9.284789257435477e-07
onset O 0 0.2438688725233078
. O 0 1.56301430251915e-05

The O 0 6.010436482029036e-05
trinucleotide O 0 0.0438273586332798
repeat O 0 0.0008570252102799714
instability O 0 0.00012209912529215217
mechanisms O 0 1.3913165275880601e-05
involved O 0 4.548633114609402e-06
in O 0 5.321701337379636e-06
DM B-Disease 1 0.9998894929885864
and O 0 1.7933192566488287e-06
other O 0 1.2091320513718529e-06
human O 0 0.0007304291939362884
genetic B-Disease 1 0.9998052716255188
diseases I-Disease 1 0.9999964237213135
are O 0 9.701910812509595e-07
unknown O 0 4.85827295051422e-05
. O 0 5.6682006288610864e-06

We O 0 8.30531553219771e-06
studied O 0 3.3396569051546976e-05
somatic O 0 5.6372642575297505e-05
instability O 0 5.2773873903788626e-05
by O 0 3.284315539531235e-07
measuring O 0 7.172423647716641e-05
the O 0 2.677014435903402e-06
CTG O 0 0.0004265331954229623
repeat O 0 1.1721718692569993e-05
length O 0 2.5580307010386605e-06
at O 0 1.4163981632009381e-06
several O 0 2.1737642796892942e-08
ages O 0 4.021737254333857e-07
in O 0 2.529655596106295e-08
various O 0 1.5776917550169856e-08
tissues O 0 4.160784101259196e-06
of O 0 3.4360983391934496e-08
transgenic O 0 6.316025974228978e-06
mice O 0 6.027807103237137e-06
carrying O 0 1.9159251678502187e-06
a O 0 1.6540396927666734e-06
( O 0 1.0101368843606906e-06
CTG O 0 0.00015641101344954222
) O 0 2.2819739342594403e-07
55expansion O 0 1.3022605344303884e-05
surrounded O 0 2.9766060833935626e-06
by O 0 5.778512601750663e-08
45 O 0 1.8805479840011685e-07
kb O 0 2.8986166853428585e-06
of O 0 8.16417653481949e-08
the O 0 9.723261200633715e-07
human O 0 3.792717325268313e-05
DM B-Disease 1 0.9998699426651001
region O 0 1.0645840120560024e-05
, O 0 8.857111311044719e-08
using O 0 9.764271879930675e-08
small O 0 9.96994572233234e-07
- O 0 0.0001038464906741865
pool O 0 3.6220841138856485e-05
PCR O 0 5.152302765054628e-05
. O 0 2.509937075956259e-06

These O 0 3.196912530256668e-07
mice O 0 6.747368843207369e-06
have O 0 7.835225090957465e-08
been O 0 8.87087310275092e-08
shown O 0 3.932509073933943e-08
to O 0 1.0965475638613498e-08
reproduce O 0 1.0838198249984998e-06
the O 0 1.791732984202099e-07
intergenerational O 0 6.368975846271496e-06
and O 0 5.243793452791579e-07
somatic O 0 1.6000520190573297e-05
instability O 0 3.219552672817372e-05
of O 0 1.240942282265678e-07
the O 0 1.6279861938528484e-06
55 O 0 2.3748300009174272e-05
CTG O 0 0.0010024020448327065
repeat O 0 6.7250854044687e-05
suggesting O 0 5.396734195528552e-06
that O 0 3.306745455233795e-08
surrounding O 0 2.6176886080975237e-07
sequences O 0 1.5194572711152432e-07
and O 0 5.6051398189538304e-08
the O 0 6.784276251892152e-08
chromatin O 0 5.5071864153433125e-06
environment O 0 7.216832500489545e-07
are O 0 4.525944774513846e-08
involved O 0 3.7058495649944234e-07
in O 0 7.881973829171329e-07
instability O 0 5.79815823584795e-05
mechanisms O 0 9.682607924332842e-05
. O 0 1.3689864317711908e-05

As O 0 1.7388591686540167e-06
observed O 0 2.280556145706214e-06
in O 0 6.064798441229868e-08
some O 0 7.259302492457209e-09
of O 0 2.041599067581501e-08
the O 0 4.966442475051736e-07
tissues O 0 0.00013044463412370533
of O 0 1.4759657460672315e-05
DM B-Disease 1 0.9999701976776123
patients O 0 0.0001664426818024367
, O 0 2.7335730123922986e-07
there O 0 4.5492260625223935e-08
is O 0 7.740028706848534e-08
a O 0 2.0015427537600772e-07
tendency O 0 5.909952278670971e-07
for O 0 2.4297548861795804e-08
repeat O 0 1.5629444760634215e-06
length O 0 7.074405061757716e-07
and O 0 1.9628910763458407e-07
somatic O 0 2.1608561837638263e-06
mosaicism O 0 6.960217433515936e-05
to O 0 2.8439348653819252e-08
increase O 0 6.268281538268639e-08
with O 0 4.6479144089062174e-08
the O 0 1.764446153629251e-07
age O 0 1.1534142458913266e-06
of O 0 3.7956233711611276e-08
the O 0 6.710789648423088e-07
mouse O 0 0.00013796568964608014
. O 0 6.633936664002249e-06

Furthermore O 0 9.67600499279797e-06
, O 0 7.405313340314024e-07
we O 0 1.2028955609366676e-07
observed O 0 4.4119872200099053e-07
no O 0 3.482455213088542e-08
correlation O 0 6.44892921286555e-08
between O 0 4.468713399319313e-08
the O 0 1.744525377489481e-07
somatic O 0 1.87905716302339e-05
mutation O 0 5.6134784244932234e-05
rate O 0 4.579641426971648e-06
and O 0 5.682927053385356e-07
tissue O 0 0.00017584649322088808
proliferation O 0 0.0017791306599974632
capacity O 0 2.2231974071473815e-05
. O 0 7.709199053351767e-06

The O 0 4.420707227836829e-06
somatic O 0 0.00010296367690898478
mutation O 0 0.00010414755524834618
rates O 0 4.0494269342161715e-06
in O 0 2.9245670774002974e-08
different O 0 1.3884495331240032e-08
tissues O 0 3.0889730169292307e-06
were O 0 1.0614493106686496e-07
also O 0 4.5529933601073935e-08
not O 0 5.074116238290571e-09
correlated O 0 8.947032625883367e-08
to O 0 1.1614324613162808e-08
the O 0 1.1147766798558223e-07
relative O 0 4.102188086108072e-06
inter O 0 0.00023699492157902569
- O 0 0.00015748341684229672
tissue O 0 1.8571323380456306e-05
difference O 0 2.421675162622705e-07
in O 0 2.7555321580052805e-08
transcriptional O 0 4.1310093479296484e-07
levels O 0 4.7005102032926516e-07
of O 0 5.665446334290891e-09
the O 0 2.3602876098038905e-08
three O 0 1.0828842533783245e-07
genes O 0 6.405545036614058e-07
( O 0 4.3797948023893696e-07
DMAHP O 0 0.00012909030192531645
, O 0 4.622668825504661e-07
DMPK O 0 0.00011870078014908358
and O 0 7.535852546425303e-07
59 O 0 7.584759714518441e-06
) O 0 7.165555615529229e-08
surrounding O 0 1.262062710338796e-06
the O 0 7.086755431373604e-07
repeat O 0 3.443786044954322e-05
. O 0 1.0798745506690466e-06
. O 0 3.6851761251455173e-06

A O 0 3.4538305044407025e-05
novel O 0 2.106730971718207e-05
missense O 0 0.0005127432523295283
mutation O 0 7.152247417252511e-05
in O 0 1.1894239833054598e-06
patients O 0 3.590484084270429e-06
from O 0 1.404643796831806e-07
a O 0 9.882636504698894e-07
retinoblastoma B-Disease 0 0.0016014126595109701
pedigree O 0 0.00021245541574899107
showing O 0 1.0494535672478378e-05
only O 0 7.305573035409907e-07
mild O 0 9.578840399626642e-05
expression O 0 1.4946340343158226e-06
of O 0 3.7609680703099e-07
the O 0 1.292247270612279e-05
tumor B-Disease 1 0.8035629391670227
phenotype O 0 0.0003653082821983844
. O 0 7.632213964825496e-06

We O 0 8.364193604393222e-07
have O 0 3.480682408962821e-08
used O 0 3.970608020154032e-08
single O 0 1.7079254632790253e-07
strand O 0 2.14609417525935e-06
conformation O 0 2.3488144051952986e-06
polymorphism O 0 7.269072739291005e-07
analysis O 0 4.444114409807298e-08
to O 0 1.314830910814635e-08
study O 0 3.3690785272710855e-08
the O 0 3.403212289754265e-08
27 O 0 7.890773190410982e-07
exons O 0 1.1385141078790184e-06
of O 0 3.8223952003590966e-08
the O 0 2.2615868999764643e-07
RB1 O 0 0.00017620735161472112
gene O 0 8.284347359222011e-07
in O 0 8.447759114460496e-08
individuals O 0 6.871147206766182e-09
from O 0 9.189863448000324e-08
a O 0 6.197121251716453e-07
family O 0 4.510520284384256e-06
showing O 0 2.3221866285894066e-05
mild O 0 0.0007055971655063331
expression O 0 2.231146027042996e-06
of O 0 2.5072716880458756e-07
the O 0 3.889589606842492e-06
retinoblastoma B-Disease 0 0.02748502790927887
phenotype O 0 0.0024315696209669113
. O 0 2.0665436750277877e-05

In O 0 1.2304334404689143e-06
this O 0 6.158049359328288e-08
family O 0 1.0792751936605782e-06
affected O 0 9.262052458325343e-07
individuals O 0 1.5141571907406615e-07
developed O 0 2.86132053588517e-05
unilateral B-Disease 0 0.08891638368368149
tumors I-Disease 1 0.999994158744812
and O 0 2.1931480205239495e-06
, O 0 1.9188897226740664e-07
as O 0 8.39076790271065e-08
a O 0 2.3553614880711393e-07
result O 0 2.847512519110751e-07
of O 0 2.6719048307199955e-08
linkage O 0 7.843245839467272e-06
analysis O 0 7.762055815874191e-07
, O 0 4.419963772761548e-07
unaffected O 0 1.786846769391559e-05
mutation O 0 5.22179334438988e-06
carriers O 0 1.1162964028699207e-06
were O 0 2.1020602503085684e-07
also O 0 1.34920540517669e-07
identified O 0 4.205826087400055e-07
within O 0 1.181066906497108e-07
the O 0 5.650415459967917e-07
pedigree O 0 0.00045591939124278724
. O 0 1.4068255950405728e-05

A O 0 6.309217042144155e-06
single O 0 5.26823441759916e-07
band O 0 4.079272457602201e-06
shift O 0 8.700321814103518e-07
using O 0 3.484661874608719e-07
SSCP O 0 0.0001901265059132129
was O 0 5.901373697270174e-06
identified O 0 7.78272067236685e-07
in O 0 6.840929955842512e-08
exon O 0 6.350465355353663e-06
21 O 0 1.823711727411137e-06
which O 0 5.3726836313217063e-08
resulted O 0 6.51711786758824e-07
in O 0 1.0954483542491289e-07
a O 0 8.032496907617315e-07
missense O 0 3.842014848487452e-05
mutation O 0 8.24672133603599e-06
converting O 0 1.1244209190408583e-06
a O 0 1.5379197066067718e-05
cys O 0 0.0031841013114899397
- O 0 0.00020653173851314932
- O 0 0.00011165990144945681
> O 0 2.550845056248363e-05
arg O 0 4.700265344581567e-05
at O 0 3.247283075324958e-06
nucleotide O 0 1.8818911939888494e-06
position O 0 2.954484216388664e-06
28 O 0 2.2000358512741514e-06
in O 0 9.677555112830305e-08
the O 0 4.148348580201855e-07
exon O 0 0.0001441776257706806
. O 0 1.081419668480521e-05

The O 0 5.14848170496407e-06
mutation O 0 7.99347908468917e-05
destroyed O 0 2.5470726541243494e-05
an O 0 5.536035132536199e-07
NdeI O 0 0.00011458910012152046
restriction O 0 2.255182607768802e-06
enzyme O 0 9.001942089525983e-06
site O 0 3.6902532883686945e-05
. O 0 3.0964733923610765e-06

Analysis O 0 7.238475632220798e-07
of O 0 5.6785392388292166e-08
all O 0 3.1099453678962163e-08
family O 0 5.198288590690936e-07
members O 0 2.2285162160073924e-08
demonstrated O 0 5.790670911665075e-07
that O 0 2.4395903963636556e-08
the O 0 2.8828867471020203e-07
missense O 0 8.694456482771784e-05
mutation O 0 4.8366302507929504e-05
co O 0 9.059136209543794e-05
- O 0 4.993842958356254e-05
segregated O 0 1.1602738595684059e-05
with O 0 3.0118658287392464e-06
patients O 0 2.8459227905841544e-05
with O 0 1.547649117128458e-05
tumors B-Disease 1 0.9999662637710571
or O 0 1.6039935871958733e-05
who O 0 1.6990388758131303e-06
, O 0 5.993615559418686e-08
as O 0 6.355466553031874e-08
a O 0 2.743392713000503e-07
result O 0 1.7865563961549924e-07
of O 0 9.320346272545521e-09
linkage O 0 2.46116769631044e-06
analysis O 0 2.5083429022743076e-07
had O 0 7.06049377185991e-07
been O 0 2.512801415832655e-07
predicted O 0 5.009028996028064e-07
to O 0 8.53093418129447e-09
carry O 0 1.835841487718426e-07
the O 0 6.649262331848149e-07
predisposing O 0 0.00017940955876838416
mutation O 0 0.00020115177903790027
. O 0 5.824061190651264e-06

These O 0 3.2256326676360914e-07
observations O 0 2.7326761937729316e-06
point O 0 9.111129770644766e-07
to O 0 2.6702794642119443e-08
another O 0 2.1234460234609287e-07
region O 0 4.5946848103994853e-07
of O 0 3.60589353931573e-08
the O 0 5.457790166474297e-07
RB1 O 0 0.00027631534612737596
gene O 0 2.4536750515835593e-06
where O 0 4.06711137657112e-07
mutations O 0 1.585431391504244e-06
only O 0 1.7397031371046978e-08
modify O 0 2.896389901252405e-07
the O 0 4.013935139823843e-08
function O 0 1.0376066938988515e-07
of O 0 1.0838282271663502e-08
the O 0 4.694090804946427e-08
gene O 0 6.278871751419501e-07
and O 0 1.8909281607193407e-07
raise O 0 2.0479100726333854e-07
important O 0 1.0189417309902637e-07
questions O 0 7.053070589790877e-07
for O 0 9.704875481020281e-08
genetic O 0 4.807599452760769e-06
counseling O 0 1.879392925729917e-06
in O 0 6.348693659674609e-08
families O 0 1.0091354418761966e-08
with O 0 2.3871399079666844e-08
these O 0 5.241473033379407e-08
distinctive O 0 2.308980947418604e-05
phenotypes O 0 0.00017750887491274625
. O 0 1.5145586758080753e-06
. O 0 3.1814665817364585e-06

Maternal B-Disease 0 0.016346653923392296
disomy I-Disease 0 0.25197938084602356
and O 0 0.00686118146404624
Prader B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999934434890747
Willi I-Disease 1 0.999996542930603
syndrome I-Disease 1 0.9999803304672241
consistent O 0 7.643966819159687e-05
with O 0 1.0089171382787754e-06
gamete O 0 7.505821849917993e-05
complementation O 0 0.00021562598703894764
in O 0 3.4582302532726317e-07
a O 0 8.451028747913369e-07
case O 0 1.1378704130038386e-06
of O 0 9.823899915772927e-08
familial O 0 0.0005955983069725335
translocation O 0 0.0003254401672165841
( O 0 9.915763712342596e-07
3 O 0 1.3021771110288682e-06
; O 0 1.704427177173784e-07
15 O 0 3.240895978251501e-07
) O 0 2.957015610149938e-08
( O 0 5.3661704413343614e-08
p25 O 0 5.67510232940549e-06
; O 0 1.5879297166065953e-07
q11 O 0 7.1072072387323715e-06
. O 0 1.3830211287313432e-07
2 O 0 1.2664827409025747e-06
) O 0 4.026929900646792e-07
. O 0 1.7096575675168424e-06

Maternal B-Disease 0 0.044874340295791626
uniparental I-Disease 1 0.9518407583236694
disomy I-Disease 1 0.8184530138969421
( I-Disease 0 5.2730058087036014e-05
UPD I-Disease 1 0.9784185290336609
) I-Disease 0 3.9633454207432806e-07
for I-Disease 0 8.596944667260686e-08
chromosome I-Disease 0 1.256416999240173e-05
15 I-Disease 0 7.313017817978107e-07
is O 0 2.513720787078455e-08
responsible O 0 9.542850420984905e-08
for O 0 1.0072009892780898e-08
an O 0 2.1938115324360297e-08
estimated O 0 8.285138619612553e-08
30 O 0 1.0817200291057816e-07
% O 0 5.526854085502464e-09
of O 0 2.2638650065687216e-08
cases O 0 2.0262193629605463e-06
of O 0 4.310072836233303e-05
Prader B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999957084655762
Willi I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999970197677612
( O 0 0.00041628783219493926
PWS B-Disease 1 0.998874843120575
) O 0 1.8885879399022087e-05
. O 0 9.082225005840883e-06

We O 0 9.50266530708177e-06
report O 0 7.962922268234252e-07
on O 0 2.5382593094036565e-07
an O 0 6.831502474824447e-08
unusual O 0 2.226966671514674e-06
case O 0 1.5579219052597182e-06
of O 0 1.383639869345643e-07
maternal B-Disease 0 0.00011844682740047574
disomy I-Disease 0 0.0016726338071748614
15 I-Disease 0 9.44048588280566e-06
in O 0 1.6655346826155437e-06
PWS B-Disease 1 0.9988142251968384
that O 0 1.7845572131136578e-07
is O 0 8.156006003900984e-08
most O 0 2.4314608992881404e-08
consistent O 0 2.9341532581383944e-07
with O 0 1.121969646078469e-07
adjacent O 0 8.783994417171925e-06
- O 0 3.0216677259886637e-05
1 O 0 1.5927663525872049e-06
segregation O 0 1.210612367685826e-06
of O 0 2.1567862162896745e-08
a O 0 6.523255251522642e-07
paternal O 0 5.540311030927114e-05
t O 0 0.0007815507706254721
( O 0 4.3944635308434954e-07
3 O 0 4.968266580362979e-07
; O 0 7.855022232661213e-08
15 O 0 2.1265670113734814e-07
) O 0 3.1384288945446315e-08
( O 0 7.799678769515594e-08
p25 O 0 7.478643510694383e-06
; O 0 1.7438166821648338e-07
q11 O 0 6.712025879096473e-06
. O 0 6.074209579765011e-08
2 O 0 2.0010179468954448e-07
) O 0 8.433974407751066e-09
with O 0 2.3502023438481956e-08
simultaneous O 0 1.5206285297608702e-06
maternal O 0 0.00021081650629639626
meiotic O 0 0.001193922245875001
nondisjunction O 0 0.0008485419093631208
for O 0 1.2139686305090436e-06
chromosome O 0 9.298903023591265e-05
15 O 0 1.1457288564997725e-05
. O 0 2.2983792860031826e-06

The O 0 2.1482203010236844e-05
patient O 0 8.44036039779894e-05
( O 0 1.0242686130368384e-06
J O 0 8.06433818070218e-05
. O 0 1.288972413249212e-07
B O 0 2.00426006813359e-06
. O 0 1.6625996579477942e-08
) O 0 9.891433450093245e-09
, O 0 1.703953422804716e-08
a O 0 1.7602813784378668e-07
17 O 0 1.8504903209759505e-06
- O 0 1.5104899830475915e-05
year O 0 2.604133442218881e-06
- O 0 2.846096504072193e-05
old O 0 3.749651295947842e-05
white O 0 7.909889973234385e-06
male O 0 1.4281566791396472e-06
with O 0 2.1898915747442516e-06
PWS B-Disease 1 0.9985514283180237
, O 0 1.3304802450875286e-06
was O 0 2.568755007814616e-06
found O 0 4.2121158116970037e-08
to O 0 5.4221160894485365e-09
have O 0 1.0227186209021966e-08
47 O 0 2.1255937099340372e-07
chromosomes O 0 1.4641632617440337e-07
with O 0 1.0668442484984553e-07
a O 0 2.735857378866058e-06
supernumerary O 0 0.00028598326025530696
, O 0 8.993001756607555e-07
paternal O 0 6.0434605984482914e-05
der O 0 0.002056879224255681
( O 0 3.0530938488482207e-07
15 O 0 2.703094423850416e-07
) O 0 8.595269385125448e-09
consisting O 0 4.478662773976794e-08
of O 0 1.8194274531424526e-08
the O 0 3.304022868633183e-07
short O 0 9.899389624479227e-06
arm O 0 0.0007797089056111872
and O 0 4.2681813283707015e-07
the O 0 5.053411769040395e-07
proximal O 0 0.0006752656190656126
long O 0 0.00011709719547070563
arm O 0 0.00027381666586734354
of O 0 1.9216035695990286e-07
chromosome O 0 2.8200491215102375e-05
15 O 0 2.873789298973861e-06
, O 0 2.3797849735274212e-07
and O 0 8.911775353226403e-07
distal O 0 0.006656701676547527
chromosome O 0 0.026488488540053368
arm O 1 0.6362258195877075
3p O 1 0.5691022276878357
. O 0 4.2473431676626205e-05

The O 0 7.1818903961684555e-06
t O 0 0.0003571454144548625
( O 0 2.734970792062086e-07
3 O 0 5.245093461780925e-07
; O 0 8.584378008436033e-08
15 O 0 1.7380720862547605e-07
) O 0 1.763083012917832e-08
was O 0 3.067959255531605e-07
present O 0 1.8266634427277495e-08
in O 0 3.667753389891004e-08
the O 0 6.875778524317866e-08
balanced O 0 6.620485351049865e-07
state O 0 2.6067672820317966e-07
in O 0 8.058002975985801e-08
the O 0 2.6499802174839715e-07
patients O 0 3.561265202733921e-06
father O 0 4.004700713267084e-06
and O 0 4.049795165883552e-07
a O 0 4.794449978362536e-06
sister O 0 0.0007124432013370097
. O 0 9.789379873836879e-06

Fluorescent O 0 0.0001646030432311818
in O 0 1.9330855138832703e-06
situ O 0 3.5395860322751105e-05
hybridization O 0 1.4670973769170814e-06
analysis O 0 3.520328561990027e-07
demonstrated O 0 1.6831066886879853e-06
that O 0 8.3085758717516e-08
the O 0 9.840654229265056e-07
PWS B-Disease 1 0.9951769113540649
critical O 0 4.6390090574277565e-05
region O 0 9.432854312763084e-06
resided O 0 1.0424671927466989e-05
on O 0 3.785610260820249e-07
the O 0 1.05924080173736e-07
derivative O 0 3.4162433166784467e-06
chromosome O 0 6.718238182656933e-06
3 O 0 3.3313466474282905e-07
and O 0 3.8010643521602105e-08
that O 0 8.654457595014264e-09
there O 0 5.163391847418097e-08
was O 0 1.9362939838174498e-06
no O 0 1.9345318946761836e-07
deletion O 0 1.5539808373432606e-06
of O 0 1.0866727251368502e-07
the O 0 2.9236468890303513e-06
PWS B-Disease 1 0.9987941980361938
region O 0 8.27015992399538e-06
on O 0 9.540244718664326e-07
the O 0 1.2855105069320416e-07
normal O 0 1.2976199741387973e-06
pair O 0 1.2064367638231488e-06
of O 0 5.3447294590114325e-08
15s O 0 2.1441266653710045e-05
present O 0 1.0807523267430952e-06
in O 0 4.315946625865763e-06
J O 0 0.005987942684441805
. O 0 7.810075658198912e-06

B O 0 0.0036639696918427944
. O 0 3.064427801291458e-05

Methylation O 0 2.5261577320634387e-05
analysis O 0 1.7511071064291173e-06
at O 0 8.191680535674095e-06
exon O 0 1.2624078408407513e-05
alpha O 0 1.35152765778912e-06
of O 0 3.639210532924153e-08
the O 0 2.6588401169647113e-07
small O 0 2.9269110655150143e-06
nuclear O 0 0.0008476473158225417
ribonucleoprotein O 0 0.002330359537154436
- O 0 0.00011989282938884571
associated O 0 4.448403615242569e-06
polypeptide O 0 3.097679291386157e-05
N O 0 5.235576827544719e-05
( O 0 4.4435725499170076e-07
SNRPN O 0 4.02162731916178e-05
) O 0 8.374891535822826e-08
gene O 0 7.180001944107062e-07
showed O 0 1.3634444258059375e-06
a O 0 5.72889689465228e-07
pattern O 0 1.3621403923025355e-05
characteristic O 0 7.64782089390792e-06
of O 0 9.435613179675784e-08
only O 0 4.6869157444007215e-08
the O 0 1.5861498070535163e-07
maternal O 0 2.0917204892612062e-05
chromosome O 0 2.8482416382757947e-05
15 O 0 2.5797362468438223e-06
in O 0 7.479968076040677e-07
J O 0 0.0018674201564863324
. O 0 4.726442512037465e-06

B O 0 0.005992780905216932
. O 0 2.9713208277826197e-05

Maternal B-Disease 0 0.004943543579429388
disomy I-Disease 0 0.010286727920174599
was O 0 0.00012000960850855336
confirmed O 0 3.0721244002052117e-06
by O 0 4.502173212017624e-08
polymerase O 0 8.41084784042323e-06
chain O 0 1.1274155440332834e-05
reaction O 0 9.80903109848441e-07
analysis O 0 8.728480338504596e-08
of O 0 3.050049457442583e-08
microsatellite O 0 3.800534250331111e-05
repeats O 0 3.382704016985372e-05
at O 0 1.1353979061823338e-05
the O 0 4.3599206378530653e-07
gamma O 0 3.307588121970184e-05
- O 0 5.161961234989576e-05
aminobutyric O 0 0.00011761677160393447
acid O 0 1.4531610759149771e-05
receptor O 0 2.375624490014161e-06
beta3 O 0 2.7514741304912604e-05
subunit O 0 3.6137264487479115e-06
( O 0 8.662997288411134e-07
GABRB3 O 0 0.00017718317394610494
) O 0 6.403236056939932e-07
locus O 0 3.870193904731423e-05
. O 0 6.1898367675894406e-06

A O 0 8.338185580214486e-05
niece O 0 0.0009484631009399891
( O 0 8.747661581764987e-07
B O 0 8.41587007016642e-06
. O 0 1.537284646246917e-07
B O 0 1.8614109649206512e-06
. O 0 1.5679450626748803e-08
) O 0 5.134662917072319e-09
with O 0 1.924574277722968e-08
45 O 0 7.024977577430036e-08
chromosomes O 0 1.4153947347494977e-07
and O 0 4.8776755079416034e-08
the O 0 2.6824544363535097e-08
derivative O 0 8.040943271225842e-07
3 O 0 5.644313887387398e-07
but O 0 7.343489016875537e-08
without O 0 8.44753387241326e-08
the O 0 1.5869034086790634e-07
der O 0 0.0002481674018781632
( O 0 9.643742515663689e-08
15 O 0 1.7682094721749309e-07
) O 0 1.5973855127526804e-08
demonstrated O 0 2.1388925119936175e-07
a O 0 2.385642972058122e-07
phenotype O 0 2.5814440505200764e-06
consistent O 0 4.545990748283657e-07
with O 0 7.537204282925813e-08
that O 0 5.941984682067414e-08
reported O 0 2.125369974237401e-06
for O 0 4.9011770641982366e-08
haploinsufficiency O 0 3.870149521389976e-05
of O 0 3.869814406698424e-07
distal O 0 0.001606430159881711
3 O 0 0.00011802539665950462
p O 0 0.0016237181844189763
. O 0 1.828135282266885e-05

Uniparental B-Disease 1 0.9965503215789795
disomy I-Disease 1 0.99798583984375
associated O 0 0.00010890126577578485
with O 0 2.8806875889131334e-06
unbalanced O 0 0.000619411701336503
segregation O 0 7.706815813435242e-05
of O 0 7.804007395861845e-07
non O 0 7.419869507430121e-05
- O 0 0.001046293182298541
Robertsonian O 0 0.0004835159343201667
translocations O 0 0.0003909514343831688
has O 0 7.388450740108965e-06
been O 0 2.736906481004553e-06
reported O 0 3.8093819512141636e-06
previously O 0 5.866622814210132e-07
but O 0 8.860186540005088e-08
has O 0 8.0156645765328e-08
not O 0 7.1441541571459766e-09
, O 0 8.662665251790713e-09
to O 0 2.8426101472689425e-09
our O 0 1.644192337835193e-08
knowledge O 0 1.3449916025365383e-07
, O 0 1.3397914244706044e-07
been O 0 8.579810639730567e-08
observed O 0 1.9097286951819115e-07
in O 0 3.544170823488457e-08
a O 0 4.977115963811229e-07
case O 0 2.741177240750403e-06
of O 0 3.960816229664488e-06
PWS B-Disease 1 0.9988981485366821
. O 0 0.00010808005026774481

Furthermore O 0 1.6739882994443178e-05
, O 0 4.963379183209327e-07
our O 0 1.8437914661717514e-07
findings O 0 4.913560474051337e-07
are O 0 1.1010745204487193e-08
best O 0 1.5422949672938557e-07
interpreted O 0 1.6816662196106336e-07
as O 0 1.5700913991167909e-07
true O 0 6.867140882604872e-07
gamete O 0 6.644002860412002e-05
complementation O 0 0.000580431311391294
resulting O 0 3.347800884512253e-05
in O 0 6.237682100618258e-06
maternal B-Disease 0 0.010515324771404266
UPD I-Disease 1 0.9994069337844849
15 I-Disease 0 0.000449140090495348
and O 0 9.660657815402374e-05
PWS B-Disease 1 0.9980260729789734

Schwartz B-Disease 0 0.09633180499076843
- I-Disease 1 0.9470925331115723
Jampel I-Disease 1 0.94138103723526
syndrome I-Disease 1 0.9995542168617249
type I-Disease 0 0.00028496721643023193
2 I-Disease 0 1.3301237231644336e-05
and O 0 7.48467982703005e-06
Stuve B-Disease 1 0.825077474117279
- I-Disease 1 0.9985650181770325
Wiedemann I-Disease 1 0.9956256151199341
syndrome I-Disease 1 0.999901533126831
: O 0 5.659530302182247e-07
a O 0 6.854499474684417e-07
case O 0 7.249079772009281e-07
for O 0 8.247629779134513e-08
" O 0 8.67432333961915e-07
lumping O 0 1.5897609046078287e-05
" O 0 5.6667627177375834e-06
. O 0 3.929333615815267e-06

Recent O 0 1.3704154298466165e-05
studies O 0 1.6338655086656217e-06
demonstrated O 0 1.1243137123528868e-06
the O 0 6.362888882449624e-08
existence O 0 4.455479540865781e-07
of O 0 1.9371990234162695e-08
a O 0 3.8552786918444326e-07
genetically O 0 1.4222727031665272e-06
distinct O 0 4.937799076287774e-07
, O 0 2.7507752520250506e-07
usually O 0 3.321322310512187e-07
lethal O 0 1.8623485402713413e-06
form O 0 3.1589505056217604e-07
of O 0 7.52410471704934e-08
the O 0 3.5677990126714576e-06
Schwartz B-Disease 0 0.02952544391155243
- I-Disease 1 0.9897747039794922
Jampel I-Disease 1 0.9874740839004517
syndrome I-Disease 1 0.9999016523361206
( O 0 1.0814371307787951e-05
SJS B-Disease 0 0.031129423528909683
) O 0 1.3011169812671142e-06
of O 0 1.3801293334836373e-06
myotonia B-Disease 1 0.9850083589553833
and O 0 5.0383241614326835e-05
skeletal B-Disease 1 0.9949186444282532
dysplasia I-Disease 1 0.9997643828392029
, O 0 2.4828398181853117e-06
which O 0 1.0539707773205009e-07
we O 0 2.8987196287744155e-07
called O 0 4.480355528357904e-06
SJS B-Disease 0 0.007661132141947746
type I-Disease 0 0.00020098520326428115
2 I-Disease 0 3.5566394217312336e-05
. O 0 5.341292308003176e-06

This O 0 3.6238430766388774e-05
disorder O 1 0.997533917427063
is O 0 1.9615415567386663e-06
reminiscent O 0 4.142595935263671e-05
of O 0 2.8764767989741813e-07
another O 0 4.982252903573681e-06
rare O 0 0.0002716195594985038
condition O 0 0.006039009895175695
, O 0 1.6199576293729478e-06
the O 0 8.679720849613659e-06
Stuve B-Disease 1 0.9216786026954651
- I-Disease 1 0.9988070726394653
Wiedemann I-Disease 1 0.9957061409950256
syndrome I-Disease 1 0.9999407529830933
( O 0 1.2353302736300975e-05
SWS B-Disease 0 0.00767001835629344
) O 0 3.2170464692171663e-07
, O 0 1.1022305557162326e-07
which O 0 3.603686238307091e-08
comprises O 0 2.873904918487824e-07
campomelia B-Disease 0 0.0001670231285970658
at O 0 3.762119013117626e-05
birth O 0 2.702908568608109e-05
with O 0 7.695756721659563e-06
skeletal B-Disease 1 0.9978780746459961
dysplasia I-Disease 1 0.9998811483383179
, O 0 3.431459845160134e-05
contractures B-Disease 1 0.7011811137199402
, O 0 1.3183788496462512e-06
and O 0 4.7221217869264365e-07
early B-Disease 0 1.1970233572355937e-05
death I-Disease 0 4.050903226016089e-05
. O 0 5.775829322374193e-06

To O 0 5.239234610598942e-07
test O 0 9.089641821447003e-07
for O 0 4.071379677839104e-08
possible O 0 7.786121045683103e-07
nosologic O 0 8.069115574471653e-05
identity O 0 9.41366124607157e-07
between O 0 1.195877530335565e-06
these O 0 1.1396297168175806e-06
disorders O 1 0.9980875849723816
, O 0 6.989305916249577e-07
we O 0 2.1543981176819216e-07
reviewed O 0 6.213892334017146e-07
the O 0 4.097406858249997e-08
literature O 0 7.603740925787861e-08
and O 0 2.9537462253870217e-08
obtained O 0 9.173751180924228e-08
a O 0 2.246646602088731e-07
follow O 0 1.9334493117639795e-07
- O 0 4.274452749086777e-06
up O 0 3.6255278246244416e-07
of O 0 9.505769504869477e-09
the O 0 3.658614389223658e-08
only O 0 1.987489284260846e-08
two O 0 5.757565801900455e-08
surviving O 0 4.554402039502747e-06
patients O 0 1.466091703150596e-06
, O 0 2.878858218480218e-08
one O 0 3.719987873296304e-08
with O 0 2.039815143461965e-07
SJS B-Disease 0 0.0011829823488369584
type I-Disease 0 2.1164994905120693e-05
2 I-Disease 0 3.7192155559750972e-06
at O 0 6.78787546348758e-06
age O 0 1.117285819418612e-06
10 O 0 1.3038952317856456e-07
years O 0 8.607347012912214e-08
and O 0 1.6010336167937567e-08
another O 0 1.2303284790959879e-07
with O 0 6.881773515488021e-07
SWS B-Disease 0 0.0029392624273896217
at O 0 4.665326196118258e-05
age O 0 6.828572168160463e-06
7 O 0 3.024885245395126e-06
years O 0 1.1435403166615288e-06
. O 0 1.8419301568428637e-06

Patients O 0 0.0002563674352131784
reported O 0 1.90769242180977e-05
as O 0 4.1551666640771145e-07
having O 0 2.675363020898658e-06
either O 0 1.2039761713822372e-05
neonatal O 1 0.9987931251525879
SJS B-Disease 1 0.9971809387207031
or O 0 0.00020299683092162013
SWS B-Disease 0 0.014729763381183147
presented O 0 2.1438236217363738e-06
a O 0 9.593600225343835e-07
combination O 0 5.8145269576925784e-06
of O 0 2.5280212412326364e-07
a O 0 2.6427560442243703e-05
severe O 1 0.9018518924713135
, O 0 2.1397107047960162e-05
prenatal O 1 0.9318716526031494
- O 1 0.9987608194351196
onset O 1 0.9987970590591431
neuromuscular B-Disease 1 0.9998989105224609
disorder I-Disease 1 0.999881386756897
( O 0 2.349200804019347e-05
with O 0 0.0003595199668779969
congenital B-Disease 1 0.9999977350234985
joint I-Disease 1 0.99857497215271
contractures I-Disease 1 0.9998682737350464
, O 0 0.007363336626440287
respiratory O 1 0.9998846054077148
and O 0 1.2967532711627427e-05
feeding O 0 7.167309377109632e-05
difficulties O 0 8.011611498659477e-05
, O 0 8.133431492751697e-07
tendency O 0 6.403702627721941e-06
to O 0 8.846489549796388e-07
hyperthermia B-Disease 0 0.0524447038769722
, O 0 2.671989705049782e-07
and O 0 1.5348557269589946e-07
frequent O 0 6.5209246713493485e-06
death O 0 2.499653237464372e-05
in O 0 5.769541644440324e-07
infancy O 0 1.172717475128593e-05
) O 0 1.822476924928651e-08
with O 0 2.150731148731211e-08
a O 0 5.90605282013712e-07
distinct O 0 4.553238341031829e-06
campomelic B-Disease 0 0.11317078769207001
- I-Disease 1 0.7622436285018921
metaphyseal I-Disease 1 0.6067019701004028
skeletal I-Disease 1 0.9949874877929688
dysplasia I-Disease 1 0.9996054768562317
. O 0 6.489275983767584e-05

The O 0 4.730555076548626e-07
similarity O 0 1.0022711194324074e-06
of O 0 1.317477398288247e-07
the O 0 7.078143653416191e-07
clinical O 0 1.9287163013359532e-05
and O 0 1.0241533345833886e-06
radiographic O 0 0.0007416037260554731
findings O 0 5.613320809061406e-06
is O 0 1.0433102204387978e-07
so O 0 4.587530355593117e-08
extensive O 0 9.266054235013144e-07
that O 0 9.300407555201673e-08
these O 0 1.8415386193737504e-07
disorders O 1 0.9643526077270508
appear O 0 7.560600465694733e-07
to O 0 2.2342106831274577e-08
be O 0 7.640493038252316e-08
a O 0 2.0417711255049653e-07
single O 0 9.526552275929134e-07
entity O 0 2.9313465347513556e-05
. O 0 9.178796972264536e-06

The O 0 1.181607103717397e-06
follow O 0 1.5737958847239497e-06
- O 0 1.966923264262732e-05
up O 0 1.4170791473588906e-06
observation O 0 3.5488260436977725e-06
of O 0 1.1298073587795443e-08
an O 0 2.566322976349511e-08
identical O 0 1.7700632497508195e-06
and O 0 1.9687948338287242e-07
unique O 0 8.542089062757441e-07
pattern O 0 8.278889436041936e-05
of O 0 3.512934426908032e-06
progressive O 1 0.9896194338798523
bone B-Disease 1 0.9996058344841003
dysplasia I-Disease 1 0.9995226860046387
in O 0 5.289211912895553e-07
the O 0 1.4926810365523124e-07
two O 0 2.120811046779636e-07
patients O 0 1.4720851595484419e-06
( O 0 1.8002999979671586e-08
one O 0 3.77103823723246e-08
with O 0 5.387460078054573e-07
SJS B-Disease 0 0.0029321678448468447
type I-Disease 0 3.8270693039521575e-05
2 I-Disease 0 3.8004809539415874e-06
, O 0 1.7951913378055906e-07
one O 0 7.880908725610425e-08
with O 0 9.760824468685314e-07
SWS B-Disease 0 0.005813933908939362
) O 0 3.09757297145552e-07
surviving O 0 4.906582489638822e-06
beyond O 0 5.4376864682126325e-06
infancy O 0 6.84356564306654e-05
adds O 0 1.9663436887640273e-06
to O 0 1.274227123815308e-08
the O 0 1.9825332486789193e-08
evidence O 0 5.1515087307052454e-08
in O 0 6.542643404827686e-08
favor O 0 2.3437277718585392e-07
of O 0 9.865887307114463e-08
identity O 0 9.876344847725704e-06
. O 0 1.0941555046883877e-05

The O 0 4.430397439136868e-06
hypothesis O 0 1.665151648921892e-05
that O 0 3.2281070616591023e-07
SWS B-Disease 0 0.001134514226578176
and O 0 3.3791877740441123e-06
SJS B-Disease 0 0.0033515889663249254
type I-Disease 0 2.6719446395873092e-05
2 I-Disease 0 1.941451273523853e-06
are O 0 2.2343598971019674e-08
the O 0 1.922908978713167e-07
same O 0 3.852408099191962e-06
disorder O 1 0.9966490864753723
should O 0 1.655799621858023e-07
be O 0 4.145761067775311e-08
testable O 0 2.975568520469096e-07
by O 0 1.8851837424449513e-08
molecular O 0 3.240628529965761e-06
methods O 0 1.8719534864430898e-06
. O 0 1.0766107152448967e-06
. O 0 2.060775159407058e-06

A O 0 2.5105997337959707e-05
mouse O 0 9.059084550244734e-05
model O 0 1.5467167031602003e-05
of O 0 1.8049702703137882e-05
severe O 1 0.9986845850944519
von B-Disease 1 0.9999943971633911
Willebrand I-Disease 1 0.9999736547470093
disease I-Disease 1 0.9999996423721313
: O 0 0.022244881838560104
defects O 1 0.9988873600959778
in O 0 3.627525802585296e-05
hemostasis O 1 0.9812284111976624
and O 0 0.0014010292943567038
thrombosis B-Disease 1 0.9985699653625488
. O 0 5.5391908972524107e-05

von B-Disease 1 0.98148512840271
Willebrand I-Disease 1 0.9865807294845581
factor I-Disease 0 0.00028774322709068656
( I-Disease 0 3.297154398751445e-05
vWf I-Disease 0 0.030817663297057152
) I-Disease 0 0.0010841551702469587
deficiency I-Disease 1 0.9998175501823425
causes O 1 0.9966362714767456
severe O 1 0.9997349381446838
von B-Disease 1 0.9999966621398926
Willebrand I-Disease 1 0.99997878074646
disease I-Disease 1 0.999997615814209
in O 0 2.593886893009767e-05
humans O 0 5.3003353968961164e-05
. O 0 1.0835907232831232e-05

We O 0 1.1632902214842034e-06
generated O 0 1.7598064516732848e-07
a O 0 5.859845941813546e-07
mouse O 0 2.4093262709357077e-06
model O 0 3.510197927880654e-07
for O 0 5.1243628007568987e-08
this O 0 1.2580103714299185e-07
disease O 0 0.00019610523304436356
by O 0 1.0491286950298218e-08
using O 0 7.657912703962211e-08
gene O 0 2.058583277175785e-06
targeting O 0 4.8298593355866615e-06
. O 0 3.462332642811816e-06

vWf B-Disease 0 0.02892903983592987
- I-Disease 0 0.01581491157412529
deficient I-Disease 0 0.004711132496595383
mice O 0 5.3369753004517406e-05
appeared O 0 3.8072719235060504e-06
normal O 0 2.6998504836228676e-06
at O 0 7.17463399269036e-06
birth O 0 1.6084429717011517e-06
; O 0 2.093940487668533e-08
they O 0 6.067017110922279e-09
were O 0 2.7875083574713244e-08
viable O 0 6.488794497272465e-07
and O 0 6.462103669946373e-07
fertile O 0 3.939811358577572e-05
. O 0 8.641150998300873e-06

Neither O 0 0.000513367005623877
vWf O 0 0.006957793142646551
nor O 0 0.0007753847748972476
vWf O 0 0.00421507190912962
propolypeptide O 0 0.008495904505252838
( O 0 2.6509118470130488e-05
von B-Disease 0 0.17116311192512512
Willebrand I-Disease 1 0.5437465906143188
antigen O 0 0.0012105387868359685
II O 0 0.09538307040929794
) O 0 4.772310830958304e-07
were O 0 1.6187314599847014e-07
detectable O 0 1.2941957720613573e-05
in O 0 1.4016558225193876e-07
plasma O 0 1.171190888271667e-05
, O 0 3.617932975430449e-07
platelets O 0 1.4595500033465214e-05
, O 0 1.347528524320296e-07
or O 0 3.323882822314772e-07
endothelial O 0 9.62249487201916e-06
cells O 0 8.005226845853031e-07
of O 0 3.6215745069512195e-08
the O 0 2.9079731689307664e-07
homozygous O 0 1.918888301588595e-05
mutant O 0 4.371489558252506e-05
mice O 0 0.00013121047231834382
. O 0 4.20811966250767e-06

The O 0 1.760003942763433e-05
mutant O 0 0.0004302677989471704
mice O 0 0.0003560633340384811
exhibited O 0 0.0008099210099317133
defects O 1 0.9865591526031494
in O 0 3.36054199578939e-06
hemostasis O 0 0.002015510108321905
with O 0 1.0267978041156312e-06
a O 0 2.4550547095714137e-05
highly O 0 0.0004397607408463955
prolonged O 0 0.3087417781352997
bleeding O 1 0.9977203011512756
time O 0 3.1420875075127697e-06
and O 0 2.381983449595282e-06
spontaneous O 0 0.00014358959742821753
bleeding O 1 0.7897534370422363
events O 0 4.058695424191683e-07
in O 0 8.413412899699324e-08
approximately O 0 3.947644700019737e-08
10 O 0 9.404960366055093e-08
% O 0 1.7508579475133956e-08
of O 0 1.4549070215252868e-07
neonates O 0 0.00028470001416280866
. O 0 7.582691523566609e-06

As O 0 1.689795681159012e-06
in O 0 3.0998663191894593e-07
the O 0 6.061133035473176e-07
human O 0 1.2693107237282675e-05
disease O 0 0.30682173371315
, O 0 1.817236210399642e-07
the O 0 7.922913169977619e-08
factor O 0 7.832967412468861e-07
VIII O 0 0.0001807257649488747
level O 0 4.668421297537861e-06
in O 0 1.5208230763619213e-07
these O 0 2.5994381758209784e-08
mice O 0 2.0225609205226647e-06
was O 0 1.1583748573684716e-06
reduced O 0 2.283746027842426e-07
strongly O 0 7.186428518934918e-08
as O 0 5.535507696663444e-08
a O 0 2.358870432317417e-07
result O 0 3.0967282782512484e-07
of O 0 2.7943913849526325e-08
the O 0 1.3929221154285187e-07
lack O 0 9.480945095674542e-07
of O 0 1.3229049500296242e-07
protection O 0 3.5018160815525334e-06
provided O 0 4.806796596312779e-07
by O 0 9.370971270072914e-07
vWf O 0 0.00037579232593998313
. O 0 1.0615242899802979e-05

Defective O 1 0.9680227041244507
thrombosis B-Disease 1 0.9923264980316162
in O 0 5.563818376685958e-06
mutant O 0 4.431118577485904e-05
mice O 0 3.534607094479725e-05
was O 0 6.916592610650696e-06
also O 0 2.3294995799005846e-07
evident O 0 4.672108673275943e-07
in O 0 3.615486576791227e-08
an O 0 2.7396685808867005e-08
in O 0 1.0763977087435705e-07
vivo O 0 1.0366990863985848e-05
model O 0 3.1361125820694724e-06
of O 0 9.31366412260104e-06
vascular B-Disease 1 0.9999094009399414
injury I-Disease 1 0.9997710585594177
. O 0 1.7030755770974793e-05

In O 0 6.625854211961268e-07
this O 0 3.022840999733489e-08
model O 0 3.5683601140590326e-07
, O 0 1.6135528824179346e-07
the O 0 2.7214309739065357e-07
exteriorized O 0 0.00026860751677304506
mesentery O 0 0.001064384588971734
was O 0 3.258435026509687e-05
superfused O 0 8.123746374621987e-05
with O 0 9.849658226812608e-07
ferric O 0 0.021547751501202583
chloride O 0 0.00019969750428572297
and O 0 1.5179017509581172e-06
the O 0 5.55246799649467e-07
accumulation O 0 5.414392944658175e-05
of O 0 1.2237652526891907e-06
fluorescently O 0 0.0027031227946281433
labeled O 0 0.0003846316540148109
platelets O 0 0.0008029600139707327
was O 0 2.439972013235092e-05
observed O 0 1.346655267298047e-06
by O 0 2.0082826779344032e-07
intravital O 0 0.00015538616571575403
microscopy O 0 0.00016883584612514824
. O 0 1.0908162039413583e-05

We O 0 2.0192305782984477e-06
conclude O 0 1.10735072667012e-06
that O 0 8.66045191116882e-09
these O 0 1.4213675569862971e-08
mice O 0 2.420960072413436e-06
very O 0 3.933357390906167e-07
closely O 0 8.40985285321949e-06
mimic O 0 0.005348179489374161
severe O 1 0.9903033375740051
human O 0 0.012484690174460411
von B-Disease 1 0.9999827146530151
Willebrand I-Disease 1 0.9999613761901855
disease I-Disease 1 0.9999982118606567
and O 0 1.1611748959694523e-05
will O 0 1.3051915459527663e-07
be O 0 1.2454363762515186e-08
very O 0 1.312538255859863e-08
useful O 0 3.929914882405683e-08
for O 0 1.7160013854322642e-08
investigating O 0 4.4181430780554365e-07
the O 0 4.002902898037064e-08
role O 0 4.492385698995349e-07
of O 0 8.295653941559067e-08
vWf O 0 2.4536177079426125e-05
in O 0 7.627264153597935e-07
normal O 0 1.3074595699436031e-05
physiology O 0 9.90040207398124e-05
and O 0 1.0196683888352709e-06
in O 0 1.429602434654953e-06
disease O 0 0.0036155099514871836
models O 0 2.4062999273155583e-06
. O 0 4.876745833826135e-07
. O 0 2.118907787007629e-06

Oral O 0 0.0010145202977582812
contraceptives O 0 0.0011190600926056504
and O 0 1.9327501377119916e-06
the O 0 5.2236459850973915e-06
risk O 0 0.0005378656787797809
of O 0 0.00018748878210317343
hereditary B-Disease 1 0.999994158744812
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 0.00012147109373472631

Hereditary B-Disease 1 0.9997978806495667
Ovarian I-Disease 1 0.9999597072601318
Cancer I-Disease 1 0.998931348323822
Clinical O 0 0.00032041521626524627
Study O 0 3.230606125725899e-06
Group O 0 6.7366954681347124e-06
. O 0 4.352137239038711e-06

BACKGROUND O 0 0.0001034191736835055
Women O 0 4.325244731262501e-07
with O 0 2.547749033965374e-07
mutations O 0 7.010640729276929e-06
in O 0 8.880590485205175e-08
either O 0 1.4106821311088424e-07
the O 0 1.401150484525715e-07
BRCA1 O 0 1.628390236874111e-05
or O 0 3.315138883408508e-07
the O 0 1.3173215052120213e-07
BRCA2 O 0 7.943422133394051e-06
gene O 0 6.84096846725879e-07
have O 0 6.005183905699596e-08
a O 0 6.85732402416761e-07
high O 0 6.767828017473221e-05
lifetime O 0 0.0005892068147659302
risk O 0 0.0031636683270335197
of O 0 0.0021618178579956293
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999969005584717
. O 0 6.765337457181886e-05

Oral O 0 0.008411609567701817
contraceptives O 0 0.32495060563087463
protect O 0 0.037926387041807175
against O 1 0.997940719127655
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999914169311523
in O 0 2.1795490283693653e-06
general O 0 5.500837687577587e-07
, O 0 1.1916181108517776e-07
but O 0 5.023179028285085e-08
it O 0 1.6946222203273464e-08
is O 0 2.0199161454570458e-08
not O 0 8.6881151162288e-09
known O 0 1.941260876492379e-07
whether O 0 5.734386121503121e-08
they O 0 8.186225386452861e-08
also O 0 5.096223389955412e-07
protect O 0 2.9793095563945826e-06
against O 0 3.783321744776913e-06
hereditary B-Disease 1 0.9773280620574951
forms I-Disease 0 0.0010855657747015357
of I-Disease 1 0.5249014496803284
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999972581863403
. O 0 5.3647956519853324e-05

METHODS O 0 2.8098320399294607e-05
We O 0 1.8429141164233442e-06
enrolled O 0 1.3525835129257757e-05
207 O 0 2.4732833480811678e-05
women O 0 2.3266029529622756e-06
with O 0 0.00020308044622652233
hereditary B-Disease 1 0.9999885559082031
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999948740005493
and O 0 1.1049033901144867e-06
161 O 0 4.803208639714285e-07
of O 0 1.357774426224978e-08
their O 0 7.080818420490687e-08
sisters O 0 2.4045655209192773e-06
as O 0 9.914064236227205e-08
controls O 0 1.3011405144425225e-06
in O 0 1.6165132876722055e-07
a O 0 1.0532709211474867e-06
case O 0 3.621944870246807e-06
- O 0 4.935660763294436e-05
control O 0 1.5259662177413702e-05
study O 0 1.401309759785363e-06
. O 0 1.2722061910608318e-06

All O 0 7.762721452309052e-07
the O 0 1.7022372276187525e-06
patients O 0 4.328324848756893e-06
carried O 0 1.0714156815083697e-06
a O 0 1.3244580259197392e-06
pathogenic O 0 3.596976966946386e-05
mutation O 0 1.3568493159255013e-05
in O 0 1.9006151319445053e-07
either O 0 8.786371950009197e-07
BRCA1 O 0 5.986640098853968e-05
( O 0 5.32462365754327e-07
179 O 0 2.6434277060616296e-06
women O 0 1.8886142072460643e-07
) O 0 8.371601012413521e-08
or O 0 1.1446850294305477e-06
BRCA2 O 0 6.641925574513152e-05
( O 0 8.559343882552639e-07
28 O 0 7.115067546692444e-06
women O 0 2.859674452793115e-07
) O 0 5.299582426232519e-07
. O 0 1.5914029063424096e-06

The O 0 5.120746209286153e-06
control O 0 2.8256674340809695e-05
women O 0 5.84599206376879e-07
were O 0 2.3664412651669409e-07
enrolled O 0 1.613869812899793e-06
regardless O 0 6.034739499227726e-07
of O 0 3.0860967115131643e-08
whether O 0 7.77168622789759e-08
or O 0 2.948827386717312e-07
not O 0 6.445866773674425e-08
they O 0 1.1392447163416364e-07
had O 0 5.128269435772381e-07
either O 0 1.5187372355285333e-06
mutation O 0 5.7509547332301736e-05
. O 0 3.3705782698234543e-06

Lifetime O 0 0.0002468206803314388
histories O 0 6.577783642569557e-05
of O 0 1.7553741145093227e-06
oral O 0 0.0002893089549615979
- O 0 4.7745117626618594e-05
contraceptive O 0 7.728912351012696e-06
use O 0 5.100326561091606e-08
were O 0 4.4027483880881846e-08
obtained O 0 1.060138217212625e-07
by O 0 6.63372006215468e-08
interview O 0 7.186687071225606e-06
or O 0 3.0609479040322185e-07
by O 0 4.878931747498427e-08
written O 0 8.89449083274485e-08
questionnaire O 0 2.708831061681849e-07
and O 0 5.1431829461989764e-08
were O 0 8.083156188831708e-08
compared O 0 3.947457116737496e-07
between O 0 2.7533840807336674e-07
patients O 0 4.415440344018862e-06
and O 0 2.3418844818934303e-07
control O 0 2.209059175584116e-06
women O 0 3.5004495657631196e-07
, O 0 1.829774589623412e-07
after O 0 5.500381234924134e-07
adjustment O 0 4.2877195483015385e-07
for O 0 1.3329559678254554e-08
year O 0 1.1710668701425675e-07
of O 0 3.0784068627554007e-08
birth O 0 4.6959630708443e-06
and O 0 7.569705076093669e-07
parity O 0 0.0002178655267925933
. O 0 1.4921936781320255e-05

RESULTS O 0 7.026828097878024e-05
The O 0 3.0018179586477345e-06
adjusted O 0 0.00012291451275814325
odds O 0 0.0008367534028366208
ratio O 0 0.0001384681963827461
for O 0 0.0007877961616031826
ovarian B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999932050704956
associated O 0 4.092618382856017e-06
with O 0 7.14278058921991e-08
any O 0 5.807483560715809e-08
past O 0 2.546726136642974e-07
use O 0 1.0797720051414217e-07
of O 0 2.6235619543513167e-07
oral O 0 0.00010293687228113413
contraceptives O 0 0.0010876660235226154
was O 0 0.00014580541756004095
0 O 0 8.744385013415013e-06
. O 0 2.240115691165556e-06

5 O 0 7.374955202976707e-06
( O 0 1.8833442538834788e-07
95 O 0 8.904010542210017e-07
percent O 0 1.3899619943913422e-06
confidence O 0 8.403298465964326e-07
interval O 0 7.541920581388695e-07
, O 0 4.793004748648855e-08
0 O 0 5.9286488607313004e-08
. O 0 5.677518899460665e-09
3 O 0 4.959867894172021e-08
to O 0 6.400938001860368e-09
0 O 0 1.8674194279810763e-07
. O 0 3.825458705364326e-08
8 O 0 6.773336735932389e-07
) O 0 2.2458497994648496e-07
. O 0 8.109096256703197e-07

The O 0 1.0254815606458578e-05
risk O 0 3.9692604332230985e-05
decreased O 0 5.005694674764527e-06
with O 0 5.627239119121441e-08
increasing O 0 1.3795251163628564e-07
duration O 0 7.01314206708048e-07
of O 0 8.755088209966289e-09
use O 0 7.068053520242756e-08
( O 0 3.510378689952631e-07
P O 0 1.5637640899512917e-05
for O 0 3.62169174650262e-08
trend O 0 1.143419353866193e-06
, O 0 1.094700579074015e-07
< O 0 2.6464542770554544e-06
0 O 0 3.9221572478709277e-07
. O 0 2.3443373464715478e-08
001 O 0 1.7017097206917242e-06
) O 0 1.0167262587401638e-08
; O 0 3.1747797724079874e-09
use O 0 2.2542208100162497e-09
for O 0 5.526020974144785e-09
six O 0 5.3613721462397734e-08
or O 0 3.8621227105295475e-08
more O 0 3.2741340749709025e-09
years O 0 1.4506605339192902e-07
was O 0 5.864116587872559e-07
associated O 0 6.157790721772471e-08
with O 0 2.0681643064790478e-08
a O 0 5.131963121129957e-07
60 O 0 1.4217465604815516e-06
percent O 0 2.7414728265284793e-06
reduction O 0 6.458114512497559e-06
in O 0 2.3556699488835875e-06
risk O 0 7.495865429518744e-05
. O 0 5.030542070016963e-06

Oral O 0 0.0009504016488790512
- O 0 0.00022020893811713904
contraceptive O 0 5.7845278206514195e-05
use O 0 4.435140454006614e-06
protected O 0 0.005135979503393173
against O 1 0.9279930591583252
ovarian B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.999975323677063
both O 0 1.178072324137247e-07
for O 0 3.403659931677794e-08
carriers O 0 4.0814256863086484e-07
of O 0 2.930245734944492e-08
the O 0 4.869890517511521e-07
BRCA1 O 0 0.00019978208001703024
mutation O 0 3.555459261406213e-05
( O 0 5.008345738133357e-07
odds O 0 2.388079337833915e-05
ratio O 0 1.5637123169653933e-06
, O 0 1.228187898050237e-07
0 O 0 1.6391392421155615e-07
. O 0 8.785465688276872e-09
5 O 0 3.865512709921859e-08
; O 0 1.1272007327534084e-08
95 O 0 1.6452315776405158e-07
percent O 0 2.741493858593458e-07
confidence O 0 3.5593532743405376e-07
interval O 0 7.319387691495649e-07
, O 0 5.130367597416807e-08
0 O 0 7.141473190586112e-08
. O 0 7.022415982049779e-09
3 O 0 4.072428083645718e-08
to O 0 6.344441860761663e-09
0 O 0 1.1281980505373213e-07
. O 0 1.1989357950881185e-08
9 O 0 1.5340860670676193e-07
) O 0 6.407546049302937e-09
and O 0 1.0189102894742064e-08
for O 0 9.067216311109405e-09
carriers O 0 2.621655994516914e-07
of O 0 2.0501136788197982e-08
the O 0 6.958087510611222e-07
BRCA2 O 0 0.0002126349718309939
mutation O 0 3.2069125154521316e-05
( O 0 5.723998697249044e-07
odds O 0 3.705812559928745e-05
ratio O 0 1.4010105360284797e-06
, O 0 1.4055791552891606e-07
0 O 0 1.6404356983912294e-07
. O 0 1.1810011635304818e-08
4 O 0 7.216481634486627e-08
; O 0 3.1472524142373004e-08
95 O 0 2.738870250595937e-07
percent O 0 4.6751304694225837e-07
confidence O 0 5.989159035379998e-07
interval O 0 4.1367417225046665e-07
, O 0 3.747863175362909e-08
0 O 0 4.009688581163573e-08
. O 0 3.794854208649667e-09
2 O 0 2.1087219082005504e-08
to O 0 2.7527096158053155e-09
1 O 0 1.5588017276968458e-07
. O 0 2.8991305356385055e-08
1 O 0 5.635208140120085e-07
) O 0 2.2269361465987458e-07
. O 0 8.435504810222483e-07

CONCLUSIONS O 0 0.00011723393981810659
Oral O 0 0.00015765678836032748
- O 0 6.185819074744359e-05
contraceptive O 0 1.3120899893692695e-05
use O 0 3.4282041383448814e-07
may O 0 1.4150992910799687e-06
reduce O 0 2.0437048533494817e-06
the O 0 2.030428731814027e-06
risk O 0 0.00023521698312833905
of O 0 0.0002950803318526596
ovarian B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999949932098389
in O 0 7.364556608990824e-07
women O 0 1.754345504423327e-07
with O 0 1.7614065939142165e-07
pathogenic O 0 4.686819374910556e-05
mutations O 0 1.0953707715088967e-05
in O 0 2.9571688742180413e-07
the O 0 3.557917693797208e-07
BRCA1 O 0 0.00011599663412198424
or O 0 1.484977656218689e-05
BRCA2 O 0 0.0017639599973335862
gene O 0 0.0007500895299017429

A O 0 2.5938026738003828e-05
Japanese O 0 8.665760105941445e-06
family O 0 1.0102283340529539e-05
with O 0 1.2809334293706343e-05
adrenoleukodystrophy B-Disease 1 0.9999809265136719
with O 0 2.1989449123793747e-06
a O 0 3.591806034819456e-06
codon O 0 1.7043787011061795e-05
291 O 0 4.1778334889386315e-06
deletion O 0 7.763330359011889e-06
: O 0 2.932181359938113e-07
a O 0 1.1488692734928918e-06
clinical O 0 8.077750862867106e-06
, O 0 2.0604517203537398e-07
biochemical O 0 1.3476699677994475e-05
, O 0 8.756392162467819e-07
pathological O 0 0.00027565070195123553
, O 0 1.141466896115162e-06
and O 0 1.141858888331626e-06
genetic O 0 5.9202666307101026e-05
report O 0 8.922506822273135e-06
. O 0 5.14928206030163e-06

We O 0 8.244928721978795e-06
report O 0 7.544740014964191e-07
a O 0 3.5137077247782145e-07
Japanese O 0 2.443666517137899e-06
family O 0 1.07862333607045e-05
with O 0 0.0006663504173047841
adrenoleukodystrophy B-Disease 1 0.9999977350234985
( O 0 0.00020248920191079378
ALD B-Disease 1 0.999855637550354
) O 0 1.5863827229622984e-07
with O 0 4.165314848592061e-08
a O 0 3.9661318851358374e-07
three O 0 1.733453700580867e-07
base O 0 2.4152523110387847e-06
pair O 0 6.497750291600823e-06
deletion O 0 1.3354366274143104e-05
( O 0 3.582161980375531e-07
delGAG O 0 1.3785501323582139e-05
291 O 0 2.1071837181807496e-06
) O 0 1.1068970451333371e-07
in O 0 2.0957232038654183e-07
the O 0 3.2982281936710933e-06
ALD B-Disease 1 0.9994865655899048
gene O 0 0.0001499856443842873
. O 0 1.2520511518232524e-05

A O 0 8.952860298450105e-06
variety O 0 2.7468638563732384e-06
of O 0 2.2943773103634157e-07
phenotypes O 0 3.8571946788579226e-05
were O 0 5.02934369706054e-07
observed O 0 2.0302561551943654e-06
within O 0 8.573562126912293e-08
this O 0 5.832493599200461e-08
family O 0 3.200413175363792e-06
. O 0 4.555974555842113e-06

While O 0 5.038021754444344e-06
the O 0 1.0078910008815e-06
proband O 0 0.00042214433779008687
( O 0 1.1188105872861343e-06
patient O 0 1.2537574548332486e-05
1 O 0 1.407800937158754e-06
) O 0 1.2671434035382845e-07
was O 0 1.8974291151607758e-06
classified O 0 1.0514042969589354e-06
as O 0 1.83920789709191e-07
having O 0 5.846320618729806e-07
a O 0 4.1910274717338325e-07
rare O 0 2.5707524855533848e-06
intermediate O 0 3.696700332511682e-06
type O 0 4.817972239834489e-06
of O 0 3.052875570119795e-07
adult O 0 2.6605635866872035e-05
cerebral O 1 0.9874352216720581
and O 0 2.3347460228251293e-05
cerebello O 1 0.6630827784538269
- O 1 0.9607244729995728
brain O 1 0.6062067747116089
stem O 0 3.342585114296526e-05
forms O 0 1.7006016150844516e-06
, O 0 4.888843250228092e-07
his O 0 1.3383411214817897e-06
younger O 0 4.11321116189356e-06
brother O 0 5.8931684179697186e-05
( O 0 8.294964572996832e-07
patient O 0 7.943664058984723e-06
2 O 0 7.596948421451089e-07
) O 0 6.933248641871614e-08
and O 0 2.82554196928686e-07
nephew O 0 0.0003263063554186374
( O 0 1.4751178696315037e-06
patient O 0 1.5878669728408568e-05
3 O 0 1.9463566331978654e-06
) O 0 1.7772643445823633e-07
had O 0 3.847459083772264e-06
a O 0 2.2650352548225783e-05
childhood O 0 0.18452391028404236
ALD B-Disease 1 0.9999074935913086
type O 0 0.08059215545654297
. O 0 3.409812779864296e-05

Another O 0 3.9752947486704215e-05
nephew O 0 0.001256100949831307
( O 0 3.230673883081181e-06
patient O 0 2.7782076358562335e-05
4 O 0 1.6692523558958783e-06
) O 0 6.931463758519385e-08
of O 0 8.889301739145594e-08
patient O 0 2.051641422440298e-05
1 O 0 2.5992057999246754e-06
was O 0 6.632026270381175e-06
classified O 0 2.790477083181031e-06
as O 0 3.1458279181606486e-07
having O 0 1.4617414763051784e-06
an O 0 1.0159110388485715e-06
adolescent O 0 0.00019784437608905137
form O 0 1.589078783581499e-05
. O 0 1.0854420906980522e-05

The O 0 2.2242054456000915e-06
tau O 0 2.3599877749802545e-05
level O 0 4.166497546975734e-06
in O 0 1.078483023775334e-06
the O 0 4.0482455005985685e-06
cerebrospinal O 0 0.03227449953556061
fluid O 0 0.003780357539653778
( O 0 8.957599675341044e-06
CSF O 0 0.010447324253618717
) O 0 3.7629985172316083e-07
in O 0 1.5388614826861158e-07
patient O 0 4.215325134282466e-06
1 O 0 9.32570799250243e-07
was O 0 3.122721182080568e-06
as O 0 1.746872726471338e-07
high O 0 2.114519247697899e-06
as O 0 4.0798763478733235e-08
that O 0 1.153920514695983e-08
of O 0 1.0365287295144299e-07
patients O 0 1.5007605725259054e-05
with O 0 8.926349255489185e-05
Alzheimers B-Disease 1 0.9999552965164185
disease I-Disease 1 0.9995219707489014
( O 0 1.420956209585711e-06
AD B-Disease 0 1.0904253031185362e-05
) O 0 8.460237950203009e-07
. O 0 2.7360922558727907e-06

His O 0 7.391168765025213e-05
brain O 0 0.004603786859661341
magnetic O 0 2.7280746508040465e-05
resonance O 0 0.00010446247324580327
image O 0 9.707522258395329e-05
( O 0 2.9979782993905246e-06
MRI O 0 0.0006828356417827308
) O 0 1.163159254247148e-06
showed O 0 2.565705290180631e-05
abnormalities B-Disease 0 0.05493280664086342
in I-Disease 0 4.3072896005469374e-07
the I-Disease 0 3.5671214959620556e-07
bilateral I-Disease 0 0.00023644378234166652
cerebellar I-Disease 1 0.9763477444648743
hemispheres I-Disease 0 0.005871975794434547
and O 0 5.033094566897489e-05
brain O 1 0.7141684293746948
stem O 0 4.311930752010085e-05
, O 0 3.307623046566732e-07
but O 0 6.219595860557092e-08
not O 0 2.4884757365839505e-08
in O 0 1.229182657880301e-07
the O 0 1.9303001863590907e-06
cerebral O 0 0.32016721367836
white O 0 2.861271241272334e-05
matter O 0 2.5975555217883084e-06
, O 0 2.284412659037116e-07
where O 0 1.2194881549021375e-07
marked O 0 4.8235669964924455e-06
reductions O 0 2.6632798835635185e-05
of O 0 1.6704198912975698e-07
the O 0 4.8839228838915005e-06
cerebral O 0 0.1580616980791092
blood O 0 4.872424324275926e-05
flow O 0 4.63813876194763e-06
and O 0 7.388925951090641e-07
oxygen O 0 5.949138994765235e-06
metabolism O 0 3.112031117780134e-05
were O 0 1.0393319627155506e-07
clearly O 0 2.1501902836007503e-07
demonstrated O 0 2.0052263494108047e-07
by O 0 4.076010284848053e-08
positron O 0 5.596171831712127e-05
emission O 0 8.095427619991824e-05
tomography O 0 8.861527749104425e-05
( O 0 1.603439386599348e-06
PET O 0 9.462398884352297e-05
) O 0 1.3940799590272945e-06
. O 0 2.6461968900548527e-06

In O 0 6.358136943163117e-06
patients O 0 9.890161891235039e-06
2 O 0 8.190190214918402e-07
and O 0 1.3318052083377552e-07
3 O 0 7.968756676746125e-07
, O 0 1.0589661059157152e-07
the O 0 2.486709149707167e-07
autopsy O 0 0.00022790636285208166
findings O 0 6.016723546053981e-06
showed O 0 3.843953527393751e-05
massive O 0 0.013441033661365509
demyelination B-Disease 1 0.9999359846115112
of I-Disease 0 5.147696356289089e-06
the I-Disease 0 2.418787516944576e-05
cerebral I-Disease 1 0.9971388578414917
white I-Disease 0 5.2610168495448306e-05
matter I-Disease 0 5.443640702651464e-07
with O 0 9.218760510520951e-08
sparing O 0 1.0089412398883724e-06
of O 0 4.77717883029527e-08
the O 0 2.911977503572416e-07
U O 0 0.00018234626622870564
- O 0 0.00012301135575398803
fibers O 0 1.753062315401621e-05
, O 0 4.590681257354845e-08
compatible O 0 2.6075852588292037e-07
with O 0 1.8877570084896433e-07
the O 0 7.391202530016017e-07
findings O 0 3.6434864796319744e-06
of O 0 2.0025368030474056e-06
childhood O 1 0.7454356551170349
ALD B-Disease 1 0.9999291896820068
. O 0 0.00016546192637179047

Oleic O 0 0.010123691521584988
and O 0 2.2705804440192878e-05
erucic O 0 0.009028397500514984
acids O 0 4.3782776629086584e-05
( O 0 1.2086225069651846e-06
Lorenzos O 0 6.243857205845416e-05
Oil O 0 4.405001163831912e-06
) O 0 4.711204937279945e-08
were O 0 1.9879177415305094e-08
administered O 0 1.3945118837455084e-07
to O 0 3.092483780164912e-08
patients O 0 8.324833515871433e-07
1 O 0 3.1659774890613335e-07
and O 0 8.174429666496508e-08
4 O 0 7.78292076120124e-07
, O 0 6.352351533678302e-08
but O 0 2.119581132831172e-08
sufficient O 0 6.627927717772764e-08
effectiveness O 0 7.67999210893322e-07
was O 0 3.948506673623342e-06
not O 0 5.751221721084221e-08
obtained O 0 1.49518155012629e-06
. O 0 2.3886966573627433e-06

The O 0 2.0225531898176996e-06
findings O 0 1.5592656836815877e-06
in O 0 9.839727255211983e-08
this O 0 1.4409970106044057e-08
family O 0 3.183714056831377e-07
suggest O 0 1.500423678635343e-07
that O 0 2.632985385275788e-08
delGAG291 O 0 1.1991244718956295e-05
is O 0 1.4922967750408134e-07
part O 0 9.087529662110683e-08
of O 0 3.4661404413327546e-08
the O 0 7.592964266223134e-07
cause O 0 1.9259796317783184e-05
of O 0 4.937215294376074e-07
Japanese O 0 0.0002796270709950477
ALD B-Disease 1 0.9999123811721802
with O 0 3.251801445003366e-06
phenotypic O 0 0.0002250339020974934
variations O 0 0.00020209068316034973
. O 0 2.9361561246332712e-05

Moreover O 0 1.397381583956303e-05
, O 0 3.3880638738992275e-07
although O 0 7.355222209071144e-08
the O 0 5.90539990241723e-08
scale O 0 2.977293206640752e-06
of O 0 2.625908912534669e-08
the O 0 6.636985716568233e-08
study O 0 1.2467084786749183e-07
is O 0 1.9345332447073815e-08
limited O 0 4.504913064806715e-08
, O 0 4.875527181980033e-08
there O 0 2.0110054066435623e-08
is O 0 4.4986794733858915e-08
a O 0 1.8560777448328736e-07
possibility O 0 5.275866215015412e-07
that O 0 3.0066772183090507e-08
PET O 0 1.8472761439625174e-05
can O 0 5.682634309778223e-07
detect O 0 0.00014968274626880884
an O 0 5.45237708138302e-06
insidious B-Disease 0 0.09107460081577301
lesion I-Disease 1 0.9885148406028748
which O 0 1.0432709132146556e-06
is O 0 4.7235855049621023e-07
undetectable O 0 5.368224447011016e-05
by O 0 1.7820130437939952e-07
computed O 0 8.178815733117517e-06
tomogram O 0 8.356318721780553e-05
( O 0 7.766113299112476e-07
CT O 0 0.00028443141491152346
) O 0 1.2107457791898923e-07
or O 0 3.800376191520627e-07
MRI O 0 1.9054539734497666e-05
analysis O 0 9.328211092451966e-08
, O 0 5.0757449798766174e-08
and O 0 1.57795660982174e-08
that O 0 2.6513735651434445e-09
the O 0 3.392842273797214e-08
higher O 0 4.101927117972082e-07
level O 0 9.615180260880152e-07
of O 0 5.1578794568740705e-08
tau O 0 6.598501840926474e-06
reflects O 0 2.026774836849654e-07
the O 0 3.780169777201081e-08
process O 0 1.1282153167258002e-07
of O 0 2.982101818815863e-07
neuronal B-Disease 0 0.00023508739832323045
degeneration I-Disease 1 0.9980816841125488
in O 0 0.0003843476006295532
ALD B-Disease 1 0.9999291896820068
. O 0 0.00012222820078022778

Lorenzos O 0 0.0010521725052967668
Oil O 0 1.8157710655941628e-05
should O 0 1.8494797870971524e-07
be O 0 2.2553271250558282e-08
given O 0 9.009499812862032e-09
in O 0 1.9346217072779837e-08
the O 0 2.700926593490749e-08
early O 0 1.2777020401699701e-06
stage O 0 1.7157553884317167e-05
. O 0 4.059299385517079e-07
. O 0 1.4412684095077566e-06

Nonsense O 0 0.0014041668036952615
mutation O 0 8.124025771394372e-05
in O 0 1.0884125458687777e-06
exon O 0 4.516391345532611e-05
4 O 0 1.908495733005111e-06
of O 0 5.553273751957022e-08
human O 0 9.190579817186517e-07
complement O 0 2.2472688669950003e-06
C9 O 0 0.0007065061945468187
gene O 0 9.802515705814585e-06
is O 0 6.204702458489919e-07
the O 0 1.5561519717266492e-07
major O 0 1.567982508277055e-05
cause O 0 1.3757437045569532e-05
of O 0 3.273842992257414e-07
Japanese O 0 4.4945823901798576e-05
complement B-Disease 0 0.0009763070847839117
C9 I-Disease 1 0.9968143105506897
deficiency I-Disease 1 0.9995044469833374
. O 0 4.8476380470674485e-05

Deficiency B-Disease 1 0.9981040954589844
of I-Disease 0 1.4311834775071475e-06
the I-Disease 0 1.234973524333327e-06
ninth I-Disease 0 0.0001379535679006949
component I-Disease 0 3.684149987748242e-06
of I-Disease 0 1.1180751613437678e-07
human I-Disease 0 6.006628154864302e-07
complement I-Disease 0 2.7547234822122846e-06
( O 0 1.146102817983774e-06
C9 O 0 0.0006761791300959885
) O 0 1.9204239265491196e-07
is O 0 4.345159609897564e-08
the O 0 2.455097281028884e-08
most O 0 1.9225129221922543e-07
common O 0 1.5565077774226665e-05
complement B-Disease 1 0.9987218976020813
deficiency I-Disease 1 0.9999955892562866
in O 0 1.662318140915886e-06
Japan O 0 4.844500836043153e-06
but O 0 2.097418700941489e-07
is O 0 5.587772733406382e-08
rare O 0 4.3509569991329045e-07
in O 0 2.6401718145052655e-08
other O 0 5.578111750281778e-09
countries O 0 6.227953974757838e-08
. O 0 2.8533565910038305e-06

We O 0 2.438782303215703e-06
studied O 0 2.755022705969168e-06
the O 0 9.544834256303147e-08
molecular O 0 9.737832442624494e-06
basis O 0 1.3842023918186896e-06
of O 0 6.483131073764525e-06
C9 B-Disease 1 0.9955573678016663
deficiency I-Disease 1 0.9991565942764282
in O 0 7.408866622427013e-07
four O 0 6.1186642597022e-07
Japanese O 0 1.3403463526628911e-05
C9 B-Disease 0 0.30498912930488586
- I-Disease 0 0.1616385132074356
deficient I-Disease 0 0.02070780284702778
patients O 0 7.504761742893606e-05
who O 0 1.4037298569746781e-05
had O 0 0.00010477791511220858
suffered O 1 0.9991291165351868
from O 0 0.0008347664843313396
meningococcal B-Disease 1 0.99994957447052
meningitis I-Disease 1 0.9999576807022095
. O 0 2.5426799766137265e-05

Direct O 0 3.535367625318031e-07
sequencing O 0 2.1716361970902653e-06
of O 0 2.5558188099239487e-07
amplified O 0 4.75311535410583e-05
C9 O 0 0.00037167553091421723
cDNA O 0 1.8479084928912926e-06
and O 0 5.29659644143976e-07
DNA O 0 2.964854274978279e-06
revealed O 0 4.679462108470034e-06
a O 0 8.265502060567087e-07
nonsense O 0 9.47775970416842e-06
substitution O 0 1.117558554142306e-06
( O 0 6.585762548638741e-07
CGA O 0 7.814478158252314e-05
- O 0 6.61683952785097e-05
- O 0 6.175640010042116e-05
> O 0 2.3787057216395624e-05
TGA O 0 4.256855754647404e-05
) O 0 1.0973597142083236e-07
at O 0 8.112879186228383e-07
codon O 0 6.26658390956436e-07
95 O 0 1.5885748894106655e-07
in O 0 5.7475588732813776e-08
exon O 0 2.3151005734689534e-06
4 O 0 6.772833103241283e-07
in O 0 9.344290674562217e-08
the O 0 2.9637135412485804e-07
four O 0 2.011172227867064e-06
C9 B-Disease 0 0.02138795144855976
- I-Disease 0 0.019315233454108238
deficient I-Disease 0 0.0028110432904213667
individuals O 0 7.544912818957528e-07
. O 0 4.922236712445738e-06

An O 0 1.4050942809262779e-06
allele O 0 2.0378452973091044e-05
- O 0 1.8802744307322428e-05
specific O 0 4.197159455543442e-07
polymerase O 0 1.9587803762988187e-05
chain O 0 3.832452784990892e-05
reaction O 0 3.01334262076125e-06
system O 0 1.4311875702333055e-06
designed O 0 5.93169090734591e-07
to O 0 2.6633772520767707e-08
detect O 0 2.311570597157697e-06
exclusively O 0 6.633340632333784e-08
only O 0 1.8854175110050164e-08
one O 0 2.1907840874746398e-08
of O 0 5.085170950991369e-09
the O 0 2.8745892777237714e-08
normal O 0 6.5798616333268e-07
and O 0 1.254661583516281e-07
mutant O 0 2.105548446706962e-06
alleles O 0 7.814955438334437e-07
indicated O 0 5.762299792877457e-07
that O 0 3.92682597549765e-09
all O 0 3.769029977007676e-09
the O 0 3.8369826427242515e-08
four O 0 1.8191903450315294e-07
patients O 0 7.037100431261933e-07
were O 0 3.947734938947178e-08
homozygous O 0 1.8676757918001385e-07
for O 0 6.595112900242839e-09
the O 0 6.10132318001888e-08
mutation O 0 1.3999100474393344e-06
in O 0 1.1414937972631378e-07
exon O 0 5.841143774887314e-06
4 O 0 9.632765340938931e-07
and O 0 7.820339931186027e-08
that O 0 8.889500691111607e-09
the O 0 6.733792190516397e-08
parents O 0 1.5192210867098765e-07
of O 0 1.0092320934518284e-07
patient O 0 8.981107384897768e-06
2 O 0 1.7857672673926572e-06
were O 0 4.919778007206332e-07
heterozygous O 0 2.702452093217289e-06
. O 0 1.8490508182367194e-06

The O 0 3.1141294130065944e-06
common O 0 8.041779437917285e-06
mutation O 0 3.080584428971633e-05
at O 0 5.285437509883195e-06
codon O 0 2.1447744984470773e-06
95 O 0 5.877498097106582e-07
in O 0 1.4314835539153137e-07
exon O 0 7.909670785011258e-06
4 O 0 1.2656520311793429e-06
might O 0 2.301108992242007e-07
be O 0 1.8832645665156633e-08
responsible O 0 2.570615151853417e-07
for O 0 3.354229249907803e-08
most O 0 9.78576622401306e-07
Japanese O 0 0.0002644281485117972
C9 B-Disease 1 0.9942065477371216
deficiency I-Disease 1 0.9994390606880188
. O 0 3.4402671644784277e-06
. O 0 4.458235252968734e-06

BRCA1 O 0 0.00029073929181322455
required O 0 6.349935119942529e-07
for O 0 7.484457142936662e-08
transcription O 0 2.9079114028718323e-05
- O 0 0.00038711741217412055
coupled O 0 7.397458102786914e-05
repair O 0 0.008486209437251091
of O 0 1.5160615021159174e-06
oxidative O 0 0.008907603099942207
DNA O 0 0.0004726732731796801
damage O 0 0.05471538379788399
. O 0 7.195163107098779e-06

The O 0 0.0002221635077148676
breast B-Disease 1 0.9982428550720215
and I-Disease 1 0.8348050713539124
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999783039093018
susceptibility O 0 0.0006455809343606234
gene O 0 1.955652260221541e-05
BRCA1 O 0 6.317476800177246e-05
encodes O 0 1.769624418557214e-06
a O 0 4.342262400314212e-06
zinc O 0 0.0008636419661343098
finger O 0 8.842568786349148e-05
protein O 0 8.832984121909249e-07
of O 0 6.550735065502522e-08
unknown O 0 6.2780663938610815e-06
function O 0 6.352627679007128e-06
. O 0 4.08893174608238e-06

Association O 0 8.08553522801958e-06
of O 0 5.207403575013814e-08
the O 0 2.1295502961038437e-07
BRCA1 O 0 1.0014437975769397e-05
protein O 0 1.9479836055324995e-07
with O 0 3.449244090347747e-08
the O 0 8.943415252815612e-08
DNA O 0 3.5090104120172327e-06
repair O 0 0.00019157557107973844
protein O 0 5.177512321097311e-06
Rad51 O 0 0.0002593738026916981
and O 0 2.418201461296121e-07
changes O 0 1.7680306996226136e-07
in O 0 1.7227504756078815e-08
the O 0 5.731190189095514e-09
phosphorylation O 0 5.766445454469249e-08
and O 0 3.915609170235257e-08
cellular O 0 7.0007258727855515e-06
localization O 0 2.9328793971217237e-06
of O 0 1.7456395440262895e-08
the O 0 3.334403686494625e-08
protein O 0 5.916798500038567e-07
after O 0 1.7731076695781667e-06
exposure O 0 5.341516498447163e-06
to O 0 5.369835420765412e-08
DNA O 0 5.013692316424567e-06
- O 0 4.1491752199362963e-05
damaging O 0 3.646608456620015e-05
agents O 0 4.0711006477067713e-07
are O 0 5.8508975442350675e-09
consistent O 0 8.911591464766389e-08
with O 0 2.4076481253132442e-08
a O 0 1.7401320917542762e-07
role O 0 3.372667265466589e-07
for O 0 6.202253644005395e-08
BRCA1 O 0 2.4819240934448317e-05
in O 0 1.0299911537003936e-06
DNA O 0 2.0398460037540644e-05
repair O 0 0.013770882971584797
. O 0 1.173162763734581e-05

Here O 0 4.137398263992509e-06
, O 0 2.650763804012968e-07
it O 0 3.04861877964413e-08
is O 0 2.2297449220332055e-08
shown O 0 6.061351598418696e-08
that O 0 1.9225087299901134e-08
mouse O 0 9.878586752165575e-06
embryonic O 0 1.4467989785771351e-05
stem O 0 1.87041332537774e-05
cells O 0 9.065765880222898e-06
deficient B-Disease 0 8.358812920050696e-05
in I-Disease 0 6.626182766922284e-07
BRCA1 I-Disease 0 2.196919740526937e-05
are O 0 9.249441745851072e-08
defective O 0 3.452674354775809e-05
in O 0 1.1557359869129868e-07
the O 0 3.024126726813847e-08
ability O 0 3.835716455569127e-08
to O 0 8.244747995433954e-09
carry O 0 9.851652293946245e-08
out O 0 2.3019781281163887e-07
transcription O 0 7.765084774291608e-06
- O 0 0.0001230430498253554
coupled O 0 4.612646807800047e-05
repair O 0 0.002025727415457368
of O 0 5.045230295763758e-07
oxidative O 0 0.0004891143180429935
DNA O 0 0.00010204731370322406
damage O 0 0.0012844792800024152
, O 0 3.096143643688265e-07
and O 0 1.7721632161737944e-07
are O 0 1.0940660644109812e-07
hypersensitive O 0 0.0003256971831433475
to O 0 1.5495854768232675e-06
ionizing O 0 0.028763359412550926
radiation O 0 0.04608122631907463
and O 0 5.254305506241508e-07
hydrogen O 0 1.0460242265253328e-05
peroxide O 0 0.0010081869550049305
. O 0 6.353930075420067e-06

These O 0 3.4410177818244847e-07
results O 0 1.5293604747057543e-06
suggest O 0 6.706163730996195e-07
that O 0 1.0891378110500227e-07
BRCA1 O 0 2.589458199508954e-05
participates O 0 3.1337117434304673e-06
, O 0 1.0615870138508399e-07
directly O 0 1.0445327802699467e-07
or O 0 3.42984236567645e-07
indirectly O 0 2.071881453957758e-06
, O 0 8.556914110613434e-08
in O 0 1.2581243424847344e-07
transcription O 0 1.67182970471913e-05
- O 0 0.00017143449804279953
coupled O 0 3.2066585845313966e-05
repair O 0 0.003885982558131218
of O 0 9.423829396837391e-07
oxidative O 0 0.0016656843945384026
DNA O 0 0.00016671618504915386
damage O 0 0.00334566249512136
. O 0 8.085358444986923e-07
. O 0 2.508991656213766e-06

Truncation O 0 0.002431504661217332
mutations O 0 0.0008560784626752138
in O 0 2.2727681425749324e-06
the O 0 6.994306431806763e-07
transactivation O 0 0.0002096180833177641
region O 0 1.4219405784388073e-05
of O 0 7.365778742496332e-07
PAX6 O 0 0.001260975026525557
result O 0 9.97113329503918e-06
in O 0 1.2673840501520317e-06
dominant O 0 0.00024589549866504967
- O 0 0.0006541271577589214
negative O 0 1.6341868104063906e-05
mutants O 0 0.00011750769772334024
. O 0 4.5777246668876614e-06

PAX6 O 0 0.004254084080457687
is O 0 1.2830087143811397e-06
a O 0 3.003376036758709e-07
transcription O 0 2.971140929730609e-06
factor O 0 1.5313058554511372e-07
with O 0 2.7220375287129173e-08
two O 0 6.061120672029574e-08
DNA O 0 1.6457130413982668e-06
- O 0 8.74254237714922e-06
binding O 0 2.22370704250352e-06
domains O 0 3.0902692742529325e-06
( O 0 1.6923021917136793e-07
paired O 0 2.5057108814507956e-06
box O 0 9.398785550729372e-06
and O 0 2.11943216754662e-07
homeobox O 0 3.6429755709832534e-06
) O 0 4.7180119366885265e-08
and O 0 8.448145649708749e-08
a O 0 9.444505053579633e-07
proline O 0 5.622113894787617e-05
- O 0 3.590048072510399e-05
serine O 0 1.3914731425757054e-05
- O 0 5.1990722568007186e-05
threonine O 0 7.232865755213425e-05
( O 0 2.0686791231128154e-06
PST O 0 0.00034689740277826786
) O 0 6.248501449590549e-07
- O 0 1.6014349967008457e-05
rich O 0 4.117394837521715e-06
transactivation O 0 0.0001705841423245147
domain O 0 2.5025061404448934e-05
. O 0 4.8594101826893166e-06

PAX6 O 0 0.03033984638750553
regulates O 0 0.001453398261219263
eye O 0 0.0024579765740782022
development O 0 1.1822428405139362e-06
in O 0 5.405441356742813e-07
animals O 0 5.539763492379279e-07
ranging O 0 6.637075330218067e-06
from O 0 2.0452537796700199e-07
jellyfish O 0 6.31075465662434e-07
to O 0 6.879737224352311e-09
Drosophila O 0 5.2224827129521145e-08
to O 0 4.3977966157626724e-08
humans O 0 2.0470267827477073e-06
. O 0 2.176022690036916e-06

Heterozygous O 0 5.4443291446659714e-05
mutations O 0 3.242112143198028e-05
in O 0 2.471297193551436e-07
the O 0 1.888300857899594e-07
human O 0 3.5380799090489745e-06
PAX6 O 0 0.0005795484757982194
gene O 0 1.1080795957241207e-05
result O 0 2.2528072349814465e-06
in O 0 7.311260930009666e-08
various O 0 5.960475135680099e-08
phenotypes O 0 2.552694786572829e-05
, O 0 1.0984471146002761e-06
including O 0 7.111119430192048e-06
aniridia B-Disease 1 0.9999287128448486
, O 0 0.00046787760220468044
Peters B-Disease 1 0.9990814924240112
anomaly I-Disease 1 0.9997108578681946
, O 0 3.873908281093463e-05
autosomal B-Disease 1 0.9670591950416565
dominant I-Disease 0 0.4183137118816376
keratitis I-Disease 1 0.9932180047035217
, O 0 1.9929191694245674e-05
and O 0 3.284810736658983e-05
familial B-Disease 1 0.997938334941864
foveal I-Disease 1 0.9992976188659668
dysplasia I-Disease 1 0.9999325275421143
. O 0 0.00012638622138183564

It O 0 1.796743049453653e-06
is O 0 4.086192575414316e-07
believed O 0 1.5290440558146656e-07
that O 0 8.628958880763093e-09
the O 0 4.4087229866818234e-08
mutated O 0 3.856242074107286e-06
allele O 0 4.315889327699551e-06
of O 0 2.3102870727598201e-07
PAX6 O 0 0.00029577885288745165
produces O 0 2.3541786049463553e-06
an O 0 1.4852983554192178e-07
inactive O 0 8.100926606857684e-06
protein O 0 1.2242905995663023e-06
and O 0 2.0533734641503543e-06
aniridia B-Disease 1 0.9996936321258545
is O 0 4.578021162160439e-06
caused O 0 2.2474068828159943e-05
due O 0 2.0482862055359874e-06
to O 0 3.389770313333429e-07
genetic O 0 4.866935341851786e-05
haploinsufficiency O 0 0.003858037991449237
. O 0 1.3271741408971138e-05

However O 0 4.180104951956309e-06
, O 0 4.0334947470910265e-07
several O 0 1.399174323069019e-07
truncation O 0 4.6391105570364743e-05
mutations O 0 2.8754599043168128e-05
have O 0 2.123450144608796e-07
been O 0 1.1830238832999385e-07
found O 0 4.7880888587314985e-08
to O 0 1.3097448459120642e-08
occur O 0 1.3225871953181922e-07
in O 0 4.4362383988527654e-08
the O 0 1.4725948460636573e-07
C O 0 2.1827523596584797e-05
- O 0 1.6872460037120618e-05
terminal O 0 3.1994011806091294e-05
half O 0 3.328926823087386e-07
of O 0 6.486270365257951e-08
PAX6 O 0 0.0003081264439970255
in O 0 2.6552090730547206e-06
patients O 0 6.694414423691342e-06
with O 0 1.0873812925638049e-06
Aniridia B-Disease 1 0.9979996085166931
resulting O 0 6.529654910991667e-06
in O 0 1.5291374211301445e-07
mutant O 0 9.93785988612217e-07
proteins O 0 3.7421628462652734e-08
that O 0 5.100080802122875e-09
retain O 0 1.4671404358068685e-07
the O 0 1.0696886221239765e-07
DNA O 0 7.704185236434569e-07
- O 0 1.674207396717975e-06
binding O 0 4.842949010708253e-07
domains O 0 1.212714323628461e-06
but O 0 7.88892506875527e-08
have O 0 1.9664973649469175e-08
lost O 0 1.7995228063227842e-06
most O 0 2.270611254573396e-08
of O 0 1.9552809149558925e-08
the O 0 2.997944648086559e-07
transactivation O 0 0.0001813299022614956
domain O 0 4.665326196118258e-05
. O 0 1.0416740224172827e-05

It O 0 1.4169979749567574e-06
is O 0 2.8839590981988295e-07
not O 0 2.8644803862221124e-08
clear O 0 1.5533125008460047e-07
whether O 0 5.669232550076231e-08
such O 0 3.458717756643637e-08
mutants O 0 5.2533255257003475e-06
really O 0 1.6532685549464077e-06
behave O 0 1.8965316712638014e-06
as O 0 1.1443596577009885e-06
loss O 0 1.8548915249994025e-05
- O 0 4.097933469893178e-06
of O 0 8.140308693782572e-08
- O 0 7.016031304374337e-06
function O 0 8.634854680167336e-07
mutants O 0 2.945346750493627e-06
as O 0 3.673071091725433e-07
predicted O 0 1.8271883845955017e-06
by O 0 2.1944354955394374e-07
haploinsufficiency O 0 0.00017275051504839212
. O 0 3.833870323433075e-06

Contrary O 0 5.6732192206254695e-06
to O 0 4.858372193439209e-08
this O 0 1.176948938308442e-08
theory O 0 3.695603822961857e-08
, O 0 1.4336990261654137e-08
our O 0 1.4596551523027301e-08
data O 0 8.560946440638872e-08
showed O 0 2.0987631899060943e-07
that O 0 1.73074621301339e-09
these O 0 2.053991421391288e-09
mutants O 0 2.4844595714057505e-07
are O 0 7.358277986924122e-09
dominant O 0 7.632752385688946e-06
- O 0 2.6104686185135506e-05
negative O 0 9.01586076906824e-07
in O 0 2.8852630862274964e-07
transient O 0 4.299530246498762e-06
transfection O 0 1.9318053091410547e-05
assays O 0 4.050639745400986e-06
when O 0 1.931167901148001e-07
they O 0 1.3335357706978357e-08
are O 0 9.2698186904272e-09
coexpressed O 0 5.28912323716213e-06
with O 0 6.560118777088064e-07
wild O 0 3.8495956687256694e-05
- O 0 0.000983733800239861
type O 0 0.00044193421490490437
PAX6 O 0 0.01295018382370472
. O 0 4.308716597734019e-05

We O 0 2.7904666239919607e-06
found O 0 4.524011671946937e-07
that O 0 1.6836489535876353e-08
the O 0 1.5650684304091556e-07
dominant O 0 7.15873611625284e-05
- O 0 0.0002098258410114795
negative O 0 2.3165184757090174e-06
effects O 0 2.9632601581397466e-06
result O 0 3.690954883950326e-07
from O 0 3.851823748846073e-08
the O 0 1.113758241189089e-08
enhanced O 0 7.170196454353572e-07
DNA O 0 8.748461937102547e-07
binding O 0 4.5523424319071637e-07
ability O 0 1.3573891521900805e-07
of O 0 1.1054998694248752e-08
these O 0 3.213945376501215e-08
mutants O 0 2.0148112525930628e-05
. O 0 2.251237219752511e-06

Kinetic O 0 4.936771802022122e-05
studies O 0 9.764604556039558e-07
of O 0 4.346751225625667e-08
binding O 0 2.788620122373686e-06
and O 0 6.154950256131997e-07
dissociation O 0 1.979761327675078e-05
revealed O 0 1.8815682096828823e-06
that O 0 2.6437532163470223e-09
various O 0 6.130624008449104e-09
truncation O 0 3.886385911755497e-06
mutants O 0 4.770686700794613e-06
have O 0 6.564367538430815e-08
3 O 0 6.365426088450477e-07
- O 0 6.5658600760798436e-06
5 O 0 1.6636391819702112e-06
- O 0 3.2598713914921973e-06
fold O 0 8.235618338403583e-07
higher O 0 1.8286162628555758e-07
affinity O 0 1.0351970303190683e-07
to O 0 3.5434797318600886e-09
various O 0 1.4244587731582214e-08
DNA O 0 5.961589408798318e-07
- O 0 9.47816090501874e-07
binding O 0 2.1549158191191964e-07
sites O 0 1.4835190143003274e-07
when O 0 1.1626030982370139e-07
compared O 0 1.6155485127455904e-07
with O 0 2.522914321900771e-08
the O 0 1.2963346307515167e-07
wild O 0 7.547499080828857e-06
- O 0 0.00018366034782957286
type O 0 0.00015067339700181037
PAX6 O 0 0.007325069047510624
. O 0 2.7075859179603867e-05

These O 0 1.6179768635993241e-07
results O 0 4.0100601950143755e-07
provide O 0 2.093010209591739e-08
a O 0 1.8816349722783343e-07
new O 0 1.292616218506737e-07
insight O 0 3.132875860956119e-07
into O 0 3.9307245458530815e-08
the O 0 6.039609701247173e-08
role O 0 4.0719316984905163e-07
of O 0 2.1668518002115889e-07
mutant O 0 3.1925497751217335e-05
PAX6 O 0 0.0019428078085184097
in O 0 1.4917042790330015e-05
causing O 0 0.0030480711720883846
aniridia B-Disease 1 0.9993926286697388
. O 0 3.4197898912680103e-06
. O 0 3.813038347288966e-06

Reversal O 0 0.00854836218059063
of O 0 0.00030591420363634825
severe O 1 0.9997695088386536
hypertrophic B-Disease 1 0.9999650716781616
cardiomyopathy I-Disease 1 0.9999961853027344
and O 0 3.966830990975723e-05
excellent O 0 5.767617403762415e-05
neuropsychologic O 0 0.0005310719134286046
outcome O 0 5.123735718370881e-06
in O 0 5.248786578704312e-07
very B-Disease 0 2.8216875307407463e-06
- I-Disease 0 0.00011017883662134409
long I-Disease 0 2.7202911951462738e-05
- I-Disease 0 7.036872557364404e-05
chain I-Disease 0 5.525463348021731e-05
acyl I-Disease 0 4.0456452552462e-05
- I-Disease 0 7.980790542205796e-05
coenzyme I-Disease 0 2.2234220523387194e-05
A I-Disease 0 0.00017813754675444216
dehydrogenase I-Disease 0 0.46586233377456665
deficiency I-Disease 1 0.999164342880249
. O 0 2.2112924852990545e-05

Very B-Disease 0 3.105389987467788e-05
- I-Disease 0 0.0003607062390074134
long I-Disease 0 4.871829514740966e-05
- I-Disease 0 6.802704592701048e-05
chain I-Disease 0 2.8152340746601112e-05
acyl I-Disease 0 1.3081516954116523e-05
- I-Disease 0 1.2363297173578758e-05
coenzyme I-Disease 0 4.328543582232669e-06
A I-Disease 0 8.351739779755007e-06
dehydrogenase I-Disease 0 0.00010910395940300077
( I-Disease 0 6.970634331082692e-06
VLCAD I-Disease 0 0.019571682438254356
) I-Disease 0 3.771161209442653e-05
deficiency I-Disease 1 0.9975320100784302
is O 0 3.6757346606464125e-06
a O 0 4.959771831636317e-05
disorder O 1 0.9973118305206299
of O 0 8.885400006874988e-07
fatty O 0 8.55218167998828e-05
acid O 0 2.534231316531077e-05
beta O 0 2.2840038127469597e-06
oxidation O 0 2.1627488422382157e-06
that O 0 4.571947087583794e-08
reportedly O 0 7.87484532338567e-06
has O 0 6.286756502049684e-07
high O 0 2.0658028006437235e-05
rates O 0 4.934042408422101e-06
of O 0 4.688310468736745e-07
morbidity O 0 0.03657960519194603
and O 0 5.951221737632295e-06
mortality O 0 0.0011677436996251345
. O 0 6.024002686899621e-06

We O 0 3.1090314678294817e-06
describe O 0 1.5217601685435511e-06
the O 0 1.2519603842520155e-07
outcome O 0 2.623201567075739e-07
of O 0 2.0801433464612273e-08
a O 0 6.004136707815633e-07
5 O 0 2.3395837160933297e-06
- O 0 2.2547423213836737e-05
year O 0 3.4629929359653033e-06
- O 0 4.742669261759147e-05
old O 0 0.00021159726020414382
girl O 0 0.0004481560317799449
with O 0 0.0001799722231226042
VLCAD B-Disease 1 0.9999442100524902
deficiency I-Disease 1 0.9999955892562866
who O 0 5.634441095025977e-06
was O 0 2.078197894661571e-06
first O 0 2.682634203665657e-07
seen O 0 2.1708242456952576e-06
at O 0 4.207461188343586e-06
5 O 0 5.099971644995094e-07
months O 0 3.5860242064700287e-07
of O 0 4.552055798967558e-08
age O 0 1.4683676454296801e-05
with O 0 0.0002348772541154176
severe O 1 0.9997336268424988
hypertrophic B-Disease 1 0.9999704360961914
cardiomyopathy I-Disease 1 0.9999994039535522
, O 1 0.9061696529388428
hepatomegaly B-Disease 1 0.9999974966049194
, O 1 0.7154632806777954
encephalopathy B-Disease 1 0.9999668598175049
, O 0 1.8341668692301027e-05
and O 0 1.8362601622357033e-05
hypotonia B-Disease 1 0.8874948024749756
. O 0 4.0256560168927535e-05

Biochemical O 0 0.00866097304970026
studies O 0 0.00047393288696184754
indicated O 1 0.5620414614677429
VLCAD B-Disease 1 0.9999847412109375
deficiency I-Disease 1 0.9999992847442627
caused O 0 0.0034222453832626343
by O 0 3.440171099100553e-07
a O 0 2.445410245854873e-06
stable O 0 6.430176290450618e-05
yet O 0 6.369874881784199e-06
inactive O 0 3.9250437112059444e-05
enzyme O 0 2.459730239934288e-05
. O 0 4.3512077354534995e-06

Molecular O 0 0.0008905104477889836
genetic O 0 6.849663623142987e-05
analysis O 0 3.7217735098238336e-06
of O 0 4.087279990017123e-07
her O 0 1.6910928025026806e-05
VLCAD O 0 0.002456008456647396
gene O 0 2.4002396457944997e-05
revealed O 0 2.424935701128561e-05
a O 0 3.227317392884288e-06
T1372C O 0 5.9979316574754193e-05
( O 0 6.311915967671666e-07
F458L O 0 2.7571903046919033e-05
) O 0 5.563683771470096e-07
missense O 0 6.625337846344337e-05
mutation O 0 3.463342727627605e-05
and O 0 1.3549412187785492e-06
a O 0 1.5501411326113157e-05
1668 O 0 0.010048791766166687
ACAG O 0 0.0048461612313985825
1669 O 0 0.0009865338215604424
splice O 0 0.0005671808030456305
site O 0 0.0001792471157386899
mutation O 0 0.0003295957576483488
. O 0 7.220692168630194e-06

After O 0 2.8874186682514846e-05
initial O 0 6.588095402548788e-06
treatment O 0 1.1933611858694348e-05
with O 0 4.082749001099728e-07
intravenous O 0 7.057961192913353e-05
glucose O 0 0.00016384717309847474
and O 0 2.5498907234577928e-06
carnitine O 0 0.00035318933078087866
, O 0 5.043628448220261e-07
the O 0 2.7126520762976725e-07
patient O 0 7.617983101226855e-06
has O 0 2.857406400380569e-07
thrived O 0 2.4592272893642075e-06
on O 0 6.915655603734194e-07
a O 0 1.5547544762739562e-06
low O 0 5.8410234487382695e-05
- O 0 4.5002001570537686e-05
fat O 0 1.76556841324782e-05
diet O 0 2.4121634396578884e-06
supplemented O 0 2.1676619610389025e-07
with O 0 9.204686790553751e-08
medium O 0 7.72104522184236e-06
- O 0 6.294998456723988e-05
chain O 0 6.3944527937565e-05
triglyceride O 0 5.62580389669165e-05
oil O 0 1.3132341337040998e-05
and O 0 8.479543680550705e-07
carnitine O 0 0.00025022061890922487
and O 0 1.5927784033920034e-06
avoidance O 0 0.00039100716821849346
of O 0 2.648908775881864e-06
fasting O 0 9.602499631000683e-05
. O 0 5.2032910389243625e-06

Her O 0 0.0010697095422074199
ventricular O 1 0.9804611802101135
hypertrophy O 0 0.1787695586681366
resolved O 0 5.44761169294361e-05
significantly O 0 7.124152489268454e-06
over O 0 6.157720804367273e-07
1 O 0 2.603030907266657e-06
year O 0 6.186563155097247e-07
, O 0 9.313242088637708e-08
and O 0 3.037321505416912e-07
cognitively O 0 0.00015058521239552647
, O 0 1.1324825663905358e-06
she O 0 1.320696924267395e-06
is O 0 7.539763657860021e-08
in O 0 5.5766143702840054e-08
the O 0 1.683554984310831e-07
superior O 0 1.077944671123987e-05
range O 0 2.3424368009727914e-06
for O 0 2.3541061011655984e-07
age O 0 1.103545946534723e-05
. O 0 3.336285772093106e-06

Clinical O 0 0.00030338295619003475
recognition O 0 7.565407577203587e-05
of O 0 0.0010285194730386138
VLCAD B-Disease 1 0.9999916553497314
deficiency I-Disease 1 0.9999991655349731
is O 0 4.862103651248617e-06
important O 0 3.7912175798737735e-07
because O 0 1.263140063656465e-07
it O 0 1.9767448122820497e-08
is O 0 1.5379614026755917e-08
one O 0 1.3427879252958519e-08
of O 0 1.1382385700642317e-08
the O 0 1.7115664263656072e-07
few O 0 2.4126118205458624e-06
directly O 0 7.473154255421832e-05
treatable O 1 0.9998376369476318
causes O 0 0.010684157721698284
of O 0 2.0723853594972752e-05
cardiomyopathy B-Disease 1 0.9999910593032837
in O 0 8.481682016281411e-06
children O 0 1.5127195638342528e-06
. O 0 7.556074024250847e-07
. O 0 2.891680878747138e-06

Cloning O 0 1.3774686522083357e-05
of O 0 1.7080736824937048e-07
a O 0 5.134939442541508e-07
novel O 0 3.640606678345648e-07
member O 0 9.076597962121014e-08
of O 0 1.5417089826996744e-08
the O 0 1.876048258964147e-07
low O 0 4.855512815993279e-05
- O 0 2.3422528101946227e-05
density O 0 2.1192431631789077e-06
lipoprotein O 0 0.0025167670100927353
receptor O 0 3.556829324224964e-05
family O 0 2.406783460173756e-05
. O 0 6.529038728331216e-06

A O 0 2.2541548787557986e-06
gene O 0 3.8365732279999065e-07
encoding O 0 2.6269970021530753e-07
a O 0 9.075972684513545e-07
novel O 0 1.2946261449542362e-06
transmembrane O 0 1.1560413440747652e-05
protein O 0 1.9284123027318856e-06
was O 0 2.805018311846652e-06
identified O 0 7.589078165892715e-08
by O 0 6.836257782083521e-09
DNA O 0 9.911398279882633e-08
sequence O 0 3.8808714464266814e-08
analysis O 0 2.067438487074469e-08
within O 0 4.8149495057714375e-08
the O 0 2.96474496508381e-07
insulin B-Disease 0 0.0009363889694213867
- I-Disease 0 0.022906556725502014
dependent I-Disease 0 0.0029698533471673727
diabetes I-Disease 1 0.9999909400939941
mellitus I-Disease 1 0.9999775886535645
( O 0 2.7351288736099377e-05
IDDM B-Disease 0 0.002711313311010599
) O 0 8.714803811926686e-07
locus O 0 4.881949644186534e-05
IDDM4 O 0 0.0005524036241695285
on O 0 1.6366495401598513e-05
chromosome O 0 0.00034195452462881804
11q13 O 0 0.0003393625665921718
. O 0 8.02881368144881e-06

Based O 0 1.2574421361932764e-06
on O 0 8.745809623178502e-07
its O 0 3.02607162439017e-07
chromosomal O 0 0.0003892044478561729
position O 0 1.0886370546359103e-05
, O 0 9.879784101940459e-08
this O 0 7.141947477862232e-09
gene O 0 1.7056026990758255e-07
is O 0 7.356568687555409e-08
a O 0 3.2070815336737724e-07
candidate O 0 6.49345622605324e-07
for O 0 5.4887124179003877e-08
conferring O 0 6.423355080187321e-05
susceptibility O 0 0.0006822248105891049
to O 0 1.5007591173343826e-05
diabetes B-Disease 1 0.9990678429603577
. O 0 1.747820533637423e-05

The O 0 1.226787162522669e-06
gene O 0 8.957599675341044e-06
, O 0 1.7189812524520676e-06
termed O 0 2.5821735107456334e-05
low O 0 4.852772690355778e-05
- O 0 1.5833787983865477e-05
density O 0 1.023237587105541e-06
lipoprotein O 0 0.0002722641220316291
receptor O 0 2.663979785211268e-06
related O 0 5.189051535126055e-07
protein O 0 4.950850893692404e-07
5 O 0 5.897542791899468e-07
( O 0 1.0932546246067432e-07
LRP5 O 0 2.5797762646107003e-05
) O 0 2.414214783641455e-08
, O 0 7.315135608365608e-09
encodes O 0 1.9205039336611662e-08
a O 0 7.480831953898814e-08
protein O 0 1.4226250755200454e-07
of O 0 6.631038473869921e-08
1615 O 0 2.720721749938093e-05
amino O 0 3.155072363369982e-07
acids O 0 2.9070915275042353e-07
that O 0 1.7648889016896874e-09
contains O 0 5.280494264070512e-09
conserved O 0 2.474211839853524e-07
modules O 0 2.9597649131574144e-07
which O 0 2.2478417349702795e-08
are O 0 2.76112310793053e-09
characteristic O 0 3.576519418402313e-07
of O 0 3.3129957444089086e-08
the O 0 4.042286150252039e-07
low O 0 0.00012568892270792276
- O 0 5.838244396727532e-05
density O 0 2.285158643644536e-06
lipoprotein O 0 0.011178609915077686
( O 0 3.330665322209825e-06
LDL O 0 0.0013900011545047164
) O 0 4.6055342295403534e-07
receptor O 0 3.62208993465174e-06
family O 0 7.617888513777871e-06
. O 0 2.9927964533271734e-06

These O 0 2.818006805682671e-07
modules O 0 1.7261585298911086e-06
include O 0 2.986496099310898e-07
a O 0 5.164110916666687e-07
putative O 0 5.319534921000013e-06
signal O 0 1.2211096418468514e-06
peptide O 0 3.556116325853509e-07
for O 0 3.908689816256583e-09
protein O 0 2.0555914304054568e-08
export O 0 1.0028958286056877e-07
, O 0 7.384263511767131e-08
four O 0 8.704407150617044e-08
epidermal O 0 1.1420721421018243e-05
growth O 0 8.121618293444044e-07
factor O 0 5.383412826631684e-07
( O 0 3.6615784893001546e-07
EGF O 0 3.917904177797027e-05
) O 0 1.3367730389290955e-07
repeats O 0 2.314191306140856e-06
with O 0 1.4796094660596282e-07
associated O 0 1.5478323120987625e-06
spacer O 0 2.252923877676949e-05
domains O 0 8.255393368017394e-06
, O 0 4.696732958109351e-07
three O 0 3.8923846545912966e-07
LDL O 0 0.0012464593164622784
- O 0 3.254751572967507e-05
receptor O 0 6.880159162392374e-06
( O 0 3.941754016523191e-07
LDLR O 0 5.491497358889319e-05
) O 0 9.897872388364704e-08
repeats O 0 1.6483944591527688e-06
, O 0 4.001674014375567e-08
a O 0 9.310630844083789e-08
single O 0 4.243379407853354e-07
transmembrane O 0 8.481650183966849e-06
spanning O 0 1.323142623732565e-05
domain O 0 1.6210084368140087e-06
, O 0 2.4433535372736515e-07
and O 0 6.062149537910955e-08
a O 0 4.5725357722403714e-07
cytoplasmic O 0 9.916105227603111e-06
domain O 0 1.6348853023373522e-05
. O 0 8.51140430313535e-06

The O 0 4.748635262785683e-08
encoded O 0 7.17138064487699e-08
protein O 0 4.573975047605927e-07
has O 0 1.2539760518848198e-07
a O 0 6.118897033502435e-08
unique O 0 1.0592105326168166e-07
organization O 0 4.725622204659885e-07
of O 0 1.4282217364325334e-07
EGF O 0 0.00023767290986143053
and O 0 3.7873760447837412e-06
LDLR O 0 0.0013595346827059984
repeats O 0 6.556816515512764e-05
; O 0 5.697747269550746e-07
therefore O 0 3.448988081800053e-07
, O 0 3.9097400872378785e-07
LRP5 O 0 0.00012500688899308443
likely O 0 5.655105610458122e-07
represents O 0 5.50696874768164e-08
a O 0 1.8785439692692307e-07
new O 0 3.1069814099282667e-07
category O 0 1.0179001037613489e-06
of O 0 1.0421408092042839e-07
the O 0 1.4079056427362957e-06
LDLR O 0 0.0023712327238172293
family O 0 6.921100430190563e-05
. O 0 1.4950125660107005e-05

Both O 0 4.845906005357392e-06
human O 0 7.128148354240693e-06
and O 0 2.8314620976743754e-06
mouse O 0 0.00011986470053670928
LRP5 O 0 0.0012281928211450577
cDNAs O 0 0.00010377302533015609
have O 0 2.402483403329825e-07
been O 0 3.170292188769963e-07
isolated O 0 1.7006697135002469e-06
and O 0 2.7751953624033376e-08
the O 0 4.8977355504575826e-09
encoded O 0 1.8223934361571992e-08
mature O 0 1.9440768994627433e-07
proteins O 0 1.3597077241911393e-08
are O 0 4.7976760342294256e-09
95 O 0 8.845125165635181e-08
% O 0 8.902090620210856e-09
identical O 0 9.251626238437893e-07
, O 0 1.2226310275309515e-07
indicating O 0 6.242724452931725e-07
a O 0 8.007044129954011e-07
high O 0 1.1075186193920672e-05
degree O 0 1.5147492149480968e-06
of O 0 6.960437559655475e-08
evolutionary O 0 9.527983820589725e-06
conservation O 0 4.8738816076365765e-06
. O 0 4.287727506380179e-07
. O 0 1.3351794905247516e-06

The O 0 3.7329457427404122e-06
APC B-Disease 0 0.00012277347559574991
variants O 0 9.289428817282896e-06
I1307K O 0 5.574004171648994e-05
and O 0 6.680318165308563e-07
E1317Q O 0 3.670949081424624e-05
are O 0 5.0793335049093e-07
associated O 0 0.0001874669687822461
with O 1 0.99831223487854
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.2052249076077715e-05
but O 0 2.2732572801942297e-07
not O 0 2.8653547090584652e-08
always O 0 7.569013860120322e-08
with O 0 3.684792559965899e-08
a O 0 9.110165706260887e-07
family O 0 4.248794994055061e-06
history O 0 6.80526545693283e-06
. O 0 3.506581606416148e-06

Classical O 0 0.21372132003307343
familial B-Disease 1 0.9999346733093262
adenomatous I-Disease 1 0.999687910079956
polyposis I-Disease 1 0.9999376535415649
( O 0 0.00022173349861986935
FAP B-Disease 0 0.0007636822410859168
) O 0 3.1694335689280706e-07
is O 0 1.2724812847864087e-07
a O 0 2.296286993441754e-06
high O 0 0.002777951071038842
- O 1 0.9487794637680054
penetrance O 1 0.9583538174629211
autosomal B-Disease 1 0.9990947246551514
dominant I-Disease 1 0.9993311166763306
disease I-Disease 1 0.9997401833534241
that O 0 1.8202888441010145e-07
predisposes O 0 4.6589120756834745e-06
to O 0 5.5438651003214545e-08
hundreds O 0 3.576625147161394e-07
or O 0 3.195125145794009e-06
thousands O 0 1.831719600886572e-05
of O 0 0.0006744738784618676
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999929666519165
and I-Disease 1 0.9981473684310913
carcinoma I-Disease 1 0.9999998807907104
and O 0 2.0264693375793286e-05
that O 0 1.4653743107828632e-07
results O 0 1.054760559782153e-06
from O 0 2.66504201817952e-07
truncating O 0 3.6937144614057615e-05
mutations O 0 2.2699134206050076e-05
in O 0 5.209693654251168e-07
the O 0 5.233800948190037e-07
APC B-Disease 0 6.43953972030431e-05
gene O 0 3.5458699130686e-05
. O 0 7.768514478811994e-06

A O 0 5.447455623652786e-05
variant O 0 0.00040124438237398863
of O 0 8.267904377134982e-06
FAP B-Disease 0 0.019726108759641647
is O 0 9.522993786958978e-05
attenuated B-Disease 1 0.8891505599021912
adenomatous I-Disease 1 0.9998745918273926
polyposis I-Disease 1 0.9994146823883057
coli I-Disease 1 0.9990842342376709
, O 0 2.934149733846425e-06
which O 0 1.3123984388130339e-07
results O 0 3.563102950465691e-07
from O 0 2.0063893657606968e-07
germ O 0 7.087326957844198e-05
- O 0 2.1077499695820734e-05
line O 0 1.2059503205819055e-05
mutations O 0 3.1460876925848424e-06
in O 0 4.762758365473019e-08
the O 0 3.911092960606766e-08
5 O 0 3.3851827652142674e-07
and O 0 8.546133045683746e-08
3 O 0 4.5716157615061093e-07
regions O 0 4.3823521878039173e-07
of O 0 6.306657240884306e-08
the O 0 4.1675329498502833e-07
APC B-Disease 0 7.938815542729571e-05
gene O 0 2.876727194234263e-05
. O 0 4.350585641077487e-06

Attenuated B-Disease 1 0.9773542284965515
adenomatous I-Disease 1 0.9997413754463196
polyposis I-Disease 1 0.9995040893554688
coli I-Disease 1 0.9991102814674377
patients O 0 0.0006310016615316272
have O 0 9.382757752973703e-07
" O 0 2.954391220555408e-06
multiple O 0 0.0002232051338069141
" O 1 0.97210294008255
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9998629093170166
( O 0 1.1650454325717874e-06
typically O 0 1.9392348349356325e-07
fewer O 0 7.657957468154564e-08
than O 0 2.6499188621187386e-08
100 O 0 9.92596511650845e-08
) O 0 2.120256503701512e-08
without O 0 7.261660073254461e-08
the O 0 2.3062278842189698e-07
florid O 0 0.0007428351673297584
phenotype O 0 7.349729276029393e-05
of O 0 6.032173587300349e-07
classical O 0 0.00023013581812847406
FAP B-Disease 0 0.007683246862143278
. O 0 2.1452065993798897e-05

Another O 0 5.916871032241033e-06
group O 0 1.4332255204863031e-06
of O 0 2.1131452854206145e-07
patients O 0 2.8308220407780027e-06
with O 0 3.723736483607354e-07
multiple O 0 3.9989907236304134e-05
adenomas B-Disease 1 0.7543849349021912
has O 0 4.7294138312281575e-06
no O 0 8.532953188478132e-07
mutations O 0 3.3638186778262025e-06
in O 0 8.534127715620343e-08
the O 0 1.2274151117708243e-07
APC B-Disease 0 9.117509762290865e-06
gene O 0 7.713779837104084e-07
, O 0 1.5808808484507608e-07
and O 0 5.314122830668566e-08
their O 0 5.277738068798499e-08
phenotype O 0 1.2862239600508474e-05
probably O 0 1.9156291273247916e-06
results O 0 4.5049176833344973e-07
from O 0 1.2756149203596578e-07
variation O 0 1.8861710486817174e-06
at O 0 1.1318464203213807e-05
a O 0 6.552853051289276e-07
locus O 0 8.77088496054057e-06
, O 0 1.8651660127488867e-07
or O 0 2.1161037011552253e-07
loci O 0 2.602425183795276e-06
, O 0 3.2881487754821137e-07
elsewhere O 0 1.0727284234235412e-06
in O 0 1.4213911470051244e-07
the O 0 2.97954670713807e-07
genome O 0 1.0576057320577092e-05
. O 0 4.7774615268281195e-06

Recently O 0 0.00014536839444190264
, O 0 7.164666726566793e-07
however O 0 1.359683636792397e-07
, O 0 1.2583535635712906e-07
a O 0 7.439765568051371e-07
missense O 0 6.393069634214044e-05
variant O 0 9.572257840773091e-05
of O 0 1.0268065580021357e-06
APC B-Disease 0 0.00019264622824266553
( O 0 1.0880721674766392e-06
I1307K O 0 1.3106968253850937e-05
) O 0 1.4581964080662146e-07
was O 0 2.7636385766527383e-06
described O 0 4.910103257316223e-07
that O 0 1.1016038747868606e-08
confers O 0 1.2219834388815798e-06
an O 0 2.7193760843147174e-07
increased O 0 6.030026270309463e-06
risk O 0 0.0011216565035283566
of O 0 0.015245884656906128
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.342113010759931e-06
including O 0 9.513687473372556e-07
multiple O 0 3.175745587213896e-05
adenomas B-Disease 0 0.45134782791137695
, O 0 2.1535897758440115e-06
in O 0 1.2048959661115077e-06
Ashkenazim O 0 0.0008980085840448737
. O 0 1.322133630310418e-05

We O 0 1.4826620144958724e-06
have O 0 3.466358577952633e-08
studied O 0 6.732726092195662e-07
a O 0 1.7827848353135778e-07
set O 0 1.9297392839234817e-07
of O 0 7.869058293863418e-08
164 O 0 1.6233900169027038e-05
patients O 0 1.1260982319072355e-05
with O 0 7.89130172051955e-06
multiple O 1 0.9955500364303589
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999815225601196
and I-Disease 0 0.0019359757425263524
/ I-Disease 1 0.8382561802864075
or I-Disease 1 0.6373094320297241
carcinoma I-Disease 1 0.9999997615814209
and O 0 2.1842641217517667e-05
analyzed O 0 0.00011511500633787364
codons O 0 0.0003383469593245536
1263 O 0 0.003696626517921686
- O 0 0.0005807710695080459
1377 O 0 0.0011764511000365019
( O 0 1.475534304518078e-06
exon O 0 4.014358637505211e-05
15G O 0 9.343896817881614e-05
) O 0 5.054356222444767e-08
of O 0 1.3303551149590476e-08
the O 0 9.605174966509367e-08
APC B-Disease 0 4.634760898625245e-06
gene O 0 7.88809529694845e-07
for O 0 1.278587831166078e-07
germ O 0 0.00020079134264960885
- O 0 4.484850069275126e-05
line O 0 2.202361065428704e-05
variants O 0 1.575143869558815e-05
. O 0 6.270197900448693e-06

Three O 0 7.834118150640279e-06
patients O 0 3.4917682114610216e-06
with O 0 9.009468726617342e-08
the O 0 2.84514840132033e-07
I1307K O 0 1.7686154023976997e-05
allele O 0 2.516240328986896e-06
were O 0 3.27779162034858e-07
detected O 0 1.0129893780685961e-05
, O 0 4.05433873140737e-08
each O 0 1.8875079277336226e-08
of O 0 1.4405796378014202e-07
Ashkenazi O 0 0.00030473791412077844
descent O 0 0.00014158473641145974
. O 0 1.5269313735188916e-05

Four O 0 6.511490482807858e-06
patients O 0 9.823646905715577e-06
had O 0 2.1923365238762926e-06
a O 0 2.0470247363846283e-06
germ O 0 0.0014997078105807304
- O 0 0.00031998541089706123
line O 0 5.500366023625247e-05
E1317Q O 0 9.625007078284398e-05
missense O 0 0.00012513426190707833
variant O 0 6.04078704782296e-05
of O 0 3.9746171864862845e-07
APC O 0 3.5717781429411843e-05
that O 0 8.750517821454196e-08
was O 0 2.3312695702770725e-06
not O 0 1.3227165140961006e-08
present O 0 3.7742186265177224e-08
in O 0 2.1782883052878788e-08
controls O 0 4.3796657678285555e-07
; O 0 4.7822656057405766e-08
one O 0 3.5266925380028624e-08
of O 0 3.787926416976006e-09
these O 0 2.9643496546327697e-09
individuals O 0 7.331198759175095e-09
had O 0 3.0623351676695165e-07
an O 0 3.114528013270501e-08
unusually O 0 2.24536029236333e-06
large O 0 3.004865902767051e-07
number O 0 1.5633409589099756e-07
of O 0 8.037792440518388e-07
metaplastic B-Disease 0 0.08232961595058441
polyps I-Disease 0 0.027843674644827843
of I-Disease 0 2.1565276142609946e-07
the I-Disease 0 1.5313921721826773e-06
colorectum I-Disease 0 0.0023021288216114044
. O 0 9.889246939565055e-06

There O 0 8.797557029538439e-07
is O 0 1.5028768984848284e-07
increasing O 0 9.168329739850378e-08
evidence O 0 6.514601125218178e-08
that O 0 9.336538653315074e-09
there O 0 2.8440705790444554e-08
exist O 0 4.872403565059358e-07
germ O 0 8.206264465115964e-05
- O 0 1.959725886990782e-05
line O 0 6.576701707672328e-06
variants O 0 1.1756496860471088e-06
of O 0 8.76581935926879e-08
the O 0 3.6833174021921877e-07
APC B-Disease 0 9.368948667543009e-06
gene O 0 4.1717797216733743e-07
that O 0 1.5093597482973564e-08
predispose O 0 1.8772904297748028e-07
to O 0 1.2484782985211496e-08
the O 0 7.780689514902406e-08
development O 0 1.4242473866943328e-07
of O 0 2.8618183023354504e-06
multiple O 1 0.9952566027641296
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999942779541016
and I-Disease 1 0.9988563060760498
carcinoma I-Disease 1 1.0
, O 0 3.9048565668053925e-05
but O 0 4.2017731516352796e-07
without O 0 2.2596336179958598e-07
the O 0 7.211761499092972e-07
florid O 0 0.001101829344406724
phenotype O 0 3.0701929063070565e-05
of O 0 1.205075932375621e-07
classical O 0 3.572718196664937e-05
FAP B-Disease 0 0.00033254214213229716
, O 0 3.52427235839059e-07
and O 0 1.5881599324529816e-07
possibly O 0 7.173992457865097e-07
with O 0 1.7427460363705904e-07
importance O 0 2.7151387257617898e-05
for O 0 0.40030452609062195
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
risk O 0 0.0003585244412533939
in O 0 1.210512721172563e-07
the O 0 6.19692031023078e-08
general O 0 9.680620394192374e-08
population O 0 2.4560012690244548e-08
. O 0 1.6273671121780353e-07
. O 0 9.95928303382243e-07

Genomic O 0 9.687362762633711e-05
structure O 0 3.123221904388629e-05
of O 0 9.101542559619702e-07
the O 0 1.1100320080004167e-05
human O 0 0.245308056473732
congenital B-Disease 1 0.9999995231628418
chloride I-Disease 1 0.999975323677063
diarrhea I-Disease 1 0.9999997615814209
( O 0 7.703407754888758e-05
CLD B-Disease 0 0.1947132647037506
) O 0 2.922977728303522e-06
gene O 0 2.28556600632146e-05
. O 0 5.00871237818501e-06

Congenital B-Disease 1 0.9999977350234985
chloride I-Disease 1 0.9999057054519653
diarrhea I-Disease 1 0.9999994039535522
( O 0 0.0002026294096140191
CLD B-Disease 1 0.7252517342567444
) O 0 2.1672497041436145e-06
is O 0 7.91581214798498e-07
caused O 0 5.163685727893608e-06
by O 0 9.499937192458674e-08
mutations O 0 3.3497458389319945e-06
in O 0 6.621786496907589e-08
a O 0 1.2239235047672992e-07
gene O 0 4.6919157625779917e-07
which O 0 3.5541898313340425e-08
encodes O 0 4.565951599033724e-07
an O 0 3.1697404665465e-06
intestinal O 1 0.9984642267227173
anion O 0 0.0018864708254113793
transporter O 0 0.00957427266985178
. O 0 1.1573915799090173e-05

We O 0 5.0017051762552e-06
report O 0 6.904011797814746e-07
here O 0 8.927667494162961e-08
the O 0 1.9522660821280624e-08
complete O 0 4.4089503603572666e-07
genomic O 0 4.280122539057629e-06
organization O 0 5.586701377069403e-07
of O 0 3.0400251205264794e-08
the O 0 3.967236352764303e-07
human O 0 5.789296210423345e-06
CLD B-Disease 0 0.001613592728972435
gene O 0 4.489209459279664e-06
which O 0 3.6155216776023735e-07
spans O 0 6.393902367562987e-06
approximately O 0 2.5074007226066897e-07
39kb O 0 3.600676791393198e-05
, O 0 2.0410975309914647e-07
and O 0 7.549247271754211e-08
comprises O 0 4.2956963852702756e-07
21 O 0 7.2139328040066175e-06
exons O 0 4.258752232999541e-05
. O 0 1.2153309398854617e-05

All O 0 3.912678039341699e-06
exon O 0 0.0003610232088249177
/ O 0 0.00010743148595793173
intron O 0 0.00014295052096713334
boundaries O 0 7.954057537062909e-07
conform O 0 5.619308467430528e-06
to O 0 2.0821049417918402e-07
the O 0 9.452145945942902e-07
GT O 0 0.00034879837767221034
/ O 0 0.0011294769356027246
AG O 1 0.996743381023407
rule O 0 0.00012877055269200355
. O 0 1.3081393262837082e-05

An O 0 5.747344289375178e-07
analysis O 0 2.874633935334714e-07
of O 0 5.397951952090807e-08
the O 0 4.709133918368025e-07
putative O 0 4.7536905185552314e-05
promoter O 0 0.00030811328906565905
region O 0 1.9207514014851768e-06
sequence O 0 4.0622734331918764e-07
shows O 0 4.138327653890883e-07
a O 0 1.0619875183692784e-06
putative O 0 3.273802576586604e-05
TATA O 0 0.0015428661135956645
box O 0 2.1303749235812575e-05
and O 0 5.233167144069739e-07
predicts O 0 3.327928197904839e-06
multiple O 0 6.196353297127644e-07
transcription O 0 7.080776413204148e-06
factor O 0 2.3272932594409212e-06
binding O 0 5.349157618184108e-06
sites O 0 1.443823020963464e-05
. O 0 6.934584234841168e-06

The O 0 2.4783309982012725e-06
genomic O 0 1.197475467051845e-05
structure O 0 1.2516715287347324e-05
was O 0 5.299190888763405e-06
determined O 0 1.943242722290961e-07
using O 0 3.668802861511722e-08
DNA O 0 2.4296119249811454e-07
from O 0 1.0040745124229034e-08
several O 0 3.7002849673228866e-09
sources O 0 1.7673151830877032e-08
including O 0 9.633904340944355e-09
multiple O 0 3.6434477124203113e-07
large O 0 3.788011554206605e-06
- O 0 0.0008038637461140752
insert O 0 9.636707545723766e-05
libaries O 0 0.00013959906937088817
and O 0 3.50121098335876e-07
genomic O 0 5.4471070143335965e-06
DNA O 0 7.195423222583486e-06
from O 0 3.058344191231299e-06
Finnish O 0 0.005672992207109928
CLD B-Disease 1 0.8988872170448303
patients O 0 0.00017841804947238415
and O 0 2.1992889287503203e-06
controls O 0 0.00010304834722774103
. O 0 1.2783926649717614e-05

Exon O 0 0.0005356467445380986
- O 0 1.9639315723907202e-05
specific O 0 1.1378287467778136e-07
primers O 0 3.7306785998225678e-06
developed O 0 9.337625215266598e-07
in O 0 8.124797545860929e-08
this O 0 6.6724723524203e-09
study O 0 2.8838867294211923e-08
will O 0 8.896013703463268e-09
facilitate O 0 7.363265552839948e-08
mutation O 0 3.949139227188425e-06
screening O 0 7.43776467970747e-07
studies O 0 1.1583753689592413e-07
of O 0 7.252883449382352e-08
patients O 0 2.550635144871194e-06
with O 0 5.38577467068535e-07
the O 0 4.141956378589384e-05
disease O 1 0.9975294470787048
. O 0 1.1093738976342138e-05

Genomic O 0 7.796205863996875e-06
sequencing O 0 1.6781077647465281e-06
of O 0 1.230720414469033e-07
a O 0 7.417771030304721e-06
BAC O 0 0.0011118926340714097
clone O 0 0.0008621171582490206
H O 1 0.9988119602203369
_ O 0 3.452928285696544e-05
RG364P16 O 0 2.299347943335306e-05
revealed O 0 2.096567641274305e-06
the O 0 4.947519016695878e-08
presence O 0 2.544749975186278e-07
of O 0 1.9212402335710976e-08
another O 0 1.7548575215187157e-07
, O 0 4.787933605143735e-08
highly O 0 4.95396875521692e-07
homologous O 0 2.1172029391891556e-06
gene O 0 1.4501033547276165e-06
3 O 0 7.664546615160361e-07
of O 0 2.8772168647606122e-08
the O 0 4.1439199094384094e-07
CLD B-Disease 0 0.0007374302949756384
gene O 0 2.428255129416357e-06
, O 0 1.302471019926088e-07
with O 0 2.819097311146379e-08
a O 0 2.925996511748963e-07
similar O 0 2.6091396421179525e-07
genomic O 0 3.156209231747198e-06
structure O 0 5.393934770836495e-06
, O 0 5.334850357030518e-07
recently O 0 5.162887646292802e-06
identified O 0 6.65517518427805e-07
as O 0 1.037165020534303e-06
the O 0 2.8336196919553913e-05
Pendred B-Disease 1 0.9998786449432373
syndrome I-Disease 1 0.9999977350234985
gene O 0 0.00016266704187728465
( O 0 4.448466825124342e-06
PDS B-Disease 0 0.0008654010598547757
) O 0 4.397503232667077e-07
. O 0 2.810255921303906e-07
. O 0 1.81454481662513e-06

The O 0 1.1427323443058413e-05
APCI1307K O 0 0.0016884916694834828
allele O 0 0.00025826977798715234
and O 0 0.0001390074467053637
cancer B-Disease 1 0.9969266057014465
risk O 0 1.5608395187882707e-05
in O 0 1.1050723713879052e-07
a O 0 3.2502930480404757e-07
community O 0 8.977665544307456e-08
- O 0 7.306741281354334e-06
based O 0 1.8104829280218837e-07
study O 0 1.9042401788738061e-07
of O 0 1.2474315269628278e-07
Ashkenazi O 0 7.782040484016761e-05
Jews O 0 1.6417519873357378e-05
. O 0 1.3579937331087422e-05

Mutations O 0 0.0008543989970348775
in O 0 5.1297693062224425e-06
APC O 0 0.000147350670886226
are O 0 6.0398753021218e-07
classically O 0 0.007515736855566502
associated O 0 0.0001773532130755484
with O 0 0.0016835842980071902
familial B-Disease 1 0.9999933242797852
adenomatous I-Disease 1 0.999962329864502
polyposis I-Disease 1 0.9999909400939941
( O 0 0.00019417241855990142
FAP B-Disease 0 0.0010024422081187367
) O 0 4.4672819399238506e-07
, O 0 4.0129637568497856e-07
a O 0 4.3753880163421854e-06
highly O 0 0.0015833699144423008
penetrant O 1 0.9968463778495789
autosomal B-Disease 1 0.9999954700469971
dominant I-Disease 1 0.9999346733093262
disorder I-Disease 1 0.9999991655349731
characterized O 1 0.8408054709434509
by O 0 5.026987855671905e-05
multiple O 1 0.8196654915809631
intestinal O 1 0.9999891519546509
polyps B-Disease 1 0.9969768524169922
and O 0 2.5915032892953604e-06
, O 0 5.203204409554019e-07
without O 0 7.823986152288853e-07
surgical O 0 0.000625642656814307
intervention O 0 3.073437255807221e-06
, O 0 9.024603286889032e-08
the O 0 1.2571074137213145e-07
development O 0 7.158012522268109e-06
of O 0 0.07801659405231476
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
( O 0 3.2328563975170255e-05
CRC B-Disease 0 0.0022920246701687574
) O 0 1.6750987015257124e-06
. O 0 4.604150944942376e-06

APC B-Disease 0 0.0011571974027901888
is O 0 8.352129043487366e-06
a O 0 3.3553635148564354e-05
tumour O 1 0.9995393753051758
- O 0 0.00011546151654329151
suppressor O 0 2.5901992557919584e-05
gene O 0 2.1005062080803327e-06
, O 0 2.9119163968971407e-07
and O 0 3.9791228800822864e-07
somatic O 0 9.069949737749994e-05
loss O 0 0.0028990621212869883
occurs O 0 6.122758350102231e-05
in O 0 3.067313809879124e-05
tumours B-Disease 1 0.9998822212219238
. O 0 4.876905950368382e-05

The O 0 8.810960025584791e-06
germline O 0 0.0007207102607935667
T O 0 0.003610751358792186
- O 0 2.4982044124044478e-05
to O 0 2.0372119990952342e-07
- O 0 1.3977587514091283e-05
A O 0 2.3275729290617164e-06
transversion O 0 2.8799053325201385e-05
responsible O 0 1.1768117929022992e-06
for O 0 5.054693374972885e-08
the O 0 2.941732191175106e-07
APC O 0 2.7664451408782043e-05
I1307K O 0 1.550299202790484e-05
allele O 0 1.77748256646737e-06
converts O 0 3.663594156932959e-07
the O 0 1.2630437140614958e-07
wild O 0 2.4355886125704274e-06
- O 0 6.23918094788678e-06
type O 0 2.6586399144434836e-06
sequence O 0 5.829484734931611e-07
to O 0 1.751871110400316e-07
a O 0 7.688033292652108e-06
homopolymer O 0 0.027942001819610596
tract O 0 0.3173621594905853
( O 0 1.3875013564756955e-06
A8 O 0 0.0010081855580210686
) O 0 2.2707546065703355e-07
that O 0 5.582648654467448e-08
is O 0 2.5890133770190005e-07
genetically O 0 6.387661414919421e-06
unstable O 0 0.009023109450936317
and O 0 5.247241915640188e-06
prone O 0 0.0014685392379760742
to O 0 5.971171503915684e-07
somatic O 0 7.687453762628138e-05
mutation O 0 0.0004295657854527235
. O 0 5.50103959540138e-06

The O 0 3.1719569051347207e-06
I1307K O 0 5.6648939789738506e-05
allele O 0 1.3812848010275047e-05
was O 0 7.983826435520314e-06
found O 0 9.675060255176504e-07
in O 0 4.352310156718886e-07
6 O 0 1.1541070307430346e-05
. O 0 2.4174969439627603e-06

1 O 0 2.1553652914008126e-05
% O 0 2.659646725078346e-07
of O 0 3.0860499578011513e-07
unselected O 0 0.00245540589094162
Ashkenazi O 0 0.0006161497440189123
Jews O 0 4.587566763802897e-06
and O 0 1.3248396726339706e-06
higher O 0 6.348490842356114e-06
proportions O 0 8.256279397755861e-05
of O 0 2.1227334912055085e-07
Ashkenazim O 0 0.00016561437223572284
with O 0 1.6044061794673325e-06
family O 0 1.3751312508247793e-05
or O 0 2.6846457785723032e-06
personal O 0 1.859730764408596e-05
histories O 0 5.733693978982046e-05
of O 0 3.785931312449975e-06
CRC B-Disease 0 0.00337950699031353
( O 0 2.303428345840075e-06
ref O 0 0.00106527260504663
. O 0 3.6911657730342995e-07
2 O 0 1.5516440043938928e-06
) O 0 4.129047965761856e-07
. O 0 1.5696468835812993e-06

To O 0 4.829426529795455e-07
evaluate O 0 1.6967460396699607e-06
the O 0 1.1826222845456869e-07
role O 0 6.311193487817945e-07
of O 0 3.175969141011592e-07
I1307K O 0 0.00010395506978966296
in O 0 8.680432983965147e-06
cancer B-Disease 0 0.142413929104805
, O 0 4.3294087959111494e-07
we O 0 4.832826903111709e-07
genotyped O 0 7.581643149023876e-05
5 O 0 4.128231012145989e-06
, O 0 9.742279871716164e-07
081 O 0 0.00030707838595844805
Ashkenazi O 0 6.59945944789797e-05
volunteers O 0 2.4561802547395928e-06
in O 0 1.7307841915226163e-07
a O 0 7.803083690305357e-07
community O 0 6.4137361732719e-07
survey O 0 4.493843789532548e-06
. O 0 2.063965439447202e-06

Risk O 0 0.0005842630052939057
of O 0 6.668302830803441e-06
developing O 0 0.019086256623268127
colorectal B-Disease 1 0.9999990463256836
, I-Disease 0 0.0001919578789966181
breast I-Disease 0 0.09360145777463913
and I-Disease 0 9.53782546275761e-07
other I-Disease 0 6.632859594901674e-07
cancers I-Disease 0 0.15800315141677856
were O 0 3.807606105965533e-07
compared O 0 9.265806966141099e-07
between O 0 3.478194230410736e-07
genotyped O 0 9.07968424144201e-05
I1307K O 0 2.843516631401144e-05
carriers O 0 1.7183518821184407e-06
and O 0 2.9983851845827303e-07
non O 0 1.1932891084143193e-06
- O 0 4.374791842565173e-06
carriers O 0 4.0016132629716594e-07
and O 0 3.446560725706149e-08
their O 0 1.257077997252054e-08
first O 0 5.322903007254354e-07
- O 0 2.9830436687916517e-05
degree O 0 5.2027503443241585e-06
relatives O 0 4.914370947517455e-06
. O 0 7.1347317316394765e-06

Sperm O 0 1.3520598258764949e-05
DNA O 0 7.052753971947823e-06
analysis O 0 6.341861649161729e-07
in O 0 9.472287274547853e-07
a O 0 2.5423891202080995e-05
Friedreich B-Disease 1 0.9684015512466431
ataxia I-Disease 1 0.9984090924263
premutation O 1 0.5402441620826721
carrier O 0 0.0005427803262136877
suggests O 0 4.209724920656299e-06
both O 0 3.6815859516536875e-07
meiotic O 0 0.00010543951793806627
and O 0 9.38721427701239e-07
mitotic O 0 1.5655459719710052e-05
expansion O 0 4.066873316332931e-06
in O 0 4.57802912023908e-07
the O 0 6.539948458339495e-07
FRDA B-Disease 0 0.00037156426697038114
gene O 0 3.478914004517719e-05
. O 0 7.045466645649867e-06

Friedreich B-Disease 1 0.990720272064209
ataxia I-Disease 1 0.9989571571350098
is O 0 0.00015981739852577448
usually O 0 1.594248715264257e-05
caused O 0 1.0608036973280832e-05
by O 0 4.593834646016148e-08
an O 0 4.9314088812479895e-08
expansion O 0 5.613313192043279e-07
of O 0 1.1425033363821058e-07
a O 0 9.68259610090172e-06
GAA O 0 0.0011125410674139857
trinucleotide O 0 0.0009547589579597116
repeat O 0 3.27781708620023e-05
in O 0 7.986133141457685e-07
intron O 0 6.952045077923685e-05
1 O 0 2.2023280052962946e-06
of O 0 8.779741023090537e-08
the O 0 8.751583209232194e-07
FRDA B-Disease 0 0.0006979465833865106
gene O 0 4.9118556489702314e-05
. O 0 6.259019755816553e-06

Occasionally O 0 3.549008761183359e-05
, O 0 4.1740833012227085e-07
a O 0 2.447098665925296e-07
fully O 0 6.339714673231356e-07
expanded O 0 4.4202923277225636e-07
allele O 0 4.9568880058359355e-06
has O 0 4.5699940187660104e-07
been O 0 2.3243291025210056e-07
found O 0 8.797677253369329e-08
to O 0 1.5079614001933805e-08
arise O 0 3.9392884332301037e-07
from O 0 5.1587651483941954e-08
a O 0 1.9273151963261625e-07
premutation O 0 1.932157283590641e-05
of O 0 4.67361473965866e-08
100 O 0 3.341139915846725e-07
or O 0 7.0301513233062e-07
less O 0 2.3486486497859005e-06
triplet O 0 0.0037433516699820757
repeats O 0 0.0007700201822444797
. O 0 1.1294946489215363e-05

We O 0 3.970786110585323e-06
have O 0 1.0457507926275866e-07
examined O 0 2.2633353182754945e-06
the O 0 2.502373952495418e-08
sperm O 0 1.7857115608421736e-07
DNA O 0 2.983746014706412e-07
of O 0 3.805591219929738e-08
a O 0 3.4323300042160554e-06
premutation O 0 0.0011897773947566748
carrier O 0 0.0004905372625216842
. O 0 8.503630851919297e-06

This O 0 1.1524795127115794e-06
mans O 0 4.57245550933294e-05
leucocyte O 0 0.0001285899052163586
DNA O 0 8.053935744101182e-06
showed O 0 1.3576328683484462e-06
one O 0 3.801426728955448e-08
normal O 0 3.057995172639494e-07
allele O 0 3.4526476611063117e-07
and O 0 3.855211971881545e-08
one O 0 2.5391978297761852e-08
allele O 0 3.2749920819696854e-07
of O 0 3.4768270040785865e-08
approximately O 0 3.7999413393663417e-07
100 O 0 1.907152977764781e-06
repeats O 0 9.116157161770388e-05
. O 0 9.897974450723268e-06

His O 0 5.946581040916499e-06
sperm O 0 5.230056558502838e-06
showed O 0 1.213803102473321e-06
an O 0 2.261870868380811e-08
expanded O 0 2.811467822994018e-07
allele O 0 1.2079379985152627e-06
in O 0 1.8010354096986703e-07
a O 0 6.37490302324295e-07
tight O 0 1.1756143067032099e-05
range O 0 8.341968396052835e-07
centering O 0 2.7984588086837903e-06
on O 0 1.1377760529285297e-06
a O 0 6.165765853438643e-07
size O 0 1.6229528227995615e-06
of O 0 1.7990682010804449e-07
approximately O 0 1.7765131588021177e-06
320 O 0 2.1696321709896438e-05
trinucleotide O 0 0.0023051570169627666
repeats O 0 0.0004740445292554796
. O 0 1.2230640095367562e-05

His O 0 5.352133302949369e-05
affected O 0 3.610380008467473e-05
son O 0 0.0010324741015210748
has O 0 2.0390596091601765e-06
repeat O 0 7.981070666573942e-06
sizes O 0 5.29569479112979e-06
of O 0 3.225205205126258e-07
1040 O 0 0.00025368601200170815
and O 0 3.1086726721696323e-06
540 O 0 5.085785232950002e-05
. O 0 9.783631867321674e-06

These O 0 2.5142443860204367e-07
data O 0 4.942463647239492e-07
suggest O 0 4.417915704379993e-07
that O 0 1.6248819179054408e-08
expansion O 0 8.069782211350685e-07
occurs O 0 4.0413610236100794e-07
in O 0 2.582231317660444e-08
two O 0 2.2296854140790856e-08
stages O 0 2.415293920421391e-06
, O 0 6.361796778264761e-08
the O 0 2.0183911431104207e-08
first O 0 1.250888601589395e-07
during O 0 3.731557285391318e-07
meiosis O 0 2.6421928396302974e-06
followed O 0 3.1782235510036116e-07
by O 0 1.8812791324762657e-08
a O 0 1.8892086472988012e-07
second O 0 9.794421202968806e-07
mitotic O 0 2.0281784600229003e-05
expansion O 0 1.4532829482050147e-05
. O 0 6.488908638857538e-06

We O 0 7.441226443916094e-07
also O 0 7.70409087635926e-08
show O 0 7.568667115265271e-08
that O 0 2.32394148369508e-09
in O 0 1.002035077135588e-08
all O 0 6.381372763542004e-09
informative O 0 6.451242597904638e-07
carrier O 0 1.0347827810619492e-05
father O 0 3.1765614494361216e-06
to O 0 6.879739800069729e-08
affected O 0 1.3454923646349926e-06
child O 0 2.808599901982234e-06
transmissions O 0 1.0376327736594249e-05
, O 0 1.8575154570044106e-07
with O 0 4.298241407241221e-08
the O 0 7.096745946455485e-08
notable O 0 2.7661067747430934e-07
exception O 0 8.238650366365619e-07
of O 0 4.1020751240239406e-08
the O 0 5.573673433900694e-07
premutation O 0 0.00041483421227894723
carrier O 0 3.441632361500524e-05
, O 0 1.6365136445983808e-07
the O 0 3.2800485882944486e-08
expansion O 0 1.2653900967052323e-06
size O 0 8.933252502174582e-06
decreases O 0 1.8737624486675486e-05
. O 0 7.643130288670363e-07
. O 0 2.847821633622516e-06

The O 0 7.075194389472017e-06
R496H O 0 0.00024381284310948104
mutation O 0 4.863715366809629e-05
of O 0 4.781700795319921e-07
arylsulfatase O 0 0.0006782463751733303
A O 0 3.22991945722606e-05
does O 0 4.708779670181684e-06
not O 0 4.222603820380755e-06
cause O 0 0.005330245476216078
metachromatic B-Disease 1 0.9994365572929382
leukodystrophy I-Disease 1 0.9998395442962646
. O 0 0.00012920126027893275

Deficiency B-Disease 1 0.9983859062194824
of I-Disease 0 1.1034017006750219e-05
arylsulfatase I-Disease 0 0.004366099368780851
A I-Disease 0 7.849147368688136e-05
( O 0 4.358126261649886e-06
ARSA O 0 0.0036304714158177376
) O 0 1.4702808357469621e-06
enzyme O 0 4.474921661312692e-05
activity O 0 0.00010024508083006367
causes O 0 0.008724258281290531
metachromatic B-Disease 1 0.9996606111526489
leukodystrophy I-Disease 1 0.9999294281005859
( O 0 0.000603672000579536
MLD B-Disease 1 0.9995940327644348
) O 0 1.0352210665587336e-05
. O 0 5.477466402226128e-06

A O 0 6.0178767853358295e-06
number O 0 3.2211599432230287e-07
of O 0 4.376099980163417e-07
ARSA O 0 0.008688281290233135
gene O 0 7.480347994714975e-05
mutations O 0 0.0001249537308467552
responsible O 0 6.924512945261085e-06
for O 0 1.3033474033363746e-06
MLD B-Disease 1 0.9995525479316711
have O 0 1.0133893511010683e-06
been O 0 2.3832512852095533e-06
identified O 0 6.42839222564362e-06
. O 0 2.3949100977915805e-06

Recently O 0 0.0003065281780436635
, O 0 8.625826239949674e-07
the O 0 7.032692224129278e-07
R496H O 0 8.976087701739743e-05
mutation O 0 3.1399995350511745e-05
of O 0 1.012441998682334e-06
ARSA O 0 0.007793608587235212
was O 0 1.5049427020130679e-05
proposed O 0 5.418706336968171e-07
to O 0 3.405718729254659e-08
be O 0 2.0448773341286142e-07
a O 0 2.1992889287503203e-06
cause O 0 4.015939703094773e-05
of O 0 3.0273208722064737e-06
MLD B-Disease 1 0.9996533393859863
( O 0 9.745348506839946e-06
Draghia O 0 0.00020760933693964034
et O 0 0.00046747864689677954
al O 0 2.9495822673197836e-05
. O 0 6.7397797920421e-07
, O 0 7.261651830958726e-07
1997 O 0 6.2855910982762e-06
) O 0 3.6014193938171957e-07
. O 0 1.5327917708418681e-06

We O 0 1.0424870197311975e-05
have O 0 7.171393008320592e-07
investigated O 0 1.9995266484329477e-05
the O 0 8.776214031058771e-07
R496H O 0 6.307689181994647e-05
mutation O 0 1.0518041563045699e-05
and O 0 1.6492751342411793e-07
found O 0 1.6064041119534522e-07
this O 0 2.3735511334166404e-08
mutation O 0 1.896803041745443e-06
at O 0 1.6327892353729112e-06
a O 0 1.686685493496043e-07
relatively O 0 2.980634690175066e-07
high O 0 2.182927346439101e-06
frequency O 0 5.34217178937979e-07
in O 0 2.0776809606104507e-08
an O 0 1.398866977808666e-08
African O 0 3.287753003178295e-08
American O 0 4.344579451753816e-08
population O 0 4.5937009751639835e-09
( O 0 7.156062764579474e-08
f O 0 1.125284416048089e-05
= O 0 3.860447577608284e-06
0 O 0 4.558059174541995e-07
. O 0 3.767055289927157e-08
09 O 0 2.0378213321237126e-06
, O 0 1.7795743190163194e-07
n O 0 7.448323231074028e-06
= O 0 1.1003439794876613e-05
61 O 0 3.2495818231836893e-06
subjects O 0 3.7529102883127052e-06
) O 0 1.0826751122294809e-06
. O 0 2.861722578018089e-06

The O 0 1.2585251170094125e-05
ARSA O 0 0.003295340109616518
enzyme O 0 1.4706044566992205e-05
activity O 0 9.018217497214209e-07
in O 0 6.713593592166944e-08
subjects O 0 3.398328374260018e-07
with O 0 1.2042717401072878e-07
and O 0 1.878454440884525e-07
without O 0 3.860893400542409e-07
the O 0 3.237769590214157e-07
R496H O 0 3.300548632978462e-05
mutation O 0 8.486472324875649e-06
was O 0 3.3171484119520755e-06
determined O 0 3.662119922864804e-07
and O 0 7.263903967213992e-08
found O 0 8.671150197869792e-08
to O 0 1.3638635110169162e-08
be O 0 2.0091735564164992e-07
normal O 0 6.71356883685803e-06
. O 0 3.182425643899478e-06

It O 0 1.8757491488941014e-06
is O 0 3.570579565348453e-07
therefore O 0 1.8206760898920038e-07
concluded O 0 1.0292114893672988e-06
that O 0 8.05846056550763e-09
the O 0 2.3787184488810453e-07
R496H O 0 6.010746074025519e-05
mutation O 0 1.4739543075847905e-05
of O 0 3.9949023289409524e-07
ARSA O 0 0.003992915153503418
does O 0 8.951348036134732e-07
not O 0 4.184585478128611e-08
negatively O 0 1.706842738258274e-07
influence O 0 2.1951890971649846e-07
the O 0 1.0690115459510707e-07
activity O 0 1.6551854287172318e-07
of O 0 5.19861096393015e-08
ARSA O 0 0.0012319424422457814
and O 0 9.788957413547905e-07
is O 0 2.485967058873939e-07
not O 0 1.0117433646428253e-07
a O 0 5.067337497166591e-06
cause O 0 0.00025749526685103774
of O 0 2.362090708629694e-05
MLD B-Disease 1 0.9994673132896423

Down O 0 0.003697996959090233
- O 0 0.0002107210602844134
regulation O 0 2.2669197278446518e-05
of O 0 1.6845229993123212e-06
transmembrane O 0 0.001101114903576672
carbonic O 0 0.015362751670181751
anhydrases O 0 0.006943278480321169
in O 0 0.00017270636453758925
renal B-Disease 1 0.9998835325241089
cell I-Disease 1 0.9994219541549683
carcinoma I-Disease 1 0.9999994039535522
cell O 0 0.014639533124864101
lines O 0 7.248256588354707e-05
by O 0 9.409461085851945e-07
wild O 0 3.148347241221927e-05
- O 0 0.0009593985159881413
type O 0 0.0010463708313181996
von B-Disease 1 0.9926732182502747
Hippel I-Disease 1 0.9825507998466492
- I-Disease 1 0.7277193665504456
Lindau I-Disease 0 0.3277493715286255
transgenes O 0 0.007281624712049961
. O 0 5.1769478886853904e-05

To O 0 4.799769612873206e-07
discover O 0 5.426201823865995e-06
genes O 0 3.7464876641024603e-06
involved O 0 3.1730885439174017e-06
in O 0 8.568003977416083e-06
von B-Disease 1 0.9651129245758057
Hippel I-Disease 1 0.974450409412384
- I-Disease 1 0.8369107842445374
Lindau I-Disease 1 0.5507998466491699
( O 0 1.0028697943198495e-05
VHL B-Disease 0 0.003782541723921895
) O 0 1.5925172647257568e-06
- O 0 5.375498585635796e-05
mediated O 0 0.00020796355966012925
carcinogenesis O 0 0.007058917544782162
, O 0 8.342079240719613e-07
we O 0 5.549874231292051e-07
used O 0 2.3792137653799728e-05
renal B-Disease 1 0.999948263168335
cell I-Disease 1 0.9997573494911194
carcinoma I-Disease 1 0.9999995231628418
cell O 0 0.24733620882034302
lines O 0 0.0006728890584781766
stably O 0 0.0009763108100742102
transfected O 0 0.00029657737468369305
with O 0 4.2136930460401345e-06
wild O 0 6.93899710313417e-05
- O 0 0.0013579088263213634
type O 0 0.0012527585495263338
VHL O 1 0.8813884854316711
- O 0 0.004541612230241299
expressing O 0 8.461086690658703e-05
transgenes O 0 0.001521754777058959
. O 0 1.593145316292066e-05

Large O 0 7.4058680183952674e-06
- O 0 4.9232323362957686e-05
scale O 0 1.3738517736783251e-05
RNA O 0 6.013866368448362e-06
differential O 0 3.5863840821548365e-06
display O 0 7.85037684636336e-07
technology O 0 6.178580065352435e-07
applied O 0 1.3575832724654902e-07
to O 0 5.174559003506829e-09
these O 0 9.89082948876785e-09
cell O 0 3.854517672152724e-06
lines O 0 5.26812164025614e-06
identified O 0 4.6457344637929054e-07
several O 0 6.146115794081197e-08
differentially O 0 5.511336894414853e-06
expressed O 0 2.061009922726953e-07
genes O 0 4.865568712375534e-07
, O 0 8.955073838023964e-08
including O 0 6.662592966222292e-08
an O 0 3.856139301205985e-07
alpha O 0 1.5827990864636377e-05
carbonic O 0 0.0006307004368864
anhydrase O 0 0.0011030160821974277
gene O 0 1.619249269424472e-05
, O 0 2.630993549246341e-06
termed O 0 0.00013779698929283768
CA12 O 0 0.009035005234181881
. O 0 2.648450572451111e-05

The O 0 4.144655179061374e-07
deduced O 0 5.428533995655016e-07
protein O 0 1.0846495257510469e-07
sequence O 0 1.9781712978783617e-07
was O 0 9.314446742791915e-07
classified O 0 3.05087041851948e-07
as O 0 6.230377636029516e-08
a O 0 2.817093047724484e-07
one O 0 4.245836464633612e-07
- O 0 5.702743146684952e-05
pass O 0 1.8860142517951317e-05
transmembrane O 0 0.0003728722222149372
CA O 0 0.00024568973458372056
possessing O 0 4.881030690739863e-06
an O 0 5.021885840506002e-07
apparently O 0 6.591181318071904e-06
intact O 0 5.506303750735242e-06
catalytic O 0 5.573027010541409e-06
domain O 0 4.809342044609366e-07
in O 0 9.03941810292963e-08
the O 0 1.2367445378913544e-07
extracellular O 0 1.4149415619613137e-05
CA O 0 0.0020373226143419743
module O 0 0.0002226779906777665
. O 0 6.564019258803455e-06

Reintroduced O 0 0.00031937038875184953
wild O 0 0.00010076780017698184
- O 0 0.0008893412305042148
type O 0 0.00027519435388967395
VHL B-Disease 0 0.023499537259340286
strongly O 0 1.3165446944185533e-05
inhibited O 0 5.992460046400083e-06
the O 0 1.820650084027875e-07
overexpression O 0 3.196027137164492e-06
of O 0 2.8151802666798176e-08
the O 0 2.432686301290232e-07
CA12 O 0 0.00010554454638622701
gene O 0 2.1344494598452e-06
in O 0 4.5163858430896653e-07
the O 0 2.124946149706375e-06
parental O 0 0.0007265019812621176
renal B-Disease 1 0.9999593496322632
cell I-Disease 1 0.9998515844345093
carcinoma I-Disease 1 0.9999997615814209
cell O 1 0.9761022329330444
lines O 0 0.00381022528745234
. O 0 2.6914367481367663e-05

Similar O 0 6.071978987165494e-06
results O 0 3.194083319613128e-06
were O 0 1.6666804469878116e-07
obtained O 0 3.0904146797183785e-07
with O 0 3.03965435932696e-07
CA9 O 0 0.0008427129359915853
, O 0 1.3464315884448297e-07
encoding O 0 2.1191755195104633e-07
another O 0 1.8257547935718321e-06
transmembrane O 0 0.0002870330063160509
CA O 0 8.463394624413922e-05
with O 0 9.490373997778079e-08
an O 0 2.3648506441986683e-07
intact O 0 1.060778413375374e-05
catalytic O 0 4.160701428190805e-05
domain O 0 2.180227056669537e-05
. O 0 3.7139873256819556e-06

Although O 0 2.5117426503129536e-06
both O 0 2.679612123301922e-07
domains O 0 2.7705102638719836e-06
of O 0 1.0854918741642905e-07
the O 0 8.15563794276386e-07
VHL B-Disease 0 0.0010058239568024874
protein O 0 2.2872059162182268e-06
contribute O 0 4.465279914711573e-07
to O 0 8.441671184300503e-08
regulation O 0 3.1620716072211508e-06
of O 0 2.3551571359803347e-07
CA12 O 0 0.00028954623849131167
expression O 0 3.1523404686595313e-06
, O 0 3.3005710520228604e-07
the O 0 2.3787842451383767e-07
elongin O 0 3.3875854569487274e-05
binding O 0 2.6858826913667144e-06
domain O 0 3.0666799375467235e-06
alone O 0 2.968798526126193e-06
could O 0 6.97374559877062e-07
effectively O 0 8.070359399425797e-06
regulate O 0 4.7812416596570984e-05
CA9 O 0 0.00894835963845253
expression O 0 5.982428046991117e-05
. O 0 1.373825580230914e-05

We O 0 2.0148130715824664e-05
mapped O 0 0.0001618043170310557
CA12 O 0 0.0018640297930687666
and O 0 8.451169378531631e-06
CA9 O 0 0.00434570387005806
loci O 0 4.561945752357133e-05
to O 0 7.841965725674527e-07
chromosome O 0 4.725938197225332e-05
bands O 0 3.911729800165631e-05
15q22 O 0 0.00010685505549190566
and O 0 2.5702424863993656e-06
17q21 O 0 0.00028809401555918157
. O 0 8.70628355187364e-06

2 O 0 2.0014287656522356e-05
respectively O 0 9.446194781048689e-06
, O 0 1.2471667787394836e-06
regions O 0 6.144109647721052e-06
prone O 0 0.0009254977339878678
to O 0 1.095502639714141e-07
amplification O 0 4.261639332980849e-06
in O 0 2.494892328286369e-07
some O 0 1.4503090994821832e-07
human O 0 5.4365886171581224e-05
cancers B-Disease 1 0.9965171813964844
. O 0 1.1744522453227546e-05

Additional O 0 2.122948075111708e-07
experiments O 0 2.2790168259234633e-06
are O 0 1.611271827073324e-08
needed O 0 6.960225107377482e-08
to O 0 1.100847679680328e-08
define O 0 3.381665862889349e-07
the O 0 2.436447630316252e-07
role O 0 2.7689939088304527e-06
of O 0 1.0281362392561277e-06
CA O 0 0.0005155191756784916
IX O 0 0.0011208555661141872
and O 0 1.162990156444721e-05
CA O 0 0.00025093162548728287
XII O 0 0.0006304004928097129
enzymes O 0 5.712465735996375e-06
in O 0 2.2782164421641937e-07
the O 0 8.988597244297125e-08
regulation O 0 2.078606257782667e-06
of O 0 9.191440852873711e-08
pH O 0 8.907753363018855e-05
in O 0 1.9090330738436023e-07
the O 0 7.978476901371323e-08
extracellular O 0 3.0649430300400127e-06
microenvironment O 0 7.558045763289556e-05
and O 0 1.9314809662773769e-07
its O 0 1.1257208143433672e-07
potential O 0 1.1168192486366024e-06
impact O 0 3.5591735922935186e-06
on O 0 4.151997563894838e-05
cancer B-Disease 1 0.5046523213386536
cell O 0 0.00017814147577155381
growth O 0 1.1213154721190222e-05
. O 0 5.260480065771844e-06

A O 0 1.9229946701670997e-06
gene O 0 4.218471758576925e-07
encoding O 0 1.7474175706411188e-07
a O 0 9.687117881185259e-07
transmembrane O 0 8.4822404460283e-06
protein O 0 1.1441633205322432e-06
is O 0 1.2269130422737362e-07
mutated O 0 3.351714440213982e-06
in O 0 6.81754784181976e-07
patients O 0 1.0275099157297518e-05
with O 0 0.00013084799866192043
diabetes B-Disease 1 0.9999972581863403
mellitus I-Disease 1 0.999997615814209
and O 1 0.9813604354858398
optic B-Disease 1 0.9999945163726807
atrophy I-Disease 1 0.9998089671134949
( O 0 0.012349610216915607
Wolfram B-Disease 1 0.999718964099884
syndrome I-Disease 1 0.9999985694885254
) O 0 1.7395595932612196e-05
. O 0 1.2946981769346166e-05

Wolfram B-Disease 1 0.9998093247413635
syndrome I-Disease 1 0.9999994039535522
( O 0 0.00023286060604732484
WFS B-Disease 0 0.4666171073913574
; O 0 3.2647207262925804e-05
OMIM O 0 0.031061727553606033
222300 O 0 0.00040807403274811804
) O 0 6.091172508604359e-07
is O 0 1.0589606063149404e-06
an O 0 9.72691850620322e-06
autosomal B-Disease 1 0.9994951486587524
recessive I-Disease 1 0.9999527931213379
neurodegenerative I-Disease 1 0.9999949932098389
disorder I-Disease 1 0.999849796295166
defined O 0 2.098361619573552e-05
by O 0 1.2271990499357344e-06
young O 0 1.2306246389925946e-05
- O 0 0.0009258292848244309
onset O 0 0.0042623430490493774
non O 0 0.0002813878527376801
- O 0 0.009597565978765488
immune O 0 0.011618118733167648
insulin B-Disease 0 0.008579838089644909
- I-Disease 0 0.012684122659265995
dependent I-Disease 0 0.00166962924413383
diabetes I-Disease 1 0.9999724626541138
mellitus I-Disease 1 0.9999749660491943
and O 0 0.00484804529696703
progressive O 1 0.9989196062088013
optic B-Disease 1 0.9999755620956421
atrophy I-Disease 1 0.9990921020507812
. O 0 8.243093907367438e-05

Linkage O 0 0.0001348342775600031
to O 0 8.420666972597246e-07
markers O 0 2.5694318537716754e-05
on O 0 7.563293365819845e-06
chromosome O 0 0.0001883800869109109
4p O 0 0.014866232872009277
was O 0 4.369035013951361e-05
confirmed O 0 2.365932004977367e-06
in O 0 9.840966441743149e-08
five O 0 2.3046690955652593e-07
families O 0 2.1681003659068665e-07
. O 0 2.419824340904597e-06

On O 0 2.228390258096624e-06
the O 0 1.8297257042831916e-07
basis O 0 2.4943309995251184e-07
of O 0 4.844843033424695e-07
meiotic O 0 0.002256167819723487
recombinants O 0 0.11836689710617065
and O 0 0.0003647675330284983
disease O 1 0.9984087347984314
- O 0 0.0017886406276375055
associated O 0 2.2263542632572353e-05
haplotypes O 0 7.246010500239208e-05
, O 0 6.986733183111937e-07
the O 0 4.815721013073926e-07
WFS B-Disease 0 0.0006402757717296481
gene O 0 9.357493581774179e-06
was O 0 8.475415597786196e-06
localized O 0 1.0259393093292601e-05
to O 0 1.3227283091055142e-07
a O 0 3.4621079976204783e-06
BAC O 0 0.00023872646852396429
/ O 0 3.213650779798627e-05
P1 O 0 0.00019644226995296776
contig O 0 3.5880282666767016e-05
of O 0 3.586728070104073e-08
less O 0 1.464800192252369e-07
than O 0 9.962344904579368e-08
250 O 0 8.335613870258385e-07
kb O 0 7.827499211998656e-05
. O 0 8.004166375030763e-06

Mutations O 0 0.0003034087421838194
in O 0 9.759455679159146e-07
a O 0 6.85275438172539e-07
novel O 0 6.344843654915167e-07
gene O 0 2.033604687312618e-06
( O 0 1.5351515969541651e-07
WFS1 O 0 1.4310307051346172e-05
) O 0 8.145492280675626e-09
encoding O 0 3.9037598043023536e-08
a O 0 4.4558024114849104e-07
putative O 0 6.661692623310955e-06
transmembrane O 0 5.531778242584551e-06
protein O 0 2.290900908974436e-07
were O 0 3.1853232940193266e-08
found O 0 5.4110124381168134e-08
in O 0 1.2396583315421594e-08
all O 0 8.158258069101976e-09
affected O 0 1.7179999645122734e-07
individuals O 0 1.1064745564226541e-08
in O 0 9.544015000528816e-08
six O 0 8.303995855385438e-07
WFS B-Disease 0 0.0004042063083034009
families O 0 8.206502144503247e-08
, O 0 7.938584900557544e-08
and O 0 2.106972907256477e-08
these O 0 1.2820379424738348e-08
mutations O 0 1.6727806269045686e-06
were O 0 1.5921801832519122e-07
associated O 0 4.2611657136149006e-07
with O 0 7.492168947464961e-07
the O 0 5.4278498282656074e-05
disease O 1 0.9980408549308777
phenotype O 0 0.0012785509461537004
. O 0 1.3187989679863676e-05

WFS1 O 0 0.0035824633669108152
appears O 0 4.896770860796096e-06
to O 0 3.573256179834061e-08
function O 0 6.849886062809674e-07
in O 0 3.676754261050519e-07
survival O 0 6.1376158555503935e-06
of O 0 1.5710051570749783e-07
islet O 0 0.00014666785136796534
beta O 0 1.6418427549069747e-05
- O 0 2.1067189663881436e-05
cells O 0 1.4773619341212907e-06
and O 0 3.188874018178467e-07
neurons O 0 3.1954116366250673e-06
. O 0 2.8038365940119547e-07
. O 0 2.08711571758613e-06

Stable O 0 1.6086076357169077e-05
interaction O 0 3.2705537478250335e-07
between O 0 8.983951715890726e-08
the O 0 4.9591019291028715e-08
products O 0 1.1569434832381376e-07
of O 0 3.0030435027583735e-08
the O 0 4.057928890688345e-07
BRCA1 O 0 0.00012253393651917577
and O 0 5.0242852012161165e-06
BRCA2 O 0 0.0007032040739431977
tumor B-Disease 0 0.0016313742380589247
suppressor O 0 1.991133285628166e-05
genes O 0 8.308256838063244e-07
in O 0 3.6471087128120416e-07
mitotic O 0 4.5979606511536986e-05
and O 0 2.2393489871319616e-06
meiotic O 0 0.0009358475799672306
cells O 0 0.00014302413910627365
. O 0 1.2407614121912047e-05

BRCA1 O 0 0.002430537948384881
and O 0 9.405205673829187e-06
BRCA2 O 0 8.461441029794514e-05
account O 0 1.9329939959789044e-07
for O 0 4.857223245835485e-08
most O 0 9.446922177858141e-08
cases O 0 4.190088418454252e-07
of O 0 2.0262356770217593e-07
familial O 0 0.010430773720145226
, O 0 1.0771452252811287e-05
early O 0 5.268939275993034e-05
onset O 0 0.2918885350227356
breast B-Disease 1 0.9325677156448364
and I-Disease 0 6.476342969108373e-05
/ I-Disease 1 0.9174899458885193
or I-Disease 1 0.9965587258338928
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999896287918091
and O 0 4.0195050843294666e-08
encode O 0 1.4752789212479911e-08
products O 0 1.1183652048885051e-07
that O 0 3.8335352670060274e-09
each O 0 5.138493186507276e-09
interact O 0 1.567246101785713e-07
with O 0 1.4690195939692785e-06
hRAD51 O 0 0.0005752870929427445
. O 0 9.038312782649882e-06

Results O 0 1.1461878784757573e-05
presented O 0 1.652009359531803e-06
here O 0 2.8482730840551085e-07
show O 0 7.973819720064057e-07
that O 0 9.212291729454591e-08
BRCA1 O 0 2.766898978734389e-05
and O 0 7.385952471850032e-07
BRCA2 O 0 7.44743665563874e-05
coexist O 0 1.1131784049212001e-05
in O 0 3.3355271966684086e-07
a O 0 1.1006566182913957e-06
biochemical O 0 1.6995274563669227e-05
complex O 0 1.2876500477432273e-05
and O 0 1.6510989553353284e-06
colocalize O 0 0.0003865519247483462
in O 0 1.7222073438460939e-06
subnuclear O 0 0.0001884733501356095
foci O 0 4.149424421484582e-05
in O 0 1.3389228570304113e-07
somatic O 0 1.6603487438260345e-06
cells O 0 7.045883307910117e-07
and O 0 8.538133045021823e-08
on O 0 1.9631926306828973e-07
the O 0 4.511155538011735e-08
axial O 0 1.2835863572036033e-06
elements O 0 2.223916055754671e-07
of O 0 1.4476628962256655e-07
developing O 0 1.873164001153782e-05
synaptonemal O 0 0.001971646910533309
complexes O 0 0.0004772995598614216
. O 0 1.8127502698916942e-05

Like O 0 6.691295857308432e-05
BRCA1 O 0 0.0007267904584296048
and O 0 9.053721441887319e-06
RAD51 O 0 0.011318203061819077
, O 0 7.342280696320813e-06
BRCA2 O 0 0.0001815523864934221
relocates O 0 2.115886309184134e-05
to O 0 4.918070430903754e-07
PCNA O 0 0.0006704635452479124
+ O 0 1.0135518095921725e-05
replication O 0 2.8433275929273805e-06
sites O 0 1.5688373196098837e-06
following O 0 1.7356815078528598e-06
exposure O 0 2.6888508728006855e-05
of O 0 3.0263603889579827e-07
S O 0 0.00022276228992268443
phase O 0 1.0212088454863988e-05
cells O 0 2.0121660782024264e-06
to O 0 1.7757193404577265e-07
hydroxyurea O 0 8.070038893492892e-05
or O 0 7.088938218657859e-06
UV O 0 0.0035794349387288094
irradiation O 0 6.54034229228273e-05
. O 0 5.26738767803181e-06

Thus O 0 1.4399549399968237e-05
, O 0 1.8024013570538955e-06
BRCA1 O 0 5.0636459491215646e-05
and O 0 5.428357781056548e-07
BRCA2 O 0 2.151324224541895e-05
participate O 0 1.621340999236054e-07
, O 0 7.671450674706648e-08
together O 0 5.000551794864805e-08
, O 0 6.445117151088198e-08
in O 0 4.866543079629082e-08
a O 0 2.7500985311235127e-07
pathway O 0 1.2444459116522921e-06
( O 0 2.6023062105196004e-07
s O 0 1.2536700523924083e-05
) O 0 4.977846401743591e-08
associated O 0 8.570389553597124e-08
with O 0 1.0104181491499276e-08
the O 0 4.4300744406200465e-08
activation O 0 6.345751444314374e-07
of O 0 9.060236294544666e-08
double O 0 2.1146375729585998e-05
- O 0 9.122923802351579e-05
strand O 0 2.369208596064709e-05
break O 0 2.7646568923955783e-05
repair O 0 0.0025437253061681986
and O 0 1.9265521586930845e-06
/ O 0 3.2110656320583075e-05
or O 0 2.511958200557274e-06
homologous O 0 4.821598849957809e-05
recombination O 0 0.00010052355355583131
. O 0 9.353745554108173e-06

Dysfunction O 0 0.1822815239429474
of O 0 3.488429172193719e-07
this O 0 1.6042730521803605e-07
pathway O 0 3.885622390953358e-06
may O 0 5.63201638215105e-07
be O 0 2.4813473942231212e-08
a O 0 1.3090185291275702e-07
general O 0 2.496891795544798e-07
phenomenon O 0 2.0498769117693882e-06
in O 0 8.510216531476544e-08
the O 0 6.355999460083694e-08
majority O 0 8.492995817732663e-08
of O 0 4.830559774404719e-08
cases O 0 8.629964440842741e-07
of O 0 1.12276870822825e-06
hereditary B-Disease 1 0.9997559189796448
breast I-Disease 1 0.999652624130249
and I-Disease 0 0.0015891107032075524
/ I-Disease 1 0.9977188110351562
or I-Disease 1 0.9993434548377991
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999936819076538
. O 0 4.6594896048191e-06
. O 0 3.893861503456719e-06

A O 0 2.8527134418254718e-05
novel O 0 1.534383227408398e-05
Arg362Ser O 0 0.00023353852157015353
mutation O 0 1.9730963686015457e-05
in O 0 1.7279441522077832e-07
the O 0 1.5753499837956042e-07
sterol O 0 0.00039539573481306434
27 O 0 8.819545473670587e-05
- O 0 0.0001677354157436639
hydroxylase O 0 0.0002765752433333546
gene O 0 7.4262507041567005e-06
( O 0 4.697458280134015e-07
CYP27 O 0 8.581837028032169e-05
) O 0 1.1821554579682925e-07
: O 0 5.305676253897218e-08
its O 0 4.688525478968586e-08
effects O 0 1.6804651750135235e-06
on O 0 5.360789714359271e-07
pre O 0 5.50011100131087e-06
- O 0 8.560454602957179e-07
mRNA O 0 8.232463244439714e-08
splicing O 0 1.8499292764317943e-06
and O 0 1.1783701836520777e-07
enzyme O 0 4.34570893048658e-06
activity O 0 3.843813374260208e-06
. O 0 1.427082338523178e-06

A O 0 1.008306207950227e-05
novel O 0 3.336132976983208e-06
C O 0 8.042009540076833e-06
to O 0 3.8024566606509325e-08
A O 0 1.1465969009805121e-06
mutation O 0 1.194555238726025e-06
in O 0 3.0199707623523864e-08
the O 0 1.0756546942047862e-07
sterol O 0 0.0001607089361641556
27 O 0 3.152048520860262e-05
- O 0 5.745665112044662e-05
hydroxylase O 0 8.682458428665996e-05
gene O 0 3.808412202488398e-06
( O 0 4.6299709310915205e-07
CYP27 O 0 7.830590766388923e-05
) O 0 2.3251627112585993e-07
was O 0 1.521249373581668e-06
identified O 0 9.875112283452836e-08
by O 0 1.2160614737410924e-08
sequencing O 0 5.963579496892635e-07
amplified O 0 2.0015395421069115e-05
CYP27 O 0 7.778983126627281e-05
gene O 0 9.69101733971911e-07
products O 0 5.938120466453256e-07
from O 0 2.856000662632141e-07
a O 0 3.058869424421573e-06
patient O 0 5.473920100484975e-05
with O 0 1.5946076018735766e-05
cerebrotendinous B-Disease 1 0.9996076226234436
xanthomatosis I-Disease 1 0.9991980195045471
( O 0 1.7551032215123996e-05
CTX B-Disease 0 0.021622896194458008
) O 0 4.433397862158017e-06
. O 0 5.714138296752935e-06

The O 0 5.837740900460631e-06
mutation O 0 8.0621633969713e-05
changed O 0 8.399545549764298e-06
the O 0 6.27378369699727e-07
adrenodoxin O 0 9.747380681801587e-05
cofactor O 0 3.7834122394997394e-06
binding O 0 1.1358072697476018e-05
residue O 0 4.241077112965286e-05
362Arg O 0 9.420866990694776e-05
to O 0 9.194121730615734e-07
362Ser O 0 0.0005321138887666166
( O 0 8.540869202988688e-06
CGT O 0 0.009571135975420475
362Arg O 0 0.00043765470036305487
to O 0 2.233662598882802e-06
AGT O 0 0.006332329474389553
362Ser O 0 0.00018568495579529554
) O 0 2.177271198888775e-07
, O 0 8.179029720167819e-08
and O 0 1.294354206038406e-07
was O 0 9.624000085750595e-06
responsible O 0 4.37658582086442e-06
for O 0 3.2409252526122145e-06
deficiency O 1 0.9931760430335999
in O 0 2.424681611046253e-07
the O 0 2.6541280817582447e-07
sterol O 0 0.00026517719379626215
27 O 0 5.0845635996665806e-05
- O 0 3.781193299801089e-05
hydroxylase O 0 0.00012903257447760552
activity O 0 3.581256748930173e-07
, O 0 3.35798695516587e-08
as O 0 4.1809634865330736e-08
confirmed O 0 2.0461413896555314e-07
by O 0 8.00663002564761e-09
expression O 0 6.197475954650145e-08
of O 0 1.3789905217720388e-08
mutant O 0 8.019516144486261e-07
cDNA O 0 4.110048905658914e-07
into O 0 1.142976657320105e-06
COS O 0 0.0009634725283831358
- O 0 6.934624252608046e-05
1 O 0 6.429097538784845e-06
cells O 0 9.451728146814276e-06
. O 0 2.165074420190649e-06

Quantitative O 0 5.934163255005842e-06
analysis O 0 1.2428400850694743e-06
showed O 0 1.7761676645022817e-06
that O 0 1.2131471827103724e-08
the O 0 4.245314144668555e-08
expression O 0 2.909973204623384e-07
of O 0 8.089170933089918e-08
CYP27 O 0 7.356320566032082e-05
gene O 0 8.373131663574895e-07
mRNA O 0 6.229770974641724e-07
in O 0 2.1242318837266794e-07
the O 0 2.553942692884448e-07
patient O 0 6.018525255058194e-06
represented O 0 1.3122962627676316e-06
52 O 0 1.9810624507954344e-05
. O 0 3.593303063098574e-06

5 O 0 4.240145244693849e-06
% O 0 3.594617936641953e-08
of O 0 1.2510932734244307e-08
the O 0 2.561377243637253e-07
normal O 0 8.662173968332354e-06
level O 0 3.5156939702574164e-05
. O 0 5.058000169810839e-06

As O 0 3.3279220588156022e-06
the O 0 8.854828479343269e-07
mutation O 0 2.721240889513865e-05
occurred O 0 1.1732455277524423e-05
at O 0 2.7130604394187685e-06
the O 0 7.494170972677239e-08
penultimate O 0 6.859587756480323e-06
nucleotide O 0 5.249297032605682e-07
of O 0 7.77488864400766e-08
exon O 0 1.607166268513538e-05
6 O 0 4.0606496440886986e-06
( O 0 1.481805185221674e-07
- O 0 4.554158749670023e-06
2 O 0 5.746582587562443e-07
position O 0 6.642075618401577e-07
of O 0 5.3099483920959756e-08
exon O 0 2.06616532523185e-05
6 O 0 7.85845986683853e-06
- O 0 1.910106402647216e-05
intron O 0 7.520423241658136e-05
6 O 0 2.296632828802103e-06
splice O 0 1.1099495168309659e-05
site O 0 3.160751248287852e-06
) O 0 1.547748951225003e-08
of O 0 3.2494231749780056e-09
the O 0 4.4119868647385374e-08
gene O 0 5.589178613263357e-07
, O 0 1.7151040765384096e-07
we O 0 7.239035682005124e-08
hypothesized O 0 8.935280675359536e-07
that O 0 1.2739379329218536e-08
the O 0 9.603250816780928e-08
mutation O 0 7.708111297688447e-06
may O 0 8.471702699353045e-07
partially O 0 6.328663857857464e-06
affect O 0 3.15967952246865e-07
the O 0 3.1575766001878947e-08
normal O 0 3.1263783739632345e-07
splicing O 0 1.6329433947248617e-06
efficiency O 0 3.016844630110427e-06
in O 0 3.732575351023115e-07
exon O 0 2.306182068423368e-05
6 O 0 4.98270901516662e-06
and O 0 3.733497635494132e-07
cause O 0 1.1452658554844675e-06
alternative O 0 1.8493669529107137e-07
splicing O 0 5.201385647524148e-06
elsewhere O 0 2.7057994884671643e-06
, O 0 1.2924250825108174e-07
which O 0 1.795594961606639e-08
resulted O 0 2.6048488166452444e-07
in O 0 9.900100650384047e-08
decreased O 0 3.624342980401707e-06
transcript O 0 9.930556188919581e-06
in O 0 4.843776082452678e-07
the O 0 1.5590812836308032e-06
patient O 0 8.731146226637065e-05
. O 0 5.685849828296341e-06

Transfection O 0 0.0010466909734532237
of O 0 1.919366923175403e-06
constructed O 0 8.785482350504026e-05
minigenes O 0 0.000888291047886014
, O 0 6.363119382513105e-07
with O 0 1.4874444786983076e-07
or O 0 9.205158448821749e-07
without O 0 1.3839104440194205e-07
the O 0 1.1935709665067407e-07
mutation O 0 1.4835375168331666e-06
, O 0 8.51846735372419e-08
into O 0 2.501506060070824e-07
COS O 0 0.0004028264374937862
- O 0 1.6534197129658423e-05
1 O 0 8.845409524838033e-07
cells O 0 5.985116331430618e-07
confirmed O 0 5.333197350410046e-07
that O 0 3.2148204098803035e-09
the O 0 4.0722259342373945e-08
mutant O 0 3.5288769595354097e-06
minigene O 0 0.00010928366828011349
was O 0 4.277176685718587e-06
responsible O 0 3.259922607412591e-07
for O 0 8.401461748519523e-09
a O 0 9.294395653114407e-08
mRNA O 0 2.6512290673963435e-07
species O 0 4.8210420544592125e-08
alternatively O 0 4.142268608120503e-07
spliced O 0 7.297144748008577e-06
at O 0 1.1065589205827564e-05
an O 0 5.518171519725001e-07
activated O 0 6.894383113831282e-05
cryptic O 0 2.4724133254494518e-05
5 O 0 1.0174031785936677e-06
splice O 0 3.5967095755040646e-05
site O 0 1.814189090509899e-05
88 O 0 7.768878276692703e-06
bp O 0 1.939018147822935e-05
upstream O 0 7.904014296400419e-07
from O 0 6.359685755796818e-08
the O 0 4.343345239021801e-08
3 O 0 4.422383881319547e-07
end O 0 9.590892204869306e-07
of O 0 1.9450671118192986e-07
exon O 0 6.522765033878386e-05
6 O 0 4.172653643763624e-05
. O 0 3.72268232240458e-06

Our O 0 1.1946715403610142e-06
data O 0 6.340990807984781e-07
suggest O 0 3.366009480032517e-07
that O 0 8.174113830250462e-09
the O 0 4.1576154075073646e-08
C O 0 1.2378317251204862e-06
to O 0 1.0125634553048712e-08
A O 0 9.200103363582457e-07
mutation O 0 3.6049457321496448e-06
at O 0 1.7283215356656e-06
the O 0 9.701507508452778e-08
penultimate O 0 8.679696293256711e-06
nucleotide O 0 5.72559315514809e-07
of O 0 3.965189421251125e-08
exon O 0 1.8640561393112876e-05
6 O 0 2.2887222712597577e-06
of O 0 2.2921721409829843e-08
the O 0 8.554140151773026e-08
CYP27 O 0 5.288854299578816e-05
gene O 0 5.451942683976085e-07
not O 0 4.9065175034002095e-08
only O 0 1.0700988894996044e-07
causes O 0 1.9573464669520035e-05
the O 0 3.3548387818882475e-06
deficiency B-Disease 1 0.9864462614059448
in I-Disease 0 9.801291867006512e-08
the I-Disease 0 2.1567210239936685e-07
sterol I-Disease 0 0.0003697469655890018
27 I-Disease 0 5.0050515710609034e-05
- I-Disease 0 4.6044027840252966e-05
hydroxylase I-Disease 0 0.00011746423842851073
activity I-Disease 0 6.784437118767528e-07
, O 0 1.0296773211848631e-07
but O 0 4.956520172072487e-08
also O 0 1.606108526175376e-07
partially O 0 7.679526788706426e-06
leads O 0 2.79208535403086e-07
to O 0 6.755826564841527e-09
alternative O 0 2.2579274627787527e-07
pre O 0 4.129951776121743e-06
- O 0 6.892965984661714e-07
mRNA O 0 7.396893408895266e-08
splicing O 0 4.492904395192454e-07
of O 0 4.763248995232061e-08
the O 0 3.9843212107371073e-07
gene O 0 1.4296829249360599e-05
. O 0 3.9700935303699225e-06

To O 0 2.3450870401120483e-07
our O 0 2.809822206017998e-07
knowledge O 0 3.831337096471543e-07
, O 0 1.4599565645312396e-07
this O 0 1.5164847155801908e-08
is O 0 3.8551533521058445e-08
the O 0 5.2893071256221447e-08
first O 0 3.3381780895069824e-07
report O 0 1.1631222207597602e-07
regarding O 0 9.664790212582375e-08
effects O 0 2.407681677141227e-06
on O 0 5.869163146599021e-07
pre O 0 4.938608981319703e-06
- O 0 6.586441259059939e-07
mRNA O 0 4.23438848429214e-08
splicing O 0 4.731394369628106e-07
of O 0 2.254854081229496e-08
a O 0 3.713257683557458e-07
mutation O 0 2.103846327372594e-06
at O 0 2.4219923488999484e-06
the O 0 1.2230216839270724e-07
- O 0 4.28120029027923e-06
2 O 0 4.390756487282488e-07
position O 0 3.465169413630065e-07
of O 0 1.4463526376573554e-08
a O 0 4.90941033604031e-07
5 O 0 9.261124773729534e-07
splice O 0 4.116883792448789e-05
site O 0 6.789574399590492e-05
. O 0 6.220644536369946e-06

ATM O 0 0.004627769347280264
germline O 0 0.007431413978338242
mutations O 0 0.001223354833200574
in O 0 2.1339739760151133e-05
classical O 0 0.01217560563236475
ataxia B-Disease 1 0.9999954700469971
- I-Disease 1 0.9998093247413635
telangiectasia I-Disease 1 0.9999387264251709
patients O 0 0.005801530554890633
in O 0 1.0326900792279048e-06
the O 0 7.714324397056771e-07
Dutch O 0 4.699288183473982e-05
population O 0 4.015145975699852e-07
. O 0 2.604510882520117e-06

Germline O 0 0.0029902104288339615
mutations O 0 0.0001254310191143304
in O 0 3.145176776797598e-07
the O 0 5.825611637533257e-08
ATM O 0 9.3688413471682e-06
gene O 0 9.749353466759203e-07
are O 0 2.2587798298445705e-08
responsible O 0 1.0129750762644107e-06
for O 0 5.817194619339716e-07
the O 0 0.0009844169253483415
autosomal B-Disease 1 0.9999988079071045
recessive I-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9998903274536133
telangiectasia I-Disease 1 0.9999529123306274
( O 0 0.0004848918179050088
A B-Disease 1 0.9996914863586426
- I-Disease 1 0.9983148574829102
T I-Disease 1 0.9997280240058899
) O 0 3.7666497973987134e-06
. O 0 3.0452706596406642e-06

In O 0 1.4774817600482493e-06
our O 0 8.636650363769149e-07
study O 0 4.5706306650572515e-07
, O 0 7.762738363226163e-08
we O 0 2.4065784032245574e-08
have O 0 9.287108859723503e-09
determined O 0 5.23578798095059e-08
the O 0 4.324209257333678e-08
ATM O 0 1.2745700587402098e-05
mutation O 0 4.867072220804403e-06
spectrum O 0 3.457640332271694e-06
in O 0 1.847068489269077e-07
19 O 0 1.0873770861508092e-06
classical O 0 1.6011372281354852e-05
A B-Disease 1 0.9990283250808716
- I-Disease 1 0.9987185001373291
T I-Disease 1 0.9998511075973511
patients O 0 2.628509719215799e-05
, O 0 7.526889334030784e-08
including O 0 3.268682036150494e-08
some O 0 8.845323584694142e-09
immigrant O 0 3.365717020642478e-07
populations O 0 1.4838656170468312e-07
, O 0 2.3499827861428457e-08
as O 0 2.6974358746656435e-08
well O 0 4.407125331340467e-08
as O 0 1.0327416788413757e-07
12 O 0 1.7930970841462113e-07
of O 0 1.1113286291219993e-08
Dutch O 0 4.923344931739848e-06
ethnic O 0 4.023517305995483e-07
origin O 0 1.2010275440843543e-06
. O 0 5.885692644369556e-06

Both O 0 3.619558412992774e-07
the O 0 1.725130260865626e-07
protein O 0 8.771427815190691e-07
truncation O 0 3.262824975536205e-05
test O 0 3.1463907816942083e-06
( O 0 2.439079196392413e-07
PTT O 0 3.97252879338339e-05
) O 0 9.214119955913702e-08
and O 0 5.181524898034695e-08
the O 0 1.1753017048476977e-07
restriction O 0 1.191338014905341e-06
endonuclease O 0 2.5736697352840565e-05
fingerprinting O 0 1.0755725270428229e-05
( O 0 3.885419630478282e-07
REF O 0 0.00017008002032525837
) O 0 1.5720416968179052e-08
method O 0 1.9792009808838884e-08
were O 0 8.727959688314968e-09
used O 0 1.5195711355886488e-08
and O 0 2.9212557706159714e-08
compared O 0 1.334844199618601e-07
for O 0 5.691048965417167e-09
their O 0 7.554788794550404e-09
detection O 0 1.4073526699576178e-06
efficiency O 0 9.049593927556998e-07
, O 0 1.0245192072488862e-07
identifying O 0 4.04604293180455e-07
76 O 0 1.1339176353430958e-06
% O 0 7.120184886133529e-09
and O 0 1.4038866957832852e-08
60 O 0 6.773957750283444e-08
% O 0 6.239222472004258e-09
of O 0 6.93657886685628e-09
the O 0 2.3598785503509134e-07
mutations O 0 1.351142145722406e-05
, O 0 1.0482505103937e-06
respectively O 0 6.437140655179974e-06
. O 0 3.8011114611435914e-06

Most O 0 3.3883720789162908e-06
patients O 0 6.062663032935234e-06
were O 0 1.6653012835377012e-07
found O 0 1.3488606498412992e-07
to O 0 3.42246693207926e-08
be O 0 3.4068301602019346e-07
compound O 0 1.6377207430195995e-05
heterozygote O 0 0.00028007905348204076
. O 0 9.064745427167509e-06

Seventeen O 0 1.7643296814640053e-05
mutations O 0 1.749383045535069e-05
were O 0 1.0312615472685138e-07
distinct O 0 9.152778801535533e-08
, O 0 1.0506730774295647e-07
of O 0 2.0290329416638997e-08
which O 0 6.01298921765192e-08
10 O 0 1.1133275279462396e-07
were O 0 1.0565933905581915e-07
not O 0 1.1310626035765381e-07
reported O 0 4.663157142204e-06
previously O 0 5.17555736223585e-06
. O 0 1.9419992440816713e-06

Mutations O 0 0.0003715502971317619
are O 0 6.532213205900916e-07
small O 0 2.4034420675889123e-06
deletions O 0 7.501558138756081e-05
or O 0 1.1972117135883309e-05
point O 0 3.029079562111292e-05
mutations O 0 9.021463483804837e-05
frequently O 0 1.2397040336509235e-05
affecting O 0 7.2156672104028985e-06
splice O 0 0.00020707615476567298
sites O 0 5.145535760675557e-05
. O 0 9.872051123238634e-06

Moreover O 0 3.436378756305203e-05
, O 0 1.0476937859493773e-06
a O 0 1.5521353589065257e-06
16 O 0 8.332607649208512e-06
. O 0 2.4608862077002414e-06

7 O 0 0.00010427078086649999
- O 0 8.869407611200586e-05
kb O 0 3.917486174032092e-05
genomic O 0 1.4679868399980478e-05
deletion O 0 7.65379718359327e-06
of O 0 4.234760098142942e-08
the O 0 1.24440759918798e-07
3 O 0 5.807782486044744e-07
end O 0 4.403932507557329e-07
of O 0 1.7998020851450747e-08
the O 0 2.3983531605153985e-08
gene O 0 4.827695079256955e-07
, O 0 9.337110640217361e-08
most O 0 2.2114647890703054e-08
likely O 0 9.789409460836396e-08
a O 0 1.5680234355386347e-07
result O 0 3.3614091421441117e-07
of O 0 1.2487665124183422e-08
recombination O 0 3.9872901425042073e-07
between O 0 1.6031596317134245e-07
two O 0 6.574316557816928e-08
LINE O 0 9.03471027413616e-06
elements O 0 8.572586125410453e-07
, O 0 1.491990815338795e-06
was O 0 1.7026339264702983e-05
identified O 0 5.745120688516181e-06
. O 0 2.050827333732741e-06

The O 0 9.36875551360572e-07
most O 0 1.845677530809553e-07
frequently O 0 2.1146502149349544e-06
found O 0 7.654641080989677e-07
mutation O 0 2.574177415226586e-06
, O 0 9.663979483320873e-08
identified O 0 2.2231337482025992e-07
in O 0 3.3860345638458966e-08
three O 0 7.125581191758101e-08
unrelated O 0 5.888645773666212e-06
Turkish O 0 3.825318344752304e-05
A B-Disease 1 0.9986268281936646
- I-Disease 1 0.9865534901618958
T I-Disease 1 0.9994931221008301
individuals O 0 4.328302622980118e-07
, O 0 8.202931098821864e-07
was O 0 5.26982967130607e-06
previously O 0 6.800852361266152e-07
described O 0 2.3391389447624533e-07
to O 0 7.508675459177994e-09
be O 0 2.084528105683603e-08
a O 0 3.5050797464464267e-07
Turkish O 0 1.0865667718462646e-05
A B-Disease 1 0.9991598129272461
- I-Disease 1 0.9979812502861023
T I-Disease 1 0.9997257590293884
founder O 0 0.000498334935400635
mutation O 0 0.00041641187272034585
. O 0 1.1367737897671759e-05

The O 0 8.5240878888726e-07
presence O 0 1.7705561958791804e-06
of O 0 9.607244777498636e-08
a O 0 2.1565244878729573e-06
founder O 0 3.98281954403501e-05
mutation O 0 1.783425068424549e-05
among O 0 1.659850141777497e-07
relatively O 0 3.730731918949459e-07
small O 0 1.7810820907016023e-07
ethnic O 0 1.098718911407559e-07
population O 0 1.0238624170710864e-08
groups O 0 9.705074965893346e-09
in O 0 2.4655431474229772e-08
Western O 0 2.740296736192249e-07
Europe O 0 1.8843875295715407e-06
could O 0 3.17719923259574e-07
indicate O 0 1.4267270387335884e-07
a O 0 2.422264060442103e-07
high O 0 2.7123412564833416e-06
carrier O 0 1.1041386187571334e-06
frequency O 0 7.180220791269676e-07
in O 0 6.054453649539937e-08
such O 0 7.11554477561549e-08
communities O 0 7.339273793149914e-07
. O 0 3.5053915325988783e-06

In O 0 1.0704591659305152e-05
patients O 0 1.1827427442767657e-05
of O 0 7.60345102435167e-08
Dutch O 0 7.749992619210389e-06
ethnic O 0 1.2096921864213073e-07
origin O 0 1.7364351379001164e-07
, O 0 2.601879316443956e-07
however O 0 9.100468645328874e-08
, O 0 4.7693674787296914e-08
no O 0 6.773466765253033e-08
significant O 0 1.8064936568862322e-07
founder O 0 1.0637172636052128e-05
effect O 0 6.668784067187516e-07
could O 0 1.1643940212024972e-07
be O 0 1.307773231928877e-07
identified O 0 1.3376852621149737e-06
. O 0 1.3623565564557794e-06

The O 0 5.3560338528768625e-06
observed O 0 2.5948666007025167e-05
genetic O 0 1.1947059647354763e-05
heterogeneity O 0 9.58843702392187e-06
including O 0 9.63758353123012e-08
the O 0 1.5875450287694548e-07
relative O 0 4.279812401364325e-06
high O 0 7.63948482926935e-05
percentage O 0 1.2073990092176246e-06
of O 0 8.026098186064701e-08
splice O 0 0.0001265733881155029
- O 0 0.0003201227227691561
site O 0 2.832371501426678e-05
mutations O 0 2.215020140283741e-05
had O 0 1.8980770164489513e-06
no O 0 2.712512241487275e-07
reflection O 0 1.20721711027727e-06
on O 0 1.8980553022629465e-06
the O 0 1.8978236084876698e-06
phenotype O 0 0.00017967796884477139
. O 0 5.921160664001945e-06

All O 0 4.848230673815124e-06
patients O 0 2.5139011995634064e-05
manifested O 0 2.172075073758606e-05
classical O 0 6.81840829201974e-05
A B-Disease 1 0.9942474365234375
- I-Disease 1 0.555623471736908
T I-Disease 1 0.9981878399848938
and O 0 4.0423708469461417e-07
increased O 0 5.325192660166067e-07
cellular O 0 3.099059176747687e-05
radioresistant O 0 6.140569894341752e-05
DNA O 0 4.648309641197557e-06
synthesis O 0 9.226831025443971e-06
. O 0 5.3456442401511595e-06

Determination O 0 1.9498158508213237e-05
of O 0 2.1798142313400604e-07
the O 0 2.937868828212231e-07
genomic O 0 3.991123776359018e-06
structure O 0 3.778205609705765e-06
of O 0 8.183992861177103e-08
the O 0 3.1200639227790816e-07
COL4A4 O 0 9.419672278454527e-05
gene O 0 2.004607949857018e-06
and O 0 2.3133384274842683e-07
of O 0 2.423812190954777e-07
novel O 0 8.25831011752598e-05
mutations O 0 0.01722557656466961
causing O 1 0.5998072624206543
autosomal B-Disease 1 0.9998078942298889
recessive I-Disease 1 0.9999649524688721
Alport I-Disease 1 0.9999905824661255
syndrome I-Disease 1 0.9999958276748657
. O 0 0.0002704054058995098

Autosomal B-Disease 1 0.9994895458221436
recessive I-Disease 1 0.9999310970306396
Alport I-Disease 1 0.9999903440475464
syndrome I-Disease 1 0.9999980926513672
is O 0 0.00035991586628369987
a O 0 0.0003868321073241532
progressive O 1 0.9929561614990234
hematuric B-Disease 1 0.996759831905365
glomerulonephritis I-Disease 1 0.9999675750732422
characterized O 0 0.03491969034075737
by O 0 3.409198689041659e-05
glomerular B-Disease 1 0.9853657484054565
basement I-Disease 1 0.9748222827911377
membrane I-Disease 0 0.03902270272374153
abnormalities I-Disease 1 0.9976159334182739
and O 0 6.148285365270567e-07
associated O 0 5.90373304021341e-07
with O 0 3.1448979598280857e-07
mutations O 0 1.3629200111608952e-05
in O 0 2.4271199094982876e-07
either O 0 2.8626513426388556e-07
the O 0 3.1701409852757934e-07
COL4A3 O 0 0.0003010063956025988
or O 0 7.06266234828945e-07
the O 0 2.919524320077471e-07
COL4A4 O 0 6.24513195361942e-05
gene O 0 8.432190838902898e-07
, O 0 7.10466849795921e-08
which O 0 3.755316946296716e-09
encode O 0 1.8720264449711976e-08
the O 0 2.456835943576152e-07
alpha3 O 0 0.00012692510790657252
and O 0 1.160307533609739e-06
alpha4 O 0 0.00048331829020753503
type O 0 0.0003031681408174336
IV O 1 0.8392797708511353
collagen O 0 0.0036087604239583015
chains O 0 0.0007604002603329718
, O 0 2.833398866641801e-06
respectively O 0 1.4050316167413257e-05
. O 0 4.339662154961843e-06

To O 0 2.3175340402303846e-07
date O 0 2.5070999072340783e-06
, O 0 1.6402401570303482e-07
mutation O 0 1.0896422963924124e-06
screening O 0 1.9857392885569425e-07
in O 0 1.734931487362701e-08
the O 0 1.874598964946017e-08
two O 0 4.242399853637835e-08
genes O 0 6.169547646095452e-07
has O 0 4.285569161766034e-07
been O 0 4.3534183191695774e-07
hampered O 0 1.7729671526467428e-05
by O 0 4.686173937784588e-08
the O 0 9.531372313631437e-08
lack O 0 4.2446905013093783e-07
of O 0 7.181248662391226e-08
genomic O 0 5.077166861156002e-06
structure O 0 1.1116782843600959e-05
information O 0 1.8113513533535297e-06
. O 0 5.397248969529755e-06

We O 0 8.579394489061087e-06
report O 0 7.58925807531341e-07
here O 0 4.984145363096104e-08
the O 0 1.0531685745718278e-08
complete O 0 1.3885360772292188e-07
characterization O 0 9.640936013965984e-07
of O 0 2.7587926609839997e-08
the O 0 1.7724606493629835e-07
48 O 0 1.0892100590353948e-06
exons O 0 3.964678853662917e-06
of O 0 8.619981173296765e-08
the O 0 6.112284154369263e-07
COL4A4 O 0 9.930147643899545e-05
gene O 0 8.552335089007101e-07
, O 0 7.10668786041424e-08
a O 0 5.934010971486714e-08
comprehensive O 0 2.4322247327290825e-07
gene O 0 2.0197589378767589e-07
screen O 0 3.6150088362774113e-06
, O 0 1.6910438205286482e-07
and O 0 2.014237665548535e-08
the O 0 1.0764546587438417e-08
subsequent O 0 1.659900732420283e-07
detection O 0 1.5863448652453371e-06
of O 0 7.687182090876377e-08
10 O 0 3.9211624880408635e-07
novel O 0 9.514622547612817e-07
mutations O 0 6.799699349357979e-06
in O 0 4.609779011843784e-07
eight O 0 9.101559044211172e-06
patients O 0 0.00036629365058615804
diagnosed O 1 0.9994732737541199
with O 0 0.00039888484752736986
autosomal B-Disease 1 0.9998961687088013
recessive I-Disease 1 0.9999756813049316
Alport I-Disease 1 0.999993085861206
syndrome I-Disease 1 0.999995231628418
. O 0 0.0004911792348138988

Furthermore O 0 1.0214816029474605e-05
, O 0 4.334019081397855e-07
we O 0 9.966221625745675e-08
identified O 0 2.5233745759578596e-07
a O 0 1.1202396876797138e-07
glycine O 0 1.8960326997330412e-06
to O 0 3.8576025929160096e-08
alanine O 0 5.0941903282364365e-06
substitution O 0 2.531210441247822e-07
in O 0 1.1343087180648581e-07
the O 0 1.1278033440476065e-07
collagenous O 0 0.00017353934526909143
domain O 0 8.963316417975875e-07
that O 0 4.7856872242846293e-08
is O 0 1.1160340562810234e-07
apparently O 0 1.1492307976368465e-06
silent O 0 7.853035640437156e-06
in O 0 1.0318537135844963e-07
the O 0 6.77296299045338e-08
heterozygous O 0 3.1301016178986174e-07
carriers O 0 7.400216190944775e-07
, O 0 1.3014404487421416e-07
in O 0 2.6212657644464343e-07
11 O 0 3.650818371170317e-06
. O 0 1.4594221511288197e-06

5 O 0 3.0302585400932003e-06
% O 0 1.9963531272537693e-08
of O 0 4.874845860314281e-09
all O 0 1.3185175617991263e-08
control O 0 7.657985747755447e-07
individuals O 0 3.0448763510548815e-08
, O 0 7.942431778928949e-08
and O 0 6.217793924179205e-08
in O 0 6.55867395948917e-08
one O 0 4.241493911649741e-08
control O 0 3.3606463034629996e-07
individual O 0 2.848511293507272e-08
homozygous O 0 5.536921889870428e-07
for O 0 1.713437391970274e-08
this O 0 4.3603527899449546e-08
glycine O 0 8.938195605878718e-06
substitution O 0 3.239367970309104e-06
. O 0 4.427161911735311e-06

There O 0 2.051787760137813e-06
has O 0 7.145996505641961e-07
been O 0 2.4782124796729477e-07
no O 0 8.966524944753473e-08
previous O 0 1.7146788877653307e-07
finding O 0 1.2785098135736916e-07
of O 0 1.1793871657062027e-08
a O 0 2.4067765025392873e-07
glycine O 0 3.724627958945348e-06
substitution O 0 1.854287177138758e-07
that O 0 1.5716967283196936e-08
is O 0 6.389669238160423e-08
not O 0 1.9538267892471595e-08
associated O 0 2.223472819196104e-07
with O 0 4.606908632354134e-08
any O 0 2.3574041563279025e-07
obvious O 0 7.103473762981594e-06
phenotype O 0 1.9800672816927545e-05
in O 0 4.53970045555252e-07
homozygous O 0 9.529728231427725e-06
individuals O 0 4.929368060402339e-07
. O 0 3.3761018585209968e-06

Founder O 0 0.0005315403686836362
BRCA1 O 0 0.0008781322976574302
and O 0 7.8880439104978e-06
BRCA2 O 0 0.0005032307235524058
mutations O 0 7.230547635117546e-05
in O 0 1.7828982663559145e-06
French O 0 0.00023617767146788538
Canadian O 0 0.002691197209060192
breast B-Disease 1 0.9994902610778809
and I-Disease 1 0.9936984777450562
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999949932098389
families O 0 5.603553745459067e-06
. O 0 7.008661668805871e-06

We O 0 9.971885219783871e-07
have O 0 5.733674868224625e-08
identified O 0 2.3674478200064186e-07
four O 0 2.8947322761041505e-08
mutations O 0 7.973591209520237e-07
in O 0 2.992711145566318e-08
each O 0 9.519196098040084e-09
of O 0 1.2621478617802495e-07
the O 0 3.433555320953019e-05
breast B-Disease 1 0.9991328120231628
cancer I-Disease 1 0.9979896545410156
- O 0 0.0002123610465787351
susceptibility O 0 2.2256834199652076e-05
genes O 0 1.3641415534948464e-06
, O 0 3.9647324001634843e-07
BRCA1 O 0 1.6572481399634853e-05
and O 0 6.351133947646304e-07
BRCA2 O 0 5.693027196684852e-05
, O 0 8.137147347042628e-07
in O 0 8.501195338794787e-07
French O 0 0.0005453756893984973
Canadian O 0 0.004605845548212528
breast B-Disease 1 0.9993046522140503
cancer I-Disease 1 0.9995542168617249
and O 0 0.0024312252644449472
breast B-Disease 1 0.9999170303344727
/ I-Disease 1 0.9999167919158936
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999948740005493
families O 0 2.2832589365862077e-06
from O 0 4.846386218559928e-06
Quebec O 0 0.0017399621428921819
. O 0 1.0826486686710268e-05

To O 0 1.6261831206065835e-06
identify O 0 1.040394272422418e-05
founder O 0 8.672777039464563e-05
effects O 0 2.6470643206266686e-05
, O 0 6.312108666861604e-07
we O 0 3.750609209873801e-07
examined O 0 5.494773631653516e-06
independently O 0 1.4899405869073234e-06
ascertained O 0 3.0876781238475814e-05
French O 0 0.0001285212638322264
Canadian O 0 0.0002733127912506461
cancer B-Disease 0 0.48298341035842896
families O 0 2.1691670681889264e-08
for O 0 6.017714326844725e-09
the O 0 7.428702542000565e-09
distribution O 0 2.950412891777887e-08
of O 0 1.269707361473138e-08
these O 0 3.4385895020250246e-08
eight O 0 2.3621962554898346e-06
mutations O 0 7.647079473827034e-05
. O 0 5.547838554775808e-06

Mutations O 0 0.00015207288379315287
were O 0 6.10484448770876e-07
found O 0 3.3224566209355544e-07
in O 0 5.931499202915802e-08
41 O 0 1.0627696838128031e-06
of O 0 6.480792080765241e-08
97 O 0 7.847577762731817e-06
families O 0 7.952783107612049e-07
. O 0 6.709306489938172e-06

Six O 0 2.2473525405075634e-06
of O 0 1.6026872629026911e-07
eight O 0 7.102568133632303e-07
mutations O 0 6.551986643898999e-06
were O 0 2.912211130023934e-07
observed O 0 1.959292376341182e-06
at O 0 9.55646737565985e-06
least O 0 4.907397510578448e-07
twice O 0 2.5933526558219455e-05
. O 0 2.433011786706629e-06

The O 0 2.0709843738586642e-05
BRCA1 O 0 0.001130158663727343
C4446T O 0 0.00020531556219793856
mutation O 0 5.3576790378428996e-05
was O 0 3.523879513522843e-06
the O 0 4.9728452466979434e-08
most O 0 7.375240329565713e-08
common O 0 1.4944373560865643e-06
mutation O 0 1.2004391464870423e-05
found O 0 9.914137990563177e-07
, O 0 1.7490897619154566e-07
followed O 0 3.5968918155049323e-07
by O 0 9.094100761330992e-08
the O 0 2.73928276328661e-06
BRCA2 O 0 0.0010160990059375763
8765delAG O 0 0.00209075422026217
mutation O 0 0.0006637415499426425
. O 0 2.0061181203345768e-05

Together O 0 1.8389954448139179e-06
, O 0 1.5441347045452858e-07
these O 0 7.943685709221882e-09
mutations O 0 1.1220718079130165e-06
were O 0 7.846740857075929e-08
found O 0 6.041671696266349e-08
in O 0 3.0016749974492996e-08
28 O 0 1.807639620210466e-07
of O 0 6.5435896701160345e-09
41 O 0 3.4487840139263426e-07
families O 0 6.2590554961161615e-09
identified O 0 6.487841375246717e-08
to O 0 1.0233099700940329e-08
have O 0 4.406091846931304e-08
a O 0 3.243955688958522e-06
mutation O 0 6.450406363001093e-05
. O 0 2.642959088916541e-06

The O 0 4.89023250338505e-06
odds O 0 0.00013808872608933598
of O 0 8.626987835214095e-08
detection O 0 8.918475032260176e-06
of O 0 5.331798647034702e-08
any O 0 6.28925107548639e-08
of O 0 2.386948594335081e-08
the O 0 1.4132770331798383e-07
four O 0 6.529353981932218e-07
BRCA1 O 0 0.00013550759467761964
mutations O 0 8.418817014899105e-05
was O 0 8.100199920590967e-05
18 O 0 5.1687452469195705e-06
. O 0 1.408523417012475e-06

7x O 0 0.0037603299133479595
greater O 0 1.025077722260903e-06
if O 0 7.3624920560178e-07
one O 0 5.792703916540631e-08
or O 0 1.5784479501235182e-07
more O 0 4.915978735198223e-08
cases O 0 3.1140759801928652e-06
of O 0 0.00011070297477999702
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999973773956299
were O 0 6.643241476922412e-07
also O 0 1.234636215485807e-07
present O 0 3.786902524893776e-08
in O 0 4.792639174411306e-08
the O 0 2.0677350676123751e-07
family O 0 1.2739672456518747e-05
. O 0 5.856108600710286e-06

The O 0 4.5349634092417546e-06
odds O 0 0.00013805950584355742
of O 0 2.5617509891162626e-07
detection O 0 1.0387595466454513e-05
of O 0 5.16033971109664e-08
any O 0 4.666461705937763e-08
of O 0 2.4343099980228544e-08
the O 0 2.2912462327440153e-07
four O 0 2.2831304704595823e-06
BRCA2 O 0 0.0001601093536010012
mutations O 0 8.692300616530702e-05
was O 0 7.75693915784359e-05
5 O 0 7.751072189421393e-06
. O 0 2.1059120172139956e-06

3x O 0 0.0006612535798922181
greater O 0 1.0664216461009346e-06
if O 0 3.879177370436082e-07
there O 0 4.559772293077913e-08
were O 0 3.999895881179327e-08
at O 0 9.72942984844849e-07
least O 0 3.6297969074894354e-08
five O 0 1.0093225455420907e-07
cases O 0 6.677936426058295e-07
of O 0 2.0650011265388457e-06
breast B-Disease 1 0.9995672106742859
cancer I-Disease 1 0.9969267249107361
in O 0 6.689383553748485e-07
the O 0 1.102749479287013e-06
family O 0 1.8197721146862023e-05
. O 0 7.006563464528881e-06

Interestingly O 0 4.35948750237003e-05
, O 0 3.644719868134416e-07
the O 0 6.86888341761005e-08
presence O 0 4.802934086001187e-07
of O 0 1.9264551553987985e-07
a O 0 6.45323671051301e-05
breast B-Disease 1 0.997856080532074
cancer I-Disease 1 0.8224859833717346
case O 0 2.838867885657237e-06
< O 0 9.46657655731542e-06
36 O 0 5.963005378362141e-07
years O 0 1.1399315269500221e-07
of O 0 1.1068818750459286e-08
age O 0 8.784243732407049e-07
was O 0 1.435211515854462e-06
strongly O 0 1.6747139852668624e-07
predictive O 0 1.905293629533844e-07
of O 0 1.0424684226961745e-08
the O 0 3.8832407511790734e-08
presence O 0 1.7053278611456335e-07
of O 0 9.819550506051655e-09
any O 0 2.5774289369451253e-08
of O 0 4.2928174792677964e-08
the O 0 2.1121458360084944e-07
eight O 0 2.037335661952966e-06
mutations O 0 2.9943874324089848e-05
screened O 0 4.106328196940012e-05
. O 0 4.221762083034264e-06

Carriers O 0 2.0080724425497465e-05
of O 0 8.494032499584137e-08
the O 0 1.4456361441261834e-07
same O 0 3.249753888212581e-07
mutation O 0 3.963968083553482e-06
, O 0 4.608543591189118e-08
from O 0 7.048569727885479e-09
different O 0 2.849379399094687e-09
families O 0 2.3815097449642053e-08
, O 0 4.155839405939332e-08
shared O 0 7.538153568020789e-08
similar O 0 1.8685702229959134e-07
haplotypes O 0 7.226085472211707e-06
, O 0 2.6334032554586884e-07
indicating O 0 4.1844259612844326e-07
that O 0 3.5036133994026386e-09
the O 0 7.644541888396361e-09
mutant O 0 5.978624244562525e-07
alleles O 0 2.520313273635111e-07
were O 0 9.957728508425134e-08
likely O 0 4.6183195934190735e-08
to O 0 4.741500525540232e-09
be O 0 1.3518826946778972e-08
identical O 0 2.4154542188625783e-07
by O 0 2.1906672031946073e-08
descent O 0 3.683541933696688e-07
for O 0 1.6012139170129558e-08
a O 0 7.235377097458695e-07
mutation O 0 2.282090008520754e-06
in O 0 2.0749097018324392e-07
the O 0 3.7013251130701974e-07
founder O 0 1.786442953743972e-05
population O 0 2.1938370764473802e-07
. O 0 1.7145052879641298e-06

The O 0 6.247501005418599e-07
identification O 0 6.85395093569241e-07
of O 0 1.9318936494983063e-07
common O 0 2.2068812540965155e-05
BRCA1 O 0 0.0005199393490329385
and O 0 4.837695996684488e-06
BRCA2 O 0 0.00017859370564110577
mutations O 0 1.262718524230877e-05
will O 0 7.004720714576251e-08
facilitate O 0 1.8242059240947128e-07
carrier O 0 1.522105867479695e-05
detection O 0 1.2899005014332943e-05
in O 0 1.0530891358939698e-06
French O 0 0.000345186039339751
Canadian O 0 0.0032911859452724457
breast B-Disease 1 0.9990399479866028
cancer I-Disease 1 0.9994163513183594
and O 0 0.005113981198519468
breast B-Disease 1 0.9999134540557861
/ I-Disease 1 0.99992835521698
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999921321868896
families O 0 8.145049832819495e-06
. O 0 9.633642548578791e-06

Are O 0 2.2330000319925603e-06
Dp71 O 0 0.0004163171979598701
and O 0 5.731286364607513e-06
Dp140 O 0 0.0004555305640678853
brain O 0 0.0023939483799040318
dystrophin O 0 0.00015004741726443172
isoforms O 0 3.026992089871783e-06
related O 0 4.5058168325340375e-06
to O 0 7.705236271249305e-07
cognitive B-Disease 0 0.001185156754218042
impairment I-Disease 1 0.9387868642807007
in O 0 0.0008957179961726069
Duchenne B-Disease 1 0.9999575614929199
muscular I-Disease 1 0.9999033212661743
dystrophy I-Disease 1 0.999840259552002
? O 0 0.020241551101207733

Molecular O 0 0.00016961262736003846
study O 0 2.919543248935952e-06
and O 0 2.572640767084522e-07
neuropsychological O 0 2.2358268324751407e-05
analysis O 0 1.816893160366817e-07
were O 0 9.007595735965879e-08
performed O 0 1.2558555226860335e-06
concurrently O 0 8.515686431564973e-07
on O 0 1.793389401427703e-06
49 O 0 2.2607062419410795e-05
patients O 0 2.7678992410073988e-05
with O 0 0.00014136580284684896
Duchenne B-Disease 1 0.9999638795852661
muscular I-Disease 1 0.9999328851699829
dystrophy I-Disease 1 0.9998493194580078
( O 0 3.230513902963139e-05
DMD B-Disease 1 0.9991374015808105
) O 0 2.755601258286333e-07
in O 0 4.087945981723351e-08
order O 0 1.6564433380494847e-08
to O 0 2.5446609264179187e-09
find O 0 1.791958048613651e-08
a O 0 8.80523174373593e-08
molecular O 0 1.6182559647859307e-06
explanation O 0 1.482567029142956e-07
for O 0 3.62998378022894e-08
the O 0 9.30897670059494e-07
cognitive B-Disease 0 0.00010299461428076029
impairment I-Disease 0 0.000688221596647054
observed O 0 7.52760206523817e-06
in O 0 9.829755072132684e-07
most O 0 5.364908702176763e-06
DMD B-Disease 1 0.9997711777687073
patients O 0 0.0009834085358306766
. O 0 1.1404471479181666e-05

Complete O 0 4.996113148081349e-06
analysis O 0 4.5853306573917507e-07
of O 0 2.8751433234219803e-08
the O 0 2.697369723136944e-07
dystrophin O 0 5.337402762961574e-05
gene O 0 3.941332124668406e-06
was O 0 8.74896431923844e-06
performed O 0 7.359262781392317e-07
to O 0 1.3021823619396855e-08
define O 0 2.8228240012140304e-07
the O 0 7.917897448805888e-08
localization O 0 5.635688012262108e-06
of O 0 1.927403445733944e-07
deletions O 0 1.0164519153477158e-05
and O 0 4.408819904710981e-07
duplications O 0 1.938873901963234e-05
in O 0 3.0143030471663224e-07
relation O 0 6.193694161993335e-07
to O 0 9.752471186175171e-08
the O 0 4.100257058325951e-07
different O 0 1.6424502291556564e-06
DMD B-Disease 1 0.9990647435188293
promoters O 0 0.0022939140908420086
. O 0 2.0723813577205874e-05

Qualitative O 0 9.987084013118874e-06
analysis O 0 8.374649382858479e-07
of O 0 8.883402813353314e-08
the O 0 2.1859095511445048e-07
Dp71 O 0 5.76096645090729e-05
transcript O 0 8.414722287852783e-06
and O 0 1.597733643166066e-07
testing O 0 1.614160822782651e-07
for O 0 1.5761629779120767e-09
the O 0 4.7022696847420775e-09
specific O 0 6.848890787836126e-09
first O 0 1.5074559200911608e-07
exon O 0 5.062749096396146e-06
of O 0 6.66170336671712e-08
Dp140 O 0 1.0880288755288348e-05
were O 0 3.667858834432991e-07
also O 0 2.4627050265735306e-07
carried O 0 7.039603815428563e-07
out O 0 7.896509828242415e-07
. O 0 2.0808636236324674e-06

Neuropsychological O 0 0.0018500101286917925
analysis O 0 9.703903742774855e-06
assessed O 0 3.312398257548921e-05
verbal O 0 2.9096063371980563e-05
and O 0 1.6979925021587405e-06
visuospatial O 0 0.0005147330812178552
intelligence O 0 3.675976040540263e-05
, O 0 1.3584190128312912e-06
verbal O 0 2.8236929210834205e-05
memory O 0 0.0002537518157623708
, O 0 2.028702056122711e-06
and O 0 1.0940301535811159e-06
reading O 0 1.6601887182332575e-05
skills O 0 7.048276893328875e-05
. O 0 2.1726160412072204e-05

Comparison O 0 8.579598215874285e-06
of O 0 2.508472221052216e-07
molecular O 0 5.416179556050338e-05
and O 0 2.287770939801703e-06
psychometric O 0 0.0001785569329513237
findings O 0 4.110168447368778e-06
demonstrated O 0 1.2696609701379202e-06
that O 0 3.4836777018654175e-08
deletions O 0 3.9168749026430305e-06
and O 0 2.6946852926812426e-07
duplications O 0 1.8968186850543134e-05
that O 0 7.478092811652459e-08
were O 0 8.939510109939874e-08
localized O 0 6.919917723280378e-06
in O 0 2.281234117162967e-07
the O 0 2.1006795236644393e-07
distal O 0 0.00010564282274572179
part O 0 6.618641918976209e-07
of O 0 5.607578046351591e-08
the O 0 1.9606368084623682e-07
gene O 0 1.2168849252702785e-06
seemed O 0 3.031527512575849e-06
to O 0 2.37098127797708e-08
be O 0 5.8329721497329956e-08
preferentially O 0 9.25488222947024e-07
associated O 0 1.1671751281028264e-06
with O 0 1.702061808828148e-06
cognitive B-Disease 0 0.0017489107558503747
impairment I-Disease 0 0.23217462003231049
. O 0 1.8258111595059745e-05

Two O 0 2.577252644186956e-06
altered O 0 4.358614387456328e-05
Dp71 O 0 0.00011510841432027519
transcripts O 0 4.359880676929606e-06
and O 0 7.678199409610897e-08
two O 0 3.470599096999649e-08
deleted O 0 1.2560759614643757e-06
Dp140 O 0 3.499673084661481e-06
DNA O 0 2.2013043121660303e-07
sequences O 0 3.304236173562458e-08
were O 0 1.891869239045718e-08
found O 0 4.975425937914224e-08
in O 0 3.080345223338554e-08
four O 0 5.483155405272555e-07
patients O 0 1.089256056729937e-05
with O 0 2.3928390874061733e-05
severe O 1 0.9995530247688293
cerebral B-Disease 1 0.9999343156814575
dysfunction I-Disease 1 0.9989964365959167
. O 0 5.65516238566488e-05

These O 0 4.027359921110474e-07
findings O 0 2.4486751044605626e-06
suggest O 0 2.46273799575647e-07
that O 0 2.8092517201372402e-09
some O 0 1.284298778436721e-09
sequences O 0 2.1925481874518482e-08
located O 0 3.345246568642324e-07
in O 0 5.788903933989786e-08
the O 0 3.945935844740234e-08
distal O 0 1.5184060430328827e-05
part O 0 1.7023008069827483e-07
of O 0 2.344520844133058e-08
the O 0 3.419609129196033e-08
gene O 0 3.734554923084943e-07
and O 0 2.371547225266113e-07
, O 0 9.778715792663206e-08
in O 0 5.429145488733411e-08
particular O 0 8.531881690032606e-08
, O 0 1.458436997836543e-07
some O 0 9.733237504860881e-08
DMD B-Disease 0 0.3515996038913727
isoforms O 0 1.8498180907045025e-06
expressed O 0 4.901429520032252e-07
in O 0 2.6077617576447665e-07
the O 0 1.047698788170237e-06
brain O 0 0.011494390666484833
may O 0 9.08548997813341e-07
be O 0 2.2422151246814792e-08
related O 0 9.295531100406151e-08
to O 0 3.8757526965582656e-08
the O 0 1.2534768529803841e-06
cognitive B-Disease 0 0.0002866214490495622
impairment I-Disease 0 0.005127886775881052
associated O 0 3.3015683584380895e-05
with O 0 3.4452645195415244e-05
DMD B-Disease 1 0.9997276663780212
. O 0 9.086035788641311e-06
. O 0 8.086368325166404e-06

I1307K O 0 0.0037746152374893427
APC O 0 0.0007002087659202516
and O 0 4.112951955903554e-06
hMLH1 O 0 0.00019423238700255752
mutations O 0 5.418194268713705e-05
in O 0 4.867536631536495e-07
a O 0 9.494661981079844e-07
non O 0 8.36001072457293e-06
- O 0 3.243194805691019e-05
Jewish O 0 2.9182263006077847e-06
family O 0 4.176829406787874e-06
with O 0 1.0707113688113168e-05
hereditary B-Disease 1 0.9996579885482788
non I-Disease 1 0.9996063113212585
- I-Disease 1 0.9999831914901733
polyposis I-Disease 1 0.9999836683273315
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
. O 0 0.00010751100489869714

We O 0 4.075943706993712e-06
describe O 0 4.165282007306814e-06
a O 0 5.757275175710674e-06
French O 0 0.00022472639102488756
Canadian O 0 0.0006217609625309706
hereditary B-Disease 1 0.9994578957557678
non I-Disease 1 0.9996070265769958
- I-Disease 1 0.9999792575836182
polyposis I-Disease 1 0.9999823570251465
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 0.0001626884622965008
HNPCC B-Disease 1 0.9699381589889526
) O 0 1.455319420529122e-06
kindred O 0 7.897670730017126e-05
which O 0 1.822018731445496e-07
carries O 0 6.653614263996133e-07
a O 0 6.515657560157706e-07
novel O 0 4.090382844879059e-06
truncating O 0 0.0001673089136602357
mutation O 0 0.00010396161815151572
in O 0 4.8375254664279055e-06
hMLH1 O 0 0.0007787621580064297
. O 0 1.3880194273951929e-05

Interestingly O 0 6.618455518037081e-05
, O 0 1.425819959877117e-06
the O 0 7.297579145415511e-07
I1307K O 0 6.540642061736435e-05
APC O 0 4.687735781772062e-05
polymorphism O 0 5.708560820494313e-06
, O 0 2.3447852015578974e-07
associated O 0 1.236904978441089e-07
with O 0 3.4685609051621213e-08
an O 0 2.557771949796006e-07
increased O 0 3.3265130241488805e-06
risk O 0 0.0007840963662602007
of O 0 0.0029153074137866497
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
, O 0 3.1359388685814338e-06
is O 0 1.2642463786960434e-07
also O 0 4.3608931576955e-08
present O 0 3.642474766252235e-08
in O 0 5.420505644337936e-08
this O 0 5.881883424763146e-08
family O 0 5.151791810931172e-06
. O 0 3.4344584491918795e-06

The O 0 3.999265572929289e-06
I1307K O 0 7.746796472929418e-05
polymorphism O 0 1.452088872611057e-05
has O 0 4.3408527972133015e-07
previously O 0 3.149541214497731e-07
only O 0 1.141486727362917e-08
been O 0 6.762572013485624e-08
identified O 0 6.458666490516407e-08
in O 0 2.2921415876453466e-08
individuals O 0 9.414935497886745e-09
of O 0 1.1637590091595484e-07
self O 0 0.0001504649262642488
- O 0 0.03483109176158905
reported O 0 6.881154695292935e-05
Ashkenazi O 0 8.62081433297135e-05
Jewish O 0 6.065404704713728e-06
origins O 0 1.562890611239709e-05
. O 0 1.2750806490657851e-05

In O 0 5.372170903683582e-07
addition O 0 2.0070918083092693e-07
, O 0 7.4942278160961e-08
in O 0 3.130567094444814e-08
this O 0 1.20815482063108e-08
family O 0 3.065458713535918e-07
, O 0 6.9745773600971e-08
there O 0 2.1043744524718022e-08
appears O 0 1.383059355930527e-07
to O 0 5.619256171485176e-09
be O 0 2.7670768787402267e-08
no O 0 5.7566431621580705e-08
relationship O 0 2.478287797202938e-07
between O 0 1.156995352857848e-07
the O 0 1.9341001689099357e-07
I1307K O 0 8.630363481643144e-06
polymorphism O 0 1.4870050790705136e-06
and O 0 9.507549947329608e-08
the O 0 5.6149843885577866e-08
presence O 0 3.0476306278615084e-07
or O 0 1.5938938986437279e-06
absence O 0 1.1078260286012664e-05
of O 0 4.368946065369528e-06
cancer B-Disease 1 0.9956592321395874
. O 0 1.0382606205894263e-06
. O 0 3.41135364578804e-06

Identification O 0 2.6704638003138825e-06
of O 0 1.9696305741945253e-07
a O 0 1.6113659739858122e-06
novel O 0 3.2078905860544182e-06
mutation O 0 6.637518254137831e-06
of O 0 4.324572344671651e-08
the O 0 1.5689569465848763e-07
CPO O 0 2.1832103811902925e-05
gene O 0 6.068976290407591e-07
in O 0 1.5141874598612048e-07
a O 0 1.102723331314337e-06
Japanese O 0 2.593904355308041e-05
hereditary B-Disease 1 0.9938430786132812
coproporphyria I-Disease 0 0.38524284958839417
family O 0 0.00022756480029784143
. O 0 1.6945539755397476e-05

Hereditary B-Disease 1 0.9974871873855591
coproporphyria I-Disease 1 0.6021531820297241
( O 0 2.3653368771192618e-05
HCP B-Disease 0 0.026354415342211723
) O 0 1.1316275276840315e-06
is O 0 6.712633080496744e-07
an O 0 1.5525691878792713e-06
autosomal B-Disease 1 0.9992203712463379
dominant I-Disease 1 0.9993950128555298
disease I-Disease 1 0.9998633861541748
characterized O 0 0.0013719707494601607
by O 0 2.921723989857128e-06
a O 0 0.00020326199592091143
deficiency B-Disease 1 0.998943030834198
of I-Disease 0 8.953363135333348e-07
coproporphyrinogen I-Disease 0 0.0012985646026208997
oxidase I-Disease 0 8.33278099889867e-05
( O 0 1.1067045306845102e-06
CPO O 0 4.994090340915136e-05
) O 0 2.0464790395635646e-07
caused O 0 1.3324446399565204e-06
by O 0 3.536574411100446e-08
a O 0 6.410531909750716e-07
mutation O 0 3.026036438313895e-06
in O 0 1.2416987260621681e-07
the O 0 4.79281311527302e-07
CPO O 0 8.846432319842279e-05
gene O 0 2.1008005205658264e-05
. O 0 5.503216925717425e-06

Only O 0 1.5922089460218558e-06
11 O 0 1.756566462063347e-06
mutations O 0 1.5929637129374896e-06
of O 0 1.1693590096228945e-08
the O 0 3.5407520471153475e-08
gene O 0 2.0428092284419108e-07
have O 0 6.016293241373205e-08
been O 0 5.540418896998744e-07
reported O 0 5.460786269395612e-06
in O 0 1.5656969480914995e-06
HCP B-Disease 0 0.4569467604160309
patients O 0 0.0002169189101550728
. O 0 6.076242698327405e-06

We O 0 4.891995558864437e-06
report O 0 5.590580940406653e-07
another O 0 1.9001439000021492e-07
mutation O 0 1.394856553815771e-06
in O 0 9.092643438179948e-08
a O 0 5.306658295012312e-07
Japanese O 0 5.907827016926603e-06
family O 0 1.1358809388184454e-05
. O 0 6.726803349010879e-06

Polymerase O 0 0.00019873410928994417
chain O 0 0.00020293256966397166
reaction O 0 1.91651070053922e-05
- O 0 1.7632228264119476e-05
single O 0 1.2932169966006768e-06
strand O 0 7.478744009858929e-06
conformational O 0 3.4788351968018105e-06
polymorphism O 0 9.455391705159855e-07
and O 0 1.2668310844787811e-08
direct O 0 1.125913673405421e-08
sequence O 0 2.4634707074255857e-07
analyses O 0 4.0330945694222464e-07
demonstrated O 0 2.0304156578276888e-07
a O 0 2.997144292748999e-07
C O 0 4.695779352914542e-06
to O 0 6.582271794286498e-08
T O 0 1.7179314454551786e-05
substitution O 0 8.028440845464502e-08
in O 0 5.768183442000918e-08
exon O 0 2.025255298576667e-06
1 O 0 2.2178205938416795e-07
of O 0 1.1647422581972933e-08
the O 0 1.053112725912797e-07
CPO O 0 1.671968675509561e-05
gene O 0 1.1015807785952347e-06
at O 0 2.1929597551206825e-06
nucleotide O 0 1.3128207001500414e-06
position O 0 3.6796416225115536e-06
85 O 0 2.2520532638736768e-06
, O 0 1.7728766010804975e-07
which O 0 1.0285526030884284e-07
lies O 0 1.356694497189892e-06
in O 0 1.1157297308272973e-07
the O 0 1.334467469860101e-07
putative O 0 1.1208054274902679e-05
presequence O 0 2.5144239771179855e-05
for O 0 2.015037026126265e-08
targeting O 0 4.4107460439590795e-07
to O 0 1.1165280255909238e-07
mitochondria O 0 4.663071013055742e-05
. O 0 8.635878657514695e-06

This O 0 1.7920318668984692e-06
mutation O 0 1.6822494217194617e-05
changes O 0 5.742451776313828e-07
the O 0 8.146739105541201e-08
codon O 0 9.111425924857031e-07
for O 0 1.0781169734741525e-08
glutamine O 0 6.682828939119645e-07
to O 0 2.1554290796643727e-08
a O 0 6.463768045250617e-07
termination O 0 1.612236701475922e-05
codon O 0 6.494678473245585e-06
at O 0 2.620403847686248e-06
amino O 0 8.611393127466727e-07
acid O 0 5.59618911211146e-06
position O 0 4.504905973590212e-06
29 O 0 2.0563600628520362e-05
. O 0 1.5207967862806981e-06

MaeI O 0 0.0012892595259472728
restriction O 0 4.837419510295149e-06
analysis O 0 4.220334801630088e-07
showed O 0 5.27779889125668e-07
two O 0 1.4080808519167931e-08
other O 0 2.0532011646423598e-08
carriers O 0 4.474299828416406e-07
in O 0 2.3427868711678457e-07
the O 0 3.45089631537121e-07
family O 0 9.386495548824314e-06
. O 0 4.987748525309144e-06

The O 0 2.9158865800127387e-05
C O 0 0.002950815251097083
- O 0 0.008687288500368595
T O 0 0.014020266011357307
mutation O 0 1.977184001589194e-05
is O 0 1.722807212445332e-07
located O 0 2.487057884081878e-07
within O 0 7.467944129757598e-08
a O 0 7.82526171860809e-07
recently O 0 6.5918225118366536e-06
proposed O 0 1.519254396953329e-06
putative O 0 7.1564431891602e-06
alternative O 0 8.818986430014775e-07
translation O 0 1.419565251126187e-06
initiation O 0 7.060695224936353e-06
codon O 0 1.5777597582200542e-05
( O 0 7.139456670302025e-07
TIC O 0 0.00012301253445912153
- O 0 8.984816304291598e-06
1 O 0 7.299026947293896e-07
) O 0 3.0493104929973924e-08
, O 0 3.29976472812632e-08
supporting O 0 1.597322238922061e-07
that O 0 1.2903080914838938e-07
TIC O 0 0.00023537313973065466
- O 0 1.258028260053834e-05
1 O 0 8.965179745246132e-07
is O 0 1.6655999957038148e-07
the O 0 9.692148950080082e-08
real O 0 5.767705260950606e-06
TIC O 0 0.00014560228737536818
rather O 0 3.5330691616763943e-07
than O 0 5.522219908016268e-07
TIC O 0 0.0004283905145712197
- O 0 2.9815224479534663e-05
2 O 0 2.3364466414932394e-06
. O 0 2.735377506724035e-07
. O 0 8.689699484420998e-07

Human B-Disease 0 3.422786176088266e-05
complement I-Disease 0 8.484274439979345e-05
factor I-Disease 0 0.0025367853231728077
H I-Disease 1 0.9999834299087524
deficiency I-Disease 1 0.9999088048934937
associated O 0 0.004455087706446648
with O 0 0.21515268087387085
hemolytic B-Disease 1 0.9999984502792358
uremic I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999961853027344
. O 0 0.00028364206082187593

This O 0 3.8642676258859865e-07
study O 0 3.8929491097405844e-07
reports O 0 1.5779376383306953e-07
on O 0 3.570211504211329e-07
six O 0 9.932743978424696e-07
cases O 0 2.312033757334575e-06
of O 0 2.4901837605284527e-06
deficiency B-Disease 1 0.9992863535881042
in I-Disease 0 3.2071852729131933e-07
the I-Disease 0 1.0837934638630031e-07
human I-Disease 0 2.6143902687181253e-07
complement I-Disease 0 4.5300816964299884e-07
regulatory I-Disease 0 7.250322141771903e-06
protein I-Disease 0 4.119629466003971e-06
Factor I-Disease 0 7.146710686356528e-06
H I-Disease 1 0.9930543303489685
( O 0 1.223851654685859e-06
FH O 0 5.692554987035692e-05
) O 0 6.344299663396669e-08
in O 0 2.5908255096851462e-08
the O 0 1.760559342756096e-08
context O 0 2.4373539986299875e-07
of O 0 4.6049939328440814e-07
an O 0 0.000252407044172287
acute B-Disease 1 0.9999425411224365
renal I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999994039535522
. O 0 0.0004351918469183147

Five O 0 1.0957853646687e-06
of O 0 5.9130865537326827e-08
the O 0 1.151149007228014e-07
cases O 0 2.9994603778504825e-07
were O 0 5.4549808226056484e-08
observed O 0 7.761063329780882e-07
in O 0 7.248886646493702e-08
children O 0 1.1698725188580283e-07
presenting O 0 1.1663889381452464e-05
with O 0 0.003012215718626976
idiopathic O 1 0.9999803304672241
hemolytic B-Disease 1 0.9999995231628418
uremic I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999984502792358
( O 0 0.0010265976889058948
HUS B-Disease 1 0.9993113279342651
) O 0 2.0692055841209367e-05
. O 0 1.0745124200184364e-05

Two O 0 7.105318218236789e-07
of O 0 1.253415433666305e-07
the O 0 3.039086209355446e-07
children O 0 7.408315241264063e-07
exhibited O 0 5.019687887397595e-05
a O 0 8.19730048533529e-05
homozygous O 0 0.013619746081531048
deficiency O 1 0.9987302422523499
characterized O 0 4.2810701415874064e-05
by O 0 1.5943545861318853e-07
the O 0 2.7623423193290364e-07
absence O 0 1.3962778666609665e-06
of O 0 3.190309172396155e-08
the O 0 1.117171350983881e-07
150 O 0 9.009896189127176e-07
- O 0 1.3083888006804045e-05
kD O 0 3.5799352190224454e-05
form O 0 2.5247251755899924e-07
of O 0 1.1337549921108803e-07
Factor O 0 3.1480683446716284e-06
H O 1 0.9976140260696411
and O 0 2.7441828365226684e-07
the O 0 6.324750501107701e-08
presence O 0 4.6847350176904e-07
, O 0 4.983879264841562e-08
upon O 0 4.5190954978124864e-08
immunoblotting O 0 1.6960462744464166e-05
, O 0 1.4052696428734635e-07
of O 0 8.66788774089855e-09
the O 0 7.626923803627506e-08
42 O 0 2.49213439929008e-06
- O 0 7.157555501180468e-06
kD O 0 3.419386121095158e-05
Factor O 0 1.416017198607733e-06
H O 0 0.014309334568679333
- O 0 6.285009476414416e-06
like O 0 2.8807320973101014e-07
protein O 0 5.628660915135697e-07
1 O 0 7.0167686772038e-07
( O 0 1.249207741693681e-07
FHL O 0 6.491651583928615e-05
- O 0 5.879387117602164e-06
1 O 0 3.6406518688636424e-07
) O 0 1.619949507869478e-08
and O 0 3.0348804358482084e-08
other O 0 5.5882630078940565e-08
FH O 0 0.00010573946929071099
- O 0 1.4880029084451962e-05
related O 0 1.3425930092125782e-06
protein O 0 1.43732779633865e-06
( O 0 6.862636610094341e-07
FHR O 0 9.187141404254362e-05
) O 0 3.639232204477594e-07
bands O 0 3.4679032978601754e-05
. O 0 3.5082341582892695e-06

Southern O 0 6.852341903140768e-05
blot O 0 0.0004898253828287125
and O 0 4.877773562839138e-07
PCR O 0 2.1336902591428952e-06
analysis O 0 4.522622276681432e-08
of O 0 1.2293029705290337e-08
DNA O 0 6.586446943401825e-07
of O 0 5.057798446728157e-08
one O 0 6.679452440039313e-07
patient O 0 3.596380338422023e-05
with O 0 1.0700988241296727e-05
homozygous O 0 0.01768522523343563
deficiency O 1 0.9994439482688904
ruled O 0 3.638181442511268e-05
out O 0 1.8230686293918552e-07
the O 0 4.515287699291548e-08
presence O 0 1.427015519084307e-07
of O 0 1.4673370962725585e-08
a O 0 2.415873723293771e-07
large O 0 4.0852145843928156e-07
deletion O 0 6.989771918597398e-06
of O 0 9.985039639559545e-08
the O 0 6.527063192152127e-07
FH O 0 9.266265988117084e-05
gene O 0 1.935856516865897e-06
as O 0 3.4395807801956835e-07
the O 0 5.535063110073679e-07
underlying O 0 9.783166024135426e-05
defect O 0 0.002616506302729249
for O 0 1.5845425878069364e-06
the O 0 0.00011546767927939072
deficiency O 1 0.9994210004806519
. O 0 2.3299860913539305e-05

The O 0 6.324859214146272e-07
other O 0 1.0721663556978456e-07
four O 0 2.070031683842899e-07
children O 0 9.805405198903827e-08
presented O 0 1.2575164873851463e-06
with O 0 7.073271262925118e-06
heterozygous O 0 0.0005023166304454207
deficiency O 1 0.9985021352767944
and O 0 5.744527697970625e-07
exhibited O 0 1.5863488442846574e-05
a O 0 1.2247506901985616e-06
normal O 0 8.370549949177075e-06
immunoblotting O 0 0.00010511886648600921
pattern O 0 5.862535090273013e-06
of O 0 2.5238193757104455e-08
proteins O 0 1.6728782270547526e-07
of O 0 1.1579678016460093e-07
the O 0 2.632082669151714e-06
FH O 0 0.002114825649186969
family O 0 3.683446630020626e-05
. O 0 1.2385554327920545e-05

Factor B-Disease 0 0.016659893095493317
H I-Disease 1 0.9999709129333496
deficiency I-Disease 1 0.9998294115066528
is O 0 2.1324981389625464e-06
the O 0 3.6691952232104086e-07
only O 0 2.656969400050002e-06
complement B-Disease 1 0.9948791265487671
deficiency I-Disease 1 0.999993085861206
associated O 0 0.00011957532115047798
with O 0 2.348609450564254e-05
HUS B-Disease 1 0.9995725750923157
. O 0 6.740147364325821e-05

These O 0 1.2758837897308695e-07
observations O 0 2.9201808047218947e-06
suggest O 0 3.8015940617697197e-07
a O 0 1.6134683278323791e-07
role O 0 8.369132729058038e-07
for O 0 2.669032710400643e-07
FH O 0 0.00016177455836441368
and O 0 9.881798632704886e-07
/ O 0 3.072392792091705e-05
or O 0 2.4556322841817746e-06
FH O 0 0.00016400942695327103
receptors O 0 6.843958090030355e-06
in O 0 3.654311910850083e-07
the O 0 1.0229467761746491e-06
pathogenesis O 0 0.0020903083495795727
of O 0 9.798328392207623e-06
idiopathic O 1 0.9996047616004944
HUS B-Disease 1 0.9998966455459595
. O 0 2.1724212274421006e-05
. O 0 7.04460626366199e-06

Further O 0 3.203993799161253e-07
evidence O 0 1.2109514102576213e-07
for O 0 3.5143237653301185e-08
a O 0 9.144295631813293e-07
major O 0 1.677995351201389e-05
ancient O 0 0.00016722310101613402
mutation O 0 0.05663815140724182
underlying O 1 0.8580496907234192
myotonic B-Disease 1 0.9999707937240601
dystrophy I-Disease 1 0.9999769926071167
from O 0 7.806337634974625e-06
linkage O 0 0.00014037084474693984
disequilibrium O 0 0.00035824396763928235
studies O 0 8.29017949399713e-07
in O 0 8.649989524656121e-08
the O 0 1.051308515798155e-07
Japanese O 0 1.4709639799548313e-06
population O 0 8.592076738977994e-08
. O 0 1.1480171906441683e-06

The O 0 0.004106552340090275
myotonic B-Disease 1 0.9999213218688965
dystrophy I-Disease 1 0.999982476234436
( O 0 0.0004317193233873695
DM B-Disease 1 0.9998646974563599
) O 0 4.58210979559226e-06
mutation O 0 3.875571201206185e-05
is O 0 9.89162231235241e-07
an O 0 1.1233877330596442e-06
unstable O 0 0.00791004579514265
( O 0 1.3580045106209582e-06
CTG O 0 0.00014177049160934985
) O 0 3.5835830658470513e-07
n O 0 7.619072675879579e-06
repeat O 0 6.705865416734014e-06
, O 0 8.249974570162522e-08
present O 0 3.149726524043217e-08
at O 0 8.663493531457789e-07
a O 0 6.619715264832848e-08
copy O 0 2.2048277514841175e-07
number O 0 1.5852661405801882e-08
of O 0 1.5504792116871613e-08
5 O 0 1.4510799246636452e-06
- O 0 1.2835905181418639e-05
37 O 0 1.5190486237770529e-06
repeats O 0 2.5703798200993333e-06
on O 0 3.2459189469591365e-07
normal O 0 5.552129778152448e-07
chromosomes O 0 3.9119370853768487e-07
but O 0 3.73413442389392e-08
amplified O 0 4.6326425717779784e-07
to O 0 2.2524556442249377e-08
50 O 0 3.0296899922177545e-07
- O 0 1.487247459408536e-06
3000 O 0 1.0918080306510092e-06
copies O 0 1.3950308357379981e-06
on O 0 2.3028724172036164e-05
DM B-Disease 1 0.9980955719947815
chromosomes O 0 0.00016286772734019905
. O 0 1.7154869055957533e-05

Previous O 0 3.628151898737997e-05
findings O 0 7.451491001120303e-06
in O 0 1.0301080237695714e-06
Caucasian O 0 4.059046841575764e-05
populations O 0 1.0222661330772098e-06
of O 0 1.7085527304061543e-07
a O 0 0.00010055316670332104
DM B-Disease 1 0.9999102354049683
founder O 0 0.0003126352094113827
chromosome O 0 7.851114787627012e-05
raise O 0 2.084760581055889e-06
a O 0 4.620125935161923e-07
question O 0 2.485767822690832e-07
about O 0 1.8617818398070085e-08
the O 0 2.914288010913424e-08
molecular O 0 1.8834424508895609e-06
events O 0 1.1739518157583007e-07
involved O 0 2.1138083639016259e-07
in O 0 8.265866568990532e-08
the O 0 1.8702210979881784e-07
expansion O 0 1.910385071823839e-05
mutation O 0 0.00011129803897347301
. O 0 3.537469183356734e-06

To O 0 6.936792829037586e-07
investigate O 0 2.9056518542347476e-06
whether O 0 1.68272023870486e-07
a O 0 7.926327043605852e-07
founder O 0 4.666391760110855e-06
chromosome O 0 1.1182921298313886e-05
for O 0 1.225971431040307e-07
the O 0 4.948999958287459e-06
DM B-Disease 1 0.9997619986534119
mutation O 0 7.330068183364347e-05
exists O 0 5.960986300124205e-07
in O 0 5.414182169261039e-08
the O 0 3.8742889785226e-08
Japanese O 0 2.5486750132586167e-07
population O 0 2.4438051582365006e-08
, O 0 8.33360473961875e-08
we O 0 8.954305030783871e-08
genotyped O 0 7.070843366818735e-06
families O 0 4.0146627355852615e-08
using O 0 2.0118405075209012e-07
polymorphic O 0 3.0545255867764354e-05
markers O 0 7.695404747209977e-06
near O 0 8.967566827777773e-06
the O 0 3.1867000416241353e-07
( O 0 5.817649935124791e-07
CTG O 0 0.00010395428398624063
) O 0 3.428491766044317e-07
n O 0 1.4151319192023948e-05
repeat O 0 1.5106283171917312e-05
region O 0 3.6942335555067984e-06
and O 0 4.7468873276557133e-07
constructed O 0 3.121482950518839e-05
haplotypes O 0 0.00017335957090836018
. O 0 8.319251719512977e-06

Six O 0 5.391047466218879e-07
different O 0 3.1879917372634736e-08
haplotypes O 0 1.1552731848496478e-05
were O 0 8.812941132418928e-07
found O 0 1.8555444967205403e-06
and O 0 2.3732172849122435e-06
DM B-Disease 1 0.9986521601676941
alleles O 0 8.023961527214851e-06
were O 0 1.0013692417487619e-06
always O 0 5.147735464561265e-06
haplotype O 0 7.994599582161754e-05
A O 0 3.198281774530187e-05
. O 0 7.391769941023085e-06

To O 0 3.394720238247828e-07
find O 0 3.414548928049044e-07
an O 0 4.132316533400626e-08
origin O 0 6.29672882723753e-08
of O 0 7.041464300527878e-08
the O 0 5.818082513542322e-07
( O 0 5.438690209302877e-07
CTG O 0 7.79869660618715e-05
) O 0 2.4720137048461766e-07
n O 0 1.0006628144765273e-05
repeat O 0 7.5483771979634184e-06
mutation O 0 3.725722308445256e-06
and O 0 5.7164218247862664e-08
to O 0 2.4580538493523818e-08
investigate O 0 2.4191012926166877e-07
the O 0 7.809041591144705e-08
mechanism O 0 6.730350605721469e-07
of O 0 2.8233106519337525e-08
the O 0 9.200140738130358e-08
expansion O 0 1.1843136462630355e-06
mutation O 0 2.2545482352143154e-06
in O 0 5.376804779189115e-08
the O 0 2.1279623396708303e-08
Japanese O 0 2.5491317501291633e-07
population O 0 3.316104502104622e-09
we O 0 1.98392910988332e-08
have O 0 1.3904663198616163e-08
studied O 0 8.272820650745416e-07
90 O 0 8.770014687797811e-07
Japanese O 0 1.207394598168321e-05
DM B-Disease 1 0.9985061287879944
families O 0 3.124056604519865e-07
comprising O 0 6.448585168072896e-07
190 O 0 1.5432440250151558e-06
affected O 0 5.966600156170898e-07
and O 0 2.59084117715247e-07
130 O 0 1.5153763115449692e-06
unaffected O 0 3.6232726415619254e-05
members O 0 3.7131476915419626e-07
. O 0 2.3930356292112265e-06

The O 0 3.2465677577420138e-06
results O 0 3.567329258657992e-06
suggest O 0 2.7302692728881084e-07
that O 0 1.8815841329455907e-08
a O 0 2.473716449458152e-07
few O 0 2.1433356778288726e-07
common O 0 1.1204816701138043e-06
ancestral O 0 1.31919514387846e-05
mutations O 0 2.9937164072180167e-05
in O 0 5.211666689319827e-07
both O 0 3.2262880722555565e-07
Caucasian O 0 2.4031573047977872e-05
and O 0 5.582541575677169e-07
Japanese O 0 1.225568553309131e-06
populations O 0 1.243098068925974e-07
have O 0 1.254883663648343e-08
originated O 0 7.339582452914328e-08
by O 0 1.0617141832369725e-08
expansion O 0 1.7263793949950923e-07
of O 0 1.4290986172227349e-08
an O 0 4.06148288334407e-08
ancestral O 0 3.4752872579701943e-06
n O 0 3.272915637353435e-05
= O 0 1.6348039935110137e-05
5 O 0 8.34559671147872e-07
repeat O 0 1.5026247410787619e-06
to O 0 1.0467105937550514e-07
n O 0 8.840063856041525e-06
= O 0 1.1298803656245582e-05
19 O 0 2.563354200901813e-06
- O 0 5.787336704088375e-06
37 O 0 1.4253686231313623e-06
copies O 0 9.419983371117269e-07
. O 0 2.8129800284659723e-06

These O 0 1.5212449966384156e-07
data O 0 3.771822605358466e-07
support O 0 1.3926658937180036e-07
multistep O 0 1.5540341337327845e-05
models O 0 3.253696831961861e-06
of O 0 4.871669716521865e-07
triplet O 0 0.0013275740202516317
repeat O 0 4.5312750444281846e-05
expansion O 0 1.6625481293885969e-06
that O 0 2.5190868058189153e-08
have O 0 2.750139849183597e-08
been O 0 4.9850768846226856e-08
proposed O 0 6.249312178852051e-08
for O 0 3.351019017827639e-08
both O 0 2.3760710519127315e-06
DM B-Disease 1 0.9999502897262573
and O 0 4.758997602039017e-05
Friedreichs B-Disease 0 0.027572857216000557
ataxia I-Disease 1 0.9933260679244995
. O 0 6.046207545296056e-06
. O 0 7.056871254462749e-06

The O 0 1.5953689853631658e-06
molecular O 0 2.544970266171731e-05
basis O 0 4.72974352305755e-06
of O 0 9.060640149982646e-05
C6 B-Disease 1 0.9999969005584717
deficiency I-Disease 1 0.9999982118606567
in O 0 3.1299809961637948e-06
the O 0 5.203621071814268e-07
western O 0 4.53123675470124e-06
Cape O 0 2.7199073883821256e-05
, O 0 6.377956083269964e-07
South O 0 6.15459782693506e-07
Africa O 0 2.5135302621492883e-06
. O 0 2.6141385660594096e-06

Deficiency B-Disease 1 0.9988700747489929
of I-Disease 0 7.335565328503435e-07
the I-Disease 0 1.3337592008610955e-06
sixth I-Disease 0 5.264870560495183e-05
component I-Disease 0 3.8196990317374e-06
of I-Disease 0 1.1884007733442559e-07
human I-Disease 0 6.370405571942683e-07
complement I-Disease 0 1.5114246707526036e-06
( O 0 1.223549475071195e-06
C6 O 0 0.001532495254650712
) O 0 2.2930517218355817e-07
has O 0 1.1226182294876708e-07
been O 0 1.7755567682797846e-07
reported O 0 3.624743101227068e-07
in O 0 6.33085539547551e-09
a O 0 1.9936095441153157e-08
number O 0 7.1674253199205396e-09
of O 0 5.557053484039898e-09
families O 0 8.391596750811914e-09
from O 0 5.3689753087837744e-08
the O 0 4.650202356515365e-08
western O 0 1.8166069821745623e-06
Cape O 0 1.632092062209267e-05
, O 0 2.7429584292804066e-07
South O 0 9.782779670786113e-07
Africa O 0 3.3012304356816458e-06
. O 0 3.774021251956583e-06

Meningococcal B-Disease 1 0.9922136664390564
disease I-Disease 1 0.9992654919624329
is O 0 2.8164075047243387e-05
endemic O 0 0.00010010122059611604
in O 0 3.1371723707707133e-07
the O 0 2.024661256427862e-07
Cape O 0 2.2665105916530592e-06
and O 0 5.6345207610775105e-08
almost O 0 7.623229691944289e-08
all O 0 1.52273660347646e-08
pedigrees O 0 6.321533874142915e-06
of O 0 1.151626975115505e-06
total O 0 0.00018086952331941575
C6 B-Disease 1 0.9999933242797852
deficiency I-Disease 1 0.9999973773956299
( O 0 1.1303372048132587e-05
C6Q0 O 0 0.0010005240328609943
) O 0 2.3562354556361242e-07
have O 0 6.416268405473602e-08
been O 0 3.372821595348796e-07
ascertained O 0 5.142308509675786e-06
because O 0 1.2882392184110358e-06
of O 0 2.9793891371809877e-06
recurrent O 1 0.9980868101119995
disease O 1 0.999462902545929
. O 0 3.085699790972285e-05

We O 0 1.5056297115734196e-06
have O 0 7.065950313744906e-08
sequenced O 0 9.089138188755896e-07
the O 0 7.090656595210021e-08
expressed O 0 1.2176136010566552e-07
exons O 0 2.732879465838778e-06
of O 0 8.160674269674928e-08
the O 0 7.098924470483325e-07
C6 O 0 0.0010989242000505328
gene O 0 1.764723492669873e-06
from O 0 2.0794736599327734e-07
selected O 0 6.177813105523455e-08
cases O 0 7.855891226427048e-08
and O 0 3.6038514394931553e-08
have O 0 2.6458382151872684e-08
found O 0 1.6886248488390265e-07
three O 0 3.1496369956585113e-07
molecular O 0 0.00024278360069729388
defects O 1 0.9927312731742859
leading O 0 5.516386590898037e-05
to O 0 6.157145548968401e-07
total O 0 1.135330785473343e-05
deficiency O 1 0.9991222023963928
879delG O 0 0.0008955225930549204
, O 0 8.584931379118643e-07
which O 0 1.0846392228813784e-07
is O 0 8.119653926996762e-08
the O 0 8.820241959028863e-08
common O 0 1.1115745110146236e-05
defect O 0 0.0011455351486802101
in O 0 7.037892260086664e-07
the O 0 9.961069054043037e-07
Cape O 0 2.888399103539996e-05
and O 0 4.709915515377361e-07
hitherto O 0 3.443924288148992e-05
unreported O 0 1.2815711670555174e-05
, O 0 5.049162723480549e-07
and O 0 4.5309633378565195e-07
1195delC O 0 8.420367521466687e-05
and O 0 1.2407616623022477e-06
1936delG O 0 5.0991842726944014e-05
, O 0 1.571890919649377e-07
which O 0 1.9254958516512488e-08
have O 0 1.8421388858769205e-08
been O 0 1.0006793615957577e-07
previously O 0 5.616901148641773e-07
reported O 0 1.0756172059700475e-06
in O 0 6.984428324585679e-08
African O 0 3.954502858505293e-07
- O 0 5.551056892727502e-05
Americans O 0 1.0940321999441949e-06
. O 0 3.567479097910109e-06

We O 0 1.64805010172131e-06
also O 0 1.2870586374447157e-07
show O 0 1.3450058133912535e-07
that O 0 7.013889025131448e-09
the O 0 1.6401760660755826e-07
879delG O 0 6.811500497860834e-05
and O 0 5.701199825125514e-06
1195delC O 0 0.006693675182759762
defects O 1 0.9578942060470581
are O 0 2.0167486525224376e-07
associated O 0 1.0999901860486716e-06
with O 0 8.583441513110301e-07
characteristic O 0 0.004139488097280264
C6 O 1 0.9977643489837646
/ O 0 0.04538123309612274
C7 O 1 0.9232661724090576
region O 0 3.301433025626466e-05
DNA O 0 2.3224169126478955e-05
marker O 0 4.7842382628005e-05
haplotypes O 0 1.6931422578636557e-05
, O 0 2.532659379994584e-07
although O 0 7.794637468805377e-08
small O 0 1.0888408752407486e-07
variations O 0 1.8814640725395293e-06
were O 0 5.530678777176945e-07
observed O 0 7.329479103646008e-06
. O 0 3.2630689474899555e-06

The O 0 1.9844075723085552e-05
1936delG O 0 0.0034459137823432684
defect O 0 0.0038039234932512045
was O 0 1.3699451301363297e-05
observed O 0 1.4298545920610195e-06
only O 0 3.760020916843132e-08
once O 0 1.6077190139185404e-06
in O 0 1.2436920826530695e-07
the O 0 2.0273699874451268e-07
Cape O 0 7.356480637099594e-06
, O 0 8.5339003419449e-08
but O 0 3.334308473768033e-08
its O 0 4.535104736191897e-08
associated O 0 1.3902615592087386e-06
haplotype O 0 3.7844223697902635e-05
could O 0 6.390071689565957e-07
be O 0 2.8495773563008697e-07
deduced O 0 1.0806392310769297e-05
. O 0 4.521330083662178e-06

The O 0 9.458719887334155e-07
data O 0 6.576348710041202e-07
from O 0 9.891720509358493e-08
the O 0 6.008839648075082e-08
haplotypes O 0 5.85398674957105e-06
indicate O 0 3.807359121310583e-07
that O 0 3.163923123494783e-09
these O 0 3.749169419364762e-09
three O 0 9.310542026241819e-08
molecular O 0 0.0001544950355309993
defects O 1 0.7948897480964661
account O 0 1.9346850876900135e-07
for O 0 5.444991302283597e-08
the O 0 1.2594512099894928e-06
defects O 1 0.6382323503494263
in O 0 1.2519984693426522e-07
all O 0 1.3510500274094284e-08
the O 0 2.481920944319427e-07
38 O 0 4.67370455226046e-06
unrelated O 0 1.1618306416494306e-05
C6Q0 O 0 0.00018084730254486203
individuals O 0 5.1830074454528585e-08
we O 0 1.321248248586926e-07
have O 0 4.718570068007466e-08
studied O 0 1.3940984899818432e-06
from O 0 3.881612542500079e-07
the O 0 9.658990620664554e-07
Cape O 0 7.31243344489485e-05
. O 0 4.0525874283048324e-06

We O 0 4.37085054727504e-06
have O 0 1.5569608535770385e-07
also O 0 1.5583067636271153e-07
observed O 0 9.503359024165547e-07
the O 0 4.867480924986012e-07
879delG O 0 0.00015255420294124633
defect O 0 0.00017010336159728467
in O 0 6.681248692075314e-07
two O 0 2.0473255517572397e-06
Dutch O 0 0.042954783886671066
C6 B-Disease 1 0.9999275207519531
- I-Disease 1 0.9984207153320312
deficient I-Disease 1 0.9990285634994507
kindreds O 0 0.002036037389189005
, O 0 1.4270960946305422e-06
but O 0 1.4910776258147962e-07
the O 0 4.010675809240638e-07
879delG O 0 0.0003811930655501783
defect O 0 0.0007142195827327669
in O 0 6.034636044205399e-07
the O 0 4.634582637663698e-07
Cape O 0 1.3166991266189143e-05
probably O 0 7.890457709436305e-07
did O 0 7.294726600548529e-08
not O 0 1.0872548195095533e-08
come O 0 3.084625177507405e-08
from O 0 1.8403197188376907e-08
The O 0 5.744534092855247e-08
Netherlands O 0 4.232243099977495e-06
. O 0 4.1007891127264884e-07
. O 0 1.7736455220074276e-06

Complement B-Disease 0 0.17511121928691864
C7 I-Disease 1 0.9999898672103882
deficiency I-Disease 1 0.9999983310699463
: O 0 6.3863822106213775e-06
seven O 0 5.924171659899002e-07
further O 0 5.073267743682663e-07
molecular O 0 0.0010523831006139517
defects O 1 0.9959043860435486
and O 0 3.251986129271245e-07
their O 0 1.4337953757603827e-07
associated O 0 1.5049470675876364e-05
marker O 0 0.00010505203681532294
haplotypes O 0 0.0004281341389287263
. O 0 1.4370232747751288e-05

Seven O 0 1.0338429774492397e-06
further O 0 7.9361321070337e-08
molecular O 0 9.945815691025928e-06
bases O 0 1.995349521166645e-05
of O 0 0.00012450179201550782
C7 B-Disease 1 0.9999979734420776
deficiency I-Disease 1 0.9999988079071045
are O 0 4.052285476063844e-06
described O 0 8.753588190302253e-05
. O 0 7.543447736679809e-06

All O 0 1.7192554935263615e-07
these O 0 5.11940037029035e-08
new O 0 1.6762331824793364e-06
molecular O 0 0.000507378950715065
defects O 0 0.2579038739204407
involve O 0 9.382703183291596e-07
single O 0 1.7598243857719353e-06
- O 0 9.307155778515153e-06
nucleotide O 0 1.4449099126068177e-06
events O 0 3.138842430416844e-07
, O 0 7.190541140289497e-08
deletions O 0 1.6157700883923098e-06
and O 0 1.1174930847346332e-07
substitutions O 0 1.0617940233714762e-06
, O 0 5.26629513331045e-08
some O 0 2.3495512202487134e-09
of O 0 8.071012302934832e-09
which O 0 3.430401207538125e-08
alter O 0 3.205942221029545e-06
splice O 0 1.5166795492405072e-05
sites O 0 2.570627430031891e-06
, O 0 2.4038908463808184e-07
and O 0 2.3502791179907945e-07
others O 0 4.1731081523721514e-07
codons O 0 2.4685636162757874e-05
. O 0 4.758477189170662e-06

They O 0 3.3774438179534627e-07
are O 0 8.64807248035504e-09
distributed O 0 4.570185652141845e-08
along O 0 3.461225901446596e-07
the O 0 3.4269356774530024e-07
C7 O 0 0.0007029024418443441
gene O 0 4.20998185290955e-06
, O 0 3.2640662084304495e-07
but O 0 3.0764581993025786e-08
predominantly O 0 2.0920083443343174e-08
towards O 0 8.875646528849757e-08
the O 0 2.1706367192564358e-07
3 O 0 3.1992842650652165e-06
end O 0 7.525276487285737e-06
. O 0 2.5268548142776126e-06

All O 0 2.499932065802568e-07
were O 0 2.3097496182344912e-07
found O 0 1.880035114254497e-07
in O 0 1.0638876801749575e-07
compound O 0 2.6751233690447407e-06
heterozygous O 0 1.5092640524017042e-06
individuals O 0 1.5195732316897193e-07
. O 0 2.0570328160829376e-06

The O 0 8.048021845752373e-05
C6 O 1 0.9593076109886169
/ O 0 0.0176575668156147
C7 O 1 0.8681591153144836
marker O 0 0.00055348826572299
haplotypes O 0 0.00024115436826832592
associated O 0 1.4710196410305798e-05
with O 0 2.3163770492828917e-06
most O 0 2.4049411877058446e-05
C7 B-Disease 1 0.9993752837181091
defects I-Disease 1 0.9996390342712402
are O 0 3.9358940284728305e-07
tabulated O 0 0.00011251066462136805
. O 0 1.0974472388625145e-06
. O 0 2.786299319268437e-06

A O 0 3.059384835069068e-05
genome O 0 1.1004593943653163e-05
- O 0 8.939457075030077e-06
wide O 0 1.401422082381032e-06
search O 0 6.592084105250251e-07
for O 0 3.11636455307962e-07
chromosomal O 0 0.0017272233963012695
loci O 0 0.00015374815848190337
linked O 0 0.0011399840004742146
to O 0 6.286424195423024e-06
mental O 0 0.34593600034713745
health O 0 0.00020611193031072617
wellness O 0 5.1969309424748644e-05
in O 0 6.95157439167815e-07
relatives O 0 9.53461949393386e-06
at O 0 0.00017913023475557566
high O 0 0.0008863984257914126
risk O 0 0.0003140706685371697
for O 0 1.657148459344171e-05
bipolar B-Disease 1 0.9999353885650635
affective I-Disease 1 0.9997993111610413
disorder I-Disease 1 0.9998511075973511
among O 0 8.303916843033221e-07
the O 0 3.747105665752315e-07
Old O 0 3.230440051993355e-05
Order O 0 1.2675099014813895e-06
Amish O 0 4.286670809960924e-05
. O 0 6.436373041651677e-06

Bipolar B-Disease 1 0.9997944235801697
affective I-Disease 1 0.9992871880531311
disorder I-Disease 1 0.9998779296875
( O 0 0.0004415501607581973
BPAD B-Disease 1 0.9997997879981995
; O 0 0.0029053655453026295
manic B-Disease 1 0.9998741149902344
- I-Disease 1 0.9999427795410156
depressive I-Disease 1 0.9999768733978271
illness I-Disease 1 0.9996265172958374
) O 0 1.1022249282177654e-06
is O 0 3.731372260062926e-07
characterized O 0 1.7859802028397098e-06
by O 0 9.196561734370334e-08
episodes O 0 1.944972382261767e-06
of O 0 6.841294180048862e-07
mania B-Disease 0 0.007001026067882776
and O 0 6.739407126588048e-06
/ O 0 0.0002833314938470721
or O 0 1.6391704775742255e-05
hypomania B-Disease 0 0.27592453360557556
interspersed O 0 9.496858547208831e-05
with O 0 3.0439468901022337e-06
periods O 0 5.431665340438485e-05
of O 0 5.471076292451471e-06
depression B-Disease 0 0.14529143273830414
. O 0 6.23107052888372e-06

Compelling O 0 5.101356236991705e-06
evidence O 0 6.570793971150124e-07
supports O 0 6.116051167737169e-07
a O 0 4.137700386763754e-07
significant O 0 3.955543945721729e-07
genetic O 0 3.8038676848373143e-06
component O 0 3.2576958801655564e-06
in O 0 2.014299838037914e-07
the O 0 2.9020580427641107e-07
susceptibility O 0 1.8239001292386092e-05
to O 0 4.955348344992672e-07
develop O 0 0.00013746287731919438
BPAD B-Disease 1 0.9997431635856628
. O 0 3.0258226615842432e-05

To O 0 4.7022004423524777e-07
date O 0 7.051569809846114e-06
, O 0 2.293869840741536e-07
however O 0 7.558424641729289e-08
, O 0 3.902114542597701e-08
linkage O 0 1.6599008176854113e-06
studies O 0 8.48536956254975e-08
have O 0 8.092963632577721e-09
attempted O 0 8.619143443411303e-08
only O 0 1.1705082236801445e-08
to O 0 1.2594779441599258e-08
identify O 0 1.4343028169605532e-06
chromosomal O 0 0.0005442386609502137
loci O 0 1.3631657566293143e-05
that O 0 1.844850316956581e-07
cause O 0 4.76425748274778e-06
or O 0 4.791162950823491e-07
increase O 0 2.71167920118387e-07
the O 0 7.743379910607473e-07
risk O 0 1.237068045156775e-05
of O 0 2.0745376616559952e-07
developing O 0 8.794594032224268e-05
BPAD B-Disease 1 0.999738872051239
. O 0 4.237863322487101e-05

To O 0 5.662866442435188e-07
determine O 0 6.086294774831913e-07
whether O 0 1.4895567801431753e-07
there O 0 9.034368275706584e-08
could O 0 1.3348825689263322e-07
be O 0 9.068067186035478e-08
protective O 0 5.7158117670041975e-06
alleles O 0 7.38617814022291e-07
that O 0 4.804152098358827e-08
prevent O 0 1.665464765210345e-06
or O 0 1.6474687072332017e-06
reduce O 0 3.5021100757148815e-06
the O 0 9.565826530888444e-07
risk O 0 9.89324598776875e-06
of O 0 7.919226874264496e-08
developing O 0 2.0174493329250254e-05
BPAD B-Disease 1 0.9997696280479431
, O 0 7.014701282059832e-07
similar O 0 1.528125608274422e-07
to O 0 2.260887477234519e-08
what O 0 4.916381968200767e-08
is O 0 6.112271933034208e-08
observed O 0 3.823446093065286e-07
in O 0 2.1396495242242963e-07
other O 0 2.903884706029203e-06
genetic B-Disease 1 0.9992013573646545
disorders I-Disease 1 0.9999974966049194
, O 0 6.856238542241044e-06
we O 0 1.7366120346196112e-06
used O 0 2.610344199638348e-05
mental O 1 0.6340393424034119
health O 0 0.0008480811375193298
wellness O 0 0.00043350295163691044
( O 0 1.784539790605777e-06
absence O 0 8.825995791994501e-06
of O 0 3.0158960839798965e-07
any O 0 3.4305961889913306e-05
psychiatric B-Disease 1 0.9993054866790771
disorder I-Disease 1 0.9996418952941895
) O 0 2.177092710553552e-07
as O 0 2.117201916007616e-07
the O 0 1.781299516778745e-07
phenotype O 0 5.721914931200445e-06
in O 0 1.3839553503203206e-07
our O 0 2.3897621304058703e-07
genome O 0 2.793429757730337e-06
- O 0 1.0336169907532167e-05
wide O 0 2.5612578156142263e-06
linkage O 0 3.613152512116358e-05
scan O 0 7.354763511102647e-05
of O 0 5.339563458051089e-08
several O 0 6.591304924086216e-08
large O 0 1.1119689133920474e-06
multigeneration O 0 0.00024500949075445533
Old O 0 2.4376464352826588e-05
Order O 0 5.866376682206464e-07
Amish O 0 9.802450222196057e-06
pedigrees O 0 3.26906047121156e-05
exhibiting O 0 1.7776193999452516e-05
an O 0 7.019204417701985e-07
extremely O 0 9.117557056015357e-05
high O 0 0.0025527351535856724
incidence O 0 0.10219363868236542
of O 0 1.689087730483152e-05
BPAD B-Disease 1 0.999728262424469
. O 0 4.9085680075222626e-05

We O 0 3.1123361168283736e-06
have O 0 1.0439551800800473e-07
found O 0 1.685850747890072e-07
strong O 0 6.059467949626196e-08
evidence O 0 2.0084716112478418e-08
for O 0 1.1190839366292948e-08
a O 0 5.032577519159531e-07
locus O 0 1.0342934729123954e-05
on O 0 4.765984613186447e-06
chromosome O 0 0.00012758863158524036
4p O 0 0.007476316299289465
at O 0 2.4123744879034348e-05
D4S2949 O 0 2.3073302145348862e-05
( O 0 2.6145650622311223e-07
maximum O 0 6.329819370876066e-07
GENEHUNTER O 0 0.00016270243213512003
- O 0 1.2666286238527391e-05
PLUS O 0 3.068713112952537e-06
nonparametric O 0 6.610664513573283e-06
linkage O 0 9.035770744958427e-06
score O 0 1.6116133565446944e-06
= O 0 4.121476649743272e-06
4 O 0 6.190104500092275e-07
. O 0 6.120892948047185e-08
05 O 0 7.3671521931828465e-06
, O 0 1.975869139414499e-07
P O 0 1.6833759218570776e-05
= O 0 2.151130729544093e-06
5 O 0 1.9981325749540702e-07
. O 0 1.4580468388203371e-08
22 O 0 1.896103469789523e-07
x O 0 1.2360434311631252e-06
10 O 0 2.0507516751422372e-07
( O 0 6.154761678089926e-08
- O 0 3.1929503165883943e-06
4 O 0 1.023455297399778e-06
) O 0 6.015238085410601e-08
; O 0 7.36898329023461e-08
SIBPAL O 0 2.0570034394040704e-05
Pempirical O 0 6.185304755490506e-06
value O 0 1.0349916834684336e-07
< O 0 1.7294224790020962e-06
3 O 0 3.6296381722422666e-07
x O 0 2.421211775072152e-06
10 O 0 3.7615814107994083e-07
( O 0 8.345503488271788e-08
- O 0 3.84446593670873e-06
5 O 0 4.795825816472643e-07
) O 0 2.1686210160964947e-08
) O 0 8.442842869271772e-09
and O 0 2.3738138565931877e-08
suggestive O 0 2.4931471216405043e-06
evidence O 0 6.479518788182759e-08
for O 0 2.1198522048848645e-08
a O 0 6.367508831317537e-07
locus O 0 1.678393891779706e-05
on O 0 1.6331227016053163e-05
chromosome O 0 0.0005599668365903199
4q O 0 0.04144883528351784
at O 0 5.186573980608955e-05
D4S397 O 0 2.956326716230251e-05
( O 0 2.218258430275455e-07
maximum O 0 9.622959851185442e-07
GENEHUNTER O 0 0.0002250793477287516
- O 0 1.6369054719689302e-05
PLUS O 0 4.122887730773073e-06
nonparametric O 0 5.516237251868006e-06
linkage O 0 5.021894594392506e-06
score O 0 1.3575280490840669e-06
= O 0 3.1940921871864703e-06
3 O 0 5.488612373483193e-07
. O 0 6.209508995880242e-08
29 O 0 1.5901558754194411e-06
, O 0 2.089883253120206e-07
P O 0 1.7859250874607824e-05
= O 0 1.6777364635345293e-06
2 O 0 1.954431354533881e-07
. O 0 1.6771776856217002e-08
57 O 0 2.3199177690003125e-07
x O 0 2.1148800897208275e-06
10 O 0 2.479283125467191e-07
( O 0 6.504271254925698e-08
- O 0 2.624102535264683e-06
3 O 0 6.32826186119928e-07
) O 0 2.1905961489210313e-08
; O 0 4.3488164180871536e-08
SIBPAL O 0 1.8439708583173342e-05
Pempirical O 0 7.511566764151212e-06
value O 0 1.8875805096740805e-07
< O 0 4.154685484536458e-06
1 O 0 6.587383154510462e-07
x O 0 3.0226965463953093e-06
10 O 0 3.786404647598829e-07
( O 0 5.99806426748728e-08
- O 0 2.3718328066024696e-06
3 O 0 3.7998685797902e-07
) O 0 1.4046526608524346e-08
) O 0 6.944297137323474e-09
that O 0 6.103765048948162e-09
are O 0 2.42698980912337e-08
linked O 0 5.06591604789719e-05
to O 0 5.4626875680696685e-06
mental O 0 0.3133503794670105
health O 0 0.0017403920646756887
wellness O 0 0.0012149462709203362
. O 0 1.3521875189326238e-05

These O 0 3.124440866031364e-07
findings O 0 9.172227350973117e-07
are O 0 7.09409020416274e-09
consistent O 0 3.2045073794506607e-07
with O 0 1.1094229535046907e-07
the O 0 2.3721806030607695e-07
hypothesis O 0 4.93432537496119e-07
that O 0 6.4297664970069945e-09
certain O 0 4.283101162627645e-08
alleles O 0 1.065966102942184e-06
could O 0 5.147078923073423e-07
prevent O 0 2.767763817246305e-06
or O 0 7.163723694247892e-07
modify O 0 4.021452241431689e-06
the O 0 5.115993531035201e-07
clinical O 0 1.8435066522215493e-05
manifestations O 0 6.800065602874383e-05
of O 0 2.054672222584486e-06
BPAD B-Disease 1 0.9999082088470459
and O 0 2.276306076964829e-06
perhaps O 0 3.4188769859611057e-06
other O 0 9.467897825743421e-07
related O 0 0.0012151846894994378
affective B-Disease 1 0.9996465444564819
disorders I-Disease 1 0.9999361038208008
. O 0 6.492313696071506e-05

Segregation O 0 0.01018248125910759
distortion O 1 0.7492873668670654
in O 0 0.002417324809357524
myotonic B-Disease 1 0.9999710321426392
dystrophy I-Disease 1 0.9999879598617554
. O 0 0.00022594761685468256

Myotonic B-Disease 1 0.9999314546585083
dystrophy I-Disease 1 0.9999797344207764
( O 0 0.0014134414959698915
DM B-Disease 1 0.9998949766159058
) O 0 3.5299674436828354e-06
is O 0 1.0067391258417047e-06
an O 0 1.4454777783612371e-06
autosomal B-Disease 1 0.9979165196418762
dominant I-Disease 1 0.999206006526947
disease I-Disease 1 0.9998764991760254
which O 0 7.932740118121728e-07
, O 0 1.7313917055616912e-07
in O 0 3.103545509475225e-08
the O 0 6.362840565543593e-08
typical O 0 2.898727188949124e-06
pedigree O 0 2.5151170120807365e-05
, O 0 9.898968045263246e-08
shows O 0 4.53536408429045e-08
a O 0 1.4917048929419252e-07
three O 0 1.1674428890273703e-07
generation O 0 4.156214799877489e-06
anticipation O 0 1.5145764336921275e-05
cascade O 0 0.0011198491556569934
. O 0 7.898220246715937e-06

This O 0 2.3287409476324683e-06
results O 0 3.27640118484851e-05
in O 0 3.5523615224519745e-05
infertility B-Disease 1 0.9961575865745544
and O 1 0.9253175854682922
congenital B-Disease 1 0.9999997615814209
myotonic I-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999974966049194
( O 0 1.638972207729239e-05
CDM B-Disease 0 0.00011584529420360923
) O 0 7.625701670121998e-08
with O 0 5.3596032500990987e-08
the O 0 2.000895733544894e-07
disappearance O 0 1.605886973266024e-05
of O 0 1.977572310352116e-06
DM B-Disease 1 0.9999088048934937
in O 0 1.1772406196541851e-06
that O 0 2.923553097389231e-07
pedigree O 0 0.00021911026851739734
. O 0 1.1198086212971248e-05

The O 0 6.410776336451818e-07
concept O 0 1.1009547051799018e-06
of O 0 7.417393135256134e-07
segregation O 0 8.881162648322061e-05
distortion O 0 0.0010680538835003972
, O 0 8.077050210886227e-07
where O 0 1.039183246120956e-07
there O 0 2.5916607526710322e-08
is O 0 2.087564077157822e-08
preferential O 0 1.2787683090209612e-07
transmission O 0 8.461258403258398e-06
of O 0 1.4731812214563433e-08
the O 0 6.646283168265654e-08
larger O 0 3.377105599611241e-07
allele O 0 5.383677034842549e-06
at O 0 1.9101209545624442e-05
the O 0 4.392299160826951e-06
DM B-Disease 1 0.9988719820976257
locus O 0 3.5745313653023914e-05
, O 0 8.887993772077607e-07
has O 0 2.884954994897271e-07
been O 0 8.644794036172243e-08
put O 0 1.9326677147546434e-07
forward O 0 2.4491697558914893e-07
to O 0 3.94507004841671e-08
explain O 0 5.980494961477234e-07
partially O 0 7.566222393506905e-06
the O 0 2.3831599094137346e-07
maintenance O 0 0.00013386858336161822
of O 0 3.0202415928215487e-06
DM B-Disease 1 0.9998714923858643
in O 0 1.501629071753996e-06
the O 0 4.0853819882613607e-07
population O 0 1.6419100745679316e-07
. O 0 1.3986876865601516e-06

In O 0 2.858444076991873e-06
a O 0 4.63829792352044e-06
survey O 0 4.544024704955518e-06
of O 0 1.1051583896914963e-06
DM B-Disease 1 0.9994551539421082
in O 0 2.318432279935223e-06
Northern O 0 4.294256541470531e-06
Ireland O 0 7.374990218522726e-06
, O 0 8.293865221276064e-07
59 O 0 5.500897714227904e-06
pedigrees O 0 1.3270045201352332e-05
were O 0 1.5190312296908814e-06
ascertained O 0 2.979356395371724e-05
. O 0 4.188904767943313e-06

Sibships O 0 0.0005769080598838627
where O 0 7.639727073183167e-07
the O 0 1.6801544688860304e-07
status O 0 3.636214103153179e-07
of O 0 1.810537675339674e-08
all O 0 1.1083353790297679e-08
the O 0 4.73196273276244e-08
members O 0 2.3022366235636582e-08
had O 0 1.7272786578814703e-07
been O 0 8.296413511743594e-08
identified O 0 1.3204697779656271e-07
were O 0 2.0635029684967776e-08
examined O 0 5.570038865698734e-07
to O 0 6.60260157658854e-09
determine O 0 3.308335294605058e-08
the O 0 6.776115668571947e-08
transmission O 0 1.4674102203571238e-05
of O 0 1.7784851991109463e-07
the O 0 5.720294211641885e-06
DM B-Disease 1 0.9990869760513306
expansion O 0 1.0263777767249849e-05
from O 0 3.1409624057232577e-07
affected O 0 2.758256698598416e-07
parents O 0 3.055208352975569e-08
to O 0 5.82159875861521e-09
their O 0 5.855265428067469e-08
offspring O 0 8.750032975513022e-06
. O 0 2.834425913533778e-06

Where O 0 2.9084799280099105e-06
the O 0 4.697888300597697e-07
transmitting O 0 0.00021953096438664943
parent O 0 5.619900912279263e-05
was O 0 1.6690579286660068e-05
male O 0 2.423924115646514e-06
, O 0 9.04911132693087e-07
58 O 0 1.3101894182909746e-05
. O 0 2.6125908334506676e-06

3 O 0 7.886253115430009e-06
% O 0 7.108287292112436e-08
of O 0 1.2853090147757484e-08
the O 0 6.187175927152566e-08
offspring O 0 6.57293128369929e-07
were O 0 1.4159711270167463e-07
affected O 0 1.724569358430017e-07
, O 0 3.5397327735608997e-08
and O 0 5.22084953047397e-08
in O 0 5.9084193537728424e-08
the O 0 5.5891160144483365e-08
case O 0 1.8165222570587503e-07
of O 0 1.6138585579028586e-08
a O 0 5.228562827142014e-07
female O 0 1.8233256469102344e-06
transmitting O 0 0.00018571276450529695
parent O 0 4.746787089970894e-05
, O 0 2.028541530307848e-06
68 O 0 2.7884078008355573e-05
. O 0 3.1840345400269143e-06

7 O 0 2.40083481912734e-05
% O 0 1.93671212400659e-07
were O 0 7.196372280304786e-07
affected O 0 9.923664038069546e-06
. O 0 6.37734456176986e-06

Studies O 0 3.899290732078953e-06
on O 0 1.651250158829498e-06
meiotic O 0 6.19331476627849e-05
drive O 0 1.2818155482818838e-05
in O 0 3.3949090720852837e-06
DM B-Disease 1 0.9981322884559631
have O 0 1.3831214573656325e-07
shown O 0 1.5792082308507815e-07
increased O 0 9.752954355235488e-08
transmission O 0 7.438470220222371e-06
of O 0 1.1692340429192427e-08
the O 0 3.778079005201107e-08
larger O 0 2.435620558571827e-07
allele O 0 5.41589861313696e-06
at O 0 2.0381174181238748e-05
the O 0 2.9851114504708676e-06
DM B-Disease 1 0.9969248175621033
locus O 0 2.3433560272678733e-05
in O 0 1.8509174424252706e-06
non O 0 0.0001725909678498283
- O 1 0.67265385389328
DM O 1 0.9989545345306396
heterozygotes O 0 0.0002828564902301878
for O 0 2.9175864710850874e-06
CTGn O 0 0.0014121218118816614
. O 0 1.179048831545515e-05

This O 0 4.855153292737668e-07
study O 0 1.6099745892006467e-07
provides O 0 2.0587735960475584e-08
further O 0 1.5544648235277236e-08
evidence O 0 3.910697898845683e-08
that O 0 2.0524062449567282e-08
the O 0 1.0122759022124228e-06
DM B-Disease 1 0.9995841383934021
expansion O 0 1.4218781871022657e-05
tends O 0 4.6466120693366975e-06
to O 0 8.26191026703782e-08
be O 0 3.974677724727371e-07
transmitted O 0 3.645106698968448e-05
preferentially O 0 1.5084645383467432e-05
. O 0 4.471174179343507e-06

Diagnosis O 1 0.9459062814712524
of O 0 0.0002789437712635845
hemochromatosis B-Disease 1 0.9999662637710571
. O 0 0.00045112200314179063

If O 0 0.00043128294055350125
untreated O 1 0.9670288562774658
, O 0 0.00018473064119461924
hemochromatosis B-Disease 1 0.9999847412109375
can O 0 0.0006449505453929305
cause O 0 0.18795640766620636
serious O 1 0.9947915077209473
illness O 1 0.9981845021247864
and O 0 1.5015962162578944e-06
early B-Disease 0 6.962216957617784e-06
death I-Disease 0 1.2611948477569968e-05
, O 0 2.2919148534583655e-07
but O 0 1.5651116314074898e-07
the O 0 1.5188603583737859e-06
disease O 0 0.3171041011810303
is O 0 3.3308322144876e-07
still O 0 6.622569230785302e-07
substantially O 0 1.012102893582778e-05
under O 0 7.910325075499713e-05
- O 1 0.9884994626045227
diagnosed O 1 0.9973618388175964
. O 0 9.563186722516548e-06

The O 0 2.5211068077624077e-06
cornerstone O 0 8.21562935016118e-05
of O 0 1.6099500044219894e-07
screening O 0 1.9313515622343402e-06
and O 0 2.85687491441422e-07
case O 0 7.126083687580831e-07
detection O 0 6.926309197297087e-06
is O 0 1.0088394475360474e-07
the O 0 6.052145096191452e-08
measurement O 0 3.953238774556667e-06
of O 0 2.0058421057456144e-07
serum O 0 3.506021312205121e-05
transferrin O 0 3.429863500059582e-05
saturation O 0 8.747939318709541e-06
and O 0 4.762962930726644e-07
the O 0 6.090324404794956e-07
serum O 0 8.52739394758828e-05
ferritin O 0 0.00034684661659412086
level O 0 4.40737530880142e-05
. O 0 5.56796430828399e-06

Once O 0 8.371967123821378e-05
the O 0 3.7473953398148296e-06
diagnosis O 0 0.002544499933719635
is O 0 2.442701998006669e-06
suspected O 0 2.562685403972864e-05
, O 0 5.559828082368767e-07
physicians O 0 3.4749955375446007e-06
must O 0 4.2205036265841045e-07
use O 0 9.792319133339333e-07
serum O 0 0.0001549573935335502
ferritin O 0 0.00047648907639086246
levels O 0 2.703911559365224e-05
and O 0 2.112056336045498e-06
hepatic O 1 0.7364311814308167
iron O 0 0.08016709983348846
stores O 0 1.5390553016914055e-05
on O 0 7.00168457115069e-05
liver O 1 0.9948433637619019
biopsy O 0 0.005118155851960182
specimens O 0 4.994150458514923e-06
to O 0 1.0235348213427642e-07
assess O 0 7.628473667864455e-06
patients O 0 7.857087211959879e-07
for O 0 7.596374196339184e-09
the O 0 1.0953772999755529e-07
presence O 0 1.2088690937162028e-06
of O 0 5.445177180263272e-07
iron B-Disease 1 0.9930770397186279
overload I-Disease 1 0.8747439384460449
. O 0 1.8299002476851456e-05

Liver O 1 0.9983184337615967
biopsy O 1 0.8679363131523132
is O 0 1.2501794799391064e-06
also O 0 3.46932864658811e-08
used O 0 1.1601129834559742e-08
to O 0 6.703239296967922e-09
establish O 0 1.084484111402162e-07
the O 0 7.36891294650377e-08
presence O 0 4.4970840917812893e-07
or O 0 1.334039097855566e-06
absence O 0 7.464279406121932e-06
of O 0 1.7988965055337758e-06
cirrhosis B-Disease 1 0.9997966885566711
, O 0 1.73734758845967e-06
which O 0 2.4756658945079835e-07
can O 0 5.238214839664579e-07
affect O 0 1.1713272215274628e-05
prognosis O 0 0.003394000232219696
and O 0 5.200949090067297e-06
management O 0 0.00011347996041877195
. O 0 1.0503656994842459e-05

A O 0 2.113452137564309e-05
DNA O 0 8.632016943010967e-06
- O 0 1.4365766219270881e-05
based O 0 1.7603989022063615e-07
test O 0 1.4143880378014728e-07
for O 0 1.2502559876281794e-08
the O 0 7.568826276838081e-08
HFE O 0 5.771315045421943e-05
gene O 0 5.038599510953645e-07
is O 0 1.9638960679912998e-08
commercially O 0 5.2402032935106035e-08
available O 0 1.6251114232090913e-08
, O 0 1.995599241411128e-08
but O 0 9.161857938977391e-09
its O 0 9.425752622860273e-09
place O 0 1.525289405890362e-07
in O 0 9.561580327499541e-08
the O 0 3.443407479153393e-07
diagnosis O 0 0.0014474630588665605
of O 0 4.005823484476423e-06
hemochromatosis B-Disease 1 0.9999897480010986
is O 0 1.6355636034859344e-05
still O 0 1.9868239178322256e-06
being O 0 4.391235052025877e-06
evaluated O 0 2.1740002921433188e-05
. O 0 4.1367511585121974e-06

Currently O 0 2.153199602616951e-06
, O 0 1.0497235791717685e-07
the O 0 2.2178856085020016e-08
most O 0 1.4561431171955519e-08
useful O 0 2.3686126837674237e-08
role O 0 5.933897995191728e-08
for O 0 9.374688580976454e-09
this O 0 1.032038365877952e-08
test O 0 5.969349103907007e-08
is O 0 1.502134061581728e-08
in O 0 9.575811255047029e-09
the O 0 5.491539312174609e-08
detection O 0 1.088396311388351e-05
of O 0 1.4629464430981898e-06
hemochromatosis B-Disease 1 0.9999445676803589
in O 0 9.461724062020949e-07
the O 0 3.086273920871463e-07
family O 0 9.634327398089226e-07
members O 0 3.8805307411848844e-08
of O 0 6.841973743121343e-08
patients O 0 1.4155649523672764e-06
with O 0 1.0155888929830326e-07
a O 0 3.0732348932360765e-06
proven O 0 2.886983384087216e-05
case O 0 1.815581640585151e-06
of O 0 1.4868572861814755e-07
the O 0 1.833911483117845e-05
disease O 1 0.9954906105995178
. O 0 7.446320523740724e-06

It O 0 1.2686272157225176e-06
is O 0 3.654123759133654e-07
crucial O 0 4.67567952000536e-06
to O 0 9.447492629988119e-06
diagnose O 1 0.9994320273399353
hemochromatosis B-Disease 1 0.9999890327453613
before O 1 0.9023370742797852
hepatic B-Disease 1 0.9997747540473938
cirrhosis I-Disease 1 0.999943733215332
develops O 0 0.0340433344244957
because O 0 7.38191301934421e-05
phlebotomy O 0 0.04775558039546013
therapy O 0 0.0017557104583829641
can O 0 5.062742638983764e-05
avert O 1 0.8793041110038757
serious O 1 0.999373733997345
chronic O 1 0.9999940395355225
disease O 1 0.9998553991317749
and O 0 1.4075189938012045e-06
can O 0 2.87191568304479e-07
even O 0 4.5358271449913445e-07
lead O 0 6.513768653348961e-07
to O 0 4.007318565868445e-08
normal O 0 1.4371316865435801e-06
life O 0 1.901135078696825e-06
expectancy O 0 9.658166163717397e-06
. O 0 3.740368583748932e-07
. O 0 1.0897358606598573e-06

Prevalence O 0 0.0008508737082593143
of O 0 3.2308787467627553e-07
the O 0 9.061944297172886e-07
I1307K O 0 7.995812484296039e-05
APC B-Disease 0 5.256036820355803e-05
gene O 0 3.5411346743785543e-06
variant O 0 1.8514456314733252e-05
in O 0 2.1285107720814267e-07
Israeli O 0 2.7027072064811364e-06
Jews O 0 2.5795540636863734e-07
of O 0 1.2634720825133172e-08
differing O 0 1.848199673304407e-07
ethnic O 0 1.1311414027659339e-07
origin O 0 3.5934257880398945e-07
and O 0 1.3585792657977436e-05
risk O 0 0.04111555218696594
for O 1 0.7211563587188721
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
. O 0 0.0001191900810226798

BACKGROUND O 0 0.00033471608185209334
& O 0 0.00011505399743327871
AIMS O 0 1.8880604329751804e-05
Israeli O 0 1.072831128112739e-05
Jews O 0 1.6574836081417743e-06
of O 0 1.868937289373207e-07
European O 0 6.020637556503061e-06
birth O 0 5.487718226504512e-05
, O 0 1.3929196711615077e-06
i O 0 9.604543265595566e-06
. O 0 1.3290646450059285e-07
e O 0 2.504437816241989e-06
. O 0 6.017968701144127e-08
, O 0 6.318673229088745e-08
Ashkenazim O 0 1.2815784430131316e-05
, O 0 2.0776221276719298e-07
have O 0 1.5733591851585516e-07
the O 0 1.578643059474416e-05
highest O 1 0.9994753003120422
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
incidence O 0 0.38350504636764526
of O 0 8.99988492619741e-08
any O 0 1.3556736178088613e-07
Israeli O 0 7.047025519568706e-06
ethnic O 0 2.1683042632503202e-06
group O 0 1.5671903383918107e-05
. O 0 8.965360393631272e-06

The O 0 2.962429334729677e-06
I1307K O 0 0.00018556194845587015
APC B-Disease 0 8.582672307966277e-05
gene O 0 6.5000808717741165e-06
variant O 0 8.487544255331159e-05
was O 0 2.0347808458609506e-05
found O 0 8.30441535981663e-07
in O 0 5.591631406787201e-07
6 O 0 1.3973509339848533e-05
. O 0 2.8808440220018383e-06

1 O 0 5.190380306885345e-06
% O 0 5.2620880097720146e-08
of O 0 1.2085005884898692e-08
American O 0 9.337431805533924e-08
Jews O 0 3.6850317997050297e-07
, O 0 1.8351464348143054e-07
28 O 0 8.960811896940868e-07
% O 0 1.3662535991443292e-08
of O 0 1.292342517444922e-07
their O 0 7.283168815774843e-05
familial O 1 0.9999706745147705
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
cases O 0 5.03728624607902e-05
, O 0 5.669907636729477e-07
but O 0 8.450692945416449e-08
not O 0 3.705979878532162e-08
in O 0 2.246051167276164e-07
non O 0 7.613617526658345e-06
- O 0 7.5590331107378e-05
Jews O 0 7.42809197618044e-06
. O 0 8.006341886357404e-06

We O 0 1.0729764653660823e-05
assessed O 0 1.0579527042864356e-05
the O 0 5.925471668888349e-07
I1307K O 0 7.237060344778001e-05
prevalence O 0 2.1142543118912727e-05
in O 0 7.921402556121393e-08
Israeli O 0 8.514550131621945e-07
Jews O 0 1.866511354364775e-07
of O 0 1.8314743499558972e-08
differing O 0 2.875116535960842e-07
ethnic O 0 2.3405648619245767e-07
origin O 0 6.330567998702463e-07
and O 0 1.1039279343094677e-05
risk O 0 0.00763873104006052
for O 1 0.7248785495758057
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
. O 0 9.301154932472855e-05

METHODS O 0 4.49206982011674e-06
DNA O 0 4.15410704590613e-06
samples O 0 5.798893880637479e-07
from O 0 6.49678142394805e-08
500 O 0 4.148198229358968e-07
unrelated O 0 8.891129823496158e-07
Jews O 0 1.4114101531959022e-07
of O 0 3.5352996974324924e-08
European O 0 1.7449858660256723e-06
or O 0 6.515944733109791e-06
non O 0 2.1861460481886752e-05
- O 0 2.4602886696811765e-05
European O 0 6.956096854082716e-07
origin O 0 1.2136753468894312e-07
, O 0 7.794815815032052e-08
with O 0 3.1542718659238744e-08
or O 0 2.636986948800768e-07
without O 0 1.0718249399133128e-07
a O 0 4.0140199075722194e-07
personal O 0 2.4214864424720872e-06
and O 0 3.596639089664677e-06
/ O 0 9.625924576539546e-05
or O 0 2.3529664758825675e-06
family O 0 3.4046518067043507e-06
history O 0 1.6827583522172063e-06
of O 0 3.208953671673953e-07
neoplasia B-Disease 0 0.05809839442372322
, O 0 5.854461164744862e-07
were O 0 1.4353453536841698e-07
examined O 0 1.5006527291916427e-06
for O 0 8.59135163011615e-09
the O 0 8.553912067554847e-08
I1307K O 0 7.137705779314274e-06
variant O 0 5.215970304561779e-06
by O 0 4.8670720786958555e-08
the O 0 1.190691136798705e-07
allele O 0 4.218269168632105e-06
- O 0 7.581563750136411e-06
specific O 0 1.949606058815334e-07
oligonucleotide O 0 6.198260234668851e-05
( O 0 3.674206254800083e-06
ASO O 0 0.03032124787569046
) O 0 3.2635932711855276e-07
method O 0 2.1160201413295e-06
. O 0 2.9719938083871966e-06

RESULTS O 0 2.4477843908243813e-05
In O 0 3.0186930644049426e-07
persons O 0 1.7259218054732628e-07
at O 0 1.7706031940178946e-05
average O 0 8.136430551530793e-05
risk O 0 0.0018565119244158268
for O 0 0.019262254238128662
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
, O 0 2.519972213121946e-06
I1307K O 0 1.9396507923374884e-05
was O 0 5.076479283161461e-06
found O 0 5.055416636423615e-07
in O 0 2.451483283039124e-07
5 O 0 3.684255716507323e-06
. O 0 2.6891659672401147e-06

0 O 0 2.7882372251042398e-06
% O 0 1.9789215599530507e-08
of O 0 5.663901347929823e-09
120 O 0 6.697031551539112e-08
European O 0 4.884136615146417e-07
and O 0 1.4349349157782854e-06
1 O 0 1.584460369485896e-05
. O 0 4.37631888416945e-06

6 O 0 1.253534992429195e-05
% O 0 6.42495123770459e-08
of O 0 7.388715062006668e-08
188 O 0 2.140542619599728e-06
non O 0 4.468408405955415e-06
- O 0 1.844097459979821e-05
European O 0 2.254902938148007e-06
Jews O 0 2.5921706310327863e-06
( O 0 8.795258850113896e-07
P O 0 8.458020602120087e-05
= O 0 1.5172769053606316e-05
0 O 0 1.3510315284293029e-06
. O 0 1.4241346946164413e-07
08 O 0 5.864491868123878e-06
) O 0 2.667500780262344e-07
. O 0 9.31977808704687e-07

It O 0 2.3233417323353933e-06
occurred O 0 1.2754759154631756e-05
in O 0 7.245554911605723e-07
15 O 0 3.339889417475206e-06
. O 0 1.7528781199871446e-06

4 O 0 6.336417754937429e-06
% O 0 1.0160732699660002e-07
of O 0 1.0794734350838553e-07
52 O 0 4.721757250081282e-06
Ashkenazi O 0 2.8120008209953085e-05
Israelis O 0 4.511750830715755e-06
with O 0 6.886415121698519e-06
familial O 1 0.9965303540229797
cancer B-Disease 1 0.9989317059516907
( O 0 1.6389749362133443e-06
P O 0 0.0002012956829275936
= O 0 1.2703834727290086e-05
0 O 0 6.641353138547856e-07
. O 0 5.5247699748406376e-08
02 O 0 2.2225408429221716e-06
) O 0 1.4097523148848268e-08
and O 0 3.3381454045411374e-08
was O 0 5.042137445343542e-07
not O 0 2.3273939220302964e-08
detected O 0 1.2683102568189497e-06
in O 0 2.725346703869036e-08
51 O 0 4.1687135876600223e-07
non O 0 1.3711663768845028e-06
- O 0 6.064744866307592e-06
European O 0 7.82112863362272e-07
Jews O 0 1.585568952577887e-06
at O 0 0.00010102091619046405
increased O 0 4.3841431761393324e-05
cancer B-Disease 1 0.9951210618019104
risk O 0 0.00014042896509636194
. O 0 5.052128472016193e-06

Colorectal B-Disease 1 0.9976134300231934
neoplasia I-Disease 1 0.9880236387252808
occurred O 0 0.0011028615990653634
personally O 0 6.771457265131176e-05
or O 0 4.4405351218301803e-07
in O 0 6.124922435901681e-08
the O 0 1.9640159720779593e-08
families O 0 1.8687302372200065e-08
of O 0 1.8649664923486853e-08
13 O 0 4.756603573241591e-07
of O 0 5.213217235677803e-08
20 O 0 1.2086743481631856e-06
Ashkenazi O 0 1.732746204652358e-05
I1307K O 0 1.87116238521412e-05
carriers O 0 1.6995574014799786e-06
, O 0 1.7877630398288602e-07
8 O 0 5.060693979430653e-07
of O 0 1.4359732070090558e-08
whom O 0 7.546971119154477e-07
also O 0 2.669216030426469e-07
had O 0 5.584724931395613e-07
a O 0 3.1237050279742107e-07
personal O 0 4.526170869212365e-06
or O 0 6.949871021788567e-06
family O 0 1.0192843546974473e-05
history O 0 1.0360783562646247e-05
of O 0 2.3493878416047664e-06
noncolonic O 0 0.13611719012260437
neoplasia B-Disease 1 0.9903931021690369
. O 0 4.8178389988606796e-05

CONCLUSIONS O 0 7.609021849930286e-05
The O 0 5.9920544117630925e-06
I1307K O 0 0.0003149939584545791
APC O 0 0.00024790276074782014
variant O 0 0.00018243562954012305
may O 0 2.141457343896036e-06
represent O 0 1.1157211332601946e-07
a O 0 1.8312738347958657e-06
susceptibility O 0 6.049710646038875e-05
gene O 0 9.756285180628765e-06
for O 0 5.313805104378844e-06
colorectal B-Disease 1 0.9999954700469971
, I-Disease 0 1.0646026566973887e-06
or I-Disease 0 6.515445534205355e-07
other I-Disease 0 2.8563303544615337e-07
, I-Disease 0 1.0419424143037759e-05
cancers I-Disease 1 0.8956780433654785
in O 0 7.112722073543409e-07
Ashkenazi O 0 4.138943404541351e-05
Jews O 0 2.1125479179318063e-06
, O 0 5.164928325029905e-07
and O 0 4.3064230226264044e-07
partially O 0 1.6749623682699166e-05
explains O 0 1.9411179437156534e-06
the O 0 4.771678163706383e-07
higher O 0 4.182641350780614e-05
incidence O 1 0.6100168824195862
of O 0 0.013230103068053722
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
in O 0 1.5707458942415542e-06
European O 0 4.269918008503737e-06
Israelis O 0 2.374922769377008e-05
. O 0 6.829092853877228e-06

Systematic O 0 1.1644683581835125e-05
analysis O 0 2.3929853796289535e-06
of O 0 1.1304625786578981e-06
coproporphyrinogen O 0 0.003495774231851101
oxidase O 0 0.0009532892145216465
gene O 0 0.0006048866780474782
defects O 1 0.9965333938598633
in O 0 8.71481461217627e-06
hereditary B-Disease 1 0.9955905675888062
coproporphyria I-Disease 0 0.10562590509653091
and O 0 1.5924710169201717e-05
mutation O 0 0.00031205895356833935
update O 0 0.00021857628598809242
. O 0 9.345284524897579e-06

Hereditary B-Disease 1 0.9961258769035339
coproporphyria I-Disease 1 0.9220427870750427
( O 0 8.306282688863575e-05
HC B-Disease 1 0.9993284940719604
) O 0 4.8274559958372265e-06
is O 0 2.4465625756420195e-06
an O 0 1.5455974789801985e-05
acute O 1 0.9989975094795227
hepatic B-Disease 1 0.9998835325241089
porphyria I-Disease 1 0.9997126460075378
with O 0 0.0012054144171997905
autosomal O 1 0.9993764758110046
dominant O 1 0.9954545497894287
inheritance O 1 0.9334964156150818
caused O 0 0.01094659510999918
by O 0 2.417810719634872e-06
deficient B-Disease 0 0.0007642891141586006
activity I-Disease 0 2.109849901898997e-06
of I-Disease 0 3.4745011134873494e-07
coproporphyrinogen I-Disease 0 0.000950781162828207
III I-Disease 0 0.04795503243803978
oxidase I-Disease 0 6.798723188694566e-05
( O 0 1.5346406598837348e-06
CPO O 0 5.263972343527712e-05
) O 0 6.314492679848627e-07
. O 0 2.03696072276216e-06

Clinical O 0 0.0008264551870524883
manifestations O 0 0.001118103158660233
of O 0 2.1065404780529207e-06
the O 0 9.179996413877234e-05
disease O 1 0.9980112314224243
are O 0 2.4117275643220637e-07
characterized O 0 6.789690814912319e-05
by O 0 2.6152531518164324e-06
acute O 1 0.9799492955207825
attacks O 0 0.00034938144381158054
of O 0 4.892044671578333e-05
neurological B-Disease 1 0.9999687671661377
dysfunction I-Disease 1 0.9987913966178894
often O 0 2.794059219013434e-05
precipitated O 0 0.0002039616520050913
by O 0 3.2267712413158733e-07
drugs O 0 3.087803634116426e-06
, O 0 4.2693375235103304e-07
fasting O 0 6.3367319853568915e-06
, O 0 1.5007315141701838e-06
cyclical O 0 0.0007779551669955254
hormonal O 0 0.0026718568988144398
changes O 0 1.6305737517541274e-05
, O 0 9.038019925355911e-06
or O 0 0.002319933380931616
infectious B-Disease 1 0.9997863173484802
diseases I-Disease 1 0.9997779726982117
. O 0 2.9249213184812106e-05

Skin O 1 0.9916609525680542
photosensitivity O 1 0.9911312460899353
may O 0 0.00014539933181367815
also O 0 9.47565752085211e-07
be O 0 2.9859094752282545e-07
present O 0 1.248936541742296e-06
. O 0 3.976470452471403e-06

The O 0 9.323476319877955e-07
seven O 0 1.0073950988953584e-06
exons O 0 1.875364250736311e-05
, O 0 5.0747678415064e-07
the O 0 4.2643122810659406e-07
exon O 0 3.936356370104477e-05
/ O 0 1.938457899086643e-05
intron O 0 3.629622369771823e-05
boundaries O 0 3.4363284839855623e-07
and O 0 1.5842418576994532e-07
part O 0 2.770161415810435e-07
of O 0 5.964682259218534e-08
3 O 0 1.9242791040596785e-06
noncoding O 0 1.3512580153474119e-05
sequence O 0 3.1612950124326744e-07
of O 0 6.062762736291916e-08
the O 0 2.5401917014278297e-07
CPO O 0 1.5002840882516466e-05
gene O 0 3.673011406135629e-07
were O 0 7.934134771403478e-08
systematically O 0 7.139947229006793e-07
analyzed O 0 5.092880428492208e-07
by O 0 4.11027514246598e-08
an O 0 9.573898296366679e-08
exon O 0 2.293638499395456e-05
- O 0 4.662639548769221e-05
by O 0 2.6424197585583897e-06
- O 0 0.0004420817131176591
exon O 0 0.0006371031631715596
denaturing O 0 0.004947581794112921
gradient O 0 0.00067098718136549
gel O 0 0.0010232384083792567
electrophoresis O 0 0.00019162616808898747
( O 0 1.2283934438528377e-06
DGGE O 0 0.00010887115786317736
) O 0 9.063415973287192e-08
strategy O 0 2.977884889787674e-07
followed O 0 8.541195484212949e-08
by O 0 2.260860609837323e-09
direct O 0 6.142374608941736e-09
sequencing O 0 1.1493214202573654e-07
in O 0 1.836683765077396e-07
seven O 0 5.839946197738755e-07
unrelated O 0 3.6539182474371046e-05
heterozygous O 0 6.979140016483143e-05
HC B-Disease 1 0.9975653886795044
patients O 0 7.31206382624805e-05
from O 0 6.539025889651384e-07
France O 0 5.111384962219745e-05
, O 0 1.134988679041271e-06
Holland O 0 3.2954601920209825e-05
, O 0 8.198410910154053e-07
and O 0 2.2016349703335436e-06
Czech O 0 0.08094187825918198
Republic O 0 0.00019234043429605663
. O 0 1.491914827056462e-05

Seven O 0 5.5552504818479065e-06
novel O 0 3.3035294109140523e-06
mutations O 0 5.492122909345198e-06
and O 0 7.159038517556837e-08
two O 0 3.6294643734891e-08
new O 0 6.218801331669965e-07
polymorphisms O 0 2.0647430574172176e-05
were O 0 1.8218812556369812e-06
detected O 0 0.0002482549462001771
. O 0 3.927445504814386e-06

Among O 0 8.514371643286722e-07
these O 0 3.8151334535996284e-08
mutations O 0 2.740030140557792e-06
two O 0 1.1509535369214063e-07
are O 0 6.239486083359225e-08
missense O 0 4.9297996156383306e-05
( O 0 7.494055580536951e-07
G197W O 0 4.343167529441416e-05
, O 0 8.634574442112353e-07
W427R O 0 9.880603101919405e-06
) O 0 7.18450934300563e-08
, O 0 6.05137131515221e-08
two O 0 3.922126978750384e-08
are O 0 7.577275340509004e-08
nonsense O 0 1.9980989236501046e-05
( O 0 5.187646365811815e-07
Q306X O 0 1.9462082491372712e-05
, O 0 3.239771046992246e-07
Q385X O 0 4.0376035030931234e-06
) O 0 4.77034980406188e-08
, O 0 3.021393979452114e-08
two O 0 1.8151501635088607e-08
are O 0 8.627708325548156e-09
small O 0 2.1917018955264211e-07
deletions O 0 1.0525627658353187e-05
( O 0 1.0446766509630834e-06
662de14bp O 0 3.52721253875643e-05
; O 0 7.98346036390285e-07
1168del3bp O 0 6.420751742552966e-05
removing O 0 7.511065177823184e-06
a O 0 1.067244738806039e-06
glycine O 0 1.3100432624923997e-05
at O 0 8.1365878941142e-06
position O 0 1.3007620509597473e-06
390 O 0 6.560256338161707e-07
) O 0 3.956674987648512e-08
, O 0 2.5995470664952336e-08
and O 0 1.831670104479599e-08
one O 0 3.2876904754175484e-08
is O 0 1.602854560189826e-08
a O 0 1.770102500131543e-07
splicing O 0 1.0127884706889745e-05
mutation O 0 2.092973591061309e-05
( O 0 6.678713475594122e-07
IVS1 O 0 0.00016925815725699067
- O 0 3.3393767807865515e-05
15c O 0 7.333403482334688e-05
- O 0 1.8091855963575654e-05
- O 0 1.2980065548617858e-05
> O 0 8.122238796204329e-06
g O 0 4.525428266788367e-06
) O 0 2.6119424845205685e-08
which O 0 1.1648801034880307e-08
creates O 0 9.134274847610868e-08
a O 0 8.357960012972399e-08
new O 0 1.4377125978626282e-07
acceptor O 0 1.5069916798893246e-06
splice O 0 0.00016941867943387479
site O 0 0.00010074906458612531
. O 0 6.959176516829757e-06

The O 0 2.9270115646795603e-06
pathological O 0 0.00024241350183729082
significance O 0 2.9680679745069938e-06
of O 0 1.5069025494085508e-07
the O 0 4.68644202555879e-07
point O 0 9.946811587724369e-06
mutations O 0 3.519595702528022e-05
G197W O 0 4.135944618610665e-05
, O 0 6.462831265707791e-07
W427R O 0 7.53112090023933e-06
, O 0 8.030615106235928e-08
and O 0 6.180641776154516e-08
the O 0 1.3367869655667164e-07
in O 0 5.78134518036677e-07
- O 0 3.1655130442231894e-05
frame O 0 3.3729309507180005e-05
deletion O 0 2.7602811314864084e-05
390delGly O 0 3.775089862756431e-05
were O 0 2.3711626795375196e-07
assessed O 0 6.56494364648097e-07
by O 0 6.4183960368779935e-09
their O 0 4.545676279832378e-09
respective O 0 8.280399299565033e-08
expression O 0 2.7409137715039833e-07
in O 0 6.278835229522883e-08
a O 0 1.2812793670491374e-07
prokaryotic O 0 5.887270617677132e-07
system O 0 7.433843052240263e-07
using O 0 2.2135964172775857e-07
site O 0 8.88079284777632e-06
- O 0 1.707032060949132e-05
directed O 0 1.3806138667860068e-06
mutagenesis O 0 6.128519453341141e-05
. O 0 4.265676579962019e-06

These O 0 1.5516380926783313e-06
mutations O 0 7.368937076535076e-05
resulted O 0 3.439004331085016e-06
in O 0 2.4774962525953015e-07
the O 0 1.8638289134287334e-07
absence O 0 2.775000211840961e-06
or O 0 6.374647796292265e-07
a O 0 1.0653288882167544e-06
dramatic O 0 8.222714313887991e-06
decrease O 0 6.234839020180516e-06
of O 0 3.1549279810860753e-07
CPO O 0 0.0001075643376680091
activity O 0 4.608341896528145e-06
. O 0 2.9332318263186608e-06

The O 0 8.469569934277388e-07
two O 0 3.1981812753656413e-07
polymorphisms O 0 8.401019840675872e-06
were O 0 1.3802778653371206e-07
localized O 0 1.9829753000522032e-05
in O 0 6.545595283569128e-07
noncoding O 0 5.700318070012145e-05
part O 0 3.358602214120765e-07
of O 0 1.2553575956530949e-08
the O 0 2.335317894619493e-08
gene O 0 2.4499291839674697e-07
1 O 0 3.270241961672582e-07
) O 0 3.19457171826798e-08
a O 0 5.378465743888228e-07
C O 0 1.8592323613120243e-05
/ O 0 1.67433317983523e-05
G O 0 3.1869345548329875e-05
polymorphism O 0 3.393371343918261e-06
in O 0 1.4425374672555336e-07
the O 0 2.870869764137751e-07
promotor O 0 0.0008558419649489224
region O 0 1.3638497875945177e-05
, O 0 6.466406716754136e-07
142 O 0 1.702665826996963e-06
bp O 0 1.666462230787147e-05
upstream O 0 7.841712204026408e-07
from O 0 4.2334114880304696e-08
the O 0 1.3915169461142796e-08
transcriptional O 0 5.406642458183342e-07
initiation O 0 1.399848542860127e-06
site O 0 3.2718814964027843e-06
( O 0 1.9267932316324732e-07
- O 0 8.334053745784331e-06
142C O 0 2.040373146883212e-05
/ O 0 1.730772783048451e-05
G O 0 1.658400651649572e-05
) O 0 4.6479676996113994e-08
, O 0 3.530582759481149e-08
and O 0 4.042724910391371e-08
2 O 0 3.071695005019137e-07
) O 0 3.8787032252685094e-08
a O 0 5.659065891450155e-07
6 O 0 4.659529622585978e-06
bp O 0 3.533643393893726e-05
deletion O 0 2.6052910016005626e-06
polymorphism O 0 1.1982634759988287e-06
in O 0 5.3818940415339966e-08
the O 0 7.041572303023713e-08
3 O 0 1.4757623603145475e-06
noncoding O 0 2.751175270532258e-05
part O 0 3.754431645575096e-07
of O 0 3.756837685386927e-08
the O 0 1.7664093832081562e-07
CPO O 0 3.222501982236281e-05
gene O 0 2.3878744741523406e-06
, O 0 5.307801984599791e-07
574 O 0 1.1798497325798962e-05
bp O 0 4.982972677680664e-05
downstream O 0 1.2013804280286422e-06
of O 0 1.4800844105877786e-08
the O 0 6.652307149579428e-08
last O 0 1.070195366992266e-06
base O 0 2.233329325918021e-07
of O 0 1.0109193482321643e-08
the O 0 2.2326437942865596e-07
normal O 0 7.94473999121692e-06
termination O 0 3.7543170037679374e-05
codon O 0 1.3760337424173485e-05
( O 0 5.736485491070198e-07
+ O 0 1.5689383872086182e-05
574 O 0 8.284972136607394e-05
delATTCTT O 0 0.00014430057490244508
) O 0 1.7261569382753805e-06
. O 0 3.27547786582727e-06

Five O 0 1.6629963283776306e-05
intragenic O 0 0.0005693364655598998
dimorphisms O 0 0.00023879815125837922
are O 0 9.12053934598589e-08
now O 0 5.009659389543231e-07
well O 0 2.3360047407550155e-07
characterized O 0 4.069977421750082e-06
and O 0 2.091278901161786e-07
the O 0 2.169854411704364e-07
high O 0 1.342783525615232e-05
degree O 0 1.3619031733469456e-06
of O 0 1.5811266962373338e-07
allelic O 0 0.00013972239685244858
heterogeneity O 0 0.00018328231817577034
in O 0 1.588733539392706e-05
HC B-Disease 1 0.9988679885864258
is O 0 6.124396918494313e-07
demonstrated O 0 2.8061265311407624e-07
with O 0 1.6797324420281257e-08
seven O 0 4.459398539324866e-08
new O 0 1.733991794594658e-08
different O 0 4.8047730238920394e-09
mutations O 0 2.8475531621552364e-07
making O 0 3.547660654135143e-08
a O 0 1.1409125022510125e-07
total O 0 2.3501845802798016e-08
of O 0 6.67626807171473e-08
nineteen O 0 1.875800808193162e-05
CPO O 0 0.0004970878944732249
gene B-Disease 0 0.00018589453247841448
defects I-Disease 1 0.9955182671546936
reported O 0 3.151555574731901e-05
so O 0 2.8615923497454787e-07
far O 0 5.379025083129818e-07
. O 0 1.503628084265074e-07
. O 0 1.5651983176212525e-06

Coincidence O 0 2.462553311488591e-05
of O 0 2.871965136819199e-07
two O 0 2.2925533471607196e-07
novel O 0 2.6486611659493065e-06
arylsulfatase O 0 4.374171112431213e-05
A O 0 1.984619757422479e-06
alleles O 0 1.8704116655499092e-06
and O 0 1.268133701159968e-06
mutation O 0 3.861320510623045e-05
459 O 0 2.788402525766287e-05
+ O 0 2.6541671104496345e-05
1G O 0 0.00027517808484844863
> O 0 1.1378561794117559e-05
A O 0 1.128574240283342e-06
within O 0 1.4041080476090428e-07
a O 0 1.1547305120984674e-06
family O 0 5.195783614908578e-06
with O 0 3.28176720358897e-05
metachromatic B-Disease 1 0.9995704293251038
leukodystrophy I-Disease 1 0.9997127652168274
: O 0 1.8014612805927754e-06
molecular O 0 6.617621693294495e-06
basis O 0 3.2457984389111516e-07
of O 0 1.2717873687506653e-07
phenotypic O 0 0.00012203044752823189
heterogeneity O 0 0.0006079979939386249
. O 0 2.50318153121043e-05

In O 0 1.7355424688503263e-06
a O 0 5.438980679173255e-07
family O 0 7.766557246213779e-07
with O 0 1.3379387553413835e-07
three O 0 3.537741974923847e-07
siblings O 0 6.474511792475823e-06
, O 0 1.908283167040281e-07
one O 0 7.371316712578846e-08
developed O 0 2.2947369870962575e-06
classical O 0 0.00015554895799141377
late O 0 0.017226681113243103
infantile O 1 0.9972013235092163
metachromatic B-Disease 1 0.999566376209259
leukodystrophy I-Disease 1 0.9996381998062134
( O 0 0.0002259318862343207
MLD B-Disease 1 0.9971858859062195
) O 0 3.692039172165096e-06
, O 0 1.5899873915259377e-06
fatal O 0 0.007912022061645985
at O 0 2.5823803298408166e-05
age O 0 3.1207264328259043e-06
5 O 0 8.550891266168037e-07
years O 0 5.107082756694581e-07
, O 0 1.1918204734229221e-07
with O 0 2.840384922819794e-07
deficient O 0 0.0011881464160978794
arylsulfatase O 0 0.00022153482132125646
A O 0 7.361309144471306e-06
( O 0 7.214685524559172e-07
ARSA O 0 0.00026664332835935056
) O 0 8.151122443678105e-08
activity O 0 2.2895162032909866e-07
and O 0 1.5409732156967948e-07
increased O 0 8.610628583483049e-07
galactosylsulfatide O 0 0.00043323644786141813
( O 0 7.312233719858341e-06
GS O 1 0.9972572922706604
) O 0 1.6585288449277868e-06
excretion O 0 4.755195914185606e-05
. O 0 4.716041985375341e-06

The O 0 2.615807090933231e-07
two O 0 1.2232246149324055e-07
other O 0 6.441847943960965e-08
siblings O 0 7.741069566691294e-06
, O 0 6.667060574727657e-07
apparently O 0 3.8420798773586284e-06
healthy O 0 2.3494908418797422e-06
at O 0 5.223924745223485e-06
12 O 0 5.770009465777548e-07
( O 0 5.0457060751796234e-08
1 O 0 3.7018264720245497e-07
/ O 0 1.8751410379991285e-06
2 O 0 3.209241583590483e-07
) O 0 2.0113812837507794e-08
and O 0 2.8994071143984e-08
15 O 0 2.7128794499731157e-07
years O 0 1.494192218842727e-07
, O 0 3.5763449091064103e-08
respectively O 0 2.639930869463569e-07
, O 0 3.381594027018764e-08
and O 0 2.5401083902920618e-08
their O 0 3.769635981143438e-08
father O 0 1.0403297892480623e-05
, O 0 5.275886678646202e-07
apparently O 0 2.8784274945792276e-06
healthy O 0 6.832505050624604e-07
as O 0 1.602436583425515e-07
well O 0 3.0620489610555524e-07
, O 0 5.100239377497928e-07
presented O 0 6.025588390912162e-06
ARSA O 0 0.0032597107347100973
and O 0 7.435832230839878e-06
GS O 1 0.9889671206474304
values O 0 1.2902604566988884e-06
within O 0 3.6226455790711043e-07
the O 0 4.184729220924055e-07
range O 0 6.062385637051193e-06
of O 0 8.131368304020725e-06
MLD B-Disease 1 0.9997466206550598
patients O 0 0.0013434552820399404
. O 0 1.1673169865389355e-05

Mutation O 0 0.00016650916950311512
screening O 0 5.82248412683839e-06
and O 0 1.259841297951425e-07
sequence O 0 3.993691279902123e-07
analysis O 0 4.278508640709333e-07
disclosed O 0 1.2283710020710714e-05
the O 0 7.603190255167647e-08
involvement O 0 5.904335580453335e-07
of O 0 3.0451900556727196e-08
three O 0 1.1289353096799459e-07
different O 0 2.1043770459527877e-07
ARSA O 0 0.004252405371516943
mutations O 0 2.2870792236062698e-05
being O 0 3.2959849249891704e-07
the O 0 3.578760399136627e-08
molecular O 0 2.5018402993737254e-06
basis O 0 1.4260604075388983e-07
of O 0 2.241343537434659e-07
intrafamilial O 0 0.00035270547959953547
phenotypic O 0 0.0004250659258104861
heterogeneity O 0 0.002350296126678586
. O 0 3.1641855457564816e-05

The O 0 3.0328861612360924e-05
late O 0 0.0020097980741411448
infantile O 1 0.9893831610679626
patient O 0 0.008362133987247944
inherited O 1 0.5324262976646423
from O 0 5.214706561673665e-06
his O 0 5.4559345699090045e-06
mother O 0 9.421903087059036e-06
the O 0 1.335135806357357e-07
frequent O 0 7.862523489166051e-06
0 O 0 3.98140355173382e-06
- O 0 2.341010986128822e-05
type O 0 2.234829298686236e-05
mutation O 0 3.3148127840831876e-05
459 O 0 1.5387486200779676e-05
+ O 0 9.816098099690862e-06
1G O 0 0.00010625638242345303
> O 0 6.0900847529410385e-06
A O 0 1.2374351854305132e-06
, O 0 1.1033242941493882e-07
and O 0 5.0868127488001846e-08
from O 0 1.0074933953774234e-07
his O 0 1.3613721421279479e-06
father O 0 1.8482771338312887e-05
a O 0 1.4447363128056168e-06
novel O 0 1.4221018318494316e-06
, O 0 1.8555024894340022e-07
single O 0 8.498446959492867e-07
basepair O 0 8.02139620645903e-05
microdeletion O 0 3.526728323777206e-05
of O 0 5.4749524025510254e-08
guanine O 0 1.677971795288613e-06
at O 0 1.822364424697298e-06
nucleotide O 0 1.0229526878902107e-06
7 O 0 8.698380042915232e-07
in O 0 1.0395916660854709e-07
exon O 0 1.4512802408717107e-05
1 O 0 6.0715797189914156e-06
( O 0 9.066733355211909e-07
7delG O 0 0.0001072286322596483
) O 0 8.552848953513603e-07
. O 0 1.681180037849117e-06

The O 0 2.485114009687095e-06
two O 0 2.1286375613271957e-06
clinically O 0 0.0008309452096000314
unaffected O 0 0.0001338719011982903
siblings O 0 2.2556414478458464e-05
carried O 0 3.0706833058502525e-06
the O 0 8.652726251057175e-07
maternal O 0 9.09068767214194e-05
mutation O 0 5.341680662240833e-05
459 O 0 2.1485726392711513e-05
+ O 0 1.5706840713392012e-05
1G O 0 0.00019806026830337942
> O 0 1.075547970685875e-05
A O 0 2.4540356662328122e-06
and O 0 3.47433541492137e-07
, O 0 7.582220717949895e-08
on O 0 1.0262715477438178e-07
their O 0 2.042354552145298e-08
paternal O 0 4.3462769099278376e-06
allele O 0 2.799451749524451e-06
, O 0 2.3225099710089125e-07
a O 0 2.982739033541293e-07
novel O 0 6.252101911741192e-07
cytosine O 0 3.381321675988147e-06
to O 0 4.282676613343028e-08
thymidine O 0 1.3444351679936517e-05
transition O 0 4.7855601224000566e-06
at O 0 7.937069312902167e-06
nucleotide O 0 7.329730124183698e-06
2435 O 0 0.00041609801701270044
in O 0 9.847103683569003e-07
exon O 0 2.0209919966873713e-05
8 O 0 3.6469871247390984e-06
, O 0 1.20073735843107e-07
resulting O 0 4.902607884105237e-07
in O 0 4.6585469704041316e-08
substitution O 0 1.4938915171569533e-07
of O 0 7.989837769173391e-08
alanine O 0 5.142249574419111e-05
464 O 0 3.092440601903945e-05
by O 0 1.9132046418235404e-06
valine O 0 0.0009958461159840226
( O 0 4.082666237081867e-06
A464V O 0 0.00010962172382278368
) O 0 1.4732663657923695e-06
. O 0 2.5262500003009336e-06

The O 0 6.454247795772972e-06
fathers O 0 2.4427707103313878e-05
genotype O 0 7.565458508906886e-05
thus O 0 1.0730460417107679e-05
was O 0 9.459962166147307e-05
7delG O 0 0.0005488278111442924
/ O 0 0.00046445688349194825
A464V O 0 0.0008695413125678897
. O 0 1.837829768192023e-05

Mutation O 0 0.0009051226079463959
A464V O 0 0.00017906432913150638
was O 0 1.1109344086435158e-05
not O 0 1.2532660775832483e-07
found O 0 3.0924667271392536e-07
in O 0 2.4659834707563277e-07
18 O 0 6.763868896086933e-06
unrelated O 0 0.00032685400219634175
MLD B-Disease 1 0.9997460246086121
patients O 0 4.732639717985876e-05
and O 0 4.2869100980169605e-07
50 O 0 1.533572685730178e-06
controls O 0 2.494357613613829e-05
. O 0 6.048531759006437e-06

A464V O 0 0.0013560387305915356
, O 0 3.4055412925226847e-06
although O 0 1.1591483826123294e-06
clearly O 0 4.57673377241008e-06
modifying O 0 5.6318753195228055e-05
ARSA O 0 0.016846895217895508
and O 0 5.5176704336190596e-05
GS O 1 0.9985141158103943
levels O 0 6.698483775835484e-05
, O 0 1.2213705531394226e-06
apparently O 0 4.752622317027999e-06
bears O 0 3.914955414074939e-06
little O 0 9.938997891367762e-07
significance O 0 1.1570201650101808e-06
for O 0 3.19299743978263e-07
clinical O 0 1.8564418496680446e-05
manifestation O 0 0.0002751990978140384
of O 0 1.0769931577669922e-05
MLD B-Disease 1 0.9997801184654236
, O 0 7.909029591246508e-06
mimicking O 0 0.0001111613237299025
the O 0 3.647400944828405e-06
frequent O 0 0.0003161971690133214
ARSA O 0 0.07886426895856857
pseudodeficiency O 0 0.004244023002684116
allele O 0 0.0006274048355408013
. O 0 2.5261504561058246e-05

Our O 0 4.429881755640963e-06
results O 0 2.1095681859151227e-06
demonstrate O 0 2.206548401773034e-07
that O 0 2.5424691685316247e-08
in O 0 6.278045106000718e-08
certain O 0 1.9973515463789226e-07
genetic O 0 0.000149667335790582
conditions O 0 0.003974446095526218
MLD B-Disease 1 0.9997699856758118
- O 0 0.0029199630953371525
like O 0 2.8890628527733497e-05
ARSA O 0 0.013149493373930454
and O 0 2.442207005515229e-05
GS O 1 0.9888306260108948
values O 0 1.6224003047682345e-06
need O 0 2.720691156810062e-07
not O 0 5.4134591920274033e-08
be O 0 6.85778260844927e-08
paralleled O 0 2.4998582830448868e-06
by O 0 9.745290299179032e-07
clinical O 0 0.00023035994672682136
disease O 1 0.9036893248558044
, O 0 1.4234693423986755e-07
a O 0 1.2103325275347743e-07
finding O 0 1.6949138625932392e-07
with O 0 5.39461609605496e-07
serious O 0 0.0004730956570710987
diagnostic O 0 0.00046104498323984444
and O 0 1.6023835996747948e-05
prognostic O 0 0.009656011126935482
implications O 0 0.0007494620513170958
. O 0 2.345468965359032e-05

Moreover O 0 4.467702456167899e-05
, O 0 1.5312957657442894e-06
further O 0 6.769423634978011e-07
ARSA O 0 0.0026692990213632584
alleles O 0 1.1101284144388046e-05
functionally O 0 4.24017125624232e-05
similar O 0 4.959858870279277e-07
to O 0 1.1628780782757531e-07
A464V O 0 1.4027743418409955e-05
might O 0 3.021262102720357e-07
exist O 0 6.01467533556388e-08
which O 0 1.6534825064695724e-08
, O 0 8.282449392993385e-09
together O 0 8.789286631838422e-09
with O 0 1.1747223283009589e-07
0 O 0 3.8027940263418714e-06
- O 0 4.551568781607784e-05
type O 0 3.995666338596493e-05
mutations O 0 7.986972195794806e-05
, O 0 1.8391234561931924e-06
may O 0 5.740278993471293e-06
cause O 0 3.853386078844778e-05
pathological O 0 0.003410941921174526
ARSA O 0 0.16967324912548065
and O 0 4.4566939322976395e-05
GS O 1 0.9988951086997986
levels O 0 2.7396867153584026e-05
, O 0 1.8792356115682196e-07
but O 0 7.576466742875709e-08
not O 0 8.050199795661683e-08
clinical O 0 5.753059667767957e-06
outbreak O 0 6.2320199504029e-05
of O 0 1.1690739398773076e-07
the O 0 9.945095371222124e-06
disease O 1 0.9846711158752441
. O 0 1.3324065548658837e-06
. O 0 3.5127136470691767e-06

Human O 0 0.02203606627881527
MLH1 O 1 0.9962607026100159
deficiency O 1 0.9995107650756836
predisposes O 0 0.010317829437553883
to O 0 3.678623397718184e-05
hematological B-Disease 1 0.996340811252594
malignancy I-Disease 1 0.9988401532173157
and O 0 4.971894304617308e-05
neurofibromatosis B-Disease 1 0.9988547563552856
type I-Disease 0 0.046086493879556656
1 I-Disease 0 0.0002756746544037014
. O 0 1.0447361091792118e-05

Heterozygous O 0 0.0001369664678350091
germ O 0 0.002715239766985178
- O 0 0.00021766246936749667
line O 0 4.812287806998938e-05
mutations O 0 2.9711847673752345e-05
in O 0 1.7703152366266295e-07
the O 0 2.581680575985956e-07
DNA O 0 1.8260199794895016e-05
mismatch O 0 0.00529632018879056
repair O 0 0.011531454510986805
genes O 0 6.578786997124553e-05
lead O 0 0.0002299811749253422
to O 0 3.591842687455937e-05
hereditary B-Disease 1 0.9998749494552612
nonpolyposis I-Disease 1 0.9999518394470215
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
. O 0 0.00016062817303463817

The O 0 9.049794607562944e-05
disease O 1 0.9877277612686157
susceptibility O 0 0.00024613100686110556
of O 0 3.3073044392040174e-07
individuals O 0 3.985092860148143e-07
who O 0 6.089376256568357e-06
constitutionally O 0 4.140009332331829e-05
lack O 0 9.327550287707709e-07
both O 0 4.2958973267559486e-07
wild O 0 1.7517821106594056e-05
- O 0 0.0001132248726207763
type O 0 2.7626987503026612e-05
alleles O 0 6.2900462580728345e-06
is O 0 1.6266577631540713e-06
unknown O 0 1.074666124623036e-05
. O 0 4.2949650378432125e-06

We O 0 1.4456294366027578e-06
have O 0 1.5654893559258198e-07
identified O 0 3.7800728591719235e-07
three O 0 5.05158048724752e-08
offspring O 0 6.271534402912948e-07
in O 0 7.745654784230283e-07
a O 0 0.00012410104682203382
hereditary B-Disease 1 0.9999376535415649
nonpolyposis I-Disease 1 0.9999618530273438
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
family O 0 0.0010573796462267637
who O 0 3.8920010410947725e-05
developed O 0 0.0001403861097060144
hematological B-Disease 1 0.9935556054115295
malignancy I-Disease 1 0.9950518012046814
at O 0 6.226258119568229e-05
a O 0 6.622101977882267e-07
very O 0 3.0742884860046615e-07
early O 0 9.8015868843504e-07
age O 0 7.732767812740349e-07
, O 0 3.755669908400705e-08
and O 0 2.3594322939857193e-08
at O 0 5.13252132350317e-07
least O 0 1.5222545002302468e-08
two O 0 4.350647397899365e-09
of O 0 2.888129291278574e-09
them O 0 1.7238219740534078e-08
displayed O 0 3.3559299481566995e-06
signs O 0 1.1723832358256914e-05
of O 0 6.921277417859528e-07
neurofibromatosis B-Disease 1 0.9962435960769653
type I-Disease 0 0.0036061119753867388
1 I-Disease 0 3.549448592821136e-05
( O 0 2.1925395685684634e-06
NF1 B-Disease 0 0.0003365514858160168
) O 0 1.7316358480456984e-06
. O 0 2.749343366303947e-06

DNA O 0 6.6662810240814e-06
sequence O 0 6.297798336163396e-07
analysis O 0 2.2716707803738245e-07
and O 0 1.3154483724520105e-07
allele O 0 3.1752408631291473e-06
- O 0 4.417449417815078e-06
specific O 0 9.989248894726188e-08
amplification O 0 4.264558356226189e-06
in O 0 1.215602765114454e-07
two O 0 9.91277957496095e-08
siblings O 0 1.0165760613745078e-05
revealed O 0 1.2015238098683767e-05
a O 0 5.181053893466014e-06
homozygous O 0 7.230610208353028e-05
MLH1 O 0 0.007926744408905506
mutation O 0 0.00017847880371846259
( O 0 1.1844456366816303e-06
C676T O 0 7.536030898336321e-05
- O 0 0.00022368128702510148
- O 0 0.00027841614792123437
> O 0 6.824457523180172e-05
Arg226Stop O 0 0.0003247750282753259
) O 0 1.8967488131238497e-06
. O 0 1.6795967212601681e-06

Thus O 0 7.501015261368593e-06
, O 0 9.329809245173237e-07
a O 0 1.9463991520751733e-06
homozygous O 0 4.4653254008153453e-05
germ O 0 0.0024689293932169676
- O 0 0.001105358125641942
line O 0 0.0003457253333181143
MLH1 O 0 0.04643978178501129
mutation O 0 0.0007373333210125566
and O 0 1.592355329194106e-05
consequent O 0 0.025099260732531548
mismatch O 1 0.9987208247184753
repair O 1 0.9997488856315613
deficiency O 1 0.9998619556427002
results O 0 7.526105764554814e-05
in O 0 1.2422783584042918e-06
a O 0 1.13730939119705e-05
mutator O 0 0.039188992232084274
phenotype O 0 0.0009242833475582302
characterized O 0 0.00015718665963504463
by O 0 1.1169949175382499e-05
leukemia B-Disease 1 0.9993911981582642
and O 0 4.025694215670228e-05
/ O 1 0.5999765992164612
or O 1 0.9361459016799927
lymphoma B-Disease 1 0.9999998807907104
associated O 0 0.0001419174950569868
with O 0 8.031279321585316e-06
neurofibromatosis B-Disease 1 0.998340368270874
type I-Disease 0 0.004252684768289328
1 I-Disease 0 4.742981764138676e-05
. O 0 9.856498763838317e-07
. O 0 2.306552005393314e-06

Missense O 0 0.002211995655670762
mutations O 0 0.00012992077972739935
in O 0 2.733197561610723e-07
the O 0 4.5108112800562594e-08
most O 0 2.919918706822955e-08
ancient O 0 4.745928094962437e-07
residues O 0 3.36019570568169e-06
of O 0 9.544160661789647e-08
the O 0 3.5935593700742174e-07
PAX6 O 0 0.0005738009349443018
paired O 0 1.7869080693344586e-05
domain O 0 3.3989385883614887e-06
underlie O 0 4.298972635297105e-05
a O 0 3.869433840009151e-06
spectrum O 0 6.927156209712848e-05
of O 0 9.073947694560047e-06
human O 0 0.33844247460365295
congenital B-Disease 1 0.9999992847442627
eye I-Disease 1 0.9998737573623657
malformations I-Disease 1 0.9998621940612793
. O 0 0.0002034836361417547

Mutations O 0 0.00024239500635303557
of O 0 6.475787017734547e-07
the O 0 1.5397937431771425e-06
human O 0 4.1594037611503154e-05
PAX6 O 0 0.019985489547252655
gene O 0 0.0009400280541740358
underlie O 1 0.6671888828277588
aniridia B-Disease 1 0.999916672706604
( O 0 0.02043342962861061
congenital B-Disease 1 0.9999957084655762
absence I-Disease 0 0.0007326035411097109
of I-Disease 0 3.147994505070528e-07
the I-Disease 0 1.4221980109141441e-06
iris I-Disease 0 0.0016743531450629234
) O 0 4.890233071819239e-07
, O 0 3.1020428536976397e-07
a O 0 2.910505372710759e-06
rare O 0 0.00039318573544733226
dominant O 1 0.9630627632141113
malformation B-Disease 1 0.999924898147583
of I-Disease 0 2.6871200589084765e-06
the I-Disease 0 1.4408436982193962e-05
eye I-Disease 1 0.9239515662193298
. O 0 1.5573630662402138e-05

The O 0 5.0158064368588384e-06
spectrum O 0 0.0001144785710494034
of O 0 5.969639005343197e-06
PAX6 O 0 0.02022826112806797
mutations O 0 0.002669293899089098
in O 0 2.5701450795168057e-05
aniridia B-Disease 1 0.9996178150177002
patients O 0 7.448565884260461e-05
is O 0 3.443151399551425e-07
highly O 0 9.736558013173635e-07
biased O 0 1.3104690879117697e-06
, O 0 1.2933807624904148e-07
with O 0 7.414111991010941e-08
92 O 0 1.7048430436261697e-06
% O 0 1.0402536609888102e-08
of O 0 8.677383256383564e-09
all O 0 1.1607840377791945e-07
reported O 0 1.5429572158609517e-05
mutations O 0 2.094375122396741e-05
leading O 0 1.039990547724301e-05
to O 0 1.662741482277852e-07
premature O 0 3.415964238229208e-05
truncation O 0 1.7744843717082404e-05
of O 0 1.052753262342776e-07
the O 0 2.0133933276156313e-07
protein O 0 9.728316854307195e-07
( O 0 2.9295651415850443e-07
nonsense O 0 8.706383596290834e-06
, O 0 1.1735006921753666e-07
splicing O 0 2.038140110016684e-06
, O 0 2.0890382756988402e-07
insertions O 0 4.774628450832097e-06
and O 0 1.6720105122658424e-07
deletions O 0 4.597367933456553e-06
) O 0 1.316809061790991e-07
and O 0 7.644545263474356e-08
just O 0 2.7470369445836695e-07
2 O 0 2.168201689300986e-07
% O 0 7.385950517857509e-09
leading O 0 2.06397601232311e-07
to O 0 2.747155170013116e-09
substitution O 0 2.5376872159199593e-08
of O 0 1.1492420348702126e-08
one O 0 7.118680400708399e-08
amino O 0 2.3057286568928248e-07
acid O 0 2.3293582671612967e-06
by O 0 4.889570703880963e-08
another O 0 4.966125288774492e-07
( O 0 5.756862151429232e-07
missense O 0 8.108207111945376e-05
) O 0 1.537261141493218e-06
. O 0 4.090772563358769e-06

The O 0 9.651321306591853e-07
extraordinary O 0 4.6091859076113906e-06
conservation O 0 1.1036080422854866e-06
of O 0 3.112331015131531e-08
the O 0 3.400847674583929e-07
PAX6 O 0 0.00016295969544444233
protein O 0 2.498545200069202e-06
at O 0 5.90912304687663e-06
the O 0 9.595597560974056e-08
amino O 0 3.7529852647821826e-07
acid O 0 3.902036041836254e-06
level O 0 1.5537377748842118e-06
amongst O 0 1.4661364957646583e-06
vertebrates O 0 4.129792796447873e-05
predicts O 0 1.3711541214433964e-05
that O 0 1.195883925220187e-07
pathological O 0 0.0003153079014737159
missense O 0 0.0004469085833989084
mutations O 0 9.500807209406048e-05
should O 0 5.732832164540014e-07
in O 0 8.552149921570162e-08
fact O 0 1.1587003001523044e-07
be O 0 3.861747188693698e-08
common O 0 3.918657682788762e-07
even O 0 1.4068250209220423e-07
though O 0 5.8363550436979494e-08
they O 0 1.0148430540368736e-08
are O 0 8.866708256505262e-09
hardly O 0 1.623592197574908e-06
ever O 0 3.837535132333869e-06
seen O 0 1.4263164302974474e-05
in O 0 7.894094778748695e-06
aniridia B-Disease 1 0.9988376498222351
patients O 0 0.00015404696750920266
. O 0 4.649005859391764e-06

This O 0 1.0328003554604948e-06
indicates O 0 1.1509857813507551e-06
that O 0 1.391453263721587e-08
there O 0 4.0743469043036384e-08
is O 0 9.630049646602856e-08
a O 0 1.1430421409386327e-06
heavy O 0 0.0004099557700101286
ascertainment O 0 0.0014375507598742843
bias O 0 1.788554982340429e-05
in O 0 2.033395958278561e-07
the O 0 5.943559955312594e-08
selection O 0 3.2068612654256867e-07
of O 0 1.2148599637384905e-07
patients O 0 3.134431835860596e-06
for O 0 2.2364156393450685e-07
PAX6 O 0 0.0007590699824504554
mutation O 0 1.341760616924148e-05
analysis O 0 1.6647184963858308e-07
and O 0 1.648608360937942e-07
that O 0 1.9309499776909433e-08
the O 0 3.036849420823273e-07
missing O 0 5.702590715372935e-05
PAX6 O 0 0.007926215417683125
missense O 0 0.004377962090075016
mutations O 0 0.0014310013502836227
frequently O 0 9.287125431001186e-05
may O 0 1.8581351469038054e-05
underlie O 0 0.0004396856820676476
phenotypes O 0 0.00019203039119020104
distinct O 0 1.3141800991434138e-05
from O 0 1.9469731341814622e-05
textbook O 0 0.015247797593474388
aniridia B-Disease 1 0.9996854066848755
. O 0 9.163622598862275e-05

Here O 0 3.4349561701674247e-06
we O 0 3.723544921285793e-07
present O 0 1.0876389922032104e-07
four O 0 4.512859561600635e-07
novel O 0 6.05307332079974e-06
PAX6 O 0 0.0016546155093237758
missense O 0 0.0007870173431001604
mutations O 0 7.449815893778577e-05
, O 0 2.949479949165834e-07
two O 0 7.506788790578867e-08
in O 0 2.418939857307123e-07
association O 0 9.559980753692798e-07
with O 0 1.3945850696472917e-06
atypical O 0 0.003254444571211934
phenotypes O 0 0.004745005629956722
ectopia B-Disease 0 0.01255571749061346
pupillae I-Disease 0 0.0025792426895350218
( O 0 1.0662203067113296e-06
displaced B-Disease 0 1.302095142818871e-06
pupils I-Disease 0 3.926561475964263e-06
) O 0 2.718499445109046e-06
and O 0 0.00010992769966833293
congenital B-Disease 1 0.9999920129776001
nystagmus I-Disease 1 0.8568571209907532
( O 0 2.4948737973318202e-06
searching B-Disease 0 3.5127873161400203e-06
gaze I-Disease 0 3.716366336448118e-05
) O 0 1.0589680954353753e-07
, O 0 3.089424183144729e-08
and O 0 1.548829864361778e-08
two O 0 2.5398906089435513e-08
in O 0 7.471562923910824e-08
association O 0 1.347089124692502e-07
with O 0 5.657156165739252e-08
more O 0 2.0186112692499592e-07
recognizable O 0 0.0020282487384974957
aniridia B-Disease 1 0.9992761015892029
phenotypes O 0 0.009434493258595467
. O 0 3.0384648198378272e-05

Strikingly O 0 0.000154228022438474
, O 0 8.421004622505279e-07
all O 0 2.756899064593199e-08
four O 0 1.5814538301128778e-07
mutations O 0 2.1237995042611146e-06
are O 0 1.5055473312486356e-08
located O 0 3.154079877276672e-07
within O 0 7.672899471344863e-08
the O 0 2.526640230371413e-07
PAX6 O 0 0.0001481785875512287
paired O 0 5.3026028581371065e-06
domain O 0 6.869485105198692e-07
and O 0 2.1429475793866004e-07
affect O 0 2.1305355346612487e-07
amino O 0 1.420205535396235e-07
acids O 0 1.3952208632872498e-07
which O 0 3.912128399008452e-09
are O 0 1.5897979599444056e-09
highly O 0 1.2474218635816214e-07
conserved O 0 3.91395190035837e-07
in O 0 2.574098090235566e-08
all O 0 1.0584829901461035e-08
known O 0 2.836194994415564e-07
paired O 0 8.291270887639257e-07
domain O 0 7.763846952002496e-07
proteins O 0 2.315197889402043e-06
. O 0 3.7994880131009268e-06

Our O 0 8.761990102357231e-06
results O 0 2.9817599624948343e-06
support O 0 5.815131487452163e-08
the O 0 7.570356075348172e-08
hypothesis O 0 1.072160245030318e-07
that O 0 1.8118702094227501e-09
the O 0 1.4635274325769387e-08
under O 0 1.8755652320123772e-07
- O 0 1.6352046259271447e-06
representation O 0 1.0760815172261573e-07
of O 0 6.035465389686578e-07
missense O 0 0.0009896857663989067
mutations O 0 0.0010684157023206353
is O 0 8.617845196567941e-06
caused O 0 7.413714774884284e-05
by O 0 1.3290587048686575e-06
ascertainment O 0 0.0011085274163633585
bias O 0 3.400649075047113e-05
and O 0 4.5426193651110225e-07
suggest O 0 2.381415100671802e-07
that O 0 6.666645901987067e-09
a O 0 1.998612901843444e-07
substantial O 0 1.2675654943450354e-06
burden O 0 3.287775325588882e-05
of O 0 1.423723347215855e-06
PAX6 B-Disease 1 0.7924647331237793
- I-Disease 1 0.901168704032898
related I-Disease 0 0.0023720001336187124
disease I-Disease 1 0.9983447790145874
remains O 0 1.0265403034281917e-05
to O 0 6.693404941415793e-08
be O 0 3.205045118193084e-07
uncovered O 0 3.207111149094999e-05
. O 0 5.582897983913426e-07
. O 0 1.9915819393645506e-06

The O 0 2.9373688903433504e-06
chromosomal O 0 0.0004858414176851511
order O 0 7.161632993302192e-07
of O 0 1.3736200799030485e-07
genes O 0 3.1174515697784955e-06
controlling O 0 0.00011926863226108253
the O 0 3.7797481127199717e-06
major O 0 0.00014395453035831451
histocompatibility O 1 0.6934722065925598
complex O 0 0.0003161284257657826
, O 0 3.941252998629352e-06
properdin O 0 0.000110838700493332
factor O 0 6.245968506846111e-06
B O 0 5.272246562526561e-05
, O 0 1.4126397900326992e-06
and O 0 8.826450539345387e-06
deficiency B-Disease 1 0.9703120589256287
of I-Disease 0 3.9970281306977995e-08
the I-Disease 0 1.824957678309147e-07
second I-Disease 0 6.857637799839722e-07
component I-Disease 0 1.1324576689730748e-06
of I-Disease 0 7.285243697197075e-08
complement I-Disease 0 9.390354534843937e-06
. O 0 6.0622355704254005e-06

The O 0 9.66194875218207e-07
relationship O 0 2.4621256216050824e-06
of O 0 5.883802245421066e-08
the O 0 1.3663154163623403e-07
genes O 0 5.483918812387856e-07
coding O 0 8.7862899817992e-06
for O 0 1.4242080226267717e-07
HLA O 0 8.936132871895097e-06
to O 0 1.327270648943113e-08
those O 0 1.9235832482422666e-08
coding O 0 3.7980603337928187e-06
for O 0 1.184993081437824e-07
properdin O 0 5.351500294636935e-05
Factor O 0 1.6603613630650216e-06
B O 0 3.75446725229267e-05
allotypes O 0 8.209269435610622e-05
and O 0 1.1127580137326731e-06
for O 0 1.8428719386065495e-06
deficiency B-Disease 1 0.9953088164329529
of I-Disease 0 6.193056378833717e-08
the I-Disease 0 1.7489831805050926e-07
second I-Disease 0 7.181769205999444e-07
component I-Disease 0 8.82574283878057e-07
of I-Disease 0 5.0628756298465305e-08
complement I-Disease 0 8.626080330031982e-07
( O 0 8.493772156725754e-07
C2 O 0 0.0001381321926601231
) O 0 7.671129509390084e-08
was O 0 6.823734111094382e-07
studied O 0 6.593140255972685e-07
in O 0 4.846701529004349e-08
families O 0 2.1782176062856706e-08
of O 0 9.004693168890299e-08
patients O 0 1.872047687356826e-05
with O 0 3.23689091601409e-05
connective O 1 0.9996423721313477
tissue O 1 0.9994613528251648
disorders O 1 0.9999271631240845
. O 0 5.959202826488763e-05

Patients O 0 3.212345836800523e-05
were O 0 2.0585014226526255e-07
selected O 0 9.844946191606141e-08
because O 0 4.7214147258500816e-08
they O 0 6.222061532668022e-09
were O 0 2.2500122653923427e-08
heterozygous O 0 4.505772892571258e-07
or O 0 1.301251018048788e-06
homozygous O 0 7.47086014598608e-05
for O 0 0.00016511914145667106
C2 B-Disease 1 0.9999749660491943
deficiency I-Disease 1 0.999992847442627
. O 0 5.8032412198372185e-05

12 O 0 4.1957532630476635e-06
families O 0 4.4604362869904435e-08
with O 0 1.8410962354664662e-07
15 O 0 1.2441493026926764e-06
matings O 0 4.424481085152365e-05
informative O 0 4.3260661186650395e-05
for O 0 0.0002669465320650488
C2 B-Disease 1 0.9999743700027466
deficiency I-Disease 1 0.9999958276748657
were O 0 7.903435289335903e-06
found O 0 7.327109415200539e-06
. O 0 4.320171683502849e-06

Of O 0 1.356611619485193e-06
57 O 0 7.75430271460209e-06
informative O 0 4.933835953124799e-06
meioses O 0 7.576085772598162e-05
, O 0 1.511463665337942e-07
two O 0 1.5226145677615932e-08
crossovers O 0 8.432512004219461e-07
were O 0 3.397071282051911e-07
noted O 0 7.49651462683687e-07
between O 0 2.128544338120264e-06
the O 0 0.0001822955091483891
C2 B-Disease 1 0.9998026490211487
deficiency I-Disease 1 0.9999233484268188
gene O 0 8.02826980361715e-06
and O 0 3.239863701764989e-07
the O 0 2.810923547258426e-07
HLA O 0 4.216944580548443e-05
- O 0 1.5740895833005197e-05
B O 0 3.063727490371093e-06
gene O 0 9.061393768661219e-08
, O 0 1.6503284072655333e-08
with O 0 5.708443495677784e-09
a O 0 6.063086743779422e-08
recombinant O 0 1.6388109713716403e-07
fraction O 0 1.3532155662687728e-07
of O 0 7.904754539822534e-08
0 O 0 5.240696282271529e-06
. O 0 1.7525873090562527e-06

035 O 0 0.11714784801006317
. O 0 0.00017638702411204576

A O 0 2.78683437500149e-05
lod O 0 0.0004509182181209326
score O 0 3.458682613199926e-06
of O 0 1.847036799063062e-07
13 O 0 1.5746605868116603e-06
was O 0 1.0233000011794502e-06
calculated O 0 3.041536444925441e-07
for O 0 1.4079887478146702e-07
linkage O 0 0.00013558979844674468
between O 0 0.0010385975474491715
C2 B-Disease 1 0.9999490976333618
deficiency I-Disease 1 0.9999841451644897
and O 0 6.8726312747458e-06
HLA O 0 0.00020429700089152902
- O 0 3.3645337680354714e-05
B O 0 9.843452971836086e-06
at O 0 1.3636785070048063e-06
a O 0 7.590902129095412e-08
maximum O 0 5.822257165277733e-08
likelihood O 0 5.103362710201509e-08
value O 0 1.0204077582898208e-08
of O 0 5.204997766128372e-09
the O 0 2.5829899996665517e-08
recombinant O 0 2.3975624685590446e-07
fraction O 0 2.874381834772066e-07
of O 0 1.48238470387696e-07
0 O 0 1.2975374374946114e-05
. O 0 4.38797405877267e-06

04 O 0 0.011180288158357143
. O 0 5.219414742896333e-05

18 O 0 7.665616067242809e-06
families O 0 3.783704016768752e-08
with O 0 1.1374165609367992e-07
21 O 0 8.766485279920744e-07
informative O 0 2.937118210866174e-07
matings O 0 9.014554052555468e-06
for O 0 5.911891065579766e-08
both O 0 2.627387516440649e-07
properdin O 0 8.841050293995067e-05
Factor O 0 3.1546142054139636e-06
B O 0 1.76345492945984e-05
allotype O 0 4.287390402168967e-05
and O 0 1.061675675373408e-06
HLA O 0 8.370258728973567e-05
- O 0 6.196126196300611e-05
B O 0 1.547951796965208e-05
were O 0 3.4349946531619935e-07
found O 0 9.709287951409351e-07
. O 0 1.176820887849317e-06

Of O 0 2.4373964606638765e-06
72 O 0 2.5170342269120738e-05
informative O 0 7.577247743029147e-06
meioses O 0 0.00022505341621581465
, O 0 3.077720691635477e-07
three O 0 5.980654549375686e-08
recombinants O 0 5.348438662622357e-06
were O 0 8.288236585940467e-08
found O 0 8.645832849651924e-08
, O 0 1.184181552815744e-08
giving O 0 1.2101891044835611e-08
a O 0 6.53861391697319e-08
recombinant O 0 1.9815263385680737e-07
fraction O 0 1.9649419868983387e-07
of O 0 1.5306621037325385e-07
0 O 0 7.354376521107042e-06
. O 0 1.5524981336056953e-06

042 O 0 0.016445975750684738
. O 0 6.532974657602608e-05

A O 0 2.1882087821722962e-05
lod O 0 0.0002653479459695518
score O 0 6.662974101345753e-07
of O 0 5.9601003243869854e-08
16 O 0 5.923641310801031e-07
between O 0 3.339999636864377e-07
HLA O 0 4.9493864935357124e-05
- O 0 2.7277468689135276e-05
B O 0 6.691344424325507e-06
and O 0 1.6431663141247554e-07
Factor O 0 6.484785899374401e-07
B O 0 9.494214282312896e-06
allotypes O 0 2.3062217223923653e-05
was O 0 1.0499333029656555e-06
calculated O 0 2.0176662474113982e-07
at O 0 6.791059377064812e-07
a O 0 7.75601876057408e-08
maximum O 0 1.068381720870093e-07
likelihood O 0 7.532518964126211e-08
value O 0 1.0304294306706652e-08
of O 0 4.464510983126502e-09
the O 0 3.3068655369561384e-08
recombinant O 0 3.8872059349159827e-07
fraction O 0 3.038738327632018e-07
of O 0 1.252698353937376e-07
0 O 0 8.808582606434356e-06
. O 0 3.5229052173235686e-06

04 O 0 0.010894488543272018
. O 0 3.806853055721149e-05

A O 0 5.003575097362045e-06
crossover O 0 2.228081939392723e-06
was O 0 3.2986688438541023e-06
shown O 0 1.0234411007559174e-07
to O 0 1.1000123478766e-08
have O 0 1.9035532261568733e-08
occurred O 0 2.439088575556525e-07
between O 0 1.570081842316995e-08
genes O 0 5.0003897911210515e-08
for O 0 2.2027423440817984e-08
Factor O 0 1.6965407212410355e-07
B O 0 4.159704076300841e-06
and O 0 9.593627510184888e-07
HLA O 0 0.000125716338516213
- O 0 0.00025635914062149823
D O 0 0.0005174095276743174
, O 0 9.105261256081576e-08
in O 0 5.066208430548613e-08
which O 0 1.8601673446028144e-07
HLA O 0 6.543062045238912e-05
- O 0 0.00019092617731075734
D O 0 0.0003138252068310976
segregared O 0 2.9684602850466035e-05
with O 0 9.355808288091794e-07
HLA O 0 6.879593274788931e-05
- O 0 1.72030213434482e-05
A O 0 2.75298475571617e-06
and O 0 9.474997568759136e-07
B O 0 9.078108996618539e-05
. O 0 4.725919552583946e-06

These O 0 2.7398942847867147e-07
studies O 0 4.1321086996504164e-07
suggest O 0 1.1811998490429687e-07
that O 0 2.456712167031583e-09
the O 0 7.0235279814312435e-09
genes O 0 6.458999024516743e-08
for O 0 5.1471278794679165e-08
Factor O 0 2.0870400021522073e-06
B O 0 0.0006613660370931029
and O 0 0.0018011352512985468
C2 B-Disease 1 0.9999756813049316
deficiency I-Disease 1 0.9999895095825195
are O 0 5.988061957395985e-08
located O 0 4.95053029681003e-07
outside O 0 2.1109397607688152e-07
those O 0 2.2469587079854136e-08
for O 0 6.78412064303302e-08
HLA O 0 2.713696812861599e-05
, O 0 8.267900142300277e-08
that O 0 3.3541569521844394e-09
the O 0 1.0498272473569159e-08
order O 0 1.3539935395101566e-08
of O 0 2.6114543416611014e-08
genese O 0 5.298031464917585e-05
is O 0 1.0759569022411597e-06
HLA O 0 1.737752063490916e-05
- O 0 5.630412488244474e-06
A O 0 1.4488867918771575e-06
, O 0 2.704086909943726e-07
- O 0 4.5238407437864225e-06
B O 0 9.273850082536228e-06
, O 0 8.631709533801768e-07
- O 0 3.693890539580025e-05
D O 0 0.00021064172324258834
, O 0 2.841056812030729e-07
Factor O 0 2.059987309621647e-06
B O 0 8.451232861261815e-05
allotype O 0 0.004755204543471336
, O 0 0.0007212846539914608
C2 B-Disease 1 0.9998726844787598
deficiency I-Disease 1 0.9999881982803345
, O 0 6.500593485725403e-07
that O 0 5.412299941554011e-09
the O 0 3.172941376305971e-08
genes O 0 1.2999721548112575e-06
coding O 0 0.00018951403035316616
for O 0 0.00020012220193166286
C2 B-Disease 1 0.9999574422836304
deficiency I-Disease 1 0.9999842643737793
and O 0 3.1610704809281742e-06
Factor O 0 2.036269279415137e-06
B O 0 1.4422239473788068e-05
allotypes O 0 1.2794244867109228e-05
are O 0 1.6964234461624983e-08
approximately O 0 4.3325144361006096e-08
3 O 0 9.728289569466142e-07
- O 0 1.14428094093455e-05
- O 0 1.537315438326914e-05
5 O 0 1.2231377013449674e-06
centimorgans O 0 6.6162269831693266e-06
from O 0 7.574053739745068e-08
the O 0 1.462496896920129e-07
HLA O 0 1.171894655271899e-05
- O 0 4.568783424474532e-06
A O 0 1.0642706911312416e-06
and O 0 5.616815315079293e-07
HLA O 0 3.343410571687855e-05
- O 0 2.121942088706419e-05
B O 0 7.01062072039349e-06
loci O 0 1.5097866707947105e-06
, O 0 8.218187019792822e-08
and O 0 2.666569365317173e-08
that O 0 8.072244206402956e-09
the O 0 1.0294004226807374e-07
apparent O 0 6.495632533187745e-06
lack O 0 6.552134550474875e-07
of O 0 9.196263306421315e-08
recombinants O 0 2.0448183931875974e-05
between O 0 1.6416204573488358e-07
the O 0 2.1804129346492118e-07
Factor O 0 7.832115898054326e-07
B O 0 1.8725333575275727e-05
gene O 0 1.7516953448648565e-05
and O 0 0.0003902647877112031
C2 B-Disease 1 0.9999403953552246
deficiency I-Disease 1 0.9999716281890869
gene O 0 1.2367872841423377e-05
suggests O 0 6.427795256058744e-07
that O 0 1.2152007178301005e-09
these O 0 1.2917548142254986e-09
two O 0 2.58384247331378e-08
genes O 0 5.418075375018816e-07
lie O 0 4.754635028803023e-06
in O 0 6.601697322139444e-08
close O 0 4.806865376849601e-07
proximity O 0 4.041973795665399e-07
to O 0 6.864298995878926e-08
one O 0 2.898725028899207e-07
another O 0 1.684466724327649e-06
. O 0 2.15929867408704e-06

Distribution O 0 6.620796739298385e-06
of O 0 1.771806068973092e-06
emerin O 0 0.0006540243048220873
and O 0 4.699430519394809e-06
lamins O 0 0.0016660889377817512
in O 0 2.0040881736349547e-06
the O 0 1.969933919099276e-06
heart O 0 0.005264316685497761
and O 0 8.859913691594556e-07
implications O 0 3.143876529065892e-05
for O 0 3.4878944461524952e-06
Emery B-Disease 0 0.27684223651885986
- I-Disease 1 0.9978354573249817
Dreifuss I-Disease 1 0.9979343414306641
muscular I-Disease 1 0.9996442794799805
dystrophy I-Disease 1 0.9993427395820618
. O 0 8.08948534540832e-05

Emerin O 0 0.0019052076386287808
is O 0 1.6563601548114093e-06
a O 0 6.728335506522853e-07
nuclear O 0 7.878104952396825e-06
membrane O 0 8.97708105185302e-07
protein O 0 3.301295237179147e-07
which O 0 2.3077408428662238e-08
is O 0 4.250150809070874e-08
missing O 0 3.998225963641744e-07
or O 0 6.033128556737211e-07
defective O 0 0.00027496463735587895
in O 0 1.2605094525497407e-05
Emery B-Disease 1 0.6584597826004028
- I-Disease 1 0.9986465573310852
Dreifuss I-Disease 1 0.9988007545471191
muscular I-Disease 1 0.999800980091095
dystrophy I-Disease 1 0.9994723200798035
( O 0 0.00010864694195333868
EDMD B-Disease 1 0.9994412064552307
) O 0 7.802052095939871e-06
. O 0 5.270654128253227e-06

It O 0 5.828734401802649e-07
is O 0 9.811915901991597e-08
one O 0 5.1692349956056205e-08
member O 0 5.651914847248918e-08
of O 0 1.1393637144863078e-08
a O 0 1.6238692523984355e-06
family O 0 4.0695658753975295e-06
of O 0 8.315185482388188e-07
lamina O 0 0.016557825729250908
- O 0 0.00018929604266304523
associated O 0 1.59294722834602e-06
proteins O 0 1.7579864675099088e-07
which O 0 1.0067019218240603e-07
includes O 0 3.072354104460828e-07
LAP1 O 0 0.00020006972772534937
, O 0 1.0108924470841885e-06
LAP2 O 0 0.00020537333330139518
and O 0 1.8543026953921071e-06
lamin O 0 0.000552778597921133
B O 0 0.0003032181703019887
receptor O 0 8.690394315635785e-05
( O 0 9.56445455813082e-06
LBR O 0 0.024308379739522934
) O 0 4.841452664550161e-06
. O 0 5.754376616096124e-06

A O 0 1.9928867914131843e-05
panel O 0 1.1453432307462208e-05
of O 0 7.816014857553455e-08
16 O 0 1.5233515568979783e-06
monoclonal O 0 1.8008240658673458e-06
antibodies O 0 1.4541442396875937e-06
( O 0 1.24753370300823e-07
mAbs O 0 4.835131676372839e-06
) O 0 7.75897817106852e-08
has O 0 1.620894352072355e-07
been O 0 5.089335886054869e-08
mapped O 0 1.960034694548085e-07
to O 0 7.733031104351085e-09
six O 0 5.881636511162469e-08
specific O 0 2.2614223382788623e-08
sites O 0 3.777366259782866e-07
throughout O 0 2.4447987811981875e-07
the O 0 1.866212357981567e-07
emerin O 0 2.6080948373419233e-05
molecule O 0 1.2367142971925205e-06
using O 0 1.1565269915081444e-06
phage O 0 2.7755248083849438e-05
- O 0 7.347485279751709e-06
displayed O 0 9.181329119201109e-07
peptide O 0 5.751418257204932e-07
libraries O 0 9.659814281803847e-08
and O 0 6.621079506885508e-08
has O 0 5.864900387564376e-08
been O 0 2.6366137717559468e-08
used O 0 2.1535553784701733e-08
to O 0 3.2544612338369916e-08
localize O 0 3.571423440007493e-05
emerin O 0 0.00012977120059076697
in O 0 6.371196263899037e-07
human O 0 1.2418934147717664e-06
and O 0 2.1237995042611146e-06
rabbit O 0 0.00253817206248641
heart O 1 0.7915338277816772
. O 0 1.26639306472498e-05

Several O 0 2.305184352735523e-06
mAbs O 0 0.00010804873454617336
against O 0 1.1844568916785647e-06
different O 0 3.1763173069521144e-07
emerin O 0 0.0002968127082567662
epitopes O 0 0.00011451798491179943
did O 0 2.717358938753023e-06
not O 0 1.5306255818359205e-07
recognize O 0 1.4187477290761308e-06
intercalated O 0 1.2972726835869253e-05
discs O 0 2.8372702217893675e-05
in O 0 4.907284960609104e-07
the O 0 5.900738528907823e-07
heart O 0 0.006623902358114719
, O 0 3.196022362317308e-07
though O 0 9.473897932821274e-08
they O 0 5.1784816434974346e-08
recognized O 0 8.057654667936731e-07
cardiomyocyte O 0 5.5810043704696e-05
nuclei O 0 1.0316690350009594e-05
strongly O 0 1.8251836308991187e-06
, O 0 1.2635544521799602e-07
both O 0 8.910588178423495e-08
at O 0 1.4805532373429742e-05
the O 0 3.5021059829887236e-07
rim O 0 1.4892649232933763e-05
and O 0 3.0145415053084434e-07
in O 0 2.747021312643483e-07
intranuclear O 0 5.719375258195214e-05
spots O 0 5.871358553122263e-06
or O 0 8.825961685943184e-07
channels O 0 1.5517296560574323e-05
. O 0 1.2133680684200954e-05

A O 0 9.05040797078982e-05
polyclonal O 0 0.0006646734545938671
rabbit O 0 0.0010115195764228702
antiserum O 0 0.001360243884846568
against O 0 9.900580153043848e-06
emerin O 0 0.00024744393886066973
did O 0 9.685288659966318e-07
recognize O 0 1.1672864275169559e-06
both O 0 1.1563930968350178e-07
nuclear O 0 5.017500734538771e-05
membrane O 0 7.000378900556825e-06
and O 0 3.550477742919611e-07
intercalated O 0 2.0067534933332354e-05
discs O 0 2.2966611140873283e-05
but O 0 2.0347441420653922e-07
, O 0 6.813388608861715e-08
after O 0 1.3206373239427194e-07
affinity O 0 4.864334641752066e-07
purification O 0 7.801457286404911e-06
against O 0 3.9447473909604014e-07
a O 0 7.19204990673461e-07
pure O 0 6.1748373809678014e-06
- O 0 9.768549352884293e-05
emerin O 0 0.00010523471428314224
band O 0 8.899037311493885e-06
on O 0 6.035862156750227e-07
a O 0 7.967981332512863e-07
western O 0 4.925279426970519e-06
blot O 0 0.0007237413665279746
, O 0 7.68251197769132e-07
it O 0 2.1021283203026542e-07
stained O 0 0.00032543708221055567
only O 0 1.389203703183739e-07
the O 0 3.5505522077983187e-07
nuclear O 0 8.193300163839012e-05
membrane O 0 4.710724897449836e-05
. O 0 7.226450634334469e-06

These O 0 3.566495649920398e-07
results O 0 1.5864432043599663e-06
would O 0 7.516990052636174e-08
not O 0 2.187397818431691e-08
be O 0 6.365753790760209e-08
expected O 0 1.7487128900484095e-07
if O 0 1.9842475751374877e-07
immunostaining O 0 3.435847975197248e-05
at O 0 4.605231424648082e-06
intercalated O 0 1.2577763300214428e-05
discs O 0 6.323668003460625e-06
were O 0 2.098330895705658e-07
due O 0 2.219430683680912e-07
to O 0 8.565891107537027e-09
a O 0 1.6000834079932247e-07
product O 0 1.553807322807188e-07
of O 0 3.712509766273797e-08
the O 0 1.461321659235182e-07
emerin O 0 2.8880080208182335e-05
gene O 0 1.040593019752123e-06
and O 0 3.958445802254573e-07
, O 0 1.7789669470857916e-07
therefore O 0 8.092704462114853e-08
, O 0 4.815197485186218e-08
cast O 0 1.9300080111861462e-07
some O 0 1.441890518094624e-08
doubt O 0 1.631830457426986e-07
upon O 0 5.2354881319160995e-08
the O 0 1.9025446817977354e-07
hypothesis O 0 4.851084668189287e-06
that O 0 8.691680477568298e-07
cardiac B-Disease 1 0.9887308478355408
defects I-Disease 1 0.9989387392997742
in O 0 2.334973032702692e-05
EDMD B-Disease 1 0.9998511075973511
are O 0 7.5098807883478e-07
caused O 0 2.1163763449294493e-05
by O 0 2.1530752292164834e-07
absence O 0 2.9936870760138845e-06
of O 0 2.972224422137515e-07
emerin O 0 0.0005138556007295847
from O 0 2.0560637494781986e-06
intercalated O 0 0.0004122416430618614
discs O 0 0.0011038591619580984
. O 0 1.698898631730117e-05

Although O 0 2.2005304344929755e-05
emerin O 0 0.0006422366132028401
was O 0 9.253759344574064e-06
abundant O 0 1.0367160712121404e-06
in O 0 1.5171072220709902e-07
the O 0 1.0808517458826827e-07
membranes O 0 1.5885336324572563e-05
of O 0 2.9583029004243144e-07
cardiomyocyte O 0 0.00026815873570740223
nuclei O 0 2.841958121280186e-05
, O 0 7.372455002041534e-07
it O 0 1.7245396577436622e-07
was O 0 4.528303634288022e-06
absent O 0 3.575660684873583e-06
from O 0 9.925852140213465e-08
many O 0 3.7807463826311505e-08
non O 0 9.317360309069045e-06
- O 0 0.00022857662406750023
myocyte O 0 0.0006178118055686355
cells O 0 6.11416544415988e-06
in O 0 5.098702899886121e-07
the O 0 1.8982036635861732e-06
heart O 0 0.017640074715018272
. O 0 6.643496362812584e-06

This O 0 1.6139053116148716e-07
distribution O 0 3.0977147957855777e-07
of O 0 2.3197230802907143e-07
emerin O 0 0.00032549415482208133
was O 0 7.71705435909098e-06
similar O 0 4.313006840561684e-08
to O 0 1.1567257374167639e-08
that O 0 6.2922960175626486e-09
of O 0 2.6286651078066825e-08
lamin O 0 5.859846714884043e-05
A O 0 6.294330887612887e-06
, O 0 1.9117150884540024e-07
a O 0 4.7345537268483895e-07
candidate O 0 4.303023501961434e-07
gene O 0 1.9985557742074889e-07
for O 0 4.491383265303739e-08
an O 0 2.1653499970852863e-07
autosomal O 0 0.010194002650678158
form O 0 2.976374344143551e-05
of O 0 1.5861143765505403e-05
EDMD B-Disease 1 0.9999074935913086
. O 0 6.408223998732865e-05

In O 0 1.1706738405337092e-05
contrast O 0 3.8430007407441735e-05
, O 0 1.0357632163504604e-05
lamin O 0 0.005040133371949196
B1 O 0 0.1817196011543274
was O 0 9.511957614449784e-05
absent O 0 2.2617023205384612e-05
from O 0 4.1060681610360916e-07
cardiomyocyte O 0 7.913826266303658e-05
nuclei O 0 1.805190731829498e-05
, O 0 4.7380319756484823e-07
showing O 0 2.8669837774941698e-06
that O 0 3.618840480612562e-07
lamin O 0 0.0007505471003241837
B1 O 0 0.0033069048076868057
is O 0 2.3782557434515184e-07
not O 0 1.1174628333776582e-08
essential O 0 5.6411550986013026e-08
for O 0 4.763421301845483e-08
localization O 0 3.6796486710954923e-06
of O 0 1.2966090423560672e-07
emerin O 0 0.0001134105259552598
to O 0 3.827678085599473e-07
the O 0 2.338907734156237e-06
nuclear O 0 0.01180803868919611
lamina O 0 0.025931084528565407
. O 0 1.9197319488739595e-05

Lamin O 0 0.06103721633553505
B1 O 0 0.21073605120182037
is O 0 2.999425532834721e-06
also O 0 3.60585261205415e-07
almost O 0 4.096598900105164e-07
completely O 0 1.194729884446133e-05
absent O 0 6.993376155151054e-05
from O 0 3.738578243428492e-06
skeletal O 0 0.02073482796549797
muscle O 0 0.006118734832853079
nuclei O 0 0.0005452937912195921
. O 0 1.2662747394642793e-05

In O 0 3.520176323945634e-05
EDMD B-Disease 1 0.9987013339996338
, O 0 7.751092425678507e-07
the O 0 5.201487240924507e-08
additional O 0 4.1548407381242214e-08
absence O 0 3.4709880765149137e-06
of O 0 8.64669630118442e-07
lamin O 0 0.009592476300895214
B1 O 0 0.29878681898117065
from O 0 1.1233759323658887e-05
heart O 0 0.143852099776268
and O 0 7.37674190531834e-06
skeletal O 0 0.2638937830924988
muscle O 0 0.003273721318691969
nuclei O 0 0.00010343555186409503
which O 0 8.956369583756896e-07
already O 0 3.507652081680135e-06
lack O 0 2.7153073460794985e-06
emerin O 0 0.0005920767434872687
may O 0 9.201366992783733e-07
offer O 0 1.1065867511206307e-07
an O 0 2.551339584044854e-08
alternative O 0 4.991661057829333e-07
explanation O 0 5.753053073931369e-07
of O 0 4.275592146996132e-08
why O 0 4.2877195483015385e-07
these O 0 1.813976879816437e-08
tissues O 0 1.2292826795601286e-05
are O 0 7.32893710164717e-08
particularly O 0 9.796643780646264e-07
affected O 0 2.3164918729889905e-06
. O 0 5.072614612799953e-07
. O 0 2.310102900082711e-06

Genetic O 0 0.0001812787086237222
mapping O 0 3.707071300595999e-05
of O 0 3.6678099490927707e-07
the O 0 4.105882453586673e-06
copper B-Disease 1 0.546567440032959
toxicosis I-Disease 1 0.6949513554573059
locus O 0 0.00011914655624423176
in O 0 3.629185130193946e-06
Bedlington O 0 0.00043193422607146204
terriers O 0 0.00019013576093129814
to O 0 2.48589117290976e-07
dog O 0 8.318664913531393e-05
chromosome O 0 2.0077586668776348e-05
10 O 0 9.028921681419888e-07
, O 0 6.326439461190603e-08
in O 0 2.9779748444980214e-08
a O 0 3.3702298196658376e-07
region O 0 3.184620709362207e-06
syntenic O 0 5.612396853393875e-05
to O 0 1.9260896522155235e-07
human O 0 3.63365279554273e-06
chromosome O 0 0.00010775898408610374
region O 0 1.4807537809247151e-05
2p13 O 0 0.0003041785676032305
- O 0 0.00040544680086895823
p16 O 0 0.00035827670944854617
. O 0 1.3328309250937309e-05

Abnormal O 1 0.9787701368331909
hepatic B-Disease 1 0.9992148876190186
copper I-Disease 1 0.9964709281921387
accumulation I-Disease 0 0.000900553073734045
is O 0 1.1671395441226196e-06
recognized O 0 1.2407273288772558e-06
as O 0 1.9031886040465906e-06
an O 0 0.00016407213115599006
inherited B-Disease 1 0.999998927116394
disorder I-Disease 1 0.9999991655349731
in O 0 1.9124428945360705e-05
man O 0 0.0003855732793454081
, O 0 8.520349297214125e-07
mouse O 0 2.316696372872684e-05
, O 0 1.8290886600880185e-06
rat O 0 0.00021207737154327333
and O 0 1.6472016568513936e-06
dog O 0 0.0006375101511366665
. O 0 1.159275143436389e-05

The O 0 1.1745351002900861e-05
major O 0 0.00015989437815733254
cause O 0 0.00030636368319392204
of O 0 6.05935747444164e-06
hepatic B-Disease 1 0.9996071457862854
copper I-Disease 1 0.9988963603973389
accumulation I-Disease 0 0.0009294735500589013
in O 0 2.6079385406774236e-06
man O 0 4.749730942421593e-05
is O 0 5.196152415010147e-07
a O 0 2.6084233013534686e-06
dysfunctional O 0 0.0016750529175624251
ATP7B O 0 0.0017382808728143573
gene O 0 7.148782606236637e-05
, O 0 1.81814484676579e-05
causing O 0 0.0047607142478227615
Wilson B-Disease 0 0.030624868348240852
disease I-Disease 1 0.9958283305168152
( O 0 6.476432645285968e-06
WD B-Disease 0 0.013699627481400967
) O 0 3.6461003674048698e-06
. O 0 2.826899390129256e-06

Mutations O 0 0.00030316293123178184
in O 0 1.6446931567770662e-06
the O 0 6.17504554156767e-07
ATP7B O 0 0.0001083388488041237
genes O 0 9.036588721755834e-07
have O 0 1.2156665718521253e-07
also O 0 6.64781723003216e-08
been O 0 8.05602056175303e-08
demonstrated O 0 2.3194220943878463e-07
in O 0 1.2502994195529027e-07
mouse O 0 1.3672224667971022e-05
and O 0 3.014083858943195e-06
rat O 0 0.001520070480182767
. O 0 5.274736849969486e-06

The O 0 1.2499728654802311e-05
ATP7B O 0 0.0006839180714450777
gene O 0 1.527253152744379e-05
has O 0 1.6411021306339535e-06
been O 0 3.9288437392315245e-07
excluded O 0 5.068624773230113e-07
in O 0 5.342202058500334e-08
the O 0 6.577477762448325e-08
much O 0 5.097340931570216e-07
rarer O 0 0.0002899786049965769
human O 0 0.00011461510439403355
copper B-Disease 1 0.9955163598060608
overload I-Disease 1 0.9965534210205078
disease O 1 0.9967148303985596
non B-Disease 0 0.00013562964159063995
- I-Disease 0 0.0017821809742599726
Indian I-Disease 0 1.8030401406576857e-05
childhood I-Disease 0 0.015647748485207558
cirrhosis I-Disease 1 0.9994595646858215
, O 0 6.36296545053483e-06
indicating O 0 1.5920426449156366e-05
genetic O 0 7.326398917939514e-05
heterogeneity O 0 0.00029887654818594456
. O 0 1.717929626465775e-05

By O 0 4.819764399144333e-06
investigating O 0 4.221700510242954e-05
the O 0 3.989122433267767e-06
common O 0 0.0002738135517574847
autosomal O 1 0.9983172416687012
recessive O 1 0.9992895126342773
copper B-Disease 1 0.9988983869552612
toxicosis I-Disease 1 0.9895762205123901
( O 0 1.6633850464131683e-05
CT B-Disease 0 0.001300805015489459
) O 0 2.835994905581174e-07
in O 0 2.5630410505073087e-07
Bedlington O 0 0.00011237792205065489
terriers O 0 0.0001177847952931188
, O 0 5.985555731058412e-07
we O 0 8.148261798623935e-08
have O 0 8.826599007250024e-09
identified O 0 6.970508081849403e-08
a O 0 1.216045717455927e-07
new O 0 4.669320219363726e-07
locus O 0 1.4272907719714567e-05
involved O 0 4.8941328714136034e-06
in O 0 2.8853044568677433e-05
progressive O 1 0.9985312223434448
liver B-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999961853027344
. O 0 0.000101414043456316

We O 0 7.510750492656371e-06
examined O 0 1.669503762968816e-05
whether O 0 2.2101393426510185e-07
the O 0 4.405386277994694e-07
WD B-Disease 0 0.00154383503831923
gene O 0 1.7610516806598753e-05
ATP7B O 0 0.000580126594286412
was O 0 9.84630696621025e-06
also O 0 2.1421342921712494e-07
causative O 0 4.61223771708319e-06
for O 0 1.892385910196026e-07
CT B-Disease 0 0.0008150602807290852
by O 0 2.3635993784409948e-07
investigating O 0 4.962308139511151e-06
the O 0 8.952945336204721e-07
chromosomal O 0 0.0010690346825867891
co O 0 0.00018757639918476343
- O 0 4.5942619181005284e-05
localization O 0 1.5109595551621169e-05
of O 0 2.9983451099724334e-07
ATP7B O 0 0.0004938892088830471
and O 0 5.393824267230229e-07
C04107 O 0 7.680273483856581e-06
, O 0 5.837579664103032e-08
using O 0 5.4412641503631676e-08
fluorescence O 0 1.5465177511941874e-06
in O 0 5.310606638886384e-07
situ O 0 2.7989528462057933e-05
hybridization O 0 2.7484936708788155e-06
( O 0 3.033020448128809e-07
FISH O 0 2.585859647297184e-06
) O 0 4.714588897059002e-07
. O 0 1.5521591194556095e-06

C04107 O 0 0.001253515831194818
is O 0 2.2338372218655422e-06
an O 0 2.988689971061831e-07
anonymous O 0 1.2905735275126062e-05
microsatellite O 0 0.0002083617146126926
marker O 0 3.05843677779194e-05
closely O 0 6.212095740920631e-06
linked O 0 5.147989941178821e-05
to O 0 1.9271842575108167e-06
CT B-Disease 0 0.02412729151546955
. O 0 1.1821755833807401e-05

However O 0 1.3186932847020216e-05
, O 0 5.5142600103863515e-06
BAC O 0 0.00034980743657797575
clones O 0 1.8443261069478467e-05
containing O 0 5.9289586715749465e-06
ATP7B O 0 0.0008173129754140973
and O 0 1.6307178611896234e-06
C04107 O 0 2.5906685550580733e-05
mapped O 0 5.1807328418362886e-06
to O 0 5.6996341868398304e-08
the O 0 4.2726898641376465e-07
canine O 0 0.0003308152954559773
chromosome O 0 0.00012502764002420008
regions O 0 5.779995262855664e-06
CFA22q11 O 0 0.00015866979083511978
and O 0 1.3659015394296148e-06
CFA10q26 O 0 0.00018273926980327815
, O 0 7.558754759884323e-07
respectively O 0 1.7101907587857568e-06
, O 0 1.6096875299353997e-07
demonstrating O 0 1.107927346311044e-06
that O 0 1.6191407326004992e-07
WD B-Disease 0 0.0005994956009089947
cannot O 0 1.2346368976068334e-06
be O 0 6.414188646886032e-08
homologous O 0 2.59673561231466e-06
to O 0 1.1909698969247984e-06
CT B-Disease 0 0.006597267929464579
. O 0 7.726569492660929e-06

The O 0 7.457974788849242e-06
copper O 0 0.0008721750928089023
transport O 0 2.0914771084790118e-05
genes O 0 1.179855280497577e-05
CTR1 O 0 0.0007457041065208614
and O 0 1.4602060218749102e-06
CTR2 O 0 0.0002320596104254946
were O 0 3.864245456952631e-07
also O 0 2.4774112716841046e-07
excluded O 0 4.961055424246297e-07
as O 0 8.410139429315677e-08
candidate O 0 1.9812655693840497e-07
genes O 0 1.0546001760758372e-07
for O 0 7.948660396550622e-08
CT B-Disease 0 0.0006729293963871896
since O 0 1.7483372403148678e-06
they O 0 2.193158898933234e-08
both O 0 2.2324046611288395e-08
mapped O 0 2.4861808469722746e-06
to O 0 2.1201721267516405e-07
canine O 0 0.0004468715633265674
chromosome O 0 0.0004813132982235402
region O 0 8.34389720694162e-05
CFA11q22 O 0 0.002579478081315756
. O 0 1.6048779798438773e-05

2 O 0 0.00016356761625502259
- O 0 0.0005141946021467447
22 O 0 3.298006413388066e-05
. O 0 3.439939064264763e-06

5 O 0 0.00021792268671561033
. O 0 2.0106497686356306e-05

A O 0 8.636290658614598e-06
transcribed O 0 1.2500550838012714e-05
sequence O 0 7.256819571921369e-07
identified O 0 9.120415143115679e-07
from O 0 9.013817248160194e-08
the O 0 2.1227941715551424e-07
C04107 O 0 3.2473668397869915e-05
- O 0 2.2865951905259863e-05
containing O 0 3.742316948773805e-06
BAC O 0 0.00020105534349568188
was O 0 5.529273039428517e-06
found O 0 5.6486488375639965e-08
to O 0 5.4618700673358944e-09
be O 0 7.484554309655778e-09
homologous O 0 9.64170112638385e-08
to O 0 7.403383239790173e-09
a O 0 1.2428562001787213e-07
gene O 0 3.9532739037895226e-07
expressed O 0 8.316597899238332e-08
from O 0 8.460062872472918e-08
human O 0 1.7084757928387262e-06
chromosome O 0 2.212355684605427e-05
2p13 O 0 5.8451019867789e-05
- O 0 3.952406405005604e-05
p16 O 0 1.718693420116324e-05
, O 0 3.369439411926578e-07
a O 0 4.6318254476318543e-07
region O 0 2.3362995307252277e-06
devoid O 0 5.2224804676370695e-06
of O 0 5.238245037730849e-08
any O 0 1.403780203190763e-07
positional O 0 4.375414573587477e-05
candidate O 0 1.938249079103116e-05
genes O 0 1.7748414393281564e-05
. O 0 8.647968570585363e-06

Molecular O 0 5.5282671382883564e-05
analysis O 0 7.627416493960482e-07
of O 0 5.373555111987116e-08
the O 0 2.1310009401531715e-07
APC B-Disease 0 9.417896762897726e-06
gene O 0 5.957315352134174e-07
in O 0 1.9258563099811e-07
205 O 0 1.1375601616236963e-06
families O 0 5.131091640464547e-08
: O 0 1.5692590693561215e-07
extended O 0 1.2657366141866078e-06
genotype O 0 4.409930988913402e-05
- O 0 8.014454215299338e-05
phenotype O 0 3.0538263672497123e-05
correlations O 0 1.4906034266459756e-05
in O 0 1.3154601674614241e-06
FAP B-Disease 0 4.7344001359306276e-05
and O 0 7.718652739185927e-08
evidence O 0 6.010627373598254e-08
for O 0 6.611019287561248e-09
the O 0 3.978659535164297e-08
role O 0 5.471256372402422e-07
of O 0 1.9745938573123567e-07
APC B-Disease 0 4.725897451862693e-05
amino O 0 6.000827397656394e-06
acid O 0 7.064035162329674e-05
changes O 0 5.775191311840899e-05
in O 0 0.00856795720756054
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
predisposition O 1 0.9690694212913513
. O 0 4.536908818408847e-05

BACKGROUND O 0 0.0003090178652200848
/ O 0 0.0001967690186575055
AIMS O 0 2.5700912374304608e-05
The O 0 9.658779163146392e-07
development O 0 5.363701347960159e-06
of O 0 0.001550019602291286
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999963045120239
and O 0 2.4251262402685825e-06
a O 0 1.1943729987251572e-06
variable O 0 8.558661647839472e-06
range O 0 5.696498647012049e-06
of O 0 1.1708228839779622e-06
extracolonic O 0 0.004288851749151945
manifestations O 0 0.012561860494315624
in O 0 0.000504339812323451
familial B-Disease 1 0.9999756813049316
adenomatous I-Disease 1 0.9998966455459595
polyposis I-Disease 1 0.9999752044677734
( O 0 0.00017437548376619816
FAP B-Disease 0 0.0008577677654102445
) O 0 2.2840117708256003e-07
is O 0 9.140340040403316e-08
the O 0 3.193219200170461e-08
result O 0 1.6867932117747841e-07
of O 0 3.051772168305433e-08
the O 0 7.51198001580633e-07
dominant O 0 0.0020625677425414324
inheritance O 0 0.018391601741313934
of O 0 0.0011786584509536624
adenomatous B-Disease 1 0.999972939491272
polyposis I-Disease 1 0.9997429251670837
coli I-Disease 1 0.9993441700935364
( O 0 2.5045115762623027e-05
APC B-Disease 0 0.00019452859123703092
) O 0 1.2673707487920183e-06
gene O 0 1.7738888345775194e-05
mutations O 0 0.00010794800618896261
. O 0 5.854969003848964e-06

In O 0 2.0266504634491866e-06
this O 0 7.560299053466224e-08
study O 0 5.8510902789521424e-08
, O 0 9.257486333069664e-09
direct O 0 2.5422654204021455e-08
mutation O 0 9.07803269001306e-07
analysis O 0 4.1768345226955716e-08
of O 0 1.0264277428007063e-08
the O 0 8.645041305044288e-08
APC B-Disease 0 8.209824954974465e-06
gene O 0 9.191964522869966e-07
was O 0 1.6623134797555394e-06
performed O 0 6.937031002962613e-07
to O 0 3.005197868333198e-08
determine O 0 5.069195481155475e-07
genotype O 0 2.0741941625601612e-05
- O 0 4.9901344027603045e-05
phenotype O 0 1.3845792636857368e-05
correlations O 0 3.1147947083809413e-06
for O 0 7.423804504469445e-08
nine O 0 1.1794116971941548e-06
extracolonic O 0 0.00012569117825478315
manifestations O 0 3.8128404412418604e-05
and O 0 2.945494088635314e-07
to O 0 7.102961063765179e-08
investigate O 0 1.8747011836239835e-06
the O 0 7.871142315707402e-07
incidence O 0 0.00026436764164827764
of O 0 3.11069015879184e-07
APC B-Disease 0 9.147541277343407e-05
mutations O 0 3.7301921111065894e-05
in O 0 5.373167823563563e-06
non O 0 0.09382299333810806
- O 1 0.9998538494110107
FAP O 1 0.9989259839057922
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999943971633911
. O 0 8.065468864515424e-05

METHODS O 0 9.434851563128177e-06
The O 0 1.4641747156929341e-06
APC B-Disease 0 3.333216955070384e-05
gene O 0 3.147924417135073e-06
was O 0 3.115959543720237e-06
analysed O 0 1.35127118028322e-06
in O 0 3.183744752277562e-07
190 O 0 1.5954479977153824e-06
unrelated O 0 1.307815000473056e-05
FAP B-Disease 0 0.00011092974455095828
and O 0 2.006275735766394e-06
15 O 0 2.550298086134717e-05
non O 0 0.024601653218269348
- O 1 0.9998621940612793
FAP O 1 0.9990929365158081
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999933242797852
patients O 0 8.593277743784711e-05
using O 0 3.746301899809623e-06
denaturing O 0 0.0028116819448769093
gradient O 0 0.00030681819771416485
gel O 0 0.0002571101067587733
electrophoresis O 0 1.837267518567387e-05
, O 0 4.1128473071694316e-08
the O 0 1.0240186476551116e-08
protein O 0 1.1457713355866872e-07
truncation O 0 8.243921911343932e-06
test O 0 8.83364123183128e-07
, O 0 4.918633322859023e-08
and O 0 1.616961142758555e-08
direct O 0 1.017912225620421e-07
sequencing O 0 3.6358705983730033e-06
. O 0 3.868444764520973e-06

RESULTS O 0 7.434812869178131e-05
Chain O 0 4.881168206338771e-05
terminating O 0 1.0135904631169979e-05
signals O 0 3.4544038953754352e-06
were O 0 1.1606544347841918e-07
only O 0 2.3069180343782136e-08
identified O 0 4.295323776659643e-07
in O 0 9.931268607488164e-08
patients O 0 4.834781179852143e-07
belonging O 0 3.0823764518572716e-07
to O 0 3.582304941573966e-08
the O 0 4.487397404773219e-07
FAP B-Disease 0 0.00010121406376129016
group O 0 1.4128014527159394e-06
( O 0 3.022247483386309e-07
105 O 0 4.15588192481664e-06
patients O 0 6.1321161410887726e-06
) O 0 5.743930842072587e-07
. O 0 2.3110285383154405e-06

Amino O 0 3.3573858672752976e-05
acid O 0 2.166601007047575e-05
changes O 0 6.010129141031939e-07
were O 0 1.1222371654184826e-07
identified O 0 3.7498011806746945e-07
in O 0 6.07546155606542e-08
four O 0 2.5302620088041294e-07
patients O 0 1.2784504406226915e-06
, O 0 4.117117313739982e-08
three O 0 2.006637700446845e-08
of O 0 2.2150953071786716e-08
whom O 0 7.409403792735247e-07
belonged O 0 1.2546631751320092e-06
to O 0 9.10149324795384e-08
the O 0 3.8400469293264905e-07
non O 0 6.900499283801764e-05
- O 0 0.010448901914060116
FAP O 0 0.002268116921186447
group O 0 0.00014583558368030936
of O 0 0.0028525139205157757
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
patients O 0 0.00964194443076849
. O 0 2.212762956332881e-05

Genotype O 0 0.0013272539945319295
- O 0 0.0008743510115891695
phenotype O 0 7.811319665051997e-05
correlations O 0 1.6768643035902642e-05
identified O 0 2.32724892157421e-06
significant O 0 2.8803637519558833e-07
differences O 0 2.813688297464978e-06
in O 0 3.4445110941305757e-07
the O 0 2.1038694342223607e-07
nature O 0 1.1791800034188782e-06
of O 0 9.02615227005299e-08
certain O 0 1.0378022352597327e-06
extracolonic O 0 0.003862180048599839
manifestations O 0 0.0012814354849979281
in O 0 1.2484657418099232e-05
FAP B-Disease 0 0.0013782535679638386
patients O 0 8.742708814679645e-06
belonging O 0 1.2189757399028167e-06
to O 0 9.105972509360072e-08
three O 0 1.066787831405236e-06
mutation O 0 6.17402620264329e-05
subgroups O 0 6.318681698758155e-05
. O 0 8.435346899204887e-06

CONCLUSIONS O 0 7.818562880856916e-05
Extended O 0 1.580072239448782e-05
genotype O 0 0.00021945418848190457
- O 0 0.00012057200365234166
phenotype O 0 2.6334075300837867e-05
correlations O 0 3.103379413005314e-06
made O 0 1.978741011043894e-07
in O 0 6.593354129336149e-08
this O 0 1.575045871504699e-08
study O 0 1.058029326372889e-07
may O 0 1.5151003651681094e-07
have O 0 6.140957520273105e-09
the O 0 1.4092576883228958e-08
potential O 0 4.948660858872245e-08
to O 0 1.0803648642365715e-08
determine O 0 6.563642074297604e-08
the O 0 3.196997511167865e-08
most O 0 1.944788508012607e-08
appropriate O 0 8.441380572321577e-08
surveillance O 0 4.655092652683379e-06
and O 0 9.20666877846088e-07
prophylactic O 0 0.0002567289920989424
treatment O 0 9.684298129286617e-05
regimens O 0 2.534296436351724e-05
for O 0 5.291386173666979e-08
those O 0 1.5268321362782444e-07
patients O 0 1.5461106386283063e-06
with O 0 2.486647474597703e-07
mutations O 0 2.0616460460587405e-05
associated O 0 1.7418068409824627e-06
with O 0 9.721129572426435e-07
life O 0 7.02815450495109e-05
threatening O 0 0.06518543511629105
conditions O 0 0.0007081658113747835
. O 0 5.84370673095691e-06

This O 0 3.157808805553941e-07
study O 0 1.9474950363473909e-07
also O 0 3.379943436243593e-08
provided O 0 1.332178278801166e-08
evidence O 0 2.0455047433642903e-08
for O 0 5.43567058031158e-09
the O 0 1.9556880204163463e-07
pathological O 0 0.00011652000102913007
nature O 0 2.0626982859539567e-06
of O 0 8.892692449080641e-08
amino O 0 2.0398999822646147e-06
acid O 0 9.474073522142135e-06
changes O 0 5.817460646539985e-07
in O 0 2.1510085446152516e-07
APC O 0 1.7175365428556688e-05
associated O 0 7.116561846487457e-07
with O 0 1.1053380433168059e-07
both O 0 6.93772619797528e-07
FAP B-Disease 0 0.0002115474344464019
and O 0 6.862276677566115e-06
non O 0 0.3648187518119812
- O 1 0.9998495578765869
FAP O 1 0.9984329342842102
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
patients O 0 0.0007804645574651659
. O 0 8.488314051646739e-07
. O 0 4.13945099353441e-06

Inherited B-Disease 1 0.9997580647468567
colorectal I-Disease 1 0.9999988079071045
polyposis I-Disease 1 0.9997535347938538
and O 0 0.12157467007637024
cancer B-Disease 1 0.9995274543762207
risk O 0 9.929967927746475e-05
of O 0 1.4265935988078127e-07
the O 0 2.2828280634712428e-06
APC O 0 0.0003557354211807251
I1307K O 0 0.0003266281564719975
polymorphism O 0 9.897552081383765e-05
. O 0 1.1907373846042901e-05

Germ O 0 0.005045471712946892
- O 0 0.00040527115925215185
line O 0 6.709845183650032e-05
and O 0 7.174211305027711e-07
somatic O 0 2.0407878764672205e-05
truncating O 0 0.00021409077453427017
mutations O 0 2.8481303161242977e-05
of O 0 3.946741244931218e-08
the O 0 1.2640680324693676e-07
APC B-Disease 0 9.10145536181517e-06
gene O 0 4.892416427537682e-07
are O 0 3.5022722499888914e-08
thought O 0 3.8984512684692163e-07
to O 0 3.548852873791475e-07
initiate O 0 0.002262566704303026
colorectal B-Disease 1 0.9999983310699463
tumor I-Disease 1 0.9985772371292114
formation O 0 0.0051992288790643215
in O 0 0.0003567938692867756
familial B-Disease 1 0.9999686479568481
adenomatous I-Disease 1 0.9999583959579468
polyposis I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.999994158744812
and O 0 0.0022067143581807613
sporadic O 1 0.9914109706878662
colorectal O 1 0.9999972581863403
carcinogenesis O 1 0.99644935131073
, O 0 1.8711696611717343e-05
respectively O 0 1.8988910596817732e-05
. O 0 5.256418262433726e-06

Recently O 0 0.00018403602007310838
, O 0 8.28047632239759e-07
an O 0 8.468367127534293e-07
isoleucine O 0 0.001149720512330532
- O 0 0.00026621302822604775
- O 0 0.00010236054367851466
> O 0 2.9283122785273008e-05
lysine O 0 3.3211912523256615e-05
polymorphism O 0 1.7871705495053902e-05
at O 0 2.0336092347861268e-05
codon O 0 3.1656640203436837e-05
1307 O 0 0.0002530294586904347
( O 0 3.904341099314479e-07
I1307K O 0 4.200861894787522e-06
) O 0 4.027670641448822e-08
of O 0 8.424279940300039e-09
the O 0 1.1251069054196705e-07
APC B-Disease 0 1.0568757716100663e-05
gene O 0 6.715699782944284e-07
has O 0 2.3461765863430628e-07
been O 0 1.2362764323370357e-07
identified O 0 6.209982927884994e-08
in O 0 5.5577558555341966e-08
6 O 0 6.615751431127137e-07
% O 0 5.172696759814244e-08
- O 0 3.47199420502875e-06
7 O 0 8.643505111649574e-07
% O 0 8.99380658836435e-09
of O 0 1.2269137705800404e-08
the O 0 2.418478288745973e-07
Ashkenazi O 0 5.883128324057907e-05
Jewish O 0 4.566109510051319e-06
population O 0 3.446942855589441e-07
. O 0 2.808431190715055e-06

To O 0 9.086608088182402e-07
assess O 0 2.088300243485719e-05
the O 0 1.60836771101458e-06
risk O 0 8.460193384962622e-06
of O 0 6.615676539922788e-08
this O 0 7.797402901132955e-08
common O 0 3.7960687677696114e-06
APC B-Disease 0 0.00022917520254850388
allelic O 0 0.000704112637322396
variant O 0 0.007344831712543964
in O 0 0.00039557216223329306
colorectal O 1 0.9999904632568359
carcinogenesis O 1 0.9296616911888123
, O 0 1.5655058405172895e-06
we O 0 7.498388754356711e-08
have O 0 1.9572397036426992e-08
analyzed O 0 3.944845161640842e-07
a O 0 4.1025455743692874e-07
large O 0 1.2045329640386626e-06
cohort O 0 1.8351993276155554e-05
of O 0 5.463888328449684e-07
unselected O 0 0.003405289724469185
Ashkenazi O 0 0.0009978646412491798
Jewish O 0 4.474567322176881e-05
subjects O 0 0.00011697266018018126
with O 0 9.243927343050018e-05
adenomatous B-Disease 1 0.99652498960495
polyps I-Disease 1 0.9565833806991577
and O 0 5.394078925746726e-06
. O 0 7.621144504810218e-06
or O 1 0.9817204475402832
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
, I-Disease 0 1.1575907592487056e-06
for O 0 4.2928828491994864e-08
the O 0 3.932029812858673e-07
APC O 0 8.953774522524327e-05
I1307K O 0 6.628080882364884e-05
polymorphism O 0 5.770324423792772e-05
. O 0 4.57588248536922e-06

The O 0 8.854914085532073e-06
APC O 0 0.0002014769852394238
I1307K O 0 6.0752758145099506e-05
allele O 0 1.0255363122269046e-05
was O 0 3.8511957427544985e-06
identified O 0 2.8389931117089873e-07
in O 0 5.425905058586977e-08
48 O 0 3.1563638458464993e-07
( O 0 2.418136624271483e-08
10 O 0 3.390519864865382e-08
. O 0 8.266604289985935e-09
1 O 0 8.369892867676754e-08
% O 0 1.0062677802125108e-08
) O 0 1.8058127437825533e-08
of O 0 5.767919475374583e-08
476 O 0 6.316043436527252e-05
patients O 0 5.666601282428019e-05
. O 0 3.94554035665351e-06

Compared O 0 5.735720606026007e-06
with O 0 6.933459673064135e-08
the O 0 5.324786300775486e-08
frequency O 0 6.879030820527987e-07
in O 0 4.7785455592475046e-08
two O 0 2.2048691761256123e-08
separate O 0 1.1872917582422815e-07
population O 0 2.3943583116192713e-08
control O 0 1.1803715551650384e-06
groups O 0 6.072854574767916e-08
, O 0 9.320562810444244e-08
the O 0 1.954418280547543e-07
APC O 0 3.63824401574675e-05
I1307K O 0 3.0086564947851002e-05
allele O 0 5.198504368308932e-06
is O 0 1.596639833678637e-07
associated O 0 2.3164534468378406e-07
with O 0 5.110619838433195e-08
an O 0 1.0404784234196995e-07
estimated O 0 3.237528858335281e-07
relative O 0 2.323973149032099e-06
risk O 0 1.255128336197231e-05
of O 0 3.209308943041833e-07
1 O 0 1.4280258255894296e-05
. O 0 6.389879217749694e-06

5 O 0 4.3614254536805674e-05
- O 0 0.00015908427303656936
1 O 0 1.4759432815480977e-05
. O 0 3.1698129987489665e-06

7 O 0 0.0002396050695097074
for O 0 4.428035390446894e-05
colorectal B-Disease 1 0.9999916553497314
neoplasia I-Disease 1 0.9664468765258789
( O 0 1.723659920571663e-06
both O 0 2.212428398706834e-06
P O 0 0.002393551869317889
= O 0 8.464088023174554e-05
. O 0 8.769637815930764e-07
01 O 0 9.897740528685972e-05
) O 0 6.878400995447009e-07
. O 0 2.3969184894667706e-06

Furthermore O 0 7.2745492616377305e-06
, O 0 1.0727745802796562e-06
compared O 0 1.2848846608903841e-06
with O 0 3.9610327462469286e-07
noncarriers O 0 0.0004330110677983612
, O 0 1.4760776139155496e-06
APC O 0 2.3748389139655046e-05
I1307K O 0 1.4418773389479611e-05
carriers O 0 1.7452138081353041e-06
had O 0 6.485329890892899e-07
increased O 0 1.4404807302526024e-07
numbers O 0 2.4695935962881777e-07
of O 0 5.728279575123452e-07
adenomas B-Disease 1 0.961181104183197
and O 0 0.13024532794952393
colorectal B-Disease 1 0.9999992847442627
cancers I-Disease 1 0.9995377063751221
per O 0 6.346251666400349e-06
patient O 0 4.155308488407172e-05
( O 0 6.268053880376101e-07
P O 0 0.00015756316133774817
= O 0 6.974815732974093e-06
. O 0 1.027529066277566e-07
03 O 0 3.4489657991798595e-06
) O 0 1.9341568346931126e-08
, O 0 1.1511726683011148e-08
as O 0 2.0926149701949726e-08
well O 0 2.316605218766199e-08
as O 0 6.870639879252849e-08
a O 0 5.928930590926029e-07
younger O 0 3.0747858090762747e-06
age O 0 8.59106148709543e-06
at O 0 0.00016256686649285257
diagnosis O 0 0.010448832996189594
. O 0 6.700865924358368e-06

We O 0 3.043528977286769e-06
conclude O 0 4.652483312383993e-06
that O 0 2.73442744003205e-08
the O 0 2.465501438564388e-07
APC O 0 4.3152627767995e-05
I1307K O 0 5.199369843467139e-05
variant O 0 6.354430661303923e-05
leads O 0 7.532212293881457e-06
to O 0 4.1362761749041965e-07
increased O 0 2.583291643531993e-05
adenoma B-Disease 1 0.9998854398727417
formation O 0 0.00012200298078823835
and O 0 3.2453124276798917e-07
directly O 0 1.711145500848943e-07
contributes O 0 5.709404149456532e-07
to O 0 2.0719269855362654e-08
3 O 0 1.9327396216795023e-07
% O 0 2.5510086487656736e-08
- O 0 1.4087867157286382e-06
4 O 0 2.7763027787841565e-07
% O 0 1.0552476226166618e-08
of O 0 2.0368732478459606e-08
all O 0 9.96690346255491e-07
Ashkenazi O 1 0.5983452200889587
Jewish O 1 0.9985913634300232
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 6.983313505770639e-05

The O 0 1.6314210142809316e-06
estimated O 0 1.2988804201086168e-06
relative O 0 4.079109203303233e-06
risk O 0 7.97925895312801e-06
for O 0 9.307381532153158e-08
carriers O 0 6.5699819060682785e-06
may O 0 1.1579485317270155e-06
justify O 0 1.1242365189900738e-06
specific O 0 8.37775147033426e-08
clinical O 0 1.6260341908491682e-06
screening O 0 2.1705871233734797e-07
for O 0 6.336339453127948e-09
the O 0 2.9781793031702364e-08
360 O 0 3.254536409258435e-07
, O 0 7.446183047932209e-08
000 O 0 1.3150558686447766e-07
Americans O 0 5.462008445533684e-08
expected O 0 1.5076601300734183e-07
to O 0 2.5415818782903443e-08
harbor O 0 3.901191576005658e-06
this O 0 1.6277637016059998e-08
allele O 0 4.121274059798452e-07
, O 0 1.1070258665313304e-07
and O 0 7.316980799032535e-08
genetic O 0 1.960544750545523e-06
testing O 0 1.0598870403555338e-06
in O 0 2.9638199450232605e-08
the O 0 3.177192553494024e-08
setting O 0 5.304785872795037e-07
of O 0 9.092470065752423e-08
long O 0 1.3992297681397758e-05
- O 0 8.480198448523879e-05
term O 0 7.397722129098838e-06
- O 0 1.4679784726467915e-05
outcome O 0 9.068921258403861e-07
studies O 0 1.6356476351120364e-07
may O 0 2.4987116375996266e-07
impact O 0 6.083590733396704e-07
significantly O 0 1.2451187103579286e-05
on O 1 0.8496314883232117
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
prevention O 0 0.005025883205235004
in O 0 2.965981025226938e-07
this O 0 2.5726450303409365e-08
population O 0 5.089491494914e-08
. O 0 8.156197850439639e-07

Localization O 0 6.675095210084692e-05
of O 0 5.308976369633456e-07
human O 0 5.992271780996816e-06
BRCA1 O 0 7.483009540010244e-05
and O 0 5.024846814194461e-07
its O 0 5.83199266657175e-07
loss O 0 4.45714031229727e-05
in O 0 7.776118309266167e-07
high O 0 0.00010364802437834442
- O 0 0.00016826626961119473
grade O 0 0.00028614088660106063
, O 0 2.622176225486328e-06
non B-Disease 0 0.00112357665784657
- I-Disease 1 0.9980459213256836
inherited I-Disease 1 0.9996321201324463
breast I-Disease 1 0.9998610019683838
carcinomas I-Disease 1 0.9999793767929077
. O 0 0.00013851971016265452

Although O 0 1.3179616189518129e-06
the O 0 1.861242822087661e-07
link O 0 5.081371455162298e-06
between O 0 9.826184168559848e-07
the O 0 5.016016984882299e-06
BRCA1 O 0 0.014558814465999603
tumour B-Disease 1 0.999700665473938
- O 0 0.00041937115020118654
suppressor O 0 9.29232410271652e-05
gene O 0 2.798726018227171e-05
and O 0 1.2214789421705063e-05
hereditary B-Disease 1 0.9995496869087219
breast I-Disease 1 0.999906063079834
and I-Disease 1 0.999131977558136
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999970197677612
is O 0 1.2336175814198214e-06
established O 0 3.6830010685662273e-07
, O 0 6.978303446203427e-08
the O 0 1.9594958544644214e-08
role O 0 5.795278070763743e-07
, O 0 1.4123729386028572e-07
if O 0 2.00405185779573e-08
any O 0 1.4564042416509437e-08
, O 0 4.476211756809789e-08
of O 0 4.8211344250148613e-08
BRCA1 O 0 3.446256960160099e-05
in O 0 1.7386337276548147e-06
non B-Disease 0 0.00022113346494734287
- I-Disease 1 0.9653273820877075
familial I-Disease 1 0.9977583885192871
cancers I-Disease 1 0.9997273087501526
is O 0 7.2407447078148834e-06
unclear O 0 7.242554147524061e-06
. O 0 4.691214144258993e-06

BRCA1 O 0 0.005061565898358822
mutations O 0 0.0002938372199423611
are O 0 4.183005444247101e-07
rare O 0 1.5268804418155923e-05
in O 0 3.0231578875827836e-06
sporadic B-Disease 0 0.003389063524082303
cancers I-Disease 1 0.998609185218811
, O 0 5.153915026312461e-06
but O 0 1.6645963114569895e-06
loss O 0 3.609505438362248e-05
of O 0 4.136299764923024e-07
BRCA1 O 0 0.00011275801807641983
resulting O 0 6.041216238372726e-06
from O 0 6.740756361978129e-07
reduced O 0 1.632396902095934e-06
expression O 0 1.1198374068044359e-06
or O 0 1.115290842790273e-06
incorrect O 0 9.027880878420547e-06
subcellular O 0 2.9583317882497795e-05
localization O 0 2.6970023100147955e-05
is O 0 1.847833175361302e-07
postulated O 0 5.039939878770383e-07
to O 0 7.195999796039132e-09
be O 0 1.6581978456997604e-08
important O 0 4.4127862253162675e-08
in O 0 4.223523717428179e-07
non B-Disease 0 8.910047472454607e-05
- I-Disease 1 0.7360568046569824
familial I-Disease 1 0.9976102113723755
breast I-Disease 1 0.9998183846473694
and I-Disease 1 0.9964486360549927
ovarian I-Disease 1 0.9999995231628418
cancers I-Disease 1 0.9999963045120239
. O 0 0.0001049754282576032

Epigenetic O 0 0.008382205851376057
loss O 0 0.013966213911771774
, O 0 1.6632490087431506e-06
however O 0 2.2905558694219508e-07
, O 0 9.407992251908581e-08
has O 0 6.821841225246317e-08
not O 0 1.3795482090017686e-08
received O 0 1.5681416698498651e-07
general O 0 7.405561319728804e-08
acceptance O 0 1.2263601547601866e-06
due O 0 5.8805985645449255e-06
to O 0 1.249286327720256e-07
controversy O 0 1.192076751976856e-06
regarding O 0 1.0494552782347455e-07
the O 0 8.282136576553967e-08
subcellular O 0 1.1802571862062905e-05
localization O 0 9.263808351533953e-06
of O 0 1.5874664427428797e-07
BRCA1 O 0 3.596489841584116e-05
proteins O 0 7.034872737676778e-07
, O 0 1.6982129125153733e-07
reports O 0 1.2199707555282657e-07
of O 0 1.031440088894442e-08
which O 0 2.6745818004769717e-08
have O 0 3.5029000144959355e-08
ranged O 0 2.124877482856391e-06
from O 0 4.987207447015862e-08
exclusively O 0 1.9217172564367502e-07
nuclear O 0 4.874357910011895e-05
, O 0 9.483841978408236e-08
to O 0 4.310359003056874e-08
conditionally O 0 1.7244328773813322e-05
nuclear O 0 4.9692494940245524e-05
, O 0 1.61551909627633e-07
to O 0 2.2088469719960813e-08
the O 0 6.647056238762161e-07
ER O 0 0.00035998004022985697
/ O 0 5.018701995140873e-05
golgi O 0 0.00046729083987884223
, O 0 2.1095310387408972e-07
to O 0 1.88980262549876e-08
cytoplasmic O 0 1.5795064882695442e-06
invaginations O 0 2.1658614059560932e-05
into O 0 1.7677778885172302e-07
the O 0 2.8964507237105863e-07
nucleus O 0 1.2220555618114304e-05
. O 0 3.688509423227515e-06

In O 0 1.3137150745023973e-06
an O 0 1.2623694090052595e-07
attempt O 0 7.983148293533304e-07
to O 0 9.068379114296476e-08
resolve O 0 3.0192766189429676e-06
this O 0 5.6365202283359395e-08
issue O 0 5.183907205719152e-07
, O 0 7.7113540442042e-08
we O 0 6.446470024457085e-08
have O 0 9.992336202913066e-08
comprehensively O 0 4.1679526475491e-05
characterized O 0 5.198120197746903e-05
19 O 0 3.664513133116998e-05
anti O 0 0.0003114998689852655
- O 0 0.0009204210946336389
BRCA1 O 0 0.0005054819048382342
antibodies O 0 4.2221839976264164e-05
. O 0 5.749439878854901e-06

These O 0 3.6532594549498754e-07
reagents O 0 2.5414048650418408e-05
detect O 0 5.1596776756923646e-05
a O 0 2.0364770989544922e-06
220 O 0 1.344862425867177e-06
- O 0 1.6483771105413325e-05
kD O 0 5.9463680372573435e-05
protein O 0 1.1274672715444467e-06
localized O 0 6.266467607929371e-06
in O 0 1.5344518544679886e-07
discrete O 0 1.7325293129033525e-06
nuclear O 0 0.00011030593304894865
foci O 0 2.7707912522600964e-05
in O 0 1.0221223334383467e-07
all O 0 4.894684124678861e-08
epithelial O 0 8.9694993221201e-05
cell O 0 0.00014421969535760581
lines O 0 4.9016081902664155e-05
, O 0 3.4268245485691295e-07
including O 0 8.02914499331564e-08
those O 0 4.886177151774973e-08
derived O 0 1.7315348941338016e-06
from O 0 1.892731415864546e-05
breast B-Disease 1 0.9758278131484985
malignancies I-Disease 1 0.8008919358253479
. O 0 2.402909922238905e-05

Immunohistochemical O 0 0.003978030290454626
staining O 0 0.0009597875759936869
of O 0 3.321618351037614e-06
human O 0 0.00010706046305131167
breast O 1 0.7528137564659119
specimens O 0 4.017422179458663e-05
also O 0 3.59901309820998e-06
revealed O 0 3.218152778572403e-05
BRCA1 O 0 0.0005031141918152571
nuclear O 0 0.0016974451718851924
foci O 0 0.0008633223478682339
in O 0 2.7035091989091597e-05
benign O 1 0.9941645264625549
breast O 1 0.995154619216919
, O 0 4.67982936243061e-05
invasive B-Disease 1 0.9838460683822632
lobular I-Disease 1 0.9994674324989319
cancers I-Disease 1 0.9993257522583008
and O 0 3.845844912575558e-05
low B-Disease 0 0.03865869343280792
- I-Disease 1 0.9719020128250122
grade I-Disease 1 0.9720944166183472
ductal I-Disease 1 0.9992089867591858
carcinomas I-Disease 1 0.9999688863754272
. O 0 0.00016680713451933116

Conversely O 0 8.364353561773896e-05
, O 0 1.9270078155386727e-06
BRCA1 O 0 4.0841143345460296e-05
expression O 0 2.8124543405283475e-06
was O 0 7.966986231622286e-06
reduced O 0 1.130969394580461e-06
or O 0 6.972834398766281e-07
undetectable O 0 5.269622852210887e-05
in O 0 6.92283563807905e-08
the O 0 2.1393979920958373e-08
majority O 0 4.698883415699129e-08
of O 0 1.3520815400624997e-07
high O 0 0.0004955713520757854
- O 0 0.0041788793168962
grade O 0 0.004569146782159805
, O 0 7.753307727398351e-05
ductal B-Disease 1 0.997868537902832
carcinomas I-Disease 1 0.9999788999557495
, O 0 3.869337888318114e-06
suggesting O 0 2.186852952945628e-06
that O 0 6.142564501487868e-08
absence O 0 1.462170871491253e-06
of O 0 2.1519215920307033e-07
BRCA1 O 0 6.692604802083224e-05
may O 0 8.884908879736031e-07
contribute O 0 5.765873112295594e-08
to O 0 1.6555873116885778e-08
the O 0 1.0954399698448469e-07
pathogenesis O 0 3.23925050906837e-05
of O 0 2.5882620491302077e-08
a O 0 4.6559978272853186e-07
significant O 0 4.7195513275255507e-07
percentage O 0 6.440671313612256e-06
of O 0 1.475638441661431e-06
sporadic B-Disease 0 0.05367579311132431
breast I-Disease 1 0.9991151690483093
cancers I-Disease 1 0.9993112087249756
. O 0 5.027683528169291e-06
. O 0 7.0851938289706595e-06

